page_number,sentence_chunk,chunk_char_count,chunk_word_count,chunk_token_count,embedding
0,"806 Peptic Ulcer Disease Francis K. L. Chan, James Y. W. Lau 53 An ulcer in the GI tract can be defined as a 5 mm or larger break in the lining of the mucosa, with appreciable depth at endoscopy or with histologic evidence of submucosal extension. An erosion is a break less than 5 mm. The distinction between an ulcer and an ero­ sion is somewhat arbitrary. The term PUD is used to include ulcer­ ations and erosions in the stomach and duodenum from a number of causes. These lesions are called “peptic” because the enzyme pepsin, proteolytic at an acidic pH (see Chapter 51), plays a major role in causing the mucosal breaks, regardless of the inciting agent. Decades of research focused on the role of gastric acid secretion and the effects of stress, personality type, and genetics in the pathogenesis of PUD. The discovery of the histamine-2 (H2) receptor and development of H2RAs,1 and subsequently PPIs, led to major changes in the management of PUD. The discovery of Hp and its role in PUD (see Chap­ ter 52) transformed PUD from a chronic, recurrent disease to a curable one.2 Hp infection remains an important cause of PUD in the world. In developed countries, frequent use of NSAIDs, including low-dose aspirin for cardiovascular indi­ cations, has emerged as a leading cause of PUD, especially among the aging population. EPIDEMIOLOGY The epidemiology of PUD has undergone remarkable changes in the past 2 centuries. The risk of developing PUD, and dying from PUD, increased in successive cohorts born between 1840 and 1890, and then declined thereafter.3 There was a peak in the inci­ dence of GU in the first half of the 19th century and a subsequent peak in the incidence of DU in the second half of the 19th century. Sonnenberg proposed a birth-cohort effect to explain the peaks in the incidence of, and mortality from, peptic ulcers. Hp infection acquired during childhood or adolescence became manifested as peptic diseases in later years. As Hp infection gradually declined in the population over time, the prevalence of infection also gradually shifted from a younger toward older age groups. The incidence of DU and GU has declined in parallel with the decline in the preva­ lence of Hp infection, likely a result of improved sanitary condi­ tions and a safer food and water supply. Based on physicians’ diagnoses, the annual incidence of PUD ranges from 0.14% to 0.19% in developed countries. Based on hospital diagnoses, the incidence is lower: 0.03% to 0.17%. The prevalence of PUD ranges from 0.12% to 4.7% for physician- diagnosed, and from 0.1% to 2.6% for hospital-diagnosed case series.4 There is a wide geographic variation in the prevalence of PUD. In an endoscopic series involving 1022 volunteers from Shanghai, China (average age, 48 years), the prevalence of PUD was 17.2%, of whom 93% were infected with Hp.5 The most frequent complication from PUD is bleeding; the reported annual incidence of bleeding among populations varies from 19 to 57 per 100,000 individuals (≈0.02% to 0.06%). Peptic ulcer perforation (PULP), less frequent than bleeding, has reported incidences of 4 to 14 per 100,000 individuals (0.004% to 0.014%).6 Along with a decline in uncomplicated PUD cases, there is a similar decline in incidence of ulcer complications in recent years. Laine and colleagues7 used a national inpatient database to calculate the annual incidence of, and mortality from, GI complications during 2001 to 2009. During this time period, the incidence of peptic ulcer bleeding fell from 48.7 to 32.1 per 100,000. Over the same period, the age- and sex-adjusted case fatality rates from UGI bleeding decreased from 3.8% to 2.7%. In 2009, the case fatality rate for UGI bleeding (2.45%) was considerably lower than for UGI perforation (10.7%). In a nationwide population-based cohort study of 403,567 Taiwan­ ese patients, hospitalizations for complicated peptic ulcers decreased significantly over a 10 year period8; thus the annual incidence of hos­ pitalizations for bleeding DU or for perforated DU fell from 108 to 40 and from 9.8 to 5.8 per 100,000, respectively. A similar decline was evident for bleeding and perforated GUs (from 117 to 61 and from 11 to 6 per 100,000, respectively).  ETIOLOGY AND PATHOGENESIS The principal risk factors of PUD are Hp infection and NSAID use (Fig.53.1) and as will be discussed, many patients with PUD have both of these risk factors. On the other hand, PUD patients may have neither of these risk factors (Hp-negative, NSAID- negative ulcers); some of these latter patients will have another cause of ulcer such as gastrinoma (ZES; see Chapter 34), whereas others will have ulcers that are idiopathic. CHAPTER OUTLINE EPIDEMIOLOGY.�.�.�.�.�.�.�.�.�.�.�.�.�.�.",4736,775,1184.0,"[-0.443083   -0.194976   -1.0122081  ...  0.20348905 -0.0111322
 -1.4254513 ]"
0,�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�806 ETIOLOGY AND PATHOGENESIS.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�806 Hp Infection.�.�.�.�.�.�.�.,137,6,34.25,"[ 0.14773934 -0.11674534 -2.2880774  ... -0.40109137  0.00895686
 -0.9532443 ]"
0,�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�807 Use of Aspirin and Other NSAIDs.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.,124,7,31.0,"[ 0.12582467 -0.60779524 -2.770172   ...  0.16003217  0.9732706
 -1.6093816 ]"
0,�807 Other Causes of Ulcers and Idiopathic Ulcers.�.�.�.�.�.�.�.�.�808 CLINICAL FEATURES AND DIAGNOSIS.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�808 MEDICAL THERAPY OF ACTIVE PEPTIC ULCER DISEASE.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.,228,19,57.0,"[ 0.19653367 -0.6044692  -1.5477078  ...  0.5445491  -0.70987475
 -0.9505095 ]"
0,�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�810 Pharmaceutical Agents.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�810 Hp-associated Ulcers .�.�.�.,142,6,35.5,"[ 0.1747831  -0.07459477 -2.1620371  ...  0.47538647  0.10337217
 -1.2260962 ]"
0,�.�.�.�.�.�.�.�.�.�.�.�812 Other Causes of Ulcers and Idiopathic Ulcers.�.�.�.�.�.�.�.�.�812 REFRACTORY ULCERS.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.,161,10,40.25,"[-0.0869652  -0.6952323  -1.9107115  ...  1.1531394  -0.62634236
 -0.8831917 ]"
0,�.�.�812 PREVENTION OF ULCER DISEASE.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�812 Antacids.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.,135,6,33.75,"[ 0.7643109  -0.52174854 -2.5308118  ...  1.180737   -0.01750907
 -2.0949426 ]"
0,�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�813 COX-2 Inhibitors (In Place of NSAIDs).�.�.�.�.�.�.�.�.�.�.,130,7,32.5,"[ 0.17192368  0.0576112  -2.2289085  ...  0.35845622  1.5010638
 -1.1249598 ]"
0,�.�.�.�.�813 Assessing Risk and Choice of Agent(s).�.�.�.�.�.�.�.�.�.�.�.�.�.�814 COMPLICATIONS AND THEIR TREATMENT .�.�.�.�.�.�.�.�.�.�.�815 Bleeding.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.,186,13,46.5,"[ 0.66866785 -0.7489153  -2.6565814  ...  0.5294499   0.56986624
 -1.547305  ]"
0,�.�.�.�.�.�.�.�.�.�817 Obstruction.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�818 STRESS ULCERS.�.,124,4,31.0,"[ 0.11508811 -0.7650084  -2.876018   ...  0.41644704  0.3230859
 -1.0633012 ]"
0,"�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�.�819 Downloaded for JongHoon Hyun (whdgnssla@hanmail.net) at Inje University from ClinicalKey.com by Elsevier on May 29, 2024. For personal use only. No other uses without permission. Copyright ©2024. Elsevier Inc. All rights reserved.",293,33,73.25,"[-0.16229366  0.22222206 -2.0561998  ...  0.40171936  0.17135061
 -0.9343204 ]"
1,"CHAPTER 53  Peptic Ulcer Disease 807 53 Hp Infection The prevalence of Hp infection varies widely among countries in the world (see Chapter 52). In series reported between 2009 and 2011, the prevalence of infection ranged from 7% to 87%, depending on the methods of diagnosis and the population that was sampled. The lowest prevalence was observed in the USA and European countries (7% to 33%).9 Those reported from Japan and China ranged from 56% to 72%. In general, the rate of Hp infection is declining. Feinstein and colleagues studied hos­ pital discharge records for PUD in the USA between 1998 and 2005.10 In parallel with a decline in annual hospitalization rates for PUD, from 71.1 to 56.5 per 100,000, there was a decrease in hospitalization due to Hp-related disease, from 35.9 to 19.2 per 100,000. The prevalence of Hp infection in patients with bleed­ ing ulcers remains high. Sanchez-Delgado and colleagues com­ piled 71 studies containing 8496 patients with bleeding peptic ulcers and found an Hp infection rate of 72%. The use of an Hp diagnostic test after the index bleed was associated with high Hp prevalence.11 As discussed in Chapters 51 and 52, Hp causes an antrum- predominant gastritis in 10% to 20% of infected patients, which results in high gastric acid secretion and an increased risk of DU. The increased acid output from the stomach results in increased acid load to the duodenum that can result in gastric metaplasia in the duodenal bulb.12 Some believe that the metaplastic epithe­ lium then becomes infected with Hp from the stomach, resulting in focal “duodenitis” (technically, gastritis), sometimes followed by erosion and ulcer formation. Most patients with Hp infection have a pan-gastritis involving both the antral and fundic mucosa that lowers gastric acid secre­ tion13 and predisposes to GU formation. In these individuals, it is proposed that weakened mucosal defense mechanisms (see Chapter 51), rather than high acid secretion, are what predisposes to gastric ulceration. The role of Hp’s genes and their protein products in the pathogenesis of PUD is discussed in Chapter 52.  Use of Aspirin and Other NSAIDs Aspirin is increasingly used on a regular basis for the prevention of cardiovascular events, either alone or in combination with a platelet adenosine diphosphate inhibitor such as clopidogrel (dual antiplatelet therapy). NSAIDs are used on a regular basis by approximately 11% of the U. S. population. Regular use of NSAIDs increases the odds of GI bleeding up to 5- to 6-fold.14 Serious ulcer-related complications often leading to hospitaliza­ tion occur in 1% to 4% of NSAID users.15 NSAID users who also take aspirin are at an especially high risk for complications. In a population-based study from Denmark, the odds ratio for GI bleeding in people taking low-dose aspirin alone was 2.6, and this ratio increased to 5.6 in patients who were also taking an NSAID.16 In a national study of mortality associated with a hos­ pital admission for adverse GI events related to NSAID use in Spain, the death rate attributed to NSAID/aspirin use was 15.3 per 100,000 population compared to 2.5 per 100,000 of the gen­ eral population.17 The gastric and duodenal mucosa have several defense mechanisms protecting them from digestion by acid and pep­ sin (see Chapter 51). NSAIDs cause mucosal damage through disruption of mucus phospholipids, cell membranes and by uncoupling mitochondrial oxidative phosphorylation, but most evidence suggests that NSAIDs damage the gastric and duode­ nal mucosa by suppression of prostaglandin synthesis.18 COX isoforms COX-1 and COX-2 are responsible for the synthesis of prostaglandins. COX-1 is expressed in the stomach and helps maintain the integrity of gastric epithelium and the mucous barrier. COX-2 is not expressed in the healthy stomach but is rapidly expressed in response to the cytokines generated by inflammatory processes. Conventional NSAIDs such as ibu­ profen inhibit the COX-1 and the COX-2 isoenzymes more or less equally. COX-1 inhibition reduces prostaglandin syn­ thesis, which leads to a reduction in mucosal defense. Animal experiments have found that neutrophil adherence to the gastric microcirculation plays a critical role in initiating NSAID injury. Neutrophil adherence liberates oxygen-free radicals, releases proteases, and obstructs capillary blood flow. Inhibition of neu­ trophil adherence has been shown to reduce NSAID-induced damage. In addition, 2 gaseous mediators, nitric oxide (NO) and hydrogen sulfide (H2S), contribute to maintaining the gas­ tric mucosal barrier. NO and H2S increase mucosal blood flow, stimulate mucus secretion, and inhibit neutrophil adherence.19 NO-releasing and H2S-releasing derivatives of NSAIDs have been shown to protect against gastric damage when compared to the parent drugs. Gastric acid plays a secondary but impor­ tant role by turning superficial mucosal lesions into deeper injury, interfering with platelet aggregation, and impairing ulcer healing.20 Hp infection appears to influence the risk of PUD in patients receiving NSAIDs. A meta-analysis showed that Hp infection raised the risk of peptic ulcer bleeding more than 6-fold in patients receiving long-term NSAIDs, whereas Hp alone and NSAID use alone raised the risk by 1.79-fold and 4.85-fold, respectively.21 An updated meta-analysis showed similar findings.22 Among patients who are about to start NSAID therapy, eradication of Hp reduces the subsequent risk of ulcer development.23,24 A systematic review has shown that testing for (and eradication of) Hp lowers the risk of peptic ulcers among NSAID users;25 however, eradication of Hp infection alone is insufficient to prevent peptic ulcer bleeding in NSAID users at high ulcer risk.26,27 There is also evidence that Hp infection increases the risk of PUD in patients receiving low-dose aspirin. Among Hp-infected patients with recent ulcer bleeding who continued to take low- dose aspirin, successful eradication of Hp infection resulted in a very low risk of recurrent ulcer bleeding, similar to that seen with aspirin/omeprazole co-therapy.26 This low risk of ulcer rebleed­ ing after eradication of Hp was not seen in patients with bleeding ulcers who continued to take NSAIDs. In a long-term prospec­ tive cohort study,28 Hp-infected low-dose aspirin users (≤160 mg/day) with bleeding ulcers who resumed their aspirin had a low risk of recurrent ulcer bleeding after eradication of Hp, a risk that was not significantly different from the risk in new aspirin users with no history of ulcer disease (<1 bleed per 100 patient- years). In contrast, aspirin users with bleeding ulcers but without None known None known ZES, other ZES, other NSAID use NSAID use Hp infection Hp infection Duodenal Gastric Fig.53.1  Pie charts depicting conditions associated with PUD. The percentages shown are rough approximations based on studies from Western countries. The relative contributions of Hp infection and NSAID use to peptic ulcer vary considerably among different populations and, within populations, vary with age and socioeconomic status. Also, the separation depicted in this figure is somewhat artificial because NSAID use and Hp infection often coexist. Downloaded for JongHoon Hyun (whdgnssla@hanmail.net) at Inje University from ClinicalKey.com by Elsevier on May 29, 2024. For personal use only. No other uses without permission. Copyright ©2024. Elsevier Inc. All rights reserved.",7470,1152,1867.5,"[ 0.2798581  -0.5809396  -0.9008291  ...  0.284071    0.44459212
 -1.2544366 ]"
2,"PART VI  Stomach and Duodenum 808 Hp infection (past or present) were at high risk of recurrent ulcer bleeding with continued enteric-coated aspirin treatment (>5 bleeds per 100 patient-years).  Other Causes of Ulcers and Idiopathic Ulcers Deep ulcers and perforations of the stomach and duodenum have been described in cocaine and methamphetamine users, presum­ ably due to mucosal ischemia.29 Bisphosphonate therapy has also been associated with gastroduodenal ulceration,30 although esophageal injury with bisphosphonates is clinically more of a concern. There is little, if any, risk for PUD in patients taking glucocorticoids.31 In combination with NSAIDs, however, gluco­ corticoids increase the risk of PUD above the risk with NSAIDs alone.32 There is also a weak association between use of selective serotonin reuptake inhibitor antidepressants and PUD, especially in those with concurrent NSAID use. Smoking, stress, type A personality, and excessive alcohol use are some of the risk factors implicated for PUD. Although these factors can contribute to PUD, none has emerged as a sole cause of the disease. Hp infection is a confounder that was not addressed in earlier studies. An uncommon cause of PUD is gastrinoma (ZES) (see Chapter 34).33 Systemic mastocytosis (see Chapter 37) is another uncommon condition in which multiple ulcers may occur in the stomach or duodenum.34 Secretion of histamine by the mast cells is thought to result in the excessive stimula­ tion of acid production through the histamine receptor. Asso­ ciations between PUD and α1-antitrypsin deficiency, chronic obstructive lung disease, and chronic kidney disease have been described. Several other diseases (e.g., gastric cancer, gastric lymphoma, Crohn disease) can cause ulcers that can mimic peptic ulcers. Rarer causes of peptic ulcers include eosinophilic gastroenteritis, viral infections (e.g., cytomegalovirus), Behcet disease in immunocompromised patients, Helicobacter heilmannii infection, and ulcers in a Meckel diverticulum with heterotopic gastric mucosa. With a global decline in the prevalence of Hp infection, the proportion of patients with idiopathic ulcers has been increasing. Studies in North America have shown that more than 10% of peptic ulcers are not associated with Hp infection or the use of NSAIDs. Whether the incidence of idiopathic ulcers is increasing or not is controversial. It has been argued that only the relative propor­ tion, but not the true incidence, of idiopathic ulcers has increased as a result of a falling incidence of Hp ulcers. However, there are prospective data showing that the absolute incidence of idiopathic bleeding ulcers has increased by 4-fold. Importantly, patients with a history of idiopathic bleeding ulcers have a 4-fold increased risk of recurrent ulcer bleeding and more than 2-fold increase in mor­ tality compared to patients with history of Hp ulcers.35  CLINICAL FEATURES AND DIAGNOSIS The predominant symptom of patients with uncomplicated PUD is epigastric pain. Pain is typically associated with hunger, occurs at night, and is often relieved by food and antacids. Often patients complain of dyspeptic symptoms such as a bloated sensation and fullness. Some patients complain of heartburn that may or may not be accompanied by erosive esophagitis. Chronic NSAID users, typically older adult patients, can present with ulcer bleed­ ing or perforation without prior ulcer symptoms. EGD is the procedure of choice for diagnosis of uncompli­ cated PUD (Fig.53.2A and B). EGD is more sensitive and spe­ cific than radiologic studies, such as UGI series with barium. Nevertheless, endoscopy is expensive and has the potential for complications (see Chapter 42). Therefore, the decision to per­ form endoscopy in a patient suspected of having PUD is based on a number of factors. As discussed later in this chapter and in Chapter 20, patients presenting with acute GI bleeding need endoscopic evaluation to allow an accurate diagnosis and for the administration of endoscopic therapy. Furthermore, patients with epigastric pain suggestive of PUD but also with “alarm” features such as weight loss or recurrent vomiting may prompt concern for gastric malignancy as well as require EGD (Box 53.1). If a DU or GU is found during EGD, gastric mucosal biopsies should be obtained for a rapid urease test to diagnose Hp infection (see Chapter 52). Biopsies should also be taken from the edges of GUs because of risk of gastric cancer. Cus­ tomarily, if the GU biopsies are benign, EGD is repeated 8 weeks later to confirm healing of the GU, because up to 4% of apparently benign GUs at initial endoscopy are subsequently found to be malignant.36,37 B A Fig.53.2  A, Endoscopic view of a clean-based antral GU in a patient taking an NSAID. Tests for infection with Hp were negative. B, Endoscopic view of a DU in a patient with a positive rapid urease test for Hp. There was no history of NSAID use. Downloaded for JongHoon Hyun (whdgnssla@hanmail.net) at Inje University from ClinicalKey.com by Elsevier on May 29, 2024. For personal use only. No other uses without permission. Copyright ©2024. Elsevier Inc. All rights reserved.",5178,805,1294.5,"[ 0.02583048 -0.2547393  -1.1692599  ...  0.23535281 -0.6054319
 -1.1565738 ]"
3,"CHAPTER 53  Peptic Ulcer Disease 809 53 Dyspeptic upper abdominal symptoms consisting of pain or dis­ comfort in the upper abdomen are common in clinical practice, accounting for 2% to 5% of visits to family practitioners (see Chap­ ter 14).38 Owing to the high cost and impracticality of subjecting all dyspeptic individuals to prompt endoscopy, 2 other nonendoscopic strategies (besides UGI series, with its inherent lower sensitivity and specificity for PUD) have been proposed as an initial step in the management of suspected PUD (Fig.53.3). The strategies are (1) “test-and-treat,” based on a noninvasive diagnosis of Hp infection and subsequent eradication therapy when Hp is detected, and (2) empirical antisecretory therapy, usually with a PPI. Gisbert and Calvet39 reviewed the literature and concluded that the Hp test-and-treat strategy will cure most cases of PUD and prevent most cases of gastroduodenal disease. A small pro­ portion of patients with Hp-related functional dyspepsia would also improve in their symptoms. The test-and-treat strategy has been compared with endoscopy-directed diagnosis in 8 random­ ized controlled trials (RCTs). These trials differed in how Hp was diagnosed, and the upper age cutoff varied from 45 to 55 years. In some studies, serology was used for diagnosis of infection, which is less specific than 13C urea breath testing (see Chapter 52). The background Hp prevalence in the study populations ranged from 23% to 53%. After a 12-month follow-up, the prevalence of dys­ peptic symptoms was similar in the 2 groups. In 7 of the 8 trials, cost data were reported, and the test-and-treat strategy was less expensive because of the many endoscopies avoided. Ford and colleagues performed a meta-analysis of 5 RCTs involving 1924 patients and found a slight benefit at 12 months of prompt EGD on dyspeptic symptoms over test-and-treat (risk ratio, 0.95; 95% confidence index [CI], 0.92 to 0.99), possibly because a normal EGD may have had a reassuring effect in some patients.40 BOX 53.1  Alarm Features in Patients With UGI Symptoms* Age older than 55 years with new-onset dyspepsia Family history of UGI cancer GI bleeding, acute or chronic, including unexplained iron deficiency Jaundice Left supraclavicular lymphadenopathy (Virchow node) Palpable abdominal mass Persistent vomiting Progressive dysphagia Unintended weight loss     *These features should prompt EGD and often other testing to establish a definitive diagnosis (see Chapter 14). Organic pathology Normal Manage according to relevant guideline Manage according to Chapter 14 Endoscopy Adult dyspepsia patient ≥ 60 years of age < 60 years of age Hp test and treat Hp eradication PPI No Response No Response Response Response Response Response Positive Negative No response TCA or prokinetic Consider psychotherapy Success Fig.53.3  ACG and Canadian Association of Gastroenterology (CAG) guideline algorithm for the management of undiagnosed PUD. This is also the current management approach for patients with suspected PUD. TCA, tricyclic antidepressant. (Adapted from Moayyedi P, Lacy BE, Andrews CN, et al. ACG and CAG clinical guide­ line: management of dyspepsia. Am J Gastroenterol 2017; 112:988-1013.)Downloaded for JongHoon Hyun (whdgnssla@hanmail.net) at Inje University from ClinicalKey.com by Elsevier on May 29, 2024. For personal use only. No other uses without permission. Copyright ©2024. Elsevier Inc. All rights reserved.",3451,521,862.75,"[ 0.21542162 -0.43158978 -1.4763386  ...  0.23530647  0.6751925
 -1.3520677 ]"
4,"PART VI  Stomach and Duodenum 810 According to a joint ACG/Canadian Association of Gastro­ enterology guidelines, it was recommended that patients with uninvestigated dyspepsia who are below 60 years of age should have a noninvasive test H and treatment if positive. Those with a negative test or do not respond to this approach should receive a trial of PPI therapy. Tricyclic antidepressants or prokinetic therapies can be tried if they are not responsive to PPI therapy. The incidence of UGI malignancies including gastric cancer rises with age and, thus, current nonendoscopic management strategies are generally reserved for younger patients with upper abdominal symptoms. The age after which prompt EGD should become routine is debated and, to a substantial degree, depends on the epidemiology of UGI cancer in the population under consideration. In Western populations, UGI cancer is uncom­ mon in young individuals, and therefore an age cutoff of 50 or 55 years is often used. Patients older than age 60 presenting with new-onset upper abdominal symptoms suggestive of PUD should therefore be referred for EGD. In Asia and Eastern Europe, where the incidence of gastric cancer is substantially higher than in Western nations, a younger age cutoff may be reasonable. The Joint ACG/Canadian Association of Gastroenterology guidelines on dyspepsia in 2017 recommended that patients with uninvestigated dyspepsia who are less than 60 years of age should have a noninvasive Hp test and treatment if positive.39,41 Those with a negative Hp test or who do not respond to this approach should receive a trial of a PPI therapy. Tricyclic antidepressants or prokinetic therapies can be tried if the patients are not respon­ sive to PPI therapy (see Chapter 14 and Fig.53.3). In areas of moderate- to- high Hp prevalence, the test-and-treat strategy is preferred. The Maastricht Consensus Conference Report in 2017 recommended a test-and-treat strategy for uninvestigated dyspepsia. This approach is subject to regional Hp prevalence and cost-benefit considerations.40,42 The test-and-treat strategy is, however, not applicable to patients with alarm symptoms or to older patients. The ability of alarm features (see Box 53.1) to accurately predict malignancy (as opposed to PUD or nonul­ cer dyspepsia) has, however, been questioned in a review of 15 studies.43 The sensitivity of alarm symptoms in the diagnosis of malignancy varied from 0% to 83% across studies.  MEDICAL THERAPY OF ACTIVE PEPTIC ULCER DISEASE Several pharmaceutical agents are available to attempt to heal active DUs and GUs. Pharmaceutical Agents Antacids Antacids neutralize gastric acid but their ability to heal ulcers is poor. Most physicians do not use antacids as primary therapy to heal ulcers but instead recommend their use to relieve dyspeptic symptoms. The most common adverse effect of magnesium-con­ taining antacids is diarrhea. In contrast, aluminum- and calcium- containing antacids may cause constipation. All antacids must be used with caution, if at all, in patients who have chronic kidney disease, in whom magnesium-containing agents can cause hyper­ magnesemia, calcium-containing antacids hypercalcemia, and aluminum-containing antacid neurotoxicity.44  Antisecretory Agents Antisecretory therapy is not routinely required for patients with uncomplicated Hp ulcers in whom ulcers heal after successful eradication of Hp even without antisecretory therapy; however, antisecretory drugs play an important role in the management of patients with PUD not associated with Hp. The role of antisecre­ tory drugs in the management of gastrinoma (ZES) is discussed in Chapter 34. H2Ras H2RAs are competitive inhibitors of histamine-stimulated acid secretion (see Chapter 51) and markedly suppress basal and meal- stimulated acid secretion.45 When administered in the evening, H2RAs are effective in suppressing nocturnal acid output.46 H2RAs are well absorbed after oral dosing, and their absorption is not affected by food. Peak blood levels are achieved within 1 to 3 hours after an oral dose. H2RAs cross the blood-brain barrier and the placenta.47,48 After oral administration, several H2RAs (cimetidine, ranitidine, and famotidine) undergo first-pass hepatic metabolism, which reduces their bioavailability by 35% to 60%. In contrast, the H2RA nizatidine does not undergo first-pass metabolism, and its bioavailability approaches 100% with oral dosing. H2RAs are eliminated by a combination of renal excre­ tion and hepatic metabolism. Dose reductions are recommended when the creatinine clearance is below 50 mL/min. Dialysis does not remove substantial amounts of H2RAs; thus, dose adjust­ ments are not necessary for dialysis patients. Dose reductions are generally not required for patients with hepatic failure unless it is accompanied by chronic kidney disease. Tolerance to the anti­ secretory effects of H2RAs develops quickly and frequently,49 although the mechanism for tolerance is not clear. H2RAs are safe and well tolerated. One meta-analysis of ran­ domized clinical trials concluded that the overall rate of adverse effects reported for H2RAs did not differ significantly from pla­ cebo treatment.50 Nevertheless, a number of untoward effects have been described, primarily in anecdotal reports and uncon­ trolled series. Cimetidine has weak antiandrogenic activity that can occasionally cause gynecomastia and impotence.51 Both cimetidine and ranitidine bind to the hepatic cytochrome P-450 (CYP) mixed-function oxidase system. This binding can inhibit the elimination of other drugs that are metabolized through the same system, including warfarin, theophylline, phe­ nytoin, lidocaine, and quinidine.52 In contrast, famotidine and nizatidine have no significant avidity for the CYP system.  PPIs. PPIs decrease gastric acid secretion through inhibition of H+, K+-ATPase, the proton pump of the parietal cell (see Chapter 51). These agents are prodrugs that must be activated by acid to inhibit the H+, K+-ATPase. Interestingly, prodrug PPIs are also acid-labile compounds that must be protected from degradation by gastric acid after oral administration by enteric coating or an antacid.53 Absorption of the enteric-coated PPIs may be erratic, and peak serum concentrations are not achieved until 2 to 5 hours after oral administration. Although the plasma half-life of PPIs is short (≈2 hours), the duration of acid inhibition is long as a result of covalent binding of the active metabolite of the prodrug to the H+, K+-ATPase. PPIs undergo significant hepatic metabolism, but dose adjustments are not required in patients with significant renal or hepatic impairment. There is genetic polymorphism in CYP2C19, one of the isoenzymes involved in PPI metabolism. Approximately 25% of Asians and 3% of white persons have deficient CYP2C19 activity.",6854,1020,1713.5,"[ 0.39945734 -0.08229047 -1.8017489  ...  0.15767622  0.10111299
 -1.5602574 ]"
4,"This polymorphism leads to sub­ stantially higher plasma levels of omeprazole, lansoprazole, and pantoprazole, but not rabeprazole.36,37,54 PPIs, as a result of their requirement for concentration and activation in acidic compartments, bind predominantly to those proton pumps that are actively secreting acid. With meal stimu­ lation, 60% to 70% of the proton pumps actively secrete acid; thus, PPIs are most effective if they are administered immediately before meals. For once-daily dosing, it is recommended that PPIs be taken immediately before breakfast.55 Unlike H2RAs, toler­ ance to the antisecretory effects of PPI therapy has not been seen. Downloaded for JongHoon Hyun (whdgnssla@hanmail.net) at Inje University from ClinicalKey.com by Elsevier on May 29, 2024. For personal use only. No other uses without permission. Copyright ©2024. Elsevier Inc. All rights reserved.",882,128,220.5,"[ 0.00141121  0.71950734 -0.88125944 ...  0.7017121   0.18060245
 -1.1799084 ]"
5,"CHAPTER 53  Peptic Ulcer Disease 811 53 PPIs, by raising the gastric pH, can affect the absorption of a number of drugs. However, this pH effect rarely has clinically important effects, except when the PPIs are given with keto­ conazole or digoxin.55-57 Ketoconazole requires gastric acid for absorption, and this antifungal drug may not be absorbed effec­ tively if PPIs have also been prescribed. If a patient requires both a PPI and antifungal therapy, it is recommended that an agent other than ketoconazole be chosen. Conversely, an elevated gastric pH facilitates absorption of digoxin, resulting in higher plasma digoxin levels. For patients treated concomitantly with PPIs and digoxin, clinicians should consider monitoring plasma digoxin levels. Because PPIs are metabolized by the CYP system, they have the potential to alter the metabolism of other drugs that are elim­ inated by CYP enzymes. The potential interaction between PPIs and clopidogrel has drawn widespread attention. Clopidogrel, a nonaspirin antiplatelet prodrug, is activated by hepatic CYP2C19 and other CYPs to its active metabolite. PPIs reduce the anti­ platelet effect of clopidogrel through competitive inhibition of CYP2C19. Meta-analysis of observational studies reported a sig­ nificant increase in major adverse cardiovascular events includ­ ing cardiovascular deaths among patients receiving concomitant PPIs and clopidogrel.58,59 However, an association between PPI and clopidogrel use has not been confirmed by prospective stud­ ies and a large-scale RCT.60,61 Despite the inconsistent findings, regulatory authorities in the USA and Europe have issued warn­ ings against the use of certain PPIs in patients receiving concomi­ tant clopidogrel. There are other concerns about the safety of long-term use of PPIs. To date, PPI use has been implicated in many condi­ tions, including osteoporosis, hypomagnesaemia, gastric cancer, enteric infections, interstitial nephritis, pneumonia, dementia, and NSAID-enteropathy. Currently, there is no definite evidence to suggest that these conditions are attributable to PPI use.62 It is possible that a new evidence will emerge to indicate a causal relationship. In the meantime, long-term use of PPI without a strong indication should be discouraged.  Potassium-Competitive Acid Blocker Potassium-competitive acid blocker (P-CAB) therapy com­ petes with potassium to inhibit H+, K+-ATPase in parietal cells at the final stage of the acid secretory pathway (see Chapter 51).63 Unlike PPIs, a P-CAB is acid stable and does not require an acidic environment for activation (i.e., a pro­ drug is not required). To date, vonoprazan is the only P-CAB commercially available in Japan and some other countries. Vonoprazan exerts a near-maximum inhibitory effect from the first dose and its effect lasts for 24 hours.63 In 2 phase 3 RCTs, vonoprazan (20 mg once daily) was not inferior to lansoprazole (30 mg once daily) for the healing of GUs and DUs. RCTs.64,65 Two other randomized trials showed that vonoprazan (10 and 20 mg) was as effective as lansoprazole (15 mg) in preventing ulcer recurrence associated with long-term use of NSAIDs and low-dose aspirin.66  Mucosal Protective Agents Sucralfate is a complex aluminum salt of sulfated sucrose. When exposed to gastric acid, the sulfate anions can bind electrostatically to positively charged proteins in damaged tissue.67,68 Sucralfate (1g 4 times daily) is equally effective to H2RAs in healing DUs and is approved by the FDA in the USA for this indication. Very little (<5%) of sucralfate is absorbed owing to its poor solubility, and the drug is excreted via the enteral route. Because of its lack of systemic absorption, sucralfate appears to have no systemic toxicity. The effect on the accumulation of aluminum in the body has not been adequately studied in patients with chronic kidney disease treated with sucralfate, and sucralfate is best avoided in this population. Important drug interactions appear to be rare and can be avoided if sucralfate is administered at a time separate from other medications. Colloidal bismuth preparations, such as colloidal bismuth subcitrate and bismuth subsalicylate (e.g., Pepto-Bismol), have modest efficacy in healing peptic ulcers, but the mechanism is unclear.69 The bismuth salts form complexes with mucus that appear to coat ulcer craters. Bismuth-induced increased muco­ sal prostaglandin synthesis and bicarbonate secretion have also been proposed. Bismuth salts have antimicrobial activity against Hp, and bismuth has been approved in the USA by the FDA for use, in combination with other agents, for the treatment of Hp infection (see Chapter 52). Bismuth is largely unabsorbed and excreted in the feces. Colonic bacteria convert bismuth salts to bismuth sulfide, which turns the stools black. Trace amounts of bismuth are absorbed in the UGI tract, with the bismuth then slowly excreted in the urine for 3 months or longer. Short-term, standard-dose therapy with bismuth appears to carry little risk of toxicity; however, there is the potential for bismuth encepha­ lopathy with neuropsychiatric symptoms if the agent is given for extended periods in high dosage, especially in patients with chronic kidney disease. Misoprostol is a prostaglandin E1 analog approved by the FDA for the prevention of NSAID-induced PUD.70 The drug not only enhances mucosal defense mechanisms but also inhibits gastric acid secretion through inhibition of histamine-stimulated cyclic 3',5'-cyclic adenosine monophosphate (AMP) produc­ tion.71 Well absorbed after oral administration, the plasma miso­ prostol concentration peaks after approximately 30 minutes, with a serum half-life of approximately 1.5 hours. The drug has no effect on hepatic CYP450. Misoprostol metabolites are excreted in the urine, but dose reductions are unnecessary in patients with chronic kidney disease. Dose-related diarrhea is the most common adverse effect, occurring in up to 30% of patients and limiting the usefulness of misoprostol. Diarrhea is related to prostaglandin-induced increases in intestinal electrolyte and water secretion and/or acceleration of intestinal transit time. Administration of misoprostol with food may reduce diarrhea. Misoprostol also stimulates uterine smooth muscle and is there­ fore contraindicated in women who may be pregnant.  Hp-associated Ulcers Treatment of Hp infection is discussed in detail in Chapter 51. It is well established that curing Hp infection not only heals pep­ tic ulcers but also prevents ulcer relapses and complications.72-75 Because Hp infection accounts for 80% to 90% of DU cases, test­ ing for the infection in patients with DU is mandatory. If the diagnosis of DU is made endoscopically, gastric biopsy specimens should be taken to detect Hp infection. There is good evidence that a 10- to 14-day course of Hp eradication therapy is suffi­ cient to heal DUs such that additional antisecretory therapy is not usually required. Follow-up endoscopic examination in order to document healing and perform testing to document Hp eradi­ cation following antibiotic therapy is not recommended routinely in patients with uncomplicated DUs. However, noninvasive tests such as the urea breath test can be used to confirm Hp eradi­ cation.",7287,1097,1821.75,"[ 0.5961005   0.08479364 -0.98723745 ...  0.27438873  0.234073
 -1.2921234 ]"
5,"Whether antisecretory therapy is required after a 7- to 14-day course of Hp eradication therapy in patients with GU is somewhat controversial. One week of antibacterial therapy without acid suppression effectively heals Hp-related GUs.72 In a meta-analysis of GU healing trials, treatment with Hp eradi­ cation therapy produced similar outcomes to treatment with an ulcer-healing drug;73 however, in patients with large or compli­ cated GUs, additional antisecretory therapy can facilitate ulcer healing. Follow-up endoscopy is recommended in patients with large or complicated GUs to document healing, exclude malig­ nancy, and confirm successful Hp eradication.  Downloaded for JongHoon Hyun (whdgnssla@hanmail.net) at Inje University from ClinicalKey.com by Elsevier on May 29, 2024. For personal use only. No other uses without permission. Copyright ©2024. Elsevier Inc. All rights reserved.",895,126,223.75,"[-0.05331333 -0.28678566 -1.50166    ...  0.2292696   0.8285022
 -1.8350456 ]"
6,"PART VI  Stomach and Duodenum 812 NSAID Ulcers H2RAs Conventional doses of H2RAs are more effective in healing NSAID-related DUs than GUs. There are limited data on the efficacy of H2RAs in healing peptic ulcers if patients continue to receive NSAIDs. Therefore, H2RAs are not preferred agents in patients with ulcers who require uninterrupted NSAID therapy.  PPIs Current evidence76-78 indicates that PPIs are superior to stan­ dard-dose H2RAs in healing NSAID-induced peptic ulcers. In a randomized comparison of esomeprazole (20 or 40 mg/day) and ranitidine (150 mg twice daily) in ulcer patients who continued to take NSAIDs, ulcer healing at 8 weeks occurred in 85% and 86% of patients given esomeprazole and in 76% of those given raniti­ dine.78 In another study of patients with NSAID-associated GUs who continued to use NSAIDs, ulcer healing at 8 weeks occurred in 69% and 73% of patients given lansoprazole (15 or 30 mg/day) but in only 53% of those given ranitidine (150 mg twice daily).77  Misoprostol In ulcer patients who continued their NSAID, misoprostol healed the ulcers in 67% of patients at 8 weeks, compared with only 26% of patients treated with placebo.79 However, misoprostol is not as effective as PPI therapy in healing NSAID-associated ulcers. One randomized trial compared full-dose misoprostol (200 μg 4 times daily) with omeprazole (20 or 40 mg daily) in DU or GU patients who continued NSAID treatment.80 After 8 weeks, DUs had healed in 89% of patients receiving either dose of omeprazole and in 77% of those receiving misoprostol. Similarly, GUs had healed in 87% of those receiving 20 mg of omeprazole, 80% of those receiving 40 mg of omeprazole, and 73% of those receiv­ ing misoprostol. Although misoprostol is seldom used for treat­ ment or prevention of peptic ulcer nowadays, 2 randomized trials have shown that misoprostol is effective for the healing of small bowel ulcers and erosions in patients with obscure bleeding taking NSAIDs and low-dose aspirin.81,82 Other Causes of Ulcers and Idiopathic Ulcers When the cause of a peptic ulcer can be identified as other than Hp or NSAID use (e.g., gastrinoma), the underlying disorder should be treated (see Chapter 34). The treatment of idiopathic, non-Hp, non-NSAID ulcers relies on acid antisecretory therapy, usually a PPI, which is often given long term (maintenance therapy), much as antisecretory therapy is used long term to prevent NSAID- induced ulcers in moderate- and high-risk patients (see later).  REFRACTORY ULCERS Most peptic ulcers heal within 8 weeks of initiation of antisecre­ tory therapy. Nevertheless, in a small but considerable minor­ ity of patients, the ulcers persist despite conventional treatment. Such ulcers can be considered refractory. There is no standardized definition for refractory peptic ulcer, making comparisons among studies difficult. In some patients with refractory ulcers, symptoms of ulcer disease persist and may be severe. In others, the refrac­ tory ulcer becomes asymptomatic and is only detected at endoscopy (e.g., at the 8-week follow-up endoscopy to assess healing of a GU). For the patient whose ulcer does not heal despite a trial of conventional therapy, the clinician should ask the following ques­ tions:     • Has the patient complied with the prescribed treatment? • Is the ulcer penetrating the pancreas, liver, or other organ? • Is there Hp infection?If antibiotic therapy had already been prescribed, the patient should be tested to confirm that the infection has indeed been eradicated. If no attempt had been made to diagnose and treat Hp infection, it should be made now. False-negative test results for Hp should be considered (see Chapter 52). • Is the patient still taking an NSAID?NSAID use may be sur­ reptitious. A careful history regarding the use of over-the- counter NSAIDs (including low-dose aspirin) should be ob­ tained, and NSAIDs should be stopped if possible. • Does the patient smoke cigarettes?If so, he or she should be counseled strongly to discontinue cigarettes. • Has the duration of ulcer treatment been adequate?Large ul­ cers require a longer duration of therapy than small ulcers to heal. A large ulcer (e.g., >2 cm) probably should not be con­ sidered refractory until it has persisted beyond 12 weeks of antisecretory therapy. • Is there evidence of a hyper-secretory condition?A family his­ tory of gastrinoma or MEN type I or a personal history of chronic diarrhea, hypercalcemia caused by hyperparathyroid­ ism, or ulcers involving the postbulbar duodenum or proximal jejunum suggest a diagnosis of ZES (see Chapter 34). • Finally, is the ulcer indeed peptic?Primary or metastatic neo­ plasms, infections (e.g., cytomegalovirus), cocaine use, eosino­ philic gastroenteritis, and Crohn disease can cause ulcerations of the stomach and duodenum that can mimic peptic ulcers. These disorders should be considered and excluded appropriately.    Treatment options for truly refractory peptic ulcers include a more prolonged course of antisecretory therapy, often at dou­ ble the prior PPI dose. Although uncommon nowadays, elective ulcer surgery may be necessary to attempt to heal a symptomatic refractory or penetrating ulcer. Surgical options are discussed later in this chapter.  PREVENTION OF ULCER DISEASE Most studies of ulcer prophylaxis have used endoscopy endpoints (rather than clinical endpoints) to assess the effectiveness of various regimens. An “endoscopic ulcer” has been arbitrarily defined as a circumscribed mucosal defect having a diameter of 5 mm or more with a perceivable depth.83 However, many studies have loosened this criterion to include flat mucosal breaks with a diameter of 3 mm or more as ulcers. The distinction between small ulcers and erosions is arbitrary and is prone to interobserver bias. The clini­ cal relevance of these minor endoscopic lesions is uncertain. It is assumed that endoscopic findings roughly correlate with clinical outcomes in subjects at low-to-average risk for ulcer complications. It is unclear if results of endoscopic studies can be generalized to high-risk patients. Because there are few prospective outcome tri­ als to evaluate the true clinical efficacy of ulcer prophylactic agents, clinical judgment relies on data largely using endoscopic endpoints.",6310,984,1577.5,"[-0.37282044 -0.22291195 -1.3605821  ...  0.9748032   0.10048844
 -1.063775  ]"
6,"Hp ulcers do not require ulcer prophylaxis if the organism can be eradicated from the stomach (see earlier and Chapter 52). Most use of ulcer prophylaxis regimens is, therefore, related to preven­ tion of NSAID ulcers in patients at moderate-to-high ulcer risk. The risk factors for NSAID-induced ulcers are listed in Table 53.1. Pharmaceutical agents that may reduce the development of NSAID-induced ulcers are discussed later. Ulcer prophylaxis is also frequently used in patients with idiopathic ulcers. Among the agents listed, only the antisecretory agents are commonly used in the prevention of idiopathic ulcers. Antacids Many clinicians prescribe antacids as co-therapy for patients tak­ ing NSAIDs, both to relieve dyspeptic symptoms and to (hope­ fully) prevent ulcers; however, antacids have no proved efficacy Downloaded for JongHoon Hyun (whdgnssla@hanmail.net) at Inje University from ClinicalKey.com by Elsevier on May 29, 2024. For personal use only. No other uses without permission. Copyright ©2024. Elsevier Inc. All rights reserved.",1052,155,263.0,"[ 0.02342206 -0.2027195  -1.3042715  ...  0.19203292  0.29468244
 -1.2794498 ]"
7,"CHAPTER 53  Peptic Ulcer Disease 813 53 in the prevention of NSAID-induced ulcers. Antacids may mask dyspeptic symptoms, thereby creating a false sense of ulcer protection and increasing the risk of silent ulcer complications with prolonged NSAID therapy. Co-prescription of antacids in patients taking NSAIDs who are at risk for ulcer should be dis­ couraged.  H2RAs Using standard doses of H2RAs is not effective in preventing NSAID-induced GUs,84,85 and, as already mentioned, may be harmful. A systematic review85 of randomized trials in NSAID users concluded that using twice the standard daily dose of H2RA significantly reduces the risk of endoscopic NSAID-induced DUs and GUs. However, whether high-dose H2RAs prevent NSAID-induced ulcer complications is unknown. In contrast, H2RAs appear to be more effective for prevention of ulcers asso­ ciated with low-dose aspirin than with NSAIDs. In a 12 month, multi-center randomized trial of low-dose aspirin users at risk for recurrent ulcer bleeding, there was no significant difference in the incidence rates of recurrent bleeding between patients receiv­ ing a PPI and patients receiving an H2RA.89  Misoprostol The efficacy of misoprostol in preventing NSAID-induced ulcers has been assessed in RCTs.86,87 A systematic review of these tri­ als indicated that all doses of misoprostol studied (400 to 800 μg/day) reduce the risk of NSAID-induced endoscopic ulcers.85 However, only full-dose misoprostol (800 μg/day) reduces ulcer complications.86 In a randomized double-blind trial in patients with rheumatoid arthritis who received NSAIDs, misoprostol (200 μg 4 times daily) lowered the rate of GI complications by 40% (from 0.95% in the placebo group to 0.57% in the misoprostol group). However, up to 30% of misoprostol-treated patients in this trial experienced GI upset, thereby limiting its clinical use. Even though endoscopic studies had suggested that lower doses of misoprostol, such as 200 μg 2 or 3 times daily, can prevent NSAID- induced ulcers with fewer adverse effects than the full dose,86 such low doses of misoprostol fail to prevent ulcer complications.88  PPIs PPIs significantly reduce the risk of endoscopic duodenal and GUs.85 The efficacy of PPIs has been compared with that of H2RAs and with misoprostol in patients who received NSAIDs. Two 6-month studies compared omeprazole 20 mg once daily with either standard-dose ranitidine (150 mg twice daily) and half-dose misoprostol (200 μg twice daily).76,80 Omeprazole was more effec­ tive than standard-dose ranitidine and comparable with half-dose misoprostol in preventing endoscopic ulcers. The superiority of omeprazole over ranitidine in preventing NSAID-related ulcer was due to a greater reduction in endoscopic DUs. A posthoc analysis revealed that most of the added protection attributable to omepra­ zole over ranitidine occurred among those with Hp infection. Another endoscopic study compared high-dose misoprostol (200 μg 4 times daily) with 2 doses of lansoprazole (15 and 30 mg daily) for the prevention of ulcers in long-term NSAID users without Hp infection and with a history of GU.88 Misoprostol was more effective than either dose of lansoprazole in preventing GU, but there was no practical advantage of misoprostol over lansoprazole because of the high withdrawal rate in the misoprostol group. In a head-to-head endoscopic ulcer prevention study comparing 2 doses of pantoprazole with 20 mg/day of omeprazole in patients with rheumatoid arthritis receiving NSAIDs, the 6-month prob­ abilities of remaining ulcer free were 91%, 95%, and 93% for pantoprazole 20 mg, pantoprazole 40 mg, and omeprazole 20 mg, respectively.89 Two identical multicenter randomized clinical trials compared esomeprazole (20 or 40 mg) with placebo in the prevention of ulcers in patients taking NSAIDs or COX-2 inhibitors over a 6 month period. Patients in both studies were Hp negative, older than age 60, and had a history of GU or DU. Overall, the rates of ulcers were 17.0%, 5.2%, and 4.6% in the groups receiving placebo, esomeprazole 20 mg, and esomeprazole 40 mg, respectively.90 Whether PPIs can reduce the risk of NSAID-associated peptic ulcer bleeding is largely based on observational studies and 1 ran­ domized trial in high-risk patients. A large-scale, case-control study found that PPI therapy was associated with a significant reduction in risk of UGI bleeding among chronic NSAID users (relative risk, 0.13; 95% CI, 0.09 to 0.19).91 The randomized trial compared long-term (6 months) omeprazole therapy to 1 week of Hp eradi­ cation therapy for the prevention of recurrent ulcer bleeding in Hp-infected patients with a recent history of NSAID-related ulcer bleeding who continued to use naproxen.92 Recurrent ulcer bleed­ ing occurred in 18.8% of patients undergoing eradication therapy compared with only 4.4% of patients receiving omeprazole.  COX-2 Inhibitors (In Place of NSAIDs) COX-2 inhibitors offer the hope of minimizing GI toxicity of NSAIDs while preserving their therapeutic effects.93-97 In a sys­ tematic review of randomized trials, when compared with nonse­ lective NSAIDs the COX-2 inhibitors led to significantly fewer gastroduodenal ulcers (relative risk, 0.26; 95% CI, 0.23 to 0.30) and ulcer complications (relative risk, 0.39; 95% CI, 0.31 to 0.5), as well as fewer withdrawals caused by GI symptoms94; however, the sparing effect of COX-2 inhibitors on ulcer development is negated by concomitant use of low-dose aspirin.59 Current evidence indicates that COX-2 inhibitors are as effec­ tive as a combination of nonselective NSAIDs combined with a PPI in patients at risk for ulcers. In a randomized comparison of the NSAID diclofenac plus omeprazole versus celecoxib for secondary prevention of ulcer bleeding in patients who either were Hp negative or had undergone Hp eradication,95 a similar proportion of patients had recurrent bleeding in 6 months (6.4% in the diclofenac/omeprazole group and 4.9% of patients in the celecoxib group). Although the 2 treatments were comparable in terms of the incidence of ulcer bleeding, a subsequent follow-up endoscopic study showed that 20% to 25% of patients receiv­ ing either treatment developed recurrent endoscopic ulcers at 6 months. These findings suggest that neither treatment can elimi­ nate the risk of recurrent bleeding in very high-risk patients. In a 13-month, double-blind randomized trial comparing celecoxib alone with celecoxib/esomeprazole in patients with a history of NSAID-associated ulcer bleeding, 8.9% of the celecoxib-alone group had recurrent ulcer bleeding compared with none of the combined therapy group (P = 0.0004).96 TABLE 53.1  Risk Factors for NSAID Ulcers* Risk factor Risk ratio History of complicated ulcer 13.5 Use of multiple NSAIDs (including aspirin, COX-2 inhibitors) 9 Use of high doses of NSAIDs 7 Use of an anticoagulant 6.4 History of an uncomplicated ulcer 6.1 Age >70 years 5.6 Hp infection 3.5 Use of a glucocorticoid 2.2     *Not all NSAIDs pose the same risk.    Downloaded for JongHoon Hyun (whdgnssla@hanmail.net) at Inje University from ClinicalKey.com by Elsevier on May 29, 2024. For personal use only. No other uses without permission. Copyright ©2024. Elsevier Inc. All rights reserved.",7259,1106,1814.75,"[-0.11797394 -0.39631176 -1.2134297  ...  0.8158919   0.35306013
 -1.2709522 ]"
8,"PART VI  Stomach and Duodenum 814 Despite the improved gastric safety profile of COX-2 inhibi­ tors, the cardiovascular risk associated with this new class of NSAIDs has been a subject of much concern. In the VIGOR study,97 the incidence of acute myocardial events, although low, was 4 times higher among patients receiving rofecoxib than among patients receiving naproxen. Whether this observed dif­ ference in myocardial infarction rates was related to an anti­ platelet property of naproxen or to a pro-thrombotic effect of rofecoxib was debated. Further data regarding the cardiovascu­ lar hazards of COX-2 inhibitors were derived from 2 long-term studies of colon polyp prevention, using either rofecoxib (the Adenomatous Polyp Prevention on Vioxx [APPROVE] study)98 and celecoxib (the Adenoma Prevention with Celecoxib [APC] study).99 In APPROVE, interim data at 18 months indicated that patients who had received 25 mg rofecoxib a day had twice the risk of serious cardiovascular events compared with patients who received placebo. In 2004, rofecoxib was voluntarily withdrawn from worldwide markets in light of this unexpected finding. In the APC study, interim data at 33 months showed that serious cardiovascular events were significantly more frequent with cele­ coxib at the high dose of 400 mg twice a day (hazard ratio, 1.9; 95% CI, 1 to 3.3). The MEDAL program was a pre-specified pooled analysis of cardiothrombotic events from 3 trials in which patients with osteoarthritis or rheumatoid arthritis were ran­ domly assigned to etoricoxib (60 mg or 90 mg daily) or diclofenac (150 mg daily). After an average treatment of 18 months, rates of cardiothrombotic events were similar between the 2 treatment groups.100 Current evidence suggests that not only COX-2 inhibitors but also nonselective NSAIDs, with the exception of full-dose naproxen (1000 mg/day), increase cardiothrombotic risk. In a meta-analysis of randomized trials of COX-2 inhibitors (data mostly derived from rofecoxib and celecoxib), all COX-2 inhibi­ tors increased the cardiothrombotic risk compared with placebo (risk ratio, 1.42; 95% CI, 1.13 to 1.78). This was largely attribut­ able to an increased risk of myocardial infarction, with little dif­ ference in other vascular outcomes. A dose-dependent increase in cardiothrombotic events was observed with celecoxib. Impor­ tantly, there was no significant difference in cardiothrombotic risk between COX-2 inhibitors and nonselective NSAIDs, with naproxen (500 mg twice daily) the only exception. In a meta-anal­ ysis of observational studies, high-dose rofecoxib (≥25 mg a day), diclofenac, and indomethacin were associated with an increase in cardiothrombotic events, whereas celecoxib did not significantly increase the cardiothrombotic risk, although an increased risk could not be excluded with doses greater than 200 mg/day.101 In a large-scale, randomized, noninferiority trial of celecoxib versus naproxen and ibuprofen in patients with arthritis (mostly osteo­ arthritis) and with increased cardiovascular risk,102 more than 24,000 patients were recruited with a mean treatment duration of 20 months and a mean follow-up period of 34 months. Celecoxib (on average approximately 200 mg/day) was found to be nonin­ ferior to ibuprofen (approximately 2000 mg/day) or naproxen (approximately 850 mg/day) with regard to cardiovascular safety. Patients treated with celecoxib had a significantly lower risk of adverse GI events than with naproxen or ibuprofen. The risk of adverse renal events was also significantly lower with celecoxib than with ibuprofen; however, the proportion of patients con­ tinued on concomitant low-dose aspirin during the study period was unclear and very few patients had a history of GI bleed­ ing. It is, therefore, unclear whether the advantage of celecoxib over naproxen or ibuprofen can be extrapolated to patients on concomitant aspirin with high risk of GI bleeding. In another 18-month randomized trial of patients at high risk of both cardio­ vascular and GI adverse events who required concomitant low- dose aspirin and an NSAID, celecoxib plus a PPI was found to be superior to naproxen plus a PPI in reducing the risk of recurrent ulcer bleeding.103, 108  Assessing Risk and Choice of Agent(s) Safe prescription of NSAIDs should be based on assessment of an individual patient’s GI and cardiovascular risks. In patients with low cardiovascular risk, the therapeutic approach can be stratified according to their levels of GI risk as follows (Table 53.2):     • Low ulcer risk: no risk factors. Patients without risk factors (see Table 53.1) are at very low risk of ulcer complications with NSAID use (≈1% per year). Rational use of NSAIDs, including avoidance of high doses of NSAIDs and use of a less ulcerogenic NSAID (e.g., ibuprofen, diclofenac) at the lowest effective dose is a cost-effective approach. • Moderate ulcer risk: 1 or 2 risk factors. These patients should receive combination therapy with an antiulcer agent (a PPI or misoprostol) and an NSAID. Alternatively, substitution with celecoxib alone is as effective as the combination therapy men­ tioned earlier.    High ulcer risk: 3 or more risk factors, history of ulcer compli­ cations, or concomitant use of low-dose aspirin, glucocorticoids, or anticoagulant therapy. In general, NSAIDs should be avoided in these patients, not only because of the high risk of ulcer com­ plications but also owing to the serious consequences of ulcer complications in the presence of comorbidities. Glucocorticoid therapy (without NSAID) can be considered if short-term anti- inflammatory therapy is required for acute, self-limiting arthritis (e.g., gout), because glucocorticoids alone do not increase the risk of ulcer. If regular anti-inflammatory therapy is required for chronic arthritis, the combination of celecoxib and a PPI offers the best GI protection. Defining patients with high cardiovascular risk remains arbi­ trary. The American Heart Association recommends that aspirin should be considered in all apparently healthy men and women whose 10-year risk for a cardiovascular event is 10% or above.104 We consider patients with arthritis to have significant cardiovas­ cular risk if they are already on aspirin for secondary prophylaxis or if they require aspirin for primary prophylaxis according to TABLE 53.2  Recommendations for Reducing the Risk of NSAID Ulcers as a Function of GI and Cardiovascular Risk GI Risk* Low Moderate High Low CV risk NSAID at the lowest effective dose NSAID plus a PPI, or celecoxib alone Celecoxib plus a PPI High CV risk† Naproxen or celecoxib, plus a PPI Naproxen or celecoxib, plus a PPI Celecoxib plus a PPI if simple analgesics failed     *Low GI risk denotes no risk factors (see Table 53.1); moderate GI risk denotes 1 or 2 risk factors; high GI risk denotes ≥3 risk factors, prior complicated ulcer, or concomitant use of low-dose aspirin or anticoagulants. All patients with a history of ulcer who require NSAIDs should be tested for Hp, and if infection is present, eradication therapy should be given (see Chapter 52).†High CV risk denotes the requirement for prophylactic low-dose aspirin for primary or secondary prevention of serious CV events. CV, cardiovascular.    Downloaded for JongHoon Hyun (whdgnssla@hanmail.net) at Inje University from ClinicalKey.com by Elsevier on May 29, 2024. For personal use only. No other uses without permission. Copyright ©2024. Elsevier Inc. All rights reserved.",7497,1149,1874.25,"[ 0.3309911  -0.3770804  -1.5550101  ...  0.08717869  0.5644036
 -1.4132904 ]"
9,"CHAPTER 53  Peptic Ulcer Disease 815 53 the American Heart Association guidelines. Because the potential cardiovascular hazards of COX-2 inhibitors and most nonselec­ tive NSAIDs, patients with high cardiovascular risk should avoid using these drugs, if possible. Ibuprofen can attenuate the cardio­ protective effect of aspirin, possibly through competitive bind­ ing to platelet COX-1, and concomitant use of ibuprofen and low-dose aspirin, therefore, should be avoided. If an NSAID is deemed necessary in patients at high cardiovascular risk, current evidence suggests that either celecoxib at moderate dose (200 mg/ day) or naproxen can be considered. One major drawback of con­ comitant use of NSAIDs such as naproxen and low-dose aspirin is that the combination will markedly increase the risk of ulcer complications; thus, combination of celecoxib and low-dose aspi­ rin may be the best available option for patients with high GI and high cardiovascular risk who require NSAIDs for long term. Because Hp infection increases the risk of ulcer complications in NSAID users, patients with a history of PUD who require NSAIDs for long term should be tested for Hp and, if present, the infection should be eradicated.  COMPLICATIONS AND THEIR TREATMENT Bleeding Acute UGI bleeding, the most common complication of PUD, is discussed in detail in Chapter 20. PUD remains the leading cause of acute UGI bleeding.105 Consensus groups have recommended a multidisciplinary approach to the care of patients presenting with UGI bleeding.106 Patients with acute UGI bleeding should be assessed promptly on presentation. Volume resuscitation should take priority and precede endoscopy. Features of liver disease should call attention to the possibility of bleeding from esophago- gastric varices rather than an ulcer. This distinction has prognostic as well as management implications. Variceal hemorrhage carries a higher death rate than ulcer bleeding. The possibility of variceal hemorrhage calls for specific measures prior to endoscopy, such as the use of vasoactive drugs (e.g., octreotide) and antibiotics (e.g., cefotaxime) as prophylaxis against infective complications such as spontaneous bacterial peritonitis (see Chapters 92 and 93). Endoscopic Therapy Early endoscopy is generally defined as EGD performed within 24 hours of the patient’s admission. In patients with signs of active UGI bleeding, urgent endoscopy establishes a diagnosis and offers a possible intervention. RCTs demonstrated that early endoscopy in patients at low risk for rebleeding allowed early hospital discharge, reduced resource utilization, and facilitated management as outpatients.107-109 Meta-analysis of 18 clinical tri­ als that compared endoscopic therapy to pharmacotherapy alone showed that endoscopic therapy was superior with regard to the rates of further bleeding (odds ratio [OR] 0.35; 95% CI, 0.27 to 0.46), surgery (OR 0.57; 95% CI, 0.41 to 0.81), and, importantly, mortality (OR 0.57; 95% CI, 0.37 to 0.89).110 An International Consensus group104 recommended the use of a prognostic score to guide patient management. The Rock­ all scoring system is a composite score using pre- and posten­ doscopy clinical parameters to predict mortality. The score was derived from data gathered from the first National UK Audit.109 The Glasgow Blatchford score (GBS), on the other hand, uses only clinical parameters to predict the need for intervention and is calculated from patient’s Hgb level and blood urea concentra­ tion, pulse and systolic blood pressure on admission, the presence or absence of melena or syncope, as well as evidence of cardiac or hepatic failure.110 The GBS has been the most widely validated score and correlates with clinical outcomes. In a multicentre prospective study111 of 3012 patients, the GBS score was the best of the 4 at predicting the need for intervention or death with an area under the receiver operat­ ing curve (AUROC) of 0.86. A GBS score of 1 appears to be the threshold for outpatient management. The GBS score, however, does not define a cutoff value above which urgent endoscopy becomes mandatory. A significant proportion of patients at low- to-median scores require endoscopic treatment. At the time of EGD, endoscopic stigmata of bleeding in a ulcer not only pinpoint PUD as the source of bleeding but are themselves prognostic for patient outcomes (see Chapter 20). The commonly used nomenclature is a version modified from Forrest and Finlayson’s112 original description. Laine and Jen­ sen113 summarized rates of further bleeding, surgery, and mor­ tality associated with stigmata of bleeding in prospective trials without endoscopic therapy.    • Type I: Active bleeding: Ia: Spurting hemorrhage (Fig.53.4) Ib: Oozing hemorrhage (see Fig.53.4) • Type II: Stigmata of recent hemorrhage: IIa: Nonbleeding visible vessel (see Fig.53.4) IIb: Adherent clot (see Fig.53.4) IIc: Flat pigmentation (see Fig.53.4) • Type III: Clean-base ulcers     Actively bleeding ulcers and ulcers with nonbleeding visible vessels (“protuberant discoloration” or a “sentinel clot”) warrant endoscopic therapy (see Chapter 20). Endoscopic therapy of ulcers with “adherent clots” had been controversial. The definition of adherent clot varies with the vigor in endoscopic washing. Two randomized controlled stud­ ies114,115 and a meta-analysis116 compared medical therapy to endoscopic treatment in ulcer patients with “adherent clots” and concluded that clot removal followed by endoscopic treatment of the vessel underneath lowers the risk of recurrent bleeding from 30% to 5%. The term sentinel clot, is often used synonymously with visible vessel.117 It represents a fibrin clot, which plugs the rent in an eroded artery. As the ulcer begins to heal, the clot resolves leav­ ing a flat pigmentation to the ulcer base, which eventually disap­ pears from the ulcer floor. This evolution of a bleeding vessel usually takes less than 72 hours. Ulcers with a flat pigmentation or a clean base do not warrant endoscopic therapy. Recently, a group from UCLA reported their experience with the use of an endoscopic Doppler probe to interrogate the ulcer base. In a prospective cohort of 163 patients with bleeding ulcers and varying endoscopic stigmata or recent hemorrhage, Doppler signals were found in ulcers with minor stigmata (adherent clots, 68.4%, and flat pigmentations, 40.5%).118 In a subsequent RCT of 148 patients with bleed­ ing peptic ulcers, Jensen and associates119 compared Doppler endoscopic probe–guided hemostasis to standard endoscopic hemostasis. The 30 day re-bleeding rate was lower with the use of a Doppler probe to guide the treatment endpoint (11.1% vs. 26.3%, P =.02). Endoscopic therapeutic modalities are discussed in more detail in Chapter 20, and the methods used are discussed briefly here.  Injection Methods Endoscopic injection of diluted epinephrine into a bleeding pep­ tic ulcer works by volume tamponade and local vasoconstriction.",6988,1056,1747.0,"[ 0.2279804  -0.4860682  -1.4833646  ...  0.12761213  0.4614604
 -1.2900932 ]"
9,"The technique is easy to learn and is not damaging to tissues. Diluted epinephrine, however, does not induce vessel thrombo­ sis. Recurrent bleeding after injection with diluted epinephrine alone occurs in 20% to 30% of patients. Injection with diluted epinephrine allows a clear view of the bleeding vessel and should then be combined with application of either thermal-coagulation or clips. In a meta-analysis,120 addition of a second modality after epinephrine injection significantly reduced the rate of recurrent Downloaded for JongHoon Hyun (whdgnssla@hanmail.net) at Inje University from ClinicalKey.com by Elsevier on May 29, 2024. For personal use only. No other uses without permission. Copyright ©2024. Elsevier Inc. All rights reserved.",748,109,187.0,"[-0.52192837 -0.00876397 -0.9385408  ...  0.31588337  0.36620843
 -0.94600207]"
10,"PART VI  Stomach and Duodenum 816 bleeding (RR 0.57, 0.43 to 0.76), emergency surgery (RR 0.68, 0.5 to 0.93), and mortality (RR 0.64, 0.39 to 1.06). Improved outcomes seem to be more evident in ulcers with active bleeding (Forrest type I ulcers). Injection with diluted epinephrine alone should no longer be considered an adequate treatment. A second treatment to induce arterial thrombosis should be added.  Thermal Methods Thermal methods include contact and noncontact methods. Contact thermal methods are more often used. Commonly used contact thermal probes are the heater probe and bipolar probes. The term coaptive thermal-coagulation emphasizes the need for firm mechanical compression of the vessel. Cessation of blood flow by compression reduces the “heat-sink” effect when heat energy is generated, welding the arterial lumen. The main noncontact method is argon plasma coagulation (see Chapter 20).  Mechanical Methods The mechanical method of hemoclipping is widely used. Tangential applications of clips in treating bleeding posterior duodenal bulbar or lesser curvature ulcers with the endoscope in a retroflexed position can be technically difficult. In meta-analy­ ses comparing endoscopic treatment modalities, hemoclips was superior to injection alone in rate of hemostasis and comparable to thermal coagulation.108,121 Recently, a multicenter RCT compared the use of over-the- scope-clips (OTSC) to standard through-the-scope clips and thermal methods in 66 patients with refractory bleeding ulcers.122 The use of OTSC was associated with a reduced rate of further bleeding (15.2% vs. 57.6%). OTSC are made of shape memory nitinol of up to 13 mm in diameter capable of strong tissue com­ pression over a wider area. The current standard is the use of either through-the-scope hemo-clips or thermal-coagulation with or without pre-injection of epinephrine. OTSC appears to be a useful rescue when other modalities fail.  Antisecretory Therapy The rationale for antisecretory therapy in bleeding PUD is based on the fact that both pepsin activity and platelet aggregation are pH dependent. An ulcer stops bleeding when a fibrin or plate­ let plug blocks the rent in a bleeding artery. When gastric pH exceeds 4, pepsin is inactivated, preventing enzymatic digestion of blood clots. A gastric pH of 6 or greater is critical for clot stability and hemostasis. Labenz and associates123 studied gastric pH in patients with GU or DU who were receiving either a high dose of omeprazole (IV bolus 80 mg, followed by 8 mg/hr) or a high dose of ranitidine (IV bolus 50 mg, followed by 0.25 mg/kg/hr). The gastric pH exceeded 6 with omeprazole 99.9% of the time, but less than 50% of the time in patients receiving ranitidine (46% of the time in GU patients and 20% of the time in DU patients). The PUB study was an international multicenter study that enrolled 764 patients with ulcer bleeding. It evaluated use of high-dose esomeprazole after endoscopic hemostasis in bleeding peptic ulcers. The PPI reduced the rate of recurrent bleeding over 30 days from 11.6% to 6.4%. In addition, fewer patients given the PPI needed further endoscopic therapy, blood transfusion, and surgery.124 A Cochrane Systematic Review of randomized trials that compared PPI use to placebo or a H2RA concluded that the use of PPI therapy significantly reduces rates of recurrent bleeding and surgery but not overall mortality.125 In a subgroup analysis among patients with active bleeding or with a nonbleeding visible vessel, a significant reduction in mortality was observed with use of PPI (OR 0.53; 95% CI, 0.31 to 0.91). Spurting (Ia) A visible vessel IIa Flat pigmentation IIc Oozing (Ib) An adherent clot (IIb) Clean base (III) Fig.53.4  Endoscopic appearances of bleeding peptic ulcers using the Forrest classification.139 Downloaded for JongHoon Hyun (whdgnssla@hanmail.net) at Inje University from ClinicalKey.com by Elsevier on May 29, 2024. For personal use only. No other uses without permission. Copyright ©2024. Elsevier Inc. All rights reserved.",4048,626,1012.0,"[-0.23633678 -0.18881506 -1.2032876  ...  0.8848426   0.27665406
 -1.3563215 ]"
11,"CHAPTER 53  Peptic Ulcer Disease 817 53 The optimal PPI dose to use and the routine of PPI admin­ istration continue to be controversial. A meta-analysis of RCTs that compared low- to high-dose PPI use after endoscopic hemo­ stasis consisted of trials that included bleeding ulcers with minor stigmata of bleeding and clean-based ulcers.126 The majority of studies were underpowered to declare equivalence between low- and high-dose PPI. An international consensus group has contin­ ued to endorse the use of a high-dose PPI, especially in high-risk patients.104 Pre-emptive use of an IV PPI infusion prior to endoscopy was studied in a large-scale randomized study.127 Patients with overt signs of UGI bleeding were randomized to receive either a high- dose PPI infusion or placebo. Most (60%) of the patients in this cohort were found at EGD to be bleeding from a peptic ulcer. The study demonstrated that early PPI infusion down-staged endoscopic bleeding stigmata in patients with peptic ulcers and thereby reduced the need for endoscopic therapy; thus, there were fewer ulcers with active bleeding or with major stigmata of recent hemorrhage observed during the following morning’s EGD in the PPI group. PPI infusion starts ulcer healing, and significantly more clean-based ulcers are seen the next day. The study has cost-saving implications, with less endoscopic therapy required with the preemptive use of an IV PPI. In patients await­ ing endoscopy, it is reasonable to start PPI therapy.  Surgical Therapy Effective endoscopic intervention and improved pharmacother­ apy have greatly reduced the need for emergency ulcer surgery. In the USA, the incidence of surgery to control ulcer bleeding has continued to decline (from 13.1% in 1993 to 9.7% in 2006), while there was an increase in the use of endoscopic treatment (12.9% to 22.2%).128 In an UK National Audit in 2006, only 2.3% of 4478 patients who presented with UGI bleeding required sur­ gery. Mortality after surgery was 29%.129 Surgery is indicated in patients with bleeding not controlled during endoscopy or with further bleeding refractory to endoscopic therapy. Independent predictors to recurrent bleeding after endoscopic hemostatic ther­ apy include hemodynamic instability, comorbid illnesses, active bleeding at endoscopy, large ulcer size, posterior DU, or lesser curvature ulcer.130 Often, an attempt at further endoscopic control is indicated. A RCT that compared endoscopic re-treatment to surgery suggested that the former can secure bleeding in 75% of cases and is associated with less procedure-related morbidities.131 The type of emergency operation to be performed for ulcer bleeding is controversial. Some surgeons maintain that oversew­ ing of ulcers alone, combined with acid-suppression therapy, is safer than “definitive” surgery using either gastrectomy or vagot­ omy. Hp eradication and PPIs have provided incentives for sur­ geons to perform the minimum operation. Two RCTs that compared minimal with definitive surgery were published before the era of endoscopic hemostasis and PPI infusion.132,133 A UK multicenter study compared minimal sur­ gery (oversewing the vessel or ulcer excision alone plus IV H2RA therapy) with a definitive ulcer operation (vagotomy and pylo­ roplasty or partial gastrectomy) in patients with bleeding GUs or DUs. The trial was aborted because of the high rate of fatal recurrent bleeding in those assigned to minimal surgery (7 in 62 patients, with 6 deaths). Of the 67 patients who received defini­ tive ulcer surgery, 4 re-bled and none died.132 In a trial conducted by the French Association of Surgical Research, patients with DU were randomized to receive oversewing plus vagotomy and drainage or partial gastrectomy.133 After oversewing and vagot­ omy, recurrent bleeding occurred in 10 of 60 patients (17%); conversion to a Billroth II gastrectomy was required in 6 of the 10 patients with recurrent bleeding. In the group of 60 patients assigned to undergo partial gastrectomy, only 2 (3%) had re- bleeding, and both recovered with conservative treatment. With an intention-to-treat analysis, no differences in overall mortality rates or duodenal leak rates were seen. These 2 RCTs suggest that simple oversewing with or without vagotomy is associated with a higher rate of recurrent bleeding. Exclusion of an ulcer or, in the case of GUs, ulcer excision is important in preventing recurrent bleeding. In a review of data from the American Col­ lege Surgeons National Surgical Quality Improvement Program, 30 day mortality was higher in patients who underwent a simple oversewing or ulcer excision (106/498, 21.3%) when compared to that after vagotomy with resection or drainage (39/283, 13.8%). There was obvious bias in this retrospective analysis.134  Angiographic Therapy Angiographic embolization of bleeding arteries is a nonoperative alternative to surgery in patients with bleeding peptic ulcer. In a pooled analysis of 6 retrospective studies comparing angiography and surgery, a higher re-bleeding rate was observed after angio­ graphic treatment (51/178, or 29% vs. 36/241, or 15%; RR 1.82; 95% CI, 1.20 to 2.67).135 Mortality was not significantly different (17% vs. 23%). When radiology skills are available, angiography is often attempted before surgery. A recent RCT that compared added embolization to standard treatment after endoscopic hemo­ stasis did not confirm a mortality benefit of prophylactic emboliza­ tion.136 In a per protocol analysis, rate of further bleeding was lower after added embolization (6/96, or 6.2% vs. 14/123, or 11.4%). In a subgroup analysis of ulcers of 15 mm or more in size, embolization reduced bleeding from 23.1% to 4.5%. The authors suggested that for larger ulcers with significant bleeding, angiographic emboliza­ tion should be considered after endoscopic hemostasis.  Perforation Perforation of a GU or DU (Fig.53.5) is a surgical emergency that may be the initial manifestation of PUD, especially in patients using NSAIDs. Ulcer perforation is associated with a mortality approaching 30%. Older adults with significant comor­ bid illnesses and a delay in performing surgery have the worst prognosis. The clinical presentation is one of peritonitis but clinical signs can be obscured in older and immunocompromised patients (see Chapter 39). Medical Therapy It has been suggested that a standardized peri-operative man­ agement protocol can improve outcomes. In a Danish multi­ center study (n = 2619),137 the PULP trial group showed that with aggressive and specific treatment of sepsis and, importantly, Fig.53.5  Laparoscopic view of a perforated DU (arrow) with fibrinous exudate on the adjacent peritoneum. Downloaded for JongHoon Hyun (whdgnssla@hanmail.net) at Inje University from ClinicalKey.com by Elsevier on May 29, 2024. For personal use only. No other uses without permission. Copyright ©2024. Elsevier Inc. All rights reserved.",6933,1052,1733.25,"[-0.17764375 -0.5583774  -1.3509634  ...  0.86498743  0.50938046
 -1.179778  ]"
12,"PART VI  Stomach and Duodenum 818 surgery within 6 hours, mortality was 17% in 117 hospitals with strict management protocols and was 27% in 512 hospitals without protocols. Other measures include goal-directed fluid therapy, general respiratory and circulatory support, intravenous broad-spectrum antibiotics, and insertion of a double-barreled NG tube, and a urinary catheter. An intravenous PPI is given routinely after surgery. Nonoperative management of ulcer perforation should sel­ dom be practiced. It involves NG suctioning, parenteral antibi­ otics, and IV fluids. In a RCT, Crofts and associates138 assigned patients with the presumptive diagnosis of perforated peptic ulcers to either conservative treatment or prompt surgery. Over­ all morbidity and mortality rates (5%) were low and similar in the medical and surgical groups. Of the 40 patients assigned to con­ servative treatment, 11 showed no improvement within 12 hours and underwent operation. Three of these 11 patients were found to have perforated carcinomas (2 gastric and 1 sigmoid colon). Findings of the study highlight common objections to the use of non-operative management: uncertainty of the site of perforation, the possibility of a perforated GI tumor, and atrophic momentum making spontaneous sealing unlikely. Older adults tolerate sepsis poorly. Any delay in definitive treatment leads to poor outcomes.  Surgical Therapy Perforated gastroduodenal ulcer carries a high mortality rate. In a review of surgery for perforated ulcers between 2011 and 2013 in Denmark, the 90-day mortality was 25.5% among 726 patients. Re-operation was required in 124 patients (17.1%), approxi­ mately one third of them caused by persistent leaks.139 Boey and associates140 identified preoperative shock, major medical illnesses, and perforation longer than 12 hours as impor­ tant adverse prognostic factors. The PULP score was recently developed from a cohort of 2668 patients who received surgery in 11 hospitals across Denmark. Variables included were age greater than 65 years, active malignant disease or acquired immunodefi­ ciency, cirrhosis, glucocorticoid use, perforation more than 24 hours, shock, raised serum creatinine level, and American Soci­ ety of Anesthesiologists (ASA) score greater than 1. The PULP score was accurate in predicting mortality from ulcer perforation (AUROC of 0.83).141 The score, however, has not been validated in centers outside Denmark. The controversies in the operative management of perfo­ rated peptic ulcers have revolved around the choice between laparoscopic and open repair and the need for a definitive ulcer operation after closure of the perforation (and which definitive operation to perform). Treatment also differs for duodenal and gastric perforations. Simple closure of a perforated duodenal or a juxta-pyloric ulcer with the use of an omental patch is widely practiced. Meta-analyses of 3 RCTs (2 from Hong Kong and the Dutch LAMA Study) that compared laparoscopic to open surgical treat­ ment of perforated peptic ulcers tends to favor laparoscopic repair with respect to rates of abdominal septic complications (OR 0.66; 95% CI, 0.3 to 1.47), and pulmonary complications (OR 0.43; 95% CI, 0.17 to 1.12)142; thus, laparoscopic repair should, at the least, be considered not inferior to open repair. There may, how­ ever, have been selection bias in these RCTs. Poor risk patients (those with delayed presentations, shock, and with significant comorbidities) may be better suited for a laparotomy. Large per­ forations (>10 mm) suggest sizable ulcerations and should also be managed by laparotomy; often, gastric resections are required in such patients. GU accounts for approximately 20% of perforated peptic ulcers. Epidemiologic data suggest a rising proportion of GUs among perforated ulcers, especially in older adult patients who use NSAIDs. Patients with perforated GUs are more likely to be older and to have significant comorbid illnesses, making their prognosis less favorable. As with perforated DUs, there has been a debate regarding the choice of surgery for perforated GUs. Simple closure should be offered to small perforations at the prepyloric area. The optimal treatment of an angular notch GU along the lesser curvature should entail an antrectomy and lesser curve ulcer excision, followed by either a Billroth type I or II reconstruction. The role of vagotomy is unclear. The advocates for primary resection in perforated GUs argue that mortality rates after gastrectomy are not increased and that the rate of post­ operative ulcer-related complications is reduced. The arguments for primary resection also include the possibility that the ulcer is malignant. Malignancy is seen in approximately 6% of perforated GUs.143 In a retrospective series comprising 287 perforated GUs, death occurred in 21.5% of patients who underwent patch closure alone and in 24.3% of those who underwent gastric resections.144 In Hp-associated ulcers, Hp eradication reduces the relapse of ulceration after patch repair. In a RCT from Hong Kong, 99 patients after patch repairs for perforated ulcers, were assigned to Hp eradication or a course of PPI. At 1 year, there were fewer relapses in those given Hp eradication (4.8% vs. 38.1%).145 A meta-analysis of 5 RCTs that compared simple closure plus Hp eradication to closure alone in patients with perforated DU showed that the pooled incidence of ulcer relapse in the year after Hp eradication was 5.2% compared to 35.2% in those without eradication. These data support the use of simple closure in the majority of perforated DUs.146  Obstruction Gastric outlet obstruction is now an infrequent complication of PUD. Its clinical manifestations—nausea and postprandial vom­ iting, abdominal fullness, pain, and early satiety—are discussed in Chapters 15 and 50, as is the diagnostic approach to patients presenting with possible gastric outlet obstruction. Gastric out­ let obstruction should alert clinicians to possible malignancy (see Chapter 54). Medical Therapy Patients with obstructing peptic ulcers are often volume depleted. The loss of fluid, hydrogen ions, and chloride ions in the vomitus leads to hypochloremic, hypokalemic metabolic alkalosis. The patient should be volume resuscitated with normal saline fol­ lowed by potassium replacement once urine output is adequate.",6363,955,1590.75,"[-0.24637626 -0.64443105 -1.1547043  ...  0.5661352   0.15609871
 -1.0430678 ]"
12,"In severely malnourished patients, parenteral nutrition should be considered. Decompression of the stomach by a large-bore NG tube relieves vomiting, helps to monitor fluid loss, and allows the stomach to regain its tone. A high-volume, non–bile-stained aspi­ rate can help distinguish gastric outlet obstruction from a high small bowel obstruction. Use of an IV PPI reduces gastric acid output, making fluid and electrolyte management easier. PPI therapy also initiates ulcer healing, ameliorates inflammatory edema, and assists in resolving obstruction. Approximately half of patients respond to this management. Improvement is especially noticeable in patients with active ulceration and edema. Surgery is, therefore, deferred until after an adequate trial of conserva­ tive management. Other factors that may influence the decision to proceed to surgery are chronicity, a history of previous ulcer complication, and the patient’s age and general medical condi­ tion. Furthermore, many authorities argue for initial endoscopic dilation before surgery.  Endoscopic Therapy Endoscopic balloon dilation has been used successfully in patients with gastric outlet obstruction from PUD (Fig.53.6).147-149 During endoscopic examination, the stenosis is traversed by means of a biliary-type guidewire with a flexible tip. A low-compliance Downloaded for JongHoon Hyun (whdgnssla@hanmail.net) at Inje University from ClinicalKey.com by Elsevier on May 29, 2024. For personal use only. No other uses without permission. Copyright ©2024. Elsevier Inc. All rights reserved.",1564,218,391.0,"[-0.09754433 -0.42299047 -1.3898239  ...  0.21400753 -0.02554546
 -0.85724497]"
13,"CHAPTER 53  Peptic Ulcer Disease 819 53 through-the-scope balloon is then passed over the guidewire, and dilation can be seen through the endoscope. The use of a balloon is preferred because its inflation produces a uniform radial force, which has a theoretical advantage over the longitudinal shearing force associated with the use of conventional dilators. The pro­ cedure is typically performed with fluoroscopic guidance. A regi­ men of gradual dilation over 2 or 3 sessions seems sensible. The targeted diameter is unclear; many authorities recommend dila­ tion to 15 mm, which is often associated with relief of symptoms. The presence of gastric atony also contributes to symptoms. The risk of perforation increases with the size of balloon. Endoscopic series reported immediate relief of obstruction in 78% to 100% of cases. In a small series of Hp-infected patients, balloon dilation followed by Hp eradication led to sustained symptom relief.150  Surgical Therapy A variety of operations have been described for obstructing DUs, pyloric channel ulcers, and pre-pyloric ulcers. They include vagotomy with either a drainage procedure (gastrojejunostomy or pyloroplasty) or an antrectomy. In the unusual event of an obstructing prepyloric GU, an antrectomy followed by a Billroth type I gastroduodenostomy is the procedure of choice.  STRESS ULCERS Stress-related gastric and duodenal mucosal injury (stress ulcers) is an illness of the critically ill who are typically cared for in an ICU. The etiology of stress ulceration is probably related to mucosal ischemia and splanchnic hypo-perfusion from shock or low cardiac output. Fortunately, only a small proportion of patients with stress-related mucosal lesions have clinically overt GI bleeding. In a cohort study151 of 2252 ICU patients, only 1.5% developed clinically important bleeding. Respiratory failure (OR 15.6) and coagulopathy (OR 4.3) were independent predictive factors for bleeding stress ulcers. In 2015, a prospective study152 of 1034 patients admitted to ICUs was published; clinically important GI bleeding occurred in 2.6% of patients. Those with 3 or more comorbid illnesses, liver disease, receiving renal replacement therapy, and with a high organ failure score were at risk. Patients in the ICU with traumatic brain injuries and burns also belong to a high- risk group of developing GI bleeding. Across different studies, there appears to be different candidate predictors for bleeding. The use of enteral nutrients buffers acid and protects against bleeding. PPI, H2RA and sucralfate are drugs used for stress ulcer prophylaxis. In a network meta-analysis of 57 RCTs (n = 7293), Alhazzani and associates153 showed that PPIs were more effec­ tive for preventing clinically important bleeding than H2RA (OR 0.38), sucralfate (OR 0.30), or placebo (OR 0.24). PPIs, how­ ever, increased the risk of nosocomial pneumonia compared with H2RA (OR 1.27), sucralfate (OR 1.65), and placebo (OR 1.52). There is concern that acid suppression predisposes patients to nosocomial infection probably linked to gut dysbiosis.154 A Euro­ pean multicenter study randomized 3298 ICU patients to receive 40 mg of intravenous PPI or placebo and found that deaths by 90 days were similar between groups (31.1% vs. 30.4%). The rate of composite adverse events (gastrointestinal bleeding, Clostrid­ ium difficile infection, pneumonia, or myocardial ischemia) were comparable (21.9 vs. 22.6%). There were fewer clinically impor­ tant bleeding events in the PPI group (2.5 vs. 4.2%).155 Full references for this chapter can be found onwww.expertconsult.com. Fig.53.6  A through-the-scope dila­ tion of an obstructed pylorus caused by an ulcer. The procedure was per­ formed under fluoroscopic guidance. A dual-channel endoscope with a 3.7 mm therapeutic channel was used. A, The stricture was first traversed with a biliary-type guidewire (arrow­ head). A through-the-scope balloon was passed over the guidewire across the stricture. B, A waist, representing the stricture (arrow), was observed and was nearly abolished on balloon inflation (C). A B C Downloaded for JongHoon Hyun (whdgnssla@hanmail.net) at Inje University from ClinicalKey.com by Elsevier on May 29, 2024. For personal use only. No other uses without permission. Copyright ©2024. Elsevier Inc. All rights reserved.",4338,651,1084.5,"[-0.25738746 -0.44916603 -1.0763762  ...  0.32195812 -0.10665585
 -1.1446699 ]"
14,"819.e1 REFERENCES 	 1.	 Black J, Duncan W, Durant D. Definition and antagonism of hista­ mine H2 receptors. Nature 1972;236:365–90.	 2.	 Marshall B, Warren J. Unidentified curved bacilli in the stomachs of patients with gastritis and peptic ulcer. Lancet 1984;1:1311–5.	 3.	 Sonnenberg A. Causes underlying the birth-cohort phenomenon of peptic ulcer: analysis of mortality data 1911-2000, England and Wales. Int J Epidemiol 2006;35:1090–7.	 4.	 Sung JJ, Kuipers EJ, El-Serag HB. Systematic review: the global incidence and prevalence of peptic ulcer disease. Aliment Pharmacol Ther 2009;29:938–46.	 5.	 Li Z, Zou D, Ma X, et al. Epidemiology of peptic ulcer disease: endoscopic results of the systematic investigation of gastrointestinal disease in China. Am J Gastroenterol 2010;105:2570–7.	 6.	 Lau JY, Sung J, Hill C, et al. Systematic review of the epidemiology of complicated peptic ulcer disease: incidence, recurrence, risk fac­ tors and mortality. Digestion 2011;84:102–13.	 7.	 Laine L, Yang H, Chang SC, et al. Trends for incidence of hospital­ ization and death due to GI complications in the United States from 2001-2009. Am J Gastroenterol 2012;107:1190–5.	 8.	 Wu CY, Wu CH, Wu MS, et al. A nationwide population-based cohort study shows reduced hospitalization for peptic ulcer disease associated with H. pylori eradication and proton pump inhibitor use. Clin Gastroenterol Hepatol 2009;7:427–31.	 9.	 Wang AY, Peura DA. The prevalence and incidence of Helicobacter pylori-associated peptic ulcer disease and upper gastrointestinal bleeding throughout the world. Gastrointest Endosc Clin N Am 2011;21:613–35.	 10.	 Feinstein LB, Holman RC, Yorita Christensen KL, et al. Trends in hospitalizations for peptic ulcer disease, United States, 1998-2005. Emerg Infect Dis 2010;16:1410–8.	 11.	 Sanchez-Delgado J, Gene E, Suarez D, et al. Has H pylori prevalence in bleeding peptic ulcer been underestimated?A meta-regression. Am J Gastroenterol 2011;106:398–405.	 12.",1988,279,497.0,"[ 0.3052448  -0.25389653 -1.1358585  ...  0.45771527 -0.13648205
 -1.4947072 ]"
14,"Olbe L, Hamlet A, Dalenback J, et al. A mechanism by which Helico­ bacter pylori infection of the antrum contributes to the development of duodenal ulcer. Gastroenterology 1996;110:1386–94.	 13.	 El-Omar EM. Mechanisms of increased acid secretion after eradica­ tion of Helicobacter pylori infection. Gut 2006;55:144–6.	 14.	 Garcia Rodriguez LA, Hernandez-Diaz S. Relative risk of upper gas­ trointestinal complications among users of acetaminophen and non­ steroidal anti-inflammatory drugs. Epidemiology 2001;12:570–6.	 15.	 Wilcox C, Allison J, Benzuly K, et al. Consensus development con­ ference on the use of nonsteroidal anti-inflammatory agents, includ­ ing cyclooxygenase-2 enzyme inhibitors and aspirin. Clin Gastroen­ terol Hepatol 2006;4:1082–9.	 16.	 Sørensen HT, Mellemkjaer L, Blot WJ, et al. Risk of upper gas­ trointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol 2000;95:2218–24.	 17.	 Lanas A, Perez-Aisa MA, Feu F, et al. A nationwide study of mortal­ ity associated with hospital admission due to severe gastrointesti­ nal events and those associated with nonsteroidal antiinflammatory drug use. Am J Gastroenterol 2005;100:1685–93.	 18.	 Bjarnason I, Scarpignato C, Holmgren E, et al. Mechanisms of dam­ age to the gastrointestinal tract from nonsteroidal anti-inflammato­ ry drugs. Gastroenterology 2018;154:500–14.	 19.	 Fiorucci S, Distrutti E, Santucci L. NSAIDs, Coxinbs CINOD and H2S-releasing NSAIDs: what lies beyond the horizon?Dig Liver Dis 2007;39:1043–51.	 20.	 Green Jr FW, Kaplan MM, Curtis LE, et al. Effect of acid and pep­ sin on blood coagulation and platelet aggregation. A possible con­ tributor prolonged gastroduodenal mucosal hemorrhage. Gastroen­ terology 1978;74:38–43.	 21.	 Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002;359:14–22.	 22.	 Vergara M, Catalan M, Gisbert JP, Calvet X. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 2005;21:1411–8.	 23.	 Chan FK, Sung JY, Chung SC, et al.",2174,294,543.5,"[-0.00658126 -0.15906554 -1.4311373  ...  0.39508364  0.6312235
 -1.9869918 ]"
14,"Randomised trial of eradication of Helicobacter pylori before starting non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 1997;350:975–9.	 24.	 Chan FK, To KF, Wu JC, et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet 2002;359:9–13.	 25.	 Leontiadis GI, Sreedharan A, Dorward S, et al. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. Health Technol Assess 2007;11:1–164.	 26.	 Chan FK, Chung SC, Suen BY, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infec­ tion who are taking low-dose aspirin or naproxen. N Engl J Med 2001;344:967–73.	 27.	 Hawkey CJ, Tulassay Z, Szczepanski L, et  al. Randomised con­ trolled trial of Helicobacter pylori eradication in patients on non- steroidal anti-inflammatory drugs. HELP NSAIDs study. Lancet 1998;352:1016–21.	 28.	 Chan FK, Ching JY, Suen BY, et al. Effects of Helicobacter pylori infection on long-term risk of peptic ulcer bleeding in low-dose as­ pirin users. Gastroenterology 2013;144:528–35.	 29.	 Pecha RE, Prindiville T, Pecha BS, et al. Association of cocaine and methamphetamine use with giant gastroduodenal ulcers. Am J Gas­ troenterol 1996;91:2523–7.	 30.	 Lanza FL, Hunt RH, Thomson AB, et al. Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendro­ nate in postmenopausal women. Gastroenterology 2000;119:631–8.	 31.	 Conn H, Blitzer B. Nonassociation of adrenocorticosteroid therapy and peptic ulcer. N Engl J Med 1976;294:473–9.	 32.	 Piper J, Ray W, Daugherty J, Griffin M. Corticosteroid use and peptic ulcer disease: role of non-steroidal anti-inflammatory drugs. Ann Intern Med 1991;114:735–40.	 33.	 Gibril F, Schumann M, Pace A, Jensen RT. Multiple endocrine neo­ plasia type I and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature. Medicine (Baltimore) 2004;83:43–83.	 34.	 Jensen RT.",2159,294,539.75,"[-0.16753505 -0.10726458 -1.3041359  ...  0.31878987  0.6771917
 -1.746015  ]"
14,"Gastrointestinal abnormalities and involvement in systemic mastocytosis. Hematol Oncol Clin North Am 2000;14: 579–623.	 35.	 Wong GL, Wong VW, Chan Y, et al. High incidence of mortality and recurrent bleeding in patients with Helicobacter pylori-negative idiopathic bleeding ulcers. Gastroenterology 2009;137:525–31.	 36.	 Li XQ, Andersson TB, Ahlstrom M, Weidolf L. Comparison of in­ hibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on hu­ man cytochrome P450 activities. Drug Metab Dispos 2004;32:821–7.	 37.	 Klotz U, Schwab M, Treiber G. CYP2C19 polymorphism and pro­ ton pump inhibitors. Basic Clin Pharmacol Toxicol 2004;95:2–8.	 38.	 Majumdar SR, Soumerai SB, Farraye FA, et al. Chronic acid-related disorders are common and underinvestigated. Am J Gastroenterol 2003;98:2409–14.	 39.	 Gisbert JP, Calvet X. Helicobacter pylori “test-and-treat” strategy for management of dyspepsia: a comprehensive review. Clin Transl Gastroenterol 2013;4:e32.	 40.	 Ford AC, Qume M, Moayyedi P, et al. Helicobacter pylori test and treat or endoscopy for managing dyspepsia: an individual patient data meta-analysis. Gastroenterology 2005;128:1838–44.	 41.	 Moayyedi PM, Lacy BE, Andrews CN, et  al. ACG and CAG clinical guideline: management of dyspepsia. Am J Gastroenterol 2017;112:988–1013.	 42.	 Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence consensus re­ port. European Helicobacter and Microbiota study group and con­ sensus panel. Gut 2017;66:6–30.	 43.	 Canga 3rd C, Vakil N. Upper GI malignancy, uncomplicated dys­ pepsia, and the age threshold for early endoscopy. Am J Gastroen­ terol 2002;97:600–3.	 44.	 Feldman M, Burton ME. Histamine2-receptor antagonists: standard therapy for acid-peptic diseases. N Engl J Med 1990;323:1672–80.	 45.	 Patel N, Ward U, Rogers MJ, Primrose JN. Night-time or morning dosing with H2-receptor antagonists: studies on acid inhibition in normal subjects. Aliment Pharmacol Ther 1992;6:381–7.",2084,276,521.0,"[ 0.19456457 -0.30108336 -1.0698161  ...  0.6331299   0.01732071
 -1.7806753 ]"
14,"46.	 Michaletz-Onody PA. Peptic ulcer disease in pregnancy. Gastroen­ terol Clin North Am 1992;21:817–26.	 47.	 Cantu TG, Korek JS. Central nervous system reactions to hista­ mine2-receptor blockers. Ann Intern Med 1991;114:1027–34.	 48.	 Wilder-Smith CH, Ernst T, Genonni M, et al. Tolerance to oral H2-receptor antagonists. Dig Dis Sci 1990;8:976–83. Downloaded for JongHoon Hyun (whdgnssla@hanmail.net) at Inje University from ClinicalKey.com by Elsevier on May 29, 2024. For personal use only. No other uses without permission. Copyright ©2024. Elsevier Inc. All rights reserved.",586,80,146.5,"[-0.25825846 -0.25658774 -1.4969014  ...  0.18888037 -0.5084822
 -0.9577792 ]"
15,"References 819.e2 	 49.	 Richter JM, Colditz GA, Huse DM, et al. Cimetidine and adverse reactions: a meta-analysis of randomized clinical trials of short-term therapy. Am J Med 1989;87:278–84.	 50.	 Garcia Rodriguez LA, Jick H. Risk of gynaecomastia associated with cimetidine, omeprazole, and other anti-ulcer drugs. BMJ 1994;308:503–6.	 51.	 Hansten PD. Drug interactions with anti-secretory agents. Aliment Pharmacol Ther 1991;5:121–8.	 52.	 Robinson M, Horn J. Clinical pharmacology of proton pump in­ hibitors: what the practising physician needs to know. Drugs 2003;63:2739–54.	 53.	 Zhang L, Mei Q, Li QS, et al. The effect of cytochrome P2C19 and interleukin-1 polymorphisms on H. pylori eradication rate of 1-week triple therapy with omeprazole or rabeprazole, amoxycillin and clarithromycin in Chinese people. J Clin Pharm Ther 2010;35: 713–22.	 54.	 Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology 2000;118:S9–31.	 55.	 Vakil N. Prescribing proton pump inhibitors: is it time to pause and rethink?Drugs 2012;72:437–45.	 56.	 Lew EA. Pharmacokinetic concerns in the selection of anti-ulcer therapy. Aliment Pharmacol Ther 1999;13:11–6.	 57.	 Kwok CS, Loke YK. Meta-analysis: the effects of proton pump in­ hibitors on cardiovascular events and mortality in patients receiving clopidogrel. Aliment Pharmacol Ther 2010;31:810–23.	 58.	 Focks JJ, Brouwer MA, van Oijen MG, et al. Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome—a systematic review. Heart 2013;99:520–7.	 59.	 Bhatt DL, Cryer BL, Contant CF, et  al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010;363:1909–17.	 60.	 O’Donoghue ML, Braunwald E, Antman EM, et al. Pharmacody­ namic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials.",2028,280,507.0,"[ 0.37184554 -0.25612855 -1.508075   ...  0.81277007  0.0192823
 -1.6795858 ]"
15,"Lancet 2009;374:989–97.	 61.	 Targownik L. Discontinuing long-term PPI therapy: WHY, with whom, and how?Am J Gastroenterol 2018;113:519–28.	 62.	 Hori Y, Imanishi A, Matsukawa J, et  al.1-[5-(2-Fluorophenyl)- 1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-compet­ itive acid blocker for the treatment of acid-related diseases. J Phar­ macol Exp Ther 2010;335:231–8.	 63.	 Sakurai Y, Mori Y, Okamoto H, et al. Acid-inhibitory effects of vo­ noprazan 20 mg compared with esomeprazole 20 mg or rabepra­ zole 10 mg in healthy adult male subjects—a randomised open-label cross-over study. Aliment Pharmacol Ther 2015;42:719–30.	 64.	 Miwa H, Uedo N, Watari J, et al. Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers—results from two phase 3, non-inferiority ran­ domised controlled trials. Aliment Pharmacol Ther 2017;45:240–52.	 65.	 Kawai T, Oda K, Funao N, et al. Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study. Gut 2018;67:1033–41.	 66.	 Mizokami Y, Oda K, Funao N, et al. Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lanso­ prazole-controlled non-inferiority and single-blind extension study. Gut 2018;67:1042–51.	 67.	 McCarthy DM. Sucralfate. N Engl J Med 1991;325:1017–25.	 68.	 Wagstaff AJ, Benfield P, Monk JP. Colloidal bismuth subcitrate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease. Drugs 1988;36:132–57.	 69.	 Walt RP. Misoprostol for the treatment of peptic ulcer and antiin­ flammatory-drug-induced gastroduodenal ulceration. N Engl J Med 1992;327:1575–80.	 70.	 Chen MC, Amirian DA, Toomey M, et al. Prostanoid inhibition of canine parietal cells: mediation by the inhibitory guanosine tri­ phosphate-binding protein of adenylate cyclase. Gastroenterology 1988;94:1121–9.	 71.	 Sung JJ, Chung SC, Ling TK, et  al.",2024,264,506.0,"[-0.15554537  0.1880368  -1.4869184  ...  0.42134678 -0.15716194
 -1.489856  ]"
15,"Antibacterial treatment of gastric ulcers associated with Helicobacter pylori. N Engl J Med 1995;332:139–42.	 72.	 Ford AC, Delaney BC, Forman D, et al. Eradication therapy in He­ licobacter pylori positive peptic ulcer disease: systematic review and economic analysis. Am J Gastroenterol 2004;99:1833–55.	 73.	 Malfertheiner P, Kirchner T, Kist M, et al. Helicobacter pylori eradi­ cation and gastric ulcer healing—comparison of three pantoprazole- based triple therapies. BYK Advanced Gastric Ulcer Study Group. Aliment Pharmacol Ther 2003;17:1125–35.	 74.	 Higuchi K, Fujiwara Y, Tominaga K, et al. Is eradication sufficient to heal gastric ulcers in patients infected with Helicobacter pylori? A randomized, controlled, prospective study. Aliment Pharmacol Ther 2003;17:111–7.	 75.	 Yeomans ND, Tulassay Z, Juhasz L, et al. A comparison of omepra­ zole with ranitidine for ulcers associated with non-steroidal an­ tiinflammatory drugs. Acid Suppression Trial: ranitidine versus Omeprazole for NSAID-Associated Ulcer Treatment (ASTRO­ NAUT) study group. N Engl J Med 1998;338:719–26.	 76.	 Agrawal NM, Campbell DR, Safdi MA, et al. Superiority of lanso­ prazole versus ranitidine in healing nonsteroidal antiinflammatory drug-associated gastric ulcers: results of a double-blind, random­ ized, multicenter study. NSAID-Associated Gastric Ulcer Study Group. Arch Intern Med 2000;160:1455–61.	 77.	 Goldstein JL, Johanson JF, Hawkey CJ, et al. Clinical trial: healing of NSAID-associated gastric ulcers in patients continuing NSAID therapy—a randomized study comparing ranitidine with esomepra­ zole. Aliment Pharmacol Ther 2007;26:1101–11.	 78.	 Roth S, Agrawal N, Mahowald M, et al. Misoprostol heals gastrodu­ odenal injury in patients with rheumatoid arthritis receiving aspirin. Arch Intern Med 1989;149:775–9.	 79.	 Hawkey CJ, Karrasch JA, Szezepanski L, et al. Omeprazole com­ pared with misoprostol for ulcers associated with non-steroidal an­ tiinflammatory drugs: omeprazole versus Misoprostol for NSAID- Induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998;338:727–34.	 80.	 Kyaw MH, Otani K, Ching JYL, et al. Misoprostol heals small bow­ el ulcers in aspirin users with small bowel bleeding. Gastroenterol­ ogy 2018;S0016–5085(18)34698–5.	 81.",2278,300,569.5,"[-0.00866168 -0.16655855 -1.2986348  ...  0.92829293  0.20926951
 -1.6280841 ]"
15,"Taha AS, McCloskey C, McSkimming P, McConnachie A. Miso­ prostol for small bowel ulcers in patients with obscure bleeding taking aspirin and non-steroidal anti-inflammatory drugs (MAS­ TERS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol 2018;3:469–76.	 82.	 Lancaster-Smith MJ, Jaderberg ME, Jackson DA. Ranitidine in the treatment of nonsteroidal anti-inflammatory drug associated gastric and duodenal ulcers. Gut 1991;32:252–5.	 83.	 Singh G, Triadafilopoulus G. Epidemiology of NSAID-induced GI complications. J Rheumatol 1999;26:18–24.	 84.	 Rostom A, Wells G, Tugwell P, et al. Prevention of NSAID-in­ duced gastroduodenal ulcers (Cochrane review). Cochrane Data­ base Syst Rev 2000;4:CD002296.	 85.	 Chan FK, Kyaw M, Tanigawa T, et al. Similar efficacy of proton- pump inhibitors vs H2-receptor antagonists in reducing risk of up­ per gastrointestinal bleeding or ulcers in high-risk users of low-dose aspirin. Gastroenterology 2017;152:105–10.	 86.	 Chan FK, Sung JJ, Ching JY, et al. Randomized trial of low-dose misoprostol and naproxen vs. nabumetone to prevent recurrent upper gastrointestinal haemorrhage in users of non-steroidal anti- inflammatory drugs. Aliment Pharmacol Ther 2001;15:19–24.	 87.	 Graham DY, Agrawal NM, Campbell DR, et al. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med 2002;62:169–75.	 88.	 Regula J, Butruk E, Dekkers CP, et al. Prevention of NSAID-as­ sociated gastrointestinal lesions: a comparison study pantoprazole versus omeprazole. Am J Gastroenterol 2006;101:1747–55.	 89.	 Lanas A, Garcia-Rodriguez LA, Arroyo MT, et al. Effect of antise­ cretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol 2007;102:507–15.	 90.	 Chan FK, To KF, Wu JC, et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long term treatment with non-steroidal anti-inflammatory drugs: a randomized trial. Lancet 2002;359:9–13.	 91.	 Chan FK, Hung LC, Suen BY, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002;347:2104–10.	 92.	 Rostom A, Muir K, Dube C, et al.",2450,327,612.5,"[-0.1758287  -0.06907541 -1.3585384  ...  0.5073494   0.43169737
 -1.3747842 ]"
15,"Gastrointestinal safety of cyclo­ oxygenase-2 inhibitors: a Cochrane collaboration systematic review. Clin Gastroenterol Hepatol 2007;5:818–28. Downloaded for JongHoon Hyun (whdgnssla@hanmail.net) at Inje University from ClinicalKey.com by Elsevier on May 29, 2024. For personal use only. No other uses without permission. Copyright ©2024. Elsevier Inc. All rights reserved.",374,47,93.5,"[ 0.48550814 -0.24660823 -1.6223269  ...  0.30561712  0.9201054
 -1.2110412 ]"
16,"References 819.e3 53 	 93.	 Chan FK, Hung LC, Suen BY, et al. Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a random­ ized double-blind trial. Gastroenterology 2004;127:1038–43.	 94.	 Chan FK, Wong VW, Suen BY, et al. Combination of a cyclo-ox­ ygenase-2 inhibitor and a proton pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind randomized trial. Lancet 2007;369:1621–6.	 95.	 Bombardier C, Laine L, Reicin A, et  al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR study group. N Engl J Med 2000;343:1520–8.	 96.	 Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events as­ sociated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092–102.	 97.	 1SD, McMurray JJV, Pfeffer MA, et al. For the Adenoma Preven­ tion with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071–80.	 98.	 Cannon CP, Curtis SP, FitzGerald GA, et al. Cardiovascular out­ comes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Di­ clofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006;368:1771–81.	 99.	 McGettigan P, Henry D. Cardiovascular risk and inhibition of cy­ clooxygenase: a systematic review of the observational studies of se­ lective and nonselective inhibitors of cyclooxygenase 2. J Am Med Assoc 2006;296:1633–44.	100.	 Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med 2016;375(26):2519–29.	101.	 Chan FKL, Ching JYL, Tse YK, et al. Gastrointestinal safety of ce­ lecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial. Lancet 2017;389:2375–82.	102.	 Pearson TA, Blair SN, Daniels SR, et al. AHA scientific statement: AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 Update, 71-0226. Circulation 2002;106:388–91.	103.	 Hearnshaw SA, Logan RF, Lowe D, et al.",2340,316,585.0,"[ 0.30737692 -0.28337488 -1.6722374  ...  0.25615653  0.9622795
 -1.7173713 ]"
16,"Acute upper gastroin­ testinal bleeding in the UK: patient characteristics, diagnoses and outcomes in the 2007 UK audit. Gut 2011;60:1327–35.	104.	 Barkun A, Bardou M, Kuipers EJ, et  al. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 2010;152:101–13.	105.	 Lin HJ, Wang K, Perng CL, et al. Early or delayed endoscopy for patients with peptic ulcer bleeding: a prospective randomized con­ trolled trial. J Clin Gastroenterol 1996;22:267–71.	106.	 Lee JG, Turnipseed S, Romano PS, et al. Endoscopy-based triage significantly reduces hospitalization rates and costs of treating up­ per GI bleeding: a randomized controlled trial. Gastrointest Endosc 1999;50:755–61.	107.	 Cipolletta L, Bianco MA, Rotondano G, et al. Outpatient manage­ ment for low-risk nonvariceal upper GI bleeding: a randomized controlled trial. Gastrointest Endosc 2002;55:1–5.	108.	 Barkun A, Martel M, Toubouti Y, Rahme E, Bardou M. Endoscopic hemostasis in peptic ulcer bleeding for patients with high-risk le­ sions: a series of meta-analyses. Gastrointest Endosc 2009;69:786– 99.	109.	 Rockall TA, Logan RF, Devlin HB, Northfield TC. Risk assessment after acute upper gastrointestinal haemorrhage. Gut 1996;38:316– 21.	110.	 Blatchford O, Murray WR, Blatchford M. A risk score to predict need for treatment for upper gastrointestinal haemorrhage. Lancet 2000;356:1318–21.	111.	 Stanley AJ, Laine L, Dalton HR, Ngu JH, Schultz M, Abazi R, et al. Comparison of risk scoring systems for patients presenting with up­ per gastrointestinal bleeding: international multicentre prospective study. BMJ 2017;356:6432.	112.	 Forrest JA, Finlayson ND, Shearman DJ. Endoscopy in gastrointes­ tinal bleeding. Lancet 1974;2:394–7.	113.	 Laine L, Jensen DM. Management of patients with ulcer bleeding. Am J Gastroenterol 2012;107:345–60.	114.	 Jensen DM, Kovacs TO, Jutabha R, et al. Randomized trial of medi­ cal or endoscopic therapy to prevent recurrent ulcer hemorrhage in patients with adherent clots.",2063,275,515.75,"[ 0.10817619 -0.63756025 -1.4185543  ...  0.2565629   0.7257484
 -1.2880871 ]"
16,"Gastroenterology 2002;123:407–13. 115.	115.	 Bleau BL, Gostout CJ, Shearman KE, et  al. Recurrent bleeding from peptic ulcer associated with adherent clot: a randomized study comparing endoscopic treatment with medical therapy. Gastrointest Endosc 2002;56:1–6.	116.	 Kahi CJ, Jensen DM, Sung JJ, et al. Endoscopic therapy versus med­ ical therapy for bleeding peptic ulcer with adherent clot: a meta- analysis. Gastroenterology 2005;129:855–62.	117.	 Johnston JH. The sentinel clot and invisible vessel: pathologic anat­ omy of bleeding peptic ulcer. Gastrointest Endosc 1984;30:313–5.	118.	 Jensen DM, Ohning GV, Kovacs TOG, et al. Doppler endoscopic probe as a guide to risk stratification an definitive hemostasis of pep­ tic ulcer bleeding. Gastrontest Endosc 2016;83:129–36.	119.	 Jensen DM, Kovacs TOG, Ohning GV, et al. Doppler endoscopic probe monitoring of blood flow improves risk stratification and outcomes of patients with severe nonvariceal upper gastrointestinal hemorrhage. Gastroenterology 2017;152:1310–8.	120.	 Vergara M, Bennett C, Calvet X, Gisbert JP. Epinephrine injec­ tion versus epinephrine injection and a second endoscopic meth­ od in high risk bleeding ulcers. Cochrane Database Syst Rev 2014;(10):CD005584.	121.	 Sung JJ, Tsoi KK, Lai LH, et al. Endoscopic clipping versus injec­ tion and thermocoagulation in the treatment of non-variceal upper gastrointestinal bleeding: a meta-analysis. Gut 2007;56:1364–73.	122.	 Schmidt A, Golder S, Goetz M, et  al. Over-the-scope clips are more effective than standard endoscopic therapy for patients with recurrent bleeding of peptic ulcers. Gastroenterology 2018;05:037. [Epub ahead of print].	123.	 Labenz J, Peitz U, Leusing C, et al. Efficacy of primed infusions with high-dose ranitidine and omeprazole to maintain high intra­ gastric pH in patients with peptic ulcer bleeding: a prospective ran­ domised controlled study. Gut 1997;40:36–41.	124.	 Sung JJY, Barkum A, Kuipers EJ, et al. Intravenous esomeprazole for prevention of recurrent peptic ulcer bleeding. Ann Int Med 2009;150:455–64.",2077,274,519.25,"[-0.1580078  -0.7218436  -1.3276869  ...  0.5617221  -0.01427777
 -1.4903753 ]"
16,"125.	 Leontiadis GI, Sharma VK, Howden CW. Proton pump inhibitor treatment for acute peptic ulcer bleeding. Cochrane Database Syst Rev 2006;25:CD902094.	126.	 Neumann I, Letelier LM, Rada G, et al. Comparison of different regimens of proton pump inhibitors for acute peptic ulcer bleeding. Cochrane Database Syst Rev 2013;60:CD007999.	127.	 Lau JY, Leung WK, Wu JC, et  al. Omeprazole before endos­ copy in patients with gastrointestinal bleeding. N Engl J Med 2007;356:1631–40.	128.	 Wang YR, Richter JE, Dempsey DT. Trends and outcomes of hos­ pitalizations for peptic ulcer disease in the united states, 1993 to 2006. Ann Surg 2010;251:51–8.	129.	 Jairath V, Kahan BC, Logan RF, et al. National audit of the use of surgery and radiological embolization after failed endoscopic he­ mostasis for non-variceal upper gastrointestinal bleeding. Br J Surg 2012;99:1672–80.	130.	 Elmunzer BJ, Young SD, Inadomi JM, et  al. Systematic review of the predictors of recurrent hemorrhage after endoscopic he­ mostatic therapy for bleeding peptic ulcer. Am J Gastroenterol 2008;103:2625–32.	131.	 Lau JY, Sung JJY, Lam YH, et al. Endoscopic re-treatment com­ pared with surgery in patients with recurrent bleeding after initial endoscopic control of bleeding ulcers. N Engl J Med 1999;340:751– 6.	132.	 Poxon VA, Keighley MRB, Dykes PW, et al. Comparison of mini­ mal and conventional surgery in patients with bleeding ulcer: A mul­ ticentre trial. Br J Surg 1991;78:1344–5.	133.	 Millat B, Hay JM, Valleur P, et al. Emergency surgical treatment for bleeding duodenal ulcer: oversewing plus vagotomy versus gas­ tric resection, a controlled randomized trial french associations for surgical research. World J Surg 1993;17:568–74.	134.	 Schroder VT, Pappas T, Vaslef S, et al. Vagotomy/Drainage is su­ perior to local oversew in patients who require emergency surgery for bleeding peptic ulcers. Ann Surg 2014;259:1111–8. Downloaded for JongHoon Hyun (whdgnssla@hanmail.net) at Inje University from ClinicalKey.com by Elsevier on May 29, 2024. For personal use only. No other uses without permission.",2099,298,524.75,"[-0.16962911 -0.4100084  -1.4640605  ...  0.64449525  0.5098343
 -1.7899991 ]"
17,"References 819.e4 	135.	 Kyaw M, Tse Y, Ang D, et al. Embolization versus surgery for pep­ tic ulcer bleeding after failed endoscopic hemostasis: a meta-analy­ sis. Endosc Int Open 2014;02:6–14.	136.	 Lau JY, Pittayanon R, Wong KT, Pinjaroen N, Chiu PWY, Rerknimitr R, et al. Prophylactic angiographic embolisation after endoscopic control of bleeding to high-risk peptic ulcers: a random­ ized controlled trial. Gut 2018;0:1–8.	137.	 Moller MH, Adamsen S, Thomsen RW, Moller AM. Peptic Ulcer Perforation (PULP) trial group Multicentre trial of a perioperative protocol to reduce mortality in patients with peptic ulcer perfora­ tions. Br J Surg 2011;98:802–10.	138.	 Crofts TJ, Park KGM, Steele RJC, et  al. A randomized trial of nonoperative treatment for perforated peptic ulcer. N Engl J Med 1989;320:970–3.	139.	 Wilhelmsen M, Moller MH, Rosenstock S. Surgical complications after open and laparoscopic surgery for perforated peptic ulcer in a nationwide cohort. Br J Surg 2015;102:382–7.	140.	 Boey J, Choi SKY, Alagaratnam TT, Poon A. Risk stratification in perforated duodenal ulcers: a prospective validation of predictive factors. Ann Surg 1987;205:22.	141.	 Moller MH, Engebjerg MC, Adamsen S, et  al. The Peptic Ul­ cer Perforation (PULP) score: a predictor of mortality following peptic ulcer perforation a cohort study. Acta Anaesthesiol Scand 2012;56:655–62.	142.	 Sanabria A, Villegas MI, Morales Uribe CH. Laparoscopic repair for perforated peptic ulcer disease. Cochrane Database Syst Rev 2013;28:CD004778.	143.	 McGee GS, Sawyers JL. Perforated gastric ulcers: a plea for man­ agement by primary gastric resection. Arch Surg 1987;122:555–61.	144.	 Lanng C, Hansen CP, Christensen A, et al. Perforated gastric ulcer. Br J Surg 1988;75:758–9.	145.	 Ng EK, Lam YH, Sung JJ, Yung MY, et al. Eradication of Heli­ cobacter pylori prevents recurrence of ulcer after simple closure of duodenal ulcer perforation randomized controlled trial. Ann Surg 2000;231:153–8.	146.",1992,279,498.0,"[-0.1728201  -0.8763816  -1.4778659  ...  0.38679382  0.39445162
 -1.6366571 ]"
17,"Tomtitchong P, Siribumrungwong B, Vilaichone RK, et  al. Sys­ temic review and meta-analysis: helicobacter pylori eradication ther­ apy after simple closure of perforated duodenal ulcer. Helicobacter 2012;17:148–52.	147.	 Lau JY, Chung SC, Sung JY, et al. Through-the-scope balloon di­ lation for pyloric stenosis: long term results. Gastrointest Endosc 1996;43:98–101.	148.	 Griffin SM, Chung SC, Leung JW, Li AK. Peptic pyloric stenosis treated by endoscopic balloon dilatation. Br J Surg 1989;76:1147–8.	149.	 Craig PI, Gillespie PE. Through the endoscope balloon dilatation of benign gastric outlet obstruction. BMJ 1988;297:396.	150.	 Lam YH, Lau JY, Fung TM, et al. Endoscopic balloon dilation for benign gastric outlet obstruction with or without Helicobacter pylori infection. Gastrointest Endosc 2004;60:229–33.	151.	 Cook DJ, Fuller HD, Guyatt GH, et al. Risk factors for gastrointes­ tinal bleeding in critically ill patients. Canadian Critical Care Trials Group. N Engl J Med 1994;330:377–81.	152.	 Krag M, Perner A, Wetterslev J, et al. Prevalence and outcome of gastrointestinal bleeding and use of acid suppressants in acutely ill adult intensive care patients. Intensive Care Med 2015;41:833–45.	153.	 Alhazzani W, Alshamsi F, Belley-Cote E, et al. Efficacy and safety of stress ulcer prophylaxis in critically ill patients: a network meta- analysis of randomized trials. Intensive Care Med 2018;44:1–11.	154.	 Cook D, Guyatt G. Prophylaxis against upper gastrointestinal bleeding in hospitalized patients. N Engl J Med 2018;378:2506–16.	155.	 Krag M, Marker S, Perner A, Wetterslev J, Wise MP,Schefold JC et al. Pantoprazole in patients at risk for gastrointestinal bleeding in the ICU. N Engl J Med 2018;379:2199–208. Downloaded for JongHoon Hyun (whdgnssla@hanmail.net) at Inje University from ClinicalKey.com by Elsevier on May 29, 2024. For personal use only. No other uses without permission. Copyright ©2024.",1941,265,485.25,"[ 0.01349081 -0.32096124 -1.129514   ...  0.4920979   0.1258219
 -1.4987115 ]"
18,"Harrison's Principles of Internal Medicine, 21e Chapter 324: Peptic Ulcer Disease and Related Disorders John Del Valle PEPTIC ULCER DISEASE A peptic ulcer is defined as disruption of the mucosal integrity of the stomach and/or duodenum leading to a local defect or excavation due to active inflammation. Although burning epigastric pain exacerbated by fasting and improved with meals is a symptom complex associated with peptic ulcer disease (PUD), it is now clear that >90% patients with this symptom complex (dyspepsia) do not have ulcers and that the majority of patients with peptic ulcers may be asymptomatic. Ulcers occur within the stomach and/or duodenum and are often chronic in nature. Acid peptic disorders are very common in the United States, with 4 million individuals (new cases and recurrences) affected per year. Lifetime overall prevalence of PUD in the United States is ~8.4% with a slightly higher prevalence in men. PUD significantly affects quality of life by impairing overall patient well­being and contributing substantially to work absenteeism. Moreover, an estimated 15,000 deaths per year occur as a consequence of complicated PUD. The financial impact of these common disorders has been substantial, with an estimated burden on direct and indirect health care costs of ~$6 billion per year in the United States, with $3 billion spent on hospitalizations, $2 billion on physician office visits, and $1 billion in decreased productivity and days lost from work. GASTRIC PHYSIOLOGY Gastric Anatomy The gastric epithelial lining consists of rugae that contain microscopic gastric pits, each branching into four or five gastric glands made up of highly specialized epithelial cells. The makeup of gastric glands varies with their anatomic location. Glands within the gastric cardia comprise <5% of the gastric gland area and contain mucous and endocrine cells. The 75% of gastric glands are found within the oxyntic mucosa and contain mucous neck, parietal, chief, endocrine, enterochromaffin, and enterochromaffin­like (ECL) cells (Fig. 324­1). Highly specialized tuft cells are located in the neck region of the gastric gland. These specialized cells are thought to sample luminal contents, which in turn may be important in regulating gastric acid secretion. Pyloric glands contain mucous and endocrine cells (including gastrin cells) and are found in the antrum. FIGURE 324­1 Diagrammatic representation of the oxyntic gastric gland. (Reproduced with permission from S Ito, RJ Winchester: The Fine Structure of the Gastric Mucosa in the Bat. J Cell Biol 16:541, 1963.)Yonsei University Medical Library Access Provided by: Downloaded 2024­5­29 3:6 A  Your IP is 116.89.178.138 Chapter 324: Peptic Ulcer Disease and Related Disorders, John Del Valle ©2024 McGraw Hill. All Rights Reserved.   Terms of Use • Privacy Policy • Notice • Accessibility Page 1 / 49",2885,33,721.25,"[ 0.01448537 -0.2960583  -0.77803516 ...  0.10838205 -0.48721248
 -1.29233   ]"
19,"FIGURE 324­1 Diagrammatic representation of the oxyntic gastric gland. (Reproduced with permission from S Ito, RJ Winchester: The Fine Structure of the Gastric Mucosa in the Bat. J Cell Biol 16:541, 1963.)The parietal cell, also known as the oxyntic cell, is usually found in the neck or isthmus or in the oxyntic gland. The resting, or unstimulated, parietal cell has prominent cytoplasmic tubulovesicles and intracellular canaliculi containing short microvilli along its apical surface (Fig. 324­2). H+,K+­ adenosine triphosphatase (ATPase) is expressed in the tubulovesicle membrane; upon cell stimulation, this membrane, along with apical membranes, transforms into a dense network of apical intracellular canaliculi containing long microvilli. Acid secretion, a process requiring high energy, occurs at the apical canalicular surface. Numerous mitochondria (30–40% of total cell volume) generate the energy required for secretion. FIGURE 324­2 Gastric parietal cell undergoing transformation after secretagogue­mediated stimulation. cAMP, cyclic adenosine monophosphate. (Reproduced with permission from SJ Hersey, G Sachs: Gastric acid secretion. Am Physiol Soc 75:155, 1995.)Yonsei University Medical Library Access Provided by: Downloaded 2024­5­29 3:6 A  Your IP is 116.89.178.138 Chapter 324: Peptic Ulcer Disease and Related Disorders, John Del Valle ©2024 McGraw Hill. All Rights Reserved.   Terms of Use • Privacy Policy • Notice • Accessibility Page 2 / 49",1470,19,367.5,"[ 0.56688756 -0.34084532 -0.97749186 ...  0.48122352 -0.18728544
 -1.3199012 ]"
20,"FIGURE 324­2 Gastric parietal cell undergoing transformation after secretagogue­mediated stimulation. cAMP, cyclic adenosine monophosphate. (Reproduced with permission from SJ Hersey, G Sachs: Gastric acid secretion. Am Physiol Soc 75:155, 1995.)Gastroduodenal Mucosal Defense The gastric epithelium is under constant assault by a series of endogenous noxious factors, including hydrochloric acid (HCl), pepsinogen/pepsin, and bile salts. In addition, a steady flow of exogenous substances such as medications, alcohol, and bacteria encounter the gastric mucosa. A highly intricate biologic system is in place to provide defense from mucosal injury and to repair any injury that may occur. The mucosal defense system can be envisioned as a three­level barrier, composed of preepithelial, epithelial, and subepithelial elements (Fig. 324­3). The first line of defense is a mucus­bicarbonate­phospholipid layer, which serves as a physicochemical barrier to multiple molecules, including hydrogen ions. Mucus is secreted in a regulated fashion by gastroduodenal surface epithelial cells. It consists primarily of water (95%) and a mixture of phospholipids and glycoproteins (mucin). The mucous gel functions as a nonstirred water layer impeding diffusion of ions and molecules such as pepsin. Bicarbonate, secreted in a regulated manner by surface epithelial cells of the gastroduodenal mucosa into the mucous gel, forms a pH gradient ranging from 1 to 2 at the gastric luminal surface and reaching 6–7 along the epithelial cell surface. FIGURE 324­3 Components involved in providing gastroduodenal mucosal defense and repair. CCK, cholecystokinin; CRF, corticotropin­releasing factor; EGF, epidermal growth factor; HCl, hydrochloride; IGF, insulin­like growth factor; TGFα, transforming growth factor α; TRF, thyrotropin releasing factor. (Republished with permission of John Wiley and Son’s Inc, from Bioregulation and Its Disorders in the Gastrointestinal Tract, T Yoshikawa, T Arakawa [eds]: 1998; permission conveyed through Copyright Clearance Center, Inc.) Yonsei University Medical Library Access Provided by: Downloaded 2024­5­29 3:6 A  Your IP is 116.89.178.138 Chapter 324: Peptic Ulcer Disease and Related Disorders, John Del Valle ©2024 McGraw Hill. All Rights Reserved.   Terms of Use • Privacy Policy • Notice • Accessibility Page 3 / 49",2349,26,587.25,"[-0.05626554 -0.15235037 -1.0227003  ...  0.8931778  -0.5586703
 -1.4710689 ]"
21,"Components involved in providing gastroduodenal mucosal defense and repair. CCK, cholecystokinin; CRF, corticotropin­releasing factor; EGF, epidermal growth factor; HCl, hydrochloride; IGF, insulin­like growth factor; TGFα, transforming growth factor α; TRF, thyrotropin releasing factor. (Republished with permission of John Wiley and Son’s Inc, from Bioregulation and Its Disorders in the Gastrointestinal Tract, T Yoshikawa, T Arakawa [eds]: 1998; permission conveyed through Copyright Clearance Center, Inc.) Surface epithelial cells provide the next line of defense through several factors, including mucus production, epithelial cell ionic transporters that maintain intracellular pH and bicarbonate production, and intracellular tight junctions. Surface epithelial cells generate heat shock proteins that prevent protein denaturation and protect cells from certain factors such as increased temperature, cytotoxic agents, or oxidative stress. Epithelial cells also generate trefoil factor family peptides and cathelicidins, which also play a role in surface cell protection and regeneration. If the preepithelial barrier is breached, gastric epithelial cells bordering a site of injury can migrate to restore a damaged region (restitution). This process occurs independent of cell division and requires uninterrupted blood flow and an alkaline pH in the surrounding environment. Several growth factors, including epidermal growth factor (EGF), transforming growth factor (TGF) α, and basic fibroblast growth factor (FGF), modulate the process of restitution. Larger defects that are not effectively repaired by restitution require cell proliferation. Epithelial cell regeneration is regulated by prostaglandins and growth factors such as EGF and TGF­α. In tandem with epithelial cell renewal, formation of new vessels (angiogenesis) within the injured microvascular bed occurs. Both FGF and vascular endothelial growth factor (VEGF) are important in regulating angiogenesis in the gastric mucosa. In addition, the gastric peptide gastrin (see below) has been recently found to stimulate cell proliferation, migration, invasion, angiogenesis, and autophagy. Finally, gastric parietal cells (see below) express sonic hedgehog, a family of proteins important in regulating cell lineage in multiple organs. This latter finding suggests that parietal cells may also have the ability to regulate gastric stem cells. An elaborate microvascular system within the gastric submucosal layer is the key component of the subepithelial defense/repair system, providing HCO3−, which neutralizes the acid generated by the parietal cell. Moreover, this microcirculatory bed provides an adequate supply of micronutrients and oxygen while removing toxic metabolic by­products. Several locally produced factors including nitric oxide (NO) (see below), hydrogen sulfide, and prostacyclin contribute to the vascular protective pathway through vasodilation of the microcirculation. Prostaglandins play a central role in gastric epithelial defense/repair (Fig. 324­4). The gastric mucosa contains abundant levels of prostaglandins that regulate the release of mucosal bicarbonate and mucus, inhibit parietal cell secretion, and are important in maintaining mucosal blood flow and epithelial cell restitution. Prostaglandins are derived from esterified arachidonic acid, which is formed from phospholipids (cell membrane) by the action of phospholipase A2. A key enzyme that controls the rate­limiting step in prostaglandin synthesis is cyclooxygenase (COX), which is present in two isoforms (COX­1, COX­2), each having distinct characteristics regarding structure, tissue distribution, and expression. COX­1 is expressed in a host of tissues, including the stomach, platelets, kidneys, and endothelial cells. This isoform is expressed in a constitutive manner and plays an important role in maintaining the integrity of renal function, platelet aggregation, and gastrointestinal (GI) mucosal integrity. In contrast, the expression of COX­2 is inducible by inflammatory stimuli, and it is expressed in macrophages, leukocytes, fibroblasts, and synovial cells. The beneficial effects of nonsteroidal anti­inflammatory drugs (NSAIDs) on tissue inflammation are due to inhibition of COX­2; the toxicity of these drugs (e.g., GI mucosal ulceration and renal dysfunction) is related to inhibition of the COX­1 isoform. The highly COX­2–selective NSAIDs have the potential to provide the beneficial effect of decreasing tissue inflammation while minimizing toxicity in the GI tract. Selective COX­2 inhibitors have had adverse effects on the cardiovascular (CV) system, leading to increased risk of myocardial infarction. Therefore, the U. S. Food and Drug Administration (FDA) has removed Yonsei University Medical Library Access Provided by: Downloaded 2024­5­29 3:6 A  Your IP is 116.89.178.138 Chapter 324: Peptic Ulcer Disease and Related Disorders, John Del Valle ©2024 McGraw Hill. All Rights Reserved.   Terms of Use • Privacy Policy • Notice • Accessibility Page 4 / 49",5054,43,1263.5,"[-0.25668895 -0.47438622 -1.0365858  ...  0.6172668  -0.8172958
 -1.3333813 ]"
22,"epithelial cell restitution. Prostaglandins are derived from esterified arachidonic acid, which is formed from phospholipids (cell membrane) by the action of phospholipase A2. A key enzyme that controls the rate­limiting step in prostaglandin synthesis is cyclooxygenase (COX), which is present in two isoforms (COX­1, COX­2), each having distinct characteristics regarding structure, tissue distribution, and expression. COX­1 is expressed in a host of tissues, including the stomach, platelets, kidneys, and endothelial cells. This isoform is expressed in a constitutive manner and plays an important role in maintaining the integrity of renal function, platelet aggregation, and gastrointestinal (GI) mucosal integrity. In contrast, the expression of COX­2 is inducible by inflammatory stimuli, and it is expressed in macrophages, leukocytes, fibroblasts, and synovial cells. The beneficial effects of nonsteroidal anti­inflammatory drugs (NSAIDs) on tissue inflammation are due to inhibition of COX­2; the toxicity of these drugs (e.g., GI mucosal ulceration and renal dysfunction) is related to inhibition of the COX­1 isoform. The highly COX­2–selective NSAIDs have the potential to provide the beneficial effect of decreasing tissue inflammation while minimizing toxicity in the GI tract. Selective COX­2 inhibitors have had adverse effects on the cardiovascular (CV) system, leading to increased risk of myocardial infarction. Therefore, the U. S. Food and Drug Administration (FDA) has removed two of these agents (valdecoxib and rofecoxib) from the market (see below). FIGURE 324­4 Schematic representation of the steps involved in synthesis of prostaglandin E2 (PGE2) and prostacyclin (PGI2). Characteristics and distribution of the cyclooxygenase (COX) enzymes 1 and 2 are also shown. TXA2, thromboxane A2. NO is important in the maintenance of gastric mucosal integrity. The key enzyme NO synthase is constitutively expressed in the mucosa and contributes to cytoprotection by stimulating gastric mucus, increasing mucosal blood flow, and maintaining epithelial cell barrier function. The central nervous system (CNS) and hormonal factors also play a role in regulating mucosal defense through multiple pathways (Fig. 324­3). Since the discovery of Helicobacter pylori and its impact on gastric pathology, it has become clear that the stomach has an elaborate and complex inherent immunologic system in place. Although a detailed description of the gastric immune system is beyond the scope of this chapter, several features are worth highlighting. The gastric immune response to certain pathogens such as H. pylori (see below) involves extensive interplay between innate (dendritic cells, epithelial cells, neutrophils, and macrophages) and adaptive (B and T cells) components. Helper T cells (TH and TH regulatory cells) have been extensively studied and appear to play an important role in a broad array of gastric physiology extending from gastric secretion to epithelial cell turnover via production of a number of cytokines. The discovery of H. pylori has also led to the understanding that the stomach, once thought to be devoid of microorganisms due to its highly adverse environment (acid and pepsin), can serve as host for bacterial communities consisting of hundreds of phylotypes, otherwise known as its microbiota. The conceptual framework of the microbiome has been receiving extensive attention in light of its importance in human health and disease. The overall relevance of the gastric microbiome and its impact on gastric pathology remain to be established, but it is likely that alteration of microorganism homeostasis will play a role in aspects of certain disorders such as PUD, gastritis, and gastric cancer. Physiology of Gastric Secretion HCl and pepsinogen are the two principal gastric secretory products capable of inducing mucosal injury. Gastric acid and pepsinogen play a physiologic role in protein digestion; absorption of iron, calcium, magnesium, and vitamin B12; and killing ingested bacteria. Acid secretion should be viewed as occurring under basal and stimulated conditions. Basal acid production occurs in a circadian pattern, with the highest levels occurring during the night and lowest levels during the morning hours. Cholinergic input via the vagus nerve and histaminergic input from local gastric sources are the principal contributors to basal acid secretion. Stimulated gastric acid secretion occurs primarily in three phases based on the site where the signal originates (cephalic, gastric, and intestinal). Sight, smell, and taste of food are the components of the cephalic phase, which stimulates gastric secretion via the vagus nerve. The gastric phase is activated once food enters the stomach. This component of secretion is driven by nutrients (amino acids and amines) that directly (via peptone and amino acid receptors) and indirectly (via stimulation of intramural gastrin releasing peptide neurons) Yonsei University Medical Library Access Provided by: Downloaded 2024­5­29 3:6 A  Your IP is 116.89.178.138 Chapter 324: Peptic Ulcer Disease and Related Disorders, John Del Valle ©2024 McGraw Hill. All Rights Reserved.   Terms of Use • Privacy Policy • Notice • Accessibility Page 5 / 49",5258,67,1314.5,"[ 0.27039814  0.07502039 -1.0010452  ...  0.11885931  0.35765624
 -1.171152  ]"
23,"Physiology of Gastric Secretion HCl and pepsinogen are the two principal gastric secretory products capable of inducing mucosal injury. Gastric acid and pepsinogen play a physiologic role in protein digestion; absorption of iron, calcium, magnesium, and vitamin B12; and killing ingested bacteria. Acid secretion should be viewed as occurring under basal and stimulated conditions. Basal acid production occurs in a circadian pattern, with the highest levels occurring during the night and lowest levels during the morning hours. Cholinergic input via the vagus nerve and histaminergic input from local gastric sources are the principal contributors to basal acid secretion. Stimulated gastric acid secretion occurs primarily in three phases based on the site where the signal originates (cephalic, gastric, and intestinal). Sight, smell, and taste of food are the components of the cephalic phase, which stimulates gastric secretion via the vagus nerve. The gastric phase is activated once food enters the stomach. This component of secretion is driven by nutrients (amino acids and amines) that directly (via peptone and amino acid receptors) and indirectly (via stimulation of intramural gastrin­releasing peptide neurons) stimulate the G cell to release gastrin, which in turn activates the parietal cell via direct and indirect mechanisms. Distention of the stomach wall also leads to gastrin release and acid production. The last phase of gastric acid secretion is initiated as food enters the intestine and is mediated by luminal distention and nutrient assimilation. A series of pathways that inhibit gastric acid production are also set into motion during these phases. The GI hormone somatostatin is released from endocrine cells found in the gastric mucosa (D cells) in response to HCl. Somatostatin can inhibit acid production by both direct (parietal cell) and indirect mechanisms (decreased histamine release from ECL cells, ghrelin release from Gr cells and gastrin release from G cells). Additional neural (central and peripheral) and humoral (amylin, atrial natriuretic peptide [ANP], cholecystokinin, ghrelin, interleukin 11 [IL­11], obestatin, secretin, and serotonin) factors play a role in counterbalancing acid secretion. Under physiologic circumstances, these phases occur simultaneously. Ghrelin, the appetite­regulating hormone expressed in Gr cells in the stomach, and its related peptide motilin (released from the duodenum) may increase gastric acid secretion through stimulation of histamine release from ECL cells, but this remains to be confirmed. The acid­secreting parietal cell is located in the oxyntic gland, adjacent to other cellular elements (ECL cell, D cell) important in the gastric secretory process (Fig. 324­5). This unique cell also secretes intrinsic factor (IF) and IL­11. The parietal cell expresses receptors for several stimulants of acid secretion, including histamine (H2), gastrin (cholecystokinin 2/gastrin receptor), and acetylcholine (muscarinic, M3). Binding of histamine to the H2 receptor leads to activation of adenylate cyclase and the phosphoinositol pathways, in turn resulting in an increase in cyclic adenosine monophosphate (AMP) and intracellular calcium, respectively. Activation of the gastrin and muscarinic receptors results in activation of the protein kinase C/phosphoinositide signaling pathway. Each of these signaling pathways in turn regulates a series of downstream kinase cascades that control the acid­secreting pump, H+,K+­ATPase. The discovery that different ligands and their corresponding receptors lead to activation of different signaling pathways explains the potentiation of acid secretion that occurs when histamine and gastrin or acetylcholine are combined. More importantly, this observation explains why blocking one receptor type (H2) decreases acid secretion stimulated by agents that activate a different pathway (gastrin, acetylcholine). Parietal cells also express receptors for ligands that inhibit acid production (glucagon­like peptide­1, prostaglandins, somatostatin, EGF, neurotensin, and urocortin). Histamine also stimulates gastric acid secretion indirectly by activating the histamine H3 receptor on D cells, which inhibits somatostatin release. FIGURE 324­5 Regulation of gastric acid secretion at the cellular level. ACh, acetylcholine; ANP, atrial natriuretic peptide; CGRP, calcitonin gene­related peptide; EC, enterochromaffin; ECL, enterochromaffin­like; GRP, gastrin­releasing peptide; PACAP, pituitary adenylate­cyclase activating peptide; SST, somatostatin; VIP, vasoactive intestinal peptide. The enzyme H+,K+­ATPase is responsible for generating the large concentration of H+. It is a membrane­bound protein that consists of two subunits, α and β. The active catalytic site is found within the α subunit; the function of the β subunit is unclear. This enzyme uses the chemical energy of adenosine triphosphate (ATP) to transfer H+ ions from parietal cell cytoplasm to the secretory canaliculi in exchange for K+. The H+,K+­ATPase is located within the secretory canaliculus and in nonsecretory cytoplasmic tubulovesicles. The tubulovesicles are impermeable to K+, which leads to an inactive pump in this location. The distribution of pumps between the nonsecretory vesicles and the secretory canaliculus varies according to parietal cell ( ) ( Yonsei University Medical Library Access Provided by: Downloaded 2024­5­29 3:6 A  Your IP is 116.89.178.138 Chapter 324: Peptic Ulcer Disease and Related Disorders, John Del Valle ©2024 McGraw Hill. All Rights Reserved.   Terms of Use • Privacy Policy • Notice • Accessibility Page 6 / 49",5650,51,1412.5,"[ 0.27502024 -0.2884543  -0.91861236 ...  0.57745624 -0.5160301
 -1.3951033 ]"
24,"The enzyme H+,K+­ATPase is responsible for generating the large concentration of H+. It is a membrane­bound protein that consists of two subunits, α and β. The active catalytic site is found within the α subunit; the function of the β subunit is unclear. This enzyme uses the chemical energy of adenosine triphosphate (ATP) to transfer H+ ions from parietal cell cytoplasm to the secretory canaliculi in exchange for K+. The H+,K+­ATPase is located within the secretory canaliculus and in nonsecretory cytoplasmic tubulovesicles. The tubulovesicles are impermeable to K+, which leads to an inactive pump in this location. The distribution of pumps between the nonsecretory vesicles and the secretory canaliculus varies according to parietal cell activity (Fig. 324­2). Proton pumps are recycled back to the inactive state in cytoplasmic vesicles once parietal cell activation ceases. Ezrin (an actin binding protein), actin, myosin, soluble N­ethylmaleimide­sensitive factor attachment protein receptors (SNAREs), small G proteins of the Rab family, and secretory carrier membrane proteins (SCAMPS) are postulated to participate in parietal cell membrane translocation. In addition, acid secretion requires a number of apical and basolateral parietal cell membrane chloride and potassium channels. Parietal cells also express members of the sonic hedgehog (Shh) family proteins, which play an important role in regulating cell types in multiple organs. This family of proteins may also regulate cell differentiation as well as restitution of mucosal defense in the gastric epithelium. The chief cell, found primarily in the gastric fundus, synthesizes and secretes pepsinogen, the inactive precursor of the proteolytic enzyme pepsin. The acid environment within the stomach leads to cleavage of the inactive precursor to pepsin and provides the low pH (<2) required for pepsin activity. Pepsin activity is significantly diminished at a pH of 4 and irreversibly inactivated and denatured at a pH of ≥7. Many of the secretagogues that stimulate acid secretion also stimulate pepsinogen release. The precise role of pepsin in the pathogenesis of PUD remains to be established. PATHOPHYSIOLOGIC BASIS OF PUD PUD encompasses both gastric ulcers (GUs) and duodenal ulcers (DUs). Ulcers are defined as breaks in the mucosal surface >5 mm in size, with depth to the submucosa. DUs and GUs share many common features in terms of pathogenesis, diagnosis, and treatment, but several factors distinguish them from one another. H. pylori and NSAIDs are the most common risk factors for PUD, with estimated odds ratios in the United States of 3.7 and 3.3, respectively. Additional risk factors (odds ratio) include chronic obstructive lung disease (2.34), chronic renal insufficiency (2.29), current tobacco use (1.99), former tobacco use (1.55), older age (1.67), three or more doctor visits in a year (1.49), coronary heart disease (1.46), former alcohol use (1.29), African­American race (1.20), obesity (1.18), and diabetes (1.13). Selective serotonin reuptake inhibitors (SSRIs) and gastric bypass surgery are also associated with an increased incidence of PUD. A rise in idiopathic PUD has also been noted. The mechanisms by which some of these risk factors lead to ulcer disease are highlighted below. Epidemiology DUODENAL ULCERS DUs are estimated to occur in 6–15% of the Western population. The incidence of DUs declined steadily from 1960 to 1980 and has remained stable since then. The death rates, need for surgery, and physician visits have decreased by >50% over the past 30 years. The reason for the reduction in the frequency of DUs is likely related to the decreasing frequency of H. pylori in turn associated with overall improved sanitary conditions across the world. Before the discovery of H. pylori, the natural history of DUs was typified by frequent recurrences after initial therapy. Eradication of H. pylori has reduced these recurrence rates by >80%. GASTRIC ULCERS GUs tend to occur later in life than duodenal lesions, with a peak incidence reported in the sixth decade. More than one­half of GUs occur in males and are less common than DUs, perhaps due to the higher likelihood of GUs being silent and presenting only after a complication develops. Autopsy studies suggest a similar incidence of DUs and GUs. Pathology DUODENAL ULCERS DUs occur most often in the first portion of the duodenum (>95%), with ~90% located within 3 cm of the pylorus. They are usually ≤1 cm in diameter but can occasionally reach 3–6 cm (giant ulcer). Ulcers are sharply demarcated, with depth at times reaching the muscularis propria. The base of the ulcer often consists of a zone of eosinophilic necrosis with surrounding fibrosis. Malignant DUs are extremely rare. GASTRIC ULCERS In contrast to DUs, GUs can represent a malignancy and should be biopsied upon discovery. Benign GUs are most often found distal to the junction between the antrum and the acid secretory mucosa. Benign GUs are quite rare in the gastric fundus and are histologically similar to DUs.",5061,43,1265.25,"[ 0.21526057  0.0953413  -1.1165076  ...  0.5163735   0.01596273
 -1.3323432 ]"
24,"Benign GUs associated with H. pylori are also associated with antral gastritis. In contrast, NSAID­related GUs are not accompanied by chronic active gastritis but Yonsei University Medical Library Access Provided by: Downloaded 2024­5­29 3:6 A  Your IP is 116.89.178.138 Chapter 324: Peptic Ulcer Disease and Related Disorders, John Del Valle ©2024 McGraw Hill. All Rights Reserved.   Terms of Use • Privacy Policy • Notice • Accessibility Page 7 / 49",451,11,112.75,"[-0.01025434 -0.04691325 -0.76024735 ...  0.01127508  0.26945692
 -1.4269565 ]"
25,"DUODENAL ULCERS DUs occur most often in the first portion of the duodenum (>95%), with ~90% located within 3 cm of the pylorus. They are usually ≤1 cm in diameter but can occasionally reach 3–6 cm (giant ulcer). Ulcers are sharply demarcated, with depth at times reaching the muscularis propria. The base of the ulcer often consists of a zone of eosinophilic necrosis with surrounding fibrosis. Malignant DUs are extremely rare. GASTRIC ULCERS In contrast to DUs, GUs can represent a malignancy and should be biopsied upon discovery. Benign GUs are most often found distal to the junction between the antrum and the acid secretory mucosa. Benign GUs are quite rare in the gastric fundus and are histologically similar to DUs. Benign GUs associated with H. pylori are also associated with antral gastritis. In contrast, NSAID­related GUs are not accompanied by chronic active gastritis but may instead have evidence of a chemical gastropathy, typified by foveolar hyperplasia, edema of the lamina propria, and epithelial regeneration in the absence of H. pylori. Extension of smooth­muscle fibers into the upper portions of the mucosa, where they are not typically found, may also occur. Pathophysiology DUODENAL ULCERS H. pylori and NSAID­induced injuries account for the majority of DUs. Many acid secretory abnormalities have been described in DU patients. Of these, average basal and nocturnal gastric acid secretion appears to be increased in DU patients as compared to controls; however, the level of overlap between DU patients and control subjects is substantial. The reason for this altered secretory process is unclear, but H. pylori infection may contribute. Bicarbonate secretion is significantly decreased in the duodenal bulb of patients with an active DU as compared to control subjects. H. pylori infection may also play a role in this process (see below). GASTRIC ULCERS As in DUs, the majority of GUs can be attributed to either H. pylori or NSAID­induced mucosal damage. Prepyloric GUs or those in the body associated with a DU or a duodenal scar are similar in pathogenesis to DUs. Gastric acid output (basal and stimulated) tends to be normal or decreased in GU patients. When GUs develop in the presence of minimal acid levels, impairment of mucosal defense factors may be present. GUs have been classified based on their location: type I occur in the gastric body and tend to be associated with low gastric acid production; type II occur in the antrum, and gastric acid can vary from low to normal; type III occur within 3 cm of the pylorus and are commonly accompanied by DUs and normal or high gastric acid production; and type IV are found in the cardia and are associated with low gastric acid production. H. PYLORI AND ACID PEPTIC DISORDERS Gastric infection with the bacterium H. pylori accounts for the majority of PUD (Chap. 163). This organism also plays a role in the development of gastric mucosa­associated lymphoid tissue (MALT) lymphoma and gastric adenocarcinoma. Although the entire genome of H. pylori has been sequenced, it is still not clear how this organism, which resides in the stomach, causes ulceration in the duodenum. H. pylori eradication efforts may lead to a decrease in gastric cancer in high­risk populations, particularly in individuals who have not developed chronic atrophic gastritis and gastric metaplasia. The Bacterium The bacterium, initially named Campylobacter pyloridis, is a gram­negative microaerophilic rod found most commonly in the deeper portions of the mucous gel coating the gastric mucosa or between the mucous layer and the gastric epithelium. It may attach to gastric epithelium but under normal circumstances does not appear to invade cells. It is strategically designed to live within the aggressive environment of the stomach. It is S­shaped (~0.5– 3 μm in size) and contains multiple sheathed flagella. Initially, H. pylori resides in the antrum but, over time, migrates toward the more proximal segments of the stomach. The organism is capable of transforming into a coccoid form, which represents a dormant state that may facilitate survival in adverse conditions. The genome of H. pylori (1.65 million base pairs) encodes ~1500 proteins. Among this multitude of proteins there are factors that are essential determinants of H. pylori–mediated pathogenesis and colonization such as the outer membrane protein (Hop proteins), urease, and the vacuolating cytotoxin (Vac A). Moreover, the majority of H. pylori strains contain a genomic fragment that encodes the cag pathogenicity island (cag­ PAI). Several of the genes that make up cag­PAI encode components of a type IV secretion island that translocates Cag A into host cells. Once in the cell, Cag A activates a series of cellular events important in cell growth and cytokine production. H. pylori also has extensive genetic diversity that in turn enhances its ability to promote disease. The first step in infection by H. pylori is dependent on the bacteria’s motility and its ability to produce urease. Urease produces ammonia from urea, an essential step in alkalinizing the surrounding pH. Additional bacterial factors include catalase, lipase, adhesins, platelet­activating factor, and pic B (induces cytokines). Multiple strains of H. pylori exist and are characterized by their ability to express several of these factors (Cag A, Vac A, etc.). It is possible that the different diseases related to H. pylori infection can be attributed to different strains of the organism with distinct pathogenic features.",5548,46,1387.0,"[-0.16857228 -0.10650942 -1.1560581  ...  0.63799614 -0.13999014
 -0.818279  ]"
25,"Epidemiology The prevalence of H. pylori varies throughout the world and depends largely on the overall standard of living in the region. In developing parts of the world 80% of the population may be infected by the age of 20 whereas the prevalence is 20–50% in industrialized countries In contrast in the United Yonsei University Medical Library Access Provided by: Downloaded 2024­5­29 3:6 A  Your IP is 116.89.178.138 Chapter 324: Peptic Ulcer Disease and Related Disorders, John Del Valle ©2024 McGraw Hill. All Rights Reserved.   Terms of Use • Privacy Policy • Notice • Accessibility Page 8 / 49",601,37,150.25,"[ 0.3751133  -0.17832753 -1.3827028  ...  0.07102297  0.34500116
 -0.72783387]"
26,"Cag A activates a series of cellular events important in cell growth and cytokine production. H. pylori also has extensive genetic diversity that in turn enhances its ability to promote disease. The first step in infection by H. pylori is dependent on the bacteria’s motility and its ability to produce urease. Urease produces ammonia from urea, an essential step in alkalinizing the surrounding pH. Additional bacterial factors include catalase, lipase, adhesins, platelet­activating factor, and pic B (induces cytokines). Multiple strains of H. pylori exist and are characterized by their ability to express several of these factors (Cag A, Vac A, etc.). It is possible that the different diseases related to H. pylori infection can be attributed to different strains of the organism with distinct pathogenic features. Epidemiology The prevalence of H. pylori varies throughout the world and depends largely on the overall standard of living in the region. In developing parts of the world, 80% of the population may be infected by the age of 20, whereas the prevalence is 20–50% in industrialized countries. In contrast, in the United States, this organism is rare in childhood. The overall prevalence of H. pylori in the United States is ~30%, with individuals born before 1950 having a higher rate of infection than those born later. About 10% of Americans <30 years of age are colonized with the bacteria. The rate of infection with H. pylori in industrialized countries has decreased substantially in recent decades. The steady increase in the prevalence of H. pylori noted with increasing age is due primarily to a cohort effect, reflecting higher transmission during a period in which the earlier cohorts were children. It has been calculated through mathematical models that improved sanitation during the latter half of the nineteenth century dramatically decreased transmission of H. pylori. Moreover, with the present rate of intervention, the organism will be ultimately eliminated from the United States. Two factors that predispose to higher colonization rates include poor socioeconomic status and less education. These factors, not race, are responsible for the rate of H. pylori infection in blacks and Hispanic Americans being double the rate seen in whites of comparable age. Other risk factors for H. pylori infection are (1) birth or residence in a developing country, (2) domestic crowding, (3) unsanitary living conditions, (4) unclean food or water, and (5) exposure to gastric contents of an infected individual. Transmission of H. pylori occurs from person to person, following an oral­oral or fecal­oral route. The risk of H. pylori infection is declining in developing countries. The rate of infection in the United States has fallen by >50% when compared to 30 years ago. Pathophysiology H. pylori infection is virtually always associated with a chronic active gastritis, but only 10–15% of infected individuals develop frank peptic ulceration. The basis for this difference is unknown but is likely due to a combination of host and bacterial factors, some of which are outlined below. Initial studies suggested that >90% of all DUs were associated with H. pylori, but H. pylori is present in only 30–60% of individuals with GUs and 50–70% of patients with DUs. The pathophysiology of ulcers not associated with H. pylori or NSAID ingestion (or the rare Zollinger­Ellison syndrome [ZES]) is becoming more relevant as the incidence of H. pylori is dropping, particularly in the Western world (see below). The particular end result of H. pylori infection (gastritis, PUD, gastric MALT lymphoma, gastric cancer) is determined by a complex interplay between bacterial and host factors (Fig. 324­6). FIGURE 324­6 Outline of the bacterial and host factors important in determining H. pylori–induced gastrointestinal disease. MALT, mucosal­associated lymphoid tissue. Bacterial factors: H. pylori is able to facilitate gastric residence, induce mucosal injury, and avoid host defense. Different strains of H. pylori produce different virulence factors including γ­glutamyl transpeptidase (GGT), cytotoxin­associated gene A (Cag A) product, and virulence components vacuolating toxin (Vac A), in addition to pathogen­associated molecular patterns (PAMPs) such as flagella and lipopolysaccharide (LPS). A specific region of the bacterial genome, the pathogenicity island (cag­PAI), encodes the virulence factors Cag A and pic B. Vac A also contributes to Yonsei University Medical Library Access Provided by: Downloaded 2024­5­29 3:6 A  Your IP is 116.89.178.138 Chapter 324: Peptic Ulcer Disease and Related Disorders, John Del Valle ©2024 McGraw Hill. All Rights Reserved.   Terms of Use • Privacy Policy • Notice • Accessibility Page 9 / 49",4765,45,1191.25,"[ 0.23141585  0.00857347 -1.0422248  ... -0.1287238   0.13417701
 -1.2223729 ]"
27,"FIGURE 324­6 Outline of the bacterial and host factors important in determining H. pylori–induced gastrointestinal disease. MALT, mucosal­associated lymphoid tissue. Bacterial factors: H. pylori is able to facilitate gastric residence, induce mucosal injury, and avoid host defense. Different strains of H. pylori produce different virulence factors including γ­glutamyl transpeptidase (GGT), cytotoxin­associated gene A (Cag A) product, and virulence components vacuolating toxin (Vac A), in addition to pathogen­associated molecular patterns (PAMPs) such as flagella and lipopolysaccharide (LPS). A specific region of the bacterial genome, the pathogenicity island (cag­PAI), encodes the virulence factors Cag A and pic B. Vac A also contributes to pathogenicity, although it is not encoded within the pathogenicity island. These virulence factors, in conjunction with additional bacterial constituents, can cause mucosal damage, in part through their ability to target the host immune cells. For example, Vac A targets human CD4 T cells, inhibiting their proliferation, and in addition can disrupt normal function of B cells, CD8 T cells, macrophages, and mast cells. Multiple studies have demonstrated that H. pylori strains that are cag­PAI positive are associated with a higher risk of PUD, premalignant gastric lesions, and gastric cancer than are strains that lack the cag­PAI. In addition, H. pylori may directly inhibit parietal cell H+,K+­ATPase activity through a Cag A–dependent mechanism, leading in part to the low acid production observed after acute infection with the organism. Urease, which allows the bacteria to reside in the acidic stomach, generates NH3, which can damage epithelial cells. The bacteria produce surface factors that are chemotactic for neutrophils and monocytes, which in turn contribute to epithelial cell injury (see below). H. pylori makes proteases and phospholipases that break down the glycoprotein lipid complex of the mucous gel, thus reducing the efficacy of this first line of mucosal defense. H. pylori expresses adhesins (outer membrane proteins like BabA), which facilitate attachment of the bacteria to gastric epithelial cells. Although LPS of gram­negative bacteria often plays an important role in the infection, H. pylori LPS has low immunologic activity compared to that of other organisms. It may promote a smoldering chronic inflammation. Host factors: Studies in twins suggest that there may be genetic predisposition to acquire H. pylori. The inflammatory response to H. pylori includes recruitment of neutrophils, lymphocytes (T and B), macrophages, and plasma cells. The pathogen leads to local injury by binding to class II major histocompatibility complex (MHC) molecules expressed on gastric epithelial cells, leading to cell death (apoptosis). Moreover, bacterial strains that encode cag­PAI can introduce Cag A into the host cells, leading to further cell injury and activation of cellular pathways involved in cytokine production and repression of tumor­suppressor genes. Elevated concentrations of multiple cytokines are found in the gastric epithelium of H. pylori–infected individuals, including interleukin (IL) 1α/β, IL­2, IL­6, IL­8, tumor necrosis factor (TNF) α, and interferon (IFN) γ. H. pylori infection also leads to both a mucosal and a systemic humoral response, which does not lead to eradication of the bacteria but further compounds epithelial cell injury. Additional mechanisms by which H. pylori may cause epithelial cell injury include (1) activated neutrophil­mediated production of reactive oxygen or nitrogen species and enhanced epithelial cell turnover and (2) apoptosis related to interaction with T cells (T helper 1 [TH1] cells) and IFN­γ. Finally, the human stomach is colonized by a host of commensal organisms that may affect the likelihood of H. pylori infection and subsequent mucosal injury. Moreover, colonization of the stomach with H. pylori likely alters the composition of the gastric microbiota. The impact of the latter on gastric pathophysiology remains unknown. H. pylori also appears to regulate NO formation via different mechanisms that in turn may contribute to the organism’s cytotoxic effects. Specifically, H. pylori–derived factors, such as urease, or the bacterium itself, stimulate NO synthase (NOS2) expression in macrophages and in gastric epithelial cells leading to NO release and subsequent cytotoxic effect on surrounding cells. H. pylori also leads to the formation of 8­ nitroguanine (8­NO2­Gua), which in conjunction with oncoprotein Cag A, may contribute to the development of gastric cancer. The reason for H. pylori–mediated duodenal ulceration remains unclear. Studies suggest that H. pylori associated with duodenal ulceration may be more virulent. In addition, certain specific bacterial factors such as the DU­promoting gene A (dupA) may be associated with the development of DUs. Another potential contributing factor is that gastric metaplasia in the duodenum of DU patients, which may be due to high acid exposure (see below), permits H. pylori to bind to it and produce local injury secondary to the host response. Another hypothesis is that H. pylori antral infection could lead to increased acid production, increased duodenal acid, and mucosal injury. Basal and stimulated (meal, gastrin­releasing peptide [GRP]) gastrin release is increased in H. pylori–infected individuals, and somatostatin­secreting D cells may be decreased. H. pylori infection might induce increased Yonsei University Medical Library Access Provided by: Downloaded 2024­5­29 3:6 A  Your IP is 116.89.178.138 Chapter 324: Peptic Ulcer Disease and Related Disorders, John Del Valle ©2024 McGraw Hill. All Rights Reserved.   Terms of Use • Privacy Policy • Notice • Accessibility Page 10 / 49",5808,48,1452.0,"[ 0.46118474  0.32174546 -1.299783   ...  0.12351857 -0.29565257
 -1.311252  ]"
28,"remains unknown. H. pylori also appears to regulate NO formation via different mechanisms that in turn may contribute to the organism s cytotoxic effects. Specifically, H. pylori–derived factors, such as urease, or the bacterium itself, stimulate NO synthase (NOS2) expression in macrophages and in gastric epithelial cells leading to NO release and subsequent cytotoxic effect on surrounding cells. H. pylori also leads to the formation of 8­ nitroguanine (8­NO2­Gua), which in conjunction with oncoprotein Cag A, may contribute to the development of gastric cancer. The reason for H. pylori–mediated duodenal ulceration remains unclear. Studies suggest that H. pylori associated with duodenal ulceration may be more virulent. In addition, certain specific bacterial factors such as the DU­promoting gene A (dupA) may be associated with the development of DUs. Another potential contributing factor is that gastric metaplasia in the duodenum of DU patients, which may be due to high acid exposure (see below), permits H. pylori to bind to it and produce local injury secondary to the host response. Another hypothesis is that H. pylori antral infection could lead to increased acid production, increased duodenal acid, and mucosal injury. Basal and stimulated (meal, gastrin­releasing peptide [GRP]) gastrin release is increased in H. pylori–infected individuals, and somatostatin­secreting D cells may be decreased. H. pylori infection might induce increased acid secretion through both direct and indirect actions of H. pylori and proinflammatory cytokines (IL­8, TNF, and IL­1) on G, D, and parietal cells (Fig.324­7). GUs, in contrast, are associated with H. pylori–induced pangastritis and normal or low gastric acid secretion. The H. pylori–mediated decrease in gastric acid secretion after long­term infection may be due to the bacterium’s ability to inhibit H+,K+­ATPase expression. H. pylori infection has also been associated with decreased duodenal mucosal bicarbonate production. Data supporting and contradicting each of these interesting theories have been demonstrated. Thus, the mechanism by which H. pylori infection of the stomach leads to duodenal ulceration remains to be established. The development of in vitro organoids, a unique tool that replicates in part the multicellular structure of the intact organ, provides a more physiologic model for experimentation in an invitro system. Moreover, the development of advanced microscopic optical imaging techniques will lead to increased understanding of parietal cell adaptation to H. pylori infection. FIGURE 324­7 Summary of potential mechanisms by which H. pylori may lead to gastric secretory abnormalities. D, somatostatin cell; ECL, enterochromaffin­like cell; G, G cell. (Reproduced with permission from J Calam et al: How does Helicobacter pylori cause mucosal damage? Its effect on acid and gastrin physiology. Gastroenterology 113:543, 1997.)In summary, the final effect of H. pylori on the GI tract is variable and determined by microbial and host factors. The type and distribution of gastritis correlate with the ultimate gastric and duodenal pathology observed. Specifically, the presence of antral­predominant gastritis is associated with DU formation; gastritis involving primarily the corpus predisposes to the development of GUs, gastric atrophy, and ultimately gastric carcinoma (Fig. 324­ 8). FIGURE 324­8 Natural history of H. pylori infection. MALT, mucosal­associated lymphoid tissue. (From S Suerbaum, P Michetti: Helicobacter pylori infection. N Engl J Med 347:1175, 2002. Copyright © 2002 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.)Yonsei University Medical Library Access Provided by: Downloaded 2024­5­29 3:6 A  Your IP is 116.89.178.138 Chapter 324: Peptic Ulcer Disease and Related Disorders, John Del Valle ©2024 McGraw Hill. All Rights Reserved.   Terms of Use • Privacy Policy • Notice • Accessibility Page 11 / 49",3968,36,992.0,"[ 0.21278332  0.08155409 -1.2644117  ...  0.61111027 -0.36479986
 -1.1263967 ]"
29,"8). FIGURE 324­8 Natural history of H. pylori infection. MALT, mucosal­associated lymphoid tissue. (From S Suerbaum, P Michetti: Helicobacter pylori infection. N Engl J Med 347:1175, 2002. Copyright © 2002 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.)NSAID­INDUCED DISEASE Epidemiology NSAIDs represent a group of the most commonly used medications in the world and the United States. It is estimated that 7 billion dollars per year are spent on NSAIDs worldwide, with >30 billion over­the­counter tablets sold. More than 30 million individuals take NSAIDs, with >100 million prescriptions sold yearly in the United States alone. In fact, after the introduction of COX­2 inhibitors in the year 2000, the number of prescriptions written for NSAIDs was >111 million at a cost of $4.8 billion. Side effects and complications due to NSAIDs are considered the most common drug­ related toxicities in the United States. The spectrum of NSAID­induced morbidity ranges from nausea and dyspepsia (prevalence reported as high as 50–60%) to a serious GI complication such as endoscopy­documented peptic ulceration (15–30% of individuals taking NSAIDs regularly), which is complicated by bleeding or perforation in as many as 1.5% of users per year. It is estimated that NSAID­induced GI bleeding accounts for 60,000– 120,000 hospital admissions per year, and deaths related to NSAID­induced toxicity may be as high as 16,000 per year in the United States. Approximately 4–5% of patients develop symptomatic ulcers within 1 year. Unfortunately, dyspeptic symptoms do not correlate with NSAID­induced pathology. Over 80% of patients with serious NSAID­related complications did not have preceding dyspepsia. In view of the lack of warning signs, it is important to identify patients who are at increased risk for morbidity and mortality related to NSAID usage. Even 75 mg/d of aspirin may lead to serious GI ulceration; thus, no dose of NSAID is completely safe. In fact, the incidence of mucosal injury (ulcers and erosions) in patients taking low­dose aspirin (75–325 mg) has been estimated to range from as low as 8 to as high as 60%. It appears that H. pylori infection increases the risk of PUD­ associated GI bleeding in chronic users of low­dose aspirin. Established risk factors include advanced age, history of ulcer, concomitant use of glucocorticoids, high­dose NSAIDs, multiple NSAIDs, concomitant use of anticoagulants or clopidogrel, and serious or multisystem disease. Possible risk factors include concomitant infection with H. pylori, cigarette smoking, and alcohol consumption. SSRIs have a synergistic effect on the induction of GI bleeding believed to be due in part to this agent’s ability to decrease platelet aggregation by decreasing serotonin content in platelets. Pathophysiology Prostaglandins play a critical role in maintaining gastroduodenal mucosal integrity and repair. It therefore follows that interruption of prostaglandin synthesis can impair mucosal defense and repair, thus facilitating mucosal injury via a systemic mechanism. Animal studies have demonstrated that neutrophil adherence to the gastric microcirculation plays an essential role in the initiation of NSAID­induced mucosal injury. A summary of the pathogenetic pathways by which systemically administered NSAIDs may lead to mucosal injury is shown in Fig. 324­9. Single nucleotide polymorphisms (SNPs) have been found in several genes, including those encoding certain subtypes of cytochrome P450 (see below), IL­1β (IL­1β), angiotensinogen (AGT), and an organic ion transporting polypeptide (SLCO1B1), but these findings need confirmation in larger­scale studies. FIGURE 324­9 Effect of nonsteroidal anti inflammatory drugs (NSAIDs) on different target organs The action of NSAIDs on major organs including Yonsei University Medical Library Access Provided by: Downloaded 2024­5­29 3:6 A  Your IP is 116.89.178.138 Chapter 324: Peptic Ulcer Disease and Related Disorders, John Del Valle ©2024 McGraw Hill. All Rights Reserved.   Terms of Use • Privacy Policy • Notice • Accessibility Page 12 / 49",4133,58,1033.25,"[ 0.12903072 -0.01060541 -1.2276124  ... -0.15859038  0.46373034
 -1.5548815 ]"
30,"Prostaglandins play a critical role in maintaining gastroduodenal mucosal integrity and repair. It therefore follows that interruption of prostaglandin synthesis can impair mucosal defense and repair, thus facilitating mucosal injury via a systemic mechanism. Animal studies have demonstrated that neutrophil adherence to the gastric microcirculation plays an essential role in the initiation of NSAID­induced mucosal injury. A summary of the pathogenetic pathways by which systemically administered NSAIDs may lead to mucosal injury is shown in Fig. 324­9. Single nucleotide polymorphisms (SNPs) have been found in several genes, including those encoding certain subtypes of cytochrome P450 (see below), IL­1β (IL­1β), angiotensinogen (AGT), and an organic ion transporting polypeptide (SLCO1B1), but these findings need confirmation in larger­scale studies. FIGURE 324­9 Effect of nonsteroidal anti­inflammatory drugs (NSAIDs) on different target organs. The action of NSAIDs on major organs including stomach, small intestine, heart, liver, kidney, respiratory tract, and brain is mainly mediated through prostaglandin endoperoxide synthase (PGHS)– dependent prostanoid modulation and alteration of mitochondrial functional integrity leading to mitochondrial oxidative stress (MOS) generation, depolarization of mitochondrial transmembrane potential (ΔΨm), and consequent cell death. However, in heart, low­dose aspirin actually offers cardioprotection through antithrombotic effect. Upward arrows indicate upregulation/elevation; downward arrows indicate downregulation/depletion. (From S Bindu et al: Non­steroidal anti­inflammatory drugs (NSAIDs) and organ damage: A current perspective. Biochem Pharmacol 180:114147, 2020.)Injury to the mucosa also occurs as a result of the topical use of NSAIDs, leading to increased epithelial surface permeability. Aspirin and many NSAIDs are weak acids that remain in a nonionized lipophilic form when found within the acid environment of the stomach. Under these conditions, NSAIDs migrate across lipid membranes of epithelial cells, leading to cell injury once trapped intracellularly in an ionized form. Topical NSAIDs can also alter the surface mucous layer, permitting back diffusion of H+ and pepsin, leading to further epithelial cell damage. Moreover, enteric­coated or buffered preparations are also associated with risk of peptic ulceration. NSAIDs can also lead to mucosal injury via production of additional proinflammatory mediators such as TNF and leukotrienes through simultaneous activation of the lipoxygenase pathway. The interplay between H. pylori and NSAIDs in the pathogenesis of PUD is complex. Meta­analysis supports the conclusion that each of these aggressive factors is an independent and synergistic risk factor for PUD and its complications such as GI bleeding. For example, eradication of H. pylori reduces the likelihood of GI complications in high­risk individuals to levels observed in individuals with average risk of NSAID­induced complications. In summary, NSAID­induced mucosal injury is a multifaceted process involving the interaction of multiple, often synergistic pathophysiologic processes at the epithelium and surrounding interfaces. PATHOGENETIC FACTORS UNRELATED TO H. PYLORI AND NSAIDS IN ACID PEPTIC DISEASE Cigarette smoking has been implicated in the pathogenesis of PUD. Not only have smokers been found to have ulcers more frequently than do nonsmokers, but smoking appears to decrease healing rates, impair response to therapy, and increase ulcer­related complications such as perforation. The mechanism responsible for increased ulcer diathesis in smokers is unknown. Theories have included altered gastric emptying, decreased proximal duodenal bicarbonate production, increased risk for H. pylori infection, and cigarette­induced generation of noxious mucosal free radicals. Genetic predisposition may play a role in ulcer development. First­degree relatives of DU patients are three times as likely to develop an ulcer; however, the potential role of H. pylori infection in contacts is a major consideration. Increased frequencies of blood group O and of the nonsecretor status have also been implicated as genetic risk factors for peptic diathesis. However, H. pylori preferentially binds to group O antigens. Additional genetic factors have been postulated to predispose certain individuals to developing PUD and/or upper GI bleeding. Specifically, genes encoding the NSAID­metabolizing enzymes cytochrome P450 2C9 and 2C8 (CYP2C9 and CYP2C8) are potential susceptibility genes for NSAID­induced PUD, but unfortunately, the studies have not been consistent in demonstrating this association. In a United Kingdom study, the CYP2C19*17 gain­of­function polymorphism was associated with PUD in a Caucasian cohort, irrespective of ulcer etiology. These findings need to be confirmed in broader studies. Psychological stress has been thought to contribute to PUD, but studies examining the role of psychological factors in its pathogenesis have generated conflicting results. Although PUD is associated with certain personality traits (neuroticism), these same traits are also present in individuals with Yonsei University Medical Library Access Provided by: Downloaded 2024­5­29 3:6 A  Your IP is 116.89.178.138 Chapter 324: Peptic Ulcer Disease and Related Disorders, John Del Valle ©2024 McGraw Hill. All Rights Reserved.   Terms of Use • Privacy Policy • Notice • Accessibility Page 13 / 49",5492,47,1373.0,"[ 0.04294299 -0.10986242 -0.94283354 ... -0.00425429 -0.05224465
 -1.2314528 ]"
31,"decreased proximal duodenal bicarbonate production, increased risk for H. pylori infection, and cigarette­induced generation of noxious mucosal free radicals. Genetic predisposition may play a role in ulcer development. First­degree relatives of DU patients are three times as likely to develop an ulcer; however, the potential role of H. pylori infection in contacts is a major consideration. Increased frequencies of blood group O and of the nonsecretor status have also been implicated as genetic risk factors for peptic diathesis. However, H. pylori preferentially binds to group O antigens. Additional genetic factors have been postulated to predispose certain individuals to developing PUD and/or upper GI bleeding. Specifically, genes encoding the NSAID­metabolizing enzymes cytochrome P450 2C9 and 2C8 (CYP2C9 and CYP2C8) are potential susceptibility genes for NSAID­induced PUD, but unfortunately, the studies have not been consistent in demonstrating this association. In a United Kingdom study, the CYP2C19*17 gain­of­function polymorphism was associated with PUD in a Caucasian cohort, irrespective of ulcer etiology. These findings need to be confirmed in broader studies. Psychological stress has been thought to contribute to PUD, but studies examining the role of psychological factors in its pathogenesis have generated conflicting results. Although PUD is associated with certain personality traits (neuroticism), these same traits are also present in individuals with nonulcer dyspepsia (NUD) and other functional and organic disorders. Diet has also been thought to play a role in peptic diseases. Certain foods and beverages can cause dyspepsia, but no convincing studies indicate an association between ulcer formation and a specific diet. Specific chronic disorders have been shown to have a strong association with PUD: (1) advanced age, (2) chronic pulmonary disease, (3) chronic renal failure, (4) cirrhosis, (5) nephrolithiasis, (6) α1­antitrypsin deficiency, and (7) systemic mastocytosis. Disorders with a possible association are (1) hyperparathyroidism, (2) coronary artery disease, (3) polycythemia vera, (4) chronic pancreatitis, (5) former alcohol use, (6) obesity, (7) African­American race, and (8) three or more doctor visits in a year. Multiple factors play a role in the pathogenesis of PUD. The two predominant causes are H. pylori infection and NSAID ingestion. PUD not related to H. pylori or NSAIDs is increasing. Other less common causes of PUD are shown in Table 324­1. These etiologic agents should be considered as the incidence of H. pylori is decreasing. Independent of the inciting or injurious agent, peptic ulcers develop as a result of an imbalance between mucosal protection/repair and aggressive factors. Gastric acid plays an important role in mucosal injury. TABLE 324­1 Causes of Ulcers Not Caused by Helicobacter pylori and NSAIDs Pathogenesis of Non­Hp and Non­NSAID Ulcer Disease Infection  Cytomegalovirus  Herpes simplex virus  Helicobacter heilmannii Drug/Toxin  Bisphosphonates  Chemotherapy  Clopidogrel  Crack cocaine  Glucocorticoids (when combined with NSAIDs)  Mycophenolate mofetil  Potassium chloride Miscellaneous  Basophilia in myeloproliferative disease  Duodenal obstruction (e.g., annular pancreas)  Infiltrating disease  Ischemia Yonsei University Medical Library Access Provided by: Downloaded 2024­5­29 3:6 A  Your IP is 116.89.178.138 Chapter 324: Peptic Ulcer Disease and Related Disorders, John Del Valle ©2024 McGraw Hill. All Rights Reserved.   Terms of Use • Privacy Policy • Notice • Accessibility Page 14 / 49",3597,49,899.25,"[-0.35838687 -0.27436876 -1.2590865  ...  0.3047842   0.01948132
 -1.6321709 ]"
32,"Abbreviations: Hp, H. pylori; NSAIDs, nonsteroidal anti­inflammatory drugs. Multiple factors play a role in the pathogenesis of PUD. The two predominant causes are H. pylori infection and NSAID ingestion. PUD not related to H. pylori or NSAIDs is increasing. Other less common causes of PUD are shown in Table 324­1. These etiologic agents should be considered as the incidence of H. pylori is decreasing. Independent of the inciting or injurious agent, peptic ulcers develop as a result of an imbalance between mucosal protection/repair and aggressive factors. Gastric acid plays an important role in mucosal injury. TABLE 324­1 Causes of Ulcers Not Caused by Helicobacter pylori and NSAIDs Pathogenesis of Non­Hp and Non­NSAID Ulcer Disease Infection  Cytomegalovirus  Herpes simplex virus  Helicobacter heilmannii Drug/Toxin  Bisphosphonates  Chemotherapy  Clopidogrel  Crack cocaine  Glucocorticoids (when combined with NSAIDs)  Mycophenolate mofetil  Potassium chloride Miscellaneous  Basophilia in myeloproliferative disease  Duodenal obstruction (e.g., annular pancreas)  Infiltrating disease  Ischemia  Radiation therapy  Eosinophilic infiltration  Sarcoidosis  Crohn’s disease  Idiopathic hypersecretory state CLINICAL FEATURES History Abdominal pain is common to many GI disorders including DU and GU but it has a poor predictive value for the presence of either DU or GU Yonsei University Medical Library Access Provided by: Downloaded 2024­5­29 3:6 A  Your IP is 116.89.178.138 Chapter 324: Peptic Ulcer Disease and Related Disorders, John Del Valle ©2024 McGraw Hill. All Rights Reserved.   Terms of Use • Privacy Policy • Notice • Accessibility Page 15 / 49",1671,68,417.75,"[ 0.01238437 -0.03607684 -0.96496594 ...  0.12579963 -0.23191738
 -1.14295   ]"
33,"Abbreviations: Hp, H. pylori; NSAIDs, nonsteroidal anti­inflammatory drugs. Idiopathic hypersecretory state CLINICAL FEATURES History Abdominal pain is common to many GI disorders, including DU and GU, but it has a poor predictive value for the presence of either DU or GU. Approximately two­thirds of patients with PUD do not have abdominal pain, and up to 87% of patients with NSAID­induced mucosal disease can present with a complication (bleeding, perforation, and obstruction) without antecedent symptoms. Despite this poor correlation, a careful history and physical examination are essential components of the approach to a patient suspected of having peptic ulcers. Epigastric pain described as a burning or gnawing discomfort can be present in both DU and GU. The discomfort is also described as an ill­defined, aching sensation or as hunger pain. The typical pain pattern in DU occurs 90 min to 3 h after a meal and is frequently relieved by antacids or food. Pain that awakes the patient from sleep (between midnight and 3 A. M.) is the most discriminating symptom, with two­thirds of DU patients describing this complaint. Unfortunately, this symptom is also present in one­third of patients with NUD (see below). Elderly patients are less likely to have abdominal pain as a manifestation of PUD and may instead present with a complication such as ulcer bleeding or perforation. The pain pattern in GU patients may be different from that in DU patients, where discomfort may actually be precipitated by food. Nausea and weight loss occur more commonly in GU patients. Endoscopy detects ulcers in <30% of patients who have dyspepsia. The mechanism for development of abdominal pain in ulcer patients is unknown. Several possible explanations include acid­induced activation of chemical receptors in the duodenum, enhanced duodenal sensitivity to bile acids and pepsin, and altered gastroduodenal motility. Variation in the intensity or distribution of the abdominal pain, as well as the onset of associated symptoms such as nausea and/or vomiting, may be indicative of an ulcer complication. Dyspepsia that becomes constant, is no longer relieved by food or antacids, or radiates to the back may indicate a penetrating ulcer (pancreas). Sudden onset of severe, generalized abdominal pain may indicate perforation. Pain worsening with meals, nausea, and vomiting of undigested food suggest gastric outlet obstruction. Tarry stools or coffee­ground emesis indicate bleeding. Physical Examination Epigastric tenderness is the most frequent finding in patients with GU or DU. Pain may be found to the right of the midline in 20% of patients. Unfortunately, the predictive value of this finding is low. Physical examination is critically important for discovering evidence of ulcer complication. Tachycardia and orthostasis suggest dehydration secondary to vomiting or active GI blood loss. A severely tender, board­like abdomen suggests a perforation. Presence of a succussion splash indicates retained fluid in the stomach, suggesting gastric outlet obstruction. PUD­Related Complications GASTROINTESTINAL BLEEDING GI bleeding is the most common complication observed in PUD. Bleeding is estimated to occur in 19.4–57 per 100,000 individuals in a general population or in ~15% of patients. Bleeding and complications of ulcer disease occur more often in individuals >60 years of age. The 30­day mortality rate is as high as 2.5–10%. The higher incidence in the elderly is likely due to the increased use of NSAIDs in this group. In addition, up to 80% of the mortality in PUD­related bleeding is due to nonbleeding causes such as multiorgan failure (24%), pulmonary complications (24%), and malignancy (34%). Greater than 50% of patients with ulcer­related hemorrhage bleed without any preceding warning signs or symptoms. PERFORATION The second most common ulcer­related complication is perforation, being reported in as many as 6–7% of PUD patients with an estimated 30­day mortality of >20%. Acute abdominal pain, tachycardia, and abdominal rigidity compose the classic triad associated with this complication. It is essential to remember that elderly patients or individuals who are immunosuppressed may not have this classic presentation. As in the case of bleeding, the incidence of perforation in the elderly appears to be increasing secondary to increased use of NSAIDs. Perforation of DUs has become less common in light of the increased rates of H. pylori eradication, with NSAID­induced GUs leading to perforation occurring more commonly. Penetration is a form of perforation in which the ulcer bed tunnels into an adjacent organ. DUs tend to penetrate posteriorly into the pancreas, leading to pancreatitis, whereas GUs tend to penetrate into the left hepatic lobe. Gastrocolic fistulas associated with GUs have also been described. Mortality for this complication can be >20% within 30 days.",4912,43,1228.0,"[-0.37704515 -0.23265994 -1.5072281  ...  0.20359921  0.26564234
 -0.86666405]"
33,"GASTRIC OUTLET OBSTRUCTION Yonsei University Medical Library Access Provided by: Downloaded 2024­5­29 3:6 A  Your IP is 116.89.178.138 Chapter 324: Peptic Ulcer Disease and Related Disorders, John Del Valle ©2024 McGraw Hill. All Rights Reserved.   Terms of Use • Privacy Policy • Notice • Accessibility Page 16 / 49",316,10,79.0,"[ 0.1823038  -0.52710545 -1.3515896  ... -0.15849188 -0.45101714
 -1.2980651 ]"
34,"mortality of >20%. Acute abdominal pain, tachycardia, and abdominal rigidity compose the classic triad associated with this complication. It is essential to remember that elderly patients or individuals who are immunosuppressed may not have this classic presentation. As in the case of bleeding, the incidence of perforation in the elderly appears to be increasing secondary to increased use of NSAIDs. Perforation of DUs has become less common in light of the increased rates of H. pylori eradication, with NSAID­induced GUs leading to perforation occurring more commonly. Penetration is a form of perforation in which the ulcer bed tunnels into an adjacent organ. DUs tend to penetrate posteriorly into the pancreas, leading to pancreatitis, whereas GUs tend to penetrate into the left hepatic lobe. Gastrocolic fistulas associated with GUs have also been described. Mortality for this complication can be >20% within 30 days. GASTRIC OUTLET OBSTRUCTION Gastric outlet obstruction is the least common ulcer­related complication, occurring in 1–2% of patients. A patient may have relative obstruction secondary to ulcer­related inflammation and edema in the peripyloric and duodenal region. This process often resolves with ulcer healing. A fixed, mechanical obstruction secondary to scar formation in the peripyloric areas is also possible. The latter requires endoscopic (balloon dilation with or without placement of a biodegradable stent) or surgical intervention with a stricturoplasty or gastrojejunostomy. Signs and symptoms relative to mechanical obstruction may develop insidiously. New onset of early satiety, nausea, vomiting, increase of postprandial abdominal pain, and weight loss should make gastric outlet obstruction a possible diagnosis. Differential Diagnosis The list of GI and non­GI disorders that can mimic ulceration of the stomach or duodenum is quite extensive. The most commonly encountered diagnosis among patients seen for upper abdominal discomfort is functional dyspepsia (FD) or essential dyspepsia, which refers to a group of heterogeneous disorders typified by upper abdominal pain without the presence of an ulcer. The symptoms can range from postprandial fullness and early satiety to epigastric burning pain. The dichotomy of this symptom complex has led to the identification of two subcategories of FD including postprandial distress syndrome (PDS) and epigastric pain syndrome (EPS). Dyspepsia has been reported to occur in up to 30% of the U. S. population. Up to 80% of patients seeking medical care for dyspepsia have a negative diagnostic evaluation. The etiology of FD is not established, but recent studies suggest that postinfectious states, certain foods, and H. pylori infection may contribute to the pathogenesis of this common disorder. Several additional disease processes that may present with “ulcer­like” symptoms include proximal GI tumors, gastroesophageal reflux, vascular disease, pancreaticobiliary disease (biliary colic, chronic pancreatitis), and gastroduodenal Crohn’s disease. Diagnostic Evaluation In view of the poor predictive value of abdominal pain for the presence of a gastroduodenal ulcer and the multiple disease processes that can mimic this disease, the clinician is often confronted with having to establish the presence of an ulcer. Documentation of an ulcer requires either a radiographic (barium study, rarely done in today’s environment) or an endoscopic procedure. However, a large percentage of patients with symptoms suggestive of an ulcer have NUD; testing for H. pylori and antibiotic therapy (see below) are appropriate for individuals who are otherwise healthy and <45 years of age, before embarking on a diagnostic evaluation (Chap. 45). Barium studies of the proximal GI tract are rarely used as a first test for documenting an ulcer. The sensitivity of older single­contrast barium meals for detecting a DU is as high as 80%, with a double­contrast study providing detection rates as high as 90%. Sensitivity for detection is decreased in small ulcers (<0.5 cm), with presence of previous scarring, or in postoperative patients. A DU appears as a well­demarcated crater, most often seen in the bulb (Fig. 324­10A). A GU may represent benign or malignant disease. Typically, a benign GU also appears as a discrete crater with radiating mucosal folds originating from the ulcer margin (Fig. 324­10B). Ulcers >3 cm in size or those associated with a mass are more often malignant. Unfortunately, up to 8% of GUs that appear to be benign by radiographic appearance are malignant by endoscopy or surgery. Radiographic studies that show a GU must be followed by endoscopy and biopsy. FIGURE 324­10 Barium study demonstrating (A) a benign duodenal ulcer and (B) a benign gastric ulcer. Yonsei University Medical Library Access Provided by: Downloaded 2024­5­29 3:6 A  Your IP is 116.89.178.138 Chapter 324: Peptic Ulcer Disease and Related Disorders, John Del Valle ©2024 McGraw Hill. All Rights Reserved.   Terms of Use • Privacy Policy • Notice • Accessibility Page 17 / 49",5060,49,1265.0,"[-0.24113743 -0.69172037 -1.2678075  ...  0.2285254   0.13356306
 -1.1735556 ]"
35,"must be followed by endoscopy and biopsy. FIGURE 324­10 Barium study demonstrating (A) a benign duodenal ulcer and (B) a benign gastric ulcer. Endoscopy provides the most sensitive and specific approach for examining the upper GI tract (Fig. 324­11). In addition to permitting direct visualization of the mucosa, endoscopy facilitates photographic documentation of a mucosal defect and tissue biopsy to rule out malignancy (GU) or H. pylori. Endoscopic examination is particularly helpful in identifying lesions too small to detect by radiographic examination, for evaluation of atypical radiographic abnormalities, or to determine if an ulcer is a source of blood loss. FIGURE 324­11 Endoscopy demonstrating (A) a benign duodenal ulcer and (B) a benign gastric ulcer. Although the methods for diagnosing H. pylori are outlined in Chap. 163, a brief summary will be included here (Table 324­2). Several biopsy urease tests have been developed (PyloriTek, CLOtest, Hpfast, Pronto Dry) that have a sensitivity and specificity of >90–95%. Several noninvasive methods for detecting this organism have been developed. Three types of studies routinely used include serologic testing, the 13C­ or 14C­urea breath test, and the fecal H. pylori (Hp) antigen test (monoclonal antibody test). A urinary Hp antigen test and a home breath test appear promising. TABLE 324­2 Tests for Detection of Helicobacter pylori TEST SENSITIVITY/SPECIFICITY, % COMMENTS Invasive (Endoscopy/Biopsy Required) Rapid urease 80–95/95–100 Simple, false negative with recent use of PPIs, antibiotics, or bismuth compounds Histology 80–90/>95 Requires pathology processing and staining; provides histologic information Culture —/— Time­consuming, expensive, dependent on experience; allows determination of antibiotic susceptibility Yonsei University Medical Library Access Provided by: Downloaded 2024­5­29 3:6 A  Your IP is 116.89.178.138 Chapter 324: Peptic Ulcer Disease and Related Disorders, John Del Valle ©2024 McGraw Hill. All Rights Reserved.   Terms of Use • Privacy Policy • Notice • Accessibility Page 18 / 49",2089,39,522.25,"[ 0.18309073 -0.3658203  -1.4044346  ...  0.76218086  0.03171033
 -1.0592604 ]"
36,"Abbreviation: PPIs, proton pump inhibitors. Although the methods for diagnosing H. pylori are outlined in Chap. 163, a brief summary will be included here (Table 324­2). Several biopsy urease tests have been developed (PyloriTek, CLOtest, Hpfast, Pronto Dry) that have a sensitivity and specificity of >90–95%. Several noninvasive methods for detecting this organism have been developed. Three types of studies routinely used include serologic testing, the 13C­ or 14C­urea breath test, and the fecal H. pylori (Hp) antigen test (monoclonal antibody test). A urinary Hp antigen test and a home breath test appear promising. TABLE 324­2 Tests for Detection of Helicobacter pylori TEST SENSITIVITY/SPECIFICITY, % COMMENTS Invasive (Endoscopy/Biopsy Required) Rapid urease 80–95/95–100 Simple, false negative with recent use of PPIs, antibiotics, or bismuth compounds Histology 80–90/>95 Requires pathology processing and staining; provides histologic information Culture —/— Time­consuming, expensive, dependent on experience; allows determination of antibiotic susceptibility Noninvasive Serology >80/>90 Inexpensive, convenient; not useful for early follow­up Urea breath test >90/>90 Simple, rapid; useful for early follow­up; false negatives with recent therapy (see rapid urease test); exposure to low­dose radiation with 14C test Stool antigen >90/>90 Inexpensive, convenient Occasionally, specialized testing such as serum gastrin and gastric acid analysis may be needed in individuals with complicated or refractory PUD (see “Zollinger­Ellison Syndrome,” below). Screening for aspirin or NSAIDs (blood or urine) may also be necessary in refractory H. pylori–negative PUD patients. TREATMENT OF PEPTIC ULCER DISEASE Before the discovery of H. pylori, the therapy of PUD was centered on the old dictum by Schwartz of “no acid, no ulcer.” Although acid secretion is still important in the pathogenesis of PUD, eradication of H. pylori and therapy/prevention of NSAID­induced disease is the mainstay of treatment. A summary of commonly used drugs for treatment of acid peptic disorders is shown in Table 324­3. TABLE 324­3 Drugs Used in the Treatment of Peptic Ulcer Disease DRUG TYPE/MECHANISM EXAMPLES DOSE Acid­Suppressing Drugs  Antacids Mylanta, Maalox, Tums, Gaviscon 100–140 meq/L 1 and 3 h after meals and hs  H2 receptor antagonists Cimetidine 400 mg bid Ranitidine 300 mg hs Famotidine 40 mg hs Nizatidine 300 mg hs  Proton pump inhibitors Omeprazole 20 mg/d Yonsei University Medical Library Access Provided by: Downloaded 2024­5­29 3:6 A  Your IP is 116.89.178.138 Chapter 324: Peptic Ulcer Disease and Related Disorders, John Del Valle ©2024 McGraw Hill. All Rights Reserved.   Terms of Use • Privacy Policy • Notice • Accessibility Page 19 / 49",2760,72,690.0,"[ 0.25619435 -0.07210949 -1.3462809  ...  0.85539126  0.3237723
 -0.80569696]"
37,"Abbreviation: hs, at bedtime (hora somni). TREATMENT OF PEPTIC ULCER DISEASE Before the discovery of H. pylori, the therapy of PUD was centered on the old dictum by Schwartz of “no acid, no ulcer.” Although acid secretion is still important in the pathogenesis of PUD, eradication of H. pylori and therapy/prevention of NSAID­induced disease is the mainstay of treatment. A summary of commonly used drugs for treatment of acid peptic disorders is shown in Table 324­3. TABLE 324­3 Drugs Used in the Treatment of Peptic Ulcer Disease DRUG TYPE/MECHANISM EXAMPLES DOSE Acid­Suppressing Drugs  Antacids Mylanta, Maalox, Tums, Gaviscon 100–140 meq/L 1 and 3 h after meals and hs  H2 receptor antagonists Cimetidine 400 mg bid Ranitidine 300 mg hs Famotidine 40 mg hs Nizatidine 300 mg hs  Proton pump inhibitors Omeprazole 20 mg/d Lansoprazole 30 mg/d Rabeprazole 20 mg/d Pantoprazole 40 mg/d Esomeprazole 20 mg/d Dexlansoprazole 30 mg/d Mucosal Protective Agents  Sucralfate Sucralfate 1 g qid  Prostaglandin analogue Misoprostol 200 μg qid  Bismuth­containing compounds Bismuth subsalicylate (BSS) See anti–H. pylori regimens (Table 324­4) Acid­Neutralizing/Inhibitory Drugs Antacids Before we understood the important role of histamine in stimulating parietal cell activity, neutralization of secreted acid with antacids constituted the main form of therapy for peptic ulcers. They are now rarely, if ever, used as the primary therapeutic agent but instead are often used by patients for symptomatic relief of dyspepsia. The most commonly used agents are mixtures of aluminum hydroxide and magnesium hydroxide. Aluminum hydroxide can produce constipation and phosphate depletion; magnesium hydroxide may cause loose stools. Many of the commonly used antacids (e.g., Maalox, Mylanta) have a combination of both aluminum and magnesium hydroxide in order to avoid these side effects. The magnesium­ containing preparation should not be used in chronic renal failure patients because of possible hypermagnesemia, and aluminum may cause chronic neurotoxicity in these patients. Calcium carbonate and sodium bicarbonate are potent antacids with varying levels of potential problems. The long­term use of calcium carbonate (converts to calcium chloride in the stomach) can lead to milk­alkali syndrome (hypercalcemia and hyperphosphatemia with possible renal calcinosis and progression to renal insufficiency). Sodium bicarbonate may induce systemic alkalosis. H Receptor Antagonists Yonsei University Medical Library Access Provided by: Downloaded 2024­5­29 3:6 A  Your IP is 116.89.178.138 Chapter 324: Peptic Ulcer Disease and Related Disorders, John Del Valle ©2024 McGraw Hill. All Rights Reserved.   Terms of Use • Privacy Policy • Notice • Accessibility Page 20 / 49",2765,70,691.25,"[ 0.19117917 -0.2715355  -1.064351   ...  0.715937   -0.11341001
 -1.5901546 ]"
38,"symptomatic relief of dyspepsia. The most commonly used agents are mixtures of aluminum hydroxide and magnesium hydroxide. Aluminum hydroxide can produce constipation and phosphate depletion; magnesium hydroxide may cause loose stools. Many of the commonly used antacids (e.g., Maalox, Mylanta) have a combination of both aluminum and magnesium hydroxide in order to avoid these side effects. The magnesium­ containing preparation should not be used in chronic renal failure patients because of possible hypermagnesemia, and aluminum may cause chronic neurotoxicity in these patients. Calcium carbonate and sodium bicarbonate are potent antacids with varying levels of potential problems. The long­term use of calcium carbonate (converts to calcium chloride in the stomach) can lead to milk­alkali syndrome (hypercalcemia and hyperphosphatemia with possible renal calcinosis and progression to renal insufficiency). Sodium bicarbonate may induce systemic alkalosis. H2 Receptor Antagonists Four of these agents are presently available (cimetidine, ranitidine, famotidine, and nizatidine), and their structures share homology with histamine. Although each has different potency, all will significantly inhibit basal and stimulated acid secretion to comparable levels when used at therapeutic doses. Moreover, similar ulcer­healing rates are achieved with each drug when used at the correct dosage. Presently, this class of drug is often used for treatment of active ulcers (4–6 weeks) in combination with antibiotics directed at eradicating H. pylori (see below). Cimetidine was the first H2 receptor antagonist used for the treatment of acid peptic disorders. Cimetidine may have weak antiandrogenic side effects resulting in reversible gynecomastia and impotence, primarily in patients receiving high doses for prolonged periods of time (months to years). In view of cimetidine’s ability to inhibit cytochrome P450, careful monitoring of drugs such as warfarin, phenytoin, and theophylline is indicated with long­ term usage. Other rare reversible adverse effects reported with cimetidine include confusion and elevated levels of serum aminotransferases, creatinine, and serum prolactin. Ranitidine, famotidine, and nizatidine are more potent H2 receptor antagonists than cimetidine. Each can be used once a day at bedtime for ulcer prevention, which was commonly done before the discovery of H. pylori and the development of proton pump inhibitors (PPIs). Patients may develop tolerance to H2 blockers, a rare event with PPIs (see below). Comparable nighttime dosing regimens are cimetidine 800 mg, ranitidine 300 mg, famotidine 40 mg, and nizatidine 300 mg. Additional rare, reversible systemic toxicities reported with H2 receptor antagonists include pancytopenia, neutropenia, anemia, and thrombocytopenia, with a prevalence rate varying from 0.01 to 0.2%. Cimetidine and ranitidine (to a lesser extent) can bind to hepatic cytochrome P450; famotidine and nizatidine do not. Ranitidine and nizatidine were taken off of the market due to contamination of the drug with N­ nitrosodimethylamine (NDMA), a known carcinogen. Proton Pump (H+, K+­ATPase) Inhibitors Omeprazole, esomeprazole, lansoprazole, rabeprazole, and pantoprazole are substituted benzimidazole derivatives that covalently bind and irreversibly inhibit H+,K+­ATPase. Esomeprazole is the S­enantiomer of omeprazole, which is a racemic mixture of both S­ and R­optical isomers. The R­ isomer of lansoprazole, dexlansoprazole, is the most recent PPI approved for clinical use. Its reported advantage is a dual delayed­release system aimed at improving treatment of gastroesophageal reflux disease (GERD). These are the most potent acid inhibitory agents available. Omeprazole and lansoprazole are the PPIs that have been used for the longest time. Both are acid­labile and are administered as enteric­coated granules in a sustained­ release capsule that dissolves within the small intestine at a pH of 6. Lansoprazole is available in an orally disintegrating tablet that can be taken with or without water, an advantage for individuals who have significant dysphagia. Absorption kinetics are similar to the capsule. In addition, a lansoprazole­ naproxen combination preparation that has been made available is targeted at decreasing NSAID­related GI injury (see below). Omeprazole is available as non–enteric­coated granules mixed with sodium bicarbonate in a powder form that can be administered orally or via gastric tube. The sodium bicarbonate has two purposes: to protect the omeprazole from acid degradation and to promote rapid gastric alkalinization and subsequent proton pump activation, which facilitates rapid action of the PPI. Pantoprazole and rabeprazole are available as enteric­coated tablets. Pantoprazole is also available as a parenteral formulation for intravenous use. These agents are lipophilic compounds; upon entering the parietal cell, they are protonated and trapped within the acid environment of the tubulovesicular and canalicular system. These agents potently inhibit all phases of gastric acid secretion. Onset of action is rapid, with a maximum acid inhibitory effect between 2 and 6 h after administration and duration of inhibition lasting up to 72–96 h. With repeated daily dosing, progressive acid inhibitory effects are observed, with basal and secretagogue­stimulated acid production being inhibited by >95% after 1 week of therapy. The half­life of PPIs is ~18 h; thus, it can take between 2 and 5 days for gastric acid secretion to return to normal levels once these drugs have been discontinued. Because the pumps need to be activated for these agents to be effective, their efficacy is maximized if they are administered before a meal (except for the immediate­release formulation of omeprazole) (e.g., in the morning before breakfast). Mild to moderate hypergastrinemia has been observed in patients taking these drugs.",5929,46,1482.25,"[ 0.52626675 -0.21208373 -1.008228   ...  0.8011708  -0.61317647
 -1.5062668 ]"
38,"Carcinoid tumors developed in some animals given the drugs preclinically; however, extensive experience has failed to demonstrate gastric carcinoid tumor development in humans. Serum gastrin levels return to normal levels within 1–2 weeks after drug cessation. Rebound gastric acid hypersecretion has been described in H. pylori–negative individuals after discontinuation of PPIs. It occurs even after relatively short­term usage (2 months) and may last for up to 2 months after the PPI has been discontinued. The mechanism involves gastrin­induced hyperplasia and hypertrophy of histamine­secreting ECL cells. The clinical relevance of this observation is that individuals may have worsening symptoms of GERD or dyspepsia upon stopping the PPI. Gradual tapering of the PPI and switching to an H2 receptor antagonist may prevent this from occurring. H. pylori–induced inflammation and concomitant decrease in acid production may explain why this does not occur in H. pylori–positive patients. IF production is also inhibited, but vitamin B12 deficiency anemia is uncommon, b bl b f th l t f th it i A ith t th t l d t i ifi t h hl h d i PPI i t f ith b ti f Yonsei University Medical Library Access Provided by: Downloaded 2024­5­29 3:6 A  Your IP is 116.89.178.138 Chapter 324: Peptic Ulcer Disease and Related Disorders, John Del Valle ©2024 McGraw Hill. All Rights Reserved.   Terms of Use • Privacy Policy • Notice • Accessibility Page 21 / 49",1447,52,361.75,"[ 0.18955283 -0.13966876 -1.3631213  ...  0.5689271  -0.36567843
 -0.9491971 ]"
39,"maximized if they are administered before a meal (except for the immediate­release formulation of omeprazole) (e.g., in the morning before breakfast). Mild to moderate hypergastrinemia has been observed in patients taking these drugs. Carcinoid tumors developed in some animals given the drugs preclinically; however, extensive experience has failed to demonstrate gastric carcinoid tumor development in humans. Serum gastrin levels return to normal levels within 1–2 weeks after drug cessation. Rebound gastric acid hypersecretion has been described in H. pylori–negative individuals after discontinuation of PPIs. It occurs even after relatively short­term usage (2 months) and may last for up to 2 months after the PPI has been discontinued. The mechanism involves gastrin­induced hyperplasia and hypertrophy of histamine­secreting ECL cells. The clinical relevance of this observation is that individuals may have worsening symptoms of GERD or dyspepsia upon stopping the PPI. Gradual tapering of the PPI and switching to an H2 receptor antagonist may prevent this from occurring. H. pylori–induced inflammation and concomitant decrease in acid production may explain why this does not occur in H. pylori–positive patients. IF production is also inhibited, but vitamin B12 deficiency anemia is uncommon, probably because of the large stores of the vitamin. As with any agent that leads to significant hypochlorhydria, PPIs may interfere with absorption of drugs such as ketoconazole, ampicillin, iron, and digoxin. Hepatic cytochrome P450 can be inhibited by the earlier PPIs (omeprazole, lansoprazole). Rabeprazole, pantoprazole, and esomeprazole do not appear to interact significantly with drugs metabolized by the cytochrome P450 system. The overall clinical significance of this observation is not definitely established. Caution should be taken when using theophylline, warfarin, diazepam, atazanavir, and phenytoin concomitantly with PPIs. The list of potential side effects with long­term PPI use has steadily grown over the years. These agents are commonly used since several formulations have become available as over­the­counter medications. Moreover, up to 70% of current prescriptions for long­term PPIs may be unwarranted and between 35 and 60% of in­hospital use of PPIs may be inappropriate. Interpretation of the multiple studies should take into consideration that the vast majority were retrospective observational studies in which confounding factors could not be accounted for entirely. Long­term acid suppression, especially with PPIs, has been associated with a higher incidence of community­acquired pneumonia as well as community­ and hospital­acquired Clostridium difficile–associated disease. A meta­analysis showed a 74% increased risk of C. difficile infection and a 2.5­fold higher risk of reinfection as compared to nonusers. In light of these concerns, the FDA published a safety alert regarding the association between C. difficile infection and PPI use. Although the risk of spontaneous bacterial peritonitis in cirrhotics was thought to be increased, the data here are less supportive. The impact of PPI­induced changes in the host microbiome is postulated to play a role in the increased risk of infection, but this theory needs to be confirmed. These observations require confirmation but should alert the practitioner to take caution when recommending these agents for long­term use, especially in elderly patients at risk for developing pneumonia or C. difficile infection. Diarrhea is also associated with PPI use, which in some cases has been associated with the development of collagenous colitis (hazard ratio of 4.5), particularly with lansoprazole. The mechanism for PPI­induced collagenous colitis is unclear, but in vitro studies demonstrate that PPIs may induce collagen gene expression. The colitis usually resolves with cessation of the PPI. A population­based study revealed that long­term use of PPIs was associated with the development of hip fractures in older women. The absolute risk of fracture remained low and may be zero despite an observed increase associated with the dose and duration of acid suppression. The mechanism for this observation is not clear, and this finding must be confirmed before making broad recommendations regarding the discontinuation of these agents in patients who benefit from them. Long­term use of PPIs has also been implicated in the development of iron, vitamin B12, and magnesium deficiency. A meta­analysis of nine observational studies found a 40% increase in hypomagnesemia in PPI users as compared to nonusers. One approach to consider in patients needing to take PPIs long term is to check a complete blood count looking for evidence of anemia due to iron or vitamin B12 deficiency, vitamin B12 level, and a magnesium level after 1–2 years of PPI use, but these recommendations are not evidence based or recommended by expert opinion. PPIs may exert a negative effect on the antiplatelet effect of clopidogrel. Although the evidence is mixed and inconclusive, a small increase in mortality and readmission rate for coronary events was seen in patients receiving a PPI while on clopidogrel in earlier studies. Subsequently, three meta­analyses reported an inverse correlation between clopidogrel and PPI use; therefore, the influence of this drug interaction on mortality is not clearly established. The mechanism involves the competition of the PPI and clopidogrel with the same cytochrome P450 (CYP2C19). Whether this is a class effect of PPIs is unclear; there appears to be at least a theoretical advantage of pantoprazole over the other PPIs, but this has not been confirmed. This drug interaction is particularly relevant in light of the common use of aspirin and clopidogrel for prevention of coronary events and the efficacy of PPIs in preventing GI bleeding in these patients. The FDA has made several recommendations while awaiting further evidence to clarify the impact of PPI therapy on clopidogrel use. Health care providers should continue to prescribe clopidogrel to patients who require it and should reevaluate the need for starting or continuing treatment with a PPI.",6185,44,1546.25,"[ 0.4624259  -0.445449   -1.2630619  ...  0.98396546 -0.23476933
 -1.2110475 ]"
39,"From a practical standpoint, additional recommendations to consider include the following: Patients taking clopidogrel with aspirin, especially with other GI risk factors for bleeding, should receive GI protective therapy. Although high­dose H2 blockers have been considered an option, these do not appear to be as effective as PPIs. If PPIs are to be given, some have recommended that there be a 12­h separation between administration of the PPI and clopidogrel to minimize competition of the two agents with the involved cytochrome P450. One option is to give the PPI 30 min before breakfast and the clopidogrel at bedtime. Insufficient data are available to firmly recommend one PPI over another. Additional concerning side effects with long­term PPI use include increased cardiac risks independent of clopidogrel use, dementia, and acute and chronic kidney injury. Again, the data are often retrospective and confounding variables were not consistently eliminated, thus making it difficult to establish a definitive association between PPIs and the toxicities outlined. A summary of the side effects with the corresponding relative risks is shown in Fig. 324–12. Ultimately, heightened awareness of inappropriate long­term use of PPIs is paramount. Patients aged ≥65 years of age have a higher risk for some of the long­term side effects of PPIs highlighted above, in part due to the higher prevalence of concomitant chronic diseases. It is therefore essential to carefully select individuals, especially among the elderly, who need long­term PPI therapy and discontinue it in those individuals who do not need it. Abrupt withdrawal of a PPI in a long­term user may result in a component of b d h idi h hi h ld b d d ll h f 2 k i h ibl i i H bl k f h Yonsei University Medical Library Access Provided by: Downloaded 2024­5­29 3:6 A  Your IP is 116.89.178.138 Chapter 324: Peptic Ulcer Disease and Related Disorders, John Del Valle ©2024 McGraw Hill. All Rights Reserved.   Terms of Use • Privacy Policy • Notice • Accessibility Page 22 / 49",2044,47,511.0,"[ 0.46546483 -0.04793902 -1.5038568  ...  0.48707384  0.2534721
 -1.1811129 ]"
40,"therapy. Although high­dose H2 blockers have been considered an option, these do not appear to be as effective as PPIs. If PPIs are to be given, some have recommended that there be a 12­h separation between administration of the PPI and clopidogrel to minimize competition of the two agents with the involved cytochrome P450. One option is to give the PPI 30 min before breakfast and the clopidogrel at bedtime. Insufficient data are available to firmly recommend one PPI over another. Additional concerning side effects with long­term PPI use include increased cardiac risks independent of clopidogrel use, dementia, and acute and chronic kidney injury. Again, the data are often retrospective and confounding variables were not consistently eliminated, thus making it difficult to establish a definitive association between PPIs and the toxicities outlined. A summary of the side effects with the corresponding relative risks is shown in Fig. 324–12. Ultimately, heightened awareness of inappropriate long­term use of PPIs is paramount. Patients aged ≥65 years of age have a higher risk for some of the long­term side effects of PPIs highlighted above, in part due to the higher prevalence of concomitant chronic diseases. It is therefore essential to carefully select individuals, especially among the elderly, who need long­term PPI therapy and discontinue it in those individuals who do not need it. Abrupt withdrawal of a PPI in a long­term user may result in a component of rebound hyperacidity; thus, this agent should be tapered gradually over the course of 1–2 weeks with possible transition to an H2 blocker for a short period of time. FIGURE 324­12. Evidence supporting the potential adverse effects of proton pump inhibitor drugs. (Adapted from AJ Schoenfeld, D Grady: Adverse effects associated with proton pump inhibitors. JAMA Intern Med 176:172, 2016.)Development of novel acid inhibitory agents continues in an attempt to primarily address the need for better agents to treat GERD. For example, modified H2 blockers with greater potency and duration as well as novel PPIs with longer half­life and potency are under study. For example, tenatoprazole is a PPI containing an imidazopyridine ring instead of a benzimidazole ring, which promotes irreversible proton pump inhibition. This agent has a longer half­life than the other PPIs and may be beneficial for inhibiting nocturnal acid secretion, which has significant relevance in GERD. Additional PPIs with longer half­life and combined with other agents are being studied, but the details are beyond the scope of this chapter. A second new class of agents is the potassium­competitive acid pump antagonists (P­CAPs). These compounds inhibit gastric acid secretion via potassium competitive binding of the H+,K+­ATPase. Revaprazan, vonoprazan and tegoprazan are agents approved for use in Korea and Japan. Vonoprazan may be superior to PPIs when combined with antibiotics for the treatment of H. pylori, and this novel agent has been awarded Fast Track status by the FDA for the treatment of H. pylori in combination with both amoxicillin and clarithromycin and with amoxicillin alone. Cytoprotective Agents Sucralfate Sucralfate is a complex sucrose salt in which the hydroxyl groups have been substituted by aluminum hydroxide and sulfate. This compound is insoluble in water and becomes a viscous paste within the stomach and duodenum, binding primarily to sites of active ulceration. Sucralfate may act by several mechanisms: serving as a physicochemical barrier, promoting a trophic action by binding growth factors such as EGF, enhancing prostaglandin synthesis, stimulating mucus and bicarbonate secretion, and enhancing mucosal defense and repair. Toxicity from this drug is rare, with constipation being most common (2–3%). It should be avoided in patients with chronic renal insufficiency to prevent aluminum­induced neurotoxicity. Hypophosphatemia and gastric bezoar formation have also been reported rarely. Standard dosing of sucralfate is 1 g qid. Bismuth­Containing Preparations Sir William Osler considered bismuth­containing compounds the drug of choice for treating PUD. The resurgence in the use of these agents is due to their effect against H. pylori. Colloidal bismuth subcitrate (CBS) and bismuth subsalicylate (BSS; Pepto­Bismol) are the most widely used preparations. The mechanism by which these agents induce ulcer healing is unclear. Adverse effects with short­term use include black stools, constipation, and darkening of the tongue. Long­term use with high doses, especially with the avidly absorbed CBS, may lead to neurotoxicity. These compounds are commonly used as one of the agents in an anti–H. pylori regimen (see below). Yonsei University Medical Library Access Provided by: Downloaded 2024­5­29 3:6 A  Your IP is 116.89.178.138 Chapter 324: Peptic Ulcer Disease and Related Disorders, John Del Valle ©2024 McGraw Hill. All Rights Reserved.   Terms of Use • Privacy Policy • Notice • Accessibility Page 23 / 49",5017,47,1254.25,"[ 0.29632556  0.02458429 -1.6049407  ...  0.553813    0.07426144
 -1.2993604 ]"
41,"p g y , g , g p y g , constipation being most common (2–3%). It should be avoided in patients with chronic renal insufficiency to prevent aluminum­induced neurotoxicity. Hypophosphatemia and gastric bezoar formation have also been reported rarely. Standard dosing of sucralfate is 1 g qid. Bismuth­Containing Preparations Sir William Osler considered bismuth­containing compounds the drug of choice for treating PUD. The resurgence in the use of these agents is due to their effect against H. pylori. Colloidal bismuth subcitrate (CBS) and bismuth subsalicylate (BSS; Pepto­Bismol) are the most widely used preparations. The mechanism by which these agents induce ulcer healing is unclear. Adverse effects with short­term use include black stools, constipation, and darkening of the tongue. Long­term use with high doses, especially with the avidly absorbed CBS, may lead to neurotoxicity. These compounds are commonly used as one of the agents in an anti–H. pylori regimen (see below). Prostaglandin Analogues In view of their central role in maintaining mucosal integrity and repair, stable prostaglandin analogues were developed for the treatment of PUD. The mechanism by which this rapidly absorbed drug provides its therapeutic effect is through enhancement of mucosal defense and repair. The most common toxicity noted with this drug is diarrhea (10–30% incidence). Other major toxicities include uterine bleeding and contractions; misoprostol is contraindicated in women who may be pregnant, and women of childbearing age must be made clearly aware of this potential drug toxicity. The standard therapeutic dose is 200 μg qid. Miscellaneous Drugs A number of drugs including anticholinergic agents and tricyclic antidepressants were used for treating acid peptic disorders, but in light of their toxicity and the development of potent antisecretory agents, these are rarely, if ever, used today. Newer agents such as teprenone, an acyclic polyisoprenoid compound used as a gastric mucosal protector that is employed to treat gastritis and GUs outside of the United States; plant­based therapies; and CCK2 receptor antagonists are intriguing therapies but require further evaluation. Therapy of H. Pylori The physician’s goal in treating PUD is to provide relief of symptoms (pain or dyspepsia), promote ulcer healing, and ultimately prevent ulcer recurrence and complications. The greatest influence of understanding the role of H. pylori in peptic disease has been the ability to prevent recurrence. Documented eradication of H. pylori in patients with PUD is associated with a dramatic decrease in ulcer recurrence to <10–20% as compared to 59% in GU patients and 67% in DU patients when the organism is not eliminated. Eradication of the organism may lead to diminished recurrent ulcer bleeding. The effect of its eradication on ulcer perforation is unclear. Extensive effort has been made in determining who of the many individuals with H. pylori infection should be treated. The common conclusion arrived at by multiple consensus conferences around the world is that H. pylori should be eradicated in patients with documented PUD. This holds true independent of time of presentation (first episode or not), severity of symptoms, presence of confounding factors such as ingestion of NSAIDs, or whether the ulcer is in remission. Some have advocated treating patients with a history of documented PUD who are found to be H. pylori positive by stool antigen or breath testing. Between 60 and 90% of patients with gastric MALT lymphoma experience complete remission of the tumor in response to H. pylori eradication. The Maastricht IV/Florence Consensus Report recommends a test­and­treat approach for patients with uninvestigated dyspepsia if the local incidence of H. pylori is >20%. The American College of Gastroenterology (ACG) clinical guidelines (developed for North America) recommend that individuals aged <60 years with uninvestigated dyspepsia should be tested and treated for H. pylori. In addition, recommendations from this consensus report and the ACG clinical guidelines include testing and offering eradication of H. pylori in patients who will be using NSAIDs (including low­dose aspirin) on a long­term basis, especially if there is a prior history of PUD. These individuals will require continued PPI treatment as well as eradication treatment, because eradication of the organism alone does not eliminate the risk of gastroduodenal ulcers in patients already receiving long­term NSAIDs. Treating patients with NUD to prevent gastric cancer or patients with GERD requiring long­term acid suppression remains controversial. Guidelines from the ACG suggest eradication of H. pylori in patients who have undergone resection of early gastric cancer. The Maastricht IV/Florence Consensus Report also evaluated H. pylori treatment in gastric cancer prevention and recommends that eradication should be considered in the following situations: first­degree relatives of family members with gastric cancer; patients with previous gastric neoplasm treated by endoscopic or subtotal resection; individuals with a risk of gastritis (severe pangastritis or body­predominant gastritis) or severe atrophy; patients with gastric acid inhibition for >1 year; individuals with strong environmental risk factors for gastric cancer (heavy smoking; high exposure to dust, coal, quartz, or cement; and/or work in quarries); and H. pylori–positive patients with a fear of gastric cancer. Finally, the ACG clinical guidelines recommend testing and offering H. pylori eradication to patients with unexplained iron deficiency anemia and idiopathic thrombocytopenic purpura. Despite this, concerns have been raised about the widespread use of antibiotics for the therapy of all cases of H. pylori positivity, including the potential for increased bacterial resistance rates, reported weight gain, and alteration of the microbiome. Multiple drugs have been evaluated in the therapy of H. pylori. No single agent is effective in eradicating the organism. Combination therapy for 14 days provides the greatest efficacy, although regimens based on sequential administration of antibiotics also appear promising (see below). A shorter administration course (7–10 days), although attractive, has not proved as successful as the 14­day regimens. The agents used with the greatest frequency include amoxicillin, metronidazole, tetracycline, clarithromycin, and bismuth compounds. Suggested treatment regimens for H pylori are outlined in Table 324­4 Choice of a particular regimen will be influenced by several factors including Yonsei University Medical Library Access Provided by: Downloaded 2024­5­29 3:6 A  Your IP is 116.89.178.138 Chapter 324: Peptic Ulcer Disease and Related Disorders, John Del Valle ©2024 McGraw Hill.",6820,89,1705.0,"[ 0.11961587 -0.09237164 -0.9916512  ...  0.520362   -0.00225753
 -1.4148053 ]"
42,"quartz, or cement; and/or work in quarries); and H. pylori–positive patients with a fear of gastric cancer. Finally, the ACG clinical guidelines recommend testing and offering H. pylori eradication to patients with unexplained iron deficiency anemia and idiopathic thrombocytopenic purpura. Despite this, concerns have been raised about the widespread use of antibiotics for the therapy of all cases of H. pylori positivity, including the potential for increased bacterial resistance rates, reported weight gain, and alteration of the microbiome. Multiple drugs have been evaluated in the therapy of H. pylori. No single agent is effective in eradicating the organism. Combination therapy for 14 days provides the greatest efficacy, although regimens based on sequential administration of antibiotics also appear promising (see below). A shorter administration course (7–10 days), although attractive, has not proved as successful as the 14­day regimens. The agents used with the greatest frequency include amoxicillin, metronidazole, tetracycline, clarithromycin, and bismuth compounds. Suggested treatment regimens for H. pylori are outlined in Table 324­4. Choice of a particular regimen will be influenced by several factors, including efficacy, patient tolerance, existing antibiotic resistance, prior antibiotic use, and cost of the drugs. The aim for initial eradication rates should be 85– 90%. Dual therapy (PPI plus amoxicillin, PPI plus clarithromycin, ranitidine bismuth citrate [Tritec] plus clarithromycin) is not recommended in view of studies demonstrating eradication rates of <80–85%. The combination of bismuth, metronidazole, and tetracycline was the first triple regimen found effective against H. pylori. The combination of two antibiotics plus either a PPI, H2 blocker, or bismuth compound has comparable success rates. Addition of acid suppression assists in providing early symptom relief and enhances bacterial eradication. TABLE 324­4 Recommended First­Line Therapies for H. pylori Infection REGIMEN DRUGS (DOSES) DOSING FREQUENCY DURATION (DAYS) FDA APPROVAL Clarithromycin triple PPI (standard or double dose) bid 14 Yesa Clarithromycin (500 mg) Amoxicillin (1 g) or metronidazole (500 mg tid) Bismuth quadruple PPI (standard dose) bid 10–14 Nob Bismuth subcitrate (120–300 mg) or subsalicylate (300 mg) qid Tetracycline (500 mg) qid Metronidazole (250–500 mg) qid (250 mg) tid to qid (500 mg) Concomitant PPI (standard dose) bid 10–14 No Clarithromycin (500 mg) Amoxicillin (1 g) Nitroimidazole (500 mg)c Sequential PPI (standard dose) bid 5–7 No PPI, clarithromycin (500 mg) + nitroimidazole (500 mg)c bid 5–7 Hybrid PPI (standard dose) + amoxicillin (1 g) bid 7 No PPI, amoxicillin, clarithromycin (500 mg), nitroimidazole (500 mg)c bid 7 Levofloxacin triple PPI (standard or double dose) + amoxicillin (1 g) bid 5–7 No Levofloxacin (500 mg) qd Amoxicillin (1 g) bid Yonsei University Medical Library Access Provided by: Downloaded 2024­5­29 3:6 A  Your IP is 116.89.178.138 Chapter 324: Peptic Ulcer Disease and Related Disorders, John Del Valle ©2024 McGraw Hill. All Rights Reserved.   Terms of Use • Privacy Policy • Notice • Accessibility Page 25 / 49",3188,86,797.0,"[ 0.26621324 -0.24386156 -1.1981316  ...  0.85210603  0.02845037
 -1.4705774 ]"
43,"aSeveral PPI, clarithromycin, and amoxicillin combinations have achieved FDA approval. The regimen of a PPI, clarithromycin, and metronidazole is not an FDA­ approved treatment regimen. bThe regimen of a PPI, bismuth, tetracycline, and metronidazole combined with a PPI for 10 days is an FDA­approved treatment regimen. cMetronidazole or tinidazole. Abbreviations: bid, twice daily; FDA, Food and Drug Administration; PPI, proton pump inhibitor; tid, three times daily; qd, once daily; qid, four times daily. Source: Reproduced with permission from WD Chey et al: ACG clinical guideline: Treatment of Helicobacter pylori infection. Am J Gastroenterol 112:212, 2017. Hybrid PPI (standard dose) + amoxicillin (1 g) bid 7 No PPI, amoxicillin, clarithromycin (500 mg), nitroimidazole (500 mg)c bid 7 Levofloxacin triple PPI (standard or double dose) + amoxicillin (1 g) bid 5–7 No Levofloxacin (500 mg) qd Amoxicillin (1 g) bid Levofloxacin sequential PPI (standard or double dose) + amoxicillin (1 g) bid 5–7 No PPI, amoxicillin, levofloxacin (500 mg qd), nitroimidazole (500 mg)c bid 5–7 LOAD Levofloxacin (250 mg) qd 7–10 No PPI (double dose) qd Nitazoxanide (500 mg) bid Doxycycline (100 mg) qd Triple therapy, although effective, has several drawbacks, including the potential for poor patient compliance and drug­induced side effects. Compliance is being addressed by simplifying the regimens so that patients can take the medications twice a day. Simpler (dual therapy) and shorter regimens (7 and 10 days) are not as effective as triple therapy for 14 days. Two anti–H. pylori regimens are available in prepackaged formulation: Prevpac (lansoprazole, clarithromycin, and amoxicillin) and Helidac (BSS, tetracycline, and metronidazole). The contents of the Prevpac are to be taken twice per day for 14 days, whereas Helidac constituents are taken four times per day with an antisecretory agent (PPI or H2 blocker), also for at least 14 days. Clarithromycin­based triple therapy should be avoided in settings where H. pylori resistance to this agent exceeds 15%. Side effects have been reported in up to 20–30% of patients on triple therapy. Bismuth may cause black stools, constipation, or darkening of the tongue. The most feared complication with amoxicillin is pseudomembranous colitis, but this occurs in <1–2% of patients. Amoxicillin can also lead to antibiotic­associated diarrhea, nausea, vomiting, skin rash, and allergic reaction. Concomitant use of probiotics may ameliorate some of the antibiotic side effects (see below). Tetracycline has been reported to cause rashes and, very rarely, hepatotoxicity and anaphylaxis. One important concern with treating patients who may not need therapy is the potential for development of antibiotic­resistant strains. The incidence and type of antibiotic­resistant H. pylori strains vary worldwide. Strains resistant to metronidazole, clarithromycin, amoxicillin, and tetracycline have been described, with the latter two being uncommon. Antibiotic­resistant strains are the most common cause for treatment failure in compliant patients. Unfortunately, in vitro resistance does not predict outcome in patients. Culture and sensitivity testing of H. pylori is not performed routinely. Although resistance to metronidazole has been found in as many as 30% of isolates in North America and 80% in developing countries, triple therapy is effective in eradicating the organism in >50% of patients infected with a resistant strain. Clarithromycin resistance is seen in 13–16% of individuals in the United States, with resistance to amoxicillin being <1% and resistance to both metronidazole and clarithromycin in the 5% range. Resistance to tetracycline and rifabutin (see below) is reported to be <2% in the United States. In light of the paucity of H. pylori antibiotic real­time resistance data, asking the patient about prior antibiotic exposure should be included in the decision­making and used as a surrogate for potential antibiotic resistance, especially when it comes to prior macrolide use. Clarithromycin use should be excluded in patients with prior macrolide usage. An approach to antibiotic selection for H. pylori therapy has been recommended in the ACG clinical guidelines (Fig. 324­13). FIGURE 324­13 Approach to selecting antibiotics for patients with H. pylori infection. LOAD, levofloxacin, omeprazole, nitazoxanide, and doxycycline. (Reproduced with permission from WD Chey et al: ACG clinical guideline: Treatment of Helicobacter pylori infection. Am J Gastroenterol 112:212, 2017.)Yonsei University Medical Library Access Provided by: Downloaded 2024­5­29 3:6 A  Your IP is 116.89.178.138 Chapter 324: Peptic Ulcer Disease and Related Disorders, John Del Valle ©2024 McGraw Hill. All Rights Reserved.   Terms of Use • Privacy Policy • Notice • Accessibility Page 26 / 49",4841,78,1210.25,"[ 0.03492954 -0.06421936 -1.2967077  ...  0.40160397 -0.11208312
 -1.2859406 ]"
44,"g y g tetracycline and rifabutin (see below) is reported to be <2% in the United States. In light of the paucity of H. pylori antibiotic real­time resistance data, asking the patient about prior antibiotic exposure should be included in the decision­making and used as a surrogate for potential antibiotic resistance, especially when it comes to prior macrolide use. Clarithromycin use should be excluded in patients with prior macrolide usage. An approach to antibiotic selection for H. pylori therapy has been recommended in the ACG clinical guidelines (Fig. 324­13). FIGURE 324­13 Approach to selecting antibiotics for patients with H. pylori infection. LOAD, levofloxacin, omeprazole, nitazoxanide, and doxycycline. (Reproduced with permission from WD Chey et al: ACG clinical guideline: Treatment of Helicobacter pylori infection. Am J Gastroenterol 112:212, 2017.)Failure of H. pylori eradication with triple therapy in a compliant patient is usually due to infection with a resistant organism. A series of salvage therapies for H. pylori are shown in Table 324­5. Quadruple therapy (Table 324­4), where clarithromycin is substituted for metronidazole (or vice versa), should be the next step. The combination of PPI, amoxicillin, and rifabutin for 10 days has also been used successfully (86% cure rate) in patients infected with resistant strains. Additional regimens considered for second­line therapy include levofloxacin­based triple therapy (levofloxacin, amoxicillin, PPI) for 10 days and furazolidone­based triple therapy (furazolidone, amoxicillin, PPI) for 14 days. Unfortunately, there is no universally accepted treatment regimen recommended for patients in whom two courses of antibiotics have failed. If eradication is still not achieved in a compliant patient, then culture and sensitivity of the organism should be considered. One challenge with this approach is that culture and sensitivity testing is cumbersome and not widely available; thus, H. pylori resistance data within specific communities are often not available. Non­culture­based approaches using molecular markers to determine potential resistance through stool testing are being developed but are not widely available. Additional factors that may lower eradication rates include the patient’s country of origin (higher in Northeast Asia than other parts of Asia or Europe) and cigarette smoking. In addition, meta­analysis suggests that even the most effective regimens (quadruple therapy including PPI, bismuth, tetracycline, and metronidazole and triple therapy including PPI, clarithromycin, and amoxicillin) may have suboptimal eradication rates (<80%), thus demonstrating the need for the development of more efficacious treatments. TABLE 324­5 Salvage Therapies for H. pylori Infection REGIMEN DRUGS (DOSES) DOSING FREQUENCY DURATION (DAYS) FDA APPROVAL Bismuth quadruple PPI (standard dose) bid 14 Noa Bismuth subcitrate (120–300 mg) or subsalicylate (300 mg) qid Tetracycline (500 mg) qid Metronidazole (500 mg) tid or qid Yonsei University Medical Library Access Provided by: Downloaded 2024­5­29 3:6 A  Your IP is 116.89.178.138 Chapter 324: Peptic Ulcer Disease and Related Disorders, John Del Valle ©2024 McGraw Hill. All Rights Reserved.   Terms of Use • Privacy Policy • Notice • Accessibility Page 27 / 49",3307,51,826.75,"[ 0.07654889  0.04406476 -1.1306374  ...  0.30534083  0.46620786
 -1.2481431 ]"
45,"aPPI, bismuth, tetracycline, and metronidazole prescribed separately is not an FDA­approved treatment regimen. However, Pylera, a combination product containing bismuth subcitrate, tetracycline, and metronidazole, combined with a PPI for 10 days is an FDA­approved treatment regimen. Abbreviations: bid, twice daily; FDA, Food and Drug Administration; PPI, proton pump inhibitor; tid, three times daily; qd, once daily; qid, four times daily. Source: Reproduced with permission from WD Chey et al: ACG clinical guideline: Treatment of Helicobacter pylori infection. Am J Gastroenterol 112:212, 2017.pp g p g g g p y Additional factors that may lower eradication rates include the patient’s country of origin (higher in Northeast Asia than other parts of Asia or Europe) and cigarette smoking. In addition, meta­analysis suggests that even the most effective regimens (quadruple therapy including PPI, bismuth, tetracycline, and metronidazole and triple therapy including PPI, clarithromycin, and amoxicillin) may have suboptimal eradication rates (<80%), thus demonstrating the need for the development of more efficacious treatments. TABLE 324­5 Salvage Therapies for H. pylori Infection REGIMEN DRUGS (DOSES) DOSING FREQUENCY DURATION (DAYS) FDA APPROVAL Bismuth quadruple PPI (standard dose) bid 14 Noa Bismuth subcitrate (120–300 mg) or subsalicylate (300 mg) qid Tetracycline (500 mg) qid Metronidazole (500 mg) tid or qid Levofloxacin triple PPI (standard dose) bid 14 No Levofloxacin (500 mg) qd Amoxicillin (1 g) bid Concomitant PPI (standard dose) bid 10–14 No Clarithromycin (500 mg) bid Amoxicillin (1 g) bid Nitroimidazole (500 mg) bid or tid Rifabutin triple PPI (standard dose) bid 10 No Rifabutin (300 mg) qd Amoxicillin (1 g) bid High­dose dual PPI (standard to double dose) tid or qid 14 No Amoxicillin (1 g tid or 750 mg qid) tid or qid In view of the observation that 15–25% of patients treated with first­line therapy may still remain infected with the organism, new approaches to treatment have been explored. One promising approach is sequential therapy. Regimens examined consist of 5 days of amoxicillin and a PPI, followed by an additional 5 days of PPI plus tinidazole and clarithromycin or levofloxacin. One promising regimen that has the benefit of being shorter in duration, easier to take, and less expensive is 5 days of concomitant therapy (PPI twice daily, amoxicillin 1 g twice daily, levofloxacin 500 mg twice daily, and tinidazole 500 mg twice daily). Initial studies have demonstrated eradication rates of >90% with good patient tolerance. Confirmation of these findings and applicability of this approach in the United States are needed, although some experts are recommending abandoning clarithromycin­ based triple therapy in the United States for the concomitant therapy or the alternative sequential therapies highlighted above. Innovative non­antibiotic­mediated approaches have been explored in an effort to improve eradication rates of H. pylori. Pretreatment of patients with N­acetylcysteine as a mucolytic agent to destroy the H. pylori biofilm and therefore impair antibiotic resistance has been examined, but more studies are needed to confirm the applicability of this approach. In vitro studies suggest that certain probiotics like Lactobacillus or its metabolites can inhibit H. pylori. Administration of probiotics has been attempted in several clinical studies in an effort to maximize antibiotic­mediated eradication with Yonsei University Medical Library Access Provided by: Downloaded 2024­5­29 3:6 A  Your IP is 116.89.178.138 Chapter 324: Peptic Ulcer Disease and Related Disorders, John Del Valle ©2024 McGraw Hill. All Rights Reserved.   Terms of Use • Privacy Policy • Notice • Accessibility Page 28 / 49",3767,89,941.75,"[ 0.1613375  -0.04458958 -1.1400836  ...  0.560755    0.21709086
 -1.4158221 ]"
46,"Abbreviations: COX­2, isoenzyme of cyclooxygenase; NSAID, nonsteroidal anti­inflammatory drug; PPI, proton pump inhibitor.by an additional 5 days of PPI plus tinidazole and clarithromycin or levofloxacin. One promising regimen that has the benefit of being shorter in duration, easier to take, and less expensive is 5 days of concomitant therapy (PPI twice daily, amoxicillin 1 g twice daily, levofloxacin 500 mg twice daily, and tinidazole 500 mg twice daily). Initial studies have demonstrated eradication rates of >90% with good patient tolerance. Confirmation of these findings and applicability of this approach in the United States are needed, although some experts are recommending abandoning clarithromycin­ based triple therapy in the United States for the concomitant therapy or the alternative sequential therapies highlighted above. Innovative non­antibiotic­mediated approaches have been explored in an effort to improve eradication rates of H. pylori. Pretreatment of patients with N­acetylcysteine as a mucolytic agent to destroy the H. pylori biofilm and therefore impair antibiotic resistance has been examined, but more studies are needed to confirm the applicability of this approach. In vitro studies suggest that certain probiotics like Lactobacillus or its metabolites can inhibit H. pylori. Administration of probiotics has been attempted in several clinical studies in an effort to maximize antibiotic­mediated eradication with varying results. Overall, it appears that the use of certain probiotics, such as Lactobacillus spp., Saccharomyces spp., Bifidobacterium spp., and Bacillus clausii, did not alter eradication rates but importantly decreased antibiotic­associated side effects including nausea, dysgeusia, diarrhea, and abdominal discomfort/pain, resulting in enhanced tolerability of H. pylori therapies. Additional studies are needed to confirm the potential benefits of probiotics in this setting. Statins, specifically atorvastatin, have been used with some success as an adjunct to quadruple therapy in patients with NUD. Reinfection after successful eradication of H. pylori is rare in the United States (<1% per year). If recurrent infection occurs within the first 6 months after completing therapy, the most likely explanation is recrudescence as opposed to reinfection. Therapy of Nsaid­Related Gastric or Duodenal Injury Medical intervention for NSAID­related mucosal injury includes treatment of an active ulcer and primary prevention of future injury. Recommendations for the treatment and primary prevention of NSAID­related mucosal injury are listed in Table 324­6. Ideally, the injurious agent should be stopped as the first step in the therapy of an active NSAID­induced ulcer. If that is possible, then treatment with one of the acid inhibitory agents (H2 blockers, PPIs) is indicated. Cessation of NSAIDs is not always possible because of the patient’s severe underlying disease. Only PPIs can heal GUs or DUs, independent of whether NSAIDs are discontinued. TABLE 324­6 Recommendations for Treatment of NSAID­Related Mucosal Injury CLINICAL SETTING RECOMMENDATION Active ulcer  NSAID discontinued H2 receptor antagonist or PPI  NSAID continued PPI Prophylactic therapy Misoprostol PPI Selective COX­2 inhibitor H. pylori infection Eradication if active ulcer present or there is a past history of peptic ulcer disease The widespread use of NSAIDs has created some concern due to the increasing likelihood of GI and CV side effects associated with these agents. The approach to primary prevention has included avoiding the agent, using the lowest possible dose of the agent for the shortest period of time possible, using NSAIDs that are theoretically less injurious, using newer topical NSAID preparations, and/or using concomitant medical therapy to prevent NSAID­induced injury. Several nonselective NSAIDs that are associated with a lower likelihood of GI and CV toxicity include naproxen and ibuprofen, although the beneficial effect may be eliminated if higher dosages of the agents are used. Primary prevention of NSAID­induced ulceration can be accomplished by a PPI and, if not tolerated, misoprostol (200 μg qid). High­dose H2 blockers (famotidine 40 mg bid) have also shown some promise in preventing endoscopically documented ulcers, although PPIs are superior. The highly selective COX­2 inhibitors, celecoxib and rofecoxib, are 100 times more selective inhibitors of COX­2 than standard NSAIDs, leading to gastric or duodenal mucosal injury that is comparable to placebo; their utilization led to an increase in CV events and withdrawal from the market. Additional caution was engendered when the CLASS study demonstrated that the advantage of celecoxib in preventing GI complications was offset when low­dose aspirin was used simultaneously. Therefore, gastric protection therapy is required in individuals taking COX­2 inhibitors and aspirin prophylaxis. Finally, much of the work demonstrating the benefit of COX­2 inhibitors and PPIs on GI injury has been performed in individuals of average risk; it is unclear if the same level of benefit will be achieved in high­risk patients. For example, concomitant use of warfarin and a COX­2 inhibitor was associated with rates of GI bleeding similar to those observed in Yonsei University Medical Library Access Provided by: Downloaded 2024­5­29 3:6 A  Your IP is 116.89.178.138 Chapter 324: Peptic Ulcer Disease and Related Disorders, John Del Valle ©2024 McGraw Hill. All Rights Reserved.   Terms of Use • Privacy Policy • Notice • Accessibility Page 29 / 49",5573,81,1393.25,"[-0.20313771  0.10133725 -1.3697708  ...  0.48408705  0.12447877
 -1.3355228 ]"
47,"Abbreviations: CV, cardiovascular; GI, gastrointestinal; NSAID, nonsteroidal anti­inflammatory drug; PPI, proton pump inhibitor. Source: Republished with permission of MJH Life Sciences, LLC, from COX­2 inhibitor use after Vioxx: careful balance orend of the rope?, Fendrick AM, 10(11 Pt 1): 2004; permission conveyed through Copyright Clearance Center, Inc. using NSAIDs that are theoretically less injurious, using newer topical NSAID preparations, and/or using concomitant medical therapy to prevent NSAID­induced injury. Several nonselective NSAIDs that are associated with a lower likelihood of GI and CV toxicity include naproxen and ibuprofen, although the beneficial effect may be eliminated if higher dosages of the agents are used. Primary prevention of NSAID­induced ulceration can be accomplished by a PPI and, if not tolerated, misoprostol (200 μg qid). High­dose H2 blockers (famotidine 40 mg bid) have also shown some promise in preventing endoscopically documented ulcers, although PPIs are superior. The highly selective COX­2 inhibitors, celecoxib and rofecoxib, are 100 times more selective inhibitors of COX­2 than standard NSAIDs, leading to gastric or duodenal mucosal injury that is comparable to placebo; their utilization led to an increase in CV events and withdrawal from the market. Additional caution was engendered when the CLASS study demonstrated that the advantage of celecoxib in preventing GI complications was offset when low­dose aspirin was used simultaneously. Therefore, gastric protection therapy is required in individuals taking COX­2 inhibitors and aspirin prophylaxis. Finally, much of the work demonstrating the benefit of COX­2 inhibitors and PPIs on GI injury has been performed in individuals of average risk; it is unclear if the same level of benefit will be achieved in high­risk patients. For example, concomitant use of warfarin and a COX­2 inhibitor was associated with rates of GI bleeding similar to those observed in patients taking nonselective NSAIDs. A combination of factors, including withdrawal of the majority of COX­2 inhibitors from the market, the observation that low­dose aspirin appears to diminish the beneficial effect of COX­2–selective inhibitors, and the growing use of aspirin for prophylaxis of CV events, has significantly altered the approach to gastric protective therapy during the use of NSAIDs. A set of guidelines for the approach to the use of NSAIDs was published by the ACG and is shown in Table 324­7. Individuals who are not at risk for CV events, do not use aspirin, and are without risk for GI complications can receive nonselective NSAIDs without gastric protection. In those without CV risk factors but with a high potential risk (prior GI bleeding or multiple GI risk factors) for NSAID­induced GI toxicity, cautious use of a selective COX­2 inhibitor and co­therapy with high­dose PPI or misoprostol are recommended. Individuals at moderate GI risk without cardiac risk factors can be treated with a COX­2 inhibitor alone or with a nonselective NSAID with PPI or misoprostol. Individuals with CV risk factors, who require low­dose aspirin and have low potential for NSAID­ induced toxicity, should be considered for a non­NSAID agent or use of a traditional NSAID such as naproxen (lower CV side effects) in combination with gastric protection, if warranted. Finally, individuals with CV and GI risks who require aspirin must be considered for non­NSAID therapy, but if that is not an option, then gastric protection with any type of NSAID must be considered. Any patient, regardless of risk status, who is being considered for long­term traditional NSAID therapy should also be considered for H. pylori testing and treatment if positive. Assuring the use of GI protective agents with NSAIDs is difficult, even in high­risk patients. This is in part due to underprescribing of the appropriate protective agent; other times, the difficulty is related to patient compliance. The latter may be due to patients forgetting to take multiple pills or preferring not to take the extra pill, especially if they have no GI symptoms. Several NSAID gastroprotective­containing combination pills are now commercially available, including double­dose famotidine with ibuprofen, diclofenac with misoprostol, and naproxen with esomeprazole. Although initial studies suggested improved compliance and a cost advantage when taking these combination drugs, their clinical benefit over the use of separate pills has not been established. One additional concern with NSAID­induced GI complications is the relatively low rate of primary care provider compliance with established guidelines outlining preventative measures. An intervention including professional education, informatics to facilitate review, and financial incentives for practices to review patients’ charts to assess appropriateness showed a reduced rate of high­risk prescribing of antiplatelet medications and NSAIDs with a tendency toward improved clinical outcomes. Efforts continue toward developing safer NSAIDs, including topical NSAIDs, NSAID formulations that are rapidly absorbed (diclofenac potassium powder mixed with a buffering agent, Prosorb and SoluMatrix technology), NO­releasing NSAIDs, hydrogen sulfide–releasing NSAIDs, dual COX/5­LOX inhibitors, NSAID prodrugs, and agents that can effectively sequester unbound NSAIDs without interfering with their efficacy. TABLE 324­7 Guide to NSAID Therapy NO/LOW NSAID GI RISK NSAID GI RISK No CV risk (no aspirin) Traditional NSAID Coxib or Traditional NSAID + PPI or misoprostol Consider non­NSAID therapy CV risk (consider aspirin) Traditional NSAID + PPI or misoprostol if GI risk warrants gastroprotection Consider non­NSAID therapy A gastroprotective agent must be added if a traditional NSAID is prescribed Consider non­NSAID therapy Approach and Therapy: Summary Controversy continues regarding the best approach to the patient who presents with dyspepsia (Chap. 45). The discovery of H. pylori and its role in pathogenesis of ulcers has added a new variable to the equation. Previously, if a patient <50 years of age presented with dyspepsia and without alarming signs or symptoms suggestive of an ulcer complication or malignancy, an empirical therapeutic trial with acid suppression was commonly Yonsei University Medical Library Access Provided by: Downloaded 2024­5­29 3:6 A  Your IP is 116.89.178.138 Chapter 324: Peptic Ulcer Disease and Related Disorders, John Del Valle ©2024 McGraw Hill. All Rights Reserved.   Terms of Use • Privacy Policy • Notice • Accessibility Page 30 / 49",6597,90,1649.25,"[ 0.09598868 -0.06355387 -1.3860918  ...  0.35832036  0.61665475
 -1.3790903 ]"
48,"Abbreviations: CV, cardiovascular; GI, gastrointestinal; NSAID, nonsteroidal anti­inflammatory drug; PPI, proton pump inhibitor. Source: Republished with permission of MJH Life Sciences, LLC, from COX­2 inhibitor use after Vioxx: careful balance orend of the rope?, Fendrick AM, 10(11 Pt 1): 2004; permission conveyed through Copyright Clearance Center, Inc. Approach and Therapy: Summary Controversy continues regarding the best approach to the patient who presents with dyspepsia (Chap. 45). The discovery of H. pylori and its role in pathogenesis of ulcers has added a new variable to the equation. Previously, if a patient <50 years of age presented with dyspepsia and without alarming signs or symptoms suggestive of an ulcer complication or malignancy, an empirical therapeutic trial with acid suppression was commonly recommended. Although this approach is practiced by some today, an approach presently gaining approval for the treatment of patients with dyspepsia is outlined in Fig. 324­14. The referral to a gastroenterologist is for the potential need of endoscopy and subsequent evaluation and treatment if the endoscopy is negative. FIGURE 324­14 Overview of new­onset dyspepsia. GERD, gastroesophageal reflux disease; Hp, Helicobacter pylori; IBS, irritable bowel syndrome; UBT, urea breath test. (Reproduced with permission from BS Anand, DY Graham: State­of­the­Art: Ulcer and Gastritis, Endoscopy 31:215, 1999. © Georg Thieme Verlag KG.)Verlag KG.)Once an ulcer (GU or DU) is documented, the main issue at stake is whether H. pylori or an NSAID is involved. With H. pylori present, independent of the NSAID status, triple therapy is recommended for 14 days, followed by continued acid­suppressing drugs (H2 receptor antagonist or PPIs) for a total of 4–6 weeks. H. pylori eradication should be documented 4 weeks after completing antibiotics. The test of choice for documenting eradication is the laboratory­based validated monoclonal stool antigen test or a urea breath test (UBT). The patient must be off antisecretory agents for at least 7 days when being tested for eradication of H. pylori with UBT or stool antigen. Serologic testing is not useful for the purpose of documenting eradication because antibody titers fall slowly and often do not become undetectable. Some recommend that patients with complicated ulcer disease or who are frail should be treated with long­term acid suppression, thus making documentation of H. pylori eradication a moot point. In view of this discrepancy in practice, it would be best to discuss with the patient the different options available. Several issues differentiate the approach to a GU versus a DU. GUs, especially of the body and fundus, have the potential of being malignant. Multiple biopsies of a GU should be taken initially; even if these are negative for neoplasm, repeat endoscopy to document healing at 8–12 weeks should be performed, with biopsy if the ulcer is still present. About 70% of GUs eventually found to be malignant undergo significant (usually incomplete) healing. Repeat endoscopy is warranted in patients with DU if symptoms persist despite medical therapy or a complication is suspected. The majority (>90%) of GUs and DUs heal with the conventional therapy outlined above. A GU that fails to heal after 12 weeks and a DU that does not heal after 8 weeks of therapy should be considered refractory. Once poor compliance and persistent H. pylori infection have been excluded, NSAID use, either inadvertent or surreptitious must be excluded In addition cigarette smoking must be eliminated For a GU malignancy must be meticulously Yonsei University Medical Library Access Provided by: Downloaded 2024­5­29 3:6 A  Your IP is 116.89.178.138 Chapter 324: Peptic Ulcer Disease and Related Disorders, John Del Valle ©2024 McGraw Hill. All Rights Reserved.   Terms of Use • Privacy Policy • Notice • Accessibility Page 31 / 49",3908,57,977.0,"[ 0.17400311 -0.1584779  -1.7031622  ...  0.35914952  0.6737405
 -1.1712757 ]"
49,"frail should be treated with long­term acid suppression, thus making documentation of H. pylori eradication a moot point. In view of this discrepancy in practice, it would be best to discuss with the patient the different options available. Several issues differentiate the approach to a GU versus a DU. GUs, especially of the body and fundus, have the potential of being malignant. Multiple biopsies of a GU should be taken initially; even if these are negative for neoplasm, repeat endoscopy to document healing at 8–12 weeks should be performed, with biopsy if the ulcer is still present. About 70% of GUs eventually found to be malignant undergo significant (usually incomplete) healing. Repeat endoscopy is warranted in patients with DU if symptoms persist despite medical therapy or a complication is suspected. The majority (>90%) of GUs and DUs heal with the conventional therapy outlined above. A GU that fails to heal after 12 weeks and a DU that does not heal after 8 weeks of therapy should be considered refractory. Once poor compliance and persistent H. pylori infection have been excluded, NSAID use, either inadvertent or surreptitious, must be excluded. In addition, cigarette smoking must be eliminated. For a GU, malignancy must be meticulously excluded. Next, consideration should be given to a gastric acid hypersecretory state such as ZES (see “Zollinger­Ellison Syndrome,” below) or the idiopathic form, which can be excluded with gastric acid analysis. Although a subset of patients has gastric acid hypersecretion of unclear etiology as a contributing factor to refractory ulcers, ZES should be excluded with a fasting gastrin or secretin stimulation test (see below). More than 90% of refractory ulcers (either DUs or GUs) heal after 8 weeks of treatment with higher doses of PPI (omeprazole 40 mg/d; lansoprazole 30–60 mg/d). This higher dose is also effective in maintaining remission. Surgical intervention may be a consideration at this point; however, other rare causes of refractory ulcers must be excluded before recommending surgery. Rare etiologies of refractory ulcers that may be diagnosed by gastric or duodenal biopsies include ischemia, Crohn’s disease, amyloidosis, sarcoidosis, lymphoma, eosinophilic gastroenteritis, smoking crack cocaine, or infection (cytomegalovirus [CMV], tuberculosis, or syphilis). Surgical Therapy Surgical intervention in PUD can be viewed as being either elective, for treatment of medically refractory disease, or as urgent/emergent, for the treatment of an ulcer­related complication. The development of pharmacologic and endoscopic approaches for the treatment of peptic disease and its complications has led to a substantial decrease in the number of operations needed for this disorder with a drop of >90% for elective ulcer surgery over the past four decades. Refractory ulcers are an exceedingly rare occurrence. Surgery is more often required for treatment of an ulcer­related complication. Hemorrhage is the most common ulcer­related complication, occurring in ~15–25% of patients. Bleeding may occur in any age group but is most often seen in older patients (sixth decade or beyond). The majority of patients stop bleeding spontaneously, but endoscopic therapy (Chap. 322) is necessary in some. Parenterally and orally administered PPIs also decrease ulcer rebleeding in patients who have undergone endoscopic therapy. Patients unresponsive or refractory to endoscopic intervention will require angiographic intervention or surgery (~5% of transfusion­requiring patients). Free peritoneal perforation occurs in ~2–3% of DU patients, with NSAID­induced GU perforations occurring more commonly. Sudden onset of severe abdominal pain with peritoneal signs and evidence of pneumoperitoneum on abdominal imaging is the classic presentation of a perforated viscous, but this presentation occurs in only two­thirds of patients. The latter is especially true in elderly patients (>70 years old), obese individuals, and immunocompromised patients. It is important to keep in mind that, as in the case of bleeding, up to 10% of these patients will not have antecedent ulcer symptoms. Delay in diagnosis clearly leads to higher mortality; thus, early suspicion and intervention with nasogastric suction, intravenous PPI, antibiotics and surgical consultation are essential. Concomitant bleeding may occur in up to 10% of patients with perforation, with mortality being increased substantially. Peptic ulcer can also penetrate into adjacent organs, especially with a posterior DU, which can penetrate into the pancreas, colon, liver, or biliary tree. Pyloric channel ulcers or DUs can lead to gastric outlet obstruction in ~2–3% of patients. This can result from chronic scarring or from impaired motility due to inflammation and/or edema with pylorospasm. Patients may present with early satiety, nausea, vomiting of undigested food, and weight loss. Conservative management with nasogastric suction, intravenous hydration/nutrition, and antisecretory agents is indicated for 7–10 days with the hope that a functional obstruction will reverse. If a mechanical obstruction persists, endoscopic intervention with balloon dilation may be effective. Surgery should be considered if all else fails. Specific Operations for Duodenal Ulcers Surgical treatment was originally designed to decrease gastric acid secretion. Operations most commonly performed include (1) vagotomy and drainage (by pyloroplasty, gastroduodenostomy, or gastrojejunostomy), (2) highly selective vagotomy (which does not require a drainage procedure), and (3) vagotomy with antrectomy.",5621,45,1405.25,"[-0.25605845 -0.13626969 -1.3923898  ...  0.9974106   0.68176734
 -1.2584106 ]"
49,"The specific procedure performed is dictated by the underlying circumstances: elective versus emergency, the degree and extent of duodenal ulceration, the etiology of the ulcer (H. pylori, NSAIDs, malignancy), and the expertise of the surgeon. Moreover, the trend has been toward a dramatic decrease in the need for surgery for treatment of refractory PUD, and when needed, minimally invasive and anatomy­preserving operations are preferred. Vagotomy is a component of each of these procedures and is aimed at decreasing acid secretion through ablating cholinergic input to the stomach. Unfortunately, both truncal and selective vagotomy (preserves the celiac and hepatic branches) result in gastric atony despite successful reduction of both basal acid output (BAO; decreased by 85%) and maximal acid output (MAO; decreased by 50%). Drainage through pyloroplasty or gastroduodenostomy is required in an effort to compensate for the vagotomy­induced gastric motility disorder. This procedure has an intermediate Yonsei University Medical Library Access Provided by: Downloaded 2024­5­29 3:6 A  Your IP is 116.89.178.138 Chapter 324: Peptic Ulcer Disease and Related Disorders, John Del Valle ©2024 McGraw Hill. All Rights Reserved.   Terms of Use • Privacy Policy • Notice • Accessibility Page 32 / 49",1301,17,325.25,"[ 0.21312462 -0.46891254 -1.2652774  ...  0.32207844 -0.428298
 -1.6969683 ]"
50,"Surgical treatment was originally designed to decrease gastric acid secretion. Operations most commonly performed include (1) vagotomy and drainage (by pyloroplasty, gastroduodenostomy, or gastrojejunostomy), (2) highly selective vagotomy (which does not require a drainage procedure), and (3) vagotomy with antrectomy. The specific procedure performed is dictated by the underlying circumstances: elective versus emergency, the degree and extent of duodenal ulceration, the etiology of the ulcer (H. pylori, NSAIDs, malignancy), and the expertise of the surgeon. Moreover, the trend has been toward a dramatic decrease in the need for surgery for treatment of refractory PUD, and when needed, minimally invasive and anatomy­preserving operations are preferred. Vagotomy is a component of each of these procedures and is aimed at decreasing acid secretion through ablating cholinergic input to the stomach. Unfortunately, both truncal and selective vagotomy (preserves the celiac and hepatic branches) result in gastric atony despite successful reduction of both basal acid output (BAO; decreased by 85%) and maximal acid output (MAO; decreased by 50%). Drainage through pyloroplasty or gastroduodenostomy is required in an effort to compensate for the vagotomy­induced gastric motility disorder. This procedure has an intermediate complication rate and a 10% ulcer recurrence rate. To minimize gastric dysmotility, highly selective vagotomy (also known as parietal cell, super­ selective, or proximal vagotomy) was developed. Only the vagal fibers innervating the portion of the stomach that contains parietal cells are transected, thus leaving fibers important for regulating gastric motility intact. Although this procedure leads to an immediate decrease in both BAO and stimulated acid output, acid secretion recovers over time. By the end of the first postoperative year, basal and stimulated acid output are ~30 and 50%, respectively, of preoperative levels. Ulcer recurrence rates are higher with highly selective vagotomy (≥10%), although the overall complication rates are the lowest of the three procedures. The procedure that provides the lowest rates of ulcer recurrence (1%) but has the highest complication rate is vagotomy (truncal or selective) in combination with antrectomy. Antrectomy is aimed at eliminating an additional stimulant of gastric acid secretion, gastrin. Two principal types of reanastomoses are used after antrectomy: gastroduodenostomy (Billroth I) or gastrojejunostomy (Billroth II) (Fig. 324­15). Although Billroth I is often preferred over II, severe duodenal inflammation or scarring may preclude its performance. Prospective, randomized studies confirm that partial gastrectomy followed by Roux­en­Y reconstruction leads to a significantly better clinical, endoscopic, and histologic outcome than Billroth II reconstruction. FIGURE 324­15 Schematic representation of Billroth I and II procedures. Of these procedures, highly selective vagotomy may be the procedure of choice in the elective setting, except in situations where ulcer recurrence rates are high (prepyloric ulcers and those refractory to medical therapy). Selection of vagotomy and antrectomy may be more appropriate in these circumstances. Yonsei University Medical Library Access Provided by: Downloaded 2024­5­29 3:6 A  Your IP is 116.89.178.138 Chapter 324: Peptic Ulcer Disease and Related Disorders, John Del Valle ©2024 McGraw Hill. All Rights Reserved.   Terms of Use • Privacy Policy • Notice • Accessibility Page 33 / 49",3534,36,883.5,"[ 0.12196431 -0.57443243 -1.2657715  ...  0.32614997 -0.17861827
 -1.4950893 ]"
51,"reconstruction. FIGURE 324­15 Schematic representation of Billroth I and II procedures. Of these procedures, highly selective vagotomy may be the procedure of choice in the elective setting, except in situations where ulcer recurrence rates are high (prepyloric ulcers and those refractory to medical therapy). Selection of vagotomy and antrectomy may be more appropriate in these circumstances. These procedures have been traditionally performed by standard laparotomy. The advent of laparoscopic surgery has led several surgical teams to successfully perform highly selective vagotomy, truncal vagotomy/pyloroplasty, and truncal vagotomy/antrectomy through this approach. An increase in the number of laparoscopic procedures for treatment of PUD has occurred. Laparoscopic repair of perforated peptic ulcers is safe, feasible for the experienced surgeon, and associated with decreased postoperative pain, although it does take longer than an open approach. Moreover, no difference between the two approaches is noted in postoperative complications or length of hospital stay. Specific Operations for GUs The location and presence of a concomitant DU dictate the operative procedure performed for a GU. Antrectomy (including the ulcer) with a Billroth I anastomosis is the treatment of choice for an antral ulcer. Vagotomy is performed only if a DU is present. Although ulcer excision with vagotomy and drainage procedure has been proposed, the higher incidence of ulcer recurrence makes this a less desirable approach. Ulcers located near the esophagogastric junction may require a more radical approach, a subtotal gastrectomy with a Roux­en­Y esophagogastrojejunostomy (Csendes’ procedure). A less aggressive approach, including antrectomy, intraoperative ulcer biopsy, and vagotomy (Kelling­Madlener procedure), may be indicated in fragile patients with a high GU. Ulcer recurrence approaches 30% with this procedure. Surgery­Related Complications Complications seen after surgery for PUD are related primarily to the extent of the anatomic modification performed. Minimal alteration (highly selective vagotomy) is associated with higher rates of ulcer recurrence and less GI disturbance. More aggressive surgical procedures have a lower rate of ulcer recurrence but a greater incidence of GI dysfunction. Overall, morbidity and mortality related to these procedures are quite low. Morbidity associated with vagotomy and antrectomy or pyloroplasty is ≤5%, with mortality ~1%. Highly selective vagotomy has lower morbidity and mortality rates of 1 and 0.3%, respectively. I dditi t th t ti l l f i t bd i l d (bl di i f ti th b b li ) t i d d l Yonsei University Medical Library Access Provided by: Downloaded 2024­5­29 3:6 A  Your IP is 116.89.178.138 Chapter 324: Peptic Ulcer Disease and Related Disorders, John Del Valle ©2024 McGraw Hill. All Rights Reserved.   Terms of Use • Privacy Policy • Notice • Accessibility Page 34 / 49",2938,63,734.5,"[-0.04051866 -0.73128957 -1.1814759  ...  0.49349624 -0.21970437
 -1.053091  ]"
52,"p ) gg pp , g y, p p y, g y ( g p ), y indicated in fragile patients with a high GU. Ulcer recurrence approaches 30% with this procedure. Surgery­Related Complications Complications seen after surgery for PUD are related primarily to the extent of the anatomic modification performed. Minimal alteration (highly selective vagotomy) is associated with higher rates of ulcer recurrence and less GI disturbance. More aggressive surgical procedures have a lower rate of ulcer recurrence but a greater incidence of GI dysfunction. Overall, morbidity and mortality related to these procedures are quite low. Morbidity associated with vagotomy and antrectomy or pyloroplasty is ≤5%, with mortality ~1%. Highly selective vagotomy has lower morbidity and mortality rates of 1 and 0.3%, respectively. In addition to the potential early consequences of any intraabdominal procedure (bleeding, infection, thromboembolism), gastroparesis, duodenal stump leak, and efferent loop obstruction can be observed. Recurrent Ulceration The risk of ulcer recurrence is directly related to the procedure performed. Ulcers that recur after partial gastric resection tend to develop at the anastomosis (stomal or marginal ulcer). Epigastric abdominal pain is the most frequent presenting complaint (>90%). Severity and duration of pain tend to be more progressive than observed with DUs before surgery. Ulcers may recur for several reasons, including incomplete vagotomy, inadequate drainage, retained antrum, and, less likely, persistent or recurrent H. pylori infection. ZES should have been excluded preoperatively. Surreptitious use of NSAIDs is an important reason for recurrent ulcers after surgery, especially if the initial procedure was done for an NSAID­induced ulcer. Once H. pylori and NSAIDs have been excluded as etiologic factors, the question of incomplete vagotomy or retained gastric antrum should be explored. For the latter, fasting plasma gastrin levels should be determined. If elevated, retained antrum or ZES (see below) should be considered. Incomplete vagotomy can be ruled out by gastric acid analysis coupled with sham feeding. In this test, gastric acid output is measured while the patient sees, smells, and chews a meal (without swallowing). The cephalic phase of gastric secretion, which is mediated by the vagus, is being assessed with this study. An increase in gastric acid output in response to sham feeding is evidence that the vagus nerve is intact. A rise in serum pancreatic polypeptide >50% within 30 min of sham feeding is also suggestive of an intact vagus nerve. Medical therapy with H2 blockers will heal postoperative ulceration in 70–90% of patients. The efficacy of PPIs has not been fully assessed in this group, but one may anticipate greater rates of ulcer healing compared to those obtained with H2 blockers. Repeat operation (complete vagotomy, partial gastrectomy) may be required in a small subgroup of patients who have not responded to aggressive medical management. Afferent Loop Syndromes Although rarely seen today as a result of the decrease in the performance of Billroth II anastomosis, two types of afferent loop syndrome can occur in patients who have undergone this type of partial gastric resection. The more common of the two is bacterial overgrowth in the afferent limb secondary to stasis. Patients may experience postprandial abdominal pain, bloating, and diarrhea with concomitant malabsorption of fats and vitamin B12. Cases refractory to antibiotics may require surgical revision of the loop. The less common afferent loop syndrome can present with severe abdominal pain and bloating that occur 20–60 min after meals. Pain is often followed by nausea and vomiting of bile­containing material. The pain and bloating may improve after emesis. The cause of this clinical picture is theorized to be incomplete drainage of bile and pancreatic secretions from an afferent loop that is partially obstructed. Cases refractory to dietary measures may need surgical revision or conversion of the Billroth II anastomosis to a Roux­en­Y gastrojejunostomy. Dumping Syndrome Dumping syndrome consists of a series of vasomotor and GI signs and symptoms and occurs in patients who have undergone vagotomy and drainage (especially Billroth procedures). Two phases of dumping, early and late, can occur. Early dumping takes place 15–30 min after meals and consists of crampy abdominal discomfort, nausea, diarrhea, belching, tachycardia, palpitations, diaphoresis, light­headedness, and, rarely, syncope. These signs and symptoms arise from the rapid emptying of hyperosmolar gastric contents into the small intestine, resulting in a fluid shift into the gut lumen with plasma volume contraction and acute intestinal distention. Release of vasoactive GI hormones (vasoactive intestinal polypeptide, neurotensin, motilin) is also theorized to play a role in early dumping. The late phase of dumping typically occurs 90 min to 3 h after meals. Vasomotor symptoms (light­headedness, diaphoresis, palpitations, tachycardia, and syncope) predominate during this phase.",5094,60,1273.5,"[-0.24970977 -0.79908    -1.3505226  ...  0.35621762  0.17952879
 -1.1517926 ]"
52,"This component of dumping is thought to be secondary to hypoglycemia from excessive insulin release. Dumping syndrome is most noticeable after meals rich in simple carbohydrates (especially sucrose) and high osmolarity. Ingestion of large amounts of fluids may also contribute. After vagotomy and drainage, up to 50% of patients will experience dumping syndrome to some degree early on. Signs and symptoms often improve with time, but a severe protracted picture can occur in up to 1% of patients. Dietary modification is the cornerstone of therapy for patients with dumping syndrome. Small, multiple (six) meals devoid of simple carbohydrates coupled with elimination of liquids during meals is important. Antidiarrheals and anticholinergic agents are complementary to diet. Guar and pectin, Yonsei University Medical Library Access Provided by: Downloaded 2024­5­29 3:6 A  Your IP is 116.89.178.138 Chapter 324: Peptic Ulcer Disease and Related Disorders, John Del Valle ©2024 McGraw Hill. All Rights Reserved.   Terms of Use • Privacy Policy • Notice • Accessibility Page 35 / 49",1082,15,270.5,"[ 0.17168109 -0.43386593 -0.75114465 ... -0.03207386  0.43258595
 -1.0506309 ]"
53,"plasma volume contraction and acute intestinal distention. Release of vasoactive GI hormones (vasoactive intestinal polypeptide, neurotensin, motilin) is also theorized to play a role in early dumping. The late phase of dumping typically occurs 90 min to 3 h after meals. Vasomotor symptoms (light­headedness, diaphoresis, palpitations, tachycardia, and syncope) predominate during this phase. This component of dumping is thought to be secondary to hypoglycemia from excessive insulin release. Dumping syndrome is most noticeable after meals rich in simple carbohydrates (especially sucrose) and high osmolarity. Ingestion of large amounts of fluids may also contribute. After vagotomy and drainage, up to 50% of patients will experience dumping syndrome to some degree early on. Signs and symptoms often improve with time, but a severe protracted picture can occur in up to 1% of patients. Dietary modification is the cornerstone of therapy for patients with dumping syndrome. Small, multiple (six) meals devoid of simple carbohydrates coupled with elimination of liquids during meals is important. Antidiarrheals and anticholinergic agents are complementary to diet. Guar and pectin, which increase the viscosity of intraluminal contents, may be beneficial in more symptomatic individuals. Acarbose, an α­glucosidase inhibitor that delays digestion of ingested carbohydrates, has also been shown to be beneficial in the treatment of the late phases of dumping. The somatostatin analogue octreotide has been successful in diet­refractory cases. This drug is administered subcutaneously (50 μg tid), titrated according to clinical response. A long­acting depot formulation of octreotide can be administered once every 28 days and provides symptom relief comparable to the short­ acting agent. In addition, patient weight gain and quality of life appear to be superior with the long­acting form. Postvagotomy Diarrhea Up to 10% of patients may seek medical attention for the treatment of postvagotomy diarrhea. This complication is most commonly observed after truncal vagotomy, which is rarely performed today. Patients may complain of intermittent diarrhea that occurs typically 1–2 h after meals. Occasionally, the symptoms may be severe and relentless. This is due to a motility disorder from interruption of the vagal fibers supplying the luminal gut. Other contributing factors may include decreased absorption of nutrients (see below), increased excretion of bile acids, and release of luminal factors that promote secretion. Diphenoxylate or loperamide is often useful in symptom control. The bile salt–binding agent cholestyramine may be helpful in severe cases. Surgical reversal of a 10­cm segment of jejunum may yield a substantial improvement in bowel frequency in a subset of patients. Bile Reflux Gastropathy A subset of post–partial gastrectomy patients who present with abdominal pain, early satiety, nausea, and vomiting will have mucosal erythema of the gastric remnant as the only finding. Histologic examination of the gastric mucosa reveals minimal inflammation but the presence of epithelial cell injury. This clinical picture is categorized as bile or alkaline reflux gastropathy/gastritis. Although reflux of bile is implicated as the reason for this disorder, the mechanism is unknown. Prokinetic agents, cholestyramine, and sucralfate have been somewhat effective treatments. Severe refractory symptoms may require using either nuclear scanning with 99mTc­HIDA to document reflux. Surgical diversion of pancreaticobiliary secretions away from the gastric remnant with a Roux­en­Y gastrojejunostomy consisting of a long (50–60 cm) Roux limb has been used in severe cases. Bilious vomiting improves, but early satiety and bloating may persist in up to 50% of patients. Maldigestion and Malabsorption Weight loss can be observed in up to 60% of patients after partial gastric resection. Patients can experience a 10% loss of body weight, which stabilizes 3 months postoperatively. A significant component of this weight reduction is due to decreased oral intake. However, mild steatorrhea can also develop. Reasons for maldigestion/malabsorption include decreased gastric acid production, rapid gastric emptying, decreased food dispersion in the stomach, reduced luminal bile concentration, reduced pancreatic secretory response to feeding, and rapid intestinal transit. Decreased serum vitamin B12 levels can be observed after partial gastrectomy. This is usually not due to deficiency of IF, since a minimal amount of parietal cells (source of IF) is removed during antrectomy. Reduced vitamin B12 may be due to competition for the vitamin by bacterial overgrowth or inability to split the vitamin from its protein­bound source due to hypochlorhydria.",4777,37,1194.25,"[-0.2142584  -0.05823022 -0.8508667  ...  0.03582978  0.42195708
 -0.75239366]"
53,"Iron­deficiency anemia may be a consequence of impaired absorption of dietary iron in patients with a Billroth II gastrojejunostomy. Absorption of iron salts is normal in these individuals; thus, a favorable response to oral iron supplementation can be anticipated. Folate deficiency with concomitant anemia can also develop in these patients. This deficiency may be secondary to decreased absorption or diminished oral intake. Malabsorption of vitamin D and calcium resulting in osteoporosis and osteomalacia is common after partial gastrectomy and gastrojejunostomy (Billroth II). Osteomalacia can occur as a late complication in up to 25% of post–partial gastrectomy patients. Bone fractures occur twice as commonly in men after gastric surgery as in a control population. It may take years before x­ray findings demonstrate diminished bone density. Elevated alkaline phosphatase, reduced serum calcium, bone pain, and pathologic fractures may be seen in patients with osteomalacia. The high incidence of these abnormalities in this subgroup of patients justifies treating them with vitamin D and calcium supplementation indefinitely. Therapy is especially important in females. Copper deficiency has also been reported in patients undergoing surgeries that bypass the duodenum, where copper is primarily absorbed. Patients may present with a rare syndrome that includes ataxia, myelopathy, and peripheral neuropathy. Gastric Adenocarcinoma The incidence of adenocarcinoma in the gastric stump is increased 15 years after resection. Some have reported a four­ to fivefold increase in gastric Yonsei University Medical Library Access Provided by: Downloaded 2024­5­29 3:6 A  Your IP is 116.89.178.138 Chapter 324: Peptic Ulcer Disease and Related Disorders, John Del Valle ©2024 McGraw Hill. All Rights Reserved.   Terms of Use • Privacy Policy • Notice • Accessibility Page 36 / 49",1884,21,471.0,"[ 0.28606528 -0.79379225 -1.4563093  ...  0.65867275 -0.61938757
 -1.0644954 ]"
54,"Malabsorption of vitamin D and calcium resulting in osteoporosis and osteomalacia is common after partial gastrectomy and gastrojejunostomy (Billroth II). Osteomalacia can occur as a late complication in up to 25% of post–partial gastrectomy patients. Bone fractures occur twice as commonly in men after gastric surgery as in a control population. It may take years before x­ray findings demonstrate diminished bone density. Elevated alkaline phosphatase, reduced serum calcium, bone pain, and pathologic fractures may be seen in patients with osteomalacia. The high incidence of these abnormalities in this subgroup of patients justifies treating them with vitamin D and calcium supplementation indefinitely. Therapy is especially important in females. Copper deficiency has also been reported in patients undergoing surgeries that bypass the duodenum, where copper is primarily absorbed. Patients may present with a rare syndrome that includes ataxia, myelopathy, and peripheral neuropathy. Gastric Adenocarcinoma The incidence of adenocarcinoma in the gastric stump is increased 15 years after resection. Some have reported a four­ to fivefold increase in gastric cancer 20–25 years after resection. The pathogenesis is unclear but may involve alkaline reflux, bacterial proliferation, or hypochlorhydria. The role of endoscopic screening is not clear, and most guidelines do not support its use. Additional Complications Reflux esophagitis and a higher incidence of gallstones and cholecystitis have been reported in patients undergoing subtotal gastrectomy. The latter is thought to be due to decreased gallbladder contractility associated with vagotomy and bypass of the duodenum, leading to decreased postprandial release of cholecystokinin. RELATED CONDITIONS ZOLLINGER­ELLISON SYNDROME Severe peptic ulcer diathesis secondary to gastric acid hypersecretion due to unregulated gastrin release from a non–β­cell, often well­differentiated neuroendocrine tumor (NET; gastrinoma) defines the components of ZES. Initially, ZES was typified by aggressive and refractory ulceration in which total gastrectomy provided the only chance for enhancing survival. Today, it can be cured by surgical resection in up to 40% of patients with the sporadic form of the disease (see below). Epidemiology The true incidence of ZES is unknown, but estimates suggest that it varies from 0.1 to 1% of individuals presenting with PUD, with 0.1–3 individuals per year having this rare diagnosis. Others have estimated an incidence of 0.5–3 per million population. Females are slightly more commonly affected than males, and the majority of patients are diagnosed between ages 30 and 50. Gastrinomas are classified into sporadic tumors (80%) and those associated with multiple endocrine neoplasia (MEN) type 1 (see below). The widespread availability and use of PPIs have led to a decreased patient referral for gastrinoma evaluation, delay in diagnosis, and an increase in false­positive diagnoses of ZES. In fact, diagnosis may be delayed for ≥6 years after symptoms consistent with ZES are displayed. Pathophysiology Hypergastrinemia originating from an autonomous neoplasm is the driving force responsible for the clinical manifestations in ZES. Gastrin stimulates acid secretion through gastrin receptors on parietal cells and by inducing histamine release from ECL cells. Gastrin also has a trophic action on gastric epithelial cells. Long­standing hypergastrinemia leads to markedly increased gastric acid secretion through both parietal cell stimulation and increased parietal cell mass. The increased gastric acid output leads to peptic ulcer diathesis, erosive esophagitis, and diarrhea. Tumor Distribution Although early studies suggested that the vast majority of gastrinomas occurred within the pancreas, a significant number of these lesions are extrapancreatic. Between 60 and 90% of these tumors are found within the hypothetical gastrinoma triangle (confluence of the cystic and common bile ducts superiorly, junction of the second and third portions of the duodenum inferiorly, and junction of the neck and body of the pancreas medially). Duodenal tumors constitute the most common nonpancreatic lesion; between 60 and 100% of gastrinomas are found here. Duodenal tumors are smaller, slower growing, and less likely to metastasize than pancreatic lesions. Less common extrapancreatic sites include stomach, bones, ovaries, heart, liver, and lymph nodes. More than 60% of tumors are considered malignant, with up to 30–50% of patients having multiple lesions or metastatic disease at presentation. Histologically, gastrin­producing cells appear well­differentiated (grade 1 or 2 histologically), expressing markers typically found in endocrine neoplasms (chromogranin, neuron­specific enolase). Although not clearly established in gastrinomas, histologic grade in pancreatic NETs generally is an important predictor of survival in these rare neoplasms (Chap. 84). Clinical Manifestations Gastric acid hypersecretion is responsible for the signs and symptoms observed in patients with ZES. The most common clinical presentation for gastrinoma patients is abdominal pain in the presence of acid peptic disorders. Peptic ulcer is the most common clinical manifestation, occurring in >90% of gastrinoma patients. Initial presentation and ulcer location (duodenal bulb) may be indistinguishable from common PUD. Clinical situations Yonsei University Medical Library Access Provided by: Downloaded 2024­5­29 3:6 A  Your IP is 116.89.178.138 Chapter 324: Peptic Ulcer Disease and Related Disorders, John Del Valle ©2024 McGraw Hill.",5625,52,1406.25,"[ 0.27454615 -0.55263567 -1.5392104  ...  0.756708   -0.41090697
 -1.290023  ]"
55,"heart, liver, and lymph nodes. More than 60% of tumors are considered malignant, with up to 30–50% of patients having multiple lesions or metastatic disease at presentation. Histologically, gastrin­producing cells appear well­differentiated (grade 1 or 2 histologically), expressing markers typically found in endocrine neoplasms (chromogranin, neuron­specific enolase). Although not clearly established in gastrinomas, histologic grade in pancreatic NETs generally is an important predictor of survival in these rare neoplasms (Chap. 84). Clinical Manifestations Gastric acid hypersecretion is responsible for the signs and symptoms observed in patients with ZES. The most common clinical presentation for gastrinoma patients is abdominal pain in the presence of acid peptic disorders. Peptic ulcer is the most common clinical manifestation, occurring in >90% of gastrinoma patients. Initial presentation and ulcer location (duodenal bulb) may be indistinguishable from common PUD. Clinical situations that should create suspicion of gastrinoma are ulcers in unusual locations (second part of the duodenum and beyond), ulcers refractory to standard medical therapy, ulcer recurrence after acid­reducing surgery, ulcers presenting with frank complications (bleeding, obstruction, and perforation), or ulcers in the absence of H. pylori or NSAID ingestion. Symptoms of esophageal origin are present in up to two­thirds of patients with ZES, with a spectrum ranging from mild esophagitis to frank ulceration with stricture and Barrett’s mucosa. Diarrhea, the next most common clinical manifestation, is found in up to 70% of patients. Although diarrhea often occurs concomitantly with acid peptic disease, it may also occur independent of an ulcer and classically will abate with PPI therapy. Etiology of the diarrhea is multifactorial, resulting from marked volume overload to the small bowel, pancreatic enzyme inactivation by acid, and damage of the intestinal epithelial surface by acid. The epithelial damage can lead to a mild degree of maldigestion and malabsorption of nutrients. The diarrhea may also have a secretory component due to the direct stimulatory effect of gastrin on enterocytes or the co­secretion of additional hormones from the tumor such as vasoactive intestinal peptide. Gastrinomas can develop in the presence of MEN 1 syndrome (Chaps. 84 and 388) in ~25% of patients. This autosomal dominant disorder involves primarily three organ sites: the parathyroid glands (80–90%), pancreas (40–80%), and pituitary gland (30–60%). The syndrome is caused by inactivating mutations of the MEN1 tumor­suppressor gene found on the long arm of chromosome 11q13. The gene encodes for menin, which has an important role in DNA replication and transcriptional regulation. A genetic diagnosis is obtained by sequencing of the MEN1 gene, which can reveal mutations in 70–90% of typical MEN 1 cases. A family may have an unknown mutation, making a genetic diagnosis impossible, and therefore, certain individuals will require a clinical diagnosis, which is determined by whether a patient has tumors in two of the three endocrine organs (parathyroid, pancreas/duodenum, or pituitary) or has a family history of MEN 1 and one of the endocrine organ tumors. In view of the stimulatory effect of calcium on gastric secretion, the hyperparathyroidism and hypercalcemia seen in MEN 1 patients may have a direct effect on ulcer disease. Resolution of hypercalcemia by parathyroidectomy reduces gastrin and gastric acid output in gastrinoma patients. An additional distinguishing feature in ZES patients with MEN 1 is the higher incidence of gastric carcinoid tumor development (as compared to patients with sporadic gastrinomas). ZES presents and is diagnosed earlier in MEN 1 patients, and they have a more indolent course as compared to patients with sporadic gastrinoma. Gastrinomas tend to be smaller, multiple, and located in the duodenal wall more often than is seen in patients with sporadic ZES. Establishing the diagnosis of MEN 1 is critical in order to provide genetic counseling to the patient and his or her family and also to determine the recommended surgical approach. Therefore, gastrinoma patients should be screened for MEN 1 by performing a detailed family history and obtaining several serum markers including calcium, parathyroid, prolactin, and pancreatic polypeptide levels. Diagnosis Establishing an early diagnosis is important in order to minimize the long­term sequelae of gastric acid hypersecretion, prevent metastatic disease, and counsel family members if a diagnosis of MEN 1 is established. Biochemical measurements of gastrin and acid secretion in patients suspected of having ZES play an important role is establishing this rare diagnosis. Often, patients suspected of having ZES will be treated with a PPI in an effort to ameliorate symptoms and decrease the likelihood of possible acid­related complications. The presence of the PPI, which will lower acid secretion and potentially elevate fasting gastrin levels in normal individuals, will make the diagnostic approach in these individuals somewhat difficult. Significant morbidity related to peptic diathesis has been described when stopping PPIs in gastrinoma patients; therefore, a systematic approach in stopping these agents is warranted (see below). The first step in the evaluation of a patient suspected of having ZES is to obtain a fasting gastrin level. A list of clinical scenarios that should arouse suspicion regarding this diagnosis is shown in Table 324­8. Fasting gastrin levels obtained using a dependable assay are usually <150 pg/mL. A normal fasting gastrin, on two separate occasions, especially if the patient is on a PPI, virtually excludes this diagnosis. Virtually all gastrinoma patients will have a gastrin level >150–200 pg/mL. Measurement of fasting gastrin should be repeated to confirm the clinical suspicion. Some of the commercial biochemical assays used for measuring serum gastrin may be inaccurate. Variable specificity of the antibodies used have led to both false­positive and false­negative fasting gastrin levels, placing in jeopardy the ability to make an accurate diagnosis of ZES. TABLE 324­8 When to Obtain a Fasting Serum Gastrin Level Multiple ulcers Ulcers in unusual locations; associated with severe esophagitis; resistant to therapy with frequent recurrences; in the absence of nonsteroidal anti­ inflammatory drug ingestion or H. pylori infection Ulcer patients awaiting surgery Yonsei University Medical Library Access Provided by: Downloaded 2024­5­29 3:6 A  Your IP is 116.89.178.138 Chapter 324: Peptic Ulcer Disease and Related Disorders, John Del Valle ©2024 McGraw Hill. All Rights Reserved.",6737,59,1684.25,"[ 0.02538663 -0.369305   -1.1771594  ...  0.33200482  0.17331643
 -0.8296996 ]"
56,"p g g g g g g p assay are usually <150 pg/mL. A normal fasting gastrin, on two separate occasions, especially if the patient is on a PPI, virtually excludes this diagnosis. Virtually all gastrinoma patients will have a gastrin level >150–200 pg/mL. Measurement of fasting gastrin should be repeated to confirm the clinical suspicion. Some of the commercial biochemical assays used for measuring serum gastrin may be inaccurate. Variable specificity of the antibodies used have led to both false­positive and false­negative fasting gastrin levels, placing in jeopardy the ability to make an accurate diagnosis of ZES. TABLE 324­8 When to Obtain a Fasting Serum Gastrin Level Multiple ulcers Ulcers in unusual locations; associated with severe esophagitis; resistant to therapy with frequent recurrences; in the absence of nonsteroidal anti­ inflammatory drug ingestion or H. pylori infection Ulcer patients awaiting surgery Extensive family history for peptic ulcer disease Postoperative ulcer recurrence Basal hyperchlorhydria Unexplained diarrhea or steatorrhea Hypercalcemia Family history of pancreatic islet, pituitary, or parathyroid tumor Prominent gastric or duodenal folds Multiple processes can lead to an elevated fasting gastrin level, the most frequent of which are gastric hypochlorhydria and achlorhydria, with or without pernicious anemia. Gastric acid induces feedback inhibition of gastrin release. A decrease in acid production will subsequently lead to failure of the feedback inhibitory pathway, resulting in net hypergastrinemia. Gastrin levels will thus be high in patients using antisecretory agents for the treatment of acid peptic disorders and dyspepsia. H. pylori infection can also cause hypergastrinemia. Additional causes of elevated gastrin include retained gastric antrum; G­cell hyperplasia; gastric outlet obstruction; renal insufficiency; massive small­bowel obstruction; and conditions such as rheumatoid arthritis, vitiligo, diabetes mellitus, and pheochromocytoma. Although a fasting gastrin >10 times normal is highly suggestive of ZES, two­ thirds of patients will have fasting gastrin levels that overlap with levels found in the more common disorders outlined above, especially if a PPI is being taken by the patient. The effect of the PPI on gastrin levels and acid secretion will linger several days after stopping the PPI; therefore, it should be stopped for a minimum of 7 days before testing. During this period, the patient should be placed on a histamine H2 antagonist, such as famotidine, twice to three times per day. Although this type of agent has a short­term effect on gastrin and acid secretion, it needs to be stopped 24 h before repeating fasting gastrin levels or performing some of the tests highlighted below. The patient may take antacids for the final day, stopping them ~12 h before testing is performed. Heightened awareness of complications related to gastric acid hypersecretion during the period of PPI cessation is critical. The next step at times needed for establishing a biochemical diagnosis of gastrinoma is to assess acid secretion. Nothing further needs to be done if decreased acid output in the absence of a PPI is observed. A pH can be measured on gastric fluid obtained either during endoscopy or through nasogastric aspiration; a pH <3 is suggestive of a gastrinoma, but a pH >3 is not helpful in excluding the diagnosis. In those situations where the pH is >3, formal gastric acid analysis should be performed if available. Normal BAO in nongastric surgery patients is typically <5 meq/h. A BAO >15 meq/h in the presence of hypergastrinemia is considered pathognomonic of ZES, but up to 12% of patients with common PUD may have elevated BAO to a lesser degree that can overlap with levels seen in ZES patients. In an effort to improve the sensitivity and specificity of gastric secretory studies, a BAO/MAO ratio was established using pentagastrin infusion as a way to maximally stimulate acid production, with a BAO/MAO ratio >0.6 being highly suggestive of ZES. Pentagastrin is no longer available in the United States, making measurement of MAO virtually impossible. An endoscopic method for measuring gastric acid output has been developed but requires further validation. Gastrin provocative tests have been developed in an effort to differentiate between the causes of hypergastrinemia and are especially helpful in patients with indeterminate acid secretory studies. The tests are the secretin stimulation test and the calcium infusion study; the latter is rarely, if ever, utilized in our current environment due to the cumbersome nature of the test and its lower sensitivity and specificity than secretin stimulation. The most sensitive and specific gastrin provocative test for the diagnosis of gastrinoma is the secretin study. An increase in gastrin of ≥120 pg within 15 min of secretin injection has a sensitivity and specificity of >90% for ZES. PPI­induced hypochlorhydria or achlorhydria may lead to a false­positive secretin test; thus, this agent must be stopped for 1 week before testing. In light of the limited availability of the biochemical studies outlined above, more studies make a diagnosis of gastrinoma based on the presence of Yonsei University Medical Library Access Provided by: Downloaded 2024­5­29 3:6 A  Your IP is 116.89.178.138 Chapter 324: Peptic Ulcer Disease and Related Disorders, John Del Valle ©2024 McGraw Hill. All Rights Reserved.   Terms of Use • Privacy Policy • Notice • Accessibility Page 39 / 49",5528,85,1382.0,"[ 0.03304593 -0.03096242 -0.72832716 ...  1.0758127   0.05773697
 -0.8833158 ]"
57,"Abbreviations: CT, computed tomography; EUS, endoscopic ultrasonography; MRI, magnetic resonance imaging; N/A, not applicable; OctreoScan, imaging with 111In­ pentetreotide; SASI, selective arterial secretin injection.of ZES. Pentagastrin is no longer available in the United States, making measurement of MAO virtually impossible. An endoscopic method for measuring gastric acid output has been developed but requires further validation. Gastrin provocative tests have been developed in an effort to differentiate between the causes of hypergastrinemia and are especially helpful in patients with indeterminate acid secretory studies. The tests are the secretin stimulation test and the calcium infusion study; the latter is rarely, if ever, utilized in our current environment due to the cumbersome nature of the test and its lower sensitivity and specificity than secretin stimulation. The most sensitive and specific gastrin provocative test for the diagnosis of gastrinoma is the secretin study. An increase in gastrin of ≥120 pg within 15 min of secretin injection has a sensitivity and specificity of >90% for ZES. PPI­induced hypochlorhydria or achlorhydria may lead to a false­positive secretin test; thus, this agent must be stopped for 1 week before testing. In light of the limited availability of the biochemical studies outlined above, more studies make a diagnosis of gastrinoma based on the presence of elevated gastrin and low gastric pH in the right clinical setting coupled with tumor localization tests outlined below and positive histology by biopsy (difficult to obtain). Revised guidelines for the best approach to establishing a diagnosis of gastrinoma taking into consideration the above outlined limitations are being considered, but none have replaced the established guidelines outlined earlier in this section. Tumor Localization Once the biochemical diagnosis of gastrinoma has been confirmed (if possible), the tumor must be located. Multiple imaging studies have been used in an effort to enhance tumor localization (Table 324­9). The broad range of sensitivity is due to the variable success rates achieved by the different investigative groups. Endoscopic ultrasound (EUS) permits imaging of the pancreas with a high degree of resolution (<5 mm). This modality is particularly helpful in excluding small neoplasms within the pancreas and in assessing the presence of surrounding lymph nodes and vascular involvement, but it is not very sensitive (43%) for finding duodenal lesions. This latter observation has led some to not include EUS in the routine preoperative evaluation of a patient suspected of having a gastrinoma. Several types of endocrine tumors express cell­surface receptors for somatostatin, in particular the subtype 2 (SSTR2). This permits the localization, staging, and prediction of therapeutic response to somatostatin analogues (see below) by gastrinomas. The original functional scinitigraphic tool developed measuring the uptake of the stable somatostatin analogue 111In­pentetreotide (OctreoScan) has demonstrated sensitivity and specificity rates of >80%. More recently, positron emission tomography (PET)– computed tomography (CT) with 68Ga­DOTATATE has been developed and is superior than OctreoScan for assessing tumor presence in patients with well­differentiated NETs such as gastrinomas, with sensitivity and specificity of >90%, making it the functional imaging study of choice when available.18F­Fluordeoxyglucose (18F­FDG) PET imaging has been found to be useful in pancreatic NETs, including gastrinomas, particularly as a prognostic marker. TABLE 324­9 Sensitivity of Imaging Studies in Zollinger­Ellison Syndrome SENSITIVITY, % STUDY PRIMARY GASTRINOMA METASTATIC GASTRINOMA Ultrasound 21–28 14 CT scan 55–70 >85 Selective angiography 35–68 33–86 Portal venous sampling 70–90 N/A SASI 55–78 41 MRI 55–70 >85 OctreoScan 67–86 80–100 EUS 80–100 N/A Up to 50% of patients have metastatic disease at diagnosis. Success in controlling gastric acid hypersecretion has shifted the emphasis of therapy toward providing a surgical cure. Detecting the primary tumor and excluding metastatic disease are critical in view of this paradigm shift. Once a biochemical diagnosis has been confirmed, the patient should first undergo an abdominal CT scan, magnetic resonance imaging (MRI), or Yonsei University Medical Library Access Provided by: Downloaded 2024­5­29 3:6 A  Your IP is 116.89.178.138 Chapter 324: Peptic Ulcer Disease and Related Disorders, John Del Valle ©2024 McGraw Hill. All Rights Reserved.   Terms of Use • Privacy Policy • Notice • Accessibility Page 40 / 49",4635,68,1158.75,"[ 0.01331042  0.1308552  -1.0038925  ...  0.6517226  -0.08296044
 -0.85195744]"
58,"Abbreviations: CT, computed tomography; EUS, endoscopic ultrasonography; MRI, magnetic resonance imaging; N/A, not applicable; OctreoScan, imaging with 111In­ pentetreotide; SASI, selective arterial secretin injection.computed tomography (CT) with 68Ga­DOTATATE has been developed and is superior than OctreoScan for assessing tumor presence in patients with well­differentiated NETs such as gastrinomas, with sensitivity and specificity of >90%, making it the functional imaging study of choice when available.18F­Fluordeoxyglucose (18F­FDG) PET imaging has been found to be useful in pancreatic NETs, including gastrinomas, particularly as a prognostic marker. TABLE 324­9 Sensitivity of Imaging Studies in Zollinger­Ellison Syndrome SENSITIVITY, % STUDY PRIMARY GASTRINOMA METASTATIC GASTRINOMA Ultrasound 21–28 14 CT scan 55–70 >85 Selective angiography 35–68 33–86 Portal venous sampling 70–90 N/A SASI 55–78 41 MRI 55–70 >85 OctreoScan 67–86 80–100 EUS 80–100 N/A Up to 50% of patients have metastatic disease at diagnosis. Success in controlling gastric acid hypersecretion has shifted the emphasis of therapy toward providing a surgical cure. Detecting the primary tumor and excluding metastatic disease are critical in view of this paradigm shift. Once a biochemical diagnosis has been confirmed, the patient should first undergo an abdominal CT scan, magnetic resonance imaging (MRI), or OctreoScan/PET­CT with 68Ga­DOTATATE (depending on availability) to exclude metastatic disease. Once metastatic disease has been excluded, an experienced endocrine surgeon may opt for exploratory laparotomy with intraoperative ultrasound or transillumination. In other centers, careful examination of the peripancreatic area with EUS, accompanied by endoscopic exploration of the duodenum for primary tumors, will be performed before surgery. Selective arterial secretin injection may be a useful adjuvant for localizing tumors in a subset of patients. The extent of the diagnostic and surgical approach must be carefully balanced with the patient’s overall physiologic condition and the natural history of a slow­growing gastrinoma. TREATMENT OF ZOLLINGER­ELLISON SYNDROME Treatment of functional endocrine tumors is directed at ameliorating the signs and symptoms related to hormone overproduction, curative resection of the neoplasm, and attempts to control tumor growth in metastatic disease. PPIs are the treatment of choice and have decreased the need for total gastrectomy. Initial PPI doses tend to be higher than those used for treatment of GERD or PUD. The initial dose of omeprazole, lansoprazole, rabeprazole, or esomeprazole should be in the range of 60 mg in divided doses in a 24­h period. When gastric acid analysis was more widely available, dosing was adjusted to achieve a BAO <10 meq/h (at the drug trough) in surgery­naive patients and to <5 meq/h in individuals who have previously undergone an acid­reducing operation. Close monitoring of clinical symptoms when starting PPIs and increasing the dose accordingly are paramount. Although the somatostatin analogue has inhibitory effects on gastrin release from receptor­bearing tumors and inhibits gastric acid secretion to some extent, PPIs have the advantage of reducing parietal cell activity to a greater degree. Despite this, octreotide or lanreotide may be considered as adjunctive therapy to the PPI in patients with tumors that express somatostatin receptors and have peptic symptoms that are difficult to control with high­dose PPI. The ultimate goal of surgery would be to provide a definitive cure. Improved understanding of tumor distribution has led to immediate cure rates as high as 33% with 10­year disease­free intervals as high as 95% in sporadic gastrinoma patients undergoing surgery. A positive outcome is highly dependent on the experience of the surgical team treating these rare tumors. Surgical therapy of gastrinoma patients with MEN 1 remains controversial because of the difficulty in rendering these patients disease­free with surgery. In contrast to the encouraging postoperative results observed in patients with sporadic disease, <5% of MEN 1 patients are disease­free 5 years after an operation. Moreover, in contrast to patients with Yonsei University Medical Library Access Provided by: Downloaded 2024­5­29 3:6 A  Your IP is 116.89.178.138 Chapter 324: Peptic Ulcer Disease and Related Disorders, John Del Valle ©2024 McGraw Hill. All Rights Reserved.   Terms of Use • Privacy Policy • Notice • Accessibility Page 41 / 49",4526,68,1131.5,"[ 0.09326147 -0.2263582  -1.3929031  ...  0.43066186  0.33331198
 -0.8524266 ]"
59,"starting PPIs and increasing the dose accordingly are paramount. Although the somatostatin analogue has inhibitory effects on gastrin release from receptor­bearing tumors and inhibits gastric acid secretion to some extent, PPIs have the advantage of reducing parietal cell activity to a greater degree. Despite this, octreotide or lanreotide may be considered as adjunctive therapy to the PPI in patients with tumors that express somatostatin receptors and have peptic symptoms that are difficult to control with high­dose PPI. The ultimate goal of surgery would be to provide a definitive cure. Improved understanding of tumor distribution has led to immediate cure rates as high as 33% with 10­year disease­free intervals as high as 95% in sporadic gastrinoma patients undergoing surgery. A positive outcome is highly dependent on the experience of the surgical team treating these rare tumors. Surgical therapy of gastrinoma patients with MEN 1 remains controversial because of the difficulty in rendering these patients disease­free with surgery. In contrast to the encouraging postoperative results observed in patients with sporadic disease, <5% of MEN 1 patients are disease­free 5 years after an operation. Moreover, in contrast to patients with sporadic ZES, the clinical course of MEN 1 patients tends to be benign and rarely leads to disease­related mortality, recommending that early surgery be deferred. Some groups suggest surgery only if a clearly identifiable, nonmetastatic lesion is documented by structural studies. Others advocate a more aggressive approach, where all patients free of hepatic metastasis are explored and all detected tumors in the duodenum are resected; this is followed by enucleation of lesions in the pancreatic head, with a distal pancreatectomy to follow. The outcome of the two approaches has not been clearly defined. Laparoscopic surgical interventions may provide attractive approaches in the future but currently seem to be of some limited benefit in patients with gastrinoma because a significant percentage of the tumors may be extrapancreatic and difficult to localize with a laparoscopic approach. Finally, patients selected for surgery should be individuals whose health status would lead them to tolerate a more aggressive operation and obtain the long­term benefits from such aggressive surgery, which are often witnessed after 10 years. Therapy of metastatic endocrine tumors in general remains suboptimal; gastrinomas are no exception. In light of the observation that in many instances tumor growth is indolent and that many individuals with metastatic disease remain relatively stable for significant periods of time, many advocate not instituting systemic tumor­targeted therapy until evidence of tumor progression or refractory symptoms not controlled with PPIs are noted. Medical approaches, including biologic therapy (IFN­α, long­acting somatostatin analogues, and peptide receptor radionuclides), systemic chemotherapy (streptozotocin, 5­fluorouracil, and doxorubicin), and hepatic artery embolization, may lead to significant toxicity without a substantial improvement in overall survival. Use of temozolomide with capecitabine has demonstrated radiographic regression and progression­free survival in patients with well­differentiated NETs in the range of 70% and 18 months, respectively. Systemic therapy with radiolabeled somatostatin analogues (peptide receptor radiotherapy [PRRT]) has been used in the therapy of metastatic NETs and appears to be very promising in terms of radiographic regression, symptoms, and progression­free survival, but additional studies are warranted. Several promising therapies are being explored, including radiofrequency ablation or cryoablation of liver lesions and use of agents that block the VEGF receptor pathway (sunitinib), the mammalian target of rapamycin, and immune checkpoint inhibitors (Chap. 87). Surgical approaches, including debulking surgery and liver transplantation for hepatic metastasis, have also produced limited benefit. The overall 5­ and 10­year survival rates for gastrinoma patients are 62–75% and 47–53%, respectively. Individuals with the entire tumor resected or those with a negative laparotomy have 5­ and 10­year survival rates >90%. Patients with incompletely resected tumors have 5­ and 10­year survival rates of 43 and 25%, respectively. Patients with hepatic metastasis have <20% survival at 5 years. Favorable prognostic indicators include primary duodenal wall tumors, isolated lymph node tumor, the presence of MEN 1, and undetectable tumor upon surgical exploration. Poor outcome is seen in patients with shorter disease duration; female sex; older age at diagnosis; higher gastrin levels (>10,000 pg/mL); poor histologic differentiation; high proliferative index; large pancreatic primary tumors (>3 cm); metastatic disease to lymph nodes, liver, and bone; and Cushing’s syndrome. Rapid growth of hepatic metastases is also predictive of poor outcome. STRESS­RELATED MUCOSAL INJURY Patients suffering from shock, sepsis, massive burns, severe trauma, or head injury can develop acute erosive gastric mucosal changes or frank ulceration with bleeding. Classified as stress­induced gastritis or ulcers, injury is most commonly observed in the acid­producing (fundus and body) portions of the stomach. The most common presentation is GI bleeding, which is usually minimal but can occasionally be life­threatening. Respiratory failure requiring mechanical ventilation and underlying coagulopathy are risk factors for bleeding, which tends to occur 48–72 h after the acute injury or insult. Histologically, stress injury does not contain inflammation or H. pylori; thus, “gastritis” is a misnomer. Although elevated gastric acid secretion may be noted in patients with stress ulceration after head trauma (Cushing’s ulcer) and severe burns (Curling’s ulcer), mucosal ischemia, breakdown of the normal protective barriers of the stomach, systemic release of cytokines, poor GI motility, and oxidative stress also play an important role in the pathogenesis. Acid must contribute to injury in view of the significant drop in bleeding noted when acid inhibitors are used as prophylaxis for stress gastritis. Improvement in the general management of intensive care unit patients has led to a significant decrease in the incidence of GI bleeding due to stress ulceration. The estimated decrease in bleeding is from 20–30% to <5%. This improvement has led to some debate regarding the need for prophylactic therapy. The high mortality associated with stress­induced clinically important GI bleeding (>40%) and the limited benefit of medical (endoscopic, angiographic) and surgical therapy in a patient with hemodynamically compromising bleeding associated with stress ulcer/gastritis support the use of preventive measures in high­risk patients (mechanically ventilated, coagulopathy, multiorgan failure, or severe burns). Meta­analysis comparing H2 blockers with PPIs for the prevention of stress­associated clinically important and overt GI bleeding demonstrates superiority of the latter without Yonsei University Medical Library Access Provided by: Downloaded 2024­5­29 3:6 A  Your IP is 116.89.178.138 Chapter 324: Peptic Ulcer Disease and Related Disorders, John Del Valle ©2024 McGraw Hill. All Rights Reserved.   Terms of Use • Privacy Policy • Notice • Accessibility Page 42 / 49",7422,62,1855.5,"[-0.08034124 -0.12292692 -1.1374578  ...  0.49372137 -0.06001471
 -1.4545809 ]"
60,"normal protective barriers of the stomach, systemic release of cytokines, poor GI motility, and oxidative stress also play an important role in the pathogenesis. Acid must contribute to injury in view of the significant drop in bleeding noted when acid inhibitors are used as prophylaxis for stress gastritis. Improvement in the general management of intensive care unit patients has led to a significant decrease in the incidence of GI bleeding due to stress ulceration. The estimated decrease in bleeding is from 20–30% to <5%. This improvement has led to some debate regarding the need for prophylactic therapy. The high mortality associated with stress­induced clinically important GI bleeding (>40%) and the limited benefit of medical (endoscopic, angiographic) and surgical therapy in a patient with hemodynamically compromising bleeding associated with stress ulcer/gastritis support the use of preventive measures in high­risk patients (mechanically ventilated, coagulopathy, multiorgan failure, or severe burns). Meta­analysis comparing H2 blockers with PPIs for the prevention of stress­associated clinically important and overt GI bleeding demonstrates superiority of the latter without increasing the risk of nosocomial infections, increasing mortality, or prolonging intensive care unit length of stay. Therefore, PPIs are the treatment of choice for stress prophylaxis. Oral PPI is the best option if the patient can tolerate enteral administration. Pantoprazole is available as an intravenous formulation for individuals in whom enteral administration is not possible. If bleeding occurs despite these measures, endoscopy, intraarterial vasopressin, and embolization are options. If all else fails, then surgery should be considered. Although vagotomy and antrectomy may be used, the better approach would be a total gastrectomy, which has an exceedingly high mortality rate in this setting. Concerns with the effect of PPIs on the immune system coupled with the high cost of this agent have led to several comparative studies of PPIs and H2 receptor antagonists for stress prophylaxis in patients requiring mechanical ventilation. Although the PEPTIC trial demonstrated comparative efficacy between the two agents regarding mortality, technical aspects of the study led to some limitation in the final interpretation of the results. GASTRITIS The term gastritis should be reserved for histologically documented inflammation of the gastric mucosa. Gastritis is not the mucosal erythema seen during endoscopy and is not interchangeable with “dyspepsia.” The etiologic factors leading to gastritis are broad and heterogeneous. Gastritis has been classified based on time course (acute vs chronic), histologic features, and anatomic distribution or proposed pathogenic mechanism (Table 324­10). TABLE 324­10 Classification of Gastritis I.  Acute gastritis A.  Acute Helicobacter pylori infection B.  Other acute infectious gastritides 1.  Bacterial (other than H. pylori) 2.  Helicobacter heilmannii 3.  Phlegmonous 4.  Mycobacterial 5.  Syphilitic 6.  Viral 7.  Parasitic 8.  Fungal II.  Chronic atrophic gastritis A.  Type A: Autoimmune, body­predominant B.  Type B: H. pylori–related, antral­predominant C.  Indeterminate III.  Uncommon forms of gastritis A.  Lymphocytic B.  Eosinophilic C.  Crohn’s disease D.  Sarcoidosis E.  Isolated granulomatous gastritis F.  Russell body gastritis The correlation between the histologic findings of gastritis, the clinical picture of abdominal pain or dyspepsia, and endoscopic findings noted on gross inspection of the gastric mucosa is poor. Therefore, there is no typical clinical manifestation of gastritis. Acute Gastritis The most common causes of acute gastritis are infectious. Acute infection with H. pylori induces gastritis. However, H. pylori acute gastritis has not Yonsei University Medical Library Access Provided by: Downloaded 2024­5­29 3:6 A  Your IP is 116.89.178.138 Chapter 324: Peptic Ulcer Disease and Related Disorders, John Del Valle ©2024 McGraw Hill. All Rights Reserved.   Terms of Use • Privacy Policy • Notice • Accessibility Page 43 / 49",4124,81,1031.0,"[-0.05526407 -0.2671211  -0.8786875  ...  0.78134596  0.02799459
 -1.461775  ]"
61,"D.  Sarcoidosis E.  Isolated granulomatous gastritis F.  Russell body gastritis The correlation between the histologic findings of gastritis, the clinical picture of abdominal pain or dyspepsia, and endoscopic findings noted on gross inspection of the gastric mucosa is poor. Therefore, there is no typical clinical manifestation of gastritis. Acute Gastritis The most common causes of acute gastritis are infectious. Acute infection with H. pylori induces gastritis. However, H. pylori acute gastritis has not been extensively studied. It is reported as presenting with sudden onset of epigastric pain, nausea, and vomiting, and limited mucosal histologic studies demonstrate a marked infiltrate of neutrophils with edema and hyperemia. If not treated, this picture will evolve into one of chronic gastritis. Hypochlorhydria lasting for up to 1 year may follow acute H. pylori infection. Bacterial infection of the stomach or phlegmonous gastritis is a rare, potentially life­threatening disorder characterized by marked and diffuse acute inflammatory infiltrates of the entire gastric wall, at times accompanied by necrosis. Elderly individuals, alcoholics, and AIDS patients may be affected. Potential iatrogenic causes include polypectomy and mucosal injection with India ink. Organisms associated with this entity include streptococci, staphylococci, Escherichia coli, Proteus, and Haemophilus species. Failure of supportive measures and antibiotics may result in gastrectomy. Other types of infectious gastritis may occur in immunocompromised individuals such as AIDS patients. Examples include herpetic (herpes simplex) or CMV gastritis. The histologic finding of intranuclear inclusions would be observed in the latter. Chronic Gastritis Chronic gastritis is identified histologically by an inflammatory cell infiltrate consisting primarily of lymphocytes and plasma cells, with very scant neutrophil involvement. Distribution of the inflammation may be patchy, initially involving superficial and glandular portions of the gastric mucosa. This picture may progress to more severe glandular destruction, with atrophy and metaplasia. Chronic gastritis has been classified according to histologic characteristics. These include superficial atrophic changes and gastric atrophy. The association of atrophic gastritis with the development of gastric cancer has led to the development of endoscopic and serologic markers of severity. Some of these include gross inspection and classification of mucosal abnormalities during standard endoscopy, magnification endoscopy, endoscopy with narrow band imaging and/or autofluorescence imaging, and measurement of several serum biomarkers including pepsinogen I and II levels, gastrin­17, and anti–H. pylori serologies. The clinical utility of these tools is currently being explored. The early phase of chronic gastritis is superficial gastritis. The inflammatory changes are limited to the lamina propria of the surface mucosa, with edema and cellular infiltrates separating intact gastric glands. The next stage is atrophic gastritis. The inflammatory infiltrate extends deeper into the mucosa, with progressive distortion and destruction of the glands. The final stage of chronic gastritis is gastric atrophy. Glandular structures are lost, and there is a paucity of inflammatory infiltrates. Endoscopically, the mucosa may be substantially thin, permitting clear visualization of the underlying blood vessels. Gastric glands may undergo morphologic transformation in chronic gastritis. Intestinal metaplasia denotes the conversion of gastric glands to a small intestinal phenotype with small­bowel mucosal glands containing goblet cells. The metaplastic changes may vary in distribution from patchy to fairly extensive gastric involvement. Intestinal metaplasia is an important predisposing factor for gastric cancer (Chap. 80). Chronic gastritis is also classified according to the predominant site of involvement. Type A refers to the body­predominant form (autoimmune), and type B is the antral­predominant form (H. pylori–related). This classification is artificial in view of the difficulty in distinguishing between these two entities. The term AB gastritis has been used to refer to a mixed antral/body picture. TYPE A GASTRITIS The less common of the two forms involves primarily the fundus and body, with antral sparing. Traditionally, this form of gastritis has been associated with pernicious anemia (Chap. 95) in the presence of circulating antibodies against parietal cells and IF; thus, it is also called autoimmune gastritis.",4590,42,1147.5,"[-0.1432113  -0.00564688 -0.6323439  ...  0.37169698 -0.00412667
 -0.8583435 ]"
61,"H. pylori infection can lead to a similar distribution of gastritis. The characteristics of an autoimmune picture are not always present. Antibodies to parietal cells have been detected in >90% of patients with pernicious anemia and in up to 50% of patients with type A gastritis. The parietal cell antibody is directed against H+,K+­ATPase. T cells are also implicated in the injury pattern of this form of gastritis. A subset of patients infected with H. pylori develop antibodies against H+,K+­ATPase, potentially leading to the atrophic gastritis pattern seen in some patients infected with this organism. The mechanism is thought to involve molecular mimicry between H. pylori LPS and H+,K+­ATPase. Parietal cell antibodies and atrophic gastritis are observed in family members of patients with pernicious anemia. These antibodies are observed in up to 20% of individuals aged >60 and in ~20% of patients with vitiligo and Addison’s disease. About one­half of patients with pernicious anemia have antibodies to thyroid antigens, and ~30% of patients with thyroid disease have circulating anti–parietal cell antibodies. Anti­IF antibodies are more ifi th i t l ll tib di f t A t iti b i t i 40% f ti t ith i i i A th t i t t ith Yonsei University Medical Library Access Provided by: Downloaded 2024­5­29 3:6 A  Your IP is 116.89.178.138 Chapter 324: Peptic Ulcer Disease and Related Disorders, John Del Valle ©2024 McGraw Hill. All Rights Reserved.   Terms of Use • Privacy Policy • Notice • Accessibility Page 44 / 49",1522,50,380.5,"[ 1.0071819  -0.00559589 -0.82845366 ...  0.14028984 -0.53200376
 -1.7181202 ]"
62,"pylori infection can lead to a similar distribution of gastritis. The characteristics of an autoimmune picture are not always present. Antibodies to parietal cells have been detected in >90% of patients with pernicious anemia and in up to 50% of patients with type A gastritis. The parietal cell antibody is directed against H+,K+­ATPase. T cells are also implicated in the injury pattern of this form of gastritis. A subset of patients infected with H. pylori develop antibodies against H+,K+­ATPase, potentially leading to the atrophic gastritis pattern seen in some patients infected with this organism. The mechanism is thought to involve molecular mimicry between H. pylori LPS and H+,K+­ATPase. Parietal cell antibodies and atrophic gastritis are observed in family members of patients with pernicious anemia. These antibodies are observed in up to 20% of individuals aged >60 and in ~20% of patients with vitiligo and Addison’s disease. About one­half of patients with pernicious anemia have antibodies to thyroid antigens, and ~30% of patients with thyroid disease have circulating anti–parietal cell antibodies. Anti­IF antibodies are more specific than parietal cell antibodies for type A gastritis, being present in ~40% of patients with pernicious anemia. Another parameter consistent with this form of gastritis being autoimmune in origin is the higher incidence of specific familial histocompatibility haplotypes such as HLA­B8 and HLA­DR3. Low pepsinogen levels have also been observed; thus, this marker has been used as an additional diagnostic tool in autoimmune gastritis. The parietal cell–containing gastric gland is preferentially targeted in this form of gastritis, and achlorhydria results. Parietal cells are the source of IF, the lack of which will lead to vitamin B12 deficiency and its sequelae (megaloblastic anemia, neurologic dysfunction). Gastric acid plays an important role in feedback inhibition of gastrin release from G cells. Achlorhydria, coupled with relative sparing of the antral mucosa (site of G cells), leads to hypergastrinemia. Gastrin levels can be markedly elevated (>500 pg/mL) in patients with pernicious anemia. ECL cell hyperplasia with frank development of gastric carcinoid tumors may result from gastrin trophic effects. Hypergastrinemia and achlorhydria may also be seen in nonpernicious anemia–associated type A gastritis. TYPE B GASTRITIS Type B, or antral­predominant, gastritis is the more common form of chronic gastritis. H. pylori infection is the cause of this entity. Although described as “antral­predominant,” this is likely a misnomer in view of studies documenting the progression of the inflammatory process toward the body and fundus of infected individuals. The conversion to a pangastritis is time dependent and estimated to require 15–20 years. This form of gastritis increases with age, being present in up to 100% of persons aged >70. Histology improves after H. pylori eradication. The number of H. pylori organisms decreases dramatically with progression to gastric atrophy, and the degree of inflammation correlates with the level of these organisms. Early on, with antral­predominant findings, the quantity of H. pylori is highest and a dense chronic inflammatory infiltrate of the lamina propria is noted, accompanied by epithelial cell infiltration with polymorphonuclear leukocytes (Fig. 324­16). FIGURE 324­16 Chronic gastritis and H. pylori organisms. Steiner silver stain of superficial gastric mucosa showing abundant darkly stained microorganisms layered over the apical portion of the surface epithelium. Note that there is no tissue invasion. Multifocal atrophic gastritis, gastric atrophy with subsequent metaplasia, has been observed in chronic H. pylori–induced gastritis. This may ultimately lead to development of gastric adenocarcinoma (Fig. 324­8; Chap. 80). H. pylori infection is now considered an independent risk factor for gastric cancer. Worldwide epidemiologic studies have documented a higher incidence of H. pylori infection in patients with adenocarcinoma of the stomach as compared to control subjects. Seropositivity for H. pylori is associated with a three­ to sixfold increased risk of gastric cancer. This risk may be as high as ninefold after adjusting for the inaccuracy of serologic testing in the elderly. The mechanism by which H. pylori infection leads to cancer is unknown, but it appears to be related to the chronic inflammation induced by the organism. Eradication of H. pylori as a general preventative measure for gastric cancer is being evaluated but is not yet recommended. Infection with H pylori is also associated with development of a low grade B cell lymphoma gastric MALT lymphoma (Chap 108) The chronic T cell Yonsei University Medical Library Access Provided by: Downloaded 2024­5­29 3:6 A  Your IP is 116.89.178.138 Chapter 324: Peptic Ulcer Disease and Related Disorders, John Del Valle ©2024 McGraw Hill.",4942,65,1235.5,"[ 0.77163965  0.08535895 -0.93133914 ...  0.13633463 -0.27828723
 -1.6100596 ]"
63,"Multifocal atrophic gastritis, gastric atrophy with subsequent metaplasia, has been observed in chronic H. pylori–induced gastritis. This may ultimately lead to development of gastric adenocarcinoma (Fig. 324­8; Chap. 80). H. pylori infection is now considered an independent risk factor for gastric cancer. Worldwide epidemiologic studies have documented a higher incidence of H. pylori infection in patients with adenocarcinoma of the stomach as compared to control subjects. Seropositivity for H. pylori is associated with a three­ to sixfold increased risk of gastric cancer. This risk may be as high as ninefold after adjusting for the inaccuracy of serologic testing in the elderly. The mechanism by which H. pylori infection leads to cancer is unknown, but it appears to be related to the chronic inflammation induced by the organism. Eradication of H. pylori as a general preventative measure for gastric cancer is being evaluated but is not yet recommended. Infection with H. pylori is also associated with development of a low­grade B­cell lymphoma, gastric MALT lymphoma (Chap. 108). The chronic T­cell stimulation caused by the infection leads to production of cytokines that promote the B­cell tumor. The tumor should be initially staged with a CT scan of the abdomen and EUS. Tumor growth remains dependent on the presence of H. pylori, and its eradication is often associated with complete regression of the tumor. The tumor may take more than a year to regress after treating the infection. Such patients should be followed by EUS every 2– 3 months. If the tumor is stable or decreasing in size, no other therapy is necessary. If the tumor grows, it may have become a high­grade B­cell lymphoma. When the tumor becomes a high­grade aggressive lymphoma histologically, it loses responsiveness to H. pylori eradication. TREATMENT OF CHRONIC GASTRITIS Treatment in chronic gastritis is aimed at the sequelae and not the underlying inflammation. Patients with pernicious anemia will require parenteral vitamin B12 supplementation on a long­term basis. Eradication of H. pylori is often recommended even if PUD or a low­grade MALT lymphoma is not present. Expert opinion suggests that patients with atrophic gastritis complicated by intestinal metaplasia without dysplasia should undergo surveillance endoscopy every 3 years. Miscellaneous Forms of Gastritis Lymphocytic gastritis is characterized histologically by intense infiltration of the surface epithelium with lymphocytes. The infiltrative process is primarily in the body of the stomach and consists of mature T cells and plasmacytes. The etiology of this form of chronic gastritis is unknown. It has been described in patients with celiac sprue, but whether there is a common factor associating these two entities is unknown. No specific symptoms suggest lymphocytic gastritis. A subgroup of patients has thickened folds noted on endoscopy. These folds are often capped by small nodules that contain a central depression or erosion; this form of the disease is called varioliform gastritis. H. pylori probably plays no significant role in lymphocytic gastritis. Therapy with glucocorticoids or sodium cromoglycate has obtained unclear results. Marked eosinophilic infiltration involving any layer of the stomach (mucosa, muscularis propria, and serosa) is characteristic of eosinophilic gastritis. Affected individuals will often have circulating eosinophilia with clinical manifestation of systemic allergy. Involvement may range from isolated gastric disease to diffuse eosinophilic gastroenteritis. Antral involvement predominates, with prominent edematous folds being observed on endoscopy. These prominent antral folds can lead to outlet obstruction. Patients can present with epigastric discomfort, nausea, and vomiting. Treatment with glucocorticoids has been successful. Several systemic disorders may be associated with granulomatous gastritis. Gastric involvement has been observed in Crohn’s disease. Involvement may range from granulomatous infiltrates noted only on gastric biopsies to frank ulceration and stricture formation.",4111,32,1027.75,"[ 0.2595786  -0.20716448 -1.1322914  ...  0.21394937 -0.1402875
 -1.5664812 ]"
63,"Gastric Crohn’s disease usually occurs in the presence of small­intestinal disease. Several rare infectious processes can lead to granulomatous gastritis, including histoplasmosis, candidiasis, syphilis, and tuberculosis. Other unusual causes of this form of gastritis include sarcoidosis, idiopathic granulomatous gastritis, and eosinophilic granulomas involving the stomach. Establishing the specific etiologic agent in this form of gastritis can be difficult, at times requiring repeat endoscopy with biopsy and cytology. Occasionally, a surgically obtained full­thickness biopsy of the stomach may be required to exclude malignancy. Russell body gastritis (RBG) is a mucosal lesion of unknown etiology that has a pseudotumoral endoscopic appearance. Histologically, it is defined by the presence of numerous plasma cells containing Russell bodies (RBs) that express kappa and lambda light chains. Only 10 cases have been reported, and 7 of these have been associated with H. pylori infection. The lesion can be confused with a neoplastic process, but it is benign in nature, and the natural history of the lesion is not known. There have been cases of resolution of the lesion when H. pylori was eradicated. Immune checkpoint inhibitor–induced enterocolitis and gastritis are recognized sequelae of these oncologic therapies. The gastritis typically occurs later in the course of therapy. The diagnosis is made by the histologic findings on gastric mucosal biopsies obtained endoscopically. This is an important diagnosis to make since therapy with glucocorticoids and potentially IL­6 receptor blockers will be required. Moreover, this side effect will have an effect on the oncologic therapy prescribed. MÉNÉTRIER’S DISEASE Ménétrier’s disease (MD) is a very rare gastropathy characterized by large, tortuous mucosal folds. MD has an average age of onset of 40–60 years with a male predominance. The differential diagnosis of large gastric folds includes ZES, malignancy (lymphoma, infiltrating carcinoma), infectious etiologies (CMV, histoplasmosis, syphilis, tuberculosis), gastritis polyposa profunda, and infiltrative disorders such as sarcoidosis. MD is most Yonsei University Medical Library Access Provided by: Downloaded 2024­5­29 3:6 A  Your IP is 116.89.178.138 Chapter 324: Peptic Ulcer Disease and Related Disorders, John Del Valle ©2024 McGraw Hill. All Rights Reserved.   Terms of Use • Privacy Policy • Notice • Accessibility Page 46 / 49",2459,27,614.75,"[ 0.06613991  0.07170552 -0.9659015  ...  0.11322975 -0.15733738
 -0.85090625]"
64,"Immune checkpoint inhibitor–induced enterocolitis and gastritis are recognized sequelae of these oncologic therapies. The gastritis typically occurs later in the course of therapy. The diagnosis is made by the histologic findings on gastric mucosal biopsies obtained endoscopically. This is an important diagnosis to make since therapy with glucocorticoids and potentially IL­6 receptor blockers will be required. Moreover, this side effect will have an effect on the oncologic therapy prescribed. MÉNÉTRIER’S DISEASE Ménétrier’s disease (MD) is a very rare gastropathy characterized by large, tortuous mucosal folds. MD has an average age of onset of 40–60 years with a male predominance. The differential diagnosis of large gastric folds includes ZES, malignancy (lymphoma, infiltrating carcinoma), infectious etiologies (CMV, histoplasmosis, syphilis, tuberculosis), gastritis polyposa profunda, and infiltrative disorders such as sarcoidosis. MD is most commonly confused with large or multiple gastric polyps (prolonged PPI use) or familial polyposis syndromes. The mucosal folds in MD are often most prominent in the body and fundus, sparing the antrum. Histologically, massive foveolar hyperplasia (hyperplasia of surface and glandular mucous cells) and a marked reduction in oxyntic glands and parietal cells and chief cells are noted. This hyperplasia produces the prominent folds observed. The pits of the gastric glands elongate and may become extremely dilated and tortuous. Although the lamina propria may contain a mild chronic inflammatory infiltrate including eosinophils and plasma cells, MD is not considered a form of gastritis. The etiology of this unusual clinical picture in children is often CMV, but the etiology in adults is unknown. Overexpression of the growth factor TGF­α has been demonstrated in patients with MD. The overexpression of TGF­α in turn results in overstimulation of the epidermal growth factor receptor (EGFR) pathway and increased proliferation of mucus cells, resulting in the observed foveolar hyperplasia. The clinical presentation in adults is usually insidious and progressive. Epigastric pain, nausea, vomiting, anorexia, peripheral edema, and weight loss are signs and symptoms in patients with MD. Occult GI bleeding may occur, but overt bleeding is unusual and, when present, is due to superficial mucosal erosions. In fact, bleeding is more often seen in one of the common mimics of MD, gastric polyposis. Twenty to 100% of patients (depending on time of presentation) develop a protein­losing gastropathy due to hypersecretion of gastric mucus accompanied by hypoalbuminemia and edema. Gastric acid secretion is usually reduced or absent because of the decreased parietal cells. Large gastric folds are readily detectable by either radiographic (barium meal) or endoscopic methods. Endoscopy with deep mucosal biopsy, preferably full thickness with a snare technique, is required to establish the diagnosis and exclude other entities that may present similarly. A nondiagnostic biopsy may lead to a surgically obtained full­ thickness biopsy to exclude malignancy. Although MD is considered premalignant by some, the risk of neoplastic progression is not defined. Complete blood count, serum gastrin, serum albumin, CMV and H. pylori serology, and pH testing of gastric aspirate during endoscopy should be included as part of the initial evaluation of patients with large gastric folds. TREATMENT OF MéNéTRIER’S DISEASE Medical therapy with anticholinergic agents, prostaglandins, PPIs, prednisone, somatostatin analogues (octreotide), and H2 receptor antagonists yields varying results. Ulcers should be treated with a standard approach. The discovery that MD is associated with overstimulation of the EGFR pathway has led to the successful use of the EGF inhibitory antibody, cetuximab, in these patients. Specifically, four of seven patients who completed a 1­month trial with this agent demonstrated near complete histologic remission and improvement in symptoms. Cetuximab is now considered the first­ line treatment for MD, leaving partial or total gastrectomy for severe disease with persistent and substantial protein loss despite therapy with this agent. FURTHER READING Bindu  S  et al: Non­steroidal anti­inflammatory drugs (NSAIDs) and organ damage: A current perspective. Biochem Pharmacol 180:114147, 2020.  [PubMed: 32653589]  Bjarnason  I  et al: Mechanisms of damage to the gastrointestinal tract from nonsteroidal anti­inflammatory drugs. Gastroenterology 154:500, 2018.  [PubMed: 29221664]  Brandi  ML  et al: Multiple endocrine neoplasia type 1: Latest insights. Endocr Rev 42:133, 2021.  [PubMed: 33249439]  Chey  WD  et al: ACG clinical guideline: Treatment of Helicobacter pylori infection. Am J Gastroenterol 112:212, 2017.  [PubMed: 28071659]  Engevik  AC  et al: The physiology of the gastric parietal cell. Physiol Rev 100:573, 2019.",4916,45,1229.0,"[ 0.49133724  0.08677024 -1.0832403  ... -0.33507004 -0.33815002
 -1.1269164 ]"
64,"[PubMed: 31670611]  Jensen  RT, Ito  T: Gastrinoma; Endotext [internet]. South Dartmouth, MA, 2020. https://europepmc.org/article/NBK/nbk279075. Kavitt  RT  et al: Diagnosis and treatment of peptic ulcer disease. Am J Med 132:447, 2019.  [PubMed: 30611829]  Pennelli  G  et al: Gastritis: Update on etiological features and histological practice approach. Pathologica 112:153, 2020.  [PubMed: 33179619]  Savarino  V  et al: Proton pump inhibitors: Use and misuse in the clinical setting. Expert Rev Clin Pharmacol 11:1123, 2018.  [PubMed: 30295105]  Yonsei University Medical Library Access Provided by: Downloaded 2024­5­29 3:6 A  Your IP is 116.89.178.138 Chapter 324: Peptic Ulcer Disease and Related Disorders, John Del Valle ©2024 McGraw Hill. All Rights Reserved.   Terms of Use • Privacy Policy • Notice • Accessibility Page 47 / 49",839,17,209.75,"[ 0.14302513 -0.05225983 -0.9983754  ...  0.30864578 -0.685861
 -1.2697287 ]"
65,"y g py , Engevik  AC  et al: The physiology of the gastric parietal cell. Physiol Rev 100:573, 2019.  [PubMed: 31670611]  Jensen  RT, Ito  T: Gastrinoma; Endotext [internet]. South Dartmouth, MA, 2020. https://europepmc.org/article/NBK/nbk279075. Kavitt  RT  et al: Diagnosis and treatment of peptic ulcer disease. Am J Med 132:447, 2019.  [PubMed: 30611829]  Pennelli  G  et al: Gastritis: Update on etiological features and histological practice approach. Pathologica 112:153, 2020.  [PubMed: 33179619]  Savarino  V  et al: Proton pump inhibitors: Use and misuse in the clinical setting. Expert Rev Clin Pharmacol 11:1123, 2018.  [PubMed: 30295105]  Yao  X, Smolka  AJ: Gastric parietal cell physiology and Helicobacter pylori­induced disease. Gastroenterology 156:2158, 2019.  [PubMed: 30831083]  Additional Online References Davis  JL, Ripley  RT: Postgastrectomy syndromes and nutritional considerations following gastric surgery. Surg Clin N Am 97:277, 2017.  [PubMed: 28325187]  Dreischulte  T: Safer prescribing—A trial of education, informatics, and financial incentives. N Engl J Med 374:1053, 2016.  [PubMed: 26981935]  Graham  DY: Helicobacter pylori update: Gastric cancer, reliable therapy, and possible benefits. Gastroenterology 148:719, 2015.  [PubMed: 25655557]  Kinoshita  Y  et al: Advantages and disadvantages of long­term proton pump inhibitor use. J Neurogastroenterol Motil 24:182, 2018.  [PubMed: 29605975]  Laine  L: Upper gastrointestinal bleeding due to a peptic ulcer. N Engl J Med 374:2367, 2016.  [PubMed: 27305194]  Lenti  MV  et al: Autoimmune gastritis. Nat Rev Dis Primers 6:56, 2020.  [PubMed: 32647173]  McCarberg  BH, Cryer  B: Evolving therapeutic strategies to improve nonsteroidal anti­inflammatory drug safety. Am J Ther 22:167, 2015.  [PubMed: 25943389]  Melcarne  L  et al: Management of NSAID­associated peptic ulcer disease. Expert Rev Gastroenterol Hepatol 6:723, 2016. Norton  JA  et al: Gastrinomas: Medical or surgical treatment. Endocrinol Metab Clin North Am 47:577, 2018.  [PubMed: 30098717]  Patel  KA, Howden  CW: Update on the diagnosis and management of Helicobacter pylori infection in adults. J Clin Gastroenterol 49:461, 2015.  [PubMed: 25811119]  Pelletier  JP  et al: Efficacy and safety of oral and analgesics in the management of osteoarthritis: Evidence from real­life setting trials and surveys. Semin Arthritis Rheum 45:S22, 2016.  [PubMed: 26806184]  Scarpignato  C  et al: Effective and safe proton pump inhibitor therapy in acid­related disease—A position paper addressing benefits and potential harms of acid suppression. BMC Med 14:179, 2016.  [PubMed: 27825371]  Schubert  ML: Physiologic, pathophysiologic, and pharmacologic regulation of gastric acid secretion. Curr Opin Gastroenterol 33:430, 2017.  [PubMed: 28787289]  Singh  S  et al: Diagnosis and management of gastrointestinal neuroendocrine tumors: An evidence­based Canadian consensus. Cancer Treat Rev 47:32, 2016.  [PubMed: 27236421]  Sugano  K  et al: Kyoto global consensus report on Helicobacter pylori gastritis. Gut 64:1353, 2015.",3070,53,767.5,"[ 0.24337482 -0.23263139 -1.0674627  ...  0.19725695 -0.32464683
 -1.3641258 ]"
65,"[PubMed: 26187502]  Sverden  E  et al: Peptic ulcer disease. BMJ 367:15495, 2019. Talley  NJ: Functional dyspepsia: New insights into pathogenesis and therapy. Korean J Intern Med 31:444, 2016.  [PubMed: 27048251]  Vinik  AI, Chaya  C: Clinical presentation and diagnosis of neuroendocrine tumors. Hematol Oncol Clin N Am 30:21, 2016. Yonsei University Medical Library Access Provided by: Downloaded 2024­5­29 3:6 A  Your IP is 116.89.178.138 Chapter 324: Peptic Ulcer Disease and Related Disorders, John Del Valle ©2024 McGraw Hill. All Rights Reserved.   Terms of Use • Privacy Policy • Notice • Accessibility Page 48 / 49",624,14,156.0,"[-0.16423243 -0.22166705 -1.2057631  ...  0.07253848 -0.3248477
 -1.2092558 ]"
66,", Sugano  K  et al: Kyoto global consensus report on Helicobacter pylori gastritis. Gut 64:1353, 2015.  [PubMed: 26187502]  Sverden  E  et al: Peptic ulcer disease. BMJ 367:15495, 2019. Talley  NJ: Functional dyspepsia: New insights into pathogenesis and therapy. Korean J Intern Med 31:444, 2016.  [PubMed: 27048251]  Vinik  AI, Chaya  C: Clinical presentation and diagnosis of neuroendocrine tumors. Hematol Oncol Clin N Am 30:21, 2016. Yonsei University Medical Library Access Provided by: Downloaded 2024­5­29 3:6 A  Your IP is 116.89.178.138 Chapter 324: Peptic Ulcer Disease and Related Disorders, John Del Valle ©2024 McGraw Hill. All Rights Reserved.   Terms of Use • Privacy Policy • Notice • Accessibility Page 49 / 49",728,16,182.0,"[-0.20419542 -0.09761293 -1.2673599  ...  0.08709934 -0.3679142
 -1.3089072 ]"
67,"CHAPTER  141  ACID PEPTIC DISEASE 886 cobblestone appearance, termed nodular gastritis (a lesion found particularly in children colonized by Helicobacter pylori), or grossly enlarged folds without evidence of cancer, termed hypertrophic gastritis. A peptic ulcer is a mucosal defect at least 0.5 cm in diameter that penetrates the muscularis mucosae. Smaller mucosal defects are called erosions (Fig. 141-1). Gastric ulcers are subdivided into proximal ulcers, located in the body of the stomach, and distal ulcers, located in the antrum and angulus of the stomach. Gastric ulcers are located mainly along the lesser curvature, in particular at the transitional zone of corpus- to antral-type mucosa. This transitional zone is often in the area of the angulus but may shift proximally. Duodenal ulcers usually are located on the anterior or posterior wall of the duodenal bulb (Fig.141-2), or occasionally at both sites (“kissing” ulcers). Lesions distal to the duodenal bulb are termed postbulbar ulcers. Patients who previously underwent a distal gastric resection (Billroth I or II procedure) can develop ulceration at the gastroduodenal anastomosis (anastomotic ulcer). However, ulcers occurring after Billroth II resection are located pre­ dominantly in the jejunal mucosa at the junction between the afferent and efferent loops. Other peptic ulcers can occur at sites of metaplastic or hetero­ topic gastric mucosa, for example, in Meckel’s diverticulum, the rectum, or Barrett’s esophagus. Patients with a large hiatal hernia can develop gastric ulceration, known as Cameron’s ulcers, at the level of the herniation. Dieulafoy’s ulcers, which are small mucosal defects over an intramural arteriole, can lead to severe bleeding. Although these lesions can occur throughout the gastro­ intestinal tract, two thirds occur in the stomach.141  ACID PEPTIC DISEASE ERNST J. KUIPERS AND MARTIN J. BLASER Acid peptic diseases can involve the esophagus (Chapter 140), the stomach, and the duodenum. Dyspeptic symptoms also can occur in patients who have no endoscopic abnormalities, in whom it is termed nonulcer dyspepsia (Chapter 139). DEFINITIONS Gastric and duodenal ulcers usually occur in an area of inflamed mucosa. This inflammation, termed gastritis, duodenitis, or bulbitis, can sometimes be rec­ ognized during endoscopy by signs of edema, reddening, and swelling of the mucosa, but microscopic evaluation of endoscopic biopsy specimens is required for a definitive diagnosis of mucosal inflammation. Gastritis is categorized by endoscopic and histologic criteria, with granu­ locytes predominating in active gastritis and mononuclear cells in chronic gastritis. Gastritis is also classified by the segment of involved stomach: antral-predominant gastritis, corpus-predominant gastritis, or pangastritis. Finally, the absence or presence of premalignant stages of damage to the mucosa as a result of long-standing inflammation defines the categories of nonatrophic and atrophic gastritis, respectively. Endoscopic findings are usually nonspecific, unless the gastric mucosa has either a typical miniature FIGURE 141-1.  Endoscopic view of uncomplicated erosive gastritis. The erosion appears as a small, superficial mucosal break with a black base (arrow). FIGURE 141-2.  Endoscopic view of an ulcer at the anterior wall of the duodenal bulb. The ulcer has a clean base, with a visible vessel appearing as a dark red protruding spot close to the lower ulcer rim. The surrounding mucosa is inflamed and swollen.",3519,515,879.75,"[ 8.1378713e-02 -3.8760623e-01 -1.2366936e+00 ...  4.9299914e-01
  7.6892972e-04 -9.7696507e-01]"
68,"CHAPTER  141  ACID PEPTIC DISEASE 887 EPIDEMIOLOGY The worldwide prevalence of gastritis reflects the prevalence of H. pylori. Colonization with this bacterium is virtually always associated with chronic active gastritis, which persists as long as an individual remains colonized and only slowly disappears 6 to 24 months after the eradication of H. pylori. In developing countries and among first-generation immigrants from these countries, the prevalence of H. pylori gastritis is high (often ≥80%) in all age groups, including children. In Western countries, the prevalence of H. pylori gastritis increases with age; it is currently less than 20% in young adults but 40 to 60% in elderly persons. Although peptic ulcer disease is strongly related to H. pylori gastritis and duodenitis, the epidemiology of ulcer disease has shown secular variations even when H. pylori was ubiquitous. The incidence of peptic ulcer disease rose steeply in Western countries in the late 19th and early 20th centuries and has decreased over the past 30 years, yet peptic ulceration remains a common disorder. The decline in incidence, associated with a decrease in hospital admissions and surgery for ulcer disease, is believed to reflect mainly the decreasing prevalence of gastric colonization with H. pylori. The declining incidence of ulcer disease is also the result of the widespread application of eradication therapy, which strongly reduced recurrent ulcers in H. pylori– positive patients. Other factors may include the widespread use of acid sup­ pressive medication. Nevertheless, hospital admissions for complications of ulcers and mortality from ulcer disease have remained relatively stable in both the United States and other countries, as the reduction in H. pylori–associated ulcers in younger persons has been counterbalanced by an increase in ulcers related to nonsteroidal anti-inflammatory drugs (NSAIDs) in older persons. In Western countries, duodenal ulcers occur more frequently than gastric ulcers. The predominant age at which duodenal ulcers occur is between 20 and 50 years, whereas gastric ulcers most commonly occur in patients older than 40 years. The incidence of gastroduodenal ulcer disease is approximately 1 to 2 per 1000 inhabitants per year. Two thirds of patients with ulcers are male, and the disease is more common in smokers. The risk of recurrent disease after initial healing is high; more than 50% of patients have a recurrent ulcer within 12 months of healing in the absence of treatment. Maintenance acid suppressive therapy reduces this recurrence rate, but only therapeutic measures that remove the underlying cause of the ulcer can prevent most ulcer recurrences. PATHOBIOLOGY Helicobacter pylori Most peptic ulcers are associated with colonization with H. pylori (Fig. 141-3). Initial clinical studies of the association between H. pylori and ulcer disease reported that approximately 85% of patients with gastric ulcer disease and 95% of patients with duodenal ulcer disease were colonized by H. pylori. Most persons who are H. pylori positive do not have any specific complaints, nor do they develop ulcer disease. The estimated risk for the development of ulcer disease during persistent H. pylori colonization is 5 to 15%—that is, three- to eight-fold higher than the risk for patients who are H. pylori negative. The risk for the development of an ulcer in the presence of H. pylori is deter­ mined by a combination of host- and bacteria-related factors. Host factors include immune response, smoking, and stress. Bacterial factors that increase the risk of ulcer include a high production of the VacA product, which reflects the presence of the s1m1 genotype; a high level of cytokine induction, owing to the presence of genes in the cag pathogenicity island; and enhanced adher­ ence, resulting from babA. Nonsteroidal Anti-inflammatory Drugs and Aspirin The other common cause of gastroduodenal ulcer disease is the use of NSAIDs. At least 2 to 4% of the population in many countries use acetylsali­ cylic acid, acetic acid derivatives (diclofenac, indomethacin, sulindac), or propionic acid derivatives (ibuprofen, ketoprofen, naproxen) on a daily basis. Within 14 days after the start of such treatment, about 5% of patients develop mucosal breaks, that is, erosions and ulcers. In patients who continue therapy for 4 weeks or longer, this proportion increases to 10%. The concomitant presence of H. pylori infection increases the incidence of NSAID-related ulcers. The risk of developing an ulcer during NSAID use is also higher in patients who are older than 60 years, those with a previous ulcer, patients who use corticosteroids or high-dose NSAIDs, and those with major comor­ bid diseases. In patients who use anticoagulants, such as warfarin, or who have severe comorbid disease, an NSAID-induced ulcer is more likely to lead to life-threatening gastroduodenal hemorrhage. On the basis of their activities, NSAIDs are divided into cyclooxygenase 1 (COX1) and COX2 inhibitors (Chapter 36). The COX1 enzyme is involved in the production of prostaglandins, which play a role in normal cell regula­ tion. The COX2 enzyme, which is also involved in the production of prosta­ glandins, is induced by inflammatory responses. Most NSAIDs have a nonselective COX inhibitory effect; selective COX2 inhibitors are associated with fewer gastroduodenal ulcers, but their use is limited by their adverse coronary effects (Chapter 36). Because of the strong association between NSAIDs and ulcer disease and the risk for recurrence of ulcers with their continued use, patients with ulcers must be thoroughly assessed for the use of NSAIDs. Helicobacter pylori–Negative, Non-NSAID Ulcer Disease In most series, H. pylori and NSAID use account for 80 to 95% of cases of ulcer disease. The remaining cases are often referred to as idiopathic or H. pylori–negative, non-NSAID acid peptic disease. The proportion of ulcer disease that is idiopathic is increasing throughout the world as the prevalence of H. pylori decreases. Further, it is likely that some ulcers in H. pylori– positive patients were not caused by H. pylori. Consistent with this notion is the fact that some H. pylori–positive patients develop recurrent ulcers after successful bacterial eradication, so presumably their ulcer disease was idio­ pathic. It is not known whether the increase in idiopathic ulcer disease is simply proportional to the decrease in H. pylori–associated ulcers or whether it reflects a true increase in the incidence of idiopathic ulcers. In patients with idiopathic ulcer disease, specific clues to the underlying cause are often provided by the medical history, including comorbidity and drug use; the endoscopic appearance of the ulcer; and the histologic features of the ulcer’s margins and surroundings. In most cases, these initial data can direct further diagnostic studies (Table 141-1).",6923,1067,1730.75,"[ 0.01978008 -0.3299771  -1.382388   ...  0.26242334  0.20151575
 -1.6425613 ]"
68,"Malignant Ulcer Disease Gastroduodenal ulcers can result from underlying malignant disease. In the stomach, these tumors are related to gastric adenocarcinoma and, rarely, to mucosa-associated lymphoid tissue (MALT) lymphomas (Chapter 198). Malignant ulcers in the duodenum may result from primary duodenal carci­ nomas or from penetrating pancreatic cancers. Duodenal cancers have an association with polyposis syndromes, especially familial adenomatous polyposis and, to a much lesser extent, MUTYH-associated polyposis and Peutz-Jeghers syndrome (Chapter 199). In both the stomach and the duode­ num, ulcer disease can also be caused by metastatic tumors, including cancers of the breast, colon, thyroid, or kidney, or by melanoma, disseminated lym­ phoma, or Kaposi’s sarcoma. Malignant ulcers are characteristically irregular in shape with heaped borders, but they may also be flat or depressed lesions. Current high-resolution and magnification endoscopes allow visualization of the altered mucosal structure surrounding an ulcer, including changes in the microvascular pattern. For a definite diagnosis of malignancy, multiple biopsy specimens are needed, usually from the ulcer margins. Systemic Inflammatory Disorders A few gastroduodenal ulcers are caused by systemic inflammatory diseases, in particular, Crohn’s disease (Chapter 143). Patients with Crohn’s disease affecting the proximal gastrointestinal tract often have multiple ulcers FIGURE 141-3.  Gastric mucosa colonized with Helicobacter pylori appearing as curved bacilli on the mucosal surface.",1566,211,391.5,"[-0.0085353  -0.32846698 -0.8041117  ...  0.30580834 -0.7627819
 -1.1296303 ]"
69,"CHAPTER  141  ACID PEPTIC DISEASE 888 characterized by irregular longitudinal shapes. Ulcers in the duodenum occur atop Kerckring’s folds. Patients with gastroduodenal ulcers from Crohn’s disease do not invariably have evidence of disease elsewhere in the digestive tract, nor do blood tests always suggest an active inflammatory bowel disor­ der. The demonstration of ulcerative inflammation elsewhere in the digestive tract, in particular in the terminal ileum and colon, strongly supports the diagnosis of Crohn’s disease, as do granulomas on a biopsy specimen. However, the absence of granulomas does not exclude Crohn’s disease, and these lesions are not specific for Crohn’s disease; they are also associated with H. pylori gastritis and other conditions, particularly sarcoidosis (Chapter 95). Sarcoidosis can also lead to gastroduodenal ulcer disease. Other inflammatory disorders that can cause gastritis or gastroduodenal ulcers include various forms of vasculitis affecting the mesenteric system, in particular Behçet’s disease (Chapter 278), Henoch-Schönlein purpura (Chapter 278), Takayasu’s arteritis (Chapter 278), polyarteritis nodosa (Chapter 278), systemic lupus erythematosus (Chapter 274), Churg-Strauss syndrome (Chapter 278), and Wegener’s granulomatosis (Chapter 278). Lymphocytic gastroduodenitis, which is strongly associated with celiac disease (Chapter 142), may lead to duodenal ulceration and subsequent ste­ notic web formation. Ulcer disease also may occur in patients with polycy­ themia vera (Chapter 169), possibly in relation to reduced mucosal blood flow. Vasculitis underlying ulcer disease should be considered in patients with chronic or recurrent ulceration in whom other causes have been excluded. Lymphocytic phlebitis, which is a rare vasculitic inflammatory disorder affecting the mesenteric veins, may cause gastric ulcer disease. Systemic amyloidosis (Chapter 194) affecting the stomach wall may lead to gastric ulcer disease. Rare cases of duodenal ulceration have been described in the presence of annular pancreas or congenital bands obstructing the descending duodenum. Hypergastrinemic Syndromes Peptic ulcers can result from chronic gastric hyperacidity related to hypergas­ trinemia. The most important hypergastrinemic disorder is Zollinger-Ellison syndrome (Chapter 201), a condition of marked hyperacidity leading to severe peptic ulcer disease caused by a gastrin-producing endocrine tumor. These patients usually have multiple therapy-resistant bulbar and postbulbar duodenal ulcers. The diagnosis can be confirmed by the presence of a high fasting serum gastrin level (often but not always ≥10-fold increased and >1000 pg/mL). Similar gastrin levels are sometimes seen in patients treated for chronic ulcer disease with high-dose proton pump inhibitors. For clarifi­ cation, secretin testing can be performed: in patients with Zollinger-Ellison syndrome, the injection of secretin (1 U/kg) increases serum gastrin levels by more than 50%, or 120 pg/mL or greater in those with fasting gastrin levels less than 10-fold above normal. Imaging techniques, such as computed tomography (CT), magnetic resonance imaging, isotope scanning, endo­ scopic ultrasonography, videocapsule endoscopy, and balloon-assisted enter­ oscopy, may be used to detect the primary tumor, which is often located in either the pancreas or the proximal small bowel. In some patients, Zollinger-Ellison syndrome occurs as part of multiple endocrine neoplasia (Chapter 239), particularly in association with hyperparathyroidism. Other TABLE 141-1	 DIFFERENTIAL DIAGNOSIS OF PEPTIC ULCER DISEASE ORIGIN CONDITION FREQUENCY* DIAGNOSTIC TEST FINDINGS Microbes Helicobacter pylori Very common Helicobacter pylori tests Bacteria, enzymes, antigens, antibodies Histology Gastritis Helicobacter heilmannii Rare Histology Spiral bacteria, gastritis Treponema pallidum Very rare Serology Antibodies Mycobacterial infection Very rare Histology, immune response testing, chest radiograph Acid-fast bacteria, granuloma, immune response, pulmonary infiltrate Cytomegalovirus, herpes simplex virus type 1 Rare Histology, serology Virus inclusions, antibodies Drug use NSAIDs, aspirin Very common History, urine test NSAID use Bisphosphonates Rare History Bisphosphonate use Corticosteroids Rare History Corticosteroid use, comorbidity Amphetamines, cocaine Rare History, drug testing Drug use Anticoagulants, coagulopathy Rare Endoscopy Ulcer after intramural bleed Malignancy Gastric cancer Common Histology Malignancy Duodenal cancer Rare Histology, CT Malignancy Pancreatic cancer Common Histology, CT Malignancy Mucosa-associated lymphoid tissue lymphoma Rare Histology Malignancy Metastatic cancer Rare Histology Malignancy Gastritis syndromes Eosinophilic gastritis Rare Histology Eosinophilic infiltration Lymphocytic gastritis Rare Histology, celiac disease screening Lymphocytic infiltration, villous atrophy Hyperacidic syndromes Zollinger-Ellison syndrome Rare Serum gastrin, secretin test Extreme hypergastrinemia, positive secretin test Antral G-cell hyperfunction Very rare Serum gastrin, secretin test Moderate hypergastrinemia, negative secretin test Retained gastric antrum Very rare Medical history, gastrin Billroth II resection, hypergastrinemia Systemic mastocytosis Very rare Histology of affected sites Mast cell infiltration Chronic myelogenous leukemia Very rare Leukemia evaluation Leukemia Ischemia Mesenteric vascular occlusion Common Angiography Vascular disease Polycythemia vera Rare Blood counts Polycythemia Specific ulcer types Cameron’s ulcer Common Endoscopy Ulcer in large hiatal hernia Marginal ulcer Common Endoscopy Ulcer at anastomosis Dieulafoy’s ulcer Common Endoscopy Singular bleeding focus with minimal mucosal disruption Systemic inflammation Crohn’s disease Common Histology, ileocolonoscopy Inflammation, granulomas Vasculitides Rare Histology, systemic evaluation Vasculitis, signs of systemic disease Gastric amyloidosis Very rare Histology Amyloid deposition Other conditions Stress ulcer Fairly common in patients in intensive care units Endoscopy — Radiation therapy, chemotherapy Rare Endoscopy, history — *Frequency as a cause of gastroduodenal ulcer disease. CT = computed tomography; NSAID = nonsteroidal anti-inflammatory drug.",6301,811,1575.25,"[-0.20936002 -0.24783465 -0.74087036 ...  0.28285193  0.0910303
 -1.0298071 ]"
70,"CHAPTER  141  ACID PEPTIC DISEASE 889 hypergastrinemic hyperacidity syndromes are the retained gastric antrum syndrome (see later) and antral G-cell hyperfunction. In the latter, fasting serum gastrin levels are only modestly increased and do not rise after the injection of secretin, but they respond in an exaggerated way to meals, thereby leading to hyperacidity. When the condition occurs in an H. pylori–positive patient, bacterial eradication therapy may be curative. However, some patients with G-cell hyperfunction are H. pylori negative. Ischemia Stenosis or occlusion of the celiac trunk or the superior mesenteric artery (Chapter 145) also can lead to ulceration in the mucosa of the proximal digestive tract (Fig.141-4). These ulcers typically occur in elderly patients with risk factors for atherosclerosis, but they can also occur in younger sub­ jects with mesenteric obstruction due to other causes. Ischemic ulcers tend to heal slowly and recur. Pallor of the mucosa, consistent with decreased mucosal blood flow, may be noted at endoscopy. Upper mesenteric isch­ emia is often associated with upper abdominal pain, which can be elicited by a meal or by physical activity. These symptoms may cause patients to decrease their food intake, leading to weight loss before their clinical pre­ sentation. The prevalence of upper mesenteric ischemia with secondary ulcer disease is unknown, in part owing to its variable presentation, often with a history of gradual symptoms; the lack of standardized and reliable diagnostic tests; and clinicians’ unfamiliarity with the condition. Diagnostic evaluation includes a duplex ultrasound scan for vascular flow and conven­ tional or CT angiography of the affected arteries. Validated functional tests for gastroduodenal mucosal perfusion are not widely available, but a tech­ nique for directly measuring mucosal oxygen saturation during endoscopy is investigational. Stress Ulcers Patients with severe medical conditions, such as major trauma, sepsis, exten­ sive burns, head injury, or multiorgan failure, can develop stress ulcers in the stomach or duodenum. Major risk factors for stress ulceration in severely ill patients include mechanical ventilation, coagulopathy, and hypotension, but factors such as hepatic and renal failure and the use of ulcerogenic medica­ tions may contribute. Stress ulcers occur independently of H. pylori coloniza­ tion. Ulcers associated with head injury are known as Cushing’s ulcers, and ulcers associated with extensive burns are known as Curling’s ulcers. Stress ulcers were once common in patients in intensive care units, but improve­ ments in overall management, including respiratory and hemodynamic care, acid inhibition, and emphasis on adequate feeding, have reduced the inci­ dence of these ulcers, which currently affect 1 to 2% of these patients. Stress ulcers may be asymptomatic, but they can also cause complications, espe­ cially bleeding. Other Factors Cameron’s Ulcer Patients with large hiatal hernias (Chapter 140) may present with proximal gastric ulcers, termed Cameron’s ulcers, at the level of the hiatus, where the stomach is compressed. These ulcers are usually asymptomatic but may cause occult or overt bleeding. During upper gastrointestinal endoscopy, patients with large hiatal hernias and iron deficiency anemia should be carefully exam­ ined in normal and retroverted positions for the presence of Cameron’s ulcers. Anastomotic or Marginal Ulceration Patients who have undergone partial gastrectomy sometimes develop recur­ rent ulcers, often located at the anastomosis or within the jejunum immedi­ ately opposite the anastomosis. Ischemia and chronic inflammation resulting from H. pylori and biliary reflux may cause such ulcers, as may underlying cancer. If biopsy excludes cancer, treatment includes acid suppression and H. pylori eradication, if needed. Ulcer disease can be caused by the retained gastric antrum syndrome after partial gastrectomy when the antrum is not completely excised from the detached duodenum. Because it then lacks expo­ sure to acid and is thus not physiologically downregulated, it continues to secrete gastrin despite normal or even high acid levels. Marginal ulcers can also occur after bariatric Roux-en-Y gastric bypass surgery. Other Microbes Colonization with Helicobacter heilmannii (formerly known as Gastrospirillum hominis), which is probably a zoonotic organism, is associated with mild gastritis and sometimes with transient ulcer disease. Ulcer disease also may be infectious, resulting from secondary syphilis (Chapter 327), mycobacterial infection (Chapter 332), infection with herpes simplex virus type 1 (Chapter 382), or cytomegalovirus infection (Chapter 384). Alcohol Short-term heavy alcohol use or long-term moderate to heavy alcohol use can lead to signs of acute and chronic gastritis. No evidence indicates that this gastritis is associated with a significant risk for peptic ulceration, although alcohol use increases the risk of bleeding in patients with peptic ulcer disease. Hyperhistaminic Syndromes Similar to the hypergastrinemic syndromes, persistent elevation of histamine can lead to hyperacidity as a result of the chronic stimulation of parietal cells. Elevated histamine levels are observed in two rare syndromes. Systemic mas­ tocytosis (Chapter 263) is characterized by a proliferation of mast cells in the bone marrow, skin, liver, spleen, and gastrointestinal tract, often associated with both spontaneous and trigger-induced (e.g., alcohol) release of hista­ mine and other vasoactive substances. Patients with systemic mastocytosis often have gastrointestinal symptoms, including pain, diarrhea, and blood loss. Ulceration results from chronic gastric acid hypersecretion. Clues to the diagnosis include symptoms of pruritus, urticaria, or rash. The bone marrow and affected organ mast cell infiltrates carry a specific C-kit mutation and express CD2 and CD25. Histamine hypersecretion leading to peptic ulcer disease can also occur in chronic myelogenous leukemia (Chapter 190) with basophilia. Other Drugs Treatment with oral bisphosphonates, widely used for osteoporosis (Chapter 251), is complicated by gastric erosions and ulceration in an estimated 3 to 10% of treated patients. The risk for ulcer disease may be synergistically increased by NSAID use but is probably independent of H. pylori coloniza­ tion.",6419,933,1604.75,"[-0.09316473 -0.34321207 -1.0855289  ...  0.528953   -0.06041567
 -1.4161314 ]"
70,"Although corticosteroid treatment can be complicated by peptic ulcer disease, the relative risk is only slightly increased, except in patients with serious comorbid diseases, using long-term or high-dose therapy, or with prior ulcers. Other patients who use corticosteroids are not at serious risk for ulcer disease and therefore do not require measures to prevent ulcers. Persons who use amphetamines and crack cocaine (Chapter 33) frequently develop ulcer disease, often with perforation, possibly as a result of vascular insufficiency. Chemotherapy, particularly when given selectively as a high- dose intra-arterial infusion in the celiac system, can be complicated by ulcer disease. Patients on anticoagulant therapy and those with other coagulopa­ thies may rarely develop intramural hematoma of the gastrointestinal tract. Depending on the location, these hematomas may cause obstruction, but they can also leave large ulcers when they rupture into the lumen. Radiation therapy of the upper abdomen is sometimes complicated by chronic ischemic ulceration, especially in long-term follow-up. CLINICAL MANIFESTATIONS The clinical manifestations of acid peptic disease (Table 141-2) do not always predict the various morphologic presentations found at endoscopy. Indeed, FIGURE 141-4.  Endoscopic view of an irregular gastric ulcer at the posterior wall and smaller curvature in a patient with chronic mesenteric ischemia due to subtotal stenosis of the celiac trunk.",1471,210,367.75,"[ 0.4071098  -0.36395204 -1.0599726  ...  0.29661393  0.14192185
 -1.4517866 ]"
71,"CHAPTER  141  ACID PEPTIC DISEASE 890 a silent ulcer may be recognized only when it presents abruptly with a com­ plication, most commonly hemorrhage or perforation, or it may be discov­ ered incidentally when a diagnostic test is performed for other reasons. Nevertheless, the typical presentation of acid peptic disease is recurrent epi­ sodes of pain. The pain is almost invariably located in the epigastrium and may radiate to the back or, less commonly, to the thorax or other regions of the abdomen (see Table 141-2). Some patients describe the pain as burning or piercing, whereas others describe it as an uncomfortable feeling of empti­ ness of the stomach, referred to as painful hunger. Indeed, the pain may improve with the ingestion of food, only to return in the postprandial period. The timing of the pain in relation to meals and the soothing effects of food are nonspecific, however, and may also occur in patients with functional dyspepsia without ulcer. Nocturnal epigastric pain that awakens a patient several hours after a late meal is more likely to represent ulcer pain. Besides the pain during symptomatic episodes, patients may complain of retrosternal burning (heartburn) or acidic regurgitation into the throat, symptoms that reflect associated gastroesophageal reflux (Chapter 140), which is aggravated by hyperacidity or delayed gastric emptying. Nausea and vomiting may also occur but are nonspecific. The presence of significant diar­ rhea should raise the possibility of Zollinger-Ellison syndrome (Chapter 201), but diarrhea also may result from the heavy use of magnesium- containing antacids. In untreated patients, symptoms tend to be intermittent, with flares of daily pain lasting 2 to 8 weeks, separated by prolonged asymp­ tomatic intervals. During periods of remission, patients may feel well and may be able to eat even heavy or spicy meals without apparent discomfort. Physical Examination The physical examination is usually unrevealing. If significant bleeding has occurred (Chapter 137), the patient may present with pallor and may be hypovolemic (Chapter 106). It is always useful to inquire about the charac­ teristics of the stool, because ulcer-related bleeding may manifest not only obviously in the form of hematemesis but also insidiously as melena (black feces). In the case of massive ulcer bleeding with the rapid bowel passage of blood, patients may also present with red rectal blood loss. When a patient has acute perforation, severe epigastric and abdominal pain develops, and the patient appears distressed. Characteristically, intense contracture of the abdominal muscles is apparent on palpation, together with rebound tender­ ness and other signs of peritoneal irritation. With large amounts of intra- abdominal air, percussion may reveal hypertympany over the liver. DIAGNOSIS In a patient who presents with symptoms consistent with ulcer disease, the diagnostic evaluation should proceed along two different but complementary paths: confirmation of the anatomic abnormality and investigation of its cause (Table 141-3). In most patients, it is advisable to follow both diagnostic paths simultaneously, but sometimes it is reasonable to skip the anatomic verification as a cost-saving strategy and proceed to management based on the probable cause. Anatomic Diagnosis Endoscopy (Chapter 136) is the primary investigative tool in patients sus­ pected of having acid peptic disease. This technique can detect erosive gas­ tritis (see Fig.141-1) or an ulcer in the gastric wall or duodenal bulb (see Fig. 141-2). Because of the high prevalence and the often spontaneous improve­ ment of dyspeptic symptoms, endoscopy usually should not be performed immediately; rather its use should be restricted to patients with persistent or recurrent symptoms. However, immediate endoscopy is indicated in patients with alarm symptoms such as weight loss, dysphagia, anorexia, considerable vomiting, anemia, or signs of overt bleeding. Endoscopy is both highly sensitive and highly specific for the detection of ulcer disease. The most common locations for a peptic ulcer are the stomach and duodenal bulb, but peptic ulcers sometimes occur in the esophagus, the small bowel, and a Meckel’s diverticulum lined with heterotopic gastric mucosa. Endoscopic ultrasound may detect an unsuspected submucosal component or enlarged lymph nodes, such as may occur in gastric neoplasia, especially lymphoma and linitis plastica (Chapter 198). Ulcers in the dorsal wall of the duodenal bulb, especially at the transition from the bulb to the postbulbar descending portion of the duodenum, are most difficult to visual­ ize, and they sometimes require a side-viewing endoscope, particularly when endoscopic treatment is needed. Other regions where gastroduodenal ulcers can be easily missed are the cardia and the gastric angulus. Dieulafoy’s lesions may be difficult to diagnose because of their small mucosal defects and inter­ mittent bleeding. Some patients require more than one endoscopy, prefera­ bly during acute bleeding, to localize the lesion. Endoscopy is also useful for ascertaining the presence of concomitant disorders, including esophagitis and duodenitis, or complications, such as bleeding or a visible vessel (see Fig.141-2); obtaining biopsy specimens, such as for histologic examination and to assess for H. pylori (see Fig.141-3); and performing therapeutic interventions. In rare cases, such as stenosis that blocks the advancing endoscope, conventional barium contrast radiographs (Chapter 135) are indicated. Additional investigations by endosonography or CT are needed when an underlying malignant disease is suspected. The endoscopist should obtain biopsy samples from all gastric ulcers, especially those with a suspicious appearance, to exclude potential malignant disease. Because duodenal ulcers are less likely to be malignant, biopsies are usually not required unless malig­ nancy is specifically suspected. TABLE 141-2	 KEY SYMPTOMS AND SIGNS OF PEPTIC ULCER UNCOMPLICATED ULCER No symptoms (“silent ulcer” in up to 40% of cases) Epigastric pain Pain may radiate to the back, thorax, other parts of abdomen (cephalad most likely, caudad least likely) Pain may be nocturnal (most specific), “painful hunger” relieved by food, or continuous (least specific) Nausea Vomiting Heartburn (mimics or associated with gastroesophageal reflex) COMPLICATED ULCER Acute perforation Severe abdominal pain Shock Abdominal board-like rigidity (and rebound and other signs of peritoneal irritation) Free intraperitoneal air Hemorrhage Hematemesis and/or melena Hemodynamic changes, anemia Previous history of ulcer symptoms (80%) Gastric outlet obstruction Satiation, inability to ingest food, eructation Nausea, vomiting (and related disturbances) Weight loss TABLE 141-3	 DIAGNOSTIC PATHS AND TOOLS IN ULCER DISEASE PATH 1: MORPHOLOGIC DIAGNOSIS Gastroduodenoscopy Barium contrast (inferior alternative) Endoscopic ultrasound (selected cases only) Computed tomography (useful in selected cases) PATH 2: ETIOLOGIC DIAGNOSIS Helicobacter pylori Testing Histologic examination of gastric mucosa Stool antigen test Carbon-13 urea breath test Serum antibodies Ulcer Associated with Nonsteroidal Anti-inflammatory Drug Use History of drug ingestion Decreased platelet adherence Molecular identification (complex, expensive) Acid Hypersecretory Syndromes Serum gastrin elevation Gastrin provocative tests (intravenous secretin, meal) Gastric analysis",7501,1088,1875.25,"[-0.34197235 -0.33512738 -1.2294784  ...  0.72273326  0.42156237
 -1.1899567 ]"
72,"CHAPTER  141  ACID PEPTIC DISEASE 891 Etiologic Diagnosis Diagnosis also must focus on establishing the cause of the ulcer. The first step is to determine whether H. pylori or NSAID use is present, because these are the major risk factors for peptic ulcers and can be contributing factors in ulcers with other precipitating causes. Testing for Helicobacter pylori In populations with a high prevalence of H. pylori, nearly all patients with peptic ulcer disease are positive for H. pylori, so diagnostic testing has little value except when antimicrobial susceptibility testing is needed. The preva­ lence of H. pylori remains high in immigrants from developing countries, where most people become H. pylori positive in youth. In Western countries, approximately 50% of individuals who are older than 65 years are colonized with H. pylori, but the prevalence is less than 20% in those younger than 30 years. In these younger persons, the proportion of patients with ulcers who are H. pylori negative is higher than in older patients, making diagnostic testing for H. pylori, followed by targeted therapy in those who are positive for the bacterium, more attractive than empirical therapy. The presence of H. pylori can be ascertained by four possible approaches. Histologic examination of gastric mucosal biopsies, which is the standard procedure when diagnostic endoscopy is initially performed, is quite sensi­ tive and specific for H. pylori. However, the accuracy of this technique may be affected by sampling error, improper orientation of the specimen, and recent therapy with proton pump inhibitors or antibiotics. A second option is serology, which is a relatively simple, inexpensive test that has reduced predictive value in areas where the prevalence of H. pylori is low. Serology is not helpful to verify whether H. pylori has been eradicated with antibiotics because it may take many months or even years for H. pylori antibodies to fall to undetectable levels. None of the diagnostic tests that do not involve endoscopy can determine whether an ulcer is present. A third option is a stool antigen test, which is more accurate than serology. Finally, the carbon-13 or carbon -14 urea breath test, which relies on the detec­ tion of H. pylori urease activity, is a noninvasive and relatively simple test, but it is more expensive than stool or blood testing. Although the test becomes negative as soon as H. pylori is eradicated, a minimum interval of 4 to 6 weeks after antibiotic treatment is recommended to reduce false-negative results. Nonsteroidal Anti-inflammatory Drugs NSAIDs are usually established as the putative cause of an ulcer based on information obtained from the patient. Assessment of NSAID use in an indi­ vidual patient presenting with ulcer disease can be difficult, both because NSAID use is common and often intermittent and because many different NSAIDs are widely available over the counter in most countries. NSAID use is usually evaluated by detailed medical history, focusing not only on current and recent drug use but also on symptoms of pain, including musculoskeletal complaints. Further information from family members, family practitioners, and pharmacists is sometimes helpful. If surreptitious use of NSAIDs is sus­ pected, direct serum and urine testing for aspirin and NSAID derivatives is feasible, or aspirin use can be assessed indirectly by a platelet adherence assay; however, these tests are not commonly used in clinical practice. Hypersecretory Syndromes Hypersecretory syndromes not related to H. pylori or NSAIDs are rare causes of ulcer disease and are diagnosed by special tests (see Table 141-3). Zollinger- Ellison syndrome should be strongly considered in patients with multiple ulcers, particularly in atypical locations such as distal to the duodenal bulb, and when diarrhea is present, because these finding are uncommon in H. pylori–related peptic ulcer disease. Hypergastrinemic syndromes (e.g., Zollinger-Ellison syndrome, antral G-cell hyperplasia) are best diagnosed by a determination of serum gastrin levels, both basal and after stimulation with intravenous secretin (gastrinoma detection) or a test meal (antral G-cell hyperplasia detection). When detected early, gastrinomas may be resectable (Chapter 201). Gastric analysis, which is performed by placing a nasogastric tube to aspi­ rate gastric juice and to quantify gastric acid output (both basal and after stimulation with subcutaneous pentagastrin), is indicated in only two rare circumstances: patients with elevated serum gastrin levels suggestive of Zollinger-Ellison syndrome or antral G-cell hyperplasia, but with equivocal responses to standard gastric provocative tests, and patients with indirect signs of gastric hypersecretion (e.g., enlarged folds and abundant clear fluid at endoscopy), normal gastrin levels, and negative provocative gastrin tests but who may still be hypersecretors, such as patients with recurrent ulcer disease despite a prior vagotomy with or without antrectomy. A basal acid output greater than 15 mEq/hour or greater than 5 mEq/hour in a post­ operative patient is considered a positive test result. The diagnosis of Zollinger-Ellison syndrome is best confirmed by gastric analysis showing a basal acid output greater than 15 mEq/hour in conjunc­ tion with a fasting serum gastrin level exceeding 1000 pg/mL in the presence of gastric pH less than 2. To skip the cumbersome gastric analysis, a gastric pH determination showing a fasting pH of 2 or less is adequate. For serum gastrin levels in the range 100 to 1000 pg/mL and intragastric pH greater than 2, an increase in the serum gastrin to more than 200 pg/mL after a secretin stimulation test is suggestive of the diagnosis. An elevated serum gastrin level alone is not sufficient to diagnose Zollinger-Ellison syndrome, because serum gastrin levels tend to increase over time with atrophic gastritis and are also increased in patients receiving proton pump inhibitor therapy. Other Causes In patients in whom a gastroduodenal ulcer cannot be ascribed to coloniza­ tion with H. pylori, use of NSAIDs, or a hypersecretory syndrome, the estab­ lishment of a definite etiologic diagnosis may require a more thorough evaluation, starting with a medical history that focuses on the use of other ulcerogenic agents and the presence of symptoms that could suggest an underlying systemic disease. The next step is to evaluate biopsy samples from ulcer borders and from the antrum, corpus, and duodenum. The ulcer speci­ mens may reveal overt or suspicious signs of malignancy, in particular adeno­ carcinoma (Chapter 198) or lymphoma. In these cases, further diagnostic evaluation should include staging of the malignancy. Alternatively, the biop­ sies may provide evidence of other infectious conditions, specific types of gastritis, celiac disease, ischemia, amyloidosis, or a systemic inflammatory condition. These data can be combined with clues provided by the endo­ scopic evaluation, including the character and location of the ulcer, signs of ischemia, and signs of inflammation at other locations. Further evaluation should focus on the presence of systemic disorders and may include a chest radiograph, angiography, ileocolonoscopy, and abdominal CT. Differential Diagnosis The differential diagnosis of ulcer-like symptoms includes many disorders of the upper abdominal organs, including malignant diseases of the stomach (Chapter 198), duodenum (Chapter 199), pancreas (Chapter 200), or bile ducts (Chapter 202). The differential diagnosis of upper abdominal symp­ toms also includes liver and gallstone disease (Chapter 158), pancreatitis (Chapter 146), and motility disorders (Chapter 138). In many patients with upper abdominal dyspeptic complaints, no underlying cause can be identi­ fied. In this “nonulcer” or functional dyspepsia group, complaints character­ istic of gastroesophageal reflux, ulcer symptoms, or dysmotility symptoms may be prominent. A few of these patients (generally 5%) benefit from eradi­ cation of H. pylori, with a slow decrease of dyspeptic complaints over 12 to 24 months, but functional dyspepsia is not a proven or widely accepted indication for treatment of H. pylori. If such treatment is considered, both the patient and the physician should be prepared for persistent symptoms despite eradication of H. pylori.",8379,1268,2094.75,"[-0.17541605 -0.03521425 -1.2041093  ...  0.43341672  0.4178561
 -1.4469631 ]"
72,"Diagnostic Scenarios: Acute or Initial Clinical Presentation Younger (≤45 years old) patients without alarm symptoms or signs such as anemia, rapid weight loss, or other evidence of serious disease do not neces­ sarily require endoscopy, and evidence indicates that malignant gastric disease is unlikely. When a generalist physician is treating a patient who lives in an area of the world with a relatively high prevalence of H. pylori infection (>10% of the population is positive), a test-and-treat approach can begin with an H. pylori stool antigen determination, urea breath test, or H. pylori sero­ logic examination. If the test is positive, the patient can be treated with the appropriate H. pylori eradication drugs (see later) and observed for 4 to 6 weeks. If the patient is also taking an NSAID, either orally or parenterally, the same approach is appropriate, but the NSAID should be discontinued. If the H. pylori test is negative in a person taking NSAIDs, these drugs should be discontinued, and the patient should be treated with a proton pump inhibitor for 4 to 6 weeks. In patients who are not taking NSAIDs or who do not improve after these drugs are discontinued, endoscopy is indicated to deter­ mine whether an ulcer is present. Conversely, gastroenterologists more commonly proceed directly to endoscopy. If no abnormalities are apparent or the endoscopic study shows only “gastritis” without an overt ulcer, a biopsy should be obtained to",1462,236,365.5,"[-0.08984771 -0.08839506 -1.3756328  ...  0.4138322   0.7757866
 -1.2008202 ]"
73,"CHAPTER  141  ACID PEPTIC DISEASE 892 TABLE 141-4	 OVERVIEW OF ANTIBIOTICS USED FOR HELICOBACTER PYLORI ERADICATION DRUG CLASS DRUG TRIPLE THERAPY* DOSE QUADRUPLE THERAPY† DOSE SEQUENTIAL THERAPY‡ DOSE Acid suppression Proton pump inhibitor 20-40 mg bid§ 20-40 mg bid§ 20-40 mg bid§ Standard antimicrobials Bismuth compound|| 2 tablets bid 2 tablets bid Amoxicillin 1 g bid 1 g bid Metronidazole¶ 500 mg bid 500 mg tid 500 mg bid Clarithromycin 500 mg bid 500 mg bid Tetracycline 500 mg qid Salvage antimicrobials Levofloxacin 300 mg bid 300 mg bid Rifabutin 150 mg bid Furazolidone 100 mg bid Doxycycline 100 mg bid Nitazoxanide 1 g bid *Triple therapy consists of a proton pump inhibitor or bismuth compound, together with two of the listed antibiotics, usually given for 7-14 days.†Quadruple therapy consists of a proton pump inhibitor plus either the combination of a bismuth compound, metronidazole, and tetracycline given for 4-10 days, or the combination of levofloxacin, doxycycline, and nitazoxanide for 10 days.‡Sequential therapy consists of 10 days of proton pump inhibitor treatment, plus amoxicillin during days 1-5 and a combination of clarithromycin and an imidazole (when available, tinidazole; otherwise, metronidazole) during days 6-10. §Proton pump inhibitor dose equivalent to omeprazole 20 mg bid.||Bismuth subsalicylate or subcitrate.¶An alternative is tinidazole 500 mg bid.urea breath test, stool H. pylori antigen, or repeated serology. Serologic deter­ mination is based on a more than 40 to 50% decrease in immunoglobulin G antibody levels in the first 6 months after treatment compared with pretreat­ ment levels in that patient. After successful H. pylori eradication, the risk of recurrent infection in most populations is small. In a minority of patients, ulcers recur either owing to re-infection or in the presence of another ulcerogenic factor, par­ ticularly NSAID use. Disease Related to Nonsteroidal Anti-inflammatory Drug Use In patients who are diagnosed with acid peptic disease while they are taking NSAIDs or aspirin, the first step is to stop such therapy. Acid suppression with a proton pump inhibitor (in doses similar to those used for H. pylori) leads to healing of 85% of NSAID-induced gastric ulcers and more than 90% of duodenal ulcers within 8 weeks of therapy, whereas acid suppression with an H2-blocker, equivalent to ranitidine 300 mg twice daily, heals approximately 70% of ulcers within 8 weeks. The mucosal protective drug misoprostol (200 mg four times daily) has a similar effect. Treatment must be continued for at least 8 weeks, and maintenance therapy is needed in patients who continue to take NSAIDs. Gastric ulcers, larger lesions, and recurrent lesions heal more slowly. Ulcer occurrence during NSAID therapy suggests a causative relationship, but patients should also be tested for H. pylori. In patients who are H. pylori positive, eradication therapy should be considered because there are no clear clinical parameters distinguishing between these etiologic factors. In patients who continue to take NSAIDs, maintenance therapy with a proton pump inhibitor is superior to H. pylori eradication for the prevention of recurrent ulcer, 6  except in patients who use aspirin, for whom H. pylori eradication alone may be curative. Idiopathic Ulcer Disease Patients with idiopathic ulcer disease despite a thorough assessment for underlying causes are treated primarily with an acid suppressant, usually a proton pump inhibitor, because they are at considerable risk for recurrent ulcer disease. After the underlying cause is identified and adequately treated, acid suppressive therapy can be withdrawn if there are no additional risk factors for ulcer disease, such as NSAID therapy or H. pylori infection.ascertain by histologic examination or urease testing whether H. pylori is present. If H. pylori is found by endoscopic biopsy, eradication treatment may be given; however, the effect of H. pylori eradication on relief of functional dyspeptic symptoms is only about 5% greater than with placebo. 1  If endoscopic examination shows an ulcer, its location determines the subsequent approach. An ulcer in the duodenal bulb has only a remote chance of representing a malignant lesion and need not routinely be exam­ ined by biopsy. By contrast, biopsy is mandatory for a gastric ulcerative lesion identified at endoscopy, because malignant gastric disease may present with similar clinical manifestations and may resemble benign ulcer disease mor­ phologically; even if histologic assessment does not identify a malignant process, repeat endoscopy is recommended about 1 month after therapy to verify complete healing and for biopsy of the scar. Helicobacter pylori Infection H. pylori–associated ulcers often heal spontaneously, but acid suppressive therapy accelerates healing and ameliorates symptoms. Four weeks of acid suppressive therapy heals 70 to 80% of ulcers, and this number increases to more than 90% after 8 weeks of therapy. If H. pylori infection persists, however, ulcers recur in 50 to 90% of patients within 12 to 24 months; this rate can be reduced to 20 to 30% with maintenance acid suppression and to less than 5% with H. pylori eradication. 2  Eradication treatment is therefore mandatory (Table 141-4). Treatment for 10 to 14 days has about a 5 to 10% advantage over 7- to 10-day therapy, 3  and quadruple drug therapy is probably better than triple therapy. 4  Nevertheless, 7-day treatment may be acceptable in regions where local studies have shown that a particular treatment is very effective, and it is probably the most economical option in countries with low health care budgets. For patients in whom such therapy fails, a 4- to 10-day course of quadruple therapy is advised. This second-line regimen eradicates H. pylori in an additional 80 to 90% of patients. Resistance of H. pylori to met­ ronidazole varies between 10 and 80% throughout the world. Clarithromycin resistance is increasing and is now estimated to be 5 to 10% in the United States because of the widespread use of macrolides to treat upper respiratory infections. Resistance to amoxicillin and tetracycline is rare and is not usually relevant in clinical practice. Sequential therapy may be superior to standard triple therapy and is a good alternative for both first- and second-line treatment. Continuation of acid suppressive therapy after antibiotic treatment is needed only when symptoms persist 5  or in cases of complicated ulcer disease until eradication of H. pylori has been confirmed. Ascertainment of therapeutic efficacy must be delayed at least 1 month after the end of treatment to prevent false-negative results related to the organism’s temporary suppression but not eradication. When repeat endoscopy is needed (e.g., a gastric ulcer requires repeated histologic examination to exclude underlying malignancy), repeat screening for H. pylori can be performed using the gastric biopsy specimens for histologic examination, culture, or urease testing. If no clinical indication exists for repeat endoscopy, H. pylori status can be determined by a carbon-13 TREATMENT PREVENTION Primary Prevention A test-and-treat strategy for H. pylori colonization may be considered for patients with dyspeptic symptoms, but there is no specific way to prevent H. pylori–associated ulcer disease. In contrast, primary prevention of NSAID- associated ulcer disease is widely advocated for patients at high risk because of a prior ulcer, severe concomitant disease, use of warfarin or high-dose corticosteroids, or older age (>65 years). H2-blockers (at a dose equivalent to ranitidine 300 mg twice daily) partially prevents duodenal ulcer disease during NSAID therapy but has no effect on preventing gastric ulcers unless a higher dose (equivalent to famotidine 40 mg twice daily) is given.",7858,1180,1964.5,"[ 0.13444039 -0.25486544 -1.1259099  ...  0.58679336  0.27640665
 -1.3420154 ]"
74,"CHAPTER  141  ACID PEPTIC DISEASE 893 pump inhibitors (at a dose equivalent to omeprazole 20 mg once daily) and misoprostol (in doses varying between 400 and 800 mg/day) partially protect against both gastric and duodenal ulcers during NSAID use. Miso­ prostol and proton pump inhibitors are equally effective, 7  but adherence with therapy is lower with misoprostol owing to its side effects. Patients should be advised of the importance of adherence because less than 80% adherence to gastroprotection is associated with a more than two-fold increased risk for ulcer disease compared with those who are fully adherent. During low-dose aspirin therapy, primary prevention of ulcers is advocated for the same risk groups, using a proton pump inhibitor or an H2-receptor antagonist. 8  Secondary Prevention Secondary prevention of H. pylori–associated ulcer disease is mandatory and consists of successful bacterial eradication. Testing to ascertain H. pylori status after eradication therapy is indicated in patients with prior complicated ulcer disease or with persistent or recurrent symptoms after therapy, as well as in patients who fail to complete the therapeutic course. Secondary prevention of NSAID-related ulcer disease is preferentially achieved by the withdrawal of NSAIDs. In patients who must continue taking NSAIDs, a change to a selective COX2 inhibitor in combination with a proton pump inhibitor at a dose equivalent to esomeprazole 20 mg twice daily is advocated, especially for patients with complicated ulcer disease. 9  This combination is associated with a lower risk of secondary peptic ulcer complications than treatment with a COX2 inhibitor alone. Secondary prevention of recurrent ulcers in patients who use aspirin may depend on H. pylori status. In H. pylori–positive patients, H. pylori eradication is as effective as a proton pump inhibitor for the prevention of recurrent ulcers. 6  In H. pylori–negative patients, additional acid suppressive therapy at a dose equivalent to esomeprazole 20 mg twice daily should be prescribed. Secondary prevention of idiopathic ulcer disease consists primarily of main­ tenance therapy with a proton pump inhibitor and treatment of the underly­ ing condition. PROGNOSIS The majority of peptic ulcers heal spontaneously within weeks to months. However, if the underlying condition is not adequately treated, a large pro­ portion of ulcers recur. Both initial and recurrent ulcers can give rise to complications. The four major complications are intractability, perforation, hemorrhage, and stenosis. Each distinct situation requires specific manage­ ment approaches. Patients with complicated ulcer disease are at particular risk for recurrent complications and need careful assessment for secondary prevention. Hemorrhage Hemorrhage (Chapter 137), which is the most common complication of peptic ulcer disease, occurs in about one in six patients with ulcers over the course of their ulcer activity. Ulcers caused by NSAIDs account for a larger proportion of these hemorrhages. Peptic ulcer is thus the most common cause of nonvariceal upper gastrointestinal bleeding, accounting for 40 to 60% of cases in most populations. Bleeding is associated with a 5 to 15% risk of rebleeding and up to a 10% risk of mortality. Hemorrhage may occur along a continuum from a serious acute event associated with hemodynamic shock and high mortality to slow or intermittent blood loss leading to chronic anemia. Approximately 80% of patients with bleeding ulcers describe a prior history of symptomatic disease, and about 20 to 30% have suffered a previous hemorrhage. Assessment of the magnitude of bleeding is of paramount importance in determining the need for transfusion and subsequent manage­ ment (Table 141-5). Initial hematocrit levels may be misleading and are likely to fall because of hemodilution. Rapid bleeding is usually apparent on the basis of clinical signs (pallor, systolic blood pressure ≤100 mm Hg, pulse ≥100/minute); immediate fluid resuscitation and transfusions are indicated to prevent circulatory collapse. Mortality is particularly related to complica­ tions of the bleed, such as aspiration, and exacerbation of underlying disease, such as pulmonary, cardiovascular, renal, and hepatic disease. On rare occa­ sions, patients may actually bleed to death, especially when a larger artery is affected, such as when an ulcer in the posterior wall of the duodenal bulb perforates the gastroduodenal artery. Initial treatment aims at hemodynamic stabilization. Endoscopy is the mainstay of therapy and should be performed within 24 hours of presentation in high-risk cases, especially patients who are hemodynamically unstable, require transfusion, or have more severe comorbidities. Endoscopy can be TABLE 141-5	 BLATCHFORD SCORING SYSTEM TO DETERMINE THE NEED FOR INTERVENTION IN PEPTIC ULCER BLEEDING VARIABLE VALUE AT ADMISSION SCORE COMPONENT VALUE Blood urea (mmol/L) 6.5-7.9 2 8.0-9.9 3 10.0-24.9 4 ≥25.0 6 Hemoglobin (g/L)   Men 120-129 1 100-119 2 <100 6   Women 100-119 1 <100 6 Systolic blood pressure (mm Hg) 100-109 1 90-99 2 <90 3 Other markers Pulse ≥100/min 1 Presentation with melena 1 Presentation with syncope 2 Hepatic disease 2 Cardiac failure 2 Data from Stanley AJ, Ashley D, Dalton HR, et al. Outpatient management of patients with low-risk upper gastrointestinal haemorrhage: multicentre validation and prospective evaluation. Lancet. 2009;373:42-47. Intervention (endoscopic hemostasis, surgery, transfusion) is rarely needed for patients with an admission score ≤2 but is required in more than 40% of patients with a score ≥6. TABLE 141-6	 ENDOSCOPY RESULTS IN PATIENTS WITH BLEEDING ULCERS ENDOSCOPY RESULT ULCER CHARACTERISTICS* RISK OF RECURRENT BLEEDING (%) Active bleeding Arterial bleeding 80-90 Oozing bleeding 10-30 Stigmata of recent bleeding Nonbleeding visible vessel 50-60 Adherent clot 25-35 Flat pigmented spot 0-8 No signs of bleeding Clean ulcer base 0-12 *The ulcer characteristics determine the risk of recurrent bleeding during follow-up.performed to ascertain the origin of the bleeding, and, if necessary, provide therapy to stop the bleed and reduce the risk of rebleeding. The appearance of the ulcer determines the need for endoscopic treatment and the risk of rebleeding (Table 141-6) and mortality. “Clean base” ulcers and those with flat pigmented spots carry a low risk of rebleeding and do not require endoscopic treatment. In contrast, ulcers with active bleeding or stigmata of recent bleeding, in particular a visible vessel or adherent clot, require treatment to stop the bleed and reduce the otherwise high risk of recurrence. Endoscopic therapy may lead to a three-fold reduction in episodes of recurrent bleeding and in the need for surgical intervention, as well as a 40% reduction in mortality.",6838,1019,1709.5,"[ 0.15579562 -0.24839976 -1.4969718  ...  0.5904731   0.35741955
 -1.6320804 ]"
74,"10  Treatment modalities include injection therapy with epinephrine or a sclerosant, thermocoagulation, and mechanical pres­ sure by means of clips. Thermocoagulation can be performed by direct contact, such as with a heater probe, or by a noncontact method, such as argon plasma coagulation. The efficacy of these methods is generally compa­ rable, except that epinephrine injection alone is inferior to the other modali­ ties but can be useful when combined with any of the others. 10,11  If an adherent clot is found, an attempt should be made to remove it by water flushing or snaring to allow an assessment of the underlying ulcer base and the treatment of any underlying visible vessels to reduce the risk of rebleeding. 12  The pre-endoscopy administration of intravenous proton pump inhibitor therapy (at a dose equivalent to a bolus of 80 mg esomeprazole, followed by a continuous infusion of 8 mg/hour until endoscopy) reduces bleeding and the need for emergent endoscopic treatment, but it has no effect on the need",1026,162,256.5,"[-0.30468744 -0.15041965 -1.3067354  ...  0.7270337   0.31337434
 -1.2275065 ]"
75,"CHAPTER  141  ACID PEPTIC DISEASE 894 for transfusion or the occurrence of rebleeding or death. For patients with active bleeding or stigmata of recent bleeding, endoscopic treatment should be followed by an intravenous proton pump inhibitor given as a bolus at a dose equivalent to 80 mg esomeprazole over 30 minutes, followed by a con­ tinuous infusion at a dose equivalent to esomeprazole 8 mg/hour for 72 hours, to reduce rebleeding and the need for further intervention. 13  Other therapies, including tranexamic acid, vasopressin, somatostatin, and octreo­ tide, should be considered experimental (Chapter 137). Second-look endos­ copy is not routinely indicated but can be considered in very high-risk cases, particularly when there is doubt about the adequacy of initial visualization or treatment. About 70 to 80% of rebleeds occur within the first 3 days and generally should be managed by repeat endoscopy. If endoscopy fails to stop the bleed or prevent further rebleeding, surgery and interventional radiology are equiv­ alent options. Surgery includes stitching of the ulcer and occlusion of the feeding artery, usually the gastroduodenal artery. Interventional radiology uses angiography to insert a coil in the culprit vessel at the site of the bleed. Single-center observational experience suggests that each of these methods is equally effective in the hands of experienced clinicians, and the choice depends on local availability and expertise. The risk for a fatal outcome of an upper gastrointestinal hemorrhage can be estimated based on five clinical and endoscopic parameters (Table 141-7). In several studies, mortality in patients with a bleeding peptic ulcer was less than 2% among those with a score of 2 points or less, 10% in those with 3 to 5 points, and up to 46% in those with 6 points or more. Management of patients who recover after a peptic ulcer hemorrhage is similar to the treat­ ment of patients with uncomplicated ulcers. Eradication of H. pylori provides excellent protection against both recurrence and rebleeding of H. pylori– related ulcers. NSAID-induced ulcers are preferentially managed by the with­ drawal of NSAIDs or, if this is not feasible, by the combination of a COX2 inhibitor and a proton pump inhibitor at a dose equivalent to esomeprazole 20 mg twice daily. In patients with a history of ulcer bleeding and concomi­ tant cardiovascular disease requiring antiplatelet therapy, the combination of low-dose aspirin and a proton pump inhibitor at a dose equivalent to eso­ meprazole 20 mg twice daily is associated with a lower risk of complicated ulcer than is clopidogrel monotherapy. 14  If a patient who requires antiplate­ let therapy presents with a bleeding ulcer, antiplatelet therapy should be continued or restarted as soon as possible if the risk of a cardiovascular event outweighs the risk of recurrent bleeding. 15  Perforation Perforation may manifest as an acute event, whereby gastric contents spill into the peritoneal cavity, or more insidiously as the ulcer slowly penetrates into surrounding tissues. Acute free perforation typically causes abrupt and severe abdominal pain associated with abdominal muscular spasm that produces board-like rigidity of the abdomen and other manifestations of peritoneal irritation. Secondary hemodynamic shock is common. The clini­ cal diagnosis can be confirmed in approximately 80% of patients by a plain chest radiograph with the patient standing (Fig.141-5); a CT scan can be obtained if doubt persists. Leukocytosis and elevated C-reactive protein levels develop rapidly, and mild hyperamylasemia may occur. Treatment begins by correcting hemodynamic, fluid, and electrolyte imbalances. Naso­ gastric suction is helpful, and prophylactic antibiotics (e.g., amoxicillin- clavulanic acid 1 g every 8 hours intra­venously) are usually administered. Unless a specific contraindication exists, emergency surgery is usually indi­ cated, although more conservative approaches are sometimes appropriate. Given the success in achieving the long-term cure of ulcer disease through the eradication of H. pylori and the withdrawal of NSAIDs, suturing of the perforated ulcer may be adequate, permitting the patient to avoid a more radical vagotomy with or without gastric resection. Intractability Intractability is a term strictly applied to an ulcer that persists even after intensive and prolonged proton pump inhibitor therapy. Symptoms may or may not be present. These rare cases may result from poor compliance with recommended treatment, surreptitious use of ulcerogenic drugs, or other diseases (e.g., Crohn’s disease, ischemia, infection with bacteria other than H. pylori, viral infection). If these issues are recognized and these diagnoses are pursued, further complications and interventions such as surgical vagot­ omy and pyloroplasty can almost always be avoided. Acid peptic disease related to alcohol or bisphosphonates should be addressed by discontinuing the precipitating agent. Treatment of Zollinger- Ellison syndrome requires high-dose proton pump inhibitors and/or surgery (Chapter 201). Those rare ulcers caused by Crohn’s disease (Chapter 143), vasculitis (Chapter 278), sarcoidosis (Chapter 95), polycythemia vera (Chapter 169), amyloidosis (Chapter 194), and other rare disorders should be addressed by treating the underlying condition. Stress ulcers and Cameron’s ulcers are treated by potent acid suppression therapy (e.g., omeprazole 20 mg twice daily). Stenosis Gastric outlet obstruction is now a rare complication of ulcer disease because of the early detection and treatment of most ulcers. Most patients who develop clinically relevant gastric outlet obstruction have had an ulcer in the duodenal bulb and/or pyloric channel. Edema and inflammation play an important role, and occasionally a patient with active disease presents with symptoms of outlet obstruction as manifested by nausea, vomiting, and gastric stasis without a tight, chronic stenosis. Management therefore involves three key steps. This first is nasogastric tube aspiration and gastric lavage to clean the stomach of retained debris, followed by early endoscopy. FIGURE 141-5.  Plain chest radiograph in an upright patient with a perforated ulcer. The radiograph shows free air under the diaphragm. TABLE 141-7	 ROCKALL SCORING SYSTEM FOR THE RISK OF MORTALITY FOLLOWING PEPTIC ULCER BLEEDING VARIABLE Score 0 1 2 3 Age (yr) <60 60-79 80 — Shock Not present Pulse >100 Systolic BP <100 mm Hg — Comorbidity None Cardiac failure Coronary insufficiency Other serious illness Renal insufficiency Liver failure Metastatic malignancy Diagnosis Mallory-Weiss syndrome or no identifiable cause Ulcer Varices Malignancy of proximal digestive tract — Endoscopy No signs of recent bleeding Bleeding, clot, or visible vessel — BP = blood pressure.",6844,1012,1711.0,"[ 0.327569   -0.6144384  -1.3643823  ...  0.59820104  0.15897399
 -1.4365791 ]"
75,"Data from Rockall TA, Logan RFA, Devlin HB, et al. Risk assessment after acute upper gastrointestinal haemorrhage. Gut.1996;38:316-321.",135,17,33.75,"[-0.16044687 -0.09455782 -2.1941998  ... -0.08412245  1.3276378
 -1.0355114 ]"
76,"This step facilitates an accurate diagnosis. Nasogastric suction may need to be maintained for several days if vomiting resumes when the tube is clamped. The second step consists of intense antisecretory therapy using intravenous proton pump inhibitors in a dose equivalent to a bolus of 80 mg esomeprazole over 30 minutes, followed by a continuous infusion of 8 mg/hour. Finally, the cause of the ulcer needs to be addressed, usually by eradicating H. pylori and withdrawing NSAIDs. If the initial treatment resolves the clinical situation and the patient can resume eating, it is often not necessary to undertake further treatment of the outlet stenosis; however, tight, fibrous scarring may require endoscopic balloon dilation or surgery.1.	 Moayyedi P, Soo S, Deeks J, et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev. 2006;2:CD002096.2.	 Ford AC, Delaney BC, Forman D, et al. Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive patients. Cochrane Database Syst Rev. 2006;2:CD003840.3.	 Fuccio L, Minardi ME, Zagari RM, et al. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for the Helicobacter pylori eradication. Ann Intern Med.2007;147:553-562.4.	 Malfertheiner P, Bazzoli F, Delchier JC, et al. Helicobacter pylori eradication with a capsule contain­ ing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet. 2011;377:905-913.5.	 Gisbert JP, Pajares JM. Systematic review and meta-analysis: is 1-week proton pump inhibitor-based triple therapy sufficient to heal peptic ulcer?Aliment Pharmacol Ther.2005;21:795-804.6.	 Chan FK, Chung SC, Suen BY, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med. 2001;344:967-973.7.	 Graham DY, Agrawal NM, Campbell DR, et al. NSAID-Associated Gastric Ulcer Prevention Study Group. Ulcer prevention in long-term users of non-steroidal anti-inflammatory drugs: results of a double blind, randomized, multicenter, active- and placebo-controlled study of misoprostol versus lansoprazole. Arch Intern Med.2002;162:169-175.8.	 Taha AS, McCloskey C, Prasad R, et al. Famotidine for the prevention of peptic ulcers and oesopha­ gitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet.",2547,345,636.75,"[-0.26360887 -0.3360752  -1.3262107  ...  0.26750737 -0.19023551
 -0.9164727 ]"
76,"2009;374:119-125.9.	 Barkun A, Bardou M, Kuipers EJ, et al. International consensus recommendations on the manage­ ment of patients with non-variceal upper gastrointestinal bleeding. Ann Intern Med.2010;152: 101-113.10.	 Barkun AN, Martel M, Toubouti Y, et al. Endoscopic hemostasis in peptic ulcer bleeding for patients with high-risk lesions: a series of meta-analyses. Gastrointest Endosc.2009;69:786-799.11.	 Laine L, McQuaid KR. Endoscopic therapy for bleeding ulcers: an evidence-based approach based on meta-analyses of randomized controlled trials. Clin Gastroenterol Hepatol.2009;7:33-47.12.	 Kahi CJ, Jansen DM, Sung JJ, et al. Endoscopic therapy versus medical therapy for bleeding peptic ulcer with adherent clot: a meta-analysis. Gastroenterology.2005;129:855-862.13.	 Sung JJ, Barkun A, Kuipers EJ, et al. Intravenous esomeprazole for prevention of recurrent peptic ulcer bleeding: a randomized trial. Ann Intern Med.2009:150;455-464.14.	 Chan FK, Ching JY, Hung LC, et al. Clopidogrel versus aspirin and esomeprazole to prevent recur­ rent ulcer bleeding. N Engl J Med.2005;352:238-244.15.	 Sung JJ, Lau YW, Ching JYL, et al. Continuation of low-dose aspirin in peptic ulcer bleeding: a randomized, controlled trial. Ann Intern Med.2010;152:1-9. SUGGESTED READINGS Lanza FL, Chan FL, Quigley EM, et al. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol.2009;104:728-738. International consensus guidelines on the prevention of NSAID-related ulcer disease. Madanick RD. Proton pump inhibitor side effects and drug interactions: much ado about nothing?",1598,210,399.5,"[-0.08858497 -0.54484785 -1.5474002  ...  0.6343174   0.1721737
 -1.4298929 ]"
76,"Cleve Clin J Med.2011;78:39-49. Review. Malfertheiner P, Chan FK, McColl KE. Peptic ulcer disease. Lancet.2009;374:1449-1461. Review. McColl KE. Helicobacter pylori infection. N Engl J Med.2010;362;1597-1604. Review.",216,26,54.0,"[ 0.35776663 -0.4297377  -1.3230096  ...  0.4178985  -0.13569878
 -1.6702709 ]"
77,"219 Upper GI Tract CHAPTER 32 Peptic ulcer C. J. Hawkey and John C. Atherton Nottingham Digestive Diseases Centre, University of Nottingham and Nottingham University Hospitals, Nottingham, UK Textbook of Clinical Gastroenterology and Hepatology, Second Edition. Edited by C. J. Hawkey, Jaime Bosch, Joel E. Richter, Guadalupe Garcia-Tsao, Francis K. L. Chan.© 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd. Introduction and definition Peptic ulcers are localized breaches of the gastric or duodenal mucosa with tissue destruction at least to the depth of the muscularis mucosa (Figure 32.1). The word “peptic” reflects a belief (probably misplaced) that peptic activity is involved in pathogenesis. Peptic ulcers include ulcers in the stomach, pylorus, duodenum, or a Meckel’s diverticulum, as well as ulcers at sites of gastrointestinal anastomosis (stomal ulcers) and at the gastroesophageal junction. The commonest symptom is pain. The most serious complications are bleeding and perforation. Causes of peptic ulceration It is only in the past 25 years that the causes of peptic ulcers have been identified and rational management defined. Common causes Most ulcers are directly caused by infection with Helicobacter pylori [1] or by nonsteroidal anti-inflammatory drugs (NSAIDs) [2,3], including aspirin [4] (Figure 32.2), which inhibit prostag- landin synthesis and abrogate mucosal defence mechanisms. In developed countries, duodenal ulcers are proportionally caused more commonly by H. pylori and gastric ulcers by NSAIDs, but either factor may produce an ulcer at either site. Absence of a history of NSAID use and a negative test for H. pylori should prompt a search for other causes, although in such patients H. pylori and NSAIDs are still the most likely causes. Tests for H. pylori have a low but measurable false negative rate and NSAIDs purchased directly and sometimes unknowingly in compound preparations, are easily ignored by doctors and patients. Uncommon causes Uncommon, but significant, causes of peptic ulcers include Crohn’s disease, conditions causing acid hypersecretion (Zollinger-Ellison syndrome, multiple endocrine neoplasia, and mastocytosis [9]; see Chapter 112) severe physical stress such as being in intensive care, and mucosal ischemia due to ESSENTIALS OF PATHOGENESIS •	 Helicobacter pylori and NSAIDs are the commonest causes of peptic ulceration •	 Most duodenal ulcers are caused by H. pylori •	 Most gastric ulcers in developed countries are caused by NSAIDs •	 Smoking is an important cofactor particularly for H. pylori-induced ulcers •	 Virulence factors (CagA, VacA and others) influence whether H. pylori colonization leads to ulceration •	 NSAIDs inhibit the synthesis of gastroprotective prostaglandins ESSENTIALS OF DIAGNOSIS •	 Typical ulcer symptoms are localized epigastric pain occurring overnight or pre-prandially and relieved by milk or antacids •	 Symptoms are however often atypical, especially with gastric ulcers and/or NSAID use •	 Many ulcers are now treated without a formal diagnosis °  In younger patients without alarm features, H. pylori infection is usually detected and eradicated in the community °	 For NSAID patients, prophylactic measures in at risk patients rather than diagnosis is key to management •	 Where formal diagnosis is needed endoscopy is the method of choice •	 Biopsy of gastric ulcers is traditionally recommended to detect gastric cancer or lymphoma but duodenal ulcers should also be biopsied if there is a possibility of Crohn’s disease (e.g., H. pylori and NSAID negative) ESSENTIALS OF TREATMENT  AND PROGNOSIS •	 Successful H. pylori eradication results in permanent ulcer healing in the vast majority of patients if there are no other risk factors (including NSAID use) •	 H. pylori eradication prior to NSAID initiation may reduce ulcer risk. Risk can be further reduced by co-prescription of PPIs. •	 Ulcers and ulcer complications are much less likely if patients take selective COX-2 inhibitors Hawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated. Created from yonseimed-ebooks on 2024-05-29 06:58:08. Copyright © 2012. John Wiley & Sons, Incorporated. All rights reserved.",4329,648,1082.25,"[-0.02678902 -0.19187796 -0.7704843  ...  0.1825782  -0.3699808
 -1.4389373 ]"
78,"Upper GI Tract Part 2:  Diseases of the Gut and Liver 220 pylori remains common, the prevalence of peptic ulcer also remains high. As the prevalence of H. pylori infection has fallen, the importance of NSAIDs as a cause of peptic ulcera- tion has increased, and low-dose aspirin is now the fastest growing cause of ulcer complications [8]. Recent studies [9–14] suggest that whilst uncomplicated ulcers continue to fall, this may not be so for ulcer complications. Risk factors The influence of risk factors depends largely but not entirely on whether the peptic ulcer is caused by H. pylori or NSAIDs [15–22] Peptic ulcer is an age-related disease for both H. pylori and NSAIDs (see Figure 32.3). In H. pylori-infected patients, smoking enhances the risk considerably [16]. Family history largely reflects “shared” H. pylori infection. A previous history of peptic ulcer increases risk for ulcers caused both by H. pylori infection and NSAID use. Risk may persist after NSAID ces- sation [8] which might explain some “idiopathic” ulceration. It is clear that different NSAIDs affect the risk of peptic ulcer to different extents, and that risk is highly dose dependent [19] (Figure 32.4). Risk factors in patients using low-dose aspirin are less well defined, but rates of ulcer bleeding are higher in patients with a past history and in elderly patients [22]. Risk factors for rare causes are unclear, and in some instances (e.g., Zollinger-Ellison syndrome) the underlying disease is a domi- nant influence. Disease associations Peptic ulcer is more common in patients with chronic obstruc- tive lung disease, cirrhosis, coronary artery disease, and renal failure [7] and in coal miners, possibly because of shared risk factors, including H. pylori infection or hypergastrinemia. Pathogenesis It is a truism that mucosal integrity represents a balance between aggressive and protective factors. H. pylori infection and acid are the main aggressive factors. The main protective factors are mucus and bicarbonate secretion, hydrophobicity (waxiness) of epithelial cells, and mucosal blood flow. These are mediated by prostaglandins (and other mediators such as nitric oxide) and abrogated when their synthesis is inhibited by NSAIDs [2]. Figure 32.1  Large pyloric ulcer with red spot (minor bleeding stigma). Figure 32.2  First demonstration of aspirin-induced gastric damage. (Reproduced with permission from Douthwaite AH, Lintott SAM. Gastropic observation of the effect of aspirin and certain other substances on the stomach. Lancet.1938;ii:1222–1225.)critical celiac axis vascular disease and radiation. Gastric ulcer- ation may also indicate gastric adenocarcinoma or gastric lymphoma There is continuing debate about whether corticosteroids alone can cause ulcers [10,11], although the ability of corticos- teroids to enhance NSAID-associated ulcers is well established (see below) [2,5]. Idiopathic ulcers are rare. Most are probably due to falsely negative H. pylori tests or sporadic or surrepti- tious NSAID use. If these causes are confidently excluded, rare conditions such as those described above should be sought. However, a small group of idiopathic peptic ulcers still exists Epidemiology The epidemiology of peptic ulceration reflects that of the main underlying causes (see Chapter 22 for H. pylori and Chapter 23 for NSAIDs). The early twentieth century saw a rapid rise in the incidence of duodenal ulceration in westernized socie- ties [6]. H. pylori has been ubiquitous in the population for centuries, so a change in environment appears the most likely cause, and one possibility is the widespread adoption of smoking – an important co-factor for duodenal ulceration in H. pylori-colonized people. The prevalence of both H. pylori and peptic ulcer is falling in westernized societies [7], probably due to improvements in hygiene in the twentieth century(Figure 32.3). In other parts of the world such as Hong Kong where H. Hawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated. Created from yonseimed-ebooks on 2024-05-29 06:58:08. Copyright © 2012. John Wiley & Sons, Incorporated. All rights reserved.",4254,649,1063.5,"[ 0.16076137 -0.5535726  -1.4555931  ... -0.09911199  0.27829957
 -1.5470806 ]"
79,"Chapter 32:  Peptic ulcer 221 Upper GI Tract Figure 32.3  Recent trends in ulcer epidemiology. Top: Deaths from gastric ulcer and unspecified peptic ulcer. Bottom: Deaths from duodenal ulcer. (Reproduced with permission from Wang YR, Richter JE, Dempsey DT. Trends and outcomes of hospitalizations for peptic ulcer disease in the United States, 1993 to 2006. Ann Surg. 2010;251(1):51–58.)Gastric ulcer 1993 5.0% 4.5% 3.5% 2.5% 1.5% 0.5% 0.0% 2.0% In-hospital deaths, % 1.0% 3.0% 4.0% 1994 1995 1996 1997 1998 1999 2000 Year 2001 2002 2003 2004 2005 2006 Duodenal ulcer Peptic ulcer, site unspecified 1993 18.0% 16.0% 12.0% 8.0% 4.0% 0.0% 6.0% In-hospital deaths, % 2.0% 10.0% 14.0% 1994 1995 1996 1997 1998 1999 2000 Year 2001 2002 2003 2004 2005 2006 Hemorrhage Perforation Obstruction H. pylori-associated ulcers H. pylori colonization is lifelong in the absence of effective treatment [24] yet only about 15% of infected people develop peptic ulceration in their lifetime. The development of ulcera- tion is due to a combination of bacterial virulence, host genetic susceptibility, and environmental co-factors. Bacterial virulence The best understood bacterial virulence factor is the cag patho- genicity island (cag PAI). H. pylori strains possessing this factor induce more inflammation and are more closely associated with peptic ulceration and gastric adenocarcinoma than cag- negative strains [23]. The cag PAI is a collection of genes encod- ing a bacterial type IV secretion system, a sort of molecular syringe through which at least one protein, CagA, is “injected” into epithelial cells [24]. Several signalling pathways are acti- vated, resulting in epithelial cell changes and pro-inflammatory cytokine release, which induces inflammation [25]. A second virulence factor is the vacuolating cytotoxin, VacA. H. pylori strains producing more active forms are more closely associated with disease [23,26]. Other factors that have been associated with increased strain pathogenicity include an adhesin, BabA, an outer membrane inflammatory protein, OipA [28], and a genetic marker of another type IV secretion system, dupA [27]. Host susceptibility Genetic polymorphisms in some cytokine genes, such as interleukin-1β, increase the level of inflammation induced by H. pylori [27], induce the pan-gastritic pattern of inflamma- tion, and increase the risk of H. pylori-associated gastric atrophy and adenocarcinoma. Peptic ulcer disease has been associated with inadequate regulatory T cell responses [28] and there is growing interest in the role of the innate immune responses [29]. Environmental factors Smoking is an important risk factor for peptic ulceration in H. pylori-colonized people [16]. Its role in NSAID-associated ulcers is less clear. Hawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated. Created from yonseimed-ebooks on 2024-05-29 06:58:08. Copyright © 2012. John Wiley & Sons, Incorporated. All rights reserved.",3066,457,766.5,"[ 0.06959079 -0.6671462  -1.1054409  ...  0.05167472 -0.01423956
 -1.2170407 ]"
80,"Upper GI Tract Part 2:  Diseases of the Gut and Liver 222 hypergastrinemia [30]. Gastrin stimulates the healthy gastric corpus to produce more acid. The increased acid load in the duodenum contributes to the formation of gastric metaplasia – a (possibly adaptive) change in the duodenal mucosa to resemble that in the stomach. H. pylori, which can colonize only gastric-type mucosa, can now colonize the duodenum and cause inflammation, damage, and ulceration (Figure 32.5). Gastric ulceration Gastric ulcers occur in H. pylori-colonized people with a corpus-predominant or pangastritis (Figure 32.5). Such persons also have hypergastrinemia, but acid production is unchanged or reduced because of the inflamed and damaged gastric corpus. This leads to a cycle of chronic damage with progres- sive atrophy of gastric glands and further hypochlorhydria. The pathogenesis of gastric ulceration in this environment is poorly understood, but ulcers usually occur in the transitional zone, between antrum and corpus mucosa, often on the lesser curve, where inflammation can be heavy. These people are also predisposed to develop distal gastric adenocarcinoma. Nonsteroidal anti-inflammatory drugs (NSAIDs) Mucosal defence NSAIDs inhibit the synthesis of gastroduodenal prostagland- ins, which are centrally important for mucosal protection via mucus and bicarbonate secretion and mucosal blood flow [2]. Abrogation of prostaglandin-dependent mechanisms is suffi- cient to cause local erosions, which deepen to form ulcers in the presence of acid and pepsin. A central role for pepsin is more likely in NSAID ulcers than in ulcers caused by H. pylori, as much greater changes in pH are needed to prevent damage [35] or heal ulcers [31,32]. Localization of H. pylori-associated ulcers Duodenal ulceration Duodenal ulcers occur against a background of H. pylori colo- nization with a predominantly antral pattern of gastritis (Figure 32.5). Antral inflammation results in reduced somato- statin production by antral D cells and, as somatostatin nor- mally has a negative feedback on gastrin, this results in Figure 32.5  Hormonal changes in duodenal and gastric ulceration. (a) In H. pylori-induced antral predominant gastritis, the illustrated hormonal changes lead to hypergastrinemia and increased acid production from the uninflamed gastric corpus. The increased acid load on the duodenum may lead to ulceration (see text for full explanation). (b) In pangastritis, the same hormonal changes pertain, but the inflamed corpus produces reduced acid despite the hypergastrinemia. Such stomachs are at increased risk of gastric ulceration and adenocarcinoma.↓Somatostatin ↑Gastrin ↑Histamine Inflammation ↑Acid D cell G cell ECL cell Parietal cell H. pylori-induced central predominant gastritis + + - + + + ↓Somatostatin ↑Gastrin ↑Histamine Inflammation ↓Acid D cell G cell ECL cell Parietal cell H. pylori-induced pan gastritis + + - - - + + + (a) (b) Figure 32.4  Differences in odds ratio for peptic ulcer bleeding with individual NSAIDs and doses. Paracetamol (acetaminophen) is also shown for comparison. Note: Confidence intervals were wide (not shown for groups). (Reproduced with permission from Lewis SC, Langman MJS, Laporte JR, et al. Dose-response relationships between individual nonaspirin nonsteroidal antiinflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data. Br J Clin Pharmacol.2002;54(3):320–326.)Para Odds ratio Ibu Diclo Nap Indo Pirox 80 0 30 20 10 40 50 60 70 Low dose Medium High Hawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated. Created from yonseimed-ebooks on 2024-05-29 06:58:08. Copyright © 2012. John Wiley & Sons, Incorporated. All rights reserved.",3871,573,967.75,"[ 0.28713775 -0.3650899  -1.0905576  ...  0.16256955 -0.06302576
 -1.4441234 ]"
81,"Chapter 32:  Peptic ulcer 223 Upper GI Tract understood. The mucosa is normally anesthetic, but contains fibers with the characteristics of acid-receptive nociceptors, which may be activated during mucosal injury and inflammation. Pathology Histologically, for a lesion to be an ulcer it must extend beneath the muscularis mucosa. More superficial lesions are classified as erosions (Figure 32.6). Endoscopically, a rough pragmatic equivalence is applied and erosions are commonly defined as lesions that are less than 3 mm in diameter and/or without discernible depth (Figure 32.6), whereas other lesions are clas- sified as ulcers. Endoscopists are poor at discriminating NSAID-associated erosions and ulcers from those caused by H. pylori [39]. Histologically, erosions show localized superfi- cial mucosal destruction with acute inflammation and local congestion. Acute ulcers are similar but with extension below the muscularis mucosa. Chronic peptic ulcers are additionally characterized by collagenous tissue in the base. Hemostasis Aspirin inhibits thromboxane synthesis and platelet aggrega- tion and reduced hemostasis likely contributes to ulcer bleed- ing in patients on low-dose aspirin. Other ulcer types Acid plays a dominant role in ulcers associated with gastrino- mas, whether sporadic or occurring in the multiple endocrine neoplasia (MEN) 1 syndrome, and in systemic mastocytosis, where histamine stimulates acid secretion. Acid output is often increased in ulcers designated as idiopathic. Conversely, stress ulcers are associated with mucosal underperfusion and abro- gation of defence mechanisms. Inflammatory pathogenic mechanisms in Crohn’s disease and radiation are considered in Chapters 50 and 116 respectively. Pathogenesis of symptoms Pain is the hallmark symptom of peptic ulceration. The origin and pathogenesis of ulcer pain and ulcer-like pain are poorly Figure 32.6  Differences between ulcers and erosions. (a) Ulcer with clear depth. (b–d) Superficial erosions. (b) Magnifying endoscopy shows erosions in villous duodenal mucosa. (a) (b) (c) (d) Hawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated. Created from yonseimed-ebooks on 2024-05-29 06:58:08. Copyright © 2012. John Wiley & Sons, Incorporated. All rights reserved.",2387,339,596.75,"[-0.2705438  -0.4017784  -0.7371572  ...  0.3364232   0.14998247
 -1.1503243 ]"
82,"Upper GI Tract Part 2:  Diseases of the Gut and Liver 224 Empiric management of dyspepsia In patients with “simple dyspepsia”, causes outside the gas- trointestinal tract are excluded as far as possible by history and examination, and stopping any drugs that may be contributing to dyspepsia. In areas of high H. pylori prevalence, patients are then managed by testing for H. pylori using non-endoscopy- based tests such as the urea breath test, stool antigen test or (less accurately) serology, and treating those positive. This “test and treat” approach effectively treats ulcers (and those without ulcers) even when a firm diagnosis is never made [36–38]. Where the prevalence of H. pylori infection is low, empiric proton pump inhibitor (PPI) treatment is an alterna- tive [37]. Management of dyspepsia is discussed further in Chapter 4. Diagnostic tests Where diagnosis is considered necessary, upper gastrointesti- nal endoscopy (see Chapter 123) is the investigation of choice. It is safe, accurate, and well tolerated by patients under light or no sedation. If possible, patients should avoid acid- suppressing agents for 4 weeks before endoscopy, as these drugs may heal ulcers and esophagitis, leading to a falsely negative endoscopy result. If possible, PPIs, antibiotics, and bismuth compounds should also be avoided for 4 weeks before endoscopy as these render biopsy-based tests for H. pylori unreliable. If a duodenal ulcer is found at endoscopy, biopsy samples should be taken from the gastric antrum and corpus to test for H. pylori (usually by biopsy urease test and/ or histologic examination and from the duodenum if Crohn’s disease is suspected. In patients with previous H. pylori treat- ment or multiple antibiotic courses for other conditions, biop- sies should also be taken for microbiologic culture and antibiotic sensitivity testing, if this service is available. Where PPIs, bismuth compounds or antibiotics have recently been consumed, a positive biopsy urease test for H. pylori is still useful but a negative test is unreliable. The best approach is later to perform a reliable non-invasive test (urea breath test or stool antigen test) one month after stopping these agents. However, many practitioners use serology, which although less accurate can be done without waiting. Similar tests are indicated for gastric ulceration, but addi- tional biopsies should be taken from the ulcer rim to exclude carcinoma or lymphoma. The usual practice is also to check gastric ulcer healing 6–8 weeks after treatment is started and take further biopsies if healing is incomplete (although the pick-up rate for cancer if original biopsies are negative is very low). Barium radiology (see Chapter 132) is less accu- rate for picking up small ulcers and does not allow gastric biopsies to be taken to test for H. pylori or to exclude malignancy. Diagnosis of the cause of an ulcer H. pylori This is most conveniently established at the time of endos- copy by urease testing and/or histology of antral and corpus Clinical presentation of uncomplicated ulcers Duodenal ulceration The classical symptom of duodenal ulceration caused by H. pylori is epigastric pain occurring before meals or overnight, relieved by antacids, milk, food, and acid-suppressing treat- ments [33,34]. The pain may radiate to the back, particularly in patients with posterior duodenal ulcers. If present, the pointing sign, in which a patient points to a discrete epigastric site of pain, is moderately predictive of duodenal ulceration. Because ulcers naturally form and heal, pain is classically epi- sodic, typically with clusters of pain lasting for 1–3 months with asymptomatic spells in between. Duodenal ulcer pain is classically described as gnawing or a “hunger” pain, but the qualitative description of the pain is not very helpful in diag- nosis. Moreover many presentations are atypical and uncom- plicated duodenal ulcers may present with any combination of heartburn, anorexia, weight loss, or vomiting. Gastric ulcer Patients with gastric ulcer have a less stereotypical presenta- tion. An epigastric location is common, but pointing is less so. Pain is more likely to occur soon after meals and somewhat less likely to be relieved by food. Anorexia, nausea, vomiting, and weight loss are more common than in duodenal ulcer and often lead to a suspicion of gastric cancer. NSAID-associated ulcers These are difficult to diagnose on the basis of symptoms. Drug-induced non-ulcer dyspepsia is common in NSAID users [35], whereas most peptic ulcers are silent, making  dyspepsia a poor predictor. Nevertheless, the onset of epigas- tric pain in an NSAID user is associated with an increased likelihood of finding an endoscopic ulcer or the development of complications. Differential diagnosis Any cause of chronic recurrent upper abdominal pain (see Chapter 3) or “dyspepsia” (see Chapter 4) enters into the dif- ferential diagnosis of peptic ulcer disease. Diagnostic approach Several conditions (including functional dyspepsia, gastro- esophageal reflux disease, and gastric adenocarcinoma) com- monly present with pain or discomfort centered predominantly in the upper abdomen and sometimes accompanied by the other symptoms detailed above. Examination is rarely helpful, and a definite diagnosis can be made only after investigation, usually upper gastrointestinal endoscopy. Because dyspeptic symptoms are so common, most healthcare systems reserve endoscopy for patients at higher risk of malignancy. This includes dyspeptic patients with “alarm” features such as overt GI bleeding, anemia due to GI blood loss, dysphagia, weight loss, persistent vomiting, or an upper GI mass. It also usually includes patients with new onset persistent dyspepsia above a specific age cut-off, typically 55 years. Hawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated. Created from yonseimed-ebooks on 2024-05-29 06:58:08. Copyright © 2012. John Wiley & Sons, Incorporated.",6092,937,1523.0,"[ 0.36886084 -0.47991657 -0.99744165 ...  0.7007976   0.3964107
 -1.049102  ]"
83,"Chapter 32:  Peptic ulcer 225 Upper GI Tract raised serum tryptase, and expression of CD2 and CD25 in c-kit positive mast cells [39]. Duodenal Crohn’s disease Duodenal involvement is reported in 0.5–13% of patients with Crohn’s disease and recognized to cause duodenal ulcer  with or without typical symptoms [40]. Thus, any patient not taking NSAIDs who is H. pylori negative should have duode- nal biopsies and the possibility of Crohn’s disease should be considered. Stress ulcer Ulcer bleeding occurring in the context of current or recent severe illness and/or intensive care should be assumed to be a stress ulcer (see below). Celiac axis stenosis The site may be atypical and pain-intense. Celiac axis angiog- raphy is necessary to establish this diagnosis. Treatment and prevention H. pylori-associated ulcers Eradication of H. pylori H. pylori eradication heals ulcers and prevents recurrence (Figure 32.8) [40]. Unfortunately, antibiotic resistance is increasing, and is a major problem in some countries [41,42,43]. Resistance to metronidazole is very common but is only partial and multi-drug regimens containing metronidazole retain near full efficacy. In contrast, resistance to clarithromycin (which is becoming common due to use of the drug for other infections, notably chest infections) leads to frequent treatment failure. In countries where clarithromycin resistance is less than 15%, triple therapy with a full dose PPI, clarithromycin 500 mg, metronidazole 400 mg, all twice daily is still commonly used. Two weeks treatment is slightly more effective than one, although it is unclear if this is cost-effective and side effects may be increased. Where clarithromycin resistance is common, other regimens are becoming more widely used, for example quadruple therapy where amoxicillin 1 g twice a day is added to the above regimen (giving three effective drugs even if clarithro- mycin resistance is present) or alternatively the same drugs are used sequentially over 10 days with the PPI given over the whole period, amoxicillin 1 g twice a day, given for days 1–5, and clarithromycin 500 mg twice a day and metronidazole 400 mg three times a day given for days 6–10. Some physicians routinely check treatment success by urea breath test one month after the end of treatment, but others check only for large or complicated ulcers or if symptoms recur. When H. pylori status is not known, PPIs can be started and antibiotics added once H. pylori test results are available. If treatment fails, the most commonly-used second line regimen is full dose PPI twice a day, bismuth subcitrate or subsalicylate one tablet four times a day, tetracycline HCl 500 mg four times a day and biopsies. Serology is less accurate. Other non-invasive testing (urea breath test or stool antigen test) is accurate but less convenient in situations where endoscopy is being performed anyway. NSAIDs Diagnosis depends on an accurate history, though this is not always forthcoming. There are no diagnostic tests for NSAID involvement, although measurement of serum thromboxane concentration has been considered. Zollinger-Ellison syndrome A random serum gastrin estimation is a useful screen but can be affected by food and PPIs. A fasting gastrin is more specific. The diagnosis is formally established by showing increased basal gastric acid output and a fasting gastrin level of less than 1000 pg/mL (10-fold increase) with an intragastric pH of  2.0, sometimes backed up by a secretin test (see Chapters 56 and 112). Multiple endocrine neoplasia This should be suspected where Zollinger-Ellison syndrome is associated with hyperparathyroidism (see Chapter 112). Systemic mastocytosis Systemic mastocytosis should be suspected in the presence of pruritus, urticaria or a characteristic rash (Figure 32.7). Diag- nosis is based on the presence of infiltrates in bone marrow and/or extracutaneous organs, detection of c-kit mutations, Figure 32.7  Cutaneous manifestations of systemic mastocytosis (urticaria pigmentosa). Patient presented with duodenal ulceration attributable to acid hypersecretion and diarrhea associated with intestinal involvement. Hawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated. Created from yonseimed-ebooks on 2024-05-29 06:58:08. Copyright © 2012. John Wiley & Sons, Incorporated. All rights reserved.",4456,670,1114.0,"[-0.28983688 -0.3763861  -1.121203   ...  0.65806794 -0.17930369
 -1.1186424 ]"
84,"Upper GI Tract Part 2:  Diseases of the Gut and Liver 226 lumiracoxib. The VIGOR and CLASS studies of rofecoxib and lumiracoxib showed a reduction in the risk of all ulcers of between 27% (celecoxib) and 57% (rofecoxib), and the TARGET study showed a 79% reduction in ulcer complications for lumi- racoxib compared with ibuprofen or naproxen (Figure 32.9). Benefits are seen within a week [48] and across most risk factors [49]. While there has been some concern about the pos- sibility that COX-2 inhibitors may enhance thrombotic compli- cations of vascular disease, these properties may well be shared by non-selective NSAIDs and the balance of risks ben- efits clearly favours reduced gastrotoxicity [51]. The MEDAL study program showed etoricoxib to reduce the incidence of uncomplicated, but not complicated, ulcers, though this may be because PPI co-prescription was allowed [47]. Prophylactic co-prescription Proton pump inhibitors have been shown to reduce develop- ment of endoscopic ulcers and relapse of endoscopic and clini- cally significant ulcers including those causing ulcer complications [52–58]. When combined with a COX-2 inhibitor the use of proton pump inhibitor has been associated with a zero rate of recurrent ulcer bleeding in patients who have already experienced one life threatening episode [58]. Generi- cally available proton pump inhibitors have been sufficiently inexpensive that they offer highly cost effective ulcer prophy- laxis in users of both NSAIDs and COX-2 inhibitors [54]. Standard doses of H2 antagonists are not effective in prevent- ing NSAID-associated gastric ulcer development [32]. The PGE-1 analogue misoprostol is effective against endoscopic and clinically complicated ulcers but seldom used because of the high level of drug related adverse effects [59]. H. pylori -positive NSAID or aspirin associated ulcers NSAIDs This is a controversial area. The evidence ranges from showing a benefit for H. pylori eradication in patients starting NSAIDs metronidazole 400 mg three times a day. This more complex regimen is now also used first-line by some practitioners. The further management of H. pylori treatment failures is discussed in Chapter 22. Ancillary drug treatment For duodenal ulcers, continuation of acid suppression after the antibiotic course is unnecessary, but some physicians give PPIs for a total of one month for very large or complicated ulcers. If this is done, checking for H. pylori eradication must be delayed for a further month. For gastric ulcers, which often heal more slowly, PPIs are usually continued until the repeat endoscopy. Management of patients taking NSAIDs Ulcer healing PPIs accelerate healing compared with standard doses of H2 antagonists [32]. Misoprostol heals NSAID-associated ulcers but causes more side effects and is now seldom used. Strategies to reduce risk of ulcer development For NSAID users, removing the cause of the ulcer, by stopping the drug or switching to one that does not damage the stomach or duodenum, is the equivalent of H. pylori eradication. An alternative is to continue the NSAID where needed, at the lowest possible dose, and to give concurrent antiulcer prophy- laxis, usually with a PPI. Low-toxicity drugs Ibuprofen at dosages of less than 1200 mg per day appears to confer less risk of bleeding peptic ulcer [23] than other NSAIDs (see Figure 32.4). Alternatively, and where higher doses are needed, selective COX-2 inhibitors have been shown to reduce the risk of ulcers that are detected endoscopically and clini- cally [44–53]. Clinical outcomes have been studied in large cohorts of patients (up to 18 500) for celecoxib, rofecoxib, and Figure 32.8  Ulcer relapse following H. pylori eradication. There is a marked reduction in relapse rates for duodenal and gastric ulcer following H. pylori eradication. (Reproduced with permission from Lind T, Megraud F, Unge P, et al. The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology. 1999;116:248–253.)Patients in remission (%) Years after termination of treatment Months after termination of treatment 0 0.5 1 1.5 2 0 2 4 6 10 8 12 100 0 25 50 75 H. pylori eradicated H. pylori positive Gastric ulcer Duodenal ulcer Hawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated. Created from yonseimed-ebooks on 2024-05-29 06:58:08. Copyright © 2012. John Wiley & Sons, Incorporated. All rights reserved.",4562,705,1140.5,"[ 0.4511382  -0.31715417 -1.3589528  ...  0.20632458  0.2810998
 -1.6350628 ]"
85,"Chapter 32:  Peptic ulcer 227 Upper GI Tract myocardial infarction (as is the case for aspirin plus NSAID [64,65]) is not known. Therefore where local rules allow, pre- scribers should consider using a selective COX-2 inhibitor with aspirin to avoid an adverse pharmacodynamic interac- tion [63]. In patients taking aspirin and a coxib, a PPI should be used where the risk of aspirin alone would warrant it. Complications and their management Bleeding (Figure 32.10) Epidemiology Peptic ulcer is the commonest cause of acute upper gastroin- testinal bleeding (see Chapters 20 and 146), accounting for nearly half of all instances and occurring in approximately 2–5 per 1000 of people aged over 60 years [5]. Clinical presentation Hematemesis and/or melena are usually obvious, especially when accompanied by tachycardia or hypotension, usually leading to emergency hospital admission. Retrospective accounts of “melena” in well patients only occasionally indi- cate significant gastrointestinal bleeding. Diagnosis and management After resuscitation, patients with a significant bleed should undergo endoscopy, both to establish the diagnosis and to institute endoscopic management if stigmata of hemorrhage are present [66]. About 20–25% of patients, however, have  no abnormality of pulse, blood pressure, hemoglobin, platelet count or urea, and in the absence of any suspicious past  history such patients are at low risk of further bleeding, and can be discharged for subsequent out-patient endoscopic assessment [67]. [60,61] through to greater effectiveness of PPI prophylaxis in patients who remain infected [62]. Overall, H. pylori eradica- tion alone is not sufficient protection against ulcer complica- tions and such patients should receive a PPI and/or a COX-2 inhibitor. Aspirin It is possible that H. pylori eradication may be sufficiently effective to protect low-dose aspirin users [55], but until there are further data this cannot be recommended above PPI prophylaxis [55,57]. Reductions in the price of generic PPIs mean that it is probably cost effective to give all patients on low dose aspirin a PPI and certainly those with age over 65 or a past ulcer history. If funds allow, patients taking low- dose aspirin should receive PPI prophylaxis if they have any significant risk factor, such as age over 65 years or a past ulcer history. Patients taking prophylactic aspirin and  a non-aspirin NSAID By competing at the level of the platelet, nonselective NSAIDs such as ibuprofen may substantially interfere with aspirin’s ability to inhibit platelet aggregation and thereby prevent coronary heart disease [63–65]. These patients should use naproxen or diclofenac where there is either no evidence for such an inhibition (dicofenac) [63] or its consequences. Selec- tive COX-2 inhibitors also avoid any pharmacodynamic inter- action but in Europe their use in patients with established coronary heart disease is contraindicated. The USA FDA by contrast rules that non-selective NSAIDs and selective COX-2 inhibitors both increase the risk of myocardial infarction. Whether patients with cardiovascular risk factors who take aspirin as well as a COX-2 inhibitor have an increased risk of Figure 32.9  Results of VIGOR and TARGET outcome studies (primary outcomes). (a) VIGOR – perforations, ulcers, and bleeds. (b) TARGET – ulcer complications. Reproduced with data from [44] and [46]. Cumulative incidence (%) Months of follow-up 1.50 1.25 1.00 0.75 0.50 0.25 0 Naproxen Rofecoxib Cumulative incidence (%) Study day 0 2 4 6 8 10 12 0 90 180 270 360 420 1.4 1.0 1.2 0.8 0.6 0.4 0.2 0 Non-steroidal anti-inflammatory drugs Lumiracoxib Logrank p < 0.0001 (a) (b) Hawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated. Created from yonseimed-ebooks on 2024-05-29 06:58:08. Copyright © 2012. John Wiley & Sons, Incorporated. All rights reserved.",3985,613,996.25,"[ 0.1690052  -0.45493126 -1.167163   ...  0.2854962   0.64868605
 -1.475454  ]"
86,"Upper GI Tract Part 2:  Diseases of the Gut and Liver 228 variation. Many perforated ulcers are H. pylori negative [72,73]. The reported incidence of H. pylori infection ranges from 0% to 100%. Clinical presentation This is usually stereotypical and obvious, with an abrupt onset of severe upper abdominal pain, rapidly spreading through the abdomen, and the development of symptoms and signs of peritonitis (see Chapter 156), hypotension, and shock. Diagnosis Diagnosis is largely based on history, examination, and plain radiography. Air within the abdominal cavity under the dia- phragm is seen on plain abdominal and erect chest radio- graphs in most cases (Figure 32.11). Endoscopy is avoided because of theoretical risks of increased peritoneal soiling. As detailed in Chapters 20 and 146, endoscopic therapy of bleeding peptic ulcers reduces rebleeding and the need for surgery, and may reduce mortality. The choices are injection therapy with epinephrine (adrenaline), light- or heat-based coagulation of the vessel, clipping (Figure 32.10) or a combina- tion – using at least two modalities is better than using one alone. Patients with endoscopic stigmata suggesting high risk of rebleed are given a 72-hour infusion of intravenous proton pump inhibitor [66]. Conventionally, aspirin is stopped but this is ill-advised as patients are at particular risk of thrombo- sis, and mortality is much higher if aspirin is stopped in those who need it [68]. Pragmatically aspirin may be stopped for 48 hours and restarted once the patient is on PPI therapy. Where H. pylori is the cause of the ulcer, eradication results in a substantial reduction in the subsequent risk of rebleeding [40]. Patients taking NSAIDs can resume these drugs if needed after healing if they take a PPI, as this has been shown sub- stantially to reduce the readmission rate for ulcer complica- tions over 6 months [54–58]. Mortality In a large, comprehensive British survey the mortality rate was 8% in patients admitted because of bleeding peptic ulcer [69]. Patients die mainly as a result of pneumonia and the throm- botic complications of bleeding or surgery (deep vein throm- bosis and pulmonary embolism, myocardial infarction), rather than exsanguination. Perforation (see also Chapters 22–24 and 156). Epidemiology The incidence of ulcer perforation is conventionally reported as about 7–10 per 100 000 population per annum [70]. A recent report suggests a higher incidence [71]. Perforation is more common in men than in women, in those with duodenal versus gastric ulcers, in cigarette smokers and in users of aspirin and NSAIDs [71] but presentation in the absence of risk factors is not uncommon. There is a diurnal and seasonal Figure 32.11  Chest radiograph showing air under the diaphragm in a patient with perforated peptic ulcer. Figure 32.10  Bleeding ulcer. Arterial bleeding from a visible vessel in an ulcer (a) before and (b) after control by application of a hemoclip. (a) (b) Hawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated. Created from yonseimed-ebooks on 2024-05-29 06:58:08. Copyright © 2012. John Wiley & Sons, Incorporated. All rights reserved.",3282,515,820.5,"[ 0.1713849  -0.52128327 -1.0766716  ...  0.39451355 -0.0481814
 -1.5239825 ]"
87,"Chapter 32:  Peptic ulcer 229 Upper GI Tract or treatment with acid suppression can restore gastric empty- ing. Some patients require surgery by antrectomy and Billroth 1 or 2 procedures (see Chapter 156). Surgery for peptic ulcer Nowadays, surgical intervention is rarely used for gastric or duodenal ulcers, except in the context of complications (see above). Postoperative syndromes Peptic ulcer surgery was an unphysiologic intervention  that resulted in significant morbidity [78] including the following. Dumping syndromes These are characterized by flushing, palpitations, sweating, light-headedness, tachycardia, postural hypotension, and fatigue, likely due to rapid fluid shifts if symptoms occur within an hour or rebound hypoglycemia if they occurs 2–3 hours after a meal (see Chapter 37). The early dumping syn- drome occurs 30–60 minutes after eating in patients who have had a gastrectomy. Dumping of food into the duodenum is thought to cause rapid fluid shifts, leading to faintness. Exces- sive release of vasoactive hormones may play a role. Octre- otide may have therapeutic value. In the late dumping syndrome, dumping of food into the duodenum stimulates excessive insulin secretion resulting in rebound hypoglycemia 2–3 hours after a meal. Postgastrectomy malnutrition Most patients who have had a gastrectomy lose weight and/ or become anemic or malnourished because of a combination of early satiety, impaired control of nutritional digestion and absorption, inadequate production of co-factors such as vitamin B12, and altered iron absorption. Problems develop over years and also include metabolic bone disease (vitamin D) and neuropathy (vitamin B12). Stomal ulceration After partial gastrectomy, ulcers may develop at the site of anastomosis and present with pain or sometimes complica- tions. They can be managed with acid-suppressing drugs. The role of H. pylori in this situation is unclear, but eradication is wise. Postgastrectomy neoplasia Surgery for peptic ulcer is associated with an increased risk of later gastric cancer. This is discussed in Chapter 32. Postvagotomy syndromes Truncal vagotomy results in diarrhea in many patients  [78]. Pathogenesis is multifactorial and management is symptomatic. Management Patients should be resuscitated with intravenous fluids and given broad-spectrum antibiotics (e.g., cefuroxime and metro- nidazole). Laparotomy to close the perforation should be carried out as soon as possible after resuscitation, although in patients with a high operative risk who are improving on conservative treatment, continued nonoperative management may be possible. Prevention of recurrence After successful recovery, management to prevent recurrence is standard (H. pylori eradication, NSAID avoidance). There are no direct data on the benefits of switching to a COX-2 inhibitor or taking PPI prophylaxis after perforation. Mortality The overall mortality rate is about 10%. Risk factors for death are age, co-morbid illness, delayed surgery, preoperative shock, heart rate, and a high serum creatinine level [70]. Penetration Posterior perforation may result in digestive penetration into an adjacent organ rather than free perforation. Posterior duo- denal ulcer penetration most commonly involves the pancreas, often resulting in different, more severe, pain than is typical. Other organs that may be involved include the left lobe of the liver, common bile duct (choledochoduodenal fistula), colon (gastrocolic fistula), lung, and pericardium. Except where fis- tulae have formed, treatment is by acid suppression with H. pylori eradication or NSAID cessation, as appropriate. Gastric outlet obstruction Epidemiology Gastric outlet obstruction by peptic ulcers is relatively uncom- mon, probably affecting less than the quoted 2% of patients with ulceration. Obstruction occurs with (pre)pyloric or duo- denal ulcers, especially in patients with a long history, and is thought particularly to be associated with NSAID use. Clinical features Obstruction should be suspected in patients with an ulcer who develop vomiting, particularly if projectile or occurring daily. Early satiety (60%), upper abdominal pain and distention (87%), and weight loss (65%) are common. A succussion splash is present in 25% or more of patients. Depending on severity, increases in serum urea concentration and electrolyte abnor- malities (low K+, metabolic alkalosis, low Na+) are common. Management Nasogastric aspiration should be performed to empty the stomach prior to endoscopy. Aspiration of more than 200 mL after an overnight fast suggests delayed gastric emptying. At endoscopy, biopsy samples should be taken to exclude malig- nancy. Endoscopic balloon dilatation (see Chapter 150) and/ Hawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated. Created from yonseimed-ebooks on 2024-05-29 06:58:08.",4976,723,1244.0,"[ 0.04693297 -0.62624085 -0.7169663  ...  0.4719343  -0.18482323
 -0.9038311 ]"
88,"Upper GI Tract Part 2:  Diseases of the Gut and Liver 230 Prophylaxis Treatment with H2 receptor antagonists, proton pump inhibi- tors and sucralfate have been shown to reduce endoscopic appearances of injury and/or blood in gastric aspirates but there is no clear evidence of an effect on survival or clinical outcome in either children or adults [76,77]. Where there is good general intensive care management, including with enteral nutrition, other specific measures are seldom needed. Practical management The following guidelines, updated from Tryba and Cook [78] are suggested: •	 Stress ulcer prophylaxis should be restricted to patients with risk factors, particularly respiratory failure, coagulopa- thy, sepsis, shock, burns, head injury, or a history of peptic ulcer disease. •	 Enteral nutrition, where given, probably reduces the inci- dence of ulcer bleeding. •	 Where there is good general intensive care management, other specific measures are seldom needed. •	 Alternatives are: 1.  Sucralfate 1 g six times daily by mouth.2.	 Enteral nutrition with sucralfate 1 g twice daily during a rest period when enteral nutrition is suspended.3.	 Ranitidine 50 mg by slow intravenous injection, then 125–250 mg/kg/h by infusion. Cameron’s ulcer These ulcers typically occur in the neck of a big hiatus hernia, and are believed to arise on an ischemic basis [79]. They may be associated with iron deficiency anemia. They often respond to PPI therapy, but non-responsive ulcers can be cured by surgical intervention. Prognosis and advice to patients with  peptic ulcer •	 Patients should be told the cause of their ulcer and be told to eat a normal diet. •	 They should understand that the prognosis is very good in the absence of complications and particularly with defini- tive therapy. •	 Patients given H. pylori treatment should be told of the importance of close compliance, warned of the common side effects with these multi-drug regimens, but told to con- tinue despite these, unless they are very severe. The problem with failed treatment is that it very commonly results in antibiotic resistance making future treatment more difficult. After proven eradication of H. pylori in patients not taking NSAIDs, the relapse rate falls to less than 5%. •	 Similarly, for patients using NSAIDs who stop these drugs, relapse is rare if they have no other risk factors such as H. pylori infection. Meckel’s diverticulum This is an ileal diverticulum with acid-secreting heterotopic gastric mucosa that arises because of developmental abnor- mality in approximately 2% of the population. It can cause ulceration with pain or bleeding, as well as obstruction due to intussusception or volvulus. Diagnosis is often made inciden- tally during barium radiology. Technetium (99mTc) pertech- netate, which has an affinity for parietal cells, is the basis of the scan. Treatment is by surgical removal. Stress ulcers Severe medical stresses such as burns, head injuries, major trauma, sepsis, multisystem organ failure, or ventilation on an intensive care unit are associated with the development of stress ulcers in the stomach or duodenum that may bleed and are associated with a high mortality rate. Curling’s ulcers are those associated with burns, and Cushing’s ulcers with head injury. Stress ulcers are seen less commonly now than previ- ously, possibly due to preventive measures in intensive care. In one large study, 31 of 2252 patients (1.4%) on an intensive care unit experienced clinically important bleeding [74]. Risk factors A need for ventilation because of respiratory failure is the most important risk factor, increasing the chance of upper gastroin- testinal bleeding by 15-fold [75,76]. The main ancillary risk factors are prolonged ventilation and coagulopathy. Sepsis, hepatic and renal failure, and glucocorticoids may enhance risk, although the evidence is less secure. Clinically important bleeding is extremely rare in patients with no risk factors [75–78]. Pathogenesis The pathogenesis varies according to etiology. Reduced mucosal defence, largely because of poor blood flow that allows increased acid back diffusion, predisposes to stress ulcers in ventilated patients and after severe burns, despite an overall reduction in acid secretion. Cushing’s ulcers differ in being associated with hypergastrinemia and hypersecretion  of acid. Clinical presentation The most common presentation is with bleeding, manifesting as shock, hematemesis, or melena. This may occur at any time during a stressful illness, but is common at 10–14 days and may therefore present as the patient is improving in other respects. Perforation and penetration are much less common. Some patients may complain of antecedent pain. Treatment and prevention Once severe stress ulcer bleeding has occurred, the patient should be managed as for other ulcer bleeding; however, the mortality rate is high. Consequently, attention has focused on prophylaxis. Hawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (",5039,773,1259.75,"[ 0.26027024 -0.8370817  -1.3164167  ...  0.38044322  0.03627463
 -1.4719833 ]"
88,"2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated. Created from yonseimed-ebooks on 2024-05-29 06:58:08. Copyright © 2012. John Wiley & Sons, Incorporated. All rights reserved.",219,29,54.75,"[ 0.7496846  -0.5186273  -1.2607996  ...  0.845299    0.11236747
 -1.9621376 ]"
89,"Chapter 32:  Peptic ulcer 231 Upper GI Tract for the first time in our evolutionary history have any dis- advantages [15]? •	 Can an effective vaccine for H. pylori be developed, and is it desirable?References   1.  Warren JR, Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet.1983;i:1273–1275.  2.  Hawkey CJ. Nonsteroidal anti-inflammatory drug gastropathy. Gastroenterology.2000;119:521–535.  3.  Hawkey CJ, Langman MJ. Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX- 2 inhibitors and proton pump inhibitors. Gut.2003;52: 600–608.  4.  Douthwaite AH, Lintott SAM. Gastropic observation of the effect of aspirin and certain other substances on the stomach. Lancet.1938;ii:1222–1225.  5.  Weil J, Langman MJ,Wainwright P et al. Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal antiin- flammatory drugs. Gut.2000;46:27–31.  6.  Susser S. Civilisation and peptic ulcer. Lancet.1962;i:115–118.  7.  Higham J, Kang JY, Majeed A. Recent trends in admissions and mortality due to peptic ulcer in England: increasing frequency of hemorrhage among older subjects. Gut.2002;50:460–464.  8.  Taha AS, Angerson WJ, Prasad R, et al. Upper gastrointestinal bleeding and the changing use of COX-2 non-steroidal anti- inflammatory drugs and low-dose aspirin. APT.2007;26 (8):1171–1178.  9.  Post PN, Kuipers EJ, Meijer GA. Declining incidence of peptic ulcer but not of its complications: a nation-wide study in The Netherlands.",1545,211,386.25,"[-0.104403   -0.3553344  -1.2594175  ...  0.43263277 -0.04752937
 -1.4055926 ]"
89,"Aliment Pharmacol Ther.2006; 23(11):1587–1593.10.  Lassen Annmarie, Hallas Jesper, de Muckadell Ove, et al. Com- plicated and Uncomplicated Peptic Ulcers in a Danish County 1993–2002: a Population-Based Cohort Study. Am J Gastroenterol. 2006;101(5):945–953.11.  Cai S, Garcia Rodriguez LA, Masso-Gonzalez EL, Hernandez- Diaz S. Uncomplicated peptic ulcer in the UK: Trends from 1997 to 2005. Aliment Pharmacol Ther.2009;30(10):1039–1048.12.  Sadic J, Borgstrom A, Manjer J, et al. Bleeding peptic ulcer – time trends in incidence, treatment and mortality in Sweden. Aliment Pharmacol Ther.2009;30(4):392–398.13.  Ahsberg K, Hoglund P, Stael von Holstein C. Mortality from peptic ulcer bleeding: the impact of comorbidity and the use of drugs that promote bleeding. Aliment Pharmacol Ther.2010;32 (6):801–810.14.  Wang YR, Richter JE, Dempsey DT. Trends and outcomes of hospitalizations for peptic ulcer disease in the United States, 1993 to 2006. Ann Surg.2010;251(1):51–58.15.  Atherton JC, Blaser MJ. Co-adaptation of Helicobacter pylori and humans: ancient history and modern implications. J Clin Invest.2009;119(9):2475–2487.16.  Borody TJ, George LL, Brandl S, et al. Smoking does not contrib- ute to duodenal ulcer relapse after Helicobacter pylori eradica- tion. Am J Gastroenterol.1992;87:1390–1393.17.  Hawkey CJ, Laine L, Harper SE, et al. Rofecoxib Osteoarthritis Endoscopy Multinational Study Group. Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials. Aliment Pharma- col Ther.2001;15:1593–1601. •	 All patients on an NSAID should receive PPI prophylaxis with additionally a COX-2 inhibitor if they have significant risk. These patients should be told about the adverse effects of PPIs and COX-2 inhibitors, with an emphasis that the benefits of each therapy outweigh the risks.",1877,260,469.25,"[ 0.46338415 -0.6241926  -1.3301691  ...  0.29318535  0.13983776
 -1.8602985 ]"
89,"SOURCES OF INFORMATION FOR PATIENTS AND DOCTORS www.nlm.nih.gov/medlineplus/pepticulcer.html www.kidshealth.org/parent/medical/digestive/peptic_ulcers.html www.digestive.niddk.nih.gov/ddiseases/pubs/hpylori/ www.digestive.niddk.nih.gov/ddiseases/pubs/nsaids/ www.netdoctor.co.uk/diseases/facts/pepticulcertreatment.htm patients.uptodate.com/topic.asp?file=digestiv/9148 Current controversies A number of recent findings may challenge conservative pre- scribers. These include fairly clear demonstrations suggesting that: •	 All patients taking NSAIDs have reduced ulcer risk if they take a PPI. PPIs are not co-prescribed as commonly as they should be. •	 The gastroduodenal benefits of selective COX-2 inhibitors outweigh any cardiac risks. However, vascular risks domi- nate current thinking. •	 The risk of vascular thrombotic events may be similar for non-selective NSAIDs (except naproxen) and selective COX-2 inhibitors. However there is generally greater concern about COX-2 inhibitors. •	 COX-2 inhibitors may be more suitable for patients needing aspirin for vascular protection because they lack the ability of non-selective NSAIDs to abrogate the effectiveness of aspirin. However the EMA contra-indicate COX-2 inhibitors in patients with vascular disease. •	 Stopping aspirin in patients with bleeding peptic ulcers has been shown to increase mortality. Despite this, most doctors stop aspirin in these patients. •	 Antibiotic resistance of H. pylori is increasing and varies between individuals and populations: the most effective treatment therefore also varies between individuals and populations. There are also some wider controversies surrounding H. pylori management, which include: •	 Should H. pylori (or at least pathogenic strains of H. pylori) be screened for and treated in some populations, with the aim of primary prevention of peptic ulcers and gastric cancer? •	 H. pylori has co-evolved with humans over millennia. Does its absence from the human stomach of many individuals Hawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated. Created from yonseimed-ebooks on 2024-05-29 06:58:08. Copyright © 2012. John Wiley & Sons, Incorporated. All rights reserved.",2309,299,577.25,"[ 0.2723822  -0.12366784 -1.4319264  ...  0.5087206   0.8713185
 -1.4728843 ]"
90,"Upper GI Tract Part 2:  Diseases of the Gut and Liver 232 selective COX-2 inhibitors (NASA1 – SPACE1). Am J Gastro. 2005;100(5):1028–1036.36.  Malfertheiner P, Megraud F, O’Morain C, et al. Current concepts in the management of Helicobacter pylori infection: The Maas- tricht III Concensus Report. Gut.2007;56:772–781.37.  Delaney BC, Qume M, Moayyedi P, et al. Helicobacter pylori test and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: multicentre randomised controlled trial (MRC-CUBE trial). BMJ.2008;336(7645): 651–654.38.  Duggan AE, Elliott CA, Miller P, et al. Clinical trial: a rand- omized trial of early endoscopy, Helicobacter pylori testing and empirical therapy for the management of dyspepsia in primary care. APT.2009;29;1:55–68.39.  Castells MC. Mastocytosis: classification, diagnosis, and clinical presentation. Allergy Asthma Proc.2004;25:33–36.40.  Lind T, Megraud F, Unge P, et al. The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology.1999;116:248–253.41.  van Hogezand RA,Witte AM,Veenendaal RA, et al. Crohn’s disease: review of the clinicopathologic features and therapy. Inflamm Bowel Dis.2001;7:328–337.42.  Gerrits MM, van Vliet AH, Kuipers EJ, et al. Helicobacter pylori and antimicrobial resistance: molecular mechanisms and clinical implications. Lancet Infect Dis.2006;6(11):699–709.43.  Raymond J, Lamarque D, Kalach N, et al. High level of antimi- crobial resistance in French Helicobacter pylori isolates. Helico- bacter.2010;15(1):21–27 44.",1584,209,396.0,"[ 0.21514337 -0.27146375 -0.9782882  ...  0.6056873  -0.02996509
 -1.5945538 ]"
90,"Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000;343:1520–1528.45.  Silverstein F, Simon L, Faich G. Reporting of 6-month vs 12- month data in a clinical trial of celecoxib. JAMA.2002;286:2399.46.  Schnitzer TJ, Burmester GR, Mysier E, et al. Comparison of lumi- racoxib with naproxen and ibuprofen in the Therapeutic Arthri- tis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet.2004;364;665–674.47.  Laine L, Curtis SP, Cryer B, et al. Assessment of upper gastroin- testinal safety of etoricoxib and diclofenac in patients with oste- oarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) pro- gramme: a randomised comparison. Lancet.2007;369 (9560): 465–473.48.  Hawkey CJ, Weinstein WM, Stricker K, et al. Clinical trial: Com- parison of the gastrointestinal safety of lumiracoxib with tradi- tional nonselective nonsteroidal anti-inflammatory drugs early after the initiation of treatment – Findings from the Therapeutic Arthritis Research and Gastrointestinal Event Trial.49.  Hawkey CJ, Weinstein WM, Smalley W, et al. Effect of Risk Factors on Complicated and Uncomplicated Ulcers in the TARGET Lumiracoxib Outcomes Study. Gastroenterology. 2007;133 (1):57–64.50.  Rostom A, Muir K, Dube C, et al. Gastrointestinal Safety of Cyclooxygenase-2 Inhibitors: a Cochrane Collaboration System- atic Review. Clin Gastroenterol Hepatol.2007;5(7):818–828.e5.51.  Van Der Linden MW, Van Der Bij S, Welsing P, et al. The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti- inflammatory drugs. Ann Rheum Dis.2009;68(5):668–673.18.  Hawkey CJ, Laine L, Harper SE, et al. Rofecoxib Osteoarthritis Endoscopy Multinational Study Group. Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials. Aliment Pharma- col Ther.2001; 15:1593–1601.",2154,290,538.5,"[ 0.25998598  0.09802961 -1.499225   ...  0.07311372  0.6061481
 -1.5489123 ]"
90,"19.  Blaser MJ, Atherton JC. Helicobacter pylori persistence: biology and disease. J Clin Invest.2004;113:321–333.20.  Crabtree JE,Taylor JD,Wyatt JI, et al. Mucosal IgA recognition of Helicobacter pylori 120 kDa protein, peptic ulceration, and gastric pathology. Lancet.1991;338:332–335.21.  Lewis SC, Langman MJS, Laporte JR, et al. Dose-response relationships between individual nonaspirin nonsteroidal anti- inflammatory drugs (NANSAIDs) and serious upper gastroin- testinal bleeding: a meta-analysis based on individual patient data. Br J Clin Pharmacol.2002;54(3):320–326.22.  Stack WA, Atherton JC, Hawkey GM, et al. Interactions between Helicobacter pylori and other risk factors for peptic ulcer bleed- ing. Aliment Pharmacol Ther.2002;16:497–506.23.  Atherton JC. The pathogenesis of Helicobacter pylori-induced gastroduodenal disease. Ann Rev Pathol Mech Dis.2006;1:63–96.24.  Odenbreit S, Puls J, Sedlmaier B, et al. Translocation of Helico- bacter pylori CagA into gastric epithelial cells by type IV secre- tion. Science.2000;287:1497–1500.25.  Argent RH, Kidd M, Owen RJ, et al. Determinants and conse- quences of different levels of CagA phosphorylation for clinical isolates of Helicobacter pylori. Gastroenterology.2004;127: 514–523.26.  Atherton J, Cao P, Peek RM, et al. Mosaicism in vacuolating cytotoxin alleles of Helicobacter pylori: association of specific vacA types with cytotoxin production and peptic ulceration. J Biol Chem.1995;270:17771–17777.27.  Macarthur M, Hold GL, El-Omar EM. Inflammation and cancer II.",1541,197,385.25,"[ 0.04172507 -0.01717708 -1.2106147  ...  0.31696814 -0.2883309
 -1.4283493 ]"
90,"Role of chronic inflammation and cytokine gene polymor- phisms in the pathogenesis of gastrointestinal malignancy. Am J Physiol Gastrointest Liver Physiol.2004;286:G515–G520.28.  Robinson K, Kenefeck R, Pidgeon EL, et al. Helicobacter pylori- induced peptic ulcer disease is associated with inadequate regu- latory T cell responses. Gut.2008;57:1375–1385.29.  Peek RM, Fiske C, Wilson KT. The role of innate immunity in Helicobacter pylori-induced gastric malignancy. Physiol Rev. 2010;90:831–858.30.  Moss SF, Legon S, Bishop AE, et al. Effect of Helicobacter pylori on gastric somatostatin in duodenal ulcer disease. Lancet. 1992;340:930–932.31.  Elliott SL, Ferris RJ, Giraud AS, et al. Indomethacin damage to rat gastric mucosa is markedly dependent on luminal pH. Clin Exp Pharmacol Physiol.1996;23:432–434.32.  Yeomans ND,Tulassay Z, Juhasz L, et al. A comparison of ome- prazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med.1998;338:719–726.33.  Earlam R. Computerized questionnaire analysis of duodenal ulcer symptoms. Gastroenterology.1976;71:314–317.34.  Horrocks JC, De Dombal FT. Clinical presentation of patients with “dyspepsia.”Detailed symptomatic study of 360 patients. Gut.1978;19:19–26.35.  Hawkey CJ, Talley NJ, Yeomans ND, et al. Improvements with esomeprazole in upper gastrointestinal symptoms in patients taking non-steroidal anti-inflammatory drugs including Hawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated.",1725,224,431.25,"[ 0.15846127 -0.3905052  -0.9218739  ...  0.6693754  -0.3233847
 -1.6509696 ]"
90,"Created from yonseimed-ebooks on 2024-05-29 06:58:08. Copyright © 2012. John Wiley & Sons, Incorporated. All rights reserved.",125,17,31.25,"[ 0.3161571  -0.07471591 -1.3820918  ...  0.7049357  -0.72206044
 -1.6224934 ]"
91,"Chapter 32:  Peptic ulcer 233 Upper GI Tract 64.  MacDonald TM,Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet.2003;361:573–574.65.  Patel TN, Goldberg KC. Use of aspirin and ibuprofen compared with aspirin alone and the risk of myocardial infarction. Arch Intern Med.2004;164:852–856.66.  Barkun AN, Bardou M, Kuipers EJ, et al. International consensus recommendations on the management of patients with non- variceal upper gastrointestinal bleeding. Ann Intern Med. 2010;152(2):101–113.67.  Stanley AJ, Ashley D, Dalton HR, et al. Outpatient management of patients with low-risk upper-gastrointestinal haemorrhage: multicentre validation and prospective evaluation. Lancet. 2009;373(9657):42–47.68.  Sung JJY, Lau JYW, Ching JYL, et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med.2010;152(1):1–9.69.  Hearnshaw SA, Logan RFA, Lowe D, et al. Use of endoscopy for management of acute upper gastrointestinal bleeding in the UK: results of a nationwide audit. Gut.2010;59(8):1022–1029.70.  Svanes C. Trends in perforated peptic ulcer: incidence, etiology, treatment, and prognosis. World J Surg.2000;24:277–283.71.  Taha AS, Angerson WJ, Prasad R, et al. Clinical trial: The inci- dence and early mortality after peptic ulcer perforation, and the use of low-dose aspirin and nonsteroidal anti-inflammatory drugs. Aliment Pharmacol Ther.2008;28(7):878–885.72.  Reinbach DH, Cruickshank G, McColl KE. Acute perforated duodenal ulcer is not associated with Helicobacter pylori infec- tion. Gut.1993;34:1344–1347.",1591,209,397.75,"[ 0.1674711  -0.4418786  -1.1721838  ...  0.2489605   0.41516322
 -1.298033  ]"
91,"73.  Gisbert JP, Pajares JM. Helicobacter pylori infection and perfo- rated peptic ulcer: prevalence of the infection and role of anti- microbial treatment. Helicobacter.2003;8:159–167.74.  Cook D, Heyland D, Griffith L, et al. Risk factors for clinically important upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group. Crit Care Med.1999;27:2812–2817.75.  Cook DJ, Fuller HD, Guyatt GH et al. Risk factors for gastroin- testinal bleeding in critically ill patients. Canadian Critical Care Trials Group. N Engl J Med.1994;339:377–381.76.  Janicki T, Stewart S. Stress-ulcer prophylaxis for general medical patients: a review of the evidence. J Hosp Med.2007;2(2):86–92.77.  Quenot JP. When should stress ulcer prophylaxis be used in the ICU?Curr Opin Crit Care.2009;15:139–143.78.  Tryba M, Cook D. Current guidelines on stress ulcer prophy- laxis. Drugs.1997;54:581–596.79.  Cameron AJ, Higgins JA. Linear gastric erosion: a lesion associ- ated with large diaphragmatic hernia and chronic blood loss. Gastroenterology.1986;91:338–342.52.  Rostom A, Muir K, Dube C, et al. Prevention of NSAID-related upper gastrointestinal toxicity: A meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors. Drug Healthc Patient Saf.2009;1(1):47–71.53.  Hawkey CJ, Karrasch JA, Szczepanski L et al. Omeprazole com- pared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs.",1470,193,367.5,"[-0.07431434 -0.46248212 -0.95396936 ...  0.47441489  0.1710078
 -1.4897721 ]"
91,"Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med.1998;338:727–734.54.  Latimer N, Lord J, Grant RL, et al. Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combina- tion with a proton pump inhibitor for people with osteoarthritis. BMJ. (Clinical research ed.)2009;339:b2538.55.  Chan FK, Chung SC, Suen BY et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med.2001;344:967–973.56.  Chan FK, Hung LC, Suen BY et al. Celecoxib versus diclof­ enac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med.2002;347: 2104–2110.57.  Lai KC, Lam SK, Chu KM et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med.2002;346:2033–2038.58.  Chan FKL, Wong VWS, Suen BY, et al. Combination of a cyclo- oxygenase-2 inhibitor and a proton-pump inhibitor for pre­ vention of recurrent ulcer bleeding in patients at very high  risk: a double-blind, randomised trial. Lancet.2007;369(9573): 1621–1626.59.  Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheuma- toid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med.1995;123(4):241–249.60.  Chan FKL, Sung JJY, Chung SCS, et al. Randomised trial of eradication of Helicobacter pylori before nonsteroidal anti- inflammatory drug therapy to prevent peptic ulcers. Lancet. 1997;350(9083):975–979.61.  Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infec- tion and nonsteroidal anti-inflammatory drugs in peptic ulcer disease: a meta analysis.",1850,256,462.5,"[ 0.11340909 -0.1308046  -1.1420139  ...  0.5461566   0.48947978
 -2.0475137 ]"
91,"Lancet.2002;359:14–22.62.  Hawkey CJ,Tulassay Z, Szczepanski L et al. Randomised control- led trial of Helicobacter pylori eradication in patients on nons- teroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. Lancet.1998; 352:1016–1021 (Erratum, Lancet 1998;352:1634).63.  Catella-Lawson F, Reilly MP, Kapoor SC et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345:1809–1817. Hawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated. Created from yonseimed-ebooks on 2024-05-29 06:58:08. Copyright © 2012. John Wiley & Sons, Incorporated. All rights reserved.",772,102,193.0,"[ 0.11289524 -0.19968417 -1.4253252  ...  0.64505905  0.5691414
 -2.0829186 ]"
92,"234 Upper GI Tract CHAPTER 33 Gastritis Richard H. Lash and Robert M. Genta Caris Diagnostics/Miraca; University of Texas Southwestern Medical Center, Irving, TX, USA Textbook of Clinical Gastroenterology and Hepatology, Second Edition. Edited by C. J. Hawkey, Jaime Bosch, Joel E. Richter, Guadalupe Garcia-Tsao, Francis K. L. Chan.© 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd. Introduction, including definition The discovery of Helicobacter pylori catapulted gastritis onto centre stage [1]. Intensive research and voluminous literature followed. In this chapter the terms “body” or “gastric body” are used as synonymous with “corpus.”The gastric mucosa is divided into four major regions, comprising different glandu- lar components in differing proportions. From proximal to distal, they are: the cardia, fundus, body (corpus), and antrum. Histologically, the gastric cardia is a narrow band of mucosa juxtaposed to the squamous mucosa of the esophagus at the Z-line. Typical cardiac glands are of the mucous type, similar to those of the gastric antrum, but they often contain scattered acid-secreting gland elements. The gastric fundus and body contain a surface layer of mucus-producing glands with deeper layers of oxyntic glands. These oxyntic glands include parietal (acid-secreting) and chief (enzyme-secreting) cells as well as scattered endocrine cells. In the gastric antrum, the glands are of the mucous type, also with gastrin-producing endocrine cells. These histologic regions, however, do not nec- essarily correspond exactly to the gross anatomic landmarks. Gastritis, simply defined as inflammation of the gastric mucosa, is a condition, not a disease [2]. With few exceptions, the inflammation of the gastric mucosa per se does not produce signs or symptoms. A subset of patients may have symptoms due to gastritis, but no independent tests are available to make that prediction in an individual patient. A second group of conditions characterized by gastric mucosal aberrations with little or no inflammation were historically included in classifi- cations of gastritis, but are now categorized as gastropathies [2]. In some gastropathies there may be an inflammatory com- ponent, but the abnormal architectural changes are considered the dominant feature structurally and pathogenetically. Classification The classification of gastritis, outlined in Table 33.1, represents a modification of the Updated Sydney System and reflects current practice by most gastrointestinal pathologists and gas- troenterologists [2]. Details of each type are provided in the following text. Helicobacter pylori gastritis (see Chapter 22) Definition H. pylori infection is predicated on the identification of H. pylori organisms via a variety of diagnostic methods. Histologically, the typical findings are chronic active gastritis. “Chronic” refers to mononuclear cell infiltrates, especially lymphocytes and plasma cells, as well as eosinophils, with or without accompanying architectural distortion. “Active” refers to the presence of neutrophils infiltrating the epithelium and lamina propria. It is noteworthy that chronic active gastritis is neither specific for H. pylori infection nor is it present in all cases. KEY POINTS •	 Inflammation of the gastric mucosa per se does not usually produce symptoms •	 H. pylori gastritis –	 Is the most common chronic infection in humans –	 Antrum-predominant H. pylori gastritis carries a 15–20% lifetime risk of peptic ulcer –	 Atrophic pangastritis is more common in less industrialized countries and populations with a high incidence of gastric adenocarcinoma –	 Carcinoma and lymphoma may present years after eradication of H. pylori infection •	 Autoimmune gastritis can cause iron deficiency or pernicious anemia •	 Lymphocytic gastritis may be associated with celiac disease, H. pylori infection, varioliform gastritis, and Ménétrier’s disease •	 Chemical gastropathy, caused by NSAIDs, alkaline reflux (bile or pancreatic secretion), or other chemical injury, is the most common pathologic finding in gastric biopsy specimens in the industrialized world ESSENTIAL FACTS ABOUT H. PYLORI GASTRITIS •	 It is the most common chronic infection in humans •	 Mechanisms of transmission are unknown; prevalence is related to level of sanitation (15% to 80% in different populations) •	 Two main types of pathology: antral-predominant non-atrophic (associated with risk for peptic ulcer) and atrophic pangastritis (associated with increased risk for gastric cancer) •	 Treatment hinges on eradication of organism; therapies include combinations of antibiotics and proton pump inhibitors •	 Eradication of H. pylori results in greatly decreased risk for peptic ulcer and decreased risk for intestinal-type gastric adenocarcinoma. Hawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated. Created from yonseimed-ebooks on 2024-05-29 06:58:08. Copyright © 2012. John Wiley & Sons, Incorporated. All rights reserved.",5116,739,1279.0,"[ 0.10382457  0.01666301 -0.8286252  ...  0.7271391   0.10201944
 -1.4238724 ]"
93,"Chapter 33:  Gastritis 235 Upper GI Tract Causes, risk factors, disease associations Humans are the only important reservoir for H. pylori. Helico- bacter heilmannii, a pathogen of dogs and cats, is responsible for approximately 1% of human Helicobacter infections; its his- topathologic aspects and clinical associations are similar to those of H. pylori gastritis [4]. Transmission occurs primarily from human to human and is most efficient in childhood, as suggested by the finding that children and their parents are often infected by strains with identical genetic fingerprints [5–8]. H. pylori is a spiral, microaerophilic, urease-producing, Gram-negative bacterium. A number of proteins expressed by H. pylori, collectively known as pathogenicity factors, have Epidemiology H. pylori gastritis is the most common chronic infection in humans [3]. It affects between three and four billion people, with a prevalence that varies from less than 20% in industrial- ized Western regions with ethnically homogeneous popula- tions (e.g., Scandinavia) to more than 80% in developing areas of the world (e.g., parts of South America, equatorial Africa, Southeast Asia). Within countries, the most important predictor of high prevalence is low socioeconomic status. Improved socioeconomic conditions have resulted in a decreased prevalence of H. pylori in most Western countries and Japan. Table 33.1  Classification of gastritis with histologic correlations Type of gastritis Etiologic factors Key Pathologic findings Non-atrophic Helicobacter gastritis Helicobacter pylori Helicobacter heilmannii Multifocal chronic active gastritis with or without erosion/ulcer Lymphoid follicles characteristic Must exclude dysplasia and lymphoma Other infectious gastritides Bacteria (other than H. pylori) Viruses Fungi Parasites Gastritis with or without ulcer/granuloma and identifiable organisms/viral cytopathic efffect Chemical gastropathy Chemical irritation Bile NSAIDs ?Other agents Foveolar hyperplasia Fibromuscular change of lamina propria Vascular dilatation Lymphocytic Idiopathic ?Immune mechanisms Gluten sensitivity Drug (e.g., ticlopidine) ?H. pylori Increased intraepithelial lymphocytes Must exclude H. pylori and lymphoma Non-infectious granulomatous Crohn’s disease Sarcoidosis Wegener’s granulomatosis and other vasculitides Foreign substances Idiopathic Granulomas, typically non-caseating Occasionally identifiable organisms and foreign material Eosinophilic Food sensitivity ?Other allergies Marked eosinophilia in mucosa and submucosa Radiation Chemotherapy Radiation injury (external and SIR spheres) Hepatic arterial infusion chemotherapy Cytologically bizarre cells (both stromal and epithelial) with normal architecture Vascular changes Yttrium-90 spheres occasionally identifiable, often with ulceration Atrophic Autoimmune Autoimmunity Cross-reactivity with H. pylori antigens Diffuse corporal atrophic gastritis with antral sparing IgG4-positive plasma cells in a minority Multifocal atrophic Helicobacter pylori, in association with dietary, environmental, and host factors Patchy intestinal metaplasia/atrophy with involvement of corpus and antrum Hawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated. Created from yonseimed-ebooks on 2024-05-29 06:58:08. Copyright © 2012. John Wiley & Sons, Incorporated. All rights reserved.",3473,451,868.25,"[ 0.3415305   0.2787295  -0.6232959  ...  0.23848474  0.19042984
 -0.9384315 ]"
94,"Part 2: Diseases of the Gut and Liver 236 Upper GI Tract been suspected of an association with particular manifesta- tions of the infection (Table 33.2). However the virulence of  H. pylori seems to be largely host-dependent, and none of these factors is unequivocally disease-specific [9,10]. H. pylori infec- tion is associated with most duodenal and gastric ulcers that are not related to the use of nonsteroidal anti-inflammatory drugs (NSAIDs) and almost all primary gastric lymphomas of the mucosa-associated lymphoid tissue (MALT) [11]. In certain populations, a considerable proportion of infected subjects develop atrophic gastritis, a documented precursor of gastric adenocarcinoma [12,13]. Pathogenesis and pathology Studies of the initial phases of H. pylori infection reveal acute mucosal inflammatory responses that usually involve all gastric regions and may be accompanied by antral erosions and subepithelial hemorrhages. The chronic phase is charac- terized by a mixed infiltrate in the lamina propria (usually most intense in its most superficial portions), consisting of lymphocytes, plasma cells, and variable amounts of eosi- nophils, with ongoing activity evidenced by neutrophilic infil- tration (Figure 33.1). The intensity of inflammation is generally greater in the antrum and the cardia than in the gastric body, where it may be minimal despite visible bacterial colonization. This distribution of inflammation is described as antrum- predominant gastritis, the most common type of gastritis in Western populations. In a proportion of infected subjects, the inflammation is equally intense in all gastric regions. This pattern, known as pangastritis, is associated with a progression toward glandu- lar destruction with resulting atrophy and intestinal metapla- sia. Atrophic pangastritis is the predominant phenotype in subjects from less industrialized areas of the world and par- ticularly in populations with high incidence of gastric adeno- carcinoma [2]. Lymphoid follicles, an expression of MALT (see Chapter 35), are virtually always found in infected stom- achs, and their presence is a reliable indication of active or recently treated H. pylori gastritis. Their greatest density is in the region of the incisura angularis and the lowest in the proximal body greater curvature [14]. H. pylori pangastritis can usually be distinguished from classical autoimmune gastritis by the presence of disease in the antrum (not found in pure autoimmune gastritis) as well as less uniform atrophy/ inflammation of the body and fundus (hence the former term “multifocal atrophic gastritis”) [15]. Such an assessment requires adequate biopsy sampling (see “Diagnostic methods” below). Clinical presentation The relationship of chronic H. pylori gastritis with dyspepsia (see Chapter 4) remains unclear. H. pylori eradication in patients with nonulcer dyspepsia has not been shown conclu- sively to improve the dyspeptic symptoms. A subset may respond, but prediction of which patients belong to that subset is not possible at this time. Subjects with antrum-predominant Table 33.2  Putative pathogenicity factors of H. pylori and their alleged associations Putative pathogenicity factor Characteristics Associations VacA (vacuolating cytotoxin) Genotypes s1 (associated with CagA positivity and s2) Not useful for predicting symptoms, presentation, degree of inflammation, or response to therapy CagA(cytotoxin- associated gene product A) Product of one of the genes in the cag pathogenicity island Induction of cytokine expression in gastric epithelial cells, with raised mucosal levels of interleukin-8 and marked neutrophil infiltration Increase risk of a symptomatic outcome (peptic ulcer and gastric cancer), but not in all populations No predictive value in individual patients) iceA (induced by contact with epithelium) Bacterial restriction enzyme No known biologic or epidemiologic evidence of a role for iceA as a virulence factor in H. pylori-related disease babA (blood group antigen- binding adhesin) Outer membrane protein, involved in adherence of  H. pylori to Lewis-b (Leb) blood group antigens on gastric epithelial cells No individual predictive value Infection with babA2 gene, cagA+ and vocA s1 (“triple-positive strains”) may be related to duodenal ulcer risk Figure 33.1  Biopsy of the gastric antrum showing moderate chronic active gastritis. The dark staining mixed inflammatory infiltrate is concentrated mostly in the upper portions of the mucosa. Various degrees of clear-staining edema and hemorrhage are seen in the subepithelial zone. Hawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated. Created from yonseimed-ebooks on 2024-05-29 06:58:08. Copyright © 2012. John Wiley & Sons, Incorporated. All rights reserved.",4894,713,1223.5,"[ 0.6382527  -0.2887782  -1.2128739  ...  0.06289105  0.08515839
 -1.4600153 ]"
95,"Chapter 33:  Gastritis 237 Upper GI Tract organisms have a characteristic tight spiral morphology and are two to three times longer (10 microns) than H. pylori. A urease test on an antral biopsy specimen (Clotest®) permits the rapid detection of urease activity in the biopsy material, with a sensitivity of 80–100% and a specificity of 92–100%, although it is not known how well such tests work post-treatment. The urea breath test (UBT) is based on the detection of labelled carbon dioxide in a sample of the subject’s breath after the ingestion of a meal containing 13C and 14C labeled urea. Although highly sensitive and specific, its use is largely limited by the need of administering the meal to the H. pylori gastritis have a lifetime risk for peptic ulcer disease of 15–20% (see Chapter 32). Most subjects who do not develop ulcer disease remain asymptomatic and are believed to have no increased risk for gastric adenocarcinoma (see Chapter 34); those with pangastritis also remain asymptomatic, but their gastric mucosa develops progressive destructive and repara- tive changes that result in expanding areas of glandular loss (atrophy) and replacement of the native gastric mucosa with an intestinal-type epithelium (intestinal metaplasia). Atrophic gastritis is epidemiologically and biologically asso- ciated with gastric adenocarcinoma of the intestinal type, and patients with this phenotype account for much of the increased risk of cancer related to H. pylori infection [15]. Based on case- controlled and other retrospective epidemiologic studies, the overall gastric cancer risk for H. pylori-infected subjects has been estimated as 3- to 10-fold that of the uninfected popula- tion [16]. H. pylori infection is also related to diffuse (signet ring cell) gastric cancer of the stomach, which accounts for 50% or more of all gastric cancers in some populations. Here there is no diffuse intestinal metaplasia or atrophy and no apparent dysplastic “soil.”The risk for primary gastric B-cell lymphoma, a rare condition, is in the range of 5- to 7-fold that of noninfected subjects. Both carcinoma and lymphoma may be diagnosed years or even decades after H. pylori infection has disappeared, possi- bly because of the combined effects of the hypochlorhydria related to atrophy, an inhospitable gastric environment brought upon by metaplasia and incipient epithelial and lymphoid neoplasia, and possibly incidental antibiotic treatments. Thus, it is likely that retrospective studies significantly underesti- mate the risk of neoplasia conferred by H. pylori infection. Studies taking into account the infecting strain of H. pylori (with regard to pathogenicity factors), the phenotype of gas- tritis, and the time elapsed between detection of the infection and the diagnosis of carcinoma, have raised the estimated risk to as much as 23-fold. Diagnostic methods (Table 33.3) Testing for H. pylori should be performed only if treatment is intended. The diagnosis can be made by endoscopic biopsy of the gastric mucosa or by noninvasive methods, depending on the clinical setting. Biopsy specimens (ideally at least two from the antrum and two separately identified and submitted from the gastric body along the greater curve) are examined for the detection of H. pylori and for the diagnosis of gastritis (Figure 33.2). Special stains have been employed to identify the curved bacillary organisms with facility. A variety of his- tochemical stains have been employed, but the most sensitive and specific (both near 100%) is the immunohistochemical stain, which can also identify organisms after treatment with proton pump inhibitors and antibiotics (Figure 33.3). Organ- isms are typically found extracellularly in the lumen at the surface and in the superficial pit layer. After treatment, organ- isms can sometimes only be found in deep glands and intracel- lularly, often with atypical (coccoid) morphology. H. heilmannii Figure 33.2  Biopsy protocol. Schematic representation of the biopsy protocol recommended by the Updated Sydney System when the objective is to map the severity and extent of gastritis. A minimum of two specimens is obtained from each of the antrum (A1 and A2 – lesser and greater curvature) and the corpus (B1 and B2 – lesser and greater curvature). In addition, one biopsy specimen from the incisura angularis (IA) is recommended to detect early atrophic and metaplastic changes, represented in blue. (This figure was published in Clinical Gastroenterology and Hepatology, Wilfred M. Weinstein, Christopher J. Hawkey, Jaime Bosch, Gastritis, Pages 223–232, Copyright Elsevier, 2005.)B1 A1 Incisura B2 A2 Figure 33.3  Anti-Helicobacter immunohistochemical stain. High-power photomicrograph of gastric mucosa with few H. pylori organisms, stained brown by an anti-Helicobacter immunohistochemical stain. Hawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated. Created from yonseimed-ebooks on 2024-05-29 06:58:08. Copyright © 2012. John Wiley & Sons, Incorporated. All rights reserved.",5149,782,1287.25,"[ 0.51624244 -0.11549634 -1.2535999  ...  0.46035385  0.2347684
 -0.7116765 ]"
96,"Part 2: Diseases of the Gut and Liver 238 Upper GI Tract Table 33.3  Invasive and non-invasive tests for the diagnosis of H. pylori infection Test Characteristics Advantages Disadvantages Invasive methods Histopathologic examination of gastric mucosal biopsy Detects current infection by direct observation with or without special staining techniques (immunohistochemistry is the most sensitive and specific) Highly sensitive and specific Can discern H. pylori from H. heilmannii Allows the evaluation of associated conditions (intestinal metaplasia, dysplasia, carcinoma, lymphoma) Guarantees a permanent record Invasive Sampling may affect yield Smear, brush, and touch preparations (cytopathology) Detects bacteria by direct observation of gastric exfoliated cells harvested by brushing Inexpensive Invasive Generally inaccurate, even with skilled operators Limited information on pathology of gastric mucosa Bacterial culture Detects bacterial growth in special media 100% specific Allows antibiotic sensitivity tests Invasive Sensitivity is laboratory-dependent No information on pathology of gastric mucosa Rapid urease tests Detect current infection by bacteria-produced urease in fresh biopsy specimens Highly sensitive Highly specific Rapid results (<2 hours) Invasive No information on pathology of gastric mucosa Non-invasive methods Urea breath tests Detects current infection, relying on H. pylori-derived urease activity in the stomach Sensitivity and specificity >90% Can be used in children Useful for initial diagnosis and to evaluate treatment Requires 13C or 14C detection equipment Expensive in some settings No information on pathology of gastric mucosa Laboratory-based serologic tests Detect anti-H. pylori IgG in serum Approved tests have high sensitivity and specificity (85%−90%) Inexpensive Useful for initial diagnosis Specificity may be “population-specific” Detect evidence of past infection No information on pathology of gastric mucosa, except indirectly when combined with gastrin and pepsinogen ratio measurements (“serologic biopsy”) Simplified “in-office” immunoenzymatic tests Detect anti-H. pylori IgG in serum or whole blood Inexpensive Immediate results (<10 minutes) Moderate specificity and sensitivity (∼85%) Detect evidence of past infection No information on current infection Sensitivity and specificity <90% No information on pathology of gastric mucosa Stool antigen assays Detect H. pylori antigens in stools Detects current infection Useful for determining eradication (8 weeks after therapy) Excellent specificity and sensitivity (>95%) Inexpensive Specimen collection inconvenient No information on pathology of gastric mucosa Urine tests Detect anti-H. pylori IgG in urine Inexpensive disposable kits Quick results (20 minutes) Recently developed tests (e.g., RAPIRUN, URINELISA) have moderate specificity and sensitivity (∼ 85%) Not yet completely validated Sensitivity and specificity may be too low for clinical use Low specificity in children No information on pathology of gastric mucosa Saliva tests Detect anti-H. pylori IgA or IgG in saliva Convenient collection of saliva Low specificity and sensitivity (70% to 85% reported) Not approved, not readily available Hawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated. Created from yonseimed-ebooks on 2024-05-29 06:58:08. Copyright © 2012. John Wiley & Sons, Incorporated. All rights reserved.",3528,480,882.0,"[ 0.5493428  -0.28243256 -1.1322175  ...  0.5429855   0.05169281
 -0.59175944]"
97,"Chapter 33:  Gastritis 239 Upper GI Tract 14 days has a reported efficacy between 75% and 95% in patients who failed first-line therapy. Levofloxacin-based therapy has grown in popularity in recent years; however, the rapidly increasing rate of quinolone resistance reported in several countries may soon limit its use [19]. Patients who fail both first and second-line therapy for H. pylori have been treated with empiric rescue regimens (“third- line therapy”) that most commonly include rifabutin or furi- zoladone. These antibiotics have, however, serious side effects (including myelotoxicity) and their use may be limited to selected patients. Recently, sequential therapy has been proposed to overcome clarithromycin resistance [20,21]. Hypothetically, during the first part of therapy, amoxicillin weakens the bacterial cell wall, which prevents the formation of the channels that block clarithromycin from binding to the bacterium and hence causes resistance to the antibiotic. A meta-analysis published in 2008 reported 93.4% eradication rates, compared with 76.9% for standard triple therapy [22]. Sequential therapy is not affected by bacterial factors (CagA status, bacterial load) and host factors (underlying disease, smoking), which until now have predicted the outcome of conventional eradication treat- ments. Even when strains were clarithromycin-resistant, the eradication rate with sequential therapy was 82.2% compared with 40.6% for triple therapy. Most studies on sequential therapy have been performed in Italy and this regimen is still untested in most countries. The American College of Gastro- enterology “Guideline on the Management of H. pylori Infec- tion” states that “sequential therapy may provide an alternative to clarithromycin-based triple therapy but requires validation within the United States before it can be recommended as a first-line therapy;” the European Maastricht III Consensus Report points out that “sequential treatment deserves further evaluation in different regions” [17,18]. Probiotics and vaccines may offer some alternatives in the future, but at the moment they are still in the early phases of evaluation. A sensible approach for therapy in patients who fail a first- and second-line treatment involves H. pylori culture and anti- biotic testing. However, susceptibility testing is limited by the fact that in vivo resistance may not accurately reflect in vitro resistance, notably with respect to metronidazole. Currently such an approach is carried out almost exclusively in special- ized centres with research interest and expertise in the treat- ment of H. pylori; however, the development of newer technologies in the field of susceptibility testing may encour- age this practice to become more widespread. This is likely to have substantial benefits and lead to more accurate prescribing and lower rates of resistance. Autoimmune gastritis and pernicious anemia Definition Autoimmune gastritis is a chronic atrophic gastritis affecting the oxyntic gland mucosa (gastric body and fundus) and patient and the relatively expensive analysers required for the evaluation of the breath sample. Culture of H. pylori with anti- biotic sensitivity testing is not performed routinely for the initial diagnosis of H. pylori infection. Some laboratories have high-quality culture facilities for H. pylori, and culture may be used if a second course of therapy also fails to eradicate the organisms. Indications for therapy Primary indications for testing and treatment include: •	 active peptic ulcer disease •	 a history of documented peptic ulcer •	 gastric MALT lymphoma. Testing of asymptomatic subjects and patients with non-ulcer dyspepsia are not recommended, except when there is a docu- mented history of gastric cancer in first-degree relatives. Despite the absence of data, many patients with life-dominating non- ulcer dyspepsia are treated if they have evidence of H. pylori. In children, testing for H. pylori is recommended when the symptoms are severe enough to justify therapy. In spite of, or perhaps because of, the many recommendations issued by gastroenterological associations and consensus groups, several issues regarding indications for therapy remain unresolved. In practice, treatment decisions are rarely based on evidence alone; frequently a number of patient- and doctor-driven con- siderations have the greatest weight in making these choices. Therapy The Maastricht-III consensus stated that for an eradication treatment regime to be considered effective, it should achieve an intention-to-treat eradication rate in excess of 80% [17]. However, eradication rates in practice for many of the most common regimens have fallen well below these levels in recent years, generally due to a combination of poor compliance and antibiotic resistance. The recommended first-line treatment in published Euro- pean and North American guidelines consists of a proton pump inhibitor (PPI) combined with amoxicillin and clarithromycin. However, while in 2000, eradication rates for standard triple therapy were in excess of 90%, recent studies have shown that this level has fallen below 70% and even as low as 60% in some areas. Therefore, Maastricht III guidelines [17] recommend sub- stituting metronidazole for clarithromycin where resistance to that antibiotic, increasing in most countries, exceeds 15–20%. Although there has been debate on the optimal duration of therapy, the 2007 American College of Gastroenterology guide- lines recommended 10-day treatment courses [18] and the most recent Maastricht consensus stated that 14 days of treatment had an advantage over 7 days in terms of eradication. Since first-line therapy fails in approximately 20% of patients, several second-line therapy regimens have been developed. The most common are bismuth-based and levofloxacin-based therapies. Bismuth-based quadruple therapy consisting of a PPI, bismuth, tetracycline, and metronidazole for 10 days or Hawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated. Created from yonseimed-ebooks on 2024-05-29 06:58:08. Copyright © 2012. John Wiley & Sons, Incorporated. All rights reserved.",6285,918,1571.25,[-0.2913382 -0.0451327 -1.0485976 ...  0.5633867  0.3553816 -1.5225589]
98,"Part 2: Diseases of the Gut and Liver 240 Upper GI Tract ESSENTIAL FACTS ABOUT AUTOIMMUNE  GASTRITIS •	 Chronic corpus-restricted atrophic gastritis is associated with circulating serum anti-parietal cell and anti-intrinsic factor antibodies along with intrinsic factor deficiency •	 Affects predominantly older women. The prevalence is 1%−5% in persons over 60 years of age; higher in subjects with specific familial histocompatibility haplotypes (HLA-B8 and -DR3) •	 Pathology: dense mononuclear infiltrates in the corpus leading to progressive disappearance of oxyntic glands and intestinal metaplasia with resultant hypochlorhydria. Endocrine cell hyperplasia, carcinoid tumours, and inflammatory polyps are common •	 Vitamin B12 deficiency and macrocytic anemia (“pernicious anemia”) characterize the advanced stage autoantibodies to the parietal cell antigen and to intrinsic factor. In the initial phases of the disease, individual parietal cells may be surrounded by lymphocytes or drop out from oxyntic glands. As the disease progresses over a period of two to three decades, the oxyntic mucosa may be completely replaced by pyloric/antral-type mucous glands, “pyloric metaplasia,” and intestinal metaplasia. At this stage the inflammation becomes less intense. In patients with classic pernicious anemia, residual small nests of parietal and chief cells may persist, but their numbers are greatly reduced. The hypochlo- rhydria induces gastrin production from endocrine cells in the antrum, which in turn stimulates enterochromaffin-like (ECL) cell hyperplasia. This common finding is often subtle histo- logically but can be highlighted with the use of immunohisto- chemical stains for neuroendocrine differentiation. The range of ECL proliferation ranges from linear hyperplasia to micro- carcinoid tumours. Such tumours are often multiple, are  associated with various levels of background endocrine pro- liferation, and almost always are innocuous. In addition, benign gastric hyperplastic polyps are frequently seen in end- stage patients [28]. Clinical presentation Most clinical manifestations of autoimmune gastritis become apparent when the parietal cell mass decreases beyond the critical point when the stomach becomes unable to produce sufficient amounts of acid, pepsinogens, and intrinsic factor. Achlorhydria occurs in the most advanced stages of the disease, but hypochlorhydria may also occur in patients with moderate numbers of surviving parietal cells, suggesting that anti-proton pump antibodies or inhibitory lymphokines released by subsets of inflammatory cells may participate in the inhibition of acid secretion. Patients with oxyntic gland atrophy and achlorhydria undergo hyperplasia of gastrin- secreting endocrine cells in the gastric antrum with resultant commonly associated with circulating serum antiparietal cell and anti-intrinsic factor antibodies and intrinsic factor defi- ciency. In its endstage it is associated with vitamin B12 deficiency. Pernicious anemia is the vitamin B12 deficiency associated with chronic atrophic autoimmune gastritis. Figure 33.4  Autoimmune gastritis. Corpus mucosa with metaplastic atrophy, complete absence of oxyntic gland, and a dense mononuclear inflammatory infiltrate. Epidemiology Autoimmune gastritis and pernicious anemia are diseases of older age, especially in women. The prevalence of pernicious anemia among Americans aged 60 years or older is 2.7% in women and 1.4% in men. There is a strong family association (see below) [23]. Pathogenesis The high prevalence of specific familial histocompatibility haplotypes (HLA-B8 and -DR3) in patients with corpus- restricted atrophic gastritis and its association with other autoimmune conditions, strongly indicate an autoimmune origin [24]. Autoantibodies to parietal cells and to their secre- tory product, intrinsic factor, are present in the serum and gastric juice. The antigen recognized by parietal cell autoanti- bodies is gastric H+/K+-ATPase, the major protein of the mem- brane lining the secretory canaliculi of parietal cells, that secretes hydrogen ions in exchange for potassium ions [25]. During the course of the disease, both parietal and chief cells disappear progressively from the oxyntic glands. H. pylori infection may induce the formation of antibodies that cross react with parietal-cell antigens, and has been proposed as a possible etiologic factor in the pathogenesis of autoimmune gastritis. This correlation, however, remains unproven, and similarly, much stronger biologic, clinical, and epidemiologic evidence is needed before H. pylori can be viewed as the cause of autoimmune gastritis [26,27]. Pathology Patients with autoimmune gastritis have a corpus-restricted chronic atrophic gastritis, and therefore the antral (and cardiac) mucosa is usually spared. Mononuclear cell infiltrates (plasma cells and lymphocytes) are found in the lamina propria between the gastric glands and may extend into the sub­ mucosa (Figure 33.4). Infiltrating plasma cells contain Hawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated. Created from yonseimed-ebooks on 2024-05-29 06:58:08. Copyright © 2012. John Wiley & Sons, Incorporated. All rights reserved.",5335,751,1333.75,"[ 0.5629775  -0.5088967  -1.0914855  ... -0.09452057 -0.08475851
 -1.2656144 ]"
99,"Chapter 33:  Gastritis 241 Upper GI Tract The atrophic gastritis is characterized histologically by chronic inflammation of the glandular mucosa with marked or complete depletion of the parietal cell mass, and intestinal and pyloric metaplasia. These findings can mimic antral gas- tritis and warrant the separate labeling of biopsies from these regions. Serum antibodies to gastric parietal cells are found in 90% of patients with pernicious anemia and in about 30% of their non-anemic first-degree relatives. The demonstration of circu- lating intrinsic factor autoantibodies is almost diagnostic of autoimmune gastritis and is present in approximately 50%. Hypergastrinemia is the result of sparing of the antrum and stimulation of the gastrin-producing G cells by achlorhydria. A low serum pepsinogen concentration results from destruc- tion of the chief cells. Treatment The standard treatment is regular monthly intramuscular injections of at least 100 µg vitamin B12 to correct the vitamin deficiency. Hydroxycobalamin 1 mg every 3 months is a common regimen. When indicated, iron supplements are given prior to B12 administration. Other gastritides Infectious gastritides due to agents other than Helicobacter spp The acid environment of the normal stomach is inhospitable to most infectious agents. However, in subjects with atrophic gastritis and decreased acid secretion, in patients with impaired immune responses, or as part of systemic infections, a number of viruses, bacteria, and parasites can infect the stomach. These infectious gastritides (see Chapter 31, “Infec- tions of the esophagus and stomach”) are rare in otherwise healthy persons, but some (e.g., cytomegalovirus) are not uncommon in immunocompromised patients. Their most important clinical and pathologic features are summarized in Table 33.4. Lymphocytic gastritis This is a distinctive type of pangastritis characterized by the presence of large numbers of mature lymphocytes infiltrating the surface and foveolar epithelium. The lamina propria is infiltrated by an often dense population of inflammatory cells in which lymphocytes and plasma cells predominate, although significant numbers of neutrophils and eosinophils are also present [31].hypergastrinemia, typically correlating with the severity of the mucosal damage. Injury to chief cells leads to a reduction of pepsin activity in gastric juice and of pepsinogens in blood. Reduced pepsinogen I concentration (<20 ng/mL) is a sensi- tive and specific indicator of atrophic gastritis. Patients with advanced autoimmune gastritis may develop: •	 iron deficiency anemia •	 pernicious anemia or •	 combined anemia. Hypochromic microcytic anemia (15% of patients) may be caused by achlorhydria, as gastric acid is important in the absorption of non-heme iron, which in Western diets sup- plies at least two-thirds of nutritional iron needs. Frank perni- cious (macrocytic) anemia is usually preceded by chronic atrophic gastritis and reduced or absent acid secretion by approximately a decade, and is generally associated with a histologic pattern of end-stage atrophic gastritis. Thus a com- bined anemia may be present, and a considerable number of patients with severe atrophic oxyntic gland gastritis may still not fulfill the criteria for the diagnosis of pernicious anemia, but are clearly at risk for the development of vitamin B12 deficiency. Disease associations Autoimmune gastritis is a risk factor for: •	 hyperplastic and adenomatous polyps •	 carcinomas •	 endocrine tumours of the stomach. Polyps, found in 20–40% of patients with per- nicious anemia, are mostly sessile, small, and multiple. Most are hyperplastic, but up to 10% may contain dysplastic foci [29]. The risk of gastric carcinoma is believed to be increased 3-fold, and that of gastric carcinoid tumours 13-fold, in patients with pernicious anemia [28]. The trophic action of gastrin may be responsible for the transformation of endocrine cells from hyperplastic to neoplastic. Diagnostic methods The diagnosis of autoimmune gastritis is frequently missed because patients (elderly people with anemia) are typically successfully treated by hematologists or general practitioners with iron and vitamin B12 supplements, and are not referred to gastroenterologists for the evaluation of atrophic gastritis, pepsinogen levels, or antiparietal cell antibodies. The diagno- sis can be confirmed by a combination of histopathologic and serologic studies. A set of at least four biopsy specimens from the gastric mid-body on the greater curvature, along with two separately submitted from the antrum, should be obtained. The coexistence of severe and diffuse atrophic gastritis of the corpus with a normal antrum is virtually pathognomonic of autoimmune atrophic gastritis [2,30]. ESSENTIAL FACTS ABOUT LYMPHOCYTIC  GASTRITIS •	 Pangastritis characterized by large numbers of mature CD8+ lymphocytes infiltrating the surface and foveolar epithelium •	 Prevalence: 0.1−1% of subjects undergoing gastric biopsies •	 Etiology is unknown; it is not caused by H. pylori infection Hawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated. Created from yonseimed-ebooks on 2024-05-29 06:58:08. Copyright © 2012. John Wiley & Sons, Incorporated. All rights reserved.",5388,786,1347.0,"[ 0.34785432 -0.28696603 -0.62384856 ...  0.38828188 -0.5552219
 -1.3940989 ]"
100,"Part 2: Diseases of the Gut and Liver 242 Upper GI Tract Table 33.4  Infectious gastritides caused by agents other than Helicobacter spp. Agent Main characteristics Pathology Viral Rotaviruses, caliciviruses Stomach may be infected during gastroenteritis None known Cytomegalovirus Children Immunocompromised patients Megaloblastic inclusions Mucosal erosions, ulcerations Rarely large-fold gastropathy Bacteria Various Overgrowth only in achlorhydric subjects No detectable changes Pyogenic bacteria (streptococci, staphylococci, Escherichia coli, Proteus, and Haemophilus spp.)Phlegmonous gastritis Exceedingly rare Large areas of purulent necrosis involving the full thickness of the gastric wall Mycobacterium tuberculosis Primary gastric tuberculosis rare Stomach may be involved in disseminated infections Necrotizing granulomas may be found in the gastric mucosa Treponema pallidum Gastric involvement in secondary syphilis Rare, more common in HIV patients Mixed inflammatory infiltrate, mostly plasma cells, and mucosal ulcerations. Swelling of gastric folds with erosions and ulcerations may mimic endoscopic appearance of lymphoma or carcinoma Fungi Candida species Histoplasma capsulatum Mucoraceae Only in immunocompromised patients Parasites Cryptosporidium spp. Giardia intestinalis Strongyloides stercoralis Rarely found in the stomach, mostly immunocompromised patients No inflammatory responses Anisakidae “Sushi worm” Many species of edible fishes have larvae of Anisakidae in their muscles. In a small proportion of individuals who eat infected fish, larvae penetrate the gastric wall causing a sudden onset of epigastric pain Mostly eosinophilic response around penetrating larvae Dead larvae may elicit granulomas lymphocytosis are similar. The first reports of lymphocytic gastritis featured endoscopic descriptions of large gastric folds with nodules and erosions, clinically accompanied by nausea, vomiting, and weight loss. These findings were presented as the signature lesions of a now rare disorder: diffuse variolif- orm (“octopus-sucker”) gastritis [32]. Another unusual and hypertrophic variant of lymphocytic gastritis resembles Ménétrier’s disease endoscopically, also in patients with protein loss. Case reports describe resolution of the intraepithelial lymphocytosis and symptomatology fol- lowing a regimen of proton pump inhibitors. H. pylori has been found in some of these patients, and in a subset of these, eradication resulted in disappearance of the thick folds and lymphocytic gastritis. Although other putative disease asso- ciations include non-Helicobacter infections and Crohn’s Epidemiology Lymphocytic gastritis is uncommon, found in 0.1–1% of sub- jects who undergo endoscopy with biopsy sampling. Causes and pathogenesis Because virtually all intraepithelial lymphocytes are CD8+ suppressor T cells (the same cells that form the intraepithelial infiltrate in celiac disease and lymphocytic colitis), an immune mechanism has been proposed. Lymphocytic gastritis is of interest primarily because of its clinical associations: approxi- mately one-third of adults and up to half of children with celiac disease (see Chapter 40) have increased gastric intraepi- thelial lymphocytes, usually concentrated in the antrum. In most cases of lymphocytic gastritis H. pylori cannot be impli- cated, as the rate of infection in those with and without Hawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated. Created from yonseimed-ebooks on 2024-05-29 06:58:08. Copyright © 2012. John Wiley & Sons, Incorporated. All rights reserved.",3696,499,924.0,"[ 0.3791008  -0.43974245 -0.67267144 ...  0.47204104 -0.23524688
 -1.0063576 ]"
101,"Chapter 33:  Gastritis 243 Upper GI Tract Primary gastric tuberculosis has been reported mostly from developing countries, typically manifesting as a large non- healing ulcer; disseminated tuberculosis also causes caseating granulomas (see Chapter 47). Histoplasma capsulatum rarely can cause gastric granulomatous inflammation. In gastric ani- sakiasis, fragments of helminthic cuticles may elicit the forma- tion of foreign body granulomas. The stomach may be involved in patients with Crohn’s disease (see Chapter 50) and sarcoidosis. In Crohn’s disease, the prevalence of gastric granulomas may be as high as 10%. However, more commonly, gastric biopsies appear largely normal but feature a focal chronic active inflammatory response, often limited to a few foveolae or oxyntic glands, termed “focally enhanced gastritis;” granulomas are not part of this response. While highly non-specific, this pattern of injury may be the first manifestation of Crohn’s disease. In sarcoidosis, involvement of the gastrointestinal tract rarely has any clinical importance, although outlet obstruction and bleeding have occasionally been reported. Endoscopic findings include nodularity, polypoid mucosal irregularity, erosions, ulcers, and segmental, usually distal, rigidity resem- bling linitis plastica. These gross changes reflect the presence of numerous small mucosal granulomas. Since the finding  of gastric mucosal granulomas may precede the discovery of these diseases in other organs, the careful interpretation of gastric biopsy findings together with radiologic and serologic testing may lead to the diagnosis. Other causes of granulomas include foreign material, such as suture material in patients who have undergone a partial gastrectomy, and food particles that may become engulfed in an ulcer crater. Rare entities causing gastric granuloma include immune-mediated vasculitis syndromes (see Chapter 111) and Wegener’s granulomatosis. The term “isolated (or idiopathic) granulomatous gastritis” should be applied only as a temporary diagnostic label to cases of granulomatous gastric inflammation for which no etiology has yet been determined. Even after careful evaluation, a large proportion of gastric granulomas will remain unexplained. These lesions are usually asymptomatic; as there is no infor- mation on their natural history or evolution, no treatment can be recommended [33,34]. Gastropathies Reactive (or chemical) gastropathy Reactive (or chemical) gastropathy is defined as the constella- tion of endoscopic and histologic changes caused by chemical injury to the gastric mucosa [35]. The term “chemical” is used broadly and refers to the gastric mucosa in some patients who take NSAIDs (see Chapter 23); it also includes patients with alkaline reflux after partial gastrectomy or those with poorly understood motility disorders resulting in bile reflux. No rela- tionship has been established between the endoscopic or his- tologic appearance of the mucosa in patients who take NSAIDs and either dyspeptic symptoms or risk for gastric hemorrhage. disease, lymphocytic gastritis is most commonly seen in gastric biopsies where there is no known association. Diagnostic methods A substantial increase in intraepithelial lymphocytes (Figure 33.5) is accompanied by a spectrum of inflammation in the lamina propria ranging from a minor increase in chronic inflammatory cells with no activity to a marked chronic and active inflammation with erosions. In most cases the histologic picture can readily be distinguished from that of H. pylori chronic gastritis, in which (exclusive of focal lymphoepithelial lesions) few intraepithelial lymphocytes are present. The diag- nostic threshold for lymphocytic gastritis is generally accepted as more than 25 intraepithelial lymphocytes per 100 epithelial cells, but in most cases the counts are greater than 50 [31]. Granulomatous gastritis Granulomatous gastritis can be considered as a histopatho- logic placeholder to which gastric biopsies bearing granulo- mas are temporarily assigned while the condition responsible for their development is identified. In most cases the morpho- logic appearance of granulomas does not provide a useful clue to their etiology, except when •	 foreign materials •	 acid-fast bacilli or •	 fungal forms are found. Thus, a specific diagnosis can be made only by integrating histopathologic findings with clinical and labora- tory information [33,34]. Etiology and pathogenesis Granulomatous inflammation in the gastrointestinal mucosa can be found in patients with a variety of bacterial, fungal, and parasitic infections as well as certain immune disorders. Figure 33.5  Lymphocytic gastritis. This is characterized by marked intraepithelial lymphocytosis and a variable plasma cell and lymphocyte infiltrate in the lamina propria. Hawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated. Created from yonseimed-ebooks on 2024-05-29 06:58:08. Copyright © 2012. John Wiley & Sons, Incorporated. All rights reserved.",5133,734,1283.25,"[ 9.2401356e-04 -1.1564791e-04 -6.3944733e-01 ...  1.5651996e-01
  2.2339608e-01 -7.7969658e-01]"
102,"Part 2: Diseases of the Gut and Liver 244 Upper GI Tract ESSENTIAL FACTS ABOUT REACTIVE  GASTROPATHY •	 Also known as chemical gastropathy, it is the constellation of endoscopic and histologic changes caused by chemical injury to the gastric mucosa •	 Most commonly associated with used of NSAIDs •	 Highly prevalent (15% to 25%) in populations living in the industrialized world, particularly in the elderly •	 Pathology: minimal or no inflammation, epithelial regeneration with foveolar hyperplasia, edema of the lamina propria, vascular congestion, and proliferation of the smooth muscle fibres Hemorrhagic gastropathies This group of conditions, characterized by subepithelial hem- orrhages and erosions, is related to: •	 severe physical stress (see Chapter 32) •	 the use of NSAIDs (see Chapter 23) •	 the ingestion of large quantities of alcohol. The most severe degrees of hemorrhagic gastropathy are those induced by stress in critically ill patients. Most patients admit- ted to an intensive care unit have mucosal lesions; approxi- mately 20% of them have overt bleeding and 2–5% have life-threatening hemorrhage (see Chapter 32). The pathogen- esis of stress-induced hemorrhagic gastropathy is incompletely understood, but when the mucosal defense mechanisms lose their integrity, luminal acid may exert a damaging effect. Vas- cular disturbances, in association with stasis, vasoconstriction, and increased vascular permeability, may contribute further to mucosal vulnerability [37]. Aspirin or other NSAIDs may induce acute mucosal injury, ranging from edema and hyperemia to multiple erosions and ulcerations. Such lesions may occur without warning symp- toms in both first-time NSAID users and patients who have taken NSAIDs regularly for years. Except for generic risk factors (older age, female sex, and previous episodes), there is no way prospectively to identify NSAID users who are sus- ceptible to severe gastric injury. Similar mucosal lesions, although usually less severe and only rarely eventuating to ulcer, can be caused by the ingestion of large quantities of alcohol. NSAIDs act by interfering with prostaglandin synthe- sis, while alcohol causes direct damage to the gastric mucosa, particularly at higher concentrations. Acute hemorrhagic gastropathy is characterized by a hyper- emic edematous mucosa with erosions and active bleeding. As the diagnosis is usually realized from the clinical context, gastric biopsies are rarely obtained. Nevertheless, in immuno- compromised patients, it may be prudent to obtain biopsies to look for evidence of infection such as cytomegalovirus. Similarly, if hemorrhagic gastropathy is encountered outside of an expected clinical setting, biopsy to exclude a diffuse process like lymphoma or carcinoma should be performed. Vascular gastropathies This heterogeneous group of conditions is characterized by alterations in the gastric circulation and their effects on the gastric mucosa. From a morphologic and pathogenetic view- point, gastric antral vascular ectasia (GAVE) and portal hyper- tensive gastropathy are the best characterized. Gastric antral vascular ectasia (GAVE) GAVE, or “watermelon stomach,” is a condition of unknown etiology frequently associated with atrophic gastritis, connec- tive tissue disorders (particularly scleroderma), and some- times portal hypertension. More than 70% of reported cases have occurred in women older than 65 years of age. Occult Interestingly, reactive gastropathy is only seen in 10–45% of those who take NSAIDs regularly. Biopsies at the edges of gastric erosions and ulcers often reveal the features of reactive or chemical gastropathy, even in settings other than those of NSAID ingestion. Figure 33.6  Reactive (“chemical”) gastropathy. Hyperplastic “corkscrew” gastric foveolae and absence of inflammation: these features are seen in up to 45% of patients on chronic NSAIDs and in alkaline reflux gastropathy. They are virtually always present in the gastric mucosa adjacent to a Bilroth II anastomotic site. Histopathologic changes associated with reactive gastropathy include: •	 Epithelial regeneration. •	 Foveolar hyperplasia. •	 Edema of the lamina propria. •	 Proliferation of the smooth muscle fibres from the muscula- ris mucosae into the upper third of the mucosa (Figure 33.6). However, both the specificity and predictive value of these features are low, and the diagnosis rests on the integration of clinical and histopathologic data [36]. When reactive gastropa- thy is found unexpectedly in a biopsy of normal-appearing gastric mucosa sampled to exclude H. pylori, the clinician should solicit a history that might reveal the etiology, usually chronic NSAID use or symptoms compatible with bile reflux. Hawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated. Created from yonseimed-ebooks on 2024-05-29 06:58:08. Copyright © 2012. John Wiley & Sons, Incorporated. All rights reserved.",5045,740,1261.25,"[-0.13460462 -0.30543458 -1.090812   ... -0.06735549  0.19284636
 -1.1169331 ]"
103,"Chapter 33:  Gastritis 245 Upper GI Tract nized and better understood. The three classic types of hyper- trophic gastropathy are: 1.	 Superficial foveolar (mucous neck region) hyperplasia with normal or atrophic deep oxyntic glands.2.	 Hyperplasia of oxyntic glands with a largely unaffected mucous neck region.3.	 A mixed type, in which both mucous neck and oxyntic glands show variable degrees of hyperplasia. Type 1 corresponds to Ménétrier’s disease, Type 2 to Zollinger- Ellison syndrome (see Chapter 112), and Type 3 incorporates a variety of conditions that may result from mixed glandular and foveolar hyperplasia, including: •	 infections (e.g., H. pylori infection, cytomegalovirus in chil- dren, syphilis) •	 other diseases of uncertain etiology such as: –	 lymphocytic gastritis –	 eosinophilic gastroenteritis –	 sarcoidosis and –	 Cronkhite-Canada syndrome. Ménétrier’s disease This rare condition is defined as an idiopathic diffuse enlarge- ment of the gastric folds largely confined to the gastric body and fundus. When well established, the massive foveolar cell (mucous neck region) hyperplasia is associated with underly- ing loss of parietal and chief cells. The amount of inflamma- tion is variable; some patients have multifocal superficial erosions whereas others have polypoid configurations of the hypertrophic mucosa. When accompanied by chronic active inflammation or intraepithelial lymphocytic infiltration, the large-fold variant of H. pylori gastritis or lymphocytic gastritis should be considered. Clinical features Most patients are men in their fifth or sixth decade who present with weight loss, epigastric and abdominal pain, nausea, and vomiting. The disease evolves over several years or decades, and eventually patients develop severe hypoalbu- minemia as a consequence of the chronic protein loss. Child- hood Ménétrier’s disease is due to gastric cytomegalovirus infection, which may sometimes produce localized hyper- trophic gastropathy in the gastric antrum or body of immu- nocompromised adults. Pathology Protein loss is caused by the large amounts of mucus and fluid secreted by hyperplastic foveolar cells. Hypochlorhydria is the rule in well-established cases. The pathogenesis is unknown, but it has been hypothesized that overproduction of transforming growth factor (TGF)α might explain several of the disturbances occurring in Ménétrier’s disease. TGF, a mediator of gastric mucosal homeostasis produced by the bleeding with iron deficiency anemia is present in almost 90% of patients, with melena or hematemesis in 60%. The pictur- esque name was inspired by the endoscopic appearance of “longitudinal antral folds seen converging on the pylorus, con- taining visible and ectatic vessels resembling the stripes on a watermelon.”The prominent dilated vessels have also been compared to a large flat mushroom or honeycomb [38]. Histopathology The lamina propria is expanded by smooth muscle prolifera- tion and fibrosis, and contains dilated mucosal capillaries whose cross-sectional area is of the caliber of adjacent antral glands. Fibrin thrombi are characteristically found within at least some of the dilated capillaries. Other localized conditions (e.g., gastric hyperplastic inflammatory polyps) may share some of these histopathologic characteristics; therefore, a diag- nosis is possible only if there is appropriate endoscopic  correlation. Sometimes the degree of histologic changes, par- ticularly dilated capillaries, is minimal relative to the striking endoscopic appearance. This may be due to shrinkage of the vessels in biopsies with formalin fixation, and also reflects the fact that the primary and most striking leashes of abnormal vessels are in the submucosa. Treatment Endoscopic obliteration of the dilated vessels by electrocoagu- lation or argon plasma coagulation is effective and has greatly reduced the need for antrectomy. Recurrence (and the need for retreatment) is not uncommon. Because atrophic gastritis is a common accompaniment, patients with watermelon stomach should have biopsies taken from the mid-body greater curvature. If atrophic gastritis is present, the patient should be monitored for the development of vitamin B12 deficiency and dysplasia [39]. Portal hypertensive gastropathy A proportion of patients with cirrhosis of the liver (see Chapter 97) have dilatation of the gastric mucosal vessels, more promi- nent in the proximal stomach; its prevalence parallels the severity of portal hypertension. Bleeding is relatively uncom- mon and rarely severe, except in patients with severe portal hypertension (see Chapter 97). The endoscopic appearance of portal hypertensive gastropathy (variously described as snake skin, mosaic, scarlatina rash, and cherry-red spots) is nonspe- cific and does not correlate well with the degree of portal hypertension. Because of the understandable reluctance to biopsy the stomach of a patient with apparent portal hyper- tensive gastropathy, the contribution of histopathology to the diagnosis of portal hypertensive gastropathy is of negligible importance. Hypertrophic gastropathies The classic description of hypertrophic gastropathies pro- posed by Ming is still useful because it serves as a scaffold that can be adapted to new and existing entities as they are recog- Hawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated. Created from yonseimed-ebooks on 2024-05-29 06:58:08. Copyright © 2012. John Wiley & Sons, Incorporated. All rights reserved.",5614,811,1403.5,"[ 0.6566619  -0.1668719  -0.7986742  ... -0.23439643  0.00897832
 -0.68860704]"
104,"Part 2: Diseases of the Gut and Liver 246 Upper GI Tract   9.  Yamaoka Y, Kato M, Asaka M. Geographic differences in gastric cancer incidence can be explained by differences between Heli­ cobacter pylori strains. Intern Med.2008;47:1077–1083.10.  Yamaoka Y, Ojo O, Fujimoto S, et al. Helicobacter pylori outer membrane proteins and gastroduodenal disease. Gut.2006;55: 775–781.11.  Isaacson PG, Du MQ. MALT lymphoma: from morphology to molecules. Nat Rev Cancer.2004;4:644–653.12.  Correa P. A new paradigm for human carcinogenesis. J Clin Gastroenterol.2000;30:341–342.13.  Cover TL, Blaser MJ. Helicobacter pylori in health and disease. Gastroenterology.2009;136:1863–1873.14.  Genta RM, Hamner HW, Graham DY. Gastric lymphoid follicles in Helicobacter pylori infection: frequency, distribution, and response to triple therapy. Hum Pathol.1993;24:577–583.15.  Correa P, Piazuelo MB. Natural history of Helicobacter pylori infection. Dig Liver Dis.2008;40:490–496.16.  Sepulveda AR, Graham DY. Role of Helicobacter pylori in gastric carcinogenesis. Gastroenterol Clin North Am.2002;31:517–35, x. 17.  Malfertheiner P, Megraud F, O’Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut.2007;56:772–781.18.",1278,166,319.5,"[ 0.72234994 -0.2901104  -1.4008682  ...  0.11865091 -0.47604626
 -1.4684767 ]"
104,"Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol.2007;102:1808–1825.19.  Graham DY, Yamaoka Y. One- or two-week triple therapy for Helicobacter pylori: questions of efficacy and inclusion of a dual therapy treatment arm. Gut.2007;56:1021–1023.20.  Francavilla R, Lionetti E, Cavallo L. Sequential treatment for Helicobacter pylori eradication in children. Gut.2008;57:1178.21.  Marshall B. Sequential therapy for Helicobacter pylori: a worth- while effort for your patients. Ann Intern Med.2008;148:962–963.22.  Jafri NS, Hornung CA, Howden CW. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann Intern Med. 2008;148:923–931.23.  Toh BH, van D, I, Gleeson PA. Pernicious anemia. N Engl J Med. 1997;337:1441–1448.24.  Marshall AC, Alderuccio F, Murphy K, et al. Mechanisms of gastric mucosal cell loss in autoimmune gastritis. Int Rev Immunol.2005;24:123–134.25.  Amedei A, Bergman MP, Appelmelk BJ, et al. Molecular mimicry between Helicobacter pylori antigens and H+, K+ -adenosine tri- phosphatase in human gastric autoimmunity. J Exp Med. 2003;198:1147–1156.26.  Appelmelk BJ, Faller G, Claeys D, et al. Bugs on trial: the case of Helicobacter pylori and autoimmunity. Immunol Today.1998;19: 296–299.27.  Negrini R. Is autoimmunity involved in the relationship between Helicobacter pylori infection, atrophic gastritis and gastric cancer?",1518,202,379.5,"[ 0.3017125  -0.20402026 -0.90823936 ...  0.24933559 -0.08862744
 -1.6917273 ]"
104,"Ital J Gastroenterol Hepatol.1999;31:842–845.28.  Solcia E, Rindi G, Fiocca R, et al. Distinct patterns of chronic gastritis associated with carcinoid and cancer and their role in tumorigenesis. Yale J Biol Med.1992;65:793–804.29.  Carmack SW, Genta RM, Graham DY, et al. Management of gastric polyps: a pathology-based guide for gastroenterologists. Nat Rev Gastroenterol Hepatol.2009;6:331–341.30.  Rugge M, Correa P, Dixon MF, et al. Gastric mucosal atrophy: interobserver consistency using new criteria for classification and grading. Aliment Pharmacol Ther.2002;16:1249–1259.gastric mucosa, inhibits acid secretion, stimulates mucosal repair after injury, and augments gastric mucin levels. Treatment A monoclonal antibody against the TGF receptor may hold some promise as a therapeutic agent. A variety of other treat- ments have been tried without uniform success. Occasionally, total gastrectomy is required because of the relentless hypoalbuminemia and the development of persistent ana- sarca. Ménétrier’s disease appears to be associated with an increased risk of gastric adenocarcinoma; however, given the rarity of the disorder, it is unlikely that any cogent surveillance strategy will emerge. Zollinger-Ellison syndrome (see Chapter 112) The oxyntic mucosa in Zollinger-Ellison syndrome shows hyperplasia of the oxyntic compartment due to the trophic effect of circulating gastrin. As with atrophic gastritis, the hypergastrinemia can also stimulate proliferation of the ECL cells of the oxyntic mucosa, ranging from hyperplasia to the formation of gastric carcinoids. Iatrogenic gastritis and gastropathies Injury due to NSAIDs (hemorrhagic gastritis, erosion, ulcer, and reactive gastropathy) has been discussed above. However, a variety of therapeutic agents, including radioactive and chemical, administered orally, intravenously, and intra- arterially, can also cause damage to the gastric mucosa that is detectable endoscopically and histologically. References   1.  Marshall BJ. The 1995 Albert Lasker Medical Research Award. Helicobacter pylori. The etiologic agent for peptic ulcer. JAMA. 1995;274:1064–1066.  2.  Dixon MF, Genta RM, Yardley JH, et al. Classification and grading of gastritis. The updated Sydney System. International workshop on the histopathology of gastritis, Houston 1994. Am J Surg Pathol.1996;20:1161–1181.  3.  Fennerty MB. Helicobacter pylori: why it still matters in 2005. Cleve Clin J Med.",2440,333,610.0,"[ 0.30839682 -0.33106065 -0.8219712  ...  0.33763236 -0.0710405
 -1.4810705 ]"
104,"2005;72 Suppl 2:S1–7; discussion S14–21.  4.  Stolte M, Kroher G, Meining A, et al. A comparison of Helico­ bacter pylori and H. heilmannii gastritis. A matched control study involving 404 patients. Scand J Gastroenterol.1997;32: 28–33.  5.  Elitsur Y, Adkins L, Saeed D, et al. Helicobacter pylori antibody profile in household members of children with H. pylori infec- tion. J Clin Gastroenterol.1999;29:178–182.  6.  Luzza F, Mancuso M, Imeneo M, et al. Evidence favouring the gastro-oral route in the transmission of Helicobacter pylori infection in children. Eur J Gastroenterol Hepatol.2000;12:623– 627.  7.  Malaty HM, Graham DY, Wattigney WA, et al. Natural history of Helicobacter pylori infection in childhood: 12-year follow-up cohort study in a biracial community. Clin Infect Dis.1999;28: 279–282.  8.  Weyermann M, Adler G, Brenner H, et al. The mother as source of Helicobacter pylori infection. Epidemiology.2006;17:332–334. Hawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated. Created from yonseimed-ebooks on 2024-05-29 06:58:08. Copyright © 2012. John Wiley & Sons, Incorporated. All rights reserved.",1245,181,311.25,"[ 0.2030717   0.30772156 -1.2479105  ...  0.38971907 -0.01615607
 -1.3465005 ]"
105,"Chapter 33:  Gastritis 247 Upper GI Tract 35.  Genta RM. Differential diagnosis of reactive gastropathy. Semin Diagn Pathol.2005;22:273–283.33.  El-Zimaity HM, Genta RM, Graham DY. Histological features  do not define NSAID-induced gastritis. Hum Pathol.1996;27: 1348–1354.37.  Laine L, Weinstein WM. Subepithelial hemorrhages and ero- sions of human stomach. Dig Dis Sci.1988;33:490–503.38.  Gostout CJ, Viggiano TR, Ahlquist DA, et al. The clinical and endoscopic spectrum of the watermelon stomach. J Clin Gastro­ enterol.1992;15:256–263.39.  Labenz J, Borsch G. Bleeding watermelon stomach treated by Nd-YAG laser photocoagulation. Endoscopy.1993;25:240–242.31.  Carmack SW, Lash RH, Gulizia JM, et al. Lymphocytic disorders of the gastrointestinal tract: a review for the practicing patholo- gist. Adv Anat Pathol.2009;16:290–306.32.  Haot J, Berger F, Andre C, et al. Lymphocytic gastritis versus varioliform gastritis. A historical series revisited. J Pathol.1989; 158:19–22.33.  Ectors NL, Dixon MF, Geboes KJ, et al. Granulomatous gastritis: a morphological and diagnostic approach. Histopathology.1993; 23:55–61.34.  Shapiro JL, Goldblum JR, Petras RE. A clinicopathologic study of 42 patients with granulomatous gastritis.",1233,160,308.25,"[ 0.37338275 -0.04039353 -0.97819567 ...  0.32915482  0.21043725
 -0.8909204 ]"
105,"Is there really an “idiopathic” granulomatous gastritis?Am J Surg Pathol.1996; 20:462–470. Hawkey, C. J., Bosch, J., Richter, J. E., Garcia-Tsao, G., & Chan, F. K. L. (Eds.). (2012). Textbook of clinical gastroenterology and hepatology. John Wiley & Sons, Incorporated. Created from yonseimed-ebooks on 2024-05-29 06:58:08. Copyright © 2012. John Wiley & Sons, Incorporated. All rights reserved.",395,56,98.75,"[ 0.11422442 -0.05952273 -0.84146833 ...  0.52699953 -0.2642507
 -1.2595035 ]"
106,"Gastrointestinal bleeding is a medical emergency and represents the most common cause of hospitalizations associated with digestive diseases in most countries1,2. Upper gastrointestinal bleeding (UGIB) is defined by any gastrointestinal bleeding above the ligament of Treitz, which includes the oesophagus, stomach and proximal duodenum. By contrast, middle and lower gastrointesti­ nal bleeding originate in the small bowel below the liga­ ment of Treitz or in the colorectum3. UGIB events can be classified as non-variceal UGIB (NVUGIB) and variceal UGIB (VUGIB). NVUGIB is most often caused by peptic ulcers (a break of the mucosal barrier that exposes the submucosa to the damaging effects of acid and pepsin present in the gastroduodenal lumen), which are com­ monly associated with Helicobacter pylori infection and the use of NSAIDs (including aspirin doses of ≥500 mg) or low-dose aspirin (LDA; which is a dose of ≤325 mg but is typically 75–100 mg). By contrast, VUGIB is caused by oesophageal or gastric varices (dilated sub­mucosal veins), which are usually associated with chronic liver diseases and/or portal hypertension. The incidence of NVUGIB in most countries is fivefold higher than that of VUGIB (BOX 1), and NVUGIB represents a serious clinical ­challenge with considerable mortality4. In this Primer, we focus on NVUGIB in the com­ munity setting, which is more common and less severe than NVUGIB in inpatient hospital settings, which occurs in association with hospitalizations due to other serious conditions (such as neurological, renal, cardiac, pulmonary, metabolic, traumatic or septic conditions). Although both conditions are life threatening, the mortality associated with NVUGIB is fourfold higher in patients who develop bleeding in the hospital than in those who develop bleeding in the community setting4,5. Epidemiology The most common cause of NVUGIB is gastroduo­ denal peptic ulcers followed by gastroduodenal ero­ sions, ­peptic oesophageal lesions (oesophagitis or oesophageal ulcers), vascular lesions (such as Dieulafoy lesions; a medical condition associated with an abnormal tortuous arteriole that penetrates into the gastrointesti­ nal mucosa) and vascular ectasias such as angio­dys­ plasia (a small vascular malformation in the gut)), Mallory–Weiss tears (lacerations in the mucosa at the gastro-­oesophageal junction that occur associated with recurrent vomiting often after excessive alcohol intake or a heavy meal) and, less often, neoplastic lesions6,7. Correspondence to A. L. Service of Digestive Diseases, University Clinic Hospital Lozano Blesa, University of Zaragoza, IIS Aragón, Zaragoza, Spain.alanas@unizar.es Article number: 18020 doi:10.1038/nrdp.2018.20 Published online 19 Apr 2018 Non-variceal upper gastrointestinal bleeding Angel Lanas1,2, Jean-Marc Dumonceau3, Richard H. Hunt4, Mitsuhiro Fujishiro5, James M. Scheiman6, Ian M. Gralnek7, Helen E. Campbell8, Alaa Rostom9, Càndid Villanueva2,10 and Joseph J. Y. Sung11 Abstract | Non-variceal upper gastrointestinal bleeding (NVUGIB) is bleeding that develops in the oesophagus, stomach or proximal duodenum. Peptic ulcers, caused by Helicobacter pylori infection or use of NSAIDs and low-dose aspirin (LDA), are the most common cause. Although the incidence and mortality associated with NVUGIB have been decreasing owing to considerable advances in the prevention and management of NVUGIB over the past 20 years, it remains a common clinical problem with an annual incidence of ~67 per 100,000 individuals in the United States in 2012. NVUGIB is a medical emergency, and mortality is in the range ~1–5%. After resuscitation and initial assessment, early (within 24 hours) diagnostic and therapeutic endoscopy together with intragastric pH control with proton pump inhibitors (PPIs) form the basis of treatment. With a growing ageing population treated with antiplatelet and/or anticoagulant medications, the clinical management of NVUGIB is complex as the risk between gastrointestinal bleeding events and adverse cardiovascular events needs to be balanced. The best clinical approach includes identification of risk factors and prevention of bleeding; available strategies include continuous treatment with PPIs or H. pylori eradication in those at increased risk of developing NVUGIB. Treatment with PPIs and/or use of cyclooxygenase‑2‑selective NSAIDs should be implemented in those patients at risk of NVUGIB who need NSAIDs and/or LDA. NATURE REVIEWS | DISEASE PRIMERS	 VOLUME 4 | ARTICLE NUMBER 18020 | 1 PRIMER ©  2018  M acm illan  Publishers  Lim ited,  part  of  Springer  Nature. All  rights  reserved.",4634,657,1158.5,"[-0.02308598 -0.31412828 -1.394659   ... -0.37214756  0.39901185
 -1.1188341 ]"
107,"Important developments in medicine in the past 20 years have affected the incidence and outcomes of NVUGIB. On the one hand, the introduction of potent medications to suppress acid secretion, the recognition of H. pylori as an important aetiological factor of peptic ulcers with subsequent eradication therapy, the progress in diag­ nostic and therapeutic endoscopy, the introduction of restrictive blood transfusion policies and improvements in the management of critically ill patients are key fac­ tors that have reduced the risk of developing NVUGIB and have improved the management and outcomes8–11. On the other hand, some risk factors are becoming more common, including an ageing population (which results in increasing prevalence of cardiovascular dis­ eases and other comorbidities that increase the risk of mortality associated with NVUGIB) and the increas­ ing use of LDA, NSAIDs and other antiplatelet and anticoagulant agents8–11. Incidence The overall incidence of NVUGIB, particularly bleeding events associated with peptic ulcers (that is, peptic ulcer bleeding (PUB)), has decreased during the past 20 years and has now stabilized globally9,12,13. In the United States, the incidence of NVUGIB associated with any cause has decreased from 78.4 per 100,000 individuals in 2001 to 60.6 per 100,000 individuals in 2009 (P = 0.004), and the incidence of PUB has decreased from 48.7 per 100,000 individuals in 2001 to 32.1 per 100,000 individuals in 2009 (P <0.001) on the basis of hospital discharge data9,14. More recent data also show a 21% decrease in the inci­ dence of NVUGIB from 2002 to 2012, from 81 to 67 cases per 100,000 individuals15. Similar trends have been reported in Europe (FIG. 1), with an incidence of NVUGIB of ~55–60 per 100,000 people in the 1990s to ~25–35 per 100,000 people in the early 2000s16–19. However, data are difficult to compare between stud­ ies owing to variability in the methodology used. Time trends of NVUGIB are less well documented outside Europe and the United States, but a few studies show a similar decline in incidence20. Although differences in incidence might be evident between ethnicities, studies are limited21. For example, in New Zealand, age-adjusted incidence seems higher among people of Maori descent than in those of European descent (91.3 versus 37.0 per 100,000 ­individuals, rate ratio of 2.47, P <0.001)22. Causes of NVUGIB The causes of NVUGIB have changed over time. Erosive gastritis as a cause of NVUGIB declined by 55% in the United States between 2001 and 2009 and peptic ulcers as a cause declined by 30%. By contrast, NVUGIB due to neoplasm increased by 50%, as did Dieulafoy lesions (33%), angiodysplasia (32%) and oesophagitis (20%)15. The decreased incidence of PUB in developed countries is linked to a decreased prevalence of H. pylori and an increased use of gastric-acid-suppressing drugs, which protects against peptic ulcer diseases3. Globally, the life­ time prevalence of peptic ulcer disease in the general population has been estimated at ~5–10% and the inci­ dence at 0.1–0.3% per year3,11–13. However, despite the decrease in PUB in the general population in developed countries, the incidence of PUB in elderly individuals is increasing (on the basis of hospital admissions for ulcer complications), which can probably be attributed to the ageing population3,18,23. Overall, compared with decades ago, fewer individuals with PUB are positive for H. pylori, whereas PUB associated with NSAID use or not related to either NSAIDs or H. pylori has increased24,25. In a multicentre study in France, 40% of PUB events were related to H. pylori infection, 18.7% to gastrotoxic drug use, 19.8% to both factors and 21.6% were unrelated to either H. pylori infection or gastrotoxic drug use26. Similar trends can be observed in some Asian popu­ lations. In 2001, one study conducted in Hong Kong reported that only 4.1% of PUB cases were unrelated to NSAID use, LDA use or H. pylori infection, whereas the remaining 51.9% of cases were related to H. pylori infection and 44% to NSAID or LDA use27. However, other studies conducted more recently have reported rates of idiopathic peptic ulcers of 23.5% in Korea28 and 13.8–18.8% in Hong Kong29,30. In a 2014 review, the prevalence of idiopathic ulcers in Asia was reported as 10–30% since the year 2000 (REF. 31). Mortality Overall global mortality associated with NVUGIB has decreased over time6,13. A large case–control study including >500,000 individuals with NVUGIB in England showed that mortality within 28 days of hos­ pital admission significantly decreased from 14.7% in 1999 to 13.1% in 2007, even after adjusting for age, sex and comorbidities32. Large observational studies docu­ mented an improvement in survival in the United States across various age groups along a similar time range9,33,34. Mortality associated with gastric and duo­denal ulcers also declined in Argentina, Australia, Chile, Hong Kong, Japan, Mexico, Singapore and Taiwan between 1971 and 2004 (REF. 20). Interestingly, mortality associ­ ated with gastric ulcers compared with duodenal ulcers Author addresses 1Service of Digestive Diseases, University Clinic Hospital Lozano Blesa, University of Zaragoza, IIS Aragón, Zaragoza, Spain.2Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Madrid, Spain.3Gedyt Endoscopy Center, Buenos Aires, Argentina.4Division of Gastroenterology and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada.5Department of Endoscopy and Endoscopic Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.6Division of Gastroenterology, University of Virginia, Charlottesville, VA, USA.7Ellen and Pinchas Mamber Institute of Gastroenterology, Emek Medical Center, Afula, Israel.8National Perinatal Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.9Division of Gastroenterology, University of Ottawa, Ottawa, Ontario, Canada.10Hospital de la Santa Creu i Sant Pau, Universitat Autónoma de Barcelona, Barcelona, Spain.11Division of Gastroenterology, The Chinese University of Hong Kong, Hong Kong, China. PRIMER 2 | ARTICLE NUMBER 18020 | VOLUME 4	 www.nature.com/nrdp ©  2018  M acm illan  Publishers  Lim ited,  part  of  Springer  Nature. All  rights  reserved.",6358,941,1589.5,"[-0.03507452 -0.3854046  -1.5724044  ... -0.33829764  0.522118
 -1.4621608 ]"
108,"was threefold higher in Mexico, twofold higher in Argentina and Chile and only slightly higher in Taiwan and Singapore, whereas no difference was observed in Hong Kong. Despite these improvements, mortality associ­ ated with NVUGIB remains high, with values varying between different studies and stable, non-­decreasing ­values over time in some countries (for example, Spain)17. A systematic review of 18 studies showed mortality of NVUGIB ranging from 1.1% in Japan to 11% in Denmark, although most studies included in the review placed that figure closer to 5%35. These dis­ crepancies in the reported mortality of NVUGIB are attributable to differences in study methodologies and populations studied. Improvement in NVUGIB outcomes is likely due to factors such as advances in endoscopic and med­ ical manage­ment and improvements in emergency and critical care or geriatric medicine8,10,11. Risk factors for mortality linked to NVUGIB include increased age, comorbidities (such as respiratory or cardiac insufficiency, renal failure and sepsis), severe haemo­ dynamic instability or develop­ment of further bleed­ ing36. However, at present, most deaths associated with NVUGIB are not due to uncontrolled bleeding but are the consequence of complications induced by bleeding (for example, organ ­failure), comorbidities or older age4. Mechanisms/pathophysiology The mechanisms involved in the development of NVUGIB are not well understood. The mucosal ­barrier and submucosal blood vessels must be damaged for the bleeding event to occur. Disruption of the mucosal ­barrier is commonly associated with H. pylori infection and/or NSAID or LDA use, but exposure of the blood vessels to the luminal content can also be the conse­ quence of causes such as Mallory–Weis syndrome, vascular lesions and neoplastic lesions. Whatever the cause, exposure of the underlying blood vessels to the action of acid and pepsin further erodes the vessel wall and interferes with blood coagulation3 (FIG. 2). Mucosal damage H. pylori infection. Mucosal damage and ulcer forma­ tion are considered to be consequences of the inter­ action between H. pylori and the host immune response. H. pylori strains show genetic diversity, but those that exhibit a cag pathogenic island encoding virulence fac­ tors such as cytotoxicity-associated immunodominant antigen (CagA), vacuolating cytotoxin autotransporter (VacA), blood group antigen-binding adhesin (BabA) or outer inflammatory protein adhesin (OipA) strongly induce the host immune response3,37,38. This immune response is initiated in the gastric epithelium, where these bacterial virulence factors elicit an intracellu­ lar cascade of events that activate kinases involved in the regulation of cell growth and differentiation and the nuclear factor-κB (NF-κB) signalling pathway. Cytokines that have a key role in the immune and inflammatory response to H. pylori infection include IL‑1β, IL‑1 recep­ tor antagonist protein (IL1RN), tumour necrosis factor (TNF), IL‑6, IL‑8 and IL‑10 (REFS 3,38). H. pylori induces different types of lesions in the ­lining of the stomach and duodenum, most commonly mild asymptomatic gastritis. Pan-gastritis is associ­ ated with hyposecretion of gastric acid and is linked to the development of gastric ulcers. However, some patients develop an antrum-predominant gastritis that is associ­ated with duodenal ulcers and increased ­gastric acid secretion due to hypersecretion of gastrin and hypo­secretion of somatostatin3,39. Gastric acid hyper­ secretion in antrum-­predominant gastritis is associated with the development of gastric metaplasia in the duo­ denal bulb, which may be colonized by H. pylori and favour ulcer formation3,40. NSAID and LDA use. Studies have shown that NSAIDs and LDA induce damage to the gastroduodenal mucosa by both systemic and local effects41. Locally, NSAIDs and LDA can decrease the hydrophobicity of the mucous layer owing to their amphiphilic properties, thereby exposing the underlying epithelium to luminal acid and pepsin. NSAIDs also uncouple mitochondrial oxid­ative phosphorylation in the epithelial cells, lead­ ing to cellular dysfunction with decreased levels of ATP and glutathione, mitochondrial swelling, generation of free radicals, calcium release into the cytosol and, eventually, loss of integrity of tight junctions, apop­tosis and cell death, all contributing to increased mucosal ­permeability and disruption. The local effects of NSAIDs depend on their acid dissociation constant; acidic NSAIDs are not ionized at the low pH of the gastric lumen and can, therefore, be absorbed by epithelial cells, where they become ‘trapped’ because of the neutral intracellular pH. The ability of an NSAID to uncouple mitochondrial oxid­ ative phosphoryl­ation (that is, its uncoupling potency) is also directly proportional to its acid dissociation Box 1 | Variceal upper gastrointestinal bleeding Variceal upper gastrointestinal bleeding (VUGIB) is due to portal hypertension and/or chronic liver diseases and in most cases is associated with liver cirrhosis. Presentation often involves vomiting large amounts of ‘fresh’ red blood. The first-line therapy combines vasoactive drugs and variceal ligation. Drugs with vasoactive properties, such as terlipressin, somatostatin or octreotide, should be given as soon as acute VUGIB is suspected. Upper gastrointestinal endoscopy should be performed within the first 12 hours after admission once haemodynamic stability has been achieved to ascertain the cause of haemorrhage; when VUGIB is confirmed, ligation should be performed within the same procedure. Early pre-emptive insertion of a covered (that is, with fabric or graft material over the metal structure) transjugular intrahepatic portosystemic shunt to treat portal hypertension should be considered in patients with high risk of failure of endoscopic ligation or when failure develops. Balloon tamponade (in which an inflated balloon applies pressure to compress bleeding varices) in the oesophagus or stomach should be used in cases of uncontrolled bleeding as a temporary measure (<24 hours) until definitive treatment can be instituted. Removable, covered and self-expanding oesophageal stents are a promising alternative to balloon tamponade. Eventually, liver transplantation should be considered when bleeding is not controlled after transjugular intrahepatic portosystemic shunt insertion and when liver function has deteriorated. Peptic ulcer bleeding (that is, non-variceal bleeding) in patients with cirrhosis has a mortality similar to that of VUGIB with a similar incidence of complications and decompensation of liver disease, which account for a great proportion of fatalities201,202. PRIMER NATURE REVIEWS | DISEASE PRIMERS	 VOLUME 4 | ARTICLE NUMBER 18020 | 3 ©  2018  M acm illan  Publishers  Lim ited,  part  of  Springer  Nature. All  rights  reserved.",6896,988,1724.0,"[-0.2640167   0.08127129 -1.4444375  ...  0.18744972  0.15343542
 -1.5863589 ]"
109,"constant, with acidic NSAIDs being the most potent. Consequently, use of acidic NSAIDs (including aspirin) may need to be combined with proton pump inhibitors (PPIs) in some high-risk patients (see below); non-acidic NSAIDs (such as paracetamol) are ­considered safer for the gastrointestinal tract41. Systemically, NSAIDs contribute to mucosal dam­ age by inhibiting the prostaglandin secretion associated with cyclooxygenase 1 (COX1; also known as PTGS1) and COX2. The reduction in prostaglandin levels dis­ rupts the mucosal barrier as prostaglandins stimulate mucous and bicarbonate secretion by epithelial cells, inhibit acid secretion and promote cell proliferation and mucosal blood flow. The ischaemic effect of NSAIDs leads to increased leukocyte adherence, damaging blood ­vessels. The gastric mucosa is especially sensitive to the reduced COX1‑derived prostaglandin levels compared with other segments of the gastrointestinal tract42 for reasons that are not yet clear. COX2 is not expressed in the absence of a pre-existing lesion or H. pylori infec­ tion. However, given that H. pylori infections are fre­ quent, many patients who take NSAIDs or LDA may be infected, which seems to exacerbate the potential ­damaging effects of these drugs41,43. Bleeding Role of pH. The coagulation system is extremely sen­ sitive to minor pH changes. In vitro studies show that coagulation becomes abnormal at pH 6.8, platelet aggregation reduces by >50% at pH 6.4 and platelet aggregation and plasma coagulation are abolished and previously aggregated platelets disaggregate at a pH <5.9  (REF. 44). In addition, an increase in pH to 6.8 (or even slightly higher) induces platelet aggregation, calcium release and serotonin release from the platelets as well as normaliza­tion of the blood clotting time (meas­ ured using ­prothrombin and partial ­thromboplastin times)44 (FIG. 3). Pepsin, a proteolytic enzyme that becomes activated at pH <6, further enhances platelet disaggregation and clot disintegration44. Acid, pepsin and other proteolytic enzymes are present in abundance in the gastric lumen; these circumstances make the stomach and proximal duodenum a hostile environment that facilitates contin­ ued bleeding once the blood vessel is breached. Thus, the medical treatment of bleeding lesions aims at attempt­ ing to keep the gastric pH above the proteolytic range for pepsin (that is, pH >6). Current medical treatment with a high-dose PPI is able to achieve this pH target45–47. As PPIs suppress acid secretion by covalent binding of the protonated drug to activated proton pumps, which are at rest in the cytoplasm in the fasting patient, the use of PPI therapy provides highly effective pH control following endoscopic treatment. Some studies have shown clinical benefits of main­ taining an intragastric pH >6 during the bleeding epi­ sode. A meta-analysis48 showed a significant decrease in further bleeding, need for surgery and mortality among patients with high-risk bleeding ulcers after endoscopic therapy and high-dose continuous infusion with PPIs when compared with placebo. Inhibition of platelets. In addition to mucosal damage, NSAIDs and LDA might also contribute to bleeding by inhibiting the formation of thromboxane A2 in platelets. Platelet COX1‑derived thromboxane A2 is activated to control bleeding following damage to blood vessels (FIG. 2). A similar mechanism has been proposed for non-aspirin antiplatelet agents49. Some have questioned the mucosal-damaging ­capacity of LDA and have suggested that the role of LDA in NVUGIB is mainly due to its antiplatelet effect. In this context, the antiplatelet effect would be similar to that of anticoagulants such as vitamin K antagonists, which do not produce mucosal damage but may induce severe bleeding of gastrointestinal lesions caused by other agents (such as NSAIDs and H. pylori). If so, LDA and non-aspirin antiplatelet agents would induce bleeding only in patients with pre-existing lesions. This hypoth­ esis is supported by one study involving individuals with osteoarthritis, in whom the rate of peptic ulcers did not differ between those taking LDA and those ­taking ­placebo50. However, this finding must be interpreted with caution because other studies have shown that even LDA can damage the gastrointestinal mucosa42. Another intriguing question is why NSAIDs and LDA have a universal effect on platelet and COX inhib­ition, but only 1 in 1,000 individuals51 receiving these agents eventually develop NVUGIB, prompting an examin­ ation of susceptibility factors. One study found that some patients who developed a bleeding event after LDA use were hyper-responsive to the drug, as demonstrated by an abnormal prolonged bleeding time due to an ­unexplained intrinsic defect, subclin­ical von Willebrand disease (in which the clotting protein von Willebrand factor (vWF) is missing or defective) or abnormalities in aspi­ rin metabolism52. Polymorphisms in genes encoding proteins involved in drug metabolism, mucosal defence or coagulation have been proposed to increase the risk of PUB in NSAID or LDA users, but more studies are needed before these factors can be taken into account for clinical purposes3,53. Nature Reviews | Disease Primers Change in the incidence of NVUGIB (%) –60 –50 –40 –30 –20 –10 0 Netherlands 1993–2000 Italy 2001–2010 Sweden 1987–2005 Spain 1996–2005 United States 1994–2009 New Zealand 2001–2010 Figure 1 | The decline in incidence of NVUGIB over time. Percentage decrements in the incidence of non-variceal upper gastrointestinal bleeding (NVUGIB) in different countries over different time periods as indicated. Graph based on data presented in REFS 9,11–14,16–20,22,23,218,219. PRIMER 4 | ARTICLE NUMBER 18020 | VOLUME 4	 www.nature.com/nrdp ©  2018  M acm illan  Publishers  Lim ited,  part  of  Springer  Nature. All  rights  reserved.",5870,869,1467.5,"[ 0.23263209 -0.00611138 -1.4010326  ...  0.5419635   0.48773515
 -1.4155623 ]"
110,"Mallory–Weiss syndrome. In Mallory–Weiss syn­ drome, mucosal disruption and laceration result from several factors, including a rapid increase of pressure in the upper part of the stomach (the cardia)54,55. The consequent hyperextension of the stomach limits the mobility between the mucosa and submucosa, resulting in insuffi­cient closure of the cardia. Furthermore, dis­ coordinated muscle contractions of the different layers in the lower part of the oesophagus and cardia, together with the longitudinal disposition of gastric mucosal folds at the gastro-oesophageal junction, lead to deep linear lacerations of the mucosa that expose submucosal vessels that are also damaged in this process. Age-related loss of collagen in the submucosal layers may contribute to loss of mucosal–submucosal mobility55. The common location of the most severe lacerations is the right lateral wall of the stomach, where the oesophagus is aligned with the lesser curvature of the stomach54 owing to dif­ ferent thicknesses and ligament arrangements of the gastric tissues55. Vascular lesions. Vascular lesions such as those that occur in Dieulafoy syndrome and vascular ectasias are associated with NVUGIB15. The Dieulafoy lesion involves an artery with an abnormally large diameter (1–3 mm) that penetrates the submucosa, runs a tor­ tuous course and protrudes into the mucosa, where a small defect with fibrinoid necrosis initiates a subse­ quent severe bleeding event. The bleeding lesion may be induced by local thrombosis or by ischaemia in the artery due to pulsation of the vessel, which damages the overlying epithelium and exposes the vessel to the gastrointestinal lumen. Dieulafoy and vascular lesions often occur in elderly individuals and are associated with severe comorbidities56. Bleeding from vascular ectasias such as angiodys­ plasia of the stomach may have a similar pathogenetic profile as Dieulafoy lesions. Intermittent submucosal venous obstruction, intermittent arterial blood flow and local vascular degeneration with local hypox­aemia and vascular endothelial growth factor-dependent proliferation have been proposed as being involved in these bleeding events. Association with cardiac, renal and other comorbidities is also common. Vascular ­ectasias, often multiple or diffuse, predominantly occur in the gastric antrum, which may be linked with the more vigor­ous muscular contraction of the antrum, ­predisposing to venous obstruction57,58 (FIG. 4). Other comorbidities. Several non-gastrointestinal comorbidities are independent risk factors for developing NVUGIB59; the mechanisms involved depend on the type of comorbidity. Reduced mucosal microperfusion and hypoxia can be important in patients with heart failure60; furthermore, chronic hypoxia and increased concentra­ tion of mucosal free radicals, corresponding to systemic inflammation, have been identified as important fac­ tors in patients with chronic pulmonary obstruction61, Greater curvature Lesser curvature Nature Reviews | Disease Primers Submucosal artery H. pylori Mucous Necrotic cell Activated platelets Aspirin Platelets NSAIDs LDA Local eﬀects Acid Pepsin Body Duodenum Oesophagus Ligament of Treitz Mucosal break Bleeding Gastric lumen ↓ Cell proliferation ↓ HCO3– secretion ↓ Mucus Systemic eﬀects ↓ COX1 ↓ Prostaglandins Mucosal damage Blood clot Inhibition of thrombosis ↓ pH Fundus Antrum Cardia Inﬂammatory response H. pylori Figure 2 | Mechanisms of upper gastrointestinal bleeding induced by NSAIDs, LDA or H. pylori infection. NSAIDs (including aspirin doses of ≥500 mg) or low-dose aspirin (LDA; which is a dose of ≤325 mg but is typically 75–100 mg) induce a break in the mucosa by acting both locally and systemically, whereas Helicobacter pylori damages the epithelial barrier by inducing a cytokine-mediated host immune response. Once the mucosal barrier is disrupted, the underlying blood vessels are exposed to gastric acid and pepsin, which affect blood vessel integrity and can induce bleeding. Platelets and the coagulation system, which should be activated to stop the bleeding, are inhibited by the low pH and pepsin. In addition, platelet cyclooxygenase 1 (COX1) activity suppression by LDA inhibits thromboxane formation and, therefore, platelet aggregation and clot formation. HCO3 −, bicarbonate. PRIMER NATURE REVIEWS | DISEASE PRIMERS	 VOLUME 4 | ARTICLE NUMBER 18020 | 5 ©  2018  M acm illan  Publishers  Lim ited,  part  of  Springer  Nature. All  rights  reserved.",4487,650,1121.75,"[-0.17462562 -0.42381904 -1.1295868  ... -0.45653045 -0.10772625
 -0.9903944 ]"
111,"whereas platelet and clotting dysfunction, platelet–­vessel interaction and haemodynamic instability are mech­ anisms involved in end-stage renal disease-­associated gastrointestinal bleeding62. Most of these conditions are also associated with poor nutritional ­status, which, together with the common use of LDA, antiplatelet thera­ pies, anticoagulants and NSAIDs in these conditions, may contribute to gastrointestinal mucosa ­damage. Most of these mechanisms, especially those related to altered microperfusion, hypoxia, free radical concen­ tration and pH, are also involved in diffuse mucosal damage or stress ulcers in patients needing ­respiratory assistance in the intensive care setting60,61 (FIG. 4). Diagnosis, screening and prevention Prevention Risk stratification. Prevention of bleeding events is the best clinical approach in NVUGIB. A careful medical history, physical examination and laboratory investi­ gations provide the basis to identify risk factors and comorbid conditions (BOX 2) and to select a sound pre­ vention strategy, which should balance the benefits and risks of preventive measures. In NSAID and LDA users, balancing risks is especially important when cardio­vascular and gastrointestinal risk factors are both present. Some risk factors can be easily identified and prevented or discontinued63,64, whereas others are not (such as advanced age or the presence of comorbidi­ ties)59 (FIG. 4). The risk of developing bleeding increases with the presence and number of risk factors, in addi­ tion to NSAID and LDA use, and appreciation of these factors offers the opportunity to stratify patients into risk categor­ies65,66. Those taking NSAIDs or LDA with no other identified risk factors are at low risk of ulcer bleeding complications, whereas individuals with one or more risk factors have increased risk. A history of previ­ ous ulcers puts any patient ­receiving NSAIDs or LDA at high risk of NVUGIB67. Preventive strategies. The role of preventive treat­ ment has not been systematically evaluated but should be considered in patients with one or more risk factor when using NSAIDs or LDA67; however, prevention is rarely required for low-risk patients. Acid suppression with antisecretory drugs is recommended in the pres­ ence of risk factors; PPIs are preferred and are superior to histamine H2 receptor antagonists67. Prostaglandins (such as misoprostol) are cytoprotective and effec­ tive in reducing acid secretion, but at the expense of adverse events that reduce their tolerability67. In those who have a history of peptic ulcers, the risk associ­ ated with NSAID use can be modified first by treating H. pylori infection if present and then by switching to a COX2‑selective NSAID. Eradication of H. pylori infec­ tion in those taking NSAIDs or LDA can considerably reduce, although not abolish, the risk of ulcers, bleeding or re‑bleeding events68,69. Concomitant NSAID treatment with several other drugs increases the risk of developing gastrointestinal bleeding64,66,70 (BOX 2; FIG. 5), but the risk might be modi­ fied by co‑treatment with antisecretory drugs. Indeed, use of omeprazole (a PPI) while continuing clopidogrel treatment decreases the number of gastrointestinal bleeding events without an increase in cardiovascular adverse events71. Monitoring international normal­ ized ratio (INR; a parameter used to standardize pro­ thrombin time) is indicated when a PPI is started or stopped in patients on vitamin K antagonists. Indeed, the metabolism of PPIs involves the hepatic cytochrome P450 (CYP) enzyme system, which might affect metabo­ lism or activation of drugs taken concomitantly. How different PPIs interact with different CYPs might inform PPI choice. For example, the selection of pantoprazole and rabeprazole rather than other PPIs has been recom­ mended in patients taking vitamin K antagonists, but the real clinical impact of this recommendation remains to be shown72. The identification of polymorphisms lead­ ing to poor metabolism of PPIs in the CYP2C19 gene in a Japanese population could be predictive of adverse events73. These findings could also be extended to other populations, but additional studies are needed. To date, no interaction has been reported with novel direct oral anticoagulants (DOACs) and CYP enzymes. When using corticosteroids, PPI treatment should be considered if an individual has a history of peptic ulcers or in the case of combined corticosteroid and NSAID or LDA use67. Identification of a history of uncomplicated or com­ plicated ulcers should prompt a test-and-treat strategy for H. pylori infection to prevent a first-bleeding or re‑­bleeding event74,75. Identification of H. pylori infec­ tion during a bleeding event represents a clin­ical chal­ lenge, as an invasive test such as urease testing during the endoscopic procedure may provide false-­negative results owing to the presence of blood in the gastric lumen, ­inadequate sampling or the previous use of PPIs. Nature Reviews | Disease Primers Aggregation (%) 100 70 60 50 40 30 20 10 0 2 1 4 Time (minutes) 0 90 80 3 5 pH 7.4 pH 5.9 pH 6.8 A ADP Figure 3 | Effects of an acidic environment on platelet aggregation. At pH 7.4, platelet aggregation induced by ADP is normal and occurs rapidly. Arrow A denotes the time point at which the pH of plasma is decreased by the addition of hydrochloric acid in an experimental setting. At pH 6.8, platelet aggregation is negatively affected, and at pH 5.9, it is completely abolished. Adapted with permission from REF. 44. PRIMER 6 | ARTICLE NUMBER 18020 | VOLUME 4	 www.nature.com/nrdp ©  2018  M acm illan  Publishers  Lim ited,  part  of  Springer  Nature. All  rights  reserved.",5698,861,1424.5,"[-0.4451006  -0.06995027 -1.600173   ...  0.04755723  0.45185548
 -1.1788555 ]"
112,"Histological analysis and/or culture of biopsy speci­ mens may also provide false-negative results76. In this clinical scenario, the presence of H. pylori infection should be tested or retested if negative after ulcer healing (4–8 weeks after the bleeding event) with patients being off PPI for at least 7 days and no antibiotic therapy the month before. A positive test should prompt eradication therapy with a confirmatory negative test performed at least 1 month after therapy3,75,76. Diagnosis In clinical practice, the diagnosis and management of NVUGIB are intermingled. Following resuscitation and initial assessment, pre-endoscopic management is per­ formed followed by endoscopic diagnosis and endoscopic management. For example, medical treatment with, for example, PPIs, is often started before endoscopic diag­ nosis and treatment. In this Primer, we ­discuss the ­diagnosis and management options separately. Initial, pre-endoscopic assessment. The presentation of overt NVUGIB varies considerably from asymptomatic outpatients with melena (black faeces due to the pres­ ence of blood) to those presenting with large-volume haematemesis (vomiting of blood), passage of ‘fresh’ red blood, severe hypotension and a compromised airway. The presence of haematemesis indicates that the source of the bleeding is the upper gastrointestinal tract (above the ligament of Treitz), whereas the source of bleeding in most individuals with melena is also the upper gastro­ intestinal tract (90%), but the small bowel and ascending colon cannot be excluded. Caution should be taken to exclude oral or nasopharyngeal sources of bleeding as patients who swallow fresh blood might present with haematemesis or melena. The probability that a patient has NVUGIB is higher when melena is observed on rectal examination than with patient-reported history of melena or the presence of blood clots in the stool77. The initial assessment and management of these patients is focused on emergency assessment and stabiliza­tion protocols aimed at restoring and protect­ ing the airway and maintaining the circulation followed by NVUGIB-specific pre-endoscopic assessment and interventions. In a minority of patients who present with large-volume haematemesis and/or diminished level of consciousness, orotracheal intubation should be consid­ ered to protect the airway and to facilitate initial resusci­ tation and subsequent endoscopy in the emergency setting. Blood should be drawn during catheter insertion to analyse complete blood count, INR, electrolytes, urea, albumin, creatinine and liver enzymes. Additional blood tests or investigations can be performed depending on the underlying comorbidities5,78. During initial resuscitation, a directed history and physical exam is conducted and aimed at ascertaining the potential aetiology for the gastrointestinal bleeding and identifying important risk factors and comorbidi­ ties that modify survival and warrant lowered thresh­ olds for transfusion or early endoscopy. A digital rectal examination enables verification of the presence of either melena or blood and may avoid unnecessary ­confirmatory tests79. Nature Reviews | Disease Primers Risk factors Comorbidities Dysregulated processes Gastrointestinal pathology NVUGIB • Renal insuﬃciency • Cardiovascular  disease • Pulmonary  insuﬃciency • Coagulopathy • Organ failure • Age • Other  comorbidities Genetic predisposition • Angiodysplasia • Vascular lesions • Ischaemia • Fibrinoid necrosis • Degeneration Mucosal damage • Chronic hypoxia • Free radicals • Clotting  dysfunction • Altered  microperfusion • Systemic  inﬂammatory  status Gastric cancer Genetic predisposition • COX inhibition • Vascular damage • Non-selective NSAIDs • LDA • COX2 inhibitors Inﬂammation H. pylori infection Previous inﬂammatory conditions Virulence factors Immune response cytokines Smoking Inhibition of coagulating factors Inhibition of platelet activation Mallory–Weiss Syndrome • Vitamin K  antagonists • DOACs • P2Y12 antagonists • SSRIs • LDA • NSAIDs • Excessive alcohol intake • Heavy meals • Other conditions Steroids Vomiting Figure 4 | Complex pathophysiology of NVUGIB. Many factors contribute to the development of non-variceal upper gastrointestinal bleeding (NVUGIB). Bleeding is usually the result of mucosal damage induced by drugs such as NSAIDs or low-dose aspirin (LDA; typically 75–100 mg) or is often associated with Helicobacter pylori infection. Additional risk factors or comorbidities might make the gastrointestinal mucosa more susceptible to bleeding. NVUGIB can also be the consequence of vascular lesions, which are also often associated with ageing or comorbidities. Bleeding from these lesions may be precipitated by antiplatelet or anticoagulation agents, which can also act on pre-existing mucosal damage induced by other factors, or other pathogenetic mechanisms, such as Mallory–Weiss syndrome or gastric carcinoma59. COX, cyclooxygenase; DOAC, direct oral anticoagulant; P2Y12, P2Y purinoceptor 12; SSRI, selective serotonin reuptake inhibitor. PRIMER NATURE REVIEWS | DISEASE PRIMERS	 VOLUME 4 | ARTICLE NUMBER 18020 | 7 ©  2018  M acm illan  Publishers  Lim ited,  part  of  Springer  Nature. All  rights  reserved.",5238,748,1309.5,"[-0.19255266  0.0981341  -1.4956021  ...  0.5201736   0.5135215
 -1.0222034 ]"
113,"Each patient presenting with NVUGIB should have pre-endoscopic risk stratification. Among the different risk-scoring systems (BOX 3), the Glasgow–Blatchford Score (GBS) performs well80 and is used globally. The GBS performs better at predicting intervention, compli­ cations or death than the full (preadmission and post-­ endoscopy) Rockall score, the admission Rockall score, the AIMS65 score and the Progetto Nazionale Emorragia Digestiva (PNED) score80. The PNED and AIMS65 scores perform best at predicting mortality80. In general, high- risk patients are those who present with hypotension, vomiting of bright red (fresh) blood, passage of red blood per rectum (in the setting of NVUGIB) and/or have con­ siderable comorbidities and are of advanced age. These patients have an increased risk of mortality and require careful assessment and early management. In individuals who develop NVUGIB when on anti­ platelet or anticoagulation therapy to prevent cardio­ vascular events, this treatment should generally be stopped and/or reversed. However, endoscopy should usually not be delayed until the action of the anticoagu­ lant is completely reversed. An INR <2.5 is adequate and enables successful endoscopic management if needed5,81. The decision to stop and when to resume antiplatelet anticoagulant agents at the time of NVUGIB is difficult and should be guided by post-endoscopy risk assess­ ment and ­consultation with a cardiologist (discussed in detail below). Endoscopy. Endoscopy is essential to reveal the cause of NVUGIB, and early upper gastrointestinal endoscopy within 24 hours of presentation improves patient out­ comes82–84. Several studies have found no differences in outcomes between patients who undergo early endoscopy and those undergoing very early endoscopy (<12 hours of patient presentation)85–87. Nevertheless, controversy per­ sists because very early endoscopy reveals active bleed­ ing stigmata and need of endoscopic treatment of lesions without evidence of reduction of the risk of re-bleeding or improved survival88,89. Endoscopy should be used to diagnose the cause of the bleeding and evaluate stigmata of recent haemorrhage (such as active bleeding, a visible blood vessel, presence of clots or red or black spots covering the ulcer lesion) and to classify them according the Forrest classification, which enables patient selection for endoscopic treatment and stratification of the risks of re-bleeding, surgery and mor­ tality90–92 (TABLE 1). Of note, the interobserver agreement for the Forrest classification is low to moderate93. Vigorous water irrigation on the ulcer base is ­recommended to improve the accuracy of Forrest classification. Endoscopic treatment should be provided to patients with bleeding of Forrest types Ia, Ib and IIa. A meta-­ analysis of randomized clinical trials (RCTs) confirmed that endoscopic therapy was effective in preventing per­ sistent or recurrent bleeding in Forrest types Ia and Ib (relative risk (RR) 0.29, 95% CI 0.20–0.43; ­number needed to treat (NNT) 2, 95% CI 2–2) and Forrest type IIa (RR 0.49, 95% CI 0.40–0.59; NNT 5, 95% CI 4–6) compared with no endoscopic therapy94. The necessity for endoscopic treatment in patients with Forrest type IIb bleeding, which is defined as a lesion with a clot that is red, maroon or black in colour and amorphous in ­texture and that cannot be dislodged by suction or forceful water irrigation, remains controversial. The above-mentioned meta-analysis showed no benefit for endoscopic ther­ apy in Forrest type IIb bleeding94; however, the studies included showed significant hetero­geneity, with two concluding that there was a bene­ficial effect of com­ bining therapeutic endoscopy with intra­venous PPI therapy compared with PPI alone95,96. Thus, at present, the approach to managing patients with Forrest type IIb bleeding should be determined on a case‑by‑case basis, considering, among others, medical resources, ­endoscopist experience and patient status. Stigmata of recent haemorrhage, which are visible on endoscopy, have been used for decades to make risk stratification and treatment decisions in NVUGIB, but Doppler assessments of arterial blood flow in the gastro­ intestinal wall, which can be measured using endoscopy, could revolutionize the field. Detection rates of arterial Box 2 | Risk factors for increased bleeding risk Drugs •	Compared with non-use, NSAID use increases the risk of developing non-variceal upper gastrointestinal bleeding (NVUGIB) fourfold, and low-dose aspirin (LDA) use increases the risk twofold3,66,203. The risk progressively increases with increasing drug dose; dangers of ‘dose creep’ or surreptitious addition of over-the-counter NSAIDs should be considered66. The risk associated with different NSAIDs is not the same in clinical practice and seems to be higher in drugs with longer half-lives, slow-release formulations or cyclooxygenase 1 (COX1) selectivity; COX2‑selective antagonists have been associated with lower NVUGIB risk67. •	Anticoagulants and non-aspirin antiplatelet agentsa (such as clopidogrel) increase the risk of NVUGIB twofold204. •	Other drugsa (such as serotonin reuptake inhibitors70, metamizole, calcium channel blockers and aldosterone antagonists) have also been associated with NVUGIB, but less consistently. •	Combined use of NSAIDs (both unselective COX inhibitors and COX2‑selective inhibitors) with LDA, thienopyridine antiplatelet agents (for example, clopidogrel), warfarin, novel antiplatelet drugs (for example, prasugrel and ticagrelor), direct oral anticoagulants, corticosteroids67 or serotonin reuptake inhibitors70 increases the risk of NVUGIB. Combining NSAIDs and aldosterone antagonists might increase the risk of developing NVUGIB more than the risk associated with individual drug use64,66,70. Gastrointestinal comorbidities •	Eradication of Helicobacter pylori infection before NSAID use reduces ulcer risk by 2.8‑fold and ulcer bleeding risk by 6.4‑fold205. •	The single most important risk factor for bleeding is a history of ulcer complications, especially in patients treated with NSAIDs or LDA67. •	A history of uncomplicated ulcers increases the risk of complications; eradication of H. pylori may not reduce the risk completely in patients treated with NSAIDs or LDA67. •	History of dyspepsia, which may be a marker of underlying peptic ulcer disease, increases the risk of NVUGIB. Other comorbidities •	Bleeding risk increases with age; >75 years of age is considered high risk67. •	Concomitant disability; for example, the prevalence of gastrointestinal bleeding events is higher in those with rheumatoid arthritis than in those with osteoarthritis65,206. •	The risk of NVUGIB increases with an increasing number of comorbidities65,66.aThese drugs do not induce damage to the gastrointestinal tract; patients must have lesions caused by other aetiology. PRIMER 8 | ARTICLE NUMBER 18020 | VOLUME 4	 www.nature.com/nrdp ©  2018  M acm illan  Publishers  Lim ited,  part  of  Springer  Nature. All  rights  reserved.",7045,998,1761.25,"[-0.16580588 -0.36924765 -1.9336236  ... -0.04734075  0.89583015
 -1.0347258 ]"
114,"signals on ulcer bases using a Doppler probe in patients with Forrest type Ia bleeding are high (100%) but are lower in those with Forrest types Ib (46.7%), IIa (90.7%), IIb (68.4%), IIc (40.5%) and III (8.3%) bleeding97. These data could explain the finding that patients with Forrest type Ib bleeding had a very low re-bleeding rate after success­ful endoscopic haemostasis in a recent RCT, although both Forrest types Ia and Ib are often included together as ‘active bleeding’ (REF. 98). Furthermore, the use of the Doppler probe facilitates tracing of the under­ lying artery for effective endoscopic haemostasis, which improves patient outcomes99. Recently, iatrogenic ulcers following mucosal or sub­ mucosal endoscopic tumour resection have become a substantial cause of NVUGIB, especially in east Asia, where endoscopic tumour resection for upper gastro­ intestinal neoplasia is more frequent than in other parts of the world100. Although evidence is limited, endoscopic evaluation and management of bleeding from these ulcers should be considered on a similar basis to those with peptic ulcers100. Literature regarding endoscopic evaluation and management methods for bleeding from other causes such as Mallory–Weiss tear, oesophagitis, erosive gastritis, duodenitis, vascular abnormalities, anasto­motic wounds after surgery and upper gastro­ intestinal neoplasia are sparse. Spontaneous haemostasis is usually achieved in these conditions, and endoscopic treatment should be considered only in cases of active bleeding­101. In cases of curative-intent treatment for neo­ plastic lesion, endoscopic or surgical removal of the entire lesion should be prioritized over endoscopic ­haemostasis to control bleeding. Second-look endoscopy. Re-bleeding after endoscopic treatment occurs in 10–15% of individuals with PUB and results in a twofold to fivefold increase in mortality5. However, current evidence-based guidelines do not recommend a routine second-look endoscopy5,8,10,11,78, which is defined as scheduled endoscopic assess­ ment within 24 hours of the initial diagnosis. A meta-­ analysis reported a significant reduction in re-bleeding (OR 0.55; 95% CI 0.37–0.81) and need for emergency surgery (OR 0.43; 95% CI 0.19–0.96), but not mortality (OR 0.65; 95% CI 0.26–1.62), when routine second-look endoscopy was performed compared with an as‑needed endoscopy102. Further analysis showed that any protec­ tive effect for second-look endoscopy was limited to high-risk patients (that is, those with active bleeding at index endoscopy). In addition, scheduled second-look endoscopy is cost effective only in patients at high risk of recurrent ulcer bleeding, defined as those with high-risk endoscopic stigmata103. Management Initial, pre-endoscopic management Peripheral intravenous access should be obtained soon after or at the same time as initial assessment and be of sufficient size to allow rapid blood transfusion if required. Resuscitation with crystalloid fluid should be guided by the haemodynamic status of the patient. The decision to provide additional blood transfusion should be individualized on the basis of the patient’s clinical ­status and should take ongoing bleeding, haemoglobin level and presence of underlying comorbidities that make the patient sensitive to reduced oxygen-­carrying capacity into consideration. In general, a restrictive blood transfusion strategy is recommended. Guidelines5 typically recommend blood transfusion for patients who have a haemoglobin level <70 g per litre and recommend targeting a haemoglobin value of 70–90 g per litre104. These targets can be individualized for patients who are sensitive to low oxygen-carrying capacity, but overtrans­ fusion should be avoided as it can be associated with harm (such as congestive heart failure)5,78. Guidelines recommend administration of intra­ venous high-dose PPI pre-endoscopy to stabilize clots, downgrade endoscopic stigmata of recent ­haemorrhage and reduce the need for endoscopic therapy5,10,78. However, the use of intravenous pre-endoscopy PPIs has not shown reductions in the rates of re-bleeding, surgi­ cal intervention or mortality in meta-analyses, therefore, its use should not delay endoscopy5,78,105,106. The use of pre-endoscopy PPIs is considered to be cost effective in high-risk patients and in low-risk patients with expected short hospitalizations or outpatient manage­ment107. The cost effectiveness of pre-endoscopic intravenous PPIs is likely maximized in patients with the likelihood of a high-risk lesion on initial assessment or in those in whom a delay in endoscopic therapy is expected. By con­ trast, post-endoscopy intravenous PPI use reduces the risk of re-bleeding and need for surgical intervention (see below). Guidelines do not support the routine use of somato­statin or somatostatin analogues (aimed mainly at splanchnic vasoconstriction) or tranexamic acid (an antifibrinolytic agent) in NVUGIB. Although not ­routinely recommended, a single dose of the anti­biotic Figure 5 | Risk of developing NVUGIB associated with certain drugs. Relative risk and 95% CIs of developing non-variceal upper gastrointestinal bleeding (NVUGIB) associated with the use of various types of drugs alone or combined with non-selective NSAIDs (nsNSAIDS) compared with no drug use. Based on data reported in European databases64. The different colours refer to the different drug classes; the dashed line highlights a relative risk= 1. COX2, cyclooxygenase 2; LDA, low-dose aspirin; SSRI, selective serotonin reuptake inhibitor. Nature Reviews | Disease Primers Treatments  No drug use COX2 inhibitors Corticosteroids SSRIs Calcium antagonists Aldosterone antagonists Anticoagulants Non-aspirin antiplatelet agents Non-aspirin antiplatelet agents + nsNSAIDs 7 14 3 11 Relative risk 0 nsNSAIDs LDA Corticosteroids + nsNSAIDs SSRIs + nsNSAIDs Calcium antagonists + nsNSAIDs Aldosterone antagonists + nsNSAIDs Anticoagulants + nsNSAIDs 5 1 9 8 4 12 6 2 10 13 Reference PRIMER NATURE REVIEWS | DISEASE PRIMERS	 VOLUME 4 | ARTICLE NUMBER 18020 | 9 ©  2018  M acm illan  Publishers  Lim ited,  part  of  Springer  Nature. All  rights  reserved.",6170,879,1542.5,"[-0.26494235 -0.3497641  -1.4275577  ...  0.5179433   0.3203975
 -0.712286  ]"
115,"erythromycin 30–120 minutes before endoscopy, ­especially in those with severe and ongoing bleeding, can improve endoscopic visualization, reduce the need for blood transfusion and second-look endoscopy and reduce the length of hospitalization5,78,108. Endoscopic management Various modalities to achieve endoscopic haemostasis aimed at stopping active bleeding in those with UGIB associated with peptic ulcers or other causes exist and are detailed in BOX 4. PUB. Meta-analyses show that injection therapy with solutions other than adrenaline, thermal therapy and haemoclip therapy (BOX 4) are all effective methods for achieving haemostasis in PUB with no single modality being superior109–114. For high-risk PUB, adrenaline plus any second haemostasis modality (except spray ther­ apy) significantly reduced re-bleeding (OR 0.53; 95% CI 0.35 – 0.81) and need for emergency surgery (OR 0.68; 95% CI 0.50 – 0.93), but not mortality, as compared with adrenaline injection monotherapy113. Thus, if adrenaline injection is used to treat PUB with high-risk stigmata, it should be used only in combination with a second endoscopic haemostasis modality. The use of soft coagu­ lation using haemostatic forceps (FIG. 6) has become more frequent along with development of endoscopic ­submucosal dissection115. Over-the-scope clip (OTSC system; OVESCO Endo­scopy AG, Tübingen, Germany) and haemo­ static powders such as TC‑325 (Haemospray; Cook Medical, Bloomington, IN, USA) and the EndoClot polysacchar­ide haemostatic system (EndoClot Plus, Santa Clara, CA, USA) are newly developed devices or substances with promising outcomes, but they still lack sufficient data to draw robust conclusions concerning efficacy116–118. Over-the-scope clips overcome the limita­ tions of haemoclips, such as smaller size and lower capacity to include the whole lesion and induce pres­ sure, and are good options for salvage or rescue endo­ scopic haemo­stasis interventions after conventional endoscopic therapies have failed before surgical or radio­logical intervention. Haemostatic powders mainly act as a tamponade and a physical barrier from factors such as gastric acid and might be more effective than conventional endoscopic therapies in cases in which targeting the bleeding point is difficult. Notably, bleed­ ing duodenal ulcers at the posterior wall may require subsequent vigilance after endoscopic therapy; if the gastroduodenal artery is affected, radiological coiling or surgery may be needed to stop the bleeding1. Non-PUB NVUGIB. For NVUGIB other than PUB, endoscopic haemostasis should be selected according to the nature of the disease, severity of bleeding and preference of the endoscopist because of the low quality Box 3 | Risk-scoring systems for NVUGIB Glasgow–Blatchford bleeding score The Glasgow–Blatchford bleeding scoring system80,207 (0–23 points) aims to predict the need for hospital-based interventions (such as endoscopic or surgical intervention and blood transfusion) or the risk of hospital-based complications (such as in‑hospital re-bleeding and substantial decrease in haemoglobin concentration after admission) or mortality. Although studies use different cut-off values, a score of ≤1 is usually considered low risk and discharge is considered safe, whereas a score of >7 is usually considered high risk. Parameters included in the scoring system are haemoglobin level, blood urea concentration, systolic blood pressure, heart rate, sex, presence of melena, recent syncope, presence of liver disease and heart failure. Admission Rockall score for NVUGIB (pre-endoscopy) This scoring system (0–7 points) aims to predict the risk of re-bleeding and mortality80,208. Parameters included in the scoring system are age, presence of hypovolaemic shock, pulse, systolic blood pressure, minor comorbidities (such as congestive cardiac failure and ischaemic heart disease) and major comorbidities (such as renal failure, liver failure and cancer). AIMS65 This scoring system (0–5 points) aims to predict the risk of re-bleeding and mortality80,209,210; a score of ≥2 is considered high risk. Parameters included in the scoring system are albumin, international normalized ratio for prothrombin time, mental status, systolic blood pressure and age, which are the basis of the name of the score. PNED The Progetto Nazoinale Emorragia Digestiva (PNED) scoring system (0–21 points) aims to predict mortality risk80,211. A score of ≤4 is considered low risk, 5–8 is considered intermediate risk and ≥9 is considered high risk. Parameters included in class 3 and 4 of the scoring system are the American Society of Anesthesiologists Physical Status score, time since admission (<8 hours), haemoglobin level (<7 g per dl), renal failure, advanced age (>80 years), re-bleeding, cirrhosis, advanced-stage cancer and failure of endoscopic treatment. Full Rockall score for NVUGIB (post-endoscopy) This scoring system (0–11 points) aims to predict the risk of re-bleeding and mortality80,212. A score of ≤2 is considered low risk, 3–4 is considered intermediate risk and ≥5 is considered high risk. Parameters included in the scoring system are the same as those of the preadmission score and those related endoscopic diagnosis and endoscopic stigmata. The presence or absence of Mallory–Weiss tears, gastrointestinal malignancy or all other diagnoses are also included in the scoring system alongside endoscopic stigmata (absence of stigmata or dark spots on ulcers, blood in the upper gastrointestinal tract, adherent clots or visible or spurting vessels). NVUGIB, non-variceal upper gastrointestinal bleeding. PRIMER 10 | ARTICLE NUMBER 18020 | VOLUME 4	 www.nature.com/nrdp ©  2018  M acm illan  Publishers  Lim ited,  part  of  Springer  Nature. All  rights  reserved.",5776,825,1444.0,"[ 0.05563627 -0.2717408  -1.4899505  ...  0.5971982   0.3738101
 -1.3024437 ]"
116,"of evidence and scarcity of comparative data. Bleeding associated with Mallory–Weiss tears is ­usually self-­ limited, and endoscopic haemostasis would be applied only when active bleeding is detected. Among various endoscopic haemostatic modalities, haemoclip and band ligation therapy are preferred as they achieve haemostasis and closing of the mucosal tear without thermal damage to the thinner lacerated tissue119,120. Endoscopic haemostasis to control bleeding associated with vascular abnormalities is usually carried out using coagulation therapy such as argon plasma coagula­ tion, laser therapy or radiofrequency ablation. Argon plasma coagulation is especially useful for lesions that are spread (for example, gastric antral vascular ectasia (longitudinal antral folds converging on the pylorus that contain visible columns of tortuous red ectatic vessels)) or for multiple lesions (arteriovenous malfor­ mations or telangiectases) as its coagulation depth is uniform and the risk of perforation is lower than that of laser therapy121. For patients with a few or localized lesions, haemo­ stasis using mechanical therapy or injection therapy are also applicable. As a new approach for refractory gastric antral vascular ectasia, radiofrequency ablation using the HALO90 Ablation Catheter System (Covidien GI Solutions, Sunnyvale, CA, USA) has been tested with promising outcomes122–125. In Dieulafoy lesions, either mechanical therapy (such as band ligation) or haemo­ clips are considered to be the first-line treatment and over-the-scope clips are a rescue treatment for refractory cases126. Medical therapy after endoscopy The goals of medical treatment are to reduce the risk of re-bleeding while healing the ulcer and preventing long-term recurrence. The rationale for raising intra­ gastric pH to >6 is based on studies that demonstrated that acidity affects platelet aggregation and destabilizes clot formation44,127,128. A meta-analysis of RCTs found a significant reduction in re-bleeding (RR 0.40, 95% CI 0.28–0.59; NNT 12, 95% CI 10–18), surgery (RR 0.43, 95% CI 0.24–0.76; NNT 28, 95% CI 21–67) and mor­ tality (RR 0.41, 95% CI 0.20–0.84; NNT 45, 95% CI 33–167) with intravenous post-endoscopic PPI ther­ apy (bolus injection followed by continuous infusion versus placebo or no treatment for 72 hours after endo­ scopic therapy)94. High-dose intravenous omeprazole (a PPI) was superior to intravenous administration of ranitidine (a histamine H2 receptor antagonist) in maintaining gastric pH >6 (percentage of time gastric pH <6 in the study period was 15.3 ± 5.9% (mean ± standard deviation) for omeprazole versus 61.8 ± 5.6% (mean ± standard deviation) for ranitidine, P <0.0001)45. Given the cost of continuous intravenous ther­ apy, less costly intermittent (including oral) therapy is a ­logical consideration, although a recent study has shown that the timing or dosing of PPI has little impact on cost, much less than efficient triage and dis­ charge of patients129,130. Several meta-analyses found that intermittent PPI use was non-inferior compared with bolus plus continuous infusion of PPIs in terms of re-bleeding (at 3, 7 and 30 days), the need for blood transfusion and urgent intervention and mortality131,132. Intermittent oral PPI may be as effective in pH control as equivalent doses of intravenous PPIs given intermit­ tently. Both oral and intravenous PPIs (lansoprazole) given intermittently achieved similar pH control during the study period (percentage time gastric pH <6 was 67.8 ± 4.5% (mean ± standard error) for intravenous PPI versus 64.8 ± 4.2% (mean ± standard error) for oral PPI), although intravenous PPI increased pH to >6 sooner than oral PPI (by 1 hour)47, but the ranges are wide. Thus, intermittent, high-dose PPIs given at least twice daily are an option, using oral PPIs in patients able to tolerate oral medications94. Table 1 | Risk prediction using the Forrest classification Endoscopic stigmata Forrest classification Risk of persistent bleeding or re-bleeding without endoscopic treatment Risk of re-bleeding after endoscopic haemostasis Risk of needing surgery for bleeding without endoscopic treatment Risk of mortality without endoscopic treatment Acute bleeding Spurting haemorrhage Type Ia Very high High High Low Oozing haemorrhage Type Ib Very lowa Signs of recent bleeding Non-bleeding visible vessel Type IIa High High High Low Adherent clot Type IIb High Very low Low Low Flat pigmented spot Type IIc Low Not applicableb Very low Very low Lesion without active bleeding or signs of bleeding Clean base (no vessel, blood or clot on the base) Type III Very low Not applicableb Extremely low Very low Table based on data in REF. 220.aA recent study demonstrates that Forrest type Ib has a very low re-bleeding rate within 72 hours after successful endoscopic haemostasis98.bIn patients with Forrest type IIc and type III, the risk of re-bleeding is <10%; thus, endoscopic haemostasis provides no advantage. PRIMER NATURE REVIEWS | DISEASE PRIMERS	 VOLUME 4 | ARTICLE NUMBER 18020 | 11 ©  2018  M acm illan  Publishers  Lim ited,  part  of  Springer  Nature. All  rights  reserved.",5158,745,1289.5,"[-0.04806696 -0.40340915 -1.1933233  ...  0.635156    0.4587984
 -1.5499157 ]"
117,"Patients with PUB have an unacceptably high rate of recurrent bleeding. In an RCT of patients with H. pylori-associated PUB, the rate of recurrent bleed­ ing after 12‑month follow‑up was 27% in patients who did not undergo H. pylori eradication therapy com­ pared with 0% in those who did133. H. pylori eradication is more effective than long-term maintenance anti­ secretory therapy in reducing recurrence; a systematic review of studies assessing re-bleeding in patients with documented H. pylori eradication revealed a 1.1% inci­ dence of re-bleeding over mean follow‑up periods of 11–53 months. However, the re-bleeding rate in patients who did not undergo H. pylori eradication therapy but were maintained with long-term anti­secretory therapy was 5.6%134. These findings set the current Cochrane rec­ ommendations to test all patients with PUB for H. pylori and provide eradication therapy if needed134. When patients have to use NSAIDs after PUB, RCTs have shown that maintenance PPI therapy significantly lowers the risk of recurrent ulcer bleeding at 6 months compared with H. pylori eradication alone (4.4% ver­ sus 18.8%, P = 0.005; NNT = 7)68,135. In a 12‑month double-blind study, patients taking celecoxib (a COX2 inhibitor) plus twice-daily PPI had fewer recurrent ulcer bleeding events than those taking celecoxib plus ­placebo (0% versus 8.9%, P = 0.0004; NNT = 12)69. Another meta-analysis also found that the combination of selective COX2 inhibitors plus PPIs provides the best gastro­intestinal protection, followed by selective COX2 inhibitors alone and non-selective NSAIDs plus PPI136. Thus, the current best practice for those patients with a PUB who must remain on NSAIDs is that they should receive a COX2‑selective NSAID at the lowest effective dose plus PPI therapy68,69. Recurrent bleeding In patients with clinical evidence of re-bleeding, repeat upper endoscopy should be performed with haemo­stasis of high-risk endoscopic stigmata of haemorrhage, if pres­ ent. A seminal RCT comparing endoscopic therapy with surgery for recurrent PUB following successful initial endoscopic control of PUB showed that 73% of patients randomly assigned to endoscopic re-treatment had long- term control of their bleeding and avoided ­surgery com­ pared with 93.1% of surgery-treated patients137. Patients in the endoscopy group had a lower rate of complica­ tions than those in the surgery group (14.5% versus 36%; P = 0.03)137. If further bleeding occurs following a second endoscopic treatment, transcatheter angiographic embo­ lization or surgery should be considered5,10,11. In those with PUB after failed endoscopic haemostasis, a higher re-bleeding rate was observed following transcatheter Box 4 | Examples of endoscopic therapy for NVUGIB Injection therapy •	Endoscopic injection of small volumes of treatment solution close to the bleeding site •	Several types of treatment solutions can be used: -- Absolute ethanol: aimed at inducing dehydration and fixation of the bleeding blood vessel, with subsequent vasoconstriction and necrosis -- Adrenaline in an isotonic or hypertonic saline solution: adrenaline induces vasoconstriction and vascular tamponade and hypertonic saline solution induces tissue swelling, fibrinoid necrosis and thrombogenesis -- Polidocanol: a sclerosant that irritates and induces endothelial cell damage and thrombogenesis Mechanical therapy •	Haemoclip: mechanical compression of the bleeding vessel using a metallic clip •	Band ligation: mechanical compression of the bleeding vessel using a rubber band commonly used for oesophageal variceal ligation •	Over-the-scope clip (OTSC system; OVESCO Endoscopy AG, Tübingen, Germany): a large superelastic nitinol clip with a bear-trap shape that fits on the endoscope tip and is commonly used for closures of perforations and fistulas Thermal therapy •	Soft coagulation using haemostatic forceps: monopolar or bipolar electrocautery or heat probe are contact devices that use heat or electrical current to coagulate the bleeding vessel •	Argon plasma coagulation: a stream of ionized argon gas conducts electricity, without direct contact, resulting in coagulation of superficial tissues •	Laser therapy: a stream of intense, small and nearly non-divergent beams of monochromatic radiation in the visible region induces heat and coagulates or cuts tissues •	Radiofrequency ablation: a flexible strap that slides over the endoscope tip and generates radiofrequency energy, commonly used for ablation of Barrett oesophagus Spray therapy •	Thrombin or fibrin glue: acceleration of the blood coagulation cascade by thrombin or supply of fibrinogen and thrombin (that is, fibrin) to create a primary tissue seal at a bleeding site •	TC‑325 (Haemospray; Cook Medical, Bloomington, IN, USA): a mineral blend powder that absorbs and acts both cohesively and adhesively by forming a mechanical barrier over the bleeding site •	EndoClot polysaccharide haemostatic system (EndoClot Plus, Santa Clara, CA, USA): a polysaccharide powder modified from plant starch that forms a gel in the presence of blood and adheres to and seals the bleeding tissue PRIMER 12 | ARTICLE NUMBER 18020 | VOLUME 4	 www.nature.com/nrdp ©  2018  M acm illan  Publishers  Lim ited,  part  of  Springer  Nature. All  rights  reserved.",5296,763,1324.0,"[ 0.03366676  0.15730494 -1.4621153  ...  0.46407333  1.0578966
 -1.2046368 ]"
118,"angiographic embolization than surgery, but no signifi­ cant difference in mortality or need for additional interventions was observed138,139. Emerging data sug­ gest that haemostatic powders and over-the-scope clips can be successfully employed as salvage haemostasis ­therapy140,141, but more data are needed10,11,118,142,143. Patients on antiplatelet therapy The evidence to guide practice in those with NVUGIB who are using antiplatelet agents is very limited and mostly restricted to LDA monotherapy. The risk of recurrent PUB, most of which occurred within the first 5 days after the index bleeding event, was increased in those on continued LDA before endoscopy (HR 1.9) compared with discontinuing LDA use for 8 weeks after PUB144. However, none of these bleeding events were fatal, whereas all-cause mortality in those who discontinued receiving LDA was increased owing to thrombo­embolic events. In a smaller retrospective study, individuals with cardiovascular disease who stopped LDA therapy had an increased risk of death or cardio­ vascular event (HR 6.8) in the first 6 months of follow-up compared with those who continued LDA therapy. Early resumption of LDA after the bleeding event was not associated with a signifi­cant increase in mortality related to PUB. These studies144–146, albeit small, provide strong evidence to continue LDA in individ­uals who develop a PUB ­during treatment or at least to resume treatment early. Indeed, the time interval from discontinuation of LDA to an adverse cardiovascular event was ~8 days for acute coronary syndrome, 14 days for cerebrovascular syndromes and 25 days for acute peripheral arterial syndromes147, whereas the risk of recurrent gastro­ intestinal bleeding is highest in the first 3 days after the index event135. As a consequence, antiplatelet therapy is often stopped and resumed after 3–5 days in those at high risk of recurrent NVUGIB to avoid the period of high risk of recurrent bleeding while the antiplatelet function of LDA to prevent cardiovascular events may persist. On the basis of existing evidence, several guide­ lines have been formulated5,49 (FIG. 7). To our knowledge, no study designed to investigate the withdrawal and/or resumption of antiplatelet agents other than LDA has been carried out. Patients on anticoagulant therapy The management of patients on anticoagulant therapy who develop an NVUGIB represents a clinical challenge, and two clinical scenarios should be considered: treat­ ment before endoscopy and treatment after diagnosis has been established and the bleeding event has been controlled. Irrespective of whether patients are taking vitamin K antagonists or DOACs, treatment should be stopped immediately and pre-endoscopic management should be initiated as usual. Endoscopy should not be delayed in patients with an INR <2.5 as outcomes (such as need for intervention or death) are similar in those with normal versus elevated INR at admission if INR is corrected to values <2.5 before endoscopy5,81,148,149. Conversely, a retrospective study in 134 patients with bleeding events with INR ≥3.5 suggested that effec­ tive therapeutic endoscopic intervention becomes less frequently possible as the INR increases150. Under these circumstances, reversal of INR (see below) seems ­appropriate before endoscopy. Vitamin K antagonists. For patients on vitamin K antagonists (such as warfarin and dicumarinics), pro­ longed INR can be reversed with vitamin K, which acts slowly (INR begins to decrease within 2–4 hours and normalizes within 24 hours) but more dur­ably than pro­ thrombin complex concentrates (PCCs) or fresh frozen plasma (FFP)151. Vitamin K should be injected slowly to minimize severe (anaphylactic or anaphy­lactoid) reactions152 and INR should be monitored as vitamin K antagonists have a long half-life153. Haemostatic factors (such as PCCs and FFP) can also be used to normal­ ize haemostasis when reversal of anticoagulation is urgent. PCCs are preferred over FFP because they can be administered more rapidly without blood group test­ ing or thawing in smaller volumes and are associated with lower mortality, quicker INR normalization (dif­ ference of 6.5 hours) and a similarly low risk of throm­ boembolism154. Four-factor PCC provides more reliable INR correction than three‑factor PCC155, but reported differences in mortality are inconsistent156,157. FFP is still widely used because of perceived lower cost than PCCs158; however, the difference in price for identical INR correction is only 50%159. Recombinant factor VIIa Figure 6 | Management of using soft coagulation.a | Fresh blood flows from the ulcer to the greater curvature of the gastric body (arrow).b | Bleeding point under the clot is near the upper rim of the ulcer (arrow).c | Slight removal of the clot shows spurting bleeding (arrow).d | Soft coagulation by using haemostatic forceps successfully stops the bleeding (arrow). Images courtesy of Prof. M. Fujishiro, The University of Tokyo Hospital, Japan.a c d b Nature Reviews | Disease Primers PRIMER NATURE REVIEWS | DISEASE PRIMERS	 VOLUME 4 | ARTICLE NUMBER 18020 | 13 ©  2018  M acm illan  Publishers  Lim ited,  part  of  Springer  Nature. All  rights  reserved.",5220,766,1305.0,"[ 0.07482727 -0.12599854 -1.9786272  ...  0.22409686  1.0316519
 -1.2795695 ]"
119,"is not recommended (high cost and 11% thromboembo­ lism risk)160. FIGURE 8 summarizes commonly accepted recommendations for patients on vitamin K antagonists who develop NVUGIB161–163. DOACs. DOACs target single enzymes of the coagu­ lation process; apixaban, edoxaban and rivaroxaban inhibit factor Xa whereas dabigatran directly inhibits thrombin72. Plasma monitoring of coagulation factors is not needed, which is a clinical advantage over vita­ min K antagonists. However, unlike vitamin K antago­ nists and dabigatran, anti-factor Xa agents currently have no widely available reversal agents, are not yet approved and normalization of clotting factor levels takes 12–24 hours164. Routine coagulation tests may be conducted, but they are unreliable (BOX 5). Renal function should be monitored as it is frequently compromised in those with UGIB on DOACs, and aggressive fluid replace­ ment may be needed to maintain renal function165,166. Creatinine clearance enables the estimation of the per­ sisting DOAC effect167. Haemodialysis can be of help for dabigatran clearance treatment only but requires haemodynamic stability. Prolonged continuous haemo­ dialysis may help to prevent bleeding rebound effects168. Finally, activated charcoal can also be used in the case of a recent (≤3 hours) overdose and when no emergency UGIB endoscopy is contemplated169–171. Haemostatic agents such as PCCs or activated PCCs have been shown to be effective at restoring coagula­ tion in patients with NVUGIB who are taking DOACs, although evidence is limited172–174. By contrast, FFP is not recommended as clotting factors are 25‑fold more dilute than in PPCs, and very large volumes are required to overwhelm the binding capacity of DOACs. The most promising therapeutic options rely on the availability of reversal agents, which could be used in the case of life-threatening gastrointestinal bleeding, but reliable data are needed because of the risk of thromboembolism175,176. Dabigatran has a specific antidote (idarucizumab), which works effectively in minutes with thromboembolism and a rebound effect reported in 6.8% and 23% of patients, respectively171. In this cohort study171, including patients who had uncontrolled bleeding (45.5% of whom had gastro­intestinal bleeding and 32.6% had intracranial haemorrhage), the median maximum percentage reversal of dabigatran was 100% on the basis of either the diluted thrombin time or the ecarin clotting time; the median time to cessation of bleeding was 2.5 hours. In those undergoing emergency procedures, haemostasis was Nature Reviews | Disease Primers Resume by day 3–5 Second-look endoscopy at the discretion of endoscopist or if re-bleeding is suspected • Continue LDA • Consult cardiologist before restarting  additional antiplatelet agent • Withhold antiplatelet agents • Re-evaluate indication • Reintroduce before discharge  if indicated Continue aspirin or DAPT • Withhold antiplatelet agents • Re-evaluate indication • Reintroduce after ulcer healing or earlier if needed Aspirin DAPT Antiplatelet agents for primary prevention Antiplatelet agents for secondary prevention Antiplatelet agents for primary prevention Antiplatelet agents for secondary prevention High-risk stigmata on endoscopy (Forrest classiﬁcation Ia, Ib, IIa or IIb) Low-risk stigmata on endoscopy (Forrest classiﬁcation IIc or III) NVUGIB in patients taking antiplatelet agents Successful endoscopic treatment Figure 7 | Management of NVUGIB in those using antiplatelet agents. If the antiplatelet therapy is taken for primary prevention of cardiovascular events, it should be discontinued in patients with a history of peptic ulcer bleeding (PUB); if an indication for continuing antiplatelet therapy exists, the risk of recurrent bleeding should be assessed by clinical and endoscopic criteria. Antiplatelet agents should not be stopped or, if stopped, they should be resumed a few days after endoscopy in those with non-variceal upper gastrointestinal bleeding (NVUGIB) who are on secondary cardiovascular prevention (for example, those with a previous ischaemic vascular event). In patients with PUB at low risk of recurrent bleeding, antiplatelet treatment should not be discontinued as the risk of a thromboembolic event outweighs the risk of recurrent bleeding from the gastrointestinal tract. In patients at high risk of recurrent bleeding, antiplatelet treatment should be stopped and can be resumed within 3–5 days. If the patient is receiving dual antiplatelet therapy (DAPT; combination of low-dose aspirin (LDA) and a P2Y purinoceptor 12 inhibitor), then the least potent antiplatelet drug should be restarted and a cardiologist’s opinion should be sought for resuming the second antiplatelet agent3. Algorithm based on recommendation of the European Society of Cardiology Working Group on Thrombosis49 and the European Society of Gastrointestinal Endoscopy guidelines5. PRIMER 14 | ARTICLE NUMBER 18020 | VOLUME 4	 www.nature.com/nrdp ©  2018  M acm illan  Publishers  Lim ited,  part  of  Springer  Nature. All  rights  reserved.",5070,731,1267.5,"[ 0.32281548 -0.17158186 -1.6010956  ...  0.11938956  0.47963274
 -1.3152212 ]"
120,"assessed as normal in 93.4% at the start of the intended procedure (1.6 hours after idarucizumab administration). At 90 days, thrombotic events had occurred in 6.3% and 7.4% of patients and the mortality was 18.8% and 18.9% in those with uncontrolled bleeding and those under­ going emergency surgery, respectively. Rebound effects may occur for up to 6 days and require repeat dosing177. The costs of these compounds may hamper the use in clinical practice. Other investigational antidotes include andexa­net alfa (for anti-factor Xa agents) and ciraparan­ tag (for many DOACs)178,179. FIGURE  9 summarizes current recommendations167,176,180. Continuing therapy following bleeding control. Once the bleeding event has been controlled, the decision to resume anticoagulation should involve a multi­disci­ plinary team and the patient; the need for anti­coagu­ lants should be reassessed using available risk scores (for example, CHA2DS2‑VASc and HAS-BLED)181,182. The implementation of alternative management (for example, ablation therapy for atrial fibrillation or catheter-­based atrial appendage occlusion), change of anti­coagulants (for example, apixaban may have a lower risk of gastro­ intestinal bleeding than other DOACs in indirect com­ parison studies)72 and optimization of treatment (for example, PPI, H. pylori eradication, stricter INR control or DOAC dose adaptation) should also be considered. Data, mostly involving vitamin K antago­nists72,183, show that resuming oral anticoagulation is associated with a lower mortality despite more frequent major bleeding184. A recent study involving 1,539 patients suggested that dabigatran offers simi­lar protection against thrombo­ embolism with less re-­bleeding than warfarin after major bleeding185. With respect to timing, although it is still a matter of debate, war­farin should be restarted 7–14 days following NVUGIB on the basis of a single available study, whereas DOACs act more rapidly186. If early anticoagulation is indicated (for example, in those with a high thrombo­embolic risk), a bridge approach with heparin may be used. A recent joint con­ sensus document composed by several international cardiology societies advocates an earlier resumption of vitamin K antago­nists — within the first week for patients with atrial ­fibrillation ­associated with valvular heart disease187. Quality of life At the time of an NVUGIB, symptoms can include vomit­ing of blood and blood in stools, abdominal pain, chest pain, cramping, burning, fatigue, dizziness, palpi­ tations and diarrhoea. Thus, the burden on patients during a bleeding event and hospitalization is con­ siderable, and health-related quality of life (HRQOL) is substantially impaired105,188,189. A negative associ­ ation exists between the number of symptoms experi­ enced by patients and self-reported levels of HRQOL189. Impairment to physical health accounts for most of the decrement in HRQOL experienced by individuals at the time of a bleeding event. Issues with mobility, performing daily activities, pain and discomfort have all been more frequently cited by patients than issues with ­anxiety and depression, and following hospital Determine INR Nature Reviews | Disease Primers Reverse vitamin K antagonistsa • Stop treatment with vitamin K antagonists • Administer vitamin K:  5–10 mg intravenous infusion over 30 minutes Reverse vitamin K antagonistsa • Stop treatment with vitamin K antagonists • Administer vitamin K: 5–10 mg intravenous infusion over 30 minutes) • PCC according to baseline INR valueb Check INR 20–30 minutes after PCC infusion • INR <1.5: recheck in 6 hours, then daily • INR >1.5: seek advice and consider PCC reinfusion No haemodynamic compromise Haemodynamic compromise INR >2.5 Stop vitamin K antagonist NVUGIB in patients taking vitamin K antagonists INR <2.5 Endoscopy Figure 8 | Management of NVUGIB in those using vitamin K antagonists. Vitamin K antagonists such as warfarin or coumadin should be stopped in patients who develop upper gastrointestinal bleeding and resumed soon after the bleeding is controlled. The international normalized ratio (INR) should be determined, and if INR is <2.5, diagnostic and therapeutic endoscopy can be performed safely. If INR is >2.5, endoscopy can be delayed until therapy to reverse the effect of the vitamin K antagonist has been implemented. The haemodynamic compromise (that is, blood pressure and volume that are not adequate to support normal organ function) will determine the type of therapy needed. The INR can be tested at intervals of 4, 12, 24, 28 and 72 hours, but this is based on little evidence.aBalancing with the risk of thrombosis, which is highest in patients who have atrial fibrillation, a CHA2DS2‑VASc score of ≥6, a mechanical mitral valve or a cardiac assist device.bFresh frozen plasma can be given at 15 ml per kg if PCC is unavailable. Algorithm based on expert consensus49,161–163. NVUGIB, non-variceal upper gastrointestinal bleeding; PCC, prothrombin complex concentrate. PRIMER NATURE REVIEWS | DISEASE PRIMERS	 VOLUME 4 | ARTICLE NUMBER 18020 | 15 ©  2018  M acm illan  Publishers  Lim ited,  part  of  Springer  Nature. All  rights  reserved.",5193,754,1298.25,"[ 0.29144132 -0.78647363 -1.58731    ...  0.30410394  0.53481805
 -1.270092  ]"
121,"admission for NVUGIB, patients have reported levels of general and physical fatigue to be considerably higher than mental and motivational fatigue105,188,190. With clinically effective endoscopic, surgical and medical therapies to stop and prevent bleeding, many physical symptoms can be resolved and improvements in HRQOL following the bleeding event can be ­realized. The few studies taking repeated HRQOL measures from patients who have had an NVUGIB have shown a signifi­cant reduction in symptoms and improvements in the physical dimensions of health following discharge compared with during the hospital stay105,188,189. The long-term consequences of an NVUGIB for patients often include anaemia, which is associated with fatigue, heart palpitations, pallor and shortness of breath191. The already high prevalence of anaemia (50–80%)192,193 in patients discharged from the hospital following a bleeding event is likely to increase, with more restrictive blood transfusion strategies being adopted for NVUGIB104,194,195. Iron supplementation in the months following an NVUGIB can help increase haemoglobin levels and correct anaemia, but little is known about whether this directly translates into improvements in HRQOL196. One small study in 97 patients diagnosed with anaemia following NVUGIB showed that 6 months after the NVUGIB, the proportion of patients who reached the normalized HRQOL score was higher and general and physical fatigue levels were lower in those patients for whom anaemia had been resolved than in those with persistent anaemia; differences at other time points were non-significant188. Iron supplemen­ tation can be provided intravenously before discharge, which will reduce the time to recover to appropriate haemoglobin levels197. HRQOL generally follows an upward trajectory in the weeks and months following hospital discharge for NVUGIB. However, a return to general popula­ tion normal levels seems unlikely, probably because of the considerable role of pre-existing comorbidi­ ties and their associated treatments in the aetiology of NVUGIB105,188–190. For patients with NVUGIB, the increased risk of re-bleeding associated with NSAIDs and antiplatelet and anticoagulant therapies must be carefully considered when planning subsequent care. NVUGIB can have a substantial impact on other aspects of quality of life (QOL) in patients and their families. Patients can require many days of informal care from family members at home during the first few weeks following a bleeding event190. In providing this help, caregivers must take time away from their usual activities, which may incur costs (financial or otherwise). In addition, for patients who are in paid employment at the time of NVUGIB, an immediate return to work is unlikely, resulting in a loss of working hours and possible earnings190. The consequences of NVUGIB can, therefore, be substantial and wide rang­ ing, affecting aspects of HRQOL and QOL for patients and their families. Outlook NVUGIB is one of the most frequent causes of hos­ pitalization, morbidity and mortality associated with digestive diseases. Despite the important advances observed in the field, the management of patients with NVUGIB has become ever more challenging owing to an ageing population with comorbidities and complex therapies. PUB remains the main cause of NVUGIB, and most advances in NVUGIB have been focused on this pathology. However, the face and profile of NVUGIB events are changing, which demands new approaches in ­prevention, diagnosis and therapy9,23. Management From a pathogenetic point of view and in addition to the appropriate endoscopic management of bleeding lesions, stabilization of the clotting process in the acidic environment of the upper gastrointestinal tract is a goal that should be achieved for the successful control of the bleeding event. Although the route of administra­ tion and best dosing regimen are still matters of debate, there is consensus that PPIs are the drug of choice. The development of new compounds such as a new class of potassium-competitive acid blockers may facilitate emergency treatment of NVUGIB as they have a faster onset and greater, more consistent and longer acid ­control198 than PPIs. Endoscopic diagnosis and treatment of gastro­ intestinal bleeding lesions probably represent the most important advances in the control of bleeding events. Innovation in endoscopic techniques continues to provide new tools for the management of NVUGIB. New therapies with compounds or devices that can be safely applied during the endoscopic procedures or new diagnostic tools such as the endoscopic Doppler probe that can improve the localization of the blood vessel responsible for the bleeding97 will probably be imple­ mented in our routine clinical practice in the future once they prove to be safe and useful in clinical trials. Patients with ongoing bleeding despite initial volume restitution could benefit from very early endoscopy (<12 hours or even <6 hours), but this should be clarified in future studies. New studies should also define whether ­routine second-look endoscopy can be performed in selected patients at high risk of therapeutic failure after first-line therapy. Box 5 | Coagulation tests for DOACs Results of routine coagulation tests in patients taking direct oral anticoagulants (DOACs) are unreliable and vary depending on the reagents used. Approximately 20% of patients who take dabigatran have a normal activated partial thromboplastin time213,214. However, the American Society of Hematology states in its practice guide that dabigatran is unlikely to contribute to bleeding if partial thromboplastin time is normal215. Similar findings have been reported with prothrombin time for rivaroxaban216. In some specialized laboratories, activity assays calibrated to the specific drug can be performed (that is, diluted thrombin time specific for dabigatran and anti-factor Xa assays specific for rivaroxaban, apixaban and edoxaban)217. PRIMER 16 | ARTICLE NUMBER 18020 | VOLUME 4	 www.nature.com/nrdp ©  2018  M acm illan  Publishers  Lim ited,  part  of  Springer  Nature. All  rights  reserved.",6159,912,1539.75,"[-0.37948346 -0.20275328 -1.939733   ...  0.35306525  0.8463859
 -1.0870289 ]"
122,"Patients on antiplatelet or anticoagulation agents The clearest changes are the progressive decline in H. pylori-related PUB in developed countries and a pro­ gressive increase in elderly patients with NVUGIB, who often take antiplatelet and anticoagulant agents. These changes demand specific approaches in both prevention and therapeutic management owing to the increased risk of thromboembolic events when these therapies are withheld during a bleeding event. In our experience, the proportion of patients with this problem is growing. The new DOACs will progressively replace vitamin K antagonists, and the development of agents to reverse each specific DOAC will be a challenge in terms of the appropriate management and costs. The opportunity to improve adherence to guideline recommendations for PPI prophylaxis for those patients on antiplatelet and/or anticoagulant therapy remains a challenge in daily ­clinical practice199. Prognostic scoring systems Several prognostic scores have been developed to facili­ tate the clinical decision path at the time of emergency admission before and/or after endoscopy. When sev­ eral prognostic scores are used or proposed, or when they are infrequently used in most emergency rooms200, the logical conclusion is to assume that none of them fulfils all demands required by the clinicians. The GBS seems to be the best at predicting most outcomes but not mortality. A low GBS score (0–1) would mandate ambulatory treatment, but few patients present at emergency rooms with such a low score, which limits its impact. With new statistical approaches, learning machines and artificial intelligence systems, efforts should be made to find the best tool to predict the best management approach. Prognosis Although overall mortality associated with NVUGIB has declined over time owing to a parallel decrease in the number of events, mortality linked to the bleeding event itself is resistant because the majority of patients with NVUGIB die from non-bleeding-related causes4. Clearly, further improvements of this outcome will be a challenge and probably require a multidisciplinary approach by specialized teams. Finally, one aspect often overlooked and rarely investigated is the prognosis of patients with NVUGIB beyond the event. Thus far, little attention has been paid to the QOL of patients following a gastrointesti­ nal bleeding event because this aspect requires con­ tact to be maintained with patients and actions to be implemented after hospital discharge. The appropriate management of anaemia and iron deficiency has the potential to directly affect the QOL and performance of most patients. Implications for physical health, mobility, performance of daily activities, pain, discomfort, ­anxiety and depression following hospital admission and dis­ charge have not been as adequately investigated and are as important to patients and families as the bleed­ ing itself. These aspects need to be featured within our agenda when ­considering the appropriate management of patients105,188,190. Figure 9 | Management of NVUGIB in those on DOACs. Direct oral anticoagulant (DOAC) treatment should be withheld in patients with an ongoing non-variceal upper gastrointestinal bleeding (NVUGIB) episode. Depending on the severity of bleeding and the specific DOAC taken, other measures might be needed. UGIB, upper gastrointestinal bleeding.aIf idarucizumab is not available (in case of dabigatran use) or the patient is treated with anti-factor Xa, use four‑factor prothrombin complex concentrate (PCC). Algorithm based on expert consensus and recommendations of the European Hearth Rhythm Association167,176,180. Nature Reviews | Disease Primers Undergo measures to control mild bleeding plus • Aggressive ﬂuid replacement • Consider charcoal (DOAC overdose  <3 hours) For dabigatran, consider • Haemodialysis • Intravenous idarucizumab For anti-factor Xaa, consider four-factor PCC Delay or interrupt DOAC Inquire about type and last dose of DOAC Blood sample to measure creatinine and speciﬁc coagulation test (if available) UGIB in patients taking DOACs Moderate to severe bleeding Undergo measures to control moderate or severe bleeding plus • For dabigatran:  intravenous idarucizumab • For anti-factor Xaa:  four-factor PCC Life-threatening bleeding or ongoing bleeding despite adequate measures Mild bleeding 1.	 Laine, L. Upper gastrointestinal bleeding due to a peptic ulcer. N. Engl. J. Med.374, 2367–2376 (2016).2.	 Gralnek, I. M., Neeman, Z. & Strate, L. L. Acute lower gastrointestinal bleeding. N. Engl. J. Med.376, 1054–1063 (2017).3.	 Lanas, A. & Chan, F. K. Peptic ulcer disease. Lancet 390, 613–624 (2017).4.	 Sung, J. J. et al. Causes of mortality in patients with peptic ulcer bleeding: a prospective cohort study of 10,428 cases. Am. J. Gastroenterol.105, 84–89 (2010).5.",4840,691,1210.0,"[ 0.05990975 -0.26011395 -1.9525143  ...  0.27728415  0.89444226
 -1.5560017 ]"
122,"Gralnek, I. M. et al. Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 47, a1–a46 (2015). This paper presents the most recent European guidelines based on the best available evidence for the complete management of NVUGIB.6.	 Rotondano, G. Epidemiology and diagnosis of acute nonvariceal upper gastrointestinal bleeding. Gastroenterol. Clin. North Am.43, 643–663 (2014).7.	 Hreinsson, J. P., Kalaitzakis, E., Gudmundsson, S. & Björnsson, E. S. Upper gastrointestinal bleeding: incidence, etiology and outcomes in a population-based setting. Scand. J. Gastroenterol.48, 439–447 (2013).8.	 Gralnek, I. M., Barkun, A. N. & Bardou, M. Management of acute bleeding from a peptic ulcer. N. Engl. J. Med.359, 928–937 (2008).9.	 Laine, L., Yang, H., Chang, S. C. & Datto, C. Trends for incidence of hospitalization and death due to GI complications in the United States from 2001 to 2009. Am. J. Gastroenterol.107, 1190–1195 (2012).10.	 Laine, L. & Jensen, D. M. Management of patients with ulcer bleeding. Am. J. Gastroenterol.107, 345–360 (2012).11.	 Lau, J. Y. et al. Challenges in the management of acute peptic ulcer bleeding. Lancet 381, 2033–2043 (2013).12.	 Quan, S. et al. Upper-gastrointestinal bleeding secondary to peptic ulcer disease: incidence and outcomes. World J. Gastroenterol.20, 17568–17577 (2014).13.	 Tielleman, T., Bujanda, D. & Cryer, B. Epidemiology and risk factors for upper gastrointestinal bleeding. Gastrointest. Endosc.",1543,174,385.75,"[-0.00984134 -0.27878857 -1.5510597  ...  0.11132172  0.3377238
 -1.0465974 ]"
122,"Clin. N. Am.25, 415–428 (2015).14.	 Everhart, J. E. & Ruhl, C. E. Burden of digestive diseases in the United States part I: overall and upper gastrointestinal diseases. Gastroenterology 136, 376–386 (2009).15.	 Wuerth, B. A. & Rockey, D. C. Changing epidemiology of upper gastrointestinal hemorrhage in the last decade: a nationwide analysis. Dig. Dis. Sci. (2017).16.	 van Leerdam, M. E. et al. Acute upper GI bleeding: did anything change?Time trend analysis of incidence and outcome of acute upper GI bleeding between 1993/1994 and 2000. Am. J. Gastroenterol.98, 1494–1499 (2003).17.	 Lanas, A. et al. A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use. Am. J. Gastroenterol.100, 1685–1693 (2005).18.	 Ahsberg, K., Ye, W., Lu, Y., Zheng, Z. & Staël von Holstein, C. Hospitalisation of and mortality from bleeding peptic ulcer in Sweden: a nationwide time-trend analysis. Aliment. Pharmacol. Ther.33, 578–584 (2011).19.	 Cavallaro, L. G. et al. Time trends and outcome of gastrointestinal bleeding in the Veneto region: a retrospective population based study from 2001 to 2010. Dig. Liver Dis.46, 313–317 (2014). PRIMER NATURE REVIEWS | DISEASE PRIMERS	 VOLUME 4 | ARTICLE NUMBER 18020 | 17 ©  2018  M acm illan  Publishers  Lim ited,  part  of  Springer  Nature. All  rights  reserved.",1407,187,351.75,"[ 0.14865272 -0.47325647 -1.2160609  ... -0.23790425  0.64667535
 -1.4474281 ]"
123,"20.	 Sonnenberg, A. Time trends of ulcer mortality in non-European countries. Am. J. Gastroenterol.102, 1101–1107 (2007).21.	 Wollenman, C. S., Chason, R., Reisch, J. S. & Rockey, D. C. Impact of ethnicity in upper gastrointestinal hemorrhage. J. Clin. Gastroenterol. 48, 343–350 (2014).22.	 Irwin, J., Ferguson, R., Weilert, F. & Smith, A. Incidence of upper gastrointestinal haemorrhage in Maori and New Zealand European ethnic groups, 2001–2010. Intern. Med. J. 44, 735–741 (2014).23.	 Lanas, A. et al. The changing face of hospitalisation due to gastrointestinal bleeding and perforation. Aliment. Pharmacol. Ther.33, 585–591 (2011).24.	 Papatheodoridis, G. V., Sougioultzis, S. & Archimandritis, A. J. Effects of Helicobacter pylori and nonsteroidal anti-inflammatory drugs on peptic ulcer disease: a systematic review. Clin. Gastroenterol. Hepatol.4, 130–142 (2006).25.	 Gisbert, J. P. & Calvet, X. Review article: Helicobacter pylori-negative duodenal ulcer disease. Aliment. Pharmacol. Ther.30, 791–815 (2009).26.	 Charpignon, C. et al. Peptic ulcer disease: one in five is related to neither Helicobacter pylori nor aspirin/NSAID intake. Aliment. Pharmacol. Ther.38, 946–954 (2013).27.	 Chan, H. L. et al.",1214,130,303.5,"[ 0.17145233 -0.5185564  -0.9691709  ...  0.3213542  -0.0232787
 -1.3751763 ]"
123,"Is non-Helicobacter pylori, non‑NSAID peptic ulcer a common cause of upper GI bleeding?A prospective study of 977 patients. Gastrointest. Endosc.53, 438–442 (2001).28.	 Yoon, H., Kim, S. G., Jung, H. C. & Song, I. S. High recurrence rate of idiopathic peptic ulcers in long-term follow‑up. Gut Liver 7, 175–181 (2013).29.	 Wong, G. L. et al. Gastroprotective therapy does not improve outcomes of patients with Helicobacter pylori-negative idiopathic bleeding ulcers. Clin. Gastroenterol. Hepatol.10, 1124–1129 (2012).30.	 Wong, G. L. et al. High incidence of mortality and recurrent bleeding in patients with Helicobacter pylori-negative idiopathic bleeding ulcers. Gastroenterology 137, 525–531 (2009).31.	 Iijima, K., Kanno, T., Koike, T. & Shimosegawa, T. Helicobacter pylori-negative, non-steroidal anti- inflammatory drug: negative idiopathic ulcers in Asia. World J. Gastroenterol.20, 706–713 (2014).32.	 Crooks, C., Card, T. & West, J. Reductions in 28‑day mortality following hospital admission for upper gastrointestinal hemorrhage. Gastroenterology 141, 62–70 (2011).33.	 Abougergi, M. S., Travis, A. C. & Saltzman, J. R. The in‑hospital mortality rate for upper GI hemorrhage has decreased over 2 decades in the United States: a nationwide analysis. Gastrointest. Endosc.81, 882–888.e1 (2015).34.	 Taefi, A., Cho, W. K. & Nouraie, M. Decreasing trend of upper gastrointestinal bleeding mortality risk over three decades. Dig. Dis. Sci.58, 2940–2948 (2013).35.	 Jairath, V., Martel, M., Logan, R. F. & Barkun, A. N. Why do mortality rates for nonvariceal upper gastrointestinal bleeding differ around the world? A systematic review of cohort studies. Can. J. Gastroenterol.26, 537–543 (2012).",1702,191,425.5,"[-0.15627272 -0.3047144  -1.172721   ...  0.21243411  0.21257713
 -1.2708826 ]"
123,"36.	 Sostres, C. & Lanas, A. Epidemiology and demographics of upper gastrointestinal bleeding: prevalence, incidence, and mortality. Gastrointest. Endosc. Clin. N. Am.21, 567–581 (2011).37.	 Wang, F., Meng, W., Wang, B. & Qiao, L. Helicobacter pylori-induced gastric inflammation and gastric cancer. Cancer Lett.345, 196–202 (2014).38.	 Datta De, D. & Roychoudhury, S. To be or not to be: The host genetic factor and beyond in Helicobacter pylori mediated gastro-duodenal diseases. World J. Gastroenterol.21, 2883–2895 (2015).39.	 Zaki, M. et al. H. pylori acutely inhibits gastric secretion by activating CGRP sensory neurons coupled to stimulation of somatostatin and inhibition of histamine secretion. Am. J. Physiol. Gastrointest. Liver Physiol.304, G715–722 (2013).40.	 Moss, S. F., Legon, S., Bishop, A. E., Polak, J. M. & Calam, J. Effect of Helicobacter pylori on gastric somatostatin in duodenal ulcer disease. Lancet 340, 930–932 (1992).41.	 Bjarnason, I. et al. Mechanisms of damage to the gastrointestinal tract from nonsteroidal anti- inflammatory drugs. Gastroenterology 154, 500–514 (2018).42.	 Cryer, B. & Feldman, M. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology 117, 17–25 (1999).43.	 Sostres, C. et al. Peptic ulcer bleeding risk. The role of Helicobacter pylori infection in NSAID/low-dose aspirin users. Am. J. Gastroenterol.110, 684–689 (2015).44.	 Green, F. W., Kaplan, M. M., Curtis, L. E. & Levine, P. H. Effect of acid and pepsin on blood coagulation and platelet aggregation. A possible contributor prolonged gastroduodenal mucosal hemorrhage.",1694,199,423.5,"[-0.10458289 -0.35842645 -1.2226133  ...  0.43156788 -0.06201883
 -1.4447247 ]"
123,"Gastroenterology 74, 38–43 (1978).45.	 Lanas, A. et al. Effect of parenteral omeprazole and ranitidine on gastric pH and the outcome of bleeding peptic ulcer. J. Clin. Gastroenterol.21, 103–106 (1995).46.	 van Rensburg, C. J. et al. Intragastric pH during continuous infusion with pantoprazole in patients with bleeding peptic ulcer. Am. J. Gastroenterol.98, 2635–2641 (2003).47.	 Laine, L., Shah, A. & Bemanian, S. Intragastric pH with oral versus intravenous bolus plus infusion proton- pump inhibitor therapy in patients with bleeding ulcers. Gastroenterology 134, 1836–1841 (2008).48.	 Bardou, M., Toubouti, Y., Benhaberou-Brun, D., Rahme, E. & Barkun, A. N. Meta-analysis: proton- pump inhibition in high-risk patients with acute peptic ulcer bleeding. Aliment. Pharmacol. Ther.21, 677–686 (2005).49.	 Halvorsen, S. et al. Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis. Eur. Heart J. 38, 1455–1462 (2017).50.	 Laine, L., Maller, E. S., Yu, C., Quan, H. & Simon, T. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX‑2 selective inhibition: a double- blind trial. Gastroenterology 127, 395–402 (2004).51.	 Hernández-Díaz, S. & García Rodríguez, L. A. Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. BMC Med.4, 22 (2006).52.	 Lanas, A. I. et al. Aspirin related gastrointestinal bleeders have an exaggerated bleeding time response due to aspirin use. Gut 39, 654–660 (1996).53.	 García-González, M. A. et al. Association of interleukin 1 gene family polymorphisms with duodenal ulcer disease. Clin. Exp.",1740,208,435.0,"[-0.05285036 -0.3349315  -1.2692866  ...  0.72017765  0.3451873
 -1.4770786 ]"
123,"Immunol.134, 525–531 (2003).54.	 Okada, M. et al. Circumferential distribution and location of Mallory-Weiss tears: recent trends. Endosc. Int. Open 3, E418–424 (2015).55.	 Cherednikov, E. F., Kunin, A. A., Cherednikov, E. E. & Moiseeva, N. S. The role of etiopathogenetic aspects in prediction and prevention of discontinuous- hemorrhagic (Mallory-Weiss) syndrome. EPMA J. 7, 7 (2016).56.	 Baxter, M. & Aly, E. H. Dieulafoy’s lesion: current trends in diagnosis and management. Ann. R. Coll. Surg. Engl.92, 548–554 (2010).57.	 Sami, S. S., Al‑Araji, S. A. & Ragunath, K. Review article: gastrointestinal angiodysplasia - pathogenesis, diagnosis and management. Aliment. Pharmacol. Ther.39, 15–34 (2014).58.	 Kim, D. B. et al. Analysis of risk factor and clinical characteristics of angiodysplasia presenting as upper gastrointestinal bleeding. Kor. J. Intern. Med.31, 669–677 (2016).59.	 Crooks, C. J., West, J. & Card, T. R. Comorbidities affect risk of nonvariceal upper gastrointestinal bleeding. Gastroenterology 144, 1384–1393.e2 (2013).60.	 De Backer, D., Creteur, J., Dubois, M. J., Sakr, Y. & Vincent, J. L. Microvascular alterations in patients with acute severe heart failure and cardiogenic shock. Am. Heart J. 147, 91–99 (2004).61.	 Huang, K. W. et al. Chronic obstructive pulmonary disease: an independent risk factor for peptic ulcer bleeding: a nationwide population-based study. Aliment. Pharmacol.",1415,158,353.75,"[-0.18970849 -0.5555614  -1.290967   ... -0.2577139   0.28180146
 -0.96867853]"
123,"Ther.35, 796–802 (2012).62.	 Luo, J. C. et al. Incidence of bleeding from gastroduodenal ulcers in patients with end-stage renal disease receiving hemodialysis. CMAJ 183, E1345–E1351 (2011).63.	 Hunt, R. H., Lanas, A., Stichtenoth, D. O. & Scarpignato, C. Myths and facts in the use of anti- inflammatory drugs. Ann. Med.41, 423–437 (2009).64.	 Masclee, G. M. et al. Risk of upper gastrointestinal bleeding from different drug combinations. Gastroenterology 147, 784–792.e9 (2014).65.	 Laine, L. et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology 123, 1006–1012 (2002).66.	 Lanas, A. & Hunt, R. Prevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategies. Ann. Med.38, 415–428 (2006).67.	 Scarpignato, C. et al. Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis — an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks. BMC Med. 13, 55 (2015).68.	 Chan, F. K. et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N. Engl. J. Med.344, 967–973 (2001).69.	 Chan, F. K. et al. Combination of a cyclo-oxygenase‑2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 369, 1621–1626 (2007). This article presents the first RCT that demonstrated the combination of a COX2 inhibitor and a PPI is the best strategy to reduce the risk of recurrent PUB in patients at very high risk (that is, those who have had a previous ulcer bleeding event) who need NSAIDs.70.	 Anglin, R. et al. Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti- inflammatory use: a systematic review and meta- analysis.",2023,255,505.75,"[-0.31019408 -0.0590906  -1.393902   ...  0.1973618   0.70475936
 -1.7575349 ]"
123,"Am. J. Gastroenterol.109, 811–819 (2014).71.	 Bhatt, D. L. et al. Clopidogrel with or without omeprazole in coronary artery disease. N. Engl. J. Med.363, 1909–1917 (2010). This is the only double-blind RCT that tested both cardiovascular and gastrointestinal events in patients who receive clopidogrel plus LDA and omeprazole versus clopidogrel and LDA. Omeprazole reduced the number of gastrointestinal events and did not increase the risk of cardiovascular events.72.	 Lanas-Gimeno, A. & Lanas, A. Risk of gastrointestinal bleeding during anticoagulant treatment. Expert Opin. Drug Saf 16, 673–685 (2017).73.	 Nuki, Y. et al. The influence of CYP2C19 polymorphisms on exacerbating effect of rabeprazole in celecoxib-induced small bowel injury. Aliment. Pharmacol. Ther.46, 331–336 (2017).74.	 Moayyedi, P. M. et al. ACG and CAG Clinical Guideline: Management of Dyspepsia. Am. J. Gastroenterol. 112, 988–1013 (2017).75.	 Malfertheiner, P. et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 66, 6–30 (2017).76.	 Huang, T. C. & Lee, C. L. Diagnosis, treatment, and outcome in patients with bleeding peptic ulcers and Helicobacter pylori infections. Biomed. Res. Int.2014, 658108 (2014).77.	 Srygley, F. D., Gerardo, C. J., Tran, T. & Fisher, D. A. Does this patient have a severe upper gastrointestinal bleed?JAMA 307, 1072–1079 (2012).78.	 Barkun, A. et al.",1406,163,351.5,"[ 0.7708759  -0.66389346 -1.2818567  ...  0.48345315  0.51584476
 -1.9504179 ]"
123,"International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann. Intern. Med.152, 101–113 (2010).79.	 Shrestha, M. P., Borgstrom, M. & Trowers, E. Digital rectal examination reduces hospital admissions, endoscopies, and medical therapy in patients with acute gastrointestinal bleeding. Am. J. Med.130, 819–825 (2017).80.	 Stanley, A. J. et al. Comparison of risk scoring systems for patients presenting with upper gastrointestinal bleeding: international multicentre prospective study. BMJ 356, i6432 (2017). This prospective study of 3,012 consecutive patients analysed the predictive accuracy and clinical utility of five risk-scoring systems in the assessment of patients with NVUGIB. The GBS was the best of all, showing high accuracy at predicting the need for hospital-based intervention or death.81.	 Wolf, A. T., Wasan, S. K. & Saltzman, J. R. Impact of anticoagulation on rebleeding following endoscopic therapy for nonvariceal upper gastrointestinal hemorrhage. Am. J. Gastroenterol.102, 290–296 (2007).82.	 Jairath, V. et al. Outcomes following acute nonvariceal upper gastrointestinal bleeding in relation to time to endoscopy: results from a nationwide study. Endoscopy 44, 723–730 (2012). PRIMER 18 | ARTICLE NUMBER 18020 | VOLUME 4	 www.nature.com/nrdp ©  2018  M acm illan  Publishers  Lim ited,  part  of  Springer  Nature. All  rights  reserved.",1423,185,355.75,"[ 0.42073846 -0.6518795  -1.885286   ...  0.20412126  0.99181074
 -1.006009  ]"
124,"83.	 Hearnshaw, S. A. et al. Use of endoscopy for management of acute upper gastrointestinal bleeding in the UK: results of a nationwide audit. Gut 59, 1022–1029 (2010).84.	 Sarin, N., Monga, N. & Adams, P. C. Time to endoscopy and outcomes in upper gastrointestinal bleeding. Can. J. Gastroenterol.23, 489–493 (2009).85.	 Targownik, L. E., Murthy, S., Keyvani, L. & Leeson, S. The role of rapid endoscopy for high-risk patients with acute nonvariceal upper gastrointestinal bleeding. Can. J. Gastroenterol.21, 425–429 (2007).86.	 Tai, C. M. et al. High-risk ED patients with nonvariceal upper gastrointestinal hemorrhage undergoing emergency or urgent endoscopy: a retrospective analysis. Am. J. Emerg. Med.25, 273–278 (2007).87.	 Spiegel, B. M., Vakil, N. B. & Ofman, J. J. Endoscopy for acute nonvariceal upper gastrointestinal tract hemorrhage: is sooner better?A systematic review. Arch. Intern. Med.161, 1393–1404 (2001).88.	 Tsoi, K. K., Ma, T. K. & Sung, J. J. Endoscopy for upper gastrointestinal bleeding: how urgent is it? Nat. Rev. Gastroenterol. Hepatol.6, 463–469 (2009).89.	 Kumar, N. L., Cohen, A. J., Nayor, J., Claggett, B. L. & Saltzman, J. R. Timing of upper endoscopy influences outcomes in patients with acute nonvariceal upper GI bleeding. Gastrointest. Endosc. 85, 945–952.e1 (2017).90.	 Forrest, J. A., Finlayson, N. D. & Shearman, D. J. Endoscopy in gastrointestinal bleeding. Lancet 2, 394–397 (1974).91.",1431,163,357.75,"[-0.22307016 -0.6808004  -1.9834275  ...  0.58847755  0.9096458
 -0.91896486]"
124,"Heldwein, W., Schreiner, J., Pedrazzoli, J. & Lehnert, P. Is the Forrest classification a useful tool for planning endoscopic therapy of bleeding peptic ulcers? Endoscopy 21, 258–262 (1989).92.	 Lau, J. Y. et al. The evolution of stigmata of hemorrhage in bleeding peptic ulcers: a sequential endoscopic study. Endoscopy 30, 513–518 (1998).93.	 Lau, J. Y. et al. Stigmata of hemorrhage in bleeding peptic ulcers: an interobserver agreement study among international experts. Gastrointest. Endosc. 46, 33–36 (1997).94.	 Laine, L. & McQuaid, K. R. Endoscopic therapy for bleeding ulcers: an evidence-based approach based on meta-analyses of randomized controlled trials. Clin. Gastroenterol. Hepatol.7, 33–47 (2009). This meta-analysis of RCTs determined the best endoscopic treatment of patients with bleeding ulcers.95.	 Sung, J. J. et al. The effect of endoscopic therapy in patients receiving omeprazole for bleeding ulcers with nonbleeding visible vessels or adherent clots: a randomized comparison. Ann. Intern. Med.139, 237–243 (2003).96.	 Jensen, D. M. et al. Randomized trial of medical or endoscopic therapy to prevent recurrent ulcer hemorrhage in patients with adherent clots. Gastroenterology 123, 407–413 (2002).97.	 Jensen, D. M. et al. Doppler endoscopic probe as a guide to risk stratification and definitive hemostasis of peptic ulcer bleeding. Gastrointest. Endosc.83, 129–136 (2016).98.	 Jensen, D. M. et al. Reassessment of rebleeding risk of Forrest IB (oozing) peptic ulcer bleeding in a large international randomized trial. Am. J. Gastroenterol. 112, 441–446 (2017).99.",1592,194,398.0,"[-0.2446066  -0.5700594  -1.2814298  ...  0.9164712   0.20723505
 -1.7134914 ]"
124,"Jensen, D. M. et al. Doppler endoscopic probe monitoring of blood flow improves risk stratification and outcomes of patients with severe nonvariceal upper gastrointestinal hemorrhage. Gastroenterology 152, 1310–1318.e1 (2017).100.	Fujishiro, M. et al. Current managements and outcomes of peptic and artificial ulcer bleeding in Japan. Dig. Endosc.22 (Suppl.1), S9–S14 (2010).101.	Fujishiro, M. et al. Guidelines for endoscopic management of non-variceal upper gastrointestinal bleeding. Dig. Endosc.28, 363–378 (2016).102.	El Ouali, S. et al. Is routine second-look endoscopy effective after endoscopic hemostasis in acute peptic ulcer bleeding?A meta-analysis. Gastrointest. Endosc. 76, 283–292 (2012). This meta-analysis of randomized trials concluded that in unselected patients and in the era of high-dose PPI, second-look endoscopy does not offer significant benefit.103.	Imperiale, T. F. & Kong, N. Second-look endoscopy for bleeding peptic ulcer disease: a decision-effectiveness and cost-effectiveness analysis. J. Clin. Gastroenterol. 46, e71–e75 (2012).104.	Villanueva, C. et al. Transfusion strategies for acute upper gastrointestinal bleeding. N. Engl. J. Med.368, 11–21 (2013). This seminal study shows that, compared with a liberal blood transfusion policy, a restrictive blood transfusion policy in patients with UGIB is associated with better survival.105.	Leontiadis, G. I. et al. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. Health Technol. Assess.11, 1–164 (2007).106.",1582,183,395.5,"[ 0.30965674 -0.59681845 -1.1663663  ...  0.48834074  0.07116069
 -1.5269152 ]"
124,"Sreedharan, A. et al. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database Syst. Rev. 7, CD005415 (2010).107.	Al‑Sabah, S. et al. Cost-effectiveness of proton-pump inhibition before endoscopy in upper gastrointestinal bleeding. Clin. Gastroenterol. Hepatol.6, 418–425 (2008).108.	Theivanayagam, S. et al. Administration of erythromycin before endoscopy in upper gastrointestinal bleeding: a meta-analysis of randomized controlled trials. Saudi J. Gastroenterol. 19, 205–210 (2013).109.	Barkun, A. N., Martel, M., Toubouti, Y., Rahme, E. & Bardou, M. Endoscopic hemostasis in peptic ulcer bleeding for patients with high-risk lesions: a series of meta-analyses. Gastrointest. Endosc.69, 786–799 (2009).110.	 Sung, J. J., Tsoi, K. K., Lai, L. H., Wu, J. C. & Lau, J. Y. Endoscopic clipping versus injection and thermo- coagulation in the treatment of non-variceal upper gastrointestinal bleeding: a meta-analysis. Gut 56, 1364–1373 (2007).111.	 Calvet, X., Vergara, M., Brullet, E., Gisbert, J. P. & Campo, R. Addition of a second endoscopic treatment following epinephrine injection improves outcome in high-risk bleeding ulcers. Gastroenterology 126, 441–450 (2004).112.	Marmo, R. et al. Dual therapy versus monotherapy in the endoscopic treatment of high-risk bleeding ulcers: a meta-analysis of controlled trials. Am. J. Gastroenterol.102, 279–289 (2007).113.	Vergara, M., Bennett, C., Calvet, X. & Gisbert, J. P. Epinephrine injection versus epinephrine injection and a second endoscopic method in high-risk bleeding ulcers. Cochrane Database Syst. Rev. 2, CD005584 (2014).114.	Hwang, J. H. et al. The role of endoscopy in the management of acute non-variceal upper GI bleeding. Gastrointest. Endosc.75, 1132–1138 (2012).",1797,194,449.25,"[ 0.0320795  -0.3514387  -1.2284232  ...  0.56039965  0.62629974
 -1.5355185 ]"
124,"115.	Fujishiro, M. et al. Retrospective multicenter study concerning electrocautery forceps with soft coagulation for nonmalignant gastroduodenal ulcer bleeding in Japan. Dig. Endosc.22 (Suppl.1), S15–S18 (2010).116.	Wedi, E. et al. Use of the over-the-scope-clip (OTSC) in non-variceal upper gastrointestinal bleeding in patients with severe cardiovascular comorbidities: a retrospective study. Endosc. Int. Open 5, E875–E882 (2017).117.	Prei, J. C. et al. EndoClot polysaccharide hemostatic system in nonvariceal gastrointestinal bleeding: results of a prospective multicenter observational pilot study. J. Clin. Gastroenterol.50, e95–e100 (2016).118.	Haddara, S. et al. A novel hemostatic powder for upper gastrointestinal bleeding: a multicenter study (the “GRAPHE” registry). Endoscopy 48, 1084–1095 (2016).119.	Lecleire, S. et al. Endoscopic band ligation could decrease recurrent bleeding in Mallory-Weiss syndrome as compared to haemostasis by hemoclips plus epinephrine. Aliment. Pharmacol. Ther.30, 399–405 (2009).120.	Yamaguchi, Y. et al. Endoscopic hemoclipping for upper GI bleeding due to Mallory-Weiss syndrome. Gastrointest. Endosc.53, 427–430 (2001).121.	Silverstein, F. E. et al. Argon versus neodymium YAG laser photocoagulation of experimental canine gastric ulcers. Gastroenterology 77, 491–496 (1979).122.	Kwan, V. et al. Argon plasma coagulation in the management of symptomatic gastrointestinal vascular lesions: experience in 100 consecutive patients with long-term follow‑up.",1501,160,375.25,"[-0.01956406 -0.40956724 -1.4437082  ...  0.77447087  0.09371443
 -1.3927406 ]"
124,"Am. J. Gastroenterol.101, 58–63 (2006).123.	Sargeant, I. R., Loizou, L. A., Rampton, D., Tulloch, M. & Bown, S. G. Laser ablation of upper gastrointestinal vascular ectasias: long term results. Gut 34, 470–475 (1993).124.	Zulli, C. et al. Refractory gastric antral vascular ectasia: a new endoscopic approach. Eur. Rev. Med. Pharmacol. Sci.19, 4119–4122 (2015).125.	Maida, M., Camilleri, S., Manganaro, M., Garufi, S. & Scarpulla, G. Radiofrequency ablation for treatment of refractory gastric antral vascular ectasia: a systematic review of the literature. Gastroenterol. Res. Pract.2017, 5609647 (2017).126.	Park, C. H. et al. A prospective, randomized trial of endoscopic band ligation versus endoscopic hemoclip placement for bleeding gastric Dieulafoy’s lesions. Endoscopy 36, 677–681 (2004).127.	Chaimoff, C., Creter, D. & Djaldetti, M. The effect of pH on platelet and coagulation factor activities. Am. J. Surg.136, 257–259 (1978).128.	Vorder Bruegge, W. F. & Peura, D. A. Stress-related mucosal damage: review of drug therapy. J. Clin. Gastroenterol.12 (Suppl.2), S35–S40 (1990).129.	Peterson, K. & Bjorkman, D. J. Editorial: Intravenous proton pump inhibitors for bleeding peptic ulcer: what is the most cost-effective approach? Am. J. Gastroenterol.111, 1399–1401 (2016).130.	Lu, Y., Adam, V., Teich, V. & Barkun, A. Timing or dosing of intravenous proton pump inhibitors in acute upper gastrointestinal bleeding has low impact on costs. Am.",1452,154,363.0,"[ 0.21285309 -0.5248517  -1.3701798  ...  0.22977746  0.2585435
 -1.2896571 ]"
124,"J. Gastroenterol.111, 1389–1398 (2016).131.	Sachar, H., Vaidya, K. & Laine, L. Intermittent versus continuous proton pump inhibitor therapy for high-risk bleeding ulcers: a systematic review and meta- analysis. JAMA Intern. Med.174, 1755–1762 (2014). This meta-analysis of available RCTs shows that intermittent PPI therapy is comparable to the current guideline-recommended regimen of intravenous bolus plus a continuous infusion in patients with endoscopically treated high-risk bleeding ulcers.132.	Jian, Z. et al. Is the era of intravenous proton pump inhibitors coming to an end in patients with bleeding peptic ulcers?Meta-analysis of the published literature. Br. J. Clin. Pharmacol.82, 880–889 (2016).133.	Jaspersen, D. et al. Helicobacter pylori eradication reduces the rate of rebleeding in ulcer hemorrhage. Gastrointest. Endosc.41, 5–7 (1995).134.	Gisbert, J. P. et al. H. pylori eradication therapy versus antisecretory non-eradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. Cochrane Database Syst. Rev. 2, CD004062 (2004).135.	Sung, J. J. et al. Intravenous esomeprazole for prevention of recurrent peptic ulcer bleeding: a randomized trial. Ann. Intern. Med.150, 455–464 (2009).136.	Yuan, J. Q. et al. Systematic review with network meta-analysis: comparative effectiveness and safety of strategies for preventing NSAID-associated gastrointestinal toxicity. Aliment. Pharmacol. Ther.43, 1262–1275 (2016).137.	Lau, J. Y. et al.",1532,174,383.0,"[-0.04175986 -0.3682258  -1.4025493  ...  0.61525685  0.2475452
 -1.2106863 ]"
124,"Endoscopic retreatment compared with surgery in patients with recurrent bleeding after initial endoscopic control of bleeding ulcers. N. Engl. J. Med. 340, 751–756 (1999).138.	Kyaw, M., Tse, Y., Ang, D., Ang, T. L. & Lau, J. Embolization versus surgery for peptic ulcer bleeding after failed endoscopic hemostasis: a meta-analysis. Endosc. Int. Open 2, E6–E14 (2014).139.	Beggs, A. D., Dilworth, M. P., Powell, S. L., Atherton, H. & Griffiths, E. A. A systematic review of transarterial embolization versus emergency surgery in treatment of major nonvariceal upper gastrointestinal bleeding. Clin. Exp. Gastroenterol.7, 93–104 (2014).140.	Sung, J. J. et al. Early clinical experience of the safety and effectiveness of Hemospray in achieving hemostasis in patients with acute peptic ulcer bleeding. Endoscopy 43, 291–295 (2011).141.	Smith, L. A. et al. Hemospray application in nonvariceal upper gastrointestinal bleeding: results of the Survey to Evaluate the Application of Hemospray in the Luminal Tract. J. Clin. Gastroenterol. 48, e89–92 (2014).142.	Manta, R. et al. Over-the-scope clip (OTSC) represents an effective endoscopic treatment for acute GI bleeding after failure of conventional techniques. Surg. Endosc.27, 3162–3164 (2013).143.	Manno, M. et al. First-line endoscopic treatment with OTSC in patients with high-risk non-variceal upper gastrointestinal bleeding: preliminary experience in 40 cases. Surg. Endosc.30, 2026–2029 (2016). PRIMER NATURE REVIEWS | DISEASE PRIMERS	 VOLUME 4 | ARTICLE NUMBER 18020 | 19 ©  2018  M acm illan  Publishers  Lim ited,  part  of  Springer  Nature. All  rights  reserved.",1623,204,405.75,"[-0.34986186 -0.49386567 -1.4756358  ...  0.57383126  0.33771157
 -1.6018935 ]"
125,"144.	Sung, J. J. et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann. Intern. Med.152, 1–9 (2010). This RCT is the first to show that, compared with withholding LDA, continuation and no interruption of LDA in patients who develop NVUGIB is associated with a lower 30‑day mortality (mostly owing to cardiovascular events) at the expense of a minor and nonsignificant increase of gastrointestinal bleeding.145.	Derogar, M. et al. Discontinuation of low-dose aspirin therapy after peptic ulcer bleeding increases risk of death and acute cardiovascular events. Clin. Gastroenterol. Hepatol.11, 38–42 (2013).146.	Kim, S. Y. et al. Risk of vascular thrombotic events following discontinuation of antithrombotics after peptic ulcer bleeding. J. Clin. Gastroenterol.50, e40–e44 (2016).147.	Burger, W., Chemnitius, J. M., Kneissl, G. D. & Rücker, G. Low-dose aspirin for secondary cardiovascular prevention — cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation — review and meta-analysis. J. Intern. Med.257, 399–414 (2005).148.	Choudari, C. P., Rajgopal, C. & Palmer, K. R. Acute gastrointestinal haemorrhage in anticoagulated patients: diagnoses and response to endoscopic treatment. Gut 35, 464–466 (1994).149.	Rubin, T. A., Murdoch, M. & Nelson, D. B. Acute GI bleeding in the setting of supratherapeutic international normalized ratio in patients taking warfarin: endoscopic diagnosis, clinical management, and outcomes. Gastrointest. Endosc.58, 369–373 (2003).150.	Peloquin, J. M. et al. Diagnostic and therapeutic yield of endoscopy in patients with elevated INR and gastrointestinal bleeding. Am. J. Med.129, 628–634 (2016).151.	Holbrook, A. et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.",1936,221,484.0,"[ 0.06260403 -0.7324054  -1.4934242  ...  0.29990107  0.93426615
 -1.7428731 ]"
125,"Chest 141 (Suppl.),e152S–e184S (2012).152.	Britt, R. B. & Brown, J. N. Characterizing the severe reactions of parenteral vitamin K1. Clin. Appl. Thromb. Hemost 24, 5–12 (2018).153.	Dhakal, P., Rayamajhi, S., Verma, V., Gundabolu, K. & Bhatt, V. R. Reversal of anticoagulation and management of bleeding in patients on anticoagulants. Clin. Appl. Thromb. Hemost.23, 410–415 (2017).154.	Chai-Adisaksopha, C. et al. Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal. A systematic review and meta-analysis. Thromb. Haemost.116, 879–890 (2016).155.	Voils, S. A. & Baird, B. Systematic review: 3‑factor versus 4‑factor prothrombin complex concentrate for warfarin reversal: does it matter?Thromb. Res.130, 833–840 (2012).156.	Voils, S. A., Holder, M. C., Premraj, S., Catlin, J. R. & Allen, B. R. Comparative effectiveness of 3- versus 4‑factor prothrombin complex concentrate for emergent warfarin reversal. Thromb. Res.136, 595–598 (2015).157.	Kuroski, J. E. & Young, S. Comparison of the safety and efficacy between 3‑factor and 4‑factor prothrombin complex concentrates for the reversal of warfarin. Am. J. Emergency Med.35, 871–874 (2017).158.	Majeed, A. et al. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation 128, 2325–2332 (2013).159.	Steiner, T., Rosand, J. & Diringer, M. Intracerebral hemorrhage associated with oral anticoagulant therapy: current practices and unresolved questions.",1471,156,367.75,"[ 0.22839634 -0.89272505 -0.94372356 ...  0.3255474   0.2786833
 -1.4198627 ]"
125,"Stroke 37, 256–262 (2006).160.	Zatta, A. et al. The Australian and New Zealand Haemostasis Registry: ten years of data on off-licence use of recombinant activated factor VII. Blood Transfus 13, 86–99 (2015).161.	Witt, D. M., Clark, N. P., Kaatz, S., Schnurr, T. & Ansell, J. E. Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism. J. Thromb. Thrombolysis 41, 187–205 (2016).162.	Makris, M. et al. Guideline on the management of bleeding in patients on antithrombotic agents. Br. J. Haematol.160, 35–46 (2013).163.	Radaelli, F. et al. Management of anticoagulation in patients with acute gastrointestinal bleeding. Dig. Liver Dis.47, 621–627 (2015).164.	Lubetsky, A. et al. Comparison of oral versus intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. Arch. Intern. Med.163, 2469–2473 (2003).165.	Heublein, V., Pannach, S., Daschkow, K., Tittl, L. & Beyer-Westendorf, J. Gastrointestinal endoscopy in patients receiving novel direct oral anticoagulants: results from the prospective Dresden NOAC registry. J. Gastroenterol.53, 236–246 (2018).166.	Bouget, J. & Oger, E. Emergency admissions for major haemorrhage associated with direct oral anticoagulants. Thromb. Res.136, 1190–1194 (2015).167.	Abraham, N. S. & Horsley-Silva, J. L. Gastrointestinal bleeding secondary to the new anticoagulants. Curr. Opin. Gastroenterol.32, 474–480 (2016).",1462,153,365.5,"[ 0.4138958  -0.8738255  -1.2571856  ...  0.06091037  0.71318066
 -1.7636387 ]"
125,"168.	Liesenfeld, K.‑H., Gruenenfelder, F. & Clemens, A. Enhanced elimination of dabigatran: Identifying the appropriate patient for the use of continuous venovenous hemodialysis instead of intermittent hemodialysis‑A simulation analysis. J. Clin. Pharmacol. 56, 597–608 (2016).169.	van Ryn, J., Sieger, P., Kink-Eiband, M., Gansser, D. & Clemens, A. Adsorption of dabigatran etexilate in water or dabigatran in pooled human plasma by activated charcoal in vitro. Blood 114, 1065–1065 (2009).170.	Wang, X. et al. Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects. Am. J. Cardiovasc. Drugs 14, 147–154 (2013).171.	Pollack, C. V. et al. Idarucizumab for dabigatran reversal — full cohort analysis. N. Engl. J. Med.377, 431–441 (2017). This large cohort study is the first to show the high efficacy and safety of the infusion of idarucizumab for dabigatran reversal in patients who had either uncontrolled bleeding or the need to undergo an urgent procedure.172.	Dager, W. E. & Banares, L. Reversing the anticoagulation effects of dabigatran. Hosp. Pract.45, 29–38 (2017).173.	Schulman, S. et al. Reversal of dabigatran-associated major bleeding with activated prothrombin concentrate: a prospective cohort study. Thromb. Res. 152, 44–48 (2017).174.	Zahir, H. et al. Edoxaban effects on bleeding following punch biopsy and reversal by a 4‑factor prothrombin complex concentrate. Circulation 131, 82–90 (2015).175.	Deutsch, D. et al. Direct oral anticoagulants and digestive bleeding: therapeutic management and preventive measures. Therap. Adv. Gastroenterol.10, 495–505 (2017).",1602,187,400.5,"[ 0.49779445 -0.8900312  -1.6409466  ...  0.53645164 -0.03910442
 -0.98157686]"
125,"176.	Heidbuchel, H. et al. Updated European Heart Rhythm Association practical guide on the use of non- vitamin‑K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary. Eur. Heart J. 38, 2137–2149 (2017).177.	Rottenstreich, A., Jahshan, N., Avraham, L. & Kalish, Y. Idarucizumab for dabigatran reversal — does one dose fit all?Thromb. Res.146, 103–104 (2016).178.	Connolly, S. J. et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N. Engl. J. Med.375, 1131–1141 (2016).179.	Ansell, J. E. et al. Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban. Thromb. Haemost.117, 238–245 (2017).180.	Chatterjee, P. & Weitz, J. I. Assessment and management of gastrointestinal hemorrhage in the setting of direct oral anticoagulants: the hematology perspective. Am. J. Gastroenterol. Suppl.3, 29–35 (2016).181.	Qureshi, W. T. & Nasir, U. Restarting oral anticoagulation among patients with atrial fibrillation with gastrointestinal bleeding was associated with lower risk of all-cause mortality and thromboembolism. Evid. Based Med.21, 152 (2016).182.	Zulkifly, H., Lip, G. Y. H. & Lane, D. A. Bleeding risk scores in atrial fibrillation and venous thromboembolism. Am. J. Cardiol.120, 1139–1145 (2017).183.	Scott, M. J., Veitch, A. & Thachil, J. Reintroduction of anti-thrombotic therapy after a gastrointestinal haemorrhage: if and when?Br. J. Haematol.177, 185–197 (2017).",1476,158,369.0,"[ 0.32945752 -1.0155591  -1.1990031  ...  0.40362698  0.16341884
 -1.5289539 ]"
125,"184.	Staerk, L. et al. Stroke and recurrent haemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: nationwide cohort study. BMJ 351, h5876 (2015).185.	Hernandez, I., Zhang, Y., Brooks, M. M., Chin, P. K. L. & Saba, S. Anticoagulation use and clinical outcomes after major bleeding on dabigatran or warfarin in atrial fibrillation. Stroke 48, 159–166 (2017).186.	Qureshi, W. et al. Restarting anticoagulation and outcomes after major gastrointestinal bleeding in atrial fibrillation. Am. J. Cardiol.113, 662–668 (2014).187.	Lip, G. Y. H. et al. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). Europace 19, 1757–1758 (2017).188.	Bager, P. & Dahlerup, J. F. Patient-reported outcomes after acute nonvariceal upper gastrointestinal hemorrhage. Scand. J. Gastroenterol.49, 909–916 (2014).189.	Sousa, K. H. & Williamson, A. Symptom status and health-related quality of life: clinical relevance. J. Adv. Nurs.42, 571–577 (2003).190.	Campbell, H. E. et al. Costs and quality of life associated with acute upper gastrointestinal bleeding in the UK: cohort analysis of patients in a cluster randomised trial. BMJ Open 5, e007230 (2015).191.	World Health Organization. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. WHO http://www.who.int/ vmnis/indicators/haemoglobin/en/ (2011).192.	Mearin, F. et al. Open questions and misconceptions in the diagnosis and management of anemia in patients with gastrointestinal bleeding. Gastroenterol. Hepatol.41, 63–76 (2018).193.	Lee, J. M. et al.",2073,236,518.25,"[ 0.20907865 -0.58811206 -1.6676767  ...  0.01338735  0.7705282
 -1.4233813 ]"
125,"Discharge hemoglobin and outcome in patients with acute nonvariceal upper gastrointestinal bleeding. Endosc. Int. Open 4, E865–869 (2016).194.	Bager, P. & Dahlerup, J. F. Lack of follow‑up of anaemia after discharge from an upper gastrointestinal bleeding centre. Danish Med. J. 60, A4583 (2013).195.	Jairath, V. et al. Restrictive versus liberal blood transfusion for acute upper gastrointestinal bleeding (TRIGGER): a pragmatic, open-label, cluster randomised feasibility trial. Lancet 386, 137–144 (2015).196.	Bager, P. & Dahlerup, J. F. Randomised clinical trial: oral versus intravenous iron after upper gastrointestinal haemorrhage — a placebo-controlled study. Aliment. Pharmacol. Ther.39, 176–187 (2014).197.	De Franceschi, L., Iolascon, A., Taher, A. & Cappellini, M. D. Clinical management of iron deficiency anemia in adults: systemic review on advances in diagnosis and treatment. Eur. J. Intern. Med.42, 16–23 (2017).198.	Hunt, R. H. & Scarpignato, C. Potassium-competitive acid blockers (P‑CABs): are they finally ready for prime time in acid-related disease?Clin. Transl Gastroenterol.6, e119 (2015).199.	Casado-Arroyo, R. et al. Underutilization of gastroprotection for at‑risk patients undergoing percutaneous coronary intervention: Spain compared with the United States. Aliment. Pharmacol. Ther.32, 689–695 (2010).200.	Lanas, A. et al. Variability in the management of nonvariceal upper gastrointestinal bleeding in Europe: an observational study. Adv. Ther.29, 1026–1036 (2012).201.",1502,167,375.5,"[ 0.22692521 -0.42416734 -1.3820108  ...  0.78773266  0.27218753
 -1.4915317 ]"
125,"Ardevol, A. et al. Survival of patients with cirrhosis and acute peptic ulcer bleeding compared with variceal bleeding using current first-line therapies. Hepatology https://doi.org/10.1002/hep.29370 (2018).202.	Mallet, M., Rudler, M. & Thabut, D. Variceal bleeding in cirrhotic patients. Gastroenterol. Rep. 5, 185–192 (2017).203.	Hunt, R. H. & Bazzoli, F. Review article: should NSAID/low-dose aspirin takers be tested routinely for H. pylori infection and treated if positive?Implications for primary risk of ulcer and ulcer relapse after initial healing. Aliment. Pharmacol. Ther.19 (Suppl.1), 9–16 (2004).204.	Lanas, Á. et al. Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants. Clin. Gastroenterol. Hepatol.13, 906–912.e2 (2015). PRIMER 20 | ARTICLE NUMBER 18020 | VOLUME 4	 www.nature.com/nrdp ©  2018  M acm illan  Publishers  Lim ited,  part  of  Springer  Nature. All  rights  reserved.",991,129,247.75,"[ 0.16190279 -0.70636266 -1.170068   ...  0.12916304  0.6906475
 -1.8444831 ]"
126,"205.	Chan, F. K. et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet 359, 9–13 (2002).206.	Scarpignato, C. & Hunt, R. H. Nonsteroidal antiinflammatory drug-related injury to the gastrointestinal tract: clinical picture, pathogenesis, and prevention. Gastroenterol. Clin. North Am.39, 433–464 (2010).207.	Blatchford, O., Murray, W. R. & Blatchford, M. A risk score to predict need for treatment for upper‑gastrointestinal haemorrhage. Lancet 356, 1318–1321 (2000).208.	Rockall, T. A., Logan, R. F., Devlin, H. B. & Northfield, T. C. Incidence of and mortality from acute upper gastrointestinal haemorrhage in the United Kingdom. Steering Committee and members of the National Audit of Acute Upper Gastrointestinal Haemorrhage. BMJ 311, 222–226 (1995).209.	Hyett, B. H. et al. The AIMS65 score compared with the Glasgow-Blatchford score in predicting outcomes in upper GI bleeding. Gastrointest. Endosc.77, 551–557 (2013).210.	Saltzman, J. R. et al. A simple risk score accurately predicts in‑hospital mortality, length of stay, and cost in acute upper GI bleeding. Gastrointest. Endosc.74, 1215–1224 (2011).211.	 Marmo, R. et al. Predicting mortality in non-variceal upper gastrointestinal bleeders: validation of the Italian PNED score and prospective comparison with the Rockall score. Am. J. Gastroenterol.105, 1284–1291 (2010).212.	Rockall, T. A., Logan, R. F., Devlin, H. B. & Northfield, T. C. Risk assessment after acute upper gastrointestinal haemorrhage. Gut 38, 316–321 (1996).213.	Adcock, D. M. & Gosselin, R. Direct Oral anticoagulantDOACs) in the laboratory: 2015 review. Thromb. Res.136, 7–12 (2015).",1741,189,435.25,"[ 0.18219186 -0.22463167 -1.6521372  ...  0.12285501  0.893723
 -1.5922583 ]"
126,"214.	Gosselin, R. C. et al. Evaluating the use of commercial drug-specific calibrators for determining PT and APTT reagent sensitivity to dabigatran and rivaroxaban. Thromb. Haemost.113, 77–84 (2015).215.	The American Society of Hemotology. Clinical practice guide on antithrombotic drug dosing and management of antithrombotic drug-associated bleeding complications in adults. Clot Connect http://files.www.clotconnect.org/ healthcare-professionals/resources-for-health-care- professionals/AnticoagPocketGuide-1.pdf (2014).216.	Bonar, R. et al. The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples. Pathology 48, 60–71 (2016).217.	Douxfils, J. & Gosselin, R. C. Laboratory assessment of direct oral anticoagulants. Semin. Thromb. Hemost. 43, 277–290 (2017).218.	Lanas, A. et al. Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. Am. J. Gastroenterol.104, 1633–1641 (2009).219.	Pérez-Aisa, M. A., Del Pino, D., Siles, M. & Lanas, A. Clinical trends in ulcer diagnosis in a population with high prevalence of Helicobacter pylori infection. Aliment. Pharmacol. Ther.21, 65–72 (2005).220.	Klein, A. & Gralnek, I. M. Acute, nonvariceal upper gastrointestinal bleeding. Curr. Opin. Crit. Care 21, 154–162 (2015). Acknowledgements A. L. declares that his work on this manuscript was partially funded by a grant from the Spanish Instituto de Salud Carlos III PI/PI08/1301 and “Fondo Europeo de Desarrollo Regional (FEDER) de la Unión Europea. –Una manera de hacer Europa –”. The authors thank M. Fujishiro, The University of Tokyo Hospital, for the images used in Fig. 6. Author contributions Introduction (A. L.); Epidemiology (C. V.); Mechanisms/ pathophysiology (A. L. and R. H. H.); Diagnosis, screening and prevention (R. H. H., A. L., A. R. and M. F.); Management (J. J. Y. S., I. M. G., J. M. S. and J.-M. D.); Quality of life (H. E. C.); Outlook (all authors); Overview of the Primer (A. L.).",2051,261,512.75,"[ 0.7357163  -0.6265222  -1.2371988  ...  0.42499426  0.5546827
 -1.3999907 ]"
126,"Competing interests A. L. is an adviser to Bayer Healthcare and Bayer AG. J. M. S. is an adviser to Aralez Pharmaceuticals. All other authors declare no competing interest. Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Reviewer information Nature Reviews Disease Primers thanks E. J. Kuipers, P. Malfertheiner, R. Marmo, F. Radaelli and other, anonymous reviewer(s) for their contribution to the peer review of this work. How to cite this Primer Lanas, A. et al. Non-variceal upper gastrointestinal bleeding. Nat. Rev. Dis. Primers 4, 18020 (2018). PRIMER NATURE REVIEWS | DISEASE PRIMERS	 VOLUME 4 | ARTICLE NUMBER 18020 | 21 ©  2018  M acm illan  Publishers  Lim ited,  part  of  Springer  Nature. All  rights  reserved.",812,131,203.0,"[-0.03034161 -0.23059401 -1.3341042  ... -0.3222403  -0.08254553
 -1.2833291 ]"
127,"1062  |  	 wileyonlinelibrary.com/journal/apt Aliment Pharmacol Ther.2024;59:1062–1081.© 2024 John Wiley & Sons Ltd. 1 | INTRODUCTION Acute upper gastrointestinal bleeding (UGIB) is a common emer- gency defined by symptoms of overt bleeding (haematemesis, melaena and haematochezia) with the source of bleeding in the oe- sophagus, stomach or duodenum. While the incidence of UGIB had been reported to be decreasing for decades, a recent evaluation of emergency department (ED) visits found that the trend has recently Received: 13 September 2023  |  First decision: 27 October 2023  |  Accepted: 4 March 2024 DOI: 10.1111/apt.17949  Review article: Upper gastrointestinal bleeding – review of current evidence and implications for management Dennis L. Shung1  |  Loren Laine1,2 The Handling Editor for this article was Professor Colin Howden, and this commissioned review was accepted for publication after full peer-­review. 1Yale School of Medicine, New Haven, Connecticut, USA 2West Haven Veterans Affairs Medical Center, West Haven, Connecticut, USA Correspondence Dennis L. Shung, Yale School of Medicine, New Haven, CT, USA. Email: dennis.shung@yale.edu Funding information National Institutes of Health, Grant/Award Number: DK125718 Summary Background: Acute upper gastrointestinal bleeding (UGIB) is a common emergency requiring hospital-­based care. Advances in care across pre-­endoscopic, endoscopic and post-­endoscopic phases have led to improvements in clinical outcomes. Aims: To provide a detailed, evidence-­based update on major aspects of care across pre-­endoscopic, endoscopic and post-­endoscopic phases. Methods: We performed a structured bibliographic database search for each topic. If a recent high-­quality meta-­analysis was not available, we performed a meta-­analysis with random effects methods and odds ratios with 95% confidence intervals. Results: Pre-­endoscopic management of UGIB includes risk stratification, a restric- tive red blood cell transfusion policy unless the patient has cardiovascular disease, and pharmacologic therapy with erythromycin and a proton pump inhibitor. Patients with cirrhosis should be treated with prophylactic antibiotics and vasoactive medica- tions. Tranexamic acid should not be used. Endoscopic management of UGIB depends on the aetiology. For peptic ulcer disease (PUD) with high-­risk stigmata, endoscopic therapy, including over-­the-­scope clips (OTSCs) and TC-­325 powder spray, should be performed. For variceal bleeding, treatment should be customised by severity and anatomic location. Post-­endoscopic management includes early enteral feeding for all UGIB patients. For high-­risk PUD, PPI should be continued for 72 h, and rebleeding should initially be evaluated with a repeat endoscopy. For variceal bleeding, high-­risk patients or those with further bleeding, a transjugular intrahepatic portosystemic shunt can be considered. Conclusions: Management of acute UGIB should include treatment plans for pre-­ endoscopic, endoscopic and post-­endoscopic phases of care, and customise treat- ment decisions based on aetiology and severity of bleeding.",3134,423,783.5,"[ 0.4859441  -0.29987377 -1.497757   ...  0.25643826  0.18509525
 -1.2290336 ]"
128,"|  1063 SHUNG and LAINE reversed.1 Furthermore, despite increasing co-­morbidities and anti-­ thrombotic drug use in patients with UGIB, case fatality rates have been decreasing.1 This review uniquely synthesises recommendations from numer- ous recent guidelines and consensus documents, together with the most recent evidence from systematic reviews of original research – both published and performed by the authors – to provide updated guidance on the management of acute UGIB from presentation in the ED throughout hospitalisation, dividing the management into three stages: pre-­endoscopic, endoscopic and post-­endoscopic. This review focuses on management from presentation in the ED throughout hospitalisation for acute UGIB, dividing the management into three stages: pre-­endoscopic, endoscopic and post-­endoscopic. We performed a structured bibliographic database search on Medline (details in Appendix A) for each topic to identify rele- vant systematic reviews and meta-­analyses for topics within each stage. When systematic reviews were not available or sufficient, we searched for randomised trials or other relevant studies in the absence of randomised trials, and we presented either the findings from individual trials or results from our own meta-­analyses. All meta-­analyses were performed with RevMan 5.4.1 using random ef- fects methods. We present odds ratios (ORs) with 95% confidence intervals (CIs) for dichotomous outcomes and mean differences with 95% CIs for continuous outcomes. The structure of this review is to present available recommendations from existing U. S. and international guidelines for the care of patients with UGIB, followed by a synthesis of the best available data and a suc- cinct statement summarising our take-­home point for each topic. Our take-­home points are collated in a table, separated by different phases of care. (Table 1) We provide a management flowchart for pre-­endoscopic (Figure 1) and endoscopic/post-­endoscopic phases (Figures 2–4).2 | PRE-­ENDOSCOPIC MANAGEMENT Resuscitation and stabilisation of underlying comorbid conditions are cornerstones of pre-­endoscopic management. Rushing to en- doscopy without first attending to haemodynamic instability and comorbidities may worsen patient outcomes.2,3 These management concepts are discussed below in sections on blood transfusion and timing of endoscopy. The increased use of antithrombotic medications among patients with UGIB requires careful consideration of the individual's cardio- vascular/thrombotic and bleeding risks. A full review of this topic is beyond the scope of this article, but is well covered in a recent U. S./Canadian guideline.4 Briefly, in addition to holding anticoagu- lants, reversal agents for direct oral anticoagulants are only recom- mended for life-­threatening bleeding, while prothrombin complex concentrate may be considered for select patients on warfarin—for example, life-­threatening bleeding, markedly supratherapeutic INR.4 Although some have suggested INR should be <2.5 before apply- ing endoscopic therapy, INR level does not predict rebleeding and recent European guidelines indicate an INR cutoff should not guide the timing of endoscopy.8 In contrast, aspirin does not need to be held in patients taking aspirin for secondary prevention (i.e., estab- lished cardiovascular disease), but those taking aspirin for primary prevention should discontinue aspirin.4 2.1 | Risk stratification scores for very-­low-­risk patients 2.1.1 | Guidelines Guidelines are uniform in recommending that patients with a Glasgow-­Blatchford Score (GBS) of 0–1 are candidates for discharge from the emergency department with outpatient follow-­up and endoscopy.5–8 U. S. guidelines also define very-­low-­risk patients as those with a ≤1% false negative rate for the outcome of hospital-­ based intervention or death.5 2.1.2 | Best available evidence In order to ensure patients who are discharged have an extremely low risk of poor outcomes, a high sensitivity cutoff (e.g., 99% or 100%) has been adopted to minimise false negative results, meaning that 0%–1% of patients who are deemed very low risk will require hospital-­based intervention (red-­blood-­cell (RBC) transfusion or endoscopic, inter- ventional radiologic or surgical haemostatic intervention) or die. The GBS, with a cutoff threshold of ≤1 is the only clinical risk assessment tool demonstrated to achieve this sensitivity threshold.5 The level of evidence to support this practice is very low, with only one multicentre prospective pre/post study that demonstrated the use of GBS with a cutoff of 0 decreased hospitalisations without any adverse outcomes detected at 28 days post evaluation.9 Another retrospective study ap- plying the GBS at ≤1 also found that none of the patients identified at very low risk required a hospital based intervention or died within 30 days.10 A machine learning model has been reported to outperform the GBS, with greater specificity at equivalent sensitivities of 99 or 100%, but has not been studied in real-­world settings.11 2.1.3 | Take-­home point Very low risk patients (e.g., GBS ≤ 1) may be considered for discharge from the emergency department with outpatient management.2.2 | Risk stratification scores for high-­risk patients 2.2.1 | Guidelines There are no recommendations across the U. S., European or inter- national guidelines for the use of high-­risk scores to guide clinical  13652036, 2024, 9, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/apt.17949 by Yonsei University, Wiley Online Library on [29/05/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License",5791,803,1447.75,"[ 0.27193803 -0.4210788  -1.3018115  ...  0.37708998  0.6904034
 -1.1143689 ]"
129,"1064  |     SHUNG and LAINE TA B LE 1 Summary of take-­home points by pre-­endoscopic, endoscopic and post-­endoscopic management phases. Pre-­endoscopic management Risk assessment Very low risk patients (e.g., GBS ≤ 1) may be considered for discharge from the emergency department with outpatient management. No risk scores are robust enough to consistently identify high-­risk patients. Red blood cell transfusion Transfuse at a threshold of haemoglobin <7 g/dL unless patient has cardiovascular disease (transfuse at haemoglobin <8 g/dL) or is haemodynamically unstable. Prokinetic therapy Erythromycin may be given before the endoscopy to reduce the need for a second endoscopy and the length of the hospital stay. Proton pump inhibitor therapy Providers who value a small reduction in endoscopic therapy may choose to give pre-­endoscopic PPIs, despite the fact that they do not improve clinical outcomes. Tranexamic acid Modern studies do not suggest that tranexamic acid should be used in patients with acute UGIB. Patients with cirrhosis Treat with antibiotics and vasoactive medications beginning soon after presentation. Endoscopic management Timing of endoscopy Perform an endoscopy within 24 h. Urgent endoscopy in high-­risk patients is not recommended before resuscitation is initiated and other co-­morbidities are addressed. Peptic Ulcer Disease Endoscopic therapy should be performed for patients with active bleeding and non-­bleeding visible vessels, while its use for adherent clots may be individualised. Epinephrine injection should not be used alone; it should only be used in combination with a second modality. Thermal therapies, absolute ethanol injection and clips are all appropriate endoscopic haemostatic modalities. OTSCs are suggested as a treatment option for recurrent bleeding after conventional endoscopic haemostatic therapy and may be considered for initial haemostatic therapy. TC-­325 powder spray is an option for the treatment of actively bleeding ulcers and other non-­variceal lesions. Severe refractory variceal bleeding Fully-­covered, self-­expanding metal stents are preferred over balloon tamponade for severe refractory variceal bleeding. Oesophageal variceal bleeding Treat with oesophageal variceal ligation as well as intravenous vasoactive medications and antibiotic therapy. Gastric variceal bleeding Endoscopic therapy with butyl-­cyanoacrylate is more effective than ligation for gastric variceal bleeding, although ligation may be considered for GOV1 bleeding because of fewer adverse events. TIPS and BRTO are superior to endoscopic therapy for the prevention of recurrent gastric variceal bleeding. BRTO may be performed if a gastrorenal shunt is present based on clinical factors (e.g. MELD score, hepatic encephalopathy). Further evidence is needed before recommendations regarding endoscopic ultrasound-­guided therapy or the use of thrombin for gastric variceal bleeding can be made. Gastric antral vascular ectasia Bleeding from GAVE is commonly treated with APC, but ligation appears to be a superior option. Mallory-­Weiss tear Patients with actively bleeding Mallory-­Weiss tears should receive endoscopic therapy, probably employing endoscopic therapies suggested for ulcer bleeding. Dieulafoy lesion Patients with Dieulafoy lesions should undergo endoscopic therapy, employing therapies suggested for ulcer bleeding. Epinephrine should not be used alone. Malignancy-­related bleeding Acute UGIB due to malignancy may be treated with endoscopic therapy, but results are variable and rebleeding is common. Treatment with TC-­325 haemostatic powder spray may hold promise, but therapy for the underlying malignancy, if possible, is most important to prevent rebleeding. Post-­endoscopic management Early versus delayed feeding Patients with low-­risk endoscopic findings (e.g., clean-­based ulcers) may begin a regular diet soon after endoscopy and be discharged home if they have no other reason for hospitalisation. Patients with higher risk endoscopic findings, even after endoscopic therapy, may be fed in less than 72 h, although the exact time and initial form of refeeding are uncertain. Peptic ulcer After endoscopic haemostatic treatment of UGIB due to ulcers, treat with either continuous infusion or intermittent intravenous or oral high-­dose PPI for 3 days. Twice-­daily oral PPI therapy should then be given for at least 14 days after the index endoscopy. Rebleeding after initial endoscopic haemostatic therapy should first be evaluated and treated with a repeat endoscopy. For those who fail endoscopic therapy, arteriography with transcatheter arterial embolisation should be performed. Varices Preemptive TIPS should be considered in high-­risk patients (Child-­Pugh class B or C with score <14) after initial endoscopic ligation and vasoactive medical therapy, if interventional radiology services are available. Patients with further variceal bleeding despite endoscopic and medical therapy should undergo TIPS (BRTO may be performed for gastric variceal bleeding). Abbreviations: APC, argon plasma coagulation; BRTO, balloon retrograde transvenous obliteration; GBS, Glasgow-­Blatchford Score; MELD, Model for End-­Stage Liver Disease; OTSC, over-­the-­scope-­clips; PPI, proton pump inhibitor therapy; TIPS, transjugular intrahepatic portosystemic shunt; UGIB, upper gastrointestinal bleeding. 13652036, 2024, 9, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/apt.17949 by Yonsei University, Wiley Online Library on [29/05/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License",5725,770,1431.25,"[ 0.2266581  -0.5700604  -1.4661024  ...  0.57909864  0.7262996
 -0.9553497 ]"
130,"|  1065 SHUNG and LAINE practice.5,6,8 The Asia-­Pacific guidelines do not recommend use of risk scores to identify high-­risk bleeding ulcers after endoscopic therapy for second-­look endoscopy.7 2.2.2 | Best available evidence The Rockall score and AIMS65 score were developed to predict all-­cause mortality for patients with UGIB.12,13 The ABC score uses pre-­endoscopic factors to identify patients with UGIB or lower GIB at risk for mortality,14 while the Re.​Co.​De score inte- grates findings during hospitalisation to predict all-­cause 30-­day mortality.15 Yet another score focused on intensive care unit (ICU) patients with acute GIB uses a machine learning model to predict in-­hospital mortality.16 Finally, two studies have evaluated the dynamic risk of patients with acute GIB in the ICU by predict- ing the need for transfusion in 5-­h increments17 and within the first 24 h of ICU admission.18 The one study that integrates a risk score into direct clinical care used a semi-­automated GBS with a cutoff of 7 to identify higher risk patients and examine the im- pact on patient placement in a monitored versus unmonitored bed and clinical outcomes.19 These currently available tools are of unclear clinical utility, and their performance characteristics are not sufficient to recommend their use in clinical practice.2.2.3 | Take-­home point No risk scores are robust enough to consistently identify high-­risk patients.2.3 | Restrictive versus Liberal red blood cell transfusion strategy 2.3.1 | Guidelines For patients with UGIB U. S. and European guidelines recommend a re- strictive policy of RBC transfusion for patients with UGIB at a thresh- old haemoglobin <7 g/dL.5,8 For patients with acute or pre-­existing cardiovascular disease, they suggest red blood cell transfusion at a haemoglobin threshold of <8 g/dL. International guidelines suggest that RBC transfusions be given at a haemoglobin <8 mg/dL, with a higher unspecified haemoglobin threshold for patients with underlying FI G U R E 1 Pre-­endoscopic management for patients with acute upper gastrointestinal bleeding. 13652036, 2024, 9, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/apt.17949 by Yonsei University, Wiley Online Library on [29/05/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License",2446,341,611.5,"[ 0.7384617  -0.45173654 -1.5020182  ...  0.28989714  0.8677402
 -1.2068583 ]"
131,"1066  |     SHUNG and LAINE cardiovascular disease.8 U. S. guidelines also noted that it is reasonable to transfuse hypotensive patients before haemoglobin reaches 7 g/dL because haemoglobin levels in these patients will be lower after fluid resuscitation even in the absence of further bleeding.5 Asia-­Pacific guidelines recommend a restrictive transfusion strategy without a spe- cific haemoglobin target or threshold.7 For patients with cirrhosis and possible acute variceal bleeding, Baveno VII guidelines recommend transfusion with a target haemoglobin between 7 and 8 g/dL.20 2.3.2 | Best available evidence The transfusion threshold of haemoglobin <7 g/dL was found to have a benefit as compared to haemoglobin <9 g/dL in mortality (5 vs. 9%, p = 0.02) with decreased further bleeding (10 vs. 16%, p = 0.01) and less transfusion reactions (3 vs. 9%, p = 0.001) in a large single-­centre randomised controlled trial.21 A multicentre cluster-­randomised trial compared an 8 g/dL threshold to a 10 g/dL threshold.22 Methodological limitations included unequal distribution in the study arms (restrictive 43%, liberal 57%) and poorer adherence in the liberal transfusion arm.22 Differences were not significant for the restrictive versus liberal transfusion strategy groups in mortality (5 vs. 7%) or fur- ther bleeding (5 vs. 9%).22 A recent small single-­centre trial com- pared transfusion thresholds of 7 g/dL (with transfusions given to reach haemoglobin of 9 g/dL) versus 8 g/dL (with a transfusion target of 10 g/dL) and found relatively similar clinical outcomes in the study arms (mortality hazard ratio = 0.83, p = 0.33).23 Current transfusion guidelines for patients with anaemia due to any cause suggest a haemoglobin threshold of 8 g/dL in patients with pre-­existing cardiovascular disease because trials in this population used a restrictive threshold of 8 rather than 7 g/dL. In addition, a recent randomised trial in patients with acute myocar- dial infarction and anaemia due to any cause found a transfusion threshold of 8 g/dL to be non-­inferior to a threshold of 10 g/dL for an outcome of cardiovascular events or death, suggesting that 8 g/ dL is an appropriate threshold in patients with acute coronary syn- drome as well.24 FI G U R E 2 (A) Endoscopic management and post-­endoscopic management for patients with acute upper gastrointestinal bleeding from peptic ulcer disease. (B) Endoscopic management and post-­endoscopic management for patients with recurrent upper gastrointestinal bleeding from peptic ulcer disease. 13652036, 2024, 9, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/apt.17949 by Yonsei University, Wiley Online Library on [29/05/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License",2894,400,723.5,"[ 1.1385318  -0.49314255 -1.0129656  ...  0.05077502  0.91953635
 -1.0658588 ]"
132,"|  1067 SHUNG and LAINE FI G U R E 3 Endoscopic management and post-­endoscopic management for patients with acute upper gastrointestinal bleeding from varices. FI G U R E 4 Endoscopic management and post-­endoscopic management for patients with acute upper gastrointestinal bleeding from other aetiologies. 13652036, 2024, 9, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/apt.17949 by Yonsei University, Wiley Online Library on [29/05/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License",650,82,162.5,"[ 0.35546732 -0.7744466  -1.4782555  ...  0.2234185   0.5646888
 -1.4470216 ]"
133,"1068  |     SHUNG and LAINE 2.3.3 | Take-­home point Transfuse at a threshold of haemoglobin <7 g/dL unless the patient has cardiovascular disease (transfuse at haemoglobin <8 g/dL) or is haemodynamically unstable.2.4 | Pre-­endoscopic pharmacologic therapy 2.4.1 | Prokinetic therapy Guidelines U. S. guidelines suggest an infusion of erythromycin 250 mg 20–90 min before endoscopy and indicated their review did not sug- gest benefit was restricted to a specific subgroup of patients, while European guidelines recommend pre-­endoscopic administration of intravenous erythromycin only in UGIB patients with clinically se- vere or ongoing active bleeding.5,8 International guidelines do not recommend routine use of promotility agents to increase diagnostic yield.6 Best available evidence A meta-­analysis of randomised trials showed a reduced rate of repeat endoscopy (odds ratio [OR] = 0.51, 0.34–0.77) and shorter hospital length of stay (mean difference = −1.75, −2.43 to −1.06 days).25 Reductions in further bleeding and death have not been documented. No randomised controlled trials have evalu- ated the role of azithromycin or other macrolide antibiotics for this purpose, and the limited data regarding metoclopramide does not provide support for its use. A 2023 abstract of a randomised, placebo-­controlled trial of metoclopramide in 64 patients with UGIB did not document the benefit of metoclopramide in the pri- mary outcome of ‘clear stomach’ (77 vs. 64%; p = 0.22), in repeat endoscopy (10 vs. 21%, p = 0.30) or in mean hospital stay (5.4 vs. 6.3 days, p = 0.59).26 Take-­home point Erythromycin may be given before an endoscopy to reduce the need for a second endoscopy and the length of the hospital stay.2.5 | Proton pump inhibitor (PPI) therapy 2.5.1 | Guidelines U. S. guidelines did not provide a recommendation for or against pre-­ endoscopic PPI therapy.5 European and international guidelines sug- gest pre-­endoscopic PPI therapy may be considered to downstage endoscopic stigmata and reduce the need for endoscopic therapy, but this should not delay endoscopy.6,8 Asia-­Pacific guidelines do not recommend pre-­endoscopic PPIs.7 2.5.2 | Best available evidence A recent meta-­analysis of randomised trials did not document re- ductions in the primary endpoint of mortality (OR = 1.14, 0.76–1.70) or other clinical outcomes.27 A closer assessment of the component studies is needed because two studies used H2-­receptor antagonists as a comparator rather than placebo one study was an abstract from 2005 that has never been published in full form and two of the three placebo-­controlled trials used a poor study design that was biased in favour of the PPI arm. The single large, well-­designed, randomised, placebo-­controlled trial showed no suggestion of a benefit for PPI in further bleeding (11/314 [3.5%] vs. 8/317 [2.5%]), mortality (8/314 [2.5%] vs. 7/317 [2.2%]), or other clinical outcomes.28 PPI therapy does appear to reduce the proportion of patients with stigmata of haemorrhage identified at endoscopy and the proportion requir- ing endoscopic haemostatic therapy.27 Guideline panels generally agree that available evidence indicates pre-­endoscopic PPIs do not improve clinical outcomes such as further bleeding or mortality, but reduce the proportion receiving endoscopic therapy (−3%, −1 to −6% in a meta-­analysis of 3 randomised trials).5 The guideline recommen- dations vary based on the value panellists felt that providers and patients may place on this outcome.2.5.3 | Take-­home point Providers who value a small reduction in endoscopic therapy may choose to give pre-­endoscopic PPIs, despite the fact that they do not improve clinical outcomes.2.6 | Tranexamic acid 2.6.1 | Guidelines U. S., international and Asia-­Pacific guidelines have no recommen- dation regarding tranexamic acid.5–7 European guidelines recom- mend against the use of tranexamic acid.8 Baveno VII guidelines recommend against tranexamic acid in patients with acute variceal bleeding.20 2.6.2 | Best available evidence Multiple small randomised trials assessing tranexamic acid versus placebo have been done, and prior meta-­analysis including, 1701 participants showed a reduction in mortality (risk ratio = 0.60, 0.42– 0.87) and a possible trend to less further bleeding (risk ratio = 0.80, 0.64–1.00 with heterogeneity (I2 = 49%)).29 This uncertainty led to the large multicentre double-­blind HALT-­IT trial, which randomly as- signed approximately 12,000 patients with GIB to intravenous bolus  13652036, 2024, 9, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/apt.17949 by Yonsei University, Wiley Online Library on [29/05/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License",4869,668,1217.25,"[ 0.22284202  0.06488332 -1.4122608  ...  0.5096957   0.8075442
 -0.79076385]"
134,"|  1069 SHUNG and LAINE and constant infusion tranexamic versus placebo. No suggestion of a benefit in all-­cause mortality, death due to bleeding or rebleeding was identified, and thromboembolic events were also similar in the two arms.30 A new meta-­analysis that we performed incorporating the HALT-­IT trial and other recent studies showed no difference in further bleeding (OR: 0.87, 95% CI: 0.69–1.11)30–37 (Figure S1) with a slight decrease in all-­cause mortality (OR: 0.83, 95% CI: 0.71– 0.98).30–41 (Figure S2) However, we note that the trials used for the meta-­analysis are heterogeneous in their dosage, duration and route of administration, and many of the trials were performed decades ago before advancements in the care of acute UGIB. In a sensitiv- ity analysis including only studies published after 2000, a benefit in all-­cause mortality was not seen (OR: 0.90, 95% CI: 0.75–1.07) (Figure S3).2.6.3 | Take-­home point Modern studies do not suggest that tranexamic acid should be used in patients with acute UGIB.2.7 | Pharmacologic therapy in patients with cirrhosis 2.7.1 | Guidelines Baveno VII and U. S. guidance recommend antibiotic prophylaxis be instituted from admission, with ceftriaxone 1 g/24 h for up to 5 days as the first choice in patients with advanced cirrhosis, in hospital set- tings with a high prevalence of quinolone-­resistant bacterial infec- tions, and for patients on previous quinolone prophylaxis. Initiation of vasoactive drugs (e.g., somatostatin, octreotide and terlipressin) as soon as possible is also recommended, with therapy continued for 2 to 5 days.20,42 2.7.2 | Best available evidence A meta-­analysis of antibiotic prophylaxis with data from 12 ran- domised controlled trials suggested reduced all-­cause mortality, rebleeding and bacterial infections, with no clear preference for quinolones or cephalosporins.43 In patients with advanced cirrhosis, a randomised trial found that intravenous ceftriaxone 1 g daily re- duced infections as compared to oral norfloxacin 400 mg twice daily over 7 days.44 Multiple randomised trials of vasoactive therapy for acute var- iceal bleeding have been performed, and meta-­analysis demon- strates benefits in mortality, haemostasis and rebleeding as compared to placebo or routine management.45 However, only three randomised trials (all double-­blind and placebo-­controlled) have assessed immediate vasoactive therapy (somatostatin, vap- reotide and terlipressin) in patients with potential variceal bleeding prior to endoscopic diagnosis.46–48 Due to study design in which patients found to have varices at endoscopy continued on placebo (a deviation from standard appropriate care in which vasoactive therapy is given to patients with confirmed variceal bleeding), only outcomes up to the time of endoscopy can be used to assess the potential benefit of pre-­endoscopic vasoactive therapy. One study showed improved bleeding control at 12 h with vasoactive ther- apy, and the other two studies showed less active bleeding at the time of endoscopy.49 2.7.3 | Take-­home point Patients with cirrhosis and UGIB should be treated with antibiotics and vasoactive medications beginning soon after presentation.3 | ENDOSCOPIC MANAGEMENT 3.1 | Timing of endoscopy 3.1.1 | Guidelines U. S., European, international and Asia-­Pacific guidelines suggest performing an early endoscopy within 24 h of presentation for pa- tients with UGIB in the hospital.5–8 European guidelines specifi- cally do not recommend urgent endoscopy (≤12 h) and recommend against emergent upper endoscopy (≤6 h).8 Baveno VII and U. S. guidance recommend that patients with suspected acute variceal bleeding should undergo endoscopy within 12 h.20,42 U. S. guidelines also suggest endoscopy as soon as possible within routine hours in haemodynamically stable patients without severe comorbidities because it may allow early discharge in a substantial proportion of patients with low-­risk endoscopic findings.5 3.1.2 | Best available evidence Observational studies suggest that performing an endoscopy within 24 h may reduce the length of hospital stay, the need for surgery and all-­cause mortality. A randomised trial comparing endoscopy ≤12 versus >12 hours after presentation in consecutive patients with UGIB showed no benefit for earlier endoscopy in mortality or further bleeding. Among high-­risk patients (e.g., haemodynamically unstable, need for endoscopic therapy), observational studies with statistical adjustment show that endoscopy within 6 h or beyond 24 h is associated with higher mortality.3,50 In contrast, a single-­ centre observational study from Asia reported reduced mortality with endoscopy within 6 versus 6–48 h after presentation in higher-­ risk patients with GBS ≥ 8.51 A randomised trial comparing endos- copy within 6 hours of gastroenterology consultation versus 6–24 h after consultation (mean of 10 vs. 25 h after presentation) in 516 high-­risk patients with GBS ≥ 12 showed no suggestion of a benefit  13652036, 2024, 9, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/apt.17949 by Yonsei University, Wiley Online Library on [29/05/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License",5351,732,1337.75,"[ 0.50849396 -0.8344618  -0.8935584  ... -0.00683138  0.92426246
 -1.2203909 ]"
135,"1070  |     SHUNG and LAINE of earlier endoscopy: further bleeding 10.9 versus 7.8%; mortality 8.9 versus 6.6%.52 Two randomised trials in low-­risk patients (haemodynamically stable, no severe comorbidities) assessed endoscopy within 2–6 h of evaluation versus elective endoscopy after admission and found low-­risk endoscopic findings (e.g., clean-­based ulcer) that should allow discharge in ≥40% of patients undergoing early endoscopy.53,54 Following recommendations for discharge of such patients reduced length of stay and costs without increasing readmissions.53 Although guidelines suggest endoscopy in patients with suspected variceal bleeding within 12 h, we do not believe current evidence provides support for this suggestion. An observational study with statistical adjustment reports reduced mortality in patients with var- iceal bleeding when endoscopy was performed within 24 hours after admission (OR = 0.85, 95% CI: 0.76–0.93).55 In addition, subgroup analysis of another observational study showing increased mortality with endoscopy ≤6 or >24 h after admission showed the magnitude of the increase was comparable for variceal and non-­variceal bleeding.3 Furthermore, a meta-­analysis of observational studies without statisti- cal adjustment did not demonstrate the benefit of endoscopy ≤12 ver- sus >12 h in mortality, further bleeding, hospital stay or transfusions.56 3.1.3 | Take-­home point Patients presenting with UGIB should undergo endoscopy within 24 hours. Urgent endoscopy in high-­risk patients is not recom- mended before resuscitation is initiated and other co-­morbidities are addressed.3.2 | Candidates for endoscopic therapy of peptic ulcer disease 3.2.1 | Guidelines Endoscopic therapy is recommended for ulcers with active bleeding (spurting or oozing) and non-­bleeding visible vessels by U. S., European and international guidelines.5,6,8 For patients with an adherent clot re- sistant to vigorous irrigation, these guidelines largely leave treatment decisions up to providers: they either did not reach a recommendation or indicate endoscopic therapy may be considered.57,58 3.2.2 | Best available evidence Meta-­analyses of randomised trials document reduced further bleeding with endoscopic therapy versus no endoscopic therapy in patients with active bleeding (RR = 0.29, 0.20–0.43) and non-­ bleeding visible vessels (RR = 0.49, 0.40–0.59).57 In contrast, the meta-­analysis did not document the benefit of endoscopic therapy in patients with adherent clots (RR = 0.31, 0.06–1.77). However, studies were small and heterogeneity was present. In addition, two randomised, double-­blind Asian studies suggested high-­dose PPI therapy alone (without endoscopic therapy) may prevent rebleeding in patients with adherent clots.3.2.3 | Take-­home point Endoscopic therapy should be performed for patients with active bleeding and non-­bleeding visible vessels, while its use for adherent clots may be individualised.3.3 | Standard forms of endoscopic therapy for peptic ulcer disease 3.3.1 | Guidelines Endoscopic modality recommended or suggested by one of the guidelines include bipolar electrocoagulation, heater probes, injec- tions of absolute ethanol, clips, argon plasma coagulation and soft monopolar electrocoagulation. U. S., European and international guidelines recommend epinephrine not be used alone but only in combination with another modality.5,6,8 European guidelines recom- mend a combination of epinephrine and a second modality for ac- tively bleeding ulcers, while U. S. and international guidelines do not indicate epinephrine therapy is required in such cases.8 3.3.2 | Best available evidence Randomised controlled trials support each of the endoscopic thera- pies listed above in guideline recommendations, but details are be- yond the scope of this review. Little high-­quality evidence is available to inform the appropriate techniques for endoscopic haemostatic therapies. Larger volumes (e.g., 30–45 mL) appear to improve efficacy in randomised trials of epinephrine monotherapy, but information on the volume when epinephrine is combined with other modalities is not available.59 A recent randomised trial did provide support for prior recommendations to apply thermal contact devices such as bipolar and heater probes around the bleeding site or visible vessel and then centrally on the bleeding site or visible vessel. Application of a bipolar probe at 3 peripheral sites equidistant from the site of bleeding, followed by application at the centre of the bleeding area, was compared to application solely at the centre of the bleeding site. Despite the total number of applications per patient being similar in the two study groups, the haemostasis rate was higher with the addi- tion of peripheral applications: 91% versus 71%; p = 0.002.60 3.3.3 | Take-­home point Epinephrine injection should not be used alone; it should only be used in combination with a second modality. Thermal therapies,  13652036, 2024, 9, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/apt.17949 by Yonsei University, Wiley Online Library on [29/05/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License",5314,712,1328.5,"[ 0.27214038 -0.64539444 -1.5687964  ...  0.5311832   1.2254547
 -0.9444708 ]"
136,"|  1071 SHUNG and LAINE absolute ethanol injection and clips are all appropriate endoscopic haemostatic modalities.3.4 | Newer endoscopic therapies for peptic ulcer disease 3.4.1 | Over the scope clips Guidelines U. S. guidelines suggest the use of over-­the-­scope clips (OTSCs) for patients who develop recurrent bleeding due to ulcers after previous successful endoscopic haemostasis.5 European guidelines suggest OTSCs may be considered as first-­line therapy in selected patients (e.g., ulcer >2 cm, excavated/fibrotic ulcers). Asia-­Pacific guidelines recommend using OTSCs for lesions refractory to conventional en- doscopic haemostatic therapy.7 Best available evidence A randomised trial of OTSC versus standard therapy in patients with recurrent bleeding after successful endoscopic haemostatic therapy found reduced further bleeding with OTSC (15.2 vs. 57.6%; p = 0.001).61 More recently, OTSCs have been proposed as first-­line therapy. Among four randomised controlled trials performed in all aeti- ologies of severe acute non-­variceal UGIB, three show benefit and one does not.62–65 A pooled meta-­analysis that we performed incorporat- ing these trials showed decreased further bleeding (OR: 0.32, 95% CI: 0.17–0.59) and no difference in all-­cause 30-­day mortality (OR: 0.60, 95% CI: 0.23–1.56) (Figures S4 and S5). However, important methodo- logical limitations in the positive trials have led to some hesitation in recommending OTSC as a routine first-­line therapy in all patients. Take-­home point OTSCs are suggested as a treatment option for recurrent bleeding after conventional endoscopic haemostatic therapy and may be con- sidered for initial haemostatic therapy.3.4.2 | Topical haemostatic therapies Guidelines U. S. guidelines suggest TC-­325 haemostatic powder spray as treat- ment for patients with actively bleeding ulcers. European, interna- tional and Asia-­Pacific guidelines suggest haemostatic powder spray for patients with bleeding refractory to conventional therapy. Best available evidence Several topical haemostatic products have been studied (e.g., TC-­325, UI-­EWD, TDM-­621, CEGP-­003, Ankaferd Blood Stopper and Endoclot). TC-­325, a haemostatic powder with aluminium phyllosilicate clay that forms a barrier at the site of bleeding, is the best studied at present. An adequately powered randomised trial in patients with active non-­variceal UGIB showed non-­inferiority of TC-­325 haemostatic powder therapy compared to standard endoscopic therapy for 30-­ day further bleeding: 9.9 versus 18.6% (difference = 8.7%, 1-­sided 95% CI: 0.95%); results for ulcers (accounting for 61% of patients in the trial) were 11.7 versus 16.2%.66 These results were the basis for the U. S. guidelines suggesting TC-­325 powder could be used as first-­ line therapy in actively bleeding lesions. A randomised trial compar- ing UI-­EWD after standard endoscopic therapy to standard therapy alone in 340 patients with non-­variceal UGIB was recently presented in abstract form. Rebleeding was reduced with the addition of UI-­ EWD at 3 days (2.9 vs. 11.3%, p = 0.005) and 30 days (7.0 vs. 18.5%, p = 0.003).67 Take-­home point TC-­325 powder spray is an option for treatment of actively bleeding ulcers and other non-­variceal lesions.3.5 | Variceal bleeding 3.5.1 | Severe refractory variceal bleeding Guidelines Baveno VII and updated U. S. guidance recommend balloon tampon- ade or self-­expandable metal stents as a bridge therapy to more def- inite treatment with transjugular intrahepatic portosystemic shunt (TIPS), noting that SEMS are a safer and more durable option than balloon tamponade.20,42 Best available evidence In patients with severe refractory variceal bleeding, fully-­covered self-­expanding metal stents are now generally preferred to balloon tamponade because they appear to be more efficacious, safer and can be maintained for a longer period of time (1 week) than balloon tamponade (24 h). A randomised controlled trial in 28 patients with massive or refractory variceal bleeding found suggestions of benefit for stent versus balloon tamponade in the composite outcome of GIB, serious adverse event or death (34% vs. 80%; p = 0.051), bleeding (15% vs. 53%; p = 0.055), device-­related serious adverse events (8% vs. 40%; p = 0.084) and median red-­blood-­cell transfusions (2 vs. 6 units; p = 0.08).68,69 Take-­home point Fully-­covered self-­expanding metal stents are preferred over balloon tamponade for severe refractory variceal bleeding.3.6 | Ligation and medical therapy for acute Oesophageal Variceal bleeding 3.6.1 | Guidelines U. S. guidance and Baveno VII recommend ligation therapy for the treatment of acute oesophageal variceal bleeding.20,42 13652036, 2024, 9, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/apt.17949 by Yonsei University, Wiley Online Library on [29/05/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License",5058,682,1264.5,"[-0.1422781  -0.34969297 -1.0575564  ...  0.54279256  0.07176428
 -1.6377858 ]"
137,"1072  |     SHUNG and LAINE 3.6.2 | Best available evidence A recent meta-­analysis of 10 randomised trials comparing sclerother- apy with ligation for acute variceal bleeding reported ligation had an increased bleeding control rate within the first 8–120 h (RR = 1.08, 1.02–1.15) and less subsequent rebleeding (RR = 0.71, 0.52–0.97), as well as lower mortality (RR = 0.72, 0.54–0.97) and fewer complica- tions (RR = 0.29, 0.20–0.44).70 In patients hospitalised with acute variceal bleeding, randomised trials indicate that ligation is superior to medical therapy alone,71–73 and combination therapy with ligation plus a vasoactive drug (terlipressin) was more effective than a vaso- active drug alone.74 Combination therapy with ligation plus octreo- tide reduced rebleeding rate (9% vs. 38%) but not inpatient mortality (9% vs. 19%) as compared with ligation alone in a randomised trial of 94 patients.75 Other published randomised trials do not show the benefit of combined therapy (ligation plus somatostatin or octreo- tide) versus ligation alone in outcomes such as fresh hematemesis within 5 days (8/31 (26%) vs. 7/30 (23%)), further bleeding or death within 5 days (2/60 (3%) vs. 1/58 (2%)) or 5-­day rebleeding (0/24 vs. 2/30 (7%)).76–78 Patients with cirrhosis found to have a non-­variceal source of bleeding should have their vasoactive medication discontinued given no benefit documented in non-­variceal bleeding, but continue antibiotic therapy given the benefit in cirrhotic patients with all sources of UGIB.3.6.3 | Take-­home point Acute oesophageal variceal bleeding should be treated with oesoph- ageal variceal ligation as well as intravenous vasoactive medications and antibiotic therapy.3.7 | Gastric varices 3.7.1 | Overall management of gastric variceal bleeding Guidelines Baveno VII suggests endoscopic therapy with tissue adhesives for bleeding from IGV and GOV-­2,20 while U. S. guidance suggests ei- ther endoscopic cyanoacrylate injection, TIPS or retrograde trans- venous obliteration (RTO) can be considered first-­line therapies to control bleeding and prevent rebleeding for GOV2 or IGV; RTO is preferred when TIPS is contraindicated.42,79 Both Baveno VII and U. S. guidelines suggest either ligation or tissue adhesive for GOV-­1. Best available evidence Gastric varices are categorised by location. Gastroesophageal varices are labelled GOV-­1 if they extend from the oesophagus along the lesser curvature of the stomach and GOV-­2 if they extend along the greater curvature. Isolated gastric varices without connection to oesophageal varices are labelled IGV-­1 if in the fundus and IGV-­2 if elsewhere in the stomach. A meta-­analysis of randomised trials of endoscopic injection of butyl-­cyanoacrylate glue injection compared to band ligation showed no benefit in control of active bleeding (RR = 1.13; 0.23–5.69), but decreased re-­bleeding after control of bleeding on initial interven- tion (RR = 0.60; 0.41–0.88).80 Two randomised trials81,82 reported no significant difference in post-­procedural complications between butyl-­cyanoacrylate and ligation, but one found more bleeding gas- tric ulcers with ligation (28% vs. 7%).83 A randomised trial found that TIPS decreased rebleeding from gastric varices (4/35 (11%) versus 14/37 (38%); p = 0.01) compared to glue injection, although the dif- ference lessened when all-­cause UGIB was assessed (15/35 (43%) vs. 22/37 (59%); p = 0.12).84 Balloon Retrograde Transvenous Obliteration (BRTO) is an inter- ventional radiologic procedure that provides transvenous sclerosis/ occlusion of gastric varices via a spontaneous gastrorenal shunt and does not divert blood from the portal system as TIPS does. A ran- domised trial showed BRTO increased the likelihood of remaining free of all-­cause UGIB compared to cyanoacrylate (1-­year 77% vs. 96%, 2-­year 65% vs. 93%; p = 0.004).85 A systematic review of BRTO com- pared to TIPS for treatment of gastric varices, comprised of 6 cohort studies (N = 655) and 1 randomised trial (N = 21) reported reductions in rebleeding (OR = 0.30, 0.18–0.48), 1-­year mortality (OR = 0.43, 0.21– 0.87) and hepatic encephalopathy (OR = 0.06, 0.02–0.15) with BRTO, although the evidence must be considered very low quality.86 Although BRTO is the RTO that is best studied, other observational studies use alternative forms of RTO, which may have fewer complications.79 GOV-­1 obliteration. For acute gastric variceal bleeding secondary to GOV-­1, ligation was inferior to butyl-­cyanoacrylate for initial haemostasis in a meta-­analysis across two randomised trials83,87 (OR: 0.37; 0.15–0.89), with more frequent rebleeding in a meta-­ analysis across three randomised trials82,83,87 (OR: 2.62; 1.32–5.22).69 However, one randomised trial found a higher frequency of immediate adverse symptoms (fever, chest pain, dysphagia: 41% vs 8%) and long-­term complications (spontaneous bacterial peritonitis, hepatic encephalopathy and hepatorenal syndrome) for patients with GOV-­1 who underwent butyl-­cyanoacrylate injection compared to ligation.87 GOV-­2 obliteration. For GOV2, no difference in rebleeding was seen when comparing butyl-­cyanoacrylate and ligation in a meta-­analysis of available data from two randomised trials82,83 (OR: 1.10; 95% CI: 0.28–4.36), though the numbers are very small (N = 38).69 IGV obliteration. For IGV, the data are even more limited but in a meta-­analysis of available data from two randomised trials (N = 24)82,83 more rebleeding occurred with ligation than with butyl-­ cyanoacrylate in IGV (OR: 15.98; 95% CI: 1.71–149.12).69 Take-­home point Endoscopic therapy with butyl-­cyanoacrylate is more effective than ligation for gastric variceal bleeding although ligation may be  13652036, 2024, 9, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/apt.17949 by Yonsei University, Wiley Online Library on [29/05/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License",6077,828,1519.25,"[ 0.46514797 -0.87359715 -1.3632678  ... -0.2727018   0.91898274
 -1.5373803 ]"
138,"|  1073 SHUNG and LAINE considered for GOV1 bleeding because of fewer adverse events. TIPS and BRTO are superior to endoscopic therapy for the prevention of recurrent gastric variceal bleeding. BRTO may be performed if a gas- trorenal shunt is present based on clinical factors (e.g. MELD score, hepatic encephalopathy).3.8 | Novel therapies with endoscopic ultrasound-­enhanced obliteration or thrombin injection 3.8.1 | Guidelines No recommendations exist yet for the use of endoscopic ultrasound or thrombin injection for the treatment of gastric varices.3.8.2 | Best available evidence The use of endoscopic ultrasound to guide treatment for gastric varices has been studied in two small randomised controlled trials, but the heterogeneity of practice limits the pooled analysis of avail- able data. One trial shows that patients treated with EUS-­guided cyanoacrylate glue injection with coils tended to have less reinter- vention (16.7% vs. 40%; p = 0.01) and less rebleeding (3.3% vs. 20%; p = 0.04) compared to EUS-­coil treatment alone.88 The other very small randomised trial evaluated EUS-­guided cyanoacrylate glue in- jection with coil versus EUS-­guided cyanoacrylate glue injection alone and a found flow reduction of 37.5% versus 50% (p = 0.48) and post-­ procedure pulmonary embolism in 25% versus 50% (p = 0.14).89 Two systematic reviews and meta-­analyses, including observational evi- dence suggest that EUS-­guided cyanoacrylate glue injection with coil embolisation has a higher technical success rate and lower rebleeding rate compared to other EUS modalities.90,91 The use of thrombin in- jection compared to cyanoacrylate glue injection has been studied in a randomised trial, which found no difference in 5-­day treatment failure (2/33 vs. 2/35; p = 0.99) but increased complications (4/33 vs. 18/35; p < 0.001), including gastric ulcers, in the cyanoacrylate group.92 3.8.3 | Take-­home point Further evidence is needed before recommendations regarding en- doscopic ultrasound-­guided therapy or use of thrombin for gastric variceal bleeding can be made.3.9 | Gastric antral vascular ectasia (GAVE) 3.9.1 | Guidelines Recent guidelines do not provide recommendations for treatment of UGIB due to GAVE.3.9.2 | Best available evidence GAVE has traditionally been treated with thermal therapy, primar- ily APC. A systematic review of outcomes in cohorts of patients treated with APC reported a mean haemoglobin increase of 3.1 g/ dL, with 88% of 110 RBC transfusion-­dependent patients becom- ing transfusion-­free post-­therapy; a mean of 3.4 treatment sessions were required, and the complication rate was 5.1% (31% of compli- cations were bleeding ulcers).93 However, ligation may be a better option based on observational studies and randomised controlled trials. A meta-­analysis of 4 randomised trials reported a higher eradi- cation rate (absolute risk difference = 29%, 14%–44%), less recur- rent bleeding (absolute risk difference = 29%, 15%–44%) and fewer transfusions (mean difference = 1.49 units, 0.28–2.71), with oblitera- tion of lesions requiring fewer sessions with ligation (mean differ- ence = 1.38, 0.35–2.42).94 3.9.3 | Take-­home point Bleeding from GAVE is commonly treated with APC, but ligation ap- pears to be a superior option.3.10 | Mallory-­Weiss tear 3.10.1 | Guidelines Recent guidelines do not provide recommendations for the treat- ment of UGIB due to Mallory-­Weiss tears, although older European and U. S. guidelines suggest only those with active ongoing bleeding require endoscopic therapy, with U. S. guidelines indicating multipo- lar (bipolar) electrocoagulation appears most effective and European guidelines stating evidence is inadequate to recommend a specific modality.95,96 3.10.2 | Best available evidence Many forms of endoscopic therapy have been reported to be ef- fective for bleeding from Mallory-­Weiss tears in observational studies, including epinephrine, sclerosant, bipolar electrocoagula- tion, heater probe, ligation, clips and haemostatic powder spray. A randomised controlled trial showed bipolar electrocoagulation was superior to sham endoscopic therapy in 17 patients with ac- tively bleeding Mallory-­Weiss tears: haemostasis in 9/9 versus 0/8, emergency intervention in 0/9 versus 4/8, units of RBCs transfused of 1.0 versus 4.8.97 Another randomised trial compared epinephrine plus polidocanol injection versus no endoscopic ther- apy: among those with active bleeding, further bleeding occurred in 1/23 receiving therapy versus 5/23 controls, and among those with non-­bleeding visible vessels, further bleeding occurred in  13652036, 2024, 9, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/apt.17949 by Yonsei University, Wiley Online Library on [29/05/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License",4959,665,1239.75,"[ 0.41994023 -0.79869354 -1.4739455  ...  0.07866091  0.47727883
 -1.0439994 ]"
139,"1074  |     SHUNG and LAINE 1/9 with endoscopic therapy and 3/8 controls – none of the fur- ther bleeding episodes was associated with hypotension.98 A ran- domised trial compared endoscopic therapy for actively bleeding Mallory-­Weiss tears and showed further bleeding in 4/9 with epi- nephrine versus 0/11 with clips,99 while two other randomised tri- als in patients with actively bleeding Mallory-­Weiss tears showed epinephrine comparable to clips in 35 patients (100% haemostasis and 6% rebleeding in both groups) and to ligation in 34 patients (100% haemostasis with no rebleeding in either group).100,101 The very low risk for rebleeding in non-­bleeding Mallory-­Weiss tears was shown in a more recent study that included 66 patients with non-­bleeding Mallory-­Weiss tears managed without endoscopic haemostatic therapy; only 1 patient experienced rebleeding and did not require intervention.102 3.10.3 | Take-­home point Patients with actively bleeding Mallory-­Weiss tears should receive endoscopic therapy, probably employing endoscopic therapies sug- gested for ulcer bleeding.3.11 | Dieulafoy lesion 3.11.1 | Guidelines Older European guidelines suggest treatment of Dieulafoy lesions with thermal therapy, clips or ligation – with or without epinephrine injection, with transcatheter embolisation or surgery if endoscopic treatment fails or is not technically feasible.95 3.11.2 | Best available evidence Multiple endoscopic haemostatic modalities are reported to be ef- fective for Dieulafoy lesions in observational studies, including epinephrine, sclerosant, cyanoacrylate, bipolar electrocoagulation, heater probe, APC, clips and ligation. Small randomised controlled trials suggest epinephrine therapy is inferior to mechanical therapy with ligation or clips, with further bleeding rates >40% versus 0%– 17%.103–105 Small randomised comparisons of clips versus ligation reveal excellent results for both therapies, with further bleeding in <8% of patients.106,107 3.11.3 | Take-­home point Patients with Dieulafoy lesions should undergo endoscopic therapy, employing therapies suggested for ulcer bleeding. Similar to ulcer bleeding, epinephrine should not be used alone.3.12 | Malignancy 3.12.1 | Guidelines Older European guidelines suggest considering endoscopic hae- mostatic therapy for bleeding from UGI neoplasia to potentially reduce the need for urgent surgery and provide a bridge to other therapy, although no endoscopic treatment appears to have long-­ term efficacy.95 3.12.2 | Best available evidence Case series suggest endoscopic therapy may achieve haemostasis in many patients with UGIB due to malignancy, although rates are highly variable. Rebleeding rates tend to be high, which would be expected if the underlying lesion is not able to be treated effec- tively. For example, a case series from Korea of 113 patients with UGIB from unresectable gastric cancer treated with endoscopic therapy revealed a haemostasis rate of 93% but rebleeding in 41% (30% at 30 days) and a median survival of 3 months.108 In a case series of 106 consecutive patients hospitalised with UGIB due to malignancy in the United States, haemostasis was achieved in 86% of patients with active bleeding at endoscopy who received endo- scopic therapy, but 18 patients with active bleeding who did not receive endoscopic therapy had spontaneous resolution of bleeding as well. Hospitalisation for rebleeding occurred in 49% of patients at a median of 30 days.109 TC-­325 haemostatic powder spray has recently been considered to have promise for malignancy-­related UGIB. A randomised trial was done in 59 patients with UGIB due to malignancy (19 with active bleed- ing from the malignant lesion): all 28 patients in the TC-­325 group re- ceived therapy and had haemostasis, while only 6 patients of 31 in the control group received endoscopic therapy. Rebleeding at 30 days was not reduced with TC-­325 versus control (32% vs. 19.4%), nor was hos- pital stay (17.4 vs. 12.8 days) or 30-­day mortality (28.6% vs. 19.4%).110 In contrast, subgroup analysis of patients with cancer in a recent large randomised trial comparing TC-­325 to standard endoscopic therapy for active UGIB reported 30-­day further bleeding in 3/29 (10%) receiv- ing TC-­325 versus 6/13 (46%) receiving standard therapy.66 Therapy with transcatheter embolisation may be employed, and treatment of the underlying malignancy (e.g., palliative or curative surgery, radiation therapy) where possible is the best option to pre- vent rebleeding.3.12.3 | Take-­home point Acute UGIB due to malignancy may be treated with endoscopic ther- apy but results are variable and rebleeding is common. Treatment with TC-­325 haemostatic powder spray may hold promise but  13652036, 2024, 9, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/apt.17949 by Yonsei University, Wiley Online Library on [29/05/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License",5083,711,1270.75,"[-0.250472   -0.03696249 -1.3786418  ...  0.48178774  1.1244135
 -1.2372527 ]"
140,"|  1075 SHUNG and LAINE therapy for the underlying malignancy, if possible, is most important to prevent rebleeding.4 | POST-­ENDOSCOPIC MANAGEMENT 4.1 | Early versus delayed oral intake for moderate to severe UGIB 4.1.1 | Guidelines International guidelines recommend that patients at low risk can eat within 24 h after endoscopy.6 No specific recommendations exist for the timing of resuming a diet for patients hospitalised with moderate to severe UGIB, though U. S. guidance for portal hypertensive bleed- ing recommends initiating enteral feeding once the variceal haemor- rhage has been controlled.42 4.1.2 | Best available evidence A randomised trial in 251 patients with UGIB with lower-­risk en- doscopic findings showed no difference in rebleeding or need for urgent intervention in those immediately given a regular diet ver- sus delaying resumption of a regular diet (clear liquids started at 36 h and regular diet at 48 h after endoscopy). Overall, rebleeding occurred in only 3/162 (2%) of patients with Mallory-­Weiss tears or clean-­based ulcers. Several randomised trials have assessed different dietary regimens in patients with higher-­risk endoscopic findings. One small trial in 22 patients with variceal bleeding that compared a liquid diet versus nothing by mouth for 3 days reported 7-­day rebleeding rates of 4/12 versus 0/10. However, other pub- lished trials in high-­risk ulcer bleeding or varices (ranging in size up to 209 patients) showed nearly identical rebleeding rates when comparing regimens including liquid diet (or liquid followed by mixed diet) versus nothing by mouth for 2–3 days, immediate solid diet versus liquids for 1 day followed by soft diet for 2 days, imme- diate normal diet vs. normal diet at day 1, or refeeding at 1 versus 2 days with liquids for 1 day followed by soft diet for 1 day. Although aggregating these trials may be questionable due to differences in refeeding regimens and populations, we performed a meta-­analysis of the 7 randomised trials in higher-­risk patients and found earlier initiation of a regular diet was not associated with more rebleed- ing (OR = 1.05, 0.51–2.13) or deaths (0.53, 0.26–1.10) than delayed resumption of a regular diet (Figures S6 and S7). Hospital stay was shorter across 6 trials that reported the length of stay (mean differ- ence: −1.55 days, −2.07 to −1.03) (Figure S8).4.1.3 | Take-­home point Patients with low-­risk endoscopic findings (e.g., clean-­based ulcers) may begin a regular diet soon after endoscopy and be discharged home if they have no other reason for hospitalisation. Patients with higher risk endoscopic findings, even after endoscopic therapy, may be fed in less than 72 h, although the exact time and initial dietary regimen are uncertain.4.2 | Peptic ulcer disease 4.2.1 | Proton pump inhibitor (PPI) therapy after endoscopic haemostatic therapy Guidelines U. S. and European guidelines recommend either continuous intrave- nous PPI therapy (80 mg bolus followed by 8 mg per hour infusion) or intermittent high-­dose intravenous or oral PPI therapy (e.g., 40 mg 2–4 times daily, possibly with an initial 80 mg bolus) for 3 days after successful endoscopic haemostatic therapy (or for those with clots not receiving endoscopic therapy).5,8 Earlier international guidelines only recommended intravenous PPIs with a loading dose and con- tinuous infusion for 3 days in patients with high-­risk stigmata who have undergone successful endoscopic therapy.6 Asia-­Pacific guide- lines recommend high-­dose oral PPI therapy for at least 3 days as an adjunct to endoscopic therapy.7 U. S. and international guidelines recommend that after this ini- tial 3-­day period, twice-­daily PPI therapy should be given through 14 days after the index endoscopy.5,6 Best available evidence High-­dose PPI therapy, defined as ≥80 mg daily for at least 3 days after endoscopic treatment, decreased further bleed- ing (RR = 0.43; 0.33–0.56) and mortality (RR = 0.41; 0.22–0.79) compared to placebo/no treatment in a meta-­analysis of 8 ran- domised comparisons.5 Furthermore, subgroup analysis showed that trials with continuous infusion and intermittent therapy had virtually identical risk ratios for further bleeding and mortality. Meta-­analysis of 9 randomised trials comparing high-­dose PPI to H2-­receptor-­antagonist therapy showed a reduction in further bleeding with high-­dose PPI (RR = 0.56; 0.41–0.77) but not in mortality.5 A single randomised trial performed in high-­risk patients (Rockall score ≥6) who had successful endoscopic haemostatic therapy for ulcers with high-­risk stigmata and 3 days of continu- ous infusion PPI therapy compared esomeprazole 40 mg twice daily to once daily for days 4–14 after the index endoscopy, with all patients receiving once-­daily PPI after 14 days. Further bleed- ing was lower at 2 weeks and at 4 weeks (10.8% vs. 28.7%, differ- ence = −18%, −29 to −7%).111 Take-­home point After endoscopic haemostatic treatment of UGIB due to ulcers, treat with either continuous infusion or intermittent intravenous or oral high-­dose PPI for 3 days. Twice-­daily oral PPI therapy should then be given for at least 14 days after the index endoscopy. 13652036, 2024, 9, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/apt.17949 by Yonsei University, Wiley Online Library on [29/05/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License",5539,784,1384.75,"[ 0.2203279  -0.6704032  -1.6927239  ...  0.06299718  1.1013591
 -0.590686  ]"
141,"1076  |     SHUNG and LAINE 4.3 | Treatment of recurrent ulcer bleeding 4.3.1 | Guidelines International, U. S. and European guidelines recommend that pa- tients with recurrent bleeding after endoscopic therapy for a bleed- ing ulcer have repeat endoscopy and endoscopic therapy rather than surgery or transcatheter arterial embolisation.5,6,8 For those who fail endoscopic therapy, U. S. and European guidelines suggest tran- scatheter arterial embolisation over surgery.5,8 4.3.2 | Best available evidence A randomised trial comparing repeat endoscopy versus surgery for patients with recurrent ulcer bleeding after initially successful endo- scopic therapy, further bleeding was more frequent with endoscopy (11/48 (23%) vs. 3/44 (7%)), but complications were less common with endoscopy (15% vs. 36%) and mortality was not significantly different (10% vs. 18%).112 Given that endoscopy prevented the need for surgery in 73% of patients in this study with a lower rate of complications and no negative impact on mortality, guideline panels suggested repeat endoscopy. A meta-­analysis of observational studies comparing transcatheter arterial embolisation to surgery after failed endoscopic therapy found that further bleeding was more common with embolisation (OR = 2.44, 1.77–3.36) but major complications were lower (OR = 0.45, 0.30–0.67) without an increase in mortality (OR = 0.77, 0.50–1.18).113 In addition, a cohort study showed hospital stays to be lower with embolisation (median 8 vs. 16 days).114 Guideline panels concluded that despite the higher risk of further bleeding, the benefits of fewer complications and a shorter hospital stays along with no increase in mortality, would sup- port initial embolisation, with surgery as a backup in those who failed embolisation. Nevertheless, patients and providers who place greater value on avoiding further bleeding over complications and hospital stays may choose differently.4.3.3 | Take-­home point Rebleeding after initial endoscopic haemostatic therapy should first be evaluated and treated with repeat endoscopy. For those who fail endoscopic therapy arteriography with transcatheter arterial embo- lisation should be performed.4.4 | Pre-­emptive transjugular intrahepatic portosystemic shunt (TIPS) for acute variceal bleeding 4.4.1 | Guidelines U. S. guidance and Baveno VII recommend pre-­emptive TIPS within 72 h (ideally 24 h per Baveno VII) for high-­risk patients (Child-­Pugh class B > 7 with active bleeding or Child-­Pugh class C with score <14) without contraindications for TIPS.20,42,79 4.4.2 | Best available evidence A pre-­emptive transjugular intrahepatic portosystemic shunt (TIPS) can be considered therapy for acute variceal bleeding episodes in selected high-­risk patients based on two randomised controlled tri- als comparing pre-­emptive TIPS within 72 h after initial endoscopic ligation therapy and vasoactive medication infusion in patients with Child-­Pugh Class B and Child-­Pugh Class C cirrhosis (excluding those with a Child-­Pugh score >13). One trial found that in 63 patients, fur- ther bleeding was reduced with TIPS (3% vs. 45%, p = 0.001), as was mortality (13% vs. 39%, p = 0.001).115 The second trial in 129 patients also showed reductions in further bleeding (HR = 0.26, 0.12–0.55) and mortality (HR = 0.47, 0.23–0.96).116 The first study only included Child-­ Pugh Class B patients if they had active bleeding, and this forms part of the rationale for guideline recommendations that high-­risk patients be defined as Child-­Pugh Class B with active bleeding. However, the second trial included Child-­Pugh Class B patients with and without active bleeding, and subgroup analysis showed the magnitude of the treatment effect to be similar in those with and without active bleed- ing, suggesting that any Child-­Pugh Class B may be considered for pre-­emptive TIPS. A third small similarly-­designed trial failed to show a benefit of pre-­emptive TIPS. However, 6 of the 29 patients assigned to TIPS did not receive them, and another 10 received them beyond the 72-­h window for pre-­emptive TIPS. A per-­protocol analysis of those re- ceiving TIPS within 72 hours revealed less rebleeding (0% vs. 28%) but similar 1-­year survival (77% vs. 76%) with TIPS versus standard care.117 Recent guidance to restrict pre-­emptive TIPS in Child-­Pugh Class B patients to those with active bleeding and a Child-­Pugh score >7 is based largely on an individual patient data meta-­analysis, with 83% of the patients from observational studies, which we believe is in- sufficient to justify this conclusion. The meta-­analysis only included patients with active bleeding, so it could not address the potential benefit to patients without active bleeding. Furthermore, outcomes for Child-­Pugh Class B stratified by score of 7 (N = 39 TIPS) and >7 (N = 99 TIPS) were assessed only in a post hoc analysis: benefit for TIPS was noted in mortality only in the score >7 group, but less re- bleeding with TIPS was seen in both groups.118 Given that the only randomised trial assessing active and non-­active bleeding in Childs-­ Pugh Class B patients showed a similar effect, we suggest that TIPS might be considered in any Childs-­Pugh Class B patient. More in- formation is necessary to make a more definitive recommendation.4.4.3 | Take-­home point Pre-­emptive TIPS should be considered in high-­risk patients (Child-­ Pugh class B or C with score <14) after initial endoscopic ligation and vasoactive medical therapy, if interventional radiology services are available. 13652036, 2024, 9, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/apt.17949 by Yonsei University, Wiley Online Library on [29/05/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License",5905,834,1476.25,"[-0.19601814 -0.4738003  -1.6007631  ...  0.44397038  0.7489711
 -1.371032  ]"
142,"|  1077 SHUNG and LAINE 4.5 | Treatment of recurrent variceal bleeding 4.5.1 | Guidelines If further bleeding occurs despite medical and endoscopic therapy, TIPS is recommended by U. S. guidance and Baveno VII.20,42 Both TIPS and BRTO are suggested as treatments for gastric varices as discussed above.4.5.2 | Best available evidence As mentioned above, in addition to endoscopic ligation, vasoactive medications are continued for a total of 2–5 days and antibiotics for up to 7 days to reduce further bleeding. In patients who fail to achieve haemostasis despite adequate endoscopic and pharmaco- logical therapy, meta-­analysis of trials of TIPS revealed rebleeding of 16% within 30–42 days; mortality was 33% at 30–42 days and 46% at 1 year, although mortality due to rebleeding was only 9%.119 A meta-­analysis of 17 randomised trials comparing TIPS and endo- scopic therapy in patients with variceal bleeding indicates TIPS is more effective in reducing rebleeding (OR = 0.28, 0.22–0.37) but not mortality (OR = 1.04, 0.81–1.33) and is associated with more hepatic encephalopathy (OR = 2.04, 1.57–2.66).120 4.5.3 | Take-­home point Patients with further variceal bleeding despite endoscopic and medical therapy should undergo TIPS (BRTO may be performed for gastric variceal bleeding). AUTHOR CONTRIBUTIONS Dennis L. Shung: Conceptualization; data curation; formal analysis; funding acquisition; investigation; methodology; project adminis- tration; resources; software; visualization; writing – original draft; writing – review and editing. Loren Laine: Conceptualization; data curation; formal analysis; investigation; methodology; project ad- ministration; resources; software; supervision; validation; visuali- zation; writing – original draft; writing – review and editing. ACKNOWLEDGEMENTS We acknowledge the assistance of Alyssa Grimshaw, medical librar- ian at Yale, in crafting the structured searches for the systematic reviews. FUNDING INFORMATION Work for DLS was funded in part through the National Institutes of Health, DK125718. AUTHORSHIP Guarantor of the article: Dennis L. Shung. Both authors approved the final version of the manuscript. CONFLICT OF INTEREST STATEMENT DLS has no conflicts of interests. LL serves as a consultant for Phathom Pharmaceuticals and Medtronic. ORCID Dennis L. Shung  https://orcid.org/0000-0001-8226-1842 Loren Laine  https://orcid.org/0000-0002-4296-7901 REFERENCES 	 1.	 Zheng NS, Tsay C, Laine L, Shung DL. Trends in characteristics, man- agement, and outcomes of patients presenting with gastrointesti- nal bleeding to emergency departments in the United States from 2006 to 2019. Aliment Pharmacol Ther.2022;56(11–12):1543–55.	 2.	 Taha AS, Saffouri E, McCloskey C, Craigen T, Angerson WJ. Falling mortality when adjusted for comorbidity in upper gastro- intestinal bleeding: relevance of multi-­disciplinary care. Frontline Gastroenterol.2014;5(4):243–8.	 3.	 Guo CLT, Wong SH, Lau LHS, Lui RNS, Mak JWY, Tang RSY, et al. Timing of endoscopy for acute upper gastrointestinal bleeding: a territory-­wide cohort study. Gut.2022;71(8):1544–50.	 4.	 Abraham NS, Barkun AN, Sauer BG, Douketis J, Laine L, Noseworthy PA, et  al. American College of Gastroenterology-­ Canadian Association of Gastroenterology clinical practice guide- line: management of anticoagulants and antiplatelets during acute gastrointestinal bleeding and the periendoscopic period. Am J Gastroenterol.2022;117(4):542–58.	 5.	 Laine L, Barkun AN, Saltzman JR, Martel M, Leontiadis GI. ACG clinical guideline: upper gastrointestinal and ulcer bleeding. Am J Gastroenterol.2021;116(5):899–917.	 6.	 Barkun AN, Almadi M, Kuipers EJ, Laine L, Sung J, Tse F, et  al. Management of nonvariceal upper gastrointestinal bleeding: guide- line recommendations from the international consensus group. Ann Intern Med.2019;171:805–22.https://​doi.​org/​10.​7326/​M7319-​1795 	 7.	 Sung JJ, Chiu PW, Chan FK, Lau JY, Goh KL, Ho LH, et al.",3950,524,987.5,"[ 0.424967   -0.7045426  -1.2669137  ... -0.5320712   0.67981076
 -1.2329606 ]"
142,"Asia-­ Pacific working group consensus on non-­variceal upper gastroin- testinal bleeding: an update 2018. Gut.2018;67(10):1757–68.	 8.	 Gralnek IM, Stanley AJ, Morris AJ, Camus M, Lau J, Lanas A, et  al. Endoscopic diagnosis and management of nonvariceal upper gastrointestinal hemorrhage (NVUGIH): European Society of Gastrointestinal Endoscopy (ESGE) guideline – update 2021. Endoscopy.2021;53(3):300–32.	 9.	 Stanley AJ, Ashley D, Dalton HR, Mowat C, Gaya DR, Thompson E, et al. Outpatient management of patients with low-­risk upper-­ gastrointestinal haemorrhage: multicentre validation and prospec- tive evaluation. Lancet.2009;373(9657):42–7.	 10.	 Banister T, Spiking J, Ayaru L. Discharge of patients with an acute upper gastrointestinal bleed from the emergency depart- ment using an extended Glasgow-­Blatchford Score. BMJ Open Gastroenterol.2018;5(1):e000225.	 11.	 Shung D, Au B, Taylor R, Tay JK, Laursen SB, Stanley AJ, et  al. Validation of a machine learning model that outperforms clin- ical risk scoring systems for upper gastrointestinal bleeding. Gastroenterology.2019;158:160–7.	 12.	 Rockall TA, Logan RF, Devlin HB, Northfield TC. Risk assessment after acute upper gastrointestinal haemorrhage. Gut.1996;38(3):316–21.	 13.	 Saltzman JR, Tabak YP, Hyett BH, Sun X, Travis AC, Johannes RS. A simple risk score accurately predicts in-­hospital mortality, length of stay, and cost in acute upper GI bleeding. Gastrointest Endosc. 2011;74(6):1215–24.	 14.	 Laursen SB, Oakland K, Laine L, Bieber V, Marmo R, Redondo-­ Cerezo E, et al. ABC score: a new risk score that accurately pre- dicts mortality in acute upper and lower gastrointestinal bleeding: an international multicentre study. Gut.2020;70:707–16. 13652036, 2024, 9, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/apt.17949 by Yonsei University, Wiley Online Library on [29/05/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License",2070,270,517.5,"[ 0.4215966  -0.31028387 -1.6728061  ...  0.1076518   0.49539155
 -1.183602  ]"
143,"1078  |     SHUNG and LAINE 	 15.	 Marmo R, Soncini M, Bucci C, Occhipinti V, Pellegrini L, Zullo A. Derivation and validation of Re. Co. De death score risk in patients with acute nonvariceal upper GI bleeding. Gastrointest Endosc. 2022;96(1):36–43.e38.	 16.	 Deshmukh F, Merchant SS. Explainable machine learning model for predicting GI bleed mortality in the intensive care unit. Am J Gastroenterol.2020;115(10):1657–68.	 17.	 Levi R, Carli F, Arévalo AR, Altinel Y, Stein DJ, Naldini MM, et al. Artificial intelligence-­based prediction of transfusion in the in- tensive care unit in patients with gastrointestinal bleeding. BMJ Health Care Inform.2021;28(1):e100245.	 18.	 Shung D, Huang J, Castro E, Tay JK, Simonov M, Laine L, et al. Neural network predicts need for red blood cell transfusion for patients with acute gastrointestinal bleeding admitted to the in- tensive care unit. Sci Rep. 2021;11(1):8827.	 19.	 Schembre DB, Ely RE, Connolly JM, Padhya KT, Sharda R, Brandabur JJ. Semiautomated Glasgow-­Blatchford Bleeding Score helps direct bed placement for patients with upper gastrointesti- nal bleeding. BMJ Open Gastroenterol.2020;7(1):e000479.	 20.	 de Franchis R, Bosch J, Garcia-­Tsao G, Reiberger T, Ripoll C. Baveno VII – renewing consensus in portal hypertension. J Hepatol. 2022;76(4):959–74.	 21.	 Villanueva C, Colomo A, Bosch A, Concepción M, Hernandez-­Gea V, Aracil C, et al. Transfusion strategies for acute upper gastroin- testinal bleeding. N Engl J Med.2013;368(1):11–21.	 22.	 Jairath V, Kahan BC, Gray A, Doré CJ, Mora A, James MW, et al. Restrictive versus liberal blood transfusion for acute upper gas- trointestinal bleeding (TRIGGER): a pragmatic, open-­label, cluster randomised feasibility trial. Lancet.2015;386(9989):137–44.	 23.	 Kola G, Sureshkumar S, Mohsina S, Sreenath GS, Kate V. Restrictive versus liberal transfusion strategy in upper gastrointestinal bleeding: a randomized controlled trial. Saudi J Gastroenterol.2021;27(1):13–9.	 24.",1987,278,496.75,"[ 1.1340219  -0.4421482  -1.1034849  ...  0.00901046 -0.01241834
 -1.6348467 ]"
143,"Ducrocq G, Gonzalez-­Juanatey JR, Puymirat E, Lemesle G, Cachanado M, Durand-­Zaleski I, et  al. Effect of a restrictive vs liberal blood transfusion strategy on major cardiovascular events among patients with acute myocardial infarction and anemia: the REALITY randomized clinical trial. JAMA.2021;325(6):552–60.	 25.	 Rahman R, Nguyen DL, Sohail U, Almashhrawi AA, Ashraf I, Puli SR, et  al. Pre-­endoscopic erythromycin administration in upper gastrointestinal bleeding: an updated meta-­analysis and system- atic review. Ann Gastroenterol.2016;29(3):312–7.	 26.	 Vimonsuntirungsri T, Thungsuk R, Nopjaroonsri P, Faknak N, Pittayanon R. The efficacy of metoclopramide of gastric visualiza- tion by endoscopy in patients with active upper gastrointestinal bleeding: double-­blind randomized controlled trial. Paper pre- sented at: digestive diseases Week2023; Chicago, IL, USA.	 27.	 Kanno T, Yuan Y, Tse F, Howden CW, Moayyedi P, Leontiadis GI. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database Syst Rev. 2022;2020:CD005415.	 28.	 Lau JY, Leung WK, Wu JCY, Chan FKL, Wong VWS, Chiu PWY, et al. Omeprazole before endoscopy in patients with gastrointesti- nal bleeding. N Engl J Med.2007;356(16):1631–40.	 29.	 Bennett C, Klingenberg SL, Langholz E, Gluud LL. Tranexamic acid for upper gastrointestinal bleeding. Cochrane Database Syst Rev. 2014;2014(11):CD006640.	 30.	 Roberts I, Shakur-­Still H, Afolabi A, Akere A, Arribas M, Brenner A, et al. Effects of a high-­dose 24-­h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastroin- testinal bleeding (HALT-­IT): an international randomised, double-­ blind, placebo-­controlled trial. Lancet.2020;395(10241):1927–36.	 31.	 Barer D, Ogilvie A, Henry D, Dronfield M, Coggon D, French S, et  al. Cimetidine and tranexamic acid in the treatment of acute upper-­gastrointestinal-­tract bleeding. N Engl J Med. 1983;308(26):1571–5.	 32.	 Cormack F, Chakrabarti RR, Jouhar AJ, Fearnley GR. Tranexamic acid in upper gastrointestinal haemorrhage. Lancet. 1973;301(7814):1207–8.	 33.	 Hawkey GM, Cole AT, McIntyre AS, Long RG, Hawkey CJ. Drug treatments in upper gastrointestinal bleeding: value of endoscopic findings as surrogate end points.",2301,309,575.25,"[ 0.05301559 -0.38420284 -1.1302226  ...  0.79297143  0.13291992
 -1.3846353 ]"
143,"Gut.2001;49(3):372–9.	 34.	 von Holstein CC, Eriksson SB, Källén R. Tranexamic acid as an aid to reducing blood transfusion requirements in gastric and duode- nal bleeding. Br Med J (Clin Res Ed).1987;294(6563):7–10.	 35.	 Karadas A, Dogan NO, Pinar SG, Yesil O, Pekdemir M, Yilmaz S, et  al. A randomized controlled trial of the effects of local tranexamic acid on mortality, rebleeding, and recurrent endos- copy need in patients with upper gastrointestinal hemorrhage. Eur J Gastroenterol Hepatol.2020;32(1):26–31.	 36.	 Saidi H, Shojaie S, Ghavami Y, Mirafzal A, Sisakht MT, Sotudehnia M. Role of intra-­gastric tranexamic acid in management of acute upper gastrointestinal bleeding. IIOAB J. 2017;8:76–81.	 37.	 Tavakoli N, Mokhtare M, Agah S, Azizi A, Masoodi M, Amiri H, et al. Comparison of the efficacy of intravenous tranexamic acid with and without topical administration versus placebo in urgent endoscopy rate for acute gastrointestinal bleeding: a double-­blind randomized controlled trial. United European Gastroenterol J. 2018;6(1):46–54.	 38.	 Bagnenko SF, Verbitskiĭ VG. Antifibrinolitic therapy for the treat- ment of massive ulcerative gastro-­intestinal bleedings. Khirurgiia (Mosk).2011;4:42–6.	 39.	 Bergqvist D, Dahlgren S, Hessman Y. Local inhibition of the fi- brinolytic system in patients with massive upper gastrointestinal hemorrhage. Ups J Med Sci.1980;85(2):173–8.	 40.	 Biggs JC, Hugh TB, Dodds AJ. Tranexamic acid and upper gastroin- testinal haemorrhage-­-­a double-­blind trial. Gut.1976;17(9):729–34.	 41.	 Engqvist A, Broström O, Feilitzen FV, Halldin M, Nyström B, Öst Å, et al. Tranexamic acid in massive haemorrhage from the upper gastrointestinal tract: a double-­blind study. Scand J Gastroenterol. 1979;14(7):839–44.	 42.	 Kaplan DE, Bosch J, Ripoll C, Thiele M, Fortune BE, Simonetto DA, et al. AASLD practice guidance on risk stratification and manage- ment of portal hypertension and varices in cirrhosis. Hepatology. 2023.https://​doi.​org/​10.​1097/​HEP.​00000​00000​000647 	 43.",2028,275,507.0,"[ 0.45526618 -0.42750058 -0.99090946 ...  0.3615124   0.13055953
 -1.4895295 ]"
143,"Chavez-­Tapia NC, Barrientos-­Gutierrez T, Tellez-­Avila F, Soares-­ Weiser K, Mendez-­Sanchez N, Gluud C, et al. Meta-­analysis: anti- biotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding – an updated Cochrane review. Aliment Pharmacol Ther. 2011;34(5):509–18.	 44.	 Fernández J, Ruiz del Arbol L, Gómez C, Durandez R, Serradilla R, Guarner C, et al. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenterology.2006;131(4):1049–56.quiz 1285.	 45.	 Wells M, Chande N, Adams P, Beaton M, Levstik M, Boyce E, et  al. Meta-­analysis: vasoactive medications for the man- agement of acute variceal bleeds. Aliment Pharmacol Ther. 2012;35(11):1267–78.	 46.	 Avgerinos A, Nevens F, Raptis S, Fevery J. Early administra- tion of somatostatin and efficacy of sclerotherapy in acute oesophageal variceal bleeds: the European Acute Bleeding Oesophageal Variceal Episodes (ABOVE) randomised trial. Lancet. 1997;350(9090):1495–9.	 47.	 Calès P, Masliah C, Bernard B, Garnier PP, Silvain C, Szostak-­ Talbodec N, et  al. Early administration of vapreotide for variceal bleeding in patients with cirrhosis. N Engl J Med. 2001;344(1):23–8.	 48.	 Levacher S, Letoumelin P, Pateron D, Blaise M, Lapandry C, Pourriat JL. Early administration of terlipressin plus glyceryl trini- trate to control active upper gastrointestinal bleeding in cirrhotic patients. Lancet.1995;346(8979):865–8. 13652036, 2024, 9, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/apt.17949 by Yonsei University, Wiley Online Library on [29/05/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License",1805,233,451.25,"[ 0.05083889 -1.0657781  -1.0203325  ...  0.29637104  0.5943818
 -1.4844307 ]"
144,"|  1079 SHUNG and LAINE 	 49.	 Huaringa-­Marcelo J, Huaman MR, Brañez-­Condorena A, Villacorta-­Landeo P, Pinto-­Ruiz DF, Urday-­Ipanaqué D, et  al. Vasoactive agents for the management of acute variceal bleeding: a systematic review and meta-­analysis. J Gastrointestin Liver Dis. 2021;30(1):110–21.	 50.	 Laursen SB, Leontiadis GI, Stanley AJ, Møller MH, Hansen JM, Schaffalitzky de Muckadell OB. Relationship between timing of endoscopy and mortality in patients with peptic ulcer bleeding: a nationwide cohort study. Gastrointest Endosc.2017;85(5):936– 944.e933.	 51.	 Cho SH, Lee YS, Kim YJ, Sohn CH, Ahn S, Seo DW, et al. Outcomes and role of urgent endoscopy in high-­risk patients with acute non- variceal gastrointestinal bleeding. Clin Gastroenterol Hepatol. 2018;16(3):370–7.	 52.	 Lau JYW, Yu Y, Tang RSY, Chan HCH, Yip HC, Chan SM, et  al. Timing of endoscopy for acute upper gastrointestinal bleeding. N Engl J Med.2020;382(14):1299–308.	 53.	 Lee JG, Turnipseed S, Romano PS, Vigil H, Azari R, Melnikoff N, et al. Endoscopy-­based triage significantly reduces hospitalization rates and costs of treating upper GI bleeding: a randomized con- trolled trial. Gastrointest Endosc.1999;50(6):755–61.	 54.	 Bjorkman DJ, Zaman A, Fennerty MB, Lieberman D, Disario JA, Guest-­Warnick G. Urgent vs. elective endoscopy for acute non-­ variceal upper-­GI bleeding: an effectiveness study. Gastrointest Endosc.2004;60(1):1–8.	 55.	 Wysocki JD, Srivastav S, Winstead NS. A nationwide analysis of risk factors for mortality and time to endoscopy in upper gastroin- testinal haemorrhage. Aliment Pharmacol Ther.2012;36(1):30–6.	 56.	 Bai Z, Wang R, Cheng G, Ma D, Ibrahim M, Chawla S, et al. Outcomes of early versus delayed endoscopy in cirrhotic patients with acute variceal bleeding: a systematic review with meta-­analysis. Eur J Gastroenterol Hepatol.2021;33(1S Suppl 1):e868–e876.	 57.	 Laine L, McQuaid KR. Endoscopic therapy for bleeding ulcers: an evidence-­based approach based on meta-­analyses of randomized controlled trials. Clin Gastroenterol Hepatol.",2066,285,516.5,"[ 0.04652563 -1.0813955  -1.5760598  ...  0.21630582  0.48516524
 -1.475388  ]"
144,"2009;7(1):33–47. quiz 31–32.	 58.	 Cook DJ, Guyatt GH, Salena BJ, Laine LA. Endoscopic therapy for acute nonvariceal upper gastrointestinal hemorrhage: a meta-­ analysis. Gastroenterology.1992;102(1):139–48.	 59.	 Laine L, Jensen DM. Management of patients with ulcer bleeding. Am J Gastroenterol.2012;107(3):345–60.quiz 361.	 60.	 Qian O, Zhang Q, Pan Y, Cheng C, Xu L, Guan J, et al. Endoscopic thermocoagulation hemostasis for acute non-­varicose upper gas- trointestinal hemorrhage: a randomized controlled study. Surg Endosc.2022;36(2):1578–83.	 61.	 Schmidt A, Golder S, Goetz M, Meining A, Lau J, von Delius S, et al. Over-­the-­scope clips are more effective than standard endoscopic therapy for patients with recurrent bleeding of peptic ulcers. Gastroenterology.2018;155(3):674–686.e6.	 62.	 Meier B, Wannhoff A, Denzer U, Stathopoulos P, Schumacher B, Albers D, et  al. Over-­the-­scope-­clips versus standard treat- ment in high-­risk patients with acute non-­variceal upper gastro- intestinal bleeding: a randomised controlled trial (STING-­2). Gut. 2022;71(7):1251–8.	 63.	 Jensen DM, Kovacs T, Ghassemi KA, Kaneshiro M, Gornbein J. Randomized controlled trial of over-­the-­scope clip as initial treat- ment of severe nonvariceal upper gastrointestinal bleeding. Clin Gastroenterol Hepatol.2021;19(11):2315–2323.e12.	 64.	 Lau JY, Li R, Tan CH, Sun XJ, Song HJ, Li L, et al. Comparison of over-­the-­scope clips to standard endoscopic treatment as the ini- tial treatment in patients with bleeding from a nonvariceal upper gastrointestinal cause. Ann Intern Med.2023;176:455–62.	 65.	 Chan S, Pittayanon R, Wang HP, Chen JH, Teoh AY, Kuo YT, et al. Use of over-­the-­scope clip (OTSC) versus standard therapy for the prevention of rebleeding in large peptic ulcers (size ≥1.5 cm): an open-­labelled, multicentre international randomised controlled trial. Gut.2023;72(4):638–43.	 66.",1897,252,474.25,"[ 0.15208657 -0.5033611  -1.5802393  ...  0.63608485  0.30711496
 -1.608053  ]"
144,"Lau JYW, Pittayanon R, Kwek A, Tang RS, Chan H, Rerknimitr R, et al. Comparison of a hemostatic powder and standard treatment in the control of active bleeding from upper nonvariceal lesions: a multicenter, noninferiority, randomized trial. Ann Intern Med. 2022;175(2):171–8.	 67.	 Lee E, Kim KO, Kim H, Hong SJ, Shin J, Cha B. A randomized con- trol study evaluating the efficacy of a hemostatic powder (UI-­ EWD) in decreasing the rate of upper gastrointestinal RE-­bleeding in patients treated with endoscopic therapy for high-­risk lesions. 2023 Paper presented at: digestive diseases Week 2023; Chicago, IL, USA.	 68.	 Escorsell À, Pavel O, Cárdenas A, Morillas R, Llop E, Villanueva C, et al. Esophageal balloon tamponade versus esophageal stent in controlling acute refractory variceal bleeding: a multicenter ran- domized, controlled trial. Hepatology.2016;63(6):1957–67.	 69.	 Laine L. Is there a role for combined sclerotherapy and liga- tion in the endoscopic treatment of gastroesophageal varices? Gastrointest Endosc.2017;86(2):316–8.	 70.	 Onofrio FQ, Pereira-­Lima JC, Valenca FM, Azeredo-­da-­Silva ALF, Stein AT. Efficacy of endoscopic treatments for acute esopha- geal variceal bleeding in cirrhotic patients: systematic review and meta-­analysis. Endosc Int Open.2019;7(11):E1503–E1514.	 71.	 Lo GH, Lai KH, Cheng JS, Lin CK, Huang JS, Hsu PI, et al. Emergency banding ligation versus sclerotherapy for the control of active bleeding from esophageal varices. Hepatology.1997;25(5):1101–4.	 72.	 Villanueva C, Piqueras M, Aracil C, Gómez C, López-­Balaguer JM, Gonzalez B, et  al. A randomized controlled trial comparing ligation and sclerotherapy as emergency endoscopic treatment added to somatostatin in acute variceal bleeding. J Hepatol. 2006;45(4):560–7.	 73.	 Chen WC, Lo GH, Tsai WL, Hsu PI, Lin CK, Lai KH. Emergency endoscopic variceal ligation versus somatostatin for acute esoph- ageal variceal bleeding. J Chin Med Assoc.2006;69(2):60–7.	 74.	 Lo GH, Chen WC, Wang HM, Lin CK, Chan HH, Tsai WL, et al. Low-­ dose terlipressin plus banding ligation versus low-­dose terlipressin alone in the prevention of very early rebleeding of oesophageal varices. Gut.2009;58(9):1275–80.	 75.	 Sung JJ, Lai CW, Lee YT, Leung VK, Li MK, Chung SC, et  al.",2271,326,567.75,"[ 0.16145599 -0.6039656  -1.33764    ...  0.37232018  0.21347326
 -1.2032474 ]"
144,"Prospective randomised study of effect of octreotide on rebleed- ing from oesophageal varices after endoscopic ligation. Lancet. 1995;346(8991–8992):1666–9.	 76.	 Kumar A, Jha SK, Mittal VV, Sharma P, Sharma BC, Sarin SK. Addition of somatostatin after successful endoscopic variceal liga- tion does not prevent early rebleeding in comparison to placebo: a double blind randomized controlled trial. J Clin Exp Hepatol. 2015;5(3):204–12.	 77.	 Lo GH, Perng DS, Chang CY, Tai CM, Wang HM, Lin HC. Controlled trial of ligation plus vasoconstrictor versus proton pump inhibitor in the control of acute esophageal variceal bleeding. J Gastroenterol Hepatol.2013;28(4):684–9.	 78.	 Lee GH, Cho SW, Kim HJ, Ko KH, Ko JH, Ko YY, et al. Endoscopic variceal ligation plus octreotide versus variceal ligation alone for the prevention of early rebleeding from esophageal varices. Korean J Hepatol.1999;5(4):299–305.	 79.	 Lee EW, Eghtesad B, Garcia-­Tsao G, Haskal ZJ, Hernandez-­ Gea V, Jalaeian H, et al. AASLD practice guidance on the use of TIPS, variceal embolization, and retrograde transvenous obliter- ation in the management of variceal hemorrhage. Hepatology. 2023;79:224–50.	 80.	 Ríos Castellanos E, Seron P, Gisbert JP, Cosp XB. Endoscopic injec- tion of cyanoacrylate glue versus other endoscopic procedures for acute bleeding gastric varices in people with portal hypertension. Cochrane Database Syst Rev. 2015;2015:CD010180. 13652036, 2024, 9, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/apt.17949 by Yonsei University, Wiley Online Library on [29/05/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License",1771,240,442.75,"[-0.00830595 -0.7787616  -1.5547755  ...  0.1025095   0.33834285
 -1.4935545 ]"
145,"1080  |     SHUNG and LAINE 	 81.	 Tantau M, Crisan D, Popa D, Vesa S, Tantau A. Band ligation vs. N-­Butyl-­2-­cyanoacrylate injection in acute gastric vari- ceal bleeding: a prospective follow-­up study. Ann Hepatol. 2014;13(1):75–83.	 82.	 Tan PC, Hou MC, Lin HC, Liu TT, Lee FY, Chang FY, et al. A ran- domized trial of endoscopic treatment of acute gastric variceal hemorrhage: N-­butyl-­2-­cyanoacrylate injection versus band liga- tion. Hepatology.2006;43(4):690–7.	 83.	 Lo G-­H, Lai K-­H, Cheng J-­S, Chen M-­H, Chiang H-­T. A prospective, randomized trial of butyl cyanoacrylate injection versus band liga- tion in the management of bleeding gastric varices. Hepatology. 2001;33(5):1060–4.	 84.	 Lo GH, Liang HL, Chen WC, Chen MH, Lai KH, Hsu PI, et al. A pro- spective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the preven- tion of gastric variceal rebleeding. Endoscopy.2007;39(8):679–85.	 85.	 Luo X, Xiang T, Wu J, Wang X, Zhu Y, Xi X, et al. Endoscopic cy- anoacrylate injection versus balloon-­occluded retrograde trans- venous obliteration for prevention of gastric variceal bleeding: a randomized controlled trial. Hepatology.2021;74(4):2074–84.	 86.	 Paleti S, Nutalapati V, Fathallah J, Jeepalyam S, Rustagi T. Balloon-­ occluded retrograde transvenous obliteration (BRTO) versus tran- sjugular intrahepatic portosystemic shunt (TIPS) for treatment of gastric varices because of portal hypertension: a systematic re- view and meta-­analysis. J Clin Gastroenterol.2020;54(7):655–60.	 87.	 El Amin H, Abdel Baky L, Sayed Z, Eid K, Fouad Y, El Khayat H. A randomized trial of endoscopic variceal ligation versus cyanoac- rylate injection for treatment of bleeding junctional varices. Trop Gastroenterol.2010;31(4):279–84.	 88.	 Robles-­Medranda C, Oleas R, Valero M, Puga-­Tejada M, Baquerizo-­ Burgos J, Ospina J, et  al. Endoscopic ultrasonography-­guided deployment of embolization coils and cyanoacrylate injection in gastric varices versus coiling alone: a randomized trial. Endoscopy. 2020;52(4):268–75.	 89.	 Lôbo MR, Chaves DM, De Moura DT, Ribeiro IB, Ikari E, De Moura EG. Safety and efficacy of EUS-­guided coil plus cyanoacrylate versus conventional cyanoacrylate technique in the treatment of gastric varices: a randomized controlled trial. Arq Gastroenterol. 2019;56(1):99–105.	 90.	 McCarty TR, Bazarbashi AN, Hathorn KE, Thompson CC, Ryou M. Combination therapy versus monotherapy for EUS-­guided man- agement of gastric varices: a systematic review and meta-­analysis.",2571,353,642.75,"[-0.08332779 -0.55668765 -1.5535208  ... -0.11766069  0.4364975
 -1.4321312 ]"
145,"Endosc Ultrasound.2020;9(1):6–15.	 91.	 Mohan BP, Chandan S, Khan SR, Kassab LL, Trakroo S, Ponnada S, et  al. Efficacy and safety of endoscopic ultrasound-­guided therapy versus direct endoscopic glue injection therapy for gas- tric varices: systematic review and meta-­analysis. Endoscopy. 2020;52(4):259–67.	 92.	 Lo G-­H, Lin C-­W, Tai C-­M, Perng DS, Chen IL, Yeh JH, et  al. A prospective, randomized trial of thrombin versus cyanoacrylate injection in the control of acute gastric variceal hemorrhage. Endoscopy.2020;52(7):548–55.	 93.	 McCarty TR, Rustagi T. Comparative effectiveness and safety of radiofrequency ablation versus argon plasma coagulation for treatment of gastric antral vascular ectasia: a systematic review and meta-­analysis. J Clin Gastroenterol.2019;53(8):599–606.	 94.	 Hirsch BS, Ribeiro IB, Funari MP, de Moura DTH, Matuguma SE, Sánchez-­Luna SA, et  al. Endoscopic band ligation versus argon plasma coagulation in the treatment of gastric antral vascular ec- tasia: a systematic review and meta-­analysis of randomized con- trolled trials. Clin Endosc.2021;54(5):669–77.	 95.	 Gralnek IM, Dumonceau JM, Kuipers EJ, Lanas A, Sanders DS, Kurien M, et al. Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) guideline. Endoscopy.2015;47(10):a1–a46.	 96.	 Hwang JH, Fisher DA, Ben-­Menachem T, Chandrasekhara V, Chathadi K, Decker GA, et al. The role of endoscopy in the man- agement of acute non-­variceal upper GI bleeding. Gastrointest Endosc.2012;75(6):1132–8.	 97.	 Laine L. Multipolar electrocoagulation in the treatment of active upper gastrointestinal tract hemorrhage. A prospective controlled trial. N Engl J Med.1987;316(26):1613–7.	 98.	 Llach J, Elizalde JI, Guevara MC, Pellisé M, Castellot A, Ginès A, et  al. Endoscopic injection therapy in bleeding Mallory-­Weiss syndrome: a randomized controlled trial. Gastrointest Endosc. 2001;54(6):679–81.	 99.	 Chung IK, Kim EJ, Hwang KY, Kim IH, Kim HS, Park SH, et  al.",2034,274,508.5,"[ 0.219065   -0.75308025 -1.5485716  ...  0.24992728  0.2726634
 -1.3149122 ]"
145,"Evaluation of endoscopic hemostasis in upper gastrointesti- nal bleeding related to Mallory-­Weiss syndrome. Endoscopy. 2002;34(6):474–9.	100.	 Huang SP, Wang HP, Lee YC, Lin CC, Yang CS, Wu MS, et  al. Endoscopic hemoclip placement and epinephrine injection for Mallory-­Weiss syndrome with active bleeding. Gastrointest Endosc.2002;55(7):842–6.	101.	 Park CH, Min SW, Sohn YH, Lee WS, Joo YE, Kim HS, et  al. A prospective, randomized trial of endoscopic band ligation vs. epi- nephrine injection for actively bleeding Mallory-­Weiss syndrome. Gastrointest Endosc.2004;60(1):22–7.	102.	 Laine L, Cohen H, Brodhead J, Cantor D, Garcia F, Mosquera M. Prospective evaluation of immediate versus delayed refeeding and prognostic value of endoscopy in patients with upper gastrointes- tinal hemorrhage. Gastroenterology.1992;102(1):314–6.	103.	 Park CH, Sohn YH, Lee WS, Joo YE, Choi SK, Rew JS, et al. The use- fulness of endoscopic hemoclipping for bleeding Dieulafoy lesions. Endoscopy.2003;35(5):388–92.	104.	 Alis H, Oner OZ, Kalayci MU, Dolay K, Kapan S, Soylu A, et al. Is en- doscopic band ligation superior to injection therapy for Dieulafoy lesion?Surg Endosc.2009;23(7):1465–9.	105.	 Chung IK, Kim EJ, Lee MS, Kim HS, Park SH, Lee MH, et al. Bleeding Dieulafoy's lesions and the choice of endoscopic method: compar- ing the hemostatic efficacy of mechanical and injection methods. Gastrointest Endosc.2000;52(6):721–4.	106.	 Park CH, Joo YE, Kim HS, Choi SK, Rew JS, Kim SJ. A prospective, randomized trial of endoscopic band ligation versus endoscopic hemoclip placement for bleeding gastric Dieulafoy's lesions. Endoscopy.2004;36(8):677–81.	107.	 Liu D, Lu F, Ou D, Zhou Y, Huo J, Zhou Z. Endoscopic band liga- tion versus endoscopic hemoclip placement for bleeding due to Dieulafoy lesions in the upper gastrointestinal tract. Zhong Nan Da Xue Xue Bao Yi Xue Ban.2009;34(9):905–9.	108.	 Kim YI, Choi IJ, Cho SJ, Lee JY, Kim CG, Kim MJ, et al.",1953,275,488.25,"[-0.2745108  -0.17858589 -1.2304051  ...  0.43408835  0.5653648
 -1.4343936 ]"
145,"Outcome of endoscopic therapy for cancer bleeding in patients with unresect- able gastric cancer. J Gastroenterol Hepatol.2013;28(9):1489–95.	109.	 Sheibani S, Kim JJ, Chen B, Park S, Saberi B, Keyashian K, et al. Natural history of acute upper GI bleeding due to tumours: short-­ term success and long-­term recurrence with or without endo- scopic therapy. Aliment Pharmacol Ther.2013;38(2):144–50.	110.	 Martins BC, Abnader Machado A, Scomparin RC, Paulo GA, Safatle-­Ribeiro A, Naschold Geiger S, et  al. TC-­325 hemostatic powder in the management of upper gastrointestinal malig- nant bleeding: a randomized controlled trial. Endosc Int Open. 2022;10(10):E1350–E1357.	111.	 Cheng HC, Wu CT, Chang WL, Cheng WC, Chen WY, Sheu BS. Double oral esomeprazole after a 3-­day intravenous esomeprazole infusion reduces recurrent peptic ulcer bleeding in high-­risk pa- tients: a randomised controlled study. Gut.2014;63(12):1864–72.	112.	 Lau JY, Sung JJ, Lam YH, Chan AC, Ng EK, Lee DW, et al. Endoscopic retreatment compared with surgery in patients with recurrent bleeding after initial endoscopic control of bleeding ulcers. N Engl J Med.1999;340(10):751–6. 13652036, 2024, 9, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/apt.17949 by Yonsei University, Wiley Online Library on [29/05/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License",1501,198,375.25,"[-0.0365213  -0.43648127 -1.6335806  ...  0.69081825 -0.30681247
 -1.4998878 ]"
146,"|  1081 SHUNG and LAINE 	113.	 Tarasconi A, Baiocchi GL, Pattonieri V, Perrone G, Abongwa HK, Molfino S, et  al. Transcatheter arterial embolization versus sur- gery for refractory non-­variceal upper gastrointestinal bleeding: a meta-­analysis. World J Emerg Surg.2019;14:3.	114.	 Sverden E, Mattsson F, Lindstrom D, Sonden A, Lu Y, Lagergren J. Transcatheter arterial embolization compared with surgery for un- controlled peptic ulcer bleeding: a population-­based cohort study. Ann Surg.2019;269(2):304–9.	115.	 García-­Pagán JC, Caca K, Bureau C, Laleman W, Appenrodt B, Luca A, et al. Early use of TIPS in patients with cirrhosis and Variceal bleeding. N Engl J Med.2010;362(25):2370–9.	116.	 Lv Y, Yang Z, Liu L, Li K, He C, Wang Z, et al. Early TIPS with cov- ered stents versus standard treatment for acute variceal bleeding in patients with advanced cirrhosis: a randomised controlled trial. Lancet Gastroenterol Hepatol.2019;4(8):587–98.	117.	 Dunne PDJ, Sinha R, Stanley AJ, Lachlan N, Ireland H, Shams A, et al. Randomised clinical trial: standard of care versus early-­ transjugular intrahepatic porto-­systemic shunt (TIPSS) in pa- tients with cirrhosis and oesophageal variceal bleeding. Aliment Pharmacol Ther.2020;52(1):98–106.	118.	 Nicoară-­Farcău O, Han G, Rudler M, Angrisani D, Monescillo A, Torres F, et al. Effects of Early placement of transjugular porto- systemic shunts in patients with high-­risk acute variceal bleed- ing: a meta-­analysis of individual patient data. Gastroenterology. 2021;160(1):193–205.e110.	119.	 Weichselbaum L, Lepida A, Marot A, Trépo E, Moreno C, Deltenre P. Salvage transjugular intrahepatic portosystemic shunt in pa- tients with cirrhosis and refractory variceal bleeding: a system- atic review with meta-­analysis. United European Gastroenterol J. 2022;10(8):874–87.	120.	 Zhang H, Zhang H, Li H, Zhang H, Zheng D, Sun CM, et al. TIPS versus endoscopic therapy for variceal rebleeding in cirrhosis: a meta-­analysis update. J Huazhong Univ Sci Technolog Med Sci. 2017;37(4):475–85. SUPPORTING INFORMATION Additional supporting information will be found online in the Supporting Information section. How to cite this article: Shung DL, Laine L. Review article: Upper gastrointestinal bleeding – review of current evidence and implications for management. Aliment Pharmacol Ther. 2024;59:1062–1081.https://doi.org/10.1111/apt.17949 APPENDIX A PubMed Search: ((gastrointestinal haemorrhage[MeSH Terms]) OR (hematemesis[MeSH Terms]) OR (melena[MeSH Terms]) OR (haemorrhage, peptic ulcer[MeSH Terms]) OR (“Gastrointestinal Hemorrhage/drug therapy”[MAJR]) OR (“Gastrointestinal Haemorrhage/mortality”[MeSH])) Medline Search: 1 exp gastrointestinal haemorrhage/.mp.2 (gastrointestinal haemorrhage* or gastrointestinal haemorrhage*).mp.",2786,357,696.5,"[ 0.26573873 -0.94691235 -1.247947   ...  0.15844166  0.49305105
 -1.3415219 ]"
146,"3 gastrointestinal bleeding.mp.4 (gi bleeding or gib).mp.5 haematochezia*.mp.6 (gastrointestinal adj3 bleeding).mp.7 melena.mp.or exp Melena/ 8 hematemesis.mp.or exp Hematemesis/ 9 (peptic ulcer adj2 (haemorrhage* or haemorrhage*)).mp.10 ""Esophageal and Gastric Varices""/ 11 variceal bleeding.mp.12 gastric bleeding.mp.13 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 13652036, 2024, 9, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/apt.17949 by Yonsei University, Wiley Online Library on [29/05/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License",724,95,181.0,[ 0.530422  -1.037378  -1.3919504 ...  0.0981974  0.7275875 -1.2266214]
147,"REVIEW Evidence-based clinical practice guidelines for peptic ulcer disease 2020 Tomoari Kamada1,2 • Kiichi Satoh2 • Toshiyuki Itoh2 • Masanori Ito2 • Junichi Iwamoto2 • Tadayoshi Okimoto2 • Takeshi Kanno2 • Mitsushige Sugimoto2 • Toshimi Chiba2 • Sachiyo Nomura2 • Mitsuyo Mieda2 • Hideyuki Hiraishi2 • Junji Yoshino2 • Atsushi Takagi2 • Sumio Watanabe2 • Kazuhiko Koike2 Received: 7 October 2020 / Accepted: 3 February 2021 / Published online: 23 February 2021  The Author(s) 2021 Abstract The Japanese Society of Gastroenterology (JSGE) revised the third edition of evidence-based clinical practice guidelines for peptic ulcer disease in 2020 and created an English version. The revised guidelines consist of nine items: epidemiology, hemorrhagic gastric and duodenal ulcers, Helicobacter pylori (H. pylori) eradica- tion therapy, non-eradication therapy, drug-induced ulcers, non-H. pylori, and nonsteroidal anti-inﬂammatory drug (NSAID) ulcers, remnant gastric ulcers, surgical treatment, and conservative therapy for perforation and stenosis. Therapeutic algorithms for the treatment of peptic ulcers differ based on ulcer complications. In patients with NSAID-induced ulcers, NSAIDs are discontinued and anti- ulcer therapy is administered. If NSAIDs cannot be dis- continued, the ulcer is treated with proton pump inhibitors (PPIs). Vonoprazan (VPZ) with antibiotics is recom- mended as the ﬁrst-line treatment for H. pylori eradication, and PPIs or VPZ with antibiotics is recommended as a second-line therapy. Patients who do not use NSAIDs and are H. pylori negative are considered to have idiopathic peptic ulcers. Algorithms for the prevention of NSAID- and low-dose aspirin (LDA)-related ulcers are presented in this guideline. These algorithms differ based on the con- comitant use of LDA or NSAIDs and ulcer history or hemorrhagic ulcer history. In patients with a history of ulcers receiving NSAID therapy, PPIs with or without celecoxib are recommended and the administration of VPZ is suggested for the prevention of ulcer recurrence. In patients with a history of ulcers receiving LDA therapy, PPIs or VPZ are recommended and the administration of a histamine 2-receptor antagonist is suggested for the pre- vention of ulcer recurrence. Keywords Peptic ulcer  Helicobacter pylori eradication  Nonsteroidal anti-inﬂammatory drug  Low-dose aspirin  Idiopathic ulcer Introduction In 2009, the Japanese Society of Gastroenterology (JSGE) developed evidence-based clinical practice guidelines for peptic ulcer disease. The guidelines were revised in 2015 and again in 2020. Of the 90 clinical questions (CQs) included in the previous guidelines, those with a clear conclusion were considered background questions (BQs) and those requiring future research were considered future research questions (FRQs) in this revised guideline. Thus, the revised guidelines consist of nine items (28 CQs and one FRQ), including, for the ﬁrst time, epidemiology and remnant gastric ulcer. Both epidemiology and conservative therapy for perforation and stenosis included only BQ. The prevention of hemorrhagic peptic ulcers in patients taking The members of the Guidelines Committee are listed in the Appendix. The original version of this article appeared in Japanese as ‘‘Shokasei Kaiyo Sinryo Guideline 2020’’ from the Japanese Society of Gastroenterology (JSGE), published by Nankodo, Tokyo, in 2020. Please see the article on the standards, methods, and process of developing the guidelines. &Tomoari Kamada tkamada@med.kawasaki-m.ac.jp 1 Department of Health Care Medicine, Kawasaki Medical School General Medical Center, 2-6-1, Nakasange, Kita-ku, Okayama 700-8505, Japan 2 Guidelines Committee for Creating and Evaluating the ‘‘Evidence-Based Clinical Practice Guidelines for Peptic Ulcer,’’ the Japanese Society of Gastroenterology (JSGE), 6F Shimbashi i-MARK Bldg.,2-6-2 Shimbashi, Minato-ku, Tokyo 105-0004, Japan 123 J Gastroenterol (2021) 56:303–322 https://doi.org/10.1007/s00535-021-01769-0",4009,567,1002.25,"[-0.10182972 -0.12854761 -1.3458245  ...  0.3761336  -0.2951421
 -1.6398927 ]"
148,"antithrombotic drugs and the treatment of ischemic duo- denal ulcers have been added as a CQ and FRQ, respectively. A literature search of Medline and the Cochrane Library was performed for data regarding the CQs published between 1983 and October 2018, and the Igaku Chuo Zasshi databases were searched for data published between 1983 and December 2018. The guidelines were developed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system [1]. The quality of evidence was graded as A (high), B (moderate), C (low), and D (very low). Recommendation strength was indicated as either a ‘‘strong recommendation’’ or a ‘‘weak recommendation’’ The systematic review (SR) team con- ducted meta-analysis (MA) and decided the total strength of the evidence from A to D. The consensus was previously deﬁned as 70% or more votes in agreement. In Japan, incidence of cerebral infarction and myocar- dial infarction are increasing, and many patients undergo antithrombotic therapy including dual antiplatelet therapy (DAPT). In endoscopic clinical practice, focus has shifted from the risk of gastrointestinal (GI) bleeding to throm- boembolism associated with the withdrawal of antithrom- botic therapy [2, 3]. In addition, for nearly 50 years, the only oral anticoagulants were vitamin K antagonists (warfarin); however, four non-vitamin K antagonist direct oral anticoagulants (DOACs) are currently available. The hemorrhagic gastric and duodenal ulcer section of the revised guidelines emphasizes methods for the discontin- uation of antithrombotic therapy including DOACs and for the prevention of hemorrhagic ulcers in patients taking anticoagulant and antiplatelet drugs, such as DAPT. Vonoprazan (VPZ) provides potent and long-lasting inhibition of gastric acid secretion, and its efﬁcacy is, therefore, expected to be superior to that of proton pump inhibitors (PPIs). Recent reports have shown that triple therapy including VPZ is as effective as ﬁrst-line and second-line therapies for the eradication of Helicobacter pylori [4]. Several reports have indicated that VPZ effec- tively heals peptic ulcers [5] and prevents the recurrence of nonsteroidal anti-inﬂammatory drugs (NSAIDs) [6] and low-dose aspirin (LDA)-related ulcers [7]. This revised version also emphasizes the clinical results of VPZ. Hemorrhagic gastric and duodenal ulcers Non-endoscopic hemostatic therapy CQ-1 Treatment of with patients with hemorrhagic peptic ulcers if they prescribed anticoagulants and/or antiplatelet agents? •Recommended that aspirin be continued for conditions at high risk for thromboembolic events. Recommendation: strong, 100% agreed, evidence level B. • Suggested to change antiplatelet agents to aspirin in patients with conditions with a high risk of throm- boembolic events. Recommendation: weak, 100% agreed, evidence level D. • Suggested to suspend antiplatelet agents, except for in patients at high risk for thromboembolic events. Recommendation: weak, 100% agreed, evidence level D. • Recommended to suspend warfarin, if necessary, in endoscopic hemostasis patients. If warfarin is discon- tinued, we suggest heparin or resuming warfarin as soon as hemostasis is established. Recommendation: strong, 100% agreed, evidence level C. • Suggested to resume DOACs early (within 1–2 days) after conﬁrming endoscopic hemostasis. Recommendation: weak, 100% agreed, evidence level D. • In patients receiving both antiplatelet agents and warfarin, suggested to change antiplatelet agents to aspirin or cilostazol. Continue warfarin under a suit- able prothrombin time-international normalized ratio (PT-INR) or to change warfarin to heparin. Recommendation: weak, 100% agreed, evidence level D. • In patients receiving dual antiplatelet agents, recom- mended that aspirin alone should be continued. Recommendation: strong, 100% agreed, evidence level D. Comment: The risk of re-bleeding due to continuing anticoagulant and/or antiplatelet agents and the risk of thromboembolism associated with their withdrawal should be considered. One randomized controlled trial (RCT) [8] reported signiﬁcantly lower mortality in the continuing LDA group compared with the group that did not. However, clinical evidence is currently lacking to support the management of patients who receive antiplatelet agents excluding aspirin, warfarin, and DOACs with peptic ulcer bleeding (PUB). We consid- ered that these recommendations are based on expert opinions of the guidelines of Japan Gastroenterological Endoscopy, Asia–Paciﬁc working group and European Society of Gastroenterological Endoscopy. It is neces- sary to collaborate closely with gastroenterologists and cardiologists as patients at high risk of thromboem- bolism with PUB could be unstable.304 J Gastroenterol (2021) 56:303–322 123",4809,682,1202.25,"[ 0.14313121 -0.35568202 -1.306113   ...  0.73290265  0.16999288
 -1.7946995 ]"
149,"CQ-2 Is interventional radiology (IVR) effective in patients undergoing refractory endoscopic treatment for hemor- rhagic peptic ulcers? •In patients undergoing refractory endoscopic treatment for hemorrhagic peptic ulcers, interventional radiology (IVR) is suggested due to its safety and effectiveness. Recommendation: weak, 100% agreed, evidence level C. Comment: The effectiveness of IVR with transcatheter arterial embolization was proven by two MAs [9, 10]. They reported that compared to surgery, IVR exhibits a higher re-bleeding rate, but no signiﬁcant difference in mortality, need for additional interventions, or compli- cation rates between treatments. IVR could be a viable option for the treatment of refractory PUB; however, a limited number of institutions can perform IVR. CQ-3 Is medication with antacid agents required after endoscopic treatment for hemorrhagic peptic ulcers? •PPI administration after endoscopic treatment for hemorrhagic peptic ulcers is recommended to improve treatment outcomes. Recommendation: strong, 100% agreed, evidence level A. Comment: Compared with placebo, intravenous PPI therapy after endoscopic treatment for hemorrhagic peptic ulcers has been proven to reduce the rate of re- bleeding, volume of blood transfusion, period of admission, and rate of conversion to surgery in two MAs [11, 12] and some randomized controlled trials. The efﬁcacy of high-dose PPI therapy is not higher than non-high-dose PPI regarding decreasing re-bleeding, surgical intervention, or mortality after post-endoscopic hemostasis [13]. There was no signiﬁcant difference effect between oral and intravenous PPI therapy on mortality, re-bleeding, need for blood transfusion, length of hospital stays, or surgery [14]. Compared to intravenous histamine 2-receptor antago- nist (H2RA) therapy, PPI therapy reduces rates of ulcer re-bleeding, surgical intervention, and overall duration of hospital stay with no signiﬁcant difference in mortality [15]. Considering patient beneﬁts, we recom- mended PPI therapy after endoscopic treatment for hemorrhagic peptic ulcers. Prevention of hemorrhagic peptic ulcer CQ-4 What drugs are recommended for the prevention of hem- orrhagic ulcers in antithrombotic users? •In DAPT, we recommend the combined use of PPIs to prevent upper gastrointestinal bleeding (UGIB). Recommendation: strong, 100% agreed, evidence level A. • If taking warfarin, we suggest using PPIs to prevent UGIB in patients taking antiplatelet drugs or NSAIDs in combination. Recommendation: weak, 100% agreed, evidence level C. (PPI is not covered by Japanese insurance for primary prevention of PUB in patients taking LDA or NSAIDs). Comment: MAs of RCTs aimed to determine whether the combination of PPIs is useful for the prevention of UGIB in DAPT with clopidogrel and aspirin. In addition to the large randomized COGENT trial [16], an MA was conducted involving three studies (two RCTs) [17, 18] comparing PPI usage. PPIs signiﬁcantly prevented UGIB (risk ratio [RR] 0.26; 95% conﬁdence interval [CI] 0.13–0.53, P = 0.0002) (Fig.1). There was no signiﬁcant difference in major adverse cardio- vascular events, with or without PPI (RR 1.01; 95% CI 0.80–1.26, P = 0.96). In the 2017 focused update on DAPT in coronary artery disease of the European Society of Cardiology, PPIs in combination with DAPT were recommended (recommendation class I) [19]. Only observational studies were available regarding the UGIB preventive effect of PPI in patients taking warfarin. Ray et al. [20], in large retrospective cohort study, found that PPI administration signiﬁcantly reduced the risk of hospitalization for UGIB in patients receiving warfarin with concomitant antiplatelet drugs or NSAIDs (45% reduction (hazard ratio 0.55; 95% CI 0.39–0.77), P = 0.0004). H. pylori eradication therapy First-line eradication therapy CQ-5 What kind of regimen should we select for ﬁrst-line H. pylori eradication therapy? •As triple eradication therapy using VPZ with amoxi- cillin and clarithromycin has a high eradication rate J Gastroenterol (2021) 56:303–322 305 123",4088,592,1022.0,"[ 0.06792133 -0.4643704  -1.56123    ...  0.75047034  0.32573628
 -1.524937  ]"
150,"compared with that of PPIs, VPZ is recommended as a ﬁrst-line therapy. Recommendation: strong, 100% agreed, evidence level A. • The recommended antibiotics for ﬁrst-line therapy include amoxicillin, clarithromycin, or metronidazole. In Japan, the combination of amoxicillin and metron- idazole is recommended due to the high incidence rate of clarithromycin-resistant strains (not covered by the Japanese insurance system). Recommendation: strong, 100% agreed, evidence level A. • When PPIs are used, sequential therapy and concomi- tant quadruple therapy are suggested due to the high eradication rate in the ﬁrst-line therapy compared with triple therapy (not covered by the Japanese insurance system). Recommendation: weak, 100% agreed, evidence level A. Comment: In the Japanese insurance system, triple therapy with a PPI or VPZ, amoxicillin, and clar- ithromycin is used as ﬁrst-line therapy [21]. As the degree and duration of acid inhibition are related to the cure rate of H. pylori [22], an MA compared the efﬁcacy of VPZ-containing therapies to PPI-containing therapies (Fig.2) [23]. In areas with high clar- ithromycin-resistance rates ([ 15%), the Maastricht V/Florence Consensus Report suggested that when culture/sensitivity testing is not performed before eradication, ﬁrst-line therapy using clarithromycin should not be used; bismuth quadruple (PPI/bismuth/ tetracycline/metronidazole) or concomitant quadruple therapy (PPI/amoxicillin/clarithromycin/nitroimidazole or metronidazole) is recommended [24]. In addition, in areas with low metronidazole- and high clarithromycin- resistance rates, PPI/amoxicillin/metronidazole has a higher eradication rate than PPI/amoxicillin/clar- ithromycin (Fig.3) [25]. Second-line eradication therapy CQ-6 What regimen should we select for second-line H. pylori eradication therapy? •Triple therapy with PPI/VPZ, amoxicillin, and metron- idazole is recommended. Recommendation: strong, 100% agreed, evidence level A. Comment: Two MAs [26, 27] found that tetracycline/ quinolone-based quintuple or quadruple therapies were more effective than other therapies. One RCT revealed that levoﬂoxacin sequential therapy was more effective than levoﬂoxacin triple therapy [28]. These drugs have not been approved for H. pylori eradication therapy in Fig.1 Forest plots of proton pump inhibitors (PPIs) against control for upper gastrointestinal bleeding preventive effect in dual antiplatelet therapy (DAPT). In meta-analysis, PPIs signiﬁcantly have reduced bleeding risk compared to controls (RR 0.26; 95%CI 0.13–0.53, P = 0.0002) Fig.2 Forest plots of eradication rates of ﬁrst-line therapy between vonoprazan-containing triple therapy and proton pump inhibitor (PPI)-containing triple therapy in the randomized control trials. In meta-analysis, the eradication rates of vonoprazan-containing triple therapy are signiﬁcantly higher than that of PPI-containing triple therapy (odds ratio 0.28; 95% CI 0.19–0.41, P \ 0.00001) 306 J Gastroenterol (2021) 56:303–322 123",3013,405,753.25,"[-0.20889097 -0.06937602 -0.95679307 ...  0.63298714 -0.04534052
 -1.5486025 ]"
151,"Japan. In addition, the rate of H. pylori infection with primary resistance to levoﬂoxacin is high in Japan. The eradication rate of triple therapy with PPI/VPZ, amox- icillin, and metronidazole is still high [4], and does not differ between the two regimens [29–31]. Third-line eradication therapy CQ-7 What regimen should we select for third-line H. pylori eradication therapy? •Triple therapy with PPI, sitaﬂoxacin, and metronida- zole or PPI, sitaﬂoxacin, and amoxicillin is suggested (not covered by the Japanese insurance system). Recommendation: weak, 100% agreed, evidence level B. Comment: Three Japanese RCTs of third-line therapies showed that the eradication rates were 70.0–90.9% [32–34]. The eradication rate of triple therapy with PPI, sitaﬂoxacin, and metronidazole was 70.0–88.9% [32–34], and that of PPI, sitaﬂoxacin, and amoxicillin was 72.4–90.9% [33, 34]. Because these eradication rates were not high enough, these regimens are not recommended, but suggested. Ulcer recurrence after H. pylori eradication CQ-8 Is maintenance treatment necessary for the recurrence of peptic ulcer after successful H. pylori eradication? •When the cause of peptic ulcer recurrence is unclear, long-term maintenance treatment with PPIs or H2RAs is suggested. Recommendation: weak, 100% agreed, evidence level D. Comment: There are currently no published RCTs or MAs. Causes of the recurrence of peptic ulcers after successful H. pylori eradication include using LDA and NSAIDs, reinfection with H. pylori, and smoking habits. To prevent peptic ulcer recurrence, the exclu- sion of these factors is necessary. Idiopathic peptic ulcers are thought to be one of unknown causes of peptic ulcers after successful H. pylori eradication; therefore, long-term maintenance treatment with PPIs or H2RAs is suggested, when the cause of peptic ulcer recurrence is unclear. Non-eradication therapy Initial therapy. Gastric ulcer CQ-9 What is the ﬁrst-line drug for the initial non-eradication treatment of gastric ulcers? •Either PPIs or P-CAB is recommended. Recommendation: strong, 100% agreed, evidence level A. • If PPIs and P-CAB cannot be prescribed, H2RAs are recommended. Recommendation: strong, 100% agreed, evidence level B. • If PPIs and P-CAB cannot be prescribed, pirenzepine, sucralfate, and misoprostol are suggested. Recommendation: weak, 100% agreed, evidence level B. • If the above drugs cannot be prescribed, gastric mucosa-protecting agents (excluding sucralfate and misoprostol) are suggested. Recommendation: weak, 100% agreed, evidence level B. Comment: We recommend either PPIs or P-CAB due to their demonstrated ulcer healing rate of PPIs being signiﬁcantly higher than that of H2RAs [35–38]. Fig.3 Forest plots of eradication rates of second-line therapy between proton pump inhibitor/amoxicillin/metronidazole (PAM) therapy and proton pump inhibitor/amoxicillin/clarithromycin (PAC) therapy in the randomized control trials in Japan. In meta- analysis, the eradication rates of PAM therapy are signiﬁcantly higher than that of PAC therapy (odds ratio 0.14; 95% CI 0.08–0.24) J Gastroenterol (2021) 56:303–322 307 123",3134,450,783.5,"[-0.09841428  0.06960142 -1.2802339  ...  0.7624961   0.33298194
 -1.3012453 ]"
152,"P-CAB gained popularity in recent years due to their high ulcer healing rate for gastric ulcers compared with lansoprazole [39]. When PPIs and P-CAB cannot be prescribed, H2RAs are recommended. There were no reported signiﬁcant differences in ulcer healing rates between H2RAs. Moreover, pirenzepine, sucralfate, and misoprostol are suggested as their ulcer healing rates are equivalent to those of H2RAs. Duodenal ulcer CQ-10 What is the ﬁrst-line drug for the initial non-eradication treatment of duodenal ulcer? •Either PPIs or P-CAB is recommended. Recommendation: strong, 100% agreed, evidence level A. • If PPIs and P-CAB cannot be prescribed, H2RAs are recommended. Recommendation: strong, 100% agreed, evidence level B. • If PPIs and P-CAB cannot be prescribed, pirenzepine, sucralfate, and misoprostol are suggested. Recommendation: weak, 100% agreed, evidence level B. Comment: We recommend either PPIs or P-CAB as the ulcer healing rate of PPIs is signiﬁcantly higher than that of H2RAs [40]. P-CAB gained popularity in recent years due to their high ulcer healing rate for duodenal ulcers compared with lansoprazole [39]. When PPIs cannot be prescribed, H2RAs are recommended. Drug-induced ulcer Nonselective NSAID-induced ulcer. Treatment CQ-11 How should NSAID-induced ulcers be treated? •NSAIDs should be discontinued, and administration of anti-ulcer drugs is recommended. Recommendation: strong, 100% agreed, evidence level A. • If NSAIDs cannot be discontinued, administration of PPIs is recommended as a ﬁrst-line therapy. Recommendation: strong, 100% agreed, evidence level A. Comment: Gastric and duodenal ulcers in NSAID users heal to a high rate when NSAIDs are withdrawn [41]. In comparative studies of PPIs vs. H2RA [42] and PPIs vs. PG analogs [43], the healing rate of gastric and duodenal ulcers was highest in PPI groups. The original MA in this guideline indicated that the healing rate of peptic ulcers over 8 weeks was higher in PPI groups than in H2RA groups; thus PPIs are recommended as the ﬁrst-line therapy (Fig.4). Prevention CQ-12 If a patient receiving NSAIDs tests positive for H. pylori infection, should H. pylori eradication therapy be administered? •Eradication of H. pylori is recommended for prevention of ulcers in NSAID-naı¨ve patients. Recommendation: strong, 100% agreed, evidence level A. Comment: In comparative studies of PPIs and H. pylori eradication, PPIs are superior to the eradication of H. pylori in preventing recurrent bleeding in patients taking NSAIDs [44]. Studies have [45, 46] indicated that H. pylori eradica- tion therapy reduces the incidence of ulcers in patients receiving NSAIDs; however, an effect of H. pylori eradication therapy on preventing peptic ulcer cannot be expected during NSAID therapy. In an MA reported in 2012, the efﬁcacy of H. pylori eradication therapy for preventing peptic ulcer was observed, especially in naı¨ve users and in Asian populations [46]. CQ-13 Is preventive therapy for NSAID-induced ulcers necessary in patients with no history of ulcers? •Prevention of NSAID-induced ulcers by administration of PPIs is necessary and suggested even in patients with no history of ulcers. Recommendation: weak, 100% agreed, evidence level A. (PPIs are not covered by Japanese insurance for primary prevention of ulcers in patients taking NSAIDs). Comment: In patients receiving NSAID therapy for more than three months, the efﬁcacy of PG analogs [47], PPIs [48], or high-dose H2RAs [49] given as primary preventions has been reported. Scally B et al. [50] showed that PPIs had larger protective effects than 308 J Gastroenterol (2021) 56:303–322 123",3641,552,910.25,"[-0.5312749  -0.23912272 -1.3562169  ...  0.77986884 -0.02919947
 -1.5392812 ]"
153,"H2RAs or PG analogs for peptic ulcers and further bleeding; therefore, PPIs are suggested as a ﬁrst-line therapy. CQ-14 How should recurrence be prevented in patients with a history of ulcers or bleeding ulcers who are starting NSAID therapy? •PPIs are recommended, and VPZ is suggested to prevent NSAID-induced ulcers in patients with a history of ulcers. Recommendation: weak, 100% agreed, evidence level B. • Concomitant administration of the selective cyclooxy- genase (COX)-2 inhibitor with a PPI is recommended for preventing recurrence of bleeding NSAID-induced ulcers in patients with a history of bleeding ulcers. Recommendation: strong, 100% agreed, evidence level B. Comment: Although the efﬁcacy of PG analogs [51] for secondary prevention was observed in high-risk patients with a history of peptic ulcers, patient drop- out due to diarrhea is common. Studies found that PPIs were superior to placebos in reducing the risk of gastric or duodenal ulcer recurrence in patients with a history of ulcers requiring long-term NSAID therapy [52, 53]. The original MA in this guideline indicated that the recurrence rate of peptic ulcers in patients with a history of ulcers requiring long-term NSAID therapy was lower in PPI groups than in placebo groups. Therefore, PPIs are recommended as the ﬁrst-line therapy (Fig.5). Chan et al. [54] suggested that combination treatment with a selective COX-2 inhibitor and a PPI was more effective than a selective COX-2 inhibitor alone for prevention of ulcer bleeding in patients at high risk. Mizokami et al. [6] reported that VPZ was not inferior to PPIs, indicating that VPZ can be recommended for the second prevention of NSAID-induced peptic ulcer as well as PPIs. CQ-15 How should NSAID-induced ulcers be prevented in patients receiving high-dose NSAIDs or a combination of NSAIDs and antithrombotic drugs or glucocorticoids or bisphosphonates, who are elderly, or have severe complications? •In patients receiving combinations of NSAIDs and glucocorticoids or antithrombotic drugs, administration of a COX-2 inhibitor is recommended for ulcer prevention. Recommendation: strong, 100% agreed, evidence level B. • In elderly or patients with severe complications, administration of PPIs is recommended for the preven- tion of NSAID-induced ulcers. Recommendation: strong, 100% agreed, evidence level A. Comment: Concomitant use of nonselective NSAIDs or LDA, but not selective COX-2 inhibitors, with corti- costeroids, or anticoagulants, increases the risk of UGIB, indicating that selective COX-2 inhibitors do not increase the risk of UGIB [55]. The efﬁcacy of PPIs for prevention of complications has been demonstrated in a previous study [56]. Selective NSAID (COX-2 selective inhibitor)-induced ulcers. CQ-16 Is a COX-2 selective inhibitor useful for the prevention of NSAID-induced ulcers? •COX-2 selective inhibitors are recommended for the prevention of NSAID-induced ulcers. Recommendation: strong, 100% agreed, evidence level Fig.4 Meta-analysis of comparison of ulcer curative effect between PPI and H2RA under the NSAIDs continuation. In meta-analysis, the healing rate of peptic ulcers for 8 weeks is higher in the PPI groups than in the H2RA groups J Gastroenterol (2021) 56:303–322 309 123",3257,488,814.25,"[-0.43370646 -0.12485081 -1.229377   ...  0.32278943  0.5807359
 -1.4976405 ]"
154,"A. Comment: The incidence rate of peptic ulcers in Western countries is signiﬁcantly lower in patients taking COX-2 selective inhibitors than in patients taking nonselective NSAIDs [57–59]. We conducted an MA and found that the incidence of gastric ulcers (RR 0.21; 95% CI 0.18–0.25, P \ 0.00001) (Fig.6a) and duodenal ulcers (RR 0.38; 95% CI 0.29–0.51, P \ 0.00001) (Fig.6b) was lower in patients using COX-2 selective inhibitors than in patients using Fig.5 Meta-analysis of preventive effect in the secondary prevention of NSAIDs ulcer. In meta-analysis, the recurrence rate of peptic ulcers in patients with a history of gastric or duodenal ulcers who required long-term NSAID therapy is lower in the PPI groups than in the placebo groups Fig.6 Forest plots of peptic ulcer risk between COX-2 selective inhibitor and NSAID therapy in the randomized control trials (a gastric ulcer, b duodenal ulcer). In meta-analysis, the incidence of gastric (risk ratio 0.21; 95% CI 0.18–0.25) (a) and duodenal ulcers (risk ratio 0.38; 95% CI 0.29–0.51) (b) are lower in patients using COX-2 selective inhibitors than in patients using NSAIDs 310 J Gastroenterol (2021) 56:303–322 123",1174,185,293.5,"[-0.16715872 -0.25988713 -1.25158    ...  0.46094325  0.74673593
 -1.4782672 ]"
155,"NSAIDs. Using COX-2 selective inhibitors had a lower risk of developing serious ulcer complications. A RCT including healthy Japanese volunteers showed that the incidence of gastroduodenal ulcers was 1.4%, 27.6%, and 2.7% in the celecoxib, loxoprofen, and placebo groups, respectively (P \ 0.0001 in favor of the celecoxib group) [60]. We conducted an MA and found that the incidence of peptic ulcers was lower in patients using COX-2 selective inhibitors than in patients using NSAIDs (RR 0.13; 95% CI 0.04–0.44, P = 0.0010), similar to ﬁndings from patients in Western countries. These results indicate that COX-2 selective inhibitors are useful for the prevention of NSAID-induced ulcers and serious ulcer complications. CQ-17 Is preventive medication with anti-ulcer agents required for patients taking a COX-2 selective inhibitor? •Prevention with anti-ulcer agents is recommended for patients taking COX-2 selective inhibitors with a history of peptic ulcers or hemorrhage. Recommendation: strong, 100% agreed, evidence level B. • No prevention with anti-ulcer agents is recommended for patients taking COX-2 selective inhibitors without a past history of peptic ulcer. Recommendation: strong, 100% agreed, evidence level B. Comment: An MA revealed that the incidence of drug- induced peptic ulcer development was similar between patients who received COX-2 selective inhibitors and placebos, suggesting that COX-2 selective inhibitors do not increase the risk of drug-induced peptic ulcers [60–62]. In a network MA, concomitant dosing of COX-2 selective inhibitors with PPIs effectively pre- vented the development of drug-induced peptic ulcer compared with COX-2 selective inhibitors alone [63]. However, patients with a history of peptic ulcers have a higher risk of developing drug-induced peptic ulcers. LDA-induced ulcer Treatment CQ-18 How should LDA-related peptic ulcers be treated? •Concomitant use of PPIs with continuous LDA therapy is recommended for LDA-related peptic ulcers. Recommendation: strong, 100% agreed, evidence level A. Comment: For patients with a history of LDA-related PUB, concomitant use of PPIs with continuous LDA therapy after endoscopic hemostasis was equivalent in the recurrence of PUB compared to concomitant use of placebos and PPIs. Furthermore, continuous LDA therapy reduces overall mortality rates related to cardiovascular (CV) events [8]. In the same study, concomitant use of PPIs with continuation of LDA therapy did not increase the incidence of PUB recur- rence [8]. The peptic ulcer healing rate was similar between the PPI alone and the LDA combined with PPI [64]. Prevention. CQ-19 What kind of concomitant use of medicine should be effective for reducing the incidence and prevalence of LDA-related peptic ulcers? •PPIs or H2RAs is recommended for the reduction of the incidence and prevalence of LDA-related peptic ulcers. Recommendation: strong, 100% agreed, evidence level A. (PPIs and H2RAs are not covered by Japanese insur- ance for primary prevention of ulcers in patients taking LDA). (H2RAs are not covered by Japanese insurance for secondary prevention of ulcers in patients taking LDA). Comment: MA indicated that LDA treatment with concomitant use of H2RAs or PPIs reduced the risk of LDA-related peptic ulcers [65, 66]. PPIs were superior to H2RAs in preventing upper GI ulcers related to LDA [67]. However, a RCT by Chan et al. [68] indicated that there were no signiﬁcant differences between rabepra- zole and famotidine in the incidence of recurrent ulcers in patients taking LDA. We used data from two RCTs [69, 70] in Mo et al. [67] and one RCT [68] to independently conduct an MA. We found no signiﬁcant difference (RR 0.26; 95% CI 0.04–1.81, P = 0.17) in the incidence of LDA-related upper GI ulcers between PPIs and H2RAs (Fig.7). CQ-20 What kind of concomitant use of medicine should be effective for reducing the incidence and prevalence rate of LDA-related PUB? •PPIs or VPZ is recommended for the reduction of the incidence and prevalence of LDA-related PUB. J Gastroenterol (2021) 56:303–322 311 123",4084,624,1021.0,"[ 0.4002121  -0.21467122 -1.3864443  ...  0.31633314  0.67134774
 -1.5937055 ]"
156,"Recommendation: strong, 100% agreed, evidence level A. (PPI and VPZ are not covered by Japanese insurance for primary and secondary prevention of PUB in patients taking LDA). Comment: MA revealed that LDA treatment with concomitant use of H2RAs or PPIs reduced the risk of LDA-related PUB [65, 71]. PPIs were superior to H2RAs in preventing upper GI ulcer bleeding related to LDA [66, 67]. We used data from three RCTs [68–70] in Mo et al. [67] and three RCTs [72–74], which compared PPIs and H2RAs to independently conduct an MA. We found that PPIs were superior to H2RAs (RR 0.28; 95% CI 0.16–0.50, P \ 0.0001) in the prevention of LDA-related upper GI bleeding (Fig.8). Further- more, the incidence of bleeding in the stomach or duodenum was signiﬁcantly lower with both 10 mg and 20 mg of VPZ compared to 15 mg of lansoprazole in patients taking LDA with a history of ulcers [7]. CQ-21 What kind of concomitant use of medicine should be effective for reducing the incidence and prevalence rate of recurrent LDA-related PUB? •PPIs in addition to the eradication of H. pylori infection are recommended for the reduction of the incidence and prevalence rate of LDA-related PUB. Recommendation: strong, 100% agreed, evidence level B. (PPI is not covered by Japanese insurance for second prevention of peptic ulcer bleeding in patients taking LDA). •H2RAs in addition to the eradication of H. pylori infection are suggested for the reduction of the incidence and prevalence rate of LDA-related PUB. Recommendation: weak, 100% agreed, evidence level C. (H2RAs are not covered by Japanese insurance for second prevention of PUB in patients taking LDA). Comment: The eradication of H. pylori is equivalent in the probability of recurrent bleeding to treatment with omeprazole in patients receiving LDA [75]. In patients with ulcer complications related to the long-term use of LDA, treatment with lansoprazole in addition to the eradication of H. pylori signiﬁcantly reduced recur- rence rates of ulcer bleeding compared to placebo plus H. pylori eradication [76]. In patients with LDA-related peptic ulcers, high-dose famotidine therapy is inferior to pantoprazole in preventing recurrent ulcer bleeding that continues to receive LDA [69]. LDA treatment Fig.7 Effects of proton pump inhibitors (PPIs) and histamine 2-receptor antagonists (H2RAs) in preventing upper gastrointestinal (GI) ulcers related to low dose aspirin (LDA). An independently meta-analysis demonstrates that no signiﬁcant difference (RR 0.26; 95% CI 0.04–1.81, P = 0.17) in the incidence of LDA-related upper GI ulcers between PPIs and H2RAs Fig.8 Effects of proton pump inhibitors (PPIs) and histamine 2-receptor antagonists (H2RAs) in preventing upper gastrointestinal (GI) ulcer bleeding related to low dose aspirin (LDA). An independently meta-analysis demonstrated that PPIs are superior to H2Ras (RR 0.28; 95% CI 0.16–0.50, P \ 0.0001) in prevention of LDA-related upper GI bleeding 312 J Gastroenterol (2021) 56:303–322 123",2998,468,749.5,"[ 0.23525746  0.04312274 -1.1733854  ...  0.72731125  0.13641463
 -1.8477715 ]"
157,"with concomitant use of rabeprazole showed no differ- ence in the incidence of recurrent upper GI ulcer bleeding rates compared to famotidine in patients with a history of LDA-related peptic ulcer bleeding [68]. CQ-22 How should LDA-related peptic ulcer recurrence be pre- vented in patients with a history of peptic ulcers? •PPI or VPZ is recommended to reduce the recurrence rate of LDA-related peptic ulcers. Recommendation: strong, 100% agreed, evidence level A. • H2RAs are suggested to reduce the recurrence rate of LDA-related peptic ulcers. Recommendation: weak, 100% agreed, evidence level C. Comment: In patients with a history of LDA-related peptic ulcers who continued to receive LDA, panto- prazole was superior to famotidine in preventing recurrent bleeding ulcers [69]. LDA treatment with concomitant use of 20 mg rabeprazole showed no difference in the recurrence of upper GI ulcer bleeding compared to 40 mg of famotidine in patients with a history of LDA-related PUB [68]. An independent MA of four RCT articles [77–80] demonstrated that PPIs were superior to control drugs, placebos, gefarnate, and teprenone, in preventing the recurrence of LDA-related upper GI ulcers (RR 0.09; 95% CI 0.06–0.15, P \ 0.00001). A study found that 47–53% of patients with gastroduodenal ulcer scars on endoscopy at baseline, famotidine was superior to placebo in pre- vention of the incidence of gastroduodenal ulcers in patients taking LDA [81]. An RCT by Kawai et al.indicated that 10 mg of VPZ was superior to 15 mg of lansoprazole in the prevention of peptic ulcer recur- rence in patients with a history of peptic ulcers who required LDA [7]. CQ-23 In patients without a history of peptic ulcer, is the pre- vention of LDA-related peptic ulcers necessary? •PPIs are recommended for the primary prevention of LDA-related peptic ulcers without a history of ulcers. Recommendation: strong, 82% agreed, evidence level A. Comment: In an RCT by Takeuchi et al.,famotidine was superior to teprenone in reducing the number of erosions during LDA use in 94% of patients without a history of peptic ulcers [82]. Scheiman et al. [83] indicated that esomeprazole reduced the occurrence of peptic ulcers in patients taking LDA in 73% of patients without a history of peptic ulcers. Ng et al. [70] found that esomeprazole was superior to famotidine in preventing upper GI complications related to LDA, clopidogrel, and thrombolytics in 95% of patients without a peptic ulcer. CQ-24 Can COX-2 selective inhibitors reduce the risk of peptic ulcers compared to nonselective NSAIDs when adminis- tered with LDA? •COX-2 selective inhibitors reduce the risk of peptic ulcers and bleeding in patients taking LDA compared to nonselective NSAIDs. Recommendation: strong, 100% agreed, evidence level A. • Concomitant use of celecoxib with PPIs is recom- mended for the prevention of gastric injury in patients with moderate or lower risk of peptic ulcers requiring LDA and NSAIDs. Recommendation: strong, 100% agreed, evidence level A. Comment: Concomitant use of a COX-2 selective inhibitor with LDA increased the incidence of peptic ulcers [84], whereas COX-2 selective inhibitors low- ered the risk of peptic ulcers compared to nonselective NSAIDs when using LDA [85, 86]. In patients taking LDA, the use of celecoxib or naproxen with PPIs resulted in similar rates of gastroduodenal ulceration [87]. In patients at high risk of both CV and GI events requiring concomitant LDA and NSAIDs, celecoxib with PPIs was the preferred treatment to reduce the risk of recurrent upper GI bleeding compared to naproxen with esomeprazole [88]. A study found that in 45% of arthritis patients taking LDA, the risk of GI events was lower with celecoxib than with naproxen or ibuprofen [89]. COX-2 selective inhibitors and nonselective NSAIDs increased the risk and incidence of CV events [90], whereas celecoxib was non-inferior to naproxen or ibuprofen with regard to CV safety [88, 89]. In addition, the American College of Gastroenterology (ACG) guidelines suggest that concomitant use of COX-2 selective inhibitors or nonselective NSAIDs in patients taking LDA should not be prescribed in patients at high risk of peptic ulcer [91]. J Gastroenterol (2021) 56:303–322 313 123",4250,670,1062.5,"[-0.00651173 -0.2665907  -1.4496912  ...  0.6907262   0.22210246
 -1.3981072 ]"
158,"CQ-25 Is PPI recommended for the prevention of recurrence of peptic ulcers with NSAID treatment in patients taking LDA? •Celecoxib with concomitant use of PPI is recom- mended for the prevention of peptic ulcer recurrence after NSAID treatment in patients taking LDA. Recommendation: strong, 100% agreed, evidence level A. (PPI is not covered by Japanese insurance for the primary prevention of ulcers in patients taking LDA). Comment: In patients with a history of ulcer who are receiving combinations of NSAIDs and LDA, con- comitant use of PPI lowered the risk for gastric ulcer recurrence as misoprostol [92]. In addition, Goldstein et al.indicated that naproxen with esomeprazole lowered the incidence of gastric ulcers compared to naproxen in LDA users [93]. There were fewer GI events in patients using both COX-2 inhibitors and LDA than nonselective NSAIDs and LDA [85, 86], and there were no differences in the occurrence of CV events between celecoxib and naproxen or ibuprofen [88, 89]. Non-H. pylori, non-NSAIDs ulcer CQ-26 How should non-H. pylori and non-NSAIDs ulcers be treated? •PPIs are suggested for the initial treatment of non-H. pylori and non-NSAID idiopathic ulcers with PPIs or H2RAs for the prevention of recurrence. Recommendation: weak, 100% agreed, evidence level: C. Comment: As hyperacidity and hypergastrinemia have been observed in patients with idiopathic ulcers [94], we suggest PPIs as the initial treatment. However, Kanno et al. [95] reported that the healing rate at 12 weeks with PPIs was 77.4% for idiopathic ulcers compared to 95.0% for H. pylori ulcers. Therefore, PPIs may be insufﬁcient for the treatment of idiopathic ulcers. Wong et al. [96] reported that the cumulative recurrence rate of the idiopathic ulcer group for 7 years without preventive treatment was 42.3%, higher than that of the H. pylori ulcer group (11.2%). Furthermore, in the following RCT conducted by them, they compared the efﬁcacy of PPI and H2RA in preventing recurrence of idiopathic ulcers and reported that the cumulative incidence of upper GI bleeding at 24 months was 0.88% for PPI (lansoprazole: 30 mg once per day) and 2.63% for H2RA (famotidine: 40 mg once per day) The effect was not signiﬁcantly different between the two groups (P = 0.336) [97]. Therefore, we suggest that both PPIs and H2RAs are candidates for the prevention of recurrence. Remnant gastric ulcer CQ-27 What is the treatment for ulcers in the gastric remnant? •PPI treatment is recommended for ulcers in the gastric remnant. Recommendation: strong, 100% agreed, evidence level C. Comment: The ﬁrst choice for the treatment of ulcers in gastric remnant is drug therapy. In an open-label trial comparing omeprazole, cimetidine, sucralfate, colloidal bismuth, and misoprostol for ulcers in the gastric remnant, omeprazole was the best in terms of cure rate and cure speed [98]. The cure rates of ulcer in 2 weeks’ treatment were 66.7, 43.3, 22.2, 22.2, and 16.7% for omeprazole, cimetidine, sucralfate, colloidal bismuth, and misoprostol, respectively. To date, there has not been a RCT regarding the H. pylori eradication effect. However, in several cross- sectional studies comparing the H. pylori positivity rate between gastric remnants with and without ulcers, there was no difference [99–102]. From these results, the eradication effect for ulcer occurrence in the gastric remnant is unknown. The preventive effect of eradica- tion for carcinogenesis in the gastric remnant is also undeﬁned. However, speculating from histological improvement after eradication, it would be effective for preventing carcinogenesis. We should be cautious about the recovery of acid secretion after eradication for ulcer occurrence in the gastric remnant. Surgical treatment CQ-28 Is eradication of H. pylori recommended after surgery for peptic ulcers? •Eradication of H. pylori is recommended after omental patch or omental ﬁlling procedure for peptic ulcers if H. pylori positive. Recommendation: strong, 100% agreed, evidence level A. Comment: For post-surgery treatment, reports 314 J Gastroenterol (2021) 56:303–322 123",4107,633,1026.75,"[-0.03540692 -0.04564396 -1.3506651  ...  0.8464567   0.24860255
 -1.5669688 ]"
159,"regarding eradication therapy were found, but not for PPI or H2RA treatment. Several reports were in agreement with the recommendation of eradication therapy for prevention of peptic ulcer recurrence after stomach preserving surgery [103–107]. El-Nakeeb et al. [107] indicated that early eradication after omental patch surgery for duodenal ulcer perforation is recom- mended for accelerating ulcer healing 8 weeks after surgery. Preventive effects for ulcer recurrence by eradication after gastrectomy were not consistent between reports. Further analysis is needed to determine the effect of acid secretion recovery after eradication of peptic ulcers. FRQ-1 What is the treatment for an ischemic duodenal ulcer? •Suggested PPIs or misoprostol as conservative treat- ments. Background conditions such as thrombosis and arterial stenosis should be investigated. IVR or surgery may be considered if the patient’s condition is exac- erbated following conservative treatment. Comment: Fourteen case reports regarding ischemic duodenal ulcers were identiﬁed. Symptoms included acute onset abdominal pain, melena or hematemesis, chronic abdominal pain, and weight loss. Typical endoscopic ﬁndings for ischemia were longitudinal ulcers, and edematous and reddish changes in the surrounding mucosa other than the ulcer. The causes of acute ischemia include embolization for GI bleeding hemostasis or embolization therapy for hepatocellular carcinoma, systemic thromboembolism [108, 109], and unknown cases. Chronic symptoms were reported in patients at risk of atherosclerotic disease and severe stenosis of the celiac artery/superior mesenteric artery. Fasting and acid-secreting inhibitors have been used as conservative treatments. However, the clinical effec- tiveness of acid suppression in the posterior part of the bulb, which is exposed to bile and pancreatic juice, remains unclear. From the viewpoint of mucosal protection, misoprostol is suggested. In the case of acute onset ischemic ulcers, careful observation is required, considering the possibility of systemic thrombosis. Therapeutic algorithm Figure 9 shows the algorithm for the treatment of peptic ulcer disease. If complications are present, they are addressed prior to the treatment of the ulcer. Perforation or stenosis is treated with surgery or conservative therapy. Hemorrhagic ulcers are treated via endoscopic hemostasis. When endoscopic hemostasis failed, surgery or IVR is performed. When no complications are present, medical therapy is provided immediately (Fig.9a). NSAIDs are discontinued, and anti-ulcer therapy is provided for the treatment of NSAID-induced ulcers. If NSAIDs cannot be discontinued, the ulcer should be trea- ted with a PPI. Patients with peptic ulcers who do not use NSAIDs should be tested for H. pylori. Eradication therapy is recommended for patients who are H. pylori positive. If ﬁrst-line therapy fails, second-line therapy is provided. If the second-line therapy fails, a specialist is consulted for third-line therapy. For patients without an indication for eradication therapy, non-eradication therapy is provided followed by maintenance therapy to prevent ulcer recur- rence. A remnant gastric ulcer is treated with a PPI, and an idiopathic ulcer is treated with PPI followed by mainte- nance therapy with a PPI or H2RA (Fig.9b). *1Contraindications. Only when administration is unavoidable as it cannot be discontinued. *2Patients who do not use NSAIDs and are H. pylori negative are considered to have idiopathic peptic ulcers. Figure 10 shows the algorithm for the prevention of NSAID-induced ulcers. In patients with no ulcer history receiving NSAID therapy, celecoxib (CXB) is recom- mended and PPIs are suggested for ulcer prevention. However, PPIs are recommended for elderly patients and patients with serious complications. If patients are both NSAID-naı¨ve and H. pylori positive, eradication therapy is recommended. For patients with a history of ulcers that do not include bleeding who are receiving NSAID therapy, a PPI with or without CXB is recommended, and the administration of VPZ is suggested for the prevention of ulcer recurrence.",4158,601,1039.5,"[-0.73558587 -0.18303595 -1.4015105  ...  0.93707734 -0.19571207
 -1.5818592 ]"
159,"For patients with a history of hemorrhagic ulcers who are receiving NSAID therapy, CXB with a PPI is recommended. CXB with a PPI is recommended for patients receiving combined NSAID therapy and LDA. Figure 11 shows the algorithm for the prevention of LDA-related ulcers. PPIs are recommended for ulcer pre- vention in patients receiving LDA therapy with no ulcer history. For patients with a history of ulcers without bleeding who are receiving LDA therapy, PPIs or VPZ are recommended and H2RAs are suggested. A PPI is recom- mended and H2RA is suggested for patients with a history of hemorrhagic ulcers who are receiving LDA therapy. However, if the patients are H. pylori positive, eradication J Gastroenterol (2021) 56:303–322 315 123",739,120,184.75,"[-0.18119328  0.3532372  -1.8026428  ...  0.6680651   0.36197644
 -1.5093576 ]"
160,"therapy is recommended. Finally, for patients receiving combinations of LDA and NSAID therapy, CXB with a PPI is recommended. Acknowledgements This article was supported by a Grant-in-Aid from JSGE. The authors thank the investigators and supporters for participating in the studies. The authors express special appreciation to Mr. Yuji Tatsugami and Miss. Ayari Sada (Nankodo) for their help in creating these guidelines. Author contributions Writing-original draft: TKa, KS, TI, MI, JI, TO, TKan, MS, TC, SN, MM. Writing-review and editing: TKa and KS Supervision: HH, JY, AT, SW, and KK Approval of ﬁnal manuscript: All authors. Compliance with ethical standards Conﬂict of interest Any ﬁnancial relationship with enterprises, businesses or academic institutions in the subject matter or materials discussed in the manuscript are listed as follows: (1) those from whom the authors, the spouse, partner or immediate relatives of authors, who have received individually any income, honoraria or any other types of remuneration: Astellas Pharma Inc., AstraZeneca K. K., DaiichiSankyo Company, Limited, Eisai Co., Ltd., Otsuka Pharma- ceutical Co.,Ltd.,Pﬁzer Japan Inc., Takeda Pharmaceutical Company Limited.and (2) those from whom the academic institutions of the Fig.9 Algorithm for the treatment of peptic ulcer disease 316 J Gastroenterol (2021) 56:303–322 123",1364,199,341.0,"[ 0.24530183  0.12208122 -1.6711799  ...  0.555144   -0.06809454
 -2.099185  ]"
161,"authors received support (commercial/academic cooperation): Aji- nomoto Pharmaceuticals Co., Ltd., AsTellas Pharma Inc., AstraZe- necaK. K., Bayer Yakuhin, Ltd., Chugai PharmaCeutical Co., Ltd., DaiichiSankyo Company, Limited, Eisai Co., Ltd., Kishuhosokawa Co., Ltd., Maruso Co., Ltd, Mitsubishi Tanabe Pharma Corporation, MSD K. K., Nihon Pharmaceutical Co. Ltd., Nippon Shinyaku Co., Ltd., Okahatanoen Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Pﬁzer Japan Inc., SanoﬁK. K., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. Fig.10 Algorithm for the prevention of NSAID-induced ulcers Fig.11 Algorithm for the prevention of LDA-related ulcers J Gastroenterol (2021) 56:303–322 317 123",1544,219,386.0,"[ 0.20239277 -0.00840527 -1.499645   ...  0.32497096 -0.2727459
 -2.2203732 ]"
162,"Appendix Members of the Guidelines Committee who created and evaluated the JSGE ‘‘Evidence-based clinical practice guidelines for peptic ulcer disease 20200’ are listed below. Executive committee Chair: Kiichi Satoh (Department of Gastroenterology, International University of Health and Welfare Hospital). Vice-Chair: Tomoari Kamada (Department of Health Care Medicine, Kawasaki Medical School). Members: Tosh- iyuki Itoh (Education Center for Medicine and Nursing, Shiga University of Medical Science), Masanori Ito (Department of General Internal Medicine, Hiroshima University Hospital), Junichi Iwamoto (Department of Gastroenterology, Tokyo Medical University Ibaraki Medical Center), Tadayoshi Okimoto (Department of Gastroenterology, Faculty of Medicine, Oita University), Takeshi Kanno (Division of Gastroenterology, Tohoku University Hospital), Mitsushige Sugimoto (Department of Gastroenterological Endoscopy, Tokyo Medical University Hospital), Toshimi Chiba (Division of Internal Medicine, Department of Oral Medicine, Iwate, Medical University), Sachiyo Nomura (Department of Gastrointestinal Surgery, Graduate School of Medicine, The University of Tokyo), and Mitsuyo Mieda (Division of Gastroenterology, Department of Medicine, Jichi Medical University). Evaluation committee Chair: Hideyuki Hiraishi (Niigataseirou Hospital). Vice-Chair: Junji Yoshino (Fujita Medical University). Member: Atsushi Takagi (Kameda Morinosato Hospital). The Japanese Society of Gastroenterology President: Kazuhiko Koike (Department of Gastroenterol- ogy, Graduate School of Medicine, The University of Tokyo). Past President: Tooru Shimosegawa (South Miyagi Medical Center). Director Responsible: Hiroto Miwa (Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine), Nobuyuki Eno- moto (First Department of Internal Medicine, Faculty of Medicine, University of Yamanashi). SR collaborator Ryo Ogawa (Department of Gastroenterology, Faculty of Medicine, Oita University), Sotaro Ozaka (Department of Gastroenterology, Faculty of Medicine, Oita University), Yoshinari Kawahara (Department of Gastroenterology, Faculty of Medicine, Oita University), Xiaoyi Jin (Division of Gastroenterology, Tohoku University Hospital), Naoki Sumi (Department of Health Care Medicine, Kawasaki Medical School), Kenichiro Nakagawa (Division of Gas- troenterology, Tohoku University Hospital), Kensuke Fukuda (Department of Gastroenterology, Faculty of Medicine, Oita University). Tomoyuki Boda (Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University), Hitomi Mizuno (Toyoda Aoba Clinic), Masaki Murata (Department of Gastroen- terology, National Hospital Organization, Kyoto Medical Center), Mohammad Yaghoobi (Division of Gastroen- terology, Health Sciences Centre, McMaster University, Canada), and Yuan Yuhong (Division of Gastroenterology, Health Sciences Centre, McMaster University, Canada). Cooperative society The Japanese Gastroenterological Association. Japan Gastroenterological Endoscopy Society. References 1. Yoshida M, Kinoshita Y, Watanabe M, et al. JSGE clinical practice guideline 2014: standards, methods, and process of developing guidelines. J Gastroenterol.2015;50:4–10.2. Fujimoto K, Fujishiro M, Kato M, et al. Guidelines for gas- troenterological endoscopy in patients undergoing antithrom- botic treatment. Dig Endosc.2014;26:1–14.3. Kato M, Uedo N, Hokimoto S, et al. Guidelines for gastroen- terological endoscopy in patients undergoing antithrombotic treatment: 2017 appendix on anticoagulants including direct oral anticoagulants. Dig Endosc.2018;30:433–40.4. Murakami K, Sakurai Y, Shiino M, et al. Vonoprazan, a novel potassium-competitive acid blocker, as a component of ﬁrst-line and second-line triple therapy for Helicobacter pylori eradica- tion: a phase III, randomised, double-blind study. Gut.2016;65:1439–46.5. Miwa H, Uedo N, Watari J, et al. Randomised clinical trial: efﬁcacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers-results from two phase 3, non- inferiority randomised controlled trials. Aliment Pharmacol Ther.2017;45:240–52.6. Mizokami Y, Oda K, Funao N, et al. Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lan- soprazole-controlled non-inferiority and single-blind extension study. Gut.",4392,535,1098.0,"[ 0.1538695   0.09174213 -1.5012703  ...  0.06435472 -0.11628126
 -1.8652619 ]"
163,"7. Kawai T, Oda K, Funao N, et al. Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study. Gut.2018;67:1033–41.8. Sung JJ, Lau JY, Ching JY, et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med.2010;152:1–9.9. Tarasconi A, Baiocchi GL, Pattonieri V, et al. Transcatheter arterial embolization versus surgery for refractory non-variceal upper gastrointestinal bleeding: a meta-analysis. World J Emerg Surg.2019;14:3.10. Kyaw M, Tse Y, Ang D, et al. Embolization versus surgery for peptic ulcer bleeding after failed endoscopic hemostasis: a meta- analysis. Endos Int Open.2014;2:E6-14.11. Selby NM, Kubba AK, Hawkey CJ. Acid suppression in peptic ulcer haemorrhage: a ‘meta-analysis.’Aliment Pharmacol Ther.2000;14:1119–26.12. Leontiadis GI, Sharma VK, Howden CW. Systematic review and meta-analysis: proton-pump inhibitor treatment for ulcer bleeding reduces transfusion requirements and hospital stay-re- sults from the Cochrane Collaboration. Aliment Pharmacol Ther.2005;22:169–74.13. George S, George G, Androniki P, et al. High-dose vs. low-dose proton pump inhibitors post endoscopic hemostasis in patients with bleeding peptic ulcer: a meta-analysis and meta-regression analysis. Turk J Gastroenterol.2018;29:22–31.14. Jian Z, Li H, Race NS, et al. Is the era of intravenous proton pump inhibitors coming to an end in patients with bleeding peptic ulcers?Meta-analysis of the published literature. Br J Clin Pharmacol.2016;82:880–9.15. Wang J, Yang K, Ma B, et al.",1562,212,390.5,"[ 0.03016111 -0.6129307  -1.2147667  ...  0.57535625  0.46642196
 -1.8626086 ]"
163,"Intravenous pantoprazole as an adjuvant therapy following successful endoscopic treatment for peptic ulcer bleeding. Can J Gastroenterol.2009;23:287–99.16. Bhatt DL, Cryer BL, Contant CF, COGENT Investigators, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med.2010;363:1909–17.17. Ren YH, Zhao M, Chen YD, et al. Omeprazole affects clopi- dogrel efﬁcacy but not ischemic events in patients with acute coronary syndrome undergoing elective percutaneous coronary intervention. Chin Med J. 2011;124:856–61.18. Wei P, Zhang YG, Ling L, et al. Effects of the short-term application of pantoprazole combined with aspirin and clopi- dogrel in the treatment of acute STEMI. Exp Ther Med.2016;12:2861–4.19. Valgimigli M, Bueno H, Byrne RA, ESC Scientiﬁc Document Group; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies, et al.2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio- Thoracic Surgery (EACTS). Eur Heart J. 2018;39:213–60.20. Ray WA, Chung CP, Murray KT, et al. Association of proton pump inhibitors with reduced risk of warfarin-related serious upper gastrointestinal bleeding. Gastroenterology.2016;151:1105–12.21. Kato M, Ota H, Okuda M, et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2016 Revised Edition. Helicobacter.2019;24:e12597.22. Sugimoto M, Furuta T, Shirai N, et al. Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy. Helicobacter.2007;12:317–23.23. Sugimoto M, Yamaoka Y. Role of vonoprazan in Helicobacter pylori eradication therapy in Japan. Front Pharmacol.2018;9:1560.24. Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report.",2024,277,506.0,"[ 0.19430636 -0.09469211 -1.3828398  ...  0.82787794  0.28522903
 -1.6477302 ]"
163,"Gut.2017;66:6–30.25. Murata M, Sugimoto M, Mizuno H, et al. Clarithromycin versus metronidazole in ﬁrst-line Helicobacter pylori triple eradication therapy based on resistance to antimicrobial agents: meta-anal- ysis. J Clin Med.2020;9:543.26. Mansour-Ghanaei F, Joukar F, Naghipour MR, et al. Seven-day quintuple regimen as a rescue therapy for Helicobacter pylori eradication. World J Gastroenterol.2015;21:661–6.27. Hsu PI, Tsai FW, Kao SS, et al. Ten-day quadruple therapy comprising proton pump inhibitor, bismuth, tetracycline, and levoﬂoxacin is more effective than standard levoﬂoxacin triple therapy in the second-line treatment of Helicobacter pylori infection: a randomized controlled trial. Am J Gastroenterol.2017;112:1374–81.28. Liou JM, Bair MJ, Chen CC, et al. Levoﬂoxacin sequential therapy vs levoﬂoxacin triple therapy in the second-line treat- ment of Helicobacter pylori: a randomized trial. Am J Gas- troenterol.2016;111:381–7.29. Tsujimae M, Yamashita H, Hashimura H, et al. A comparative study of a new class of gastric acid suppressant agent named vonoparazan versus esomeprazole for the eradication of Heli- cobacter pylori. Digestion.2016;94:240–6.30. Sakurai K, Suda H, Ido Y, et al. Comparative study: Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy. World J Gastroenterol.2017;23:668–75.31. Sue S, Kuwashima H, Iwata Y, et al. The superiority of vono- prazan-based ﬁrst-line triple therapy with clarithromycin: a prospective multi-center cohort study on Helicobacter pylori eradication. Intern Med.2017;56:1277–85.32. Murakami K, Furuta T, Ando T, et al. Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan. J Gastroenterol.2013;48:1128–35.33.",1785,234,446.25,"[-0.22566177 -0.02602372 -1.1151247  ...  0.5328906   0.14914416
 -1.7245322 ]"
163,"Furuta T, Sugimoto M, Kodaira C, et al. Sitaﬂoxacin-based third-line rescue regimens for Helicobacter pylori infection in Japan. J Gastroenterol Hepatol.2014;29:487–93.34. Mori H, Suzuki H, Matsuzaki J, et al. Efﬁcacy of 10-day sita- ﬂoxacin-containing third-line therapies for Helicobacter pylori strains containing the gyrA mutation. Helicobacter.2015;21:286–94.35. Di Mario F, Battaglia G, Leandro G, et al. Short-term treatment of gastric ulcer: a meta-analytical evaluation of blind trials. Dig Dis Sci.1996;41:1108–31.36. Eriksson S, Langstrom G, Rikner L, et al. Omeprazole and H2- receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reﬂux oesophagitis: a meta-analysis. Eur J Gastroenterol Hepatol.1995;7:467–75.37. Salas M, Ward A, Caro J. Are proton pump inhibitors the ﬁrst choice for acute treatment of gastric ulcers?A meta-analysis of randomized clinical trials. BMC Gastroenterol.2002;2:17.38. Tunis SR, Sheinhait IA, Schmid CH, et al. Lansoprazole com- pared with histamine 2-receptor antagonists in healing gastric ulcers: a meta-analysis. Clin Ther.1997;19:743–57.39. Echizen H. The ﬁrst-in-class potassium-competitive acid blocker, vonoprazan fumarate: pharmacokinetic and pharmaco- dynamic considerations. Clin Pharmacokinet.2015;55:409–18 ([Epub ahead of print]).40. Poynard T, Lemaire M, Agostini H. Meta-analysis of random- ized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer. Eur J Gastroenterol Hepatol.1995;7:661–5.41. Tildesley G, Ehsanullah RS, Wood JR. Ranitidine in the treat- ment of gastric and duodenal ulcers associated with non-ster- oidal anti-inﬂammatory drugs. Br J Rheumatol.1993;32:474–8. J Gastroenterol (2021) 56:303–322 319 123",1762,228,440.5,"[-0.5326421   0.10446402 -0.9922904  ...  0.6334953   0.14140464
 -1.8770959 ]"
164,"42. Agrawal NM, Campbell DR, Safdi MA, NSAID-Associated Gastric Ulcer Study Group, et al. Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inﬂammatory drug-asso- ciated gastric ulcers: results of a double-blind, randomized, multicenter study. Arch Intern Med.2000;160:1455–61.43. Hawkey CJ, Karrasch JA, Szczepan˜ski L, Omeprazole vs. Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Group, et al. Omeprazole compared with miso- prostol for ulcers associated with nonsteroidal antiinﬂammatory drugs. N Engl J Med.1998;338:727–34.44. Chan FK, To KF, Wu JC, et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inﬂammatory drugs: a ran- domised trial. Lancet.2002;359:9–13.45. Vergara M, Catalan M, Gisbert JP, et al. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther.2005;21:1411–8.46. Tang CL, Ye F, Liu W, et al. Eradication of Helicobacter pylori infection reduces the incidence of peptic ulcer disease in patients using nonsteroidal anti-inﬂammatory drugs: a meta-analysis. Helicobacter.2012;17:286–96.47. Koch M. Non-steroidal anti-inﬂammatory drug gastropathy: clinical results with misoprostol. Ital J Gastroenterol Hepatol.1999;31(Suppl 1):S54-62.48. Bianchi Porro G, Lazzaroni M, Petrillo M, et al. Prevention of gastroduodenal damage with omeprazole in patients receiving continuous NSAIDs treatment: a double blind placebo con- trolled study. Ital J Gastroenterol Hepatol.1998;30:43–7.49. Taha AS, Hudson N, Hawkey CJ, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinﬂammatory drugs. N Engl J Med.1996;334:1435–9.50. Scally B, Emberson JR, Spata E, et al. Effects of gastroprotec- tant drugs for the prevention and treatment of peptic ulcer dis- ease and its complications: a meta-analysis of randomised trials. Lancet Gastroenterol Hepatol.",1987,263,496.75,"[-0.32478565 -0.31396246 -1.4674888  ...  0.7105451   0.51310855
 -1.6535085 ]"
164,"2018;3:231–41.51. Koch M, Deiz A, Tarquini M, et al. Prevention of non-steroidal anti-inﬂammatory drug-induced gastrointestinal mucosal injury: risk factors for serious complications. Digest Liver Dis.2000;32:138–51.52. Sugano K, Kontani T, Katsuo S, et al. Lansoprazole for sec- ondary prevention of gastric or duodenal ulcers associated with long-term non-steroidal anti-inﬂammatory drug (NSAID) ther- apy: results of a prospective, multicenter, double-blind, ran- domized, double-dummy, active-controlled trial. J Gastroenterol.2012;47:540–52.53. Sugano K, Kinoshita Y, Miwa H, Esomeprazole NSAID Preventive Study Group, et al. Randomised clinical trial: esomeprazole for the prevention of nonsteroidal anti-inﬂam- matory drug-related peptic ulcers in Japanese patients. Aliment Pharmacol Ther.2012;36:115–25.54. Chan FK, Wong VW, Suen BY, et al. Combination of a cyclooxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet.2007;369:1621–6.55. Masclee GM, Valkhoff VE, Coloma PM, et al. Risk of upper gastrointestinal bleeding from different drug combinations. Gastroenterology.2014;147:784–92.56. Vonkeman HE, Fernandes RW, van der Palen J, et al. Proton- pump inhibitors are associated with a reduced risk for bleeding and perforated gastroduodenal ulcers attributable to non-ster- oidal anti-inﬂammatory drugs: a nested case-control study. Arthritis Res Ther.2007;9:R52.57. Emery P, Zeidler H, Kvien TK, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomized double-blind comparison. Lancet.1999;354:2106–11.58. Laine L, Harper S, Simon T, et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-speciﬁc inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis: Rofecoxib Osteoarthritis Endoscopy Study Group. Gastroenterology.1999;117:776–83.59. Pavelka K, Recker DP, Verburg KM.",1998,253,499.5,"[-0.15019305 -0.21524405 -1.4688474  ...  0.41901225  0.38236094
 -1.7388691 ]"
164,"Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: results of a 26-week trial. Rheumatology.2003;42:1207–15.60. Sakamoto C, Kawai T, Nakamura S, et al. Comparison of gas- troduodenal ulcer incidence in healthy Japanese subjects taking celecoxib or loxoprofen evaluated by endoscopy: a placebo- controlled, double-blind 2-week study. Aliment Pharmacol Ther.2013;37:346–54.61. Goldstein JL, Kivitz AJ, Verburg KM, et al. A comparison of the upper gastrointestinal mucosal effects of valdecoxib, naproxen and placebo in healthy elderly subjects. Aliment Pharmacol Ther.2003;18:125–32.62. Feng GS, Ma JL, Wong BC, et al. Celecoxib-related gastro- duodenal ulcer and cardiovascular events in a randomized trial for gastric cancer prevention. World J Gastroenterol.2008;14:4535–9.63. Yuan JQ, Tsoi KK, Yang M, et al. Systematic review with network meta-analysis: comparative effectiveness and safety of strategies for preventing NSAID-associated gastrointestinal toxicity. Aliment Pharmacol Ther.2016;43:1262–75.64. Liu CP, Chen WC, Lai KH, et al. Esomeprazole alone compared with esomeprazole plus aspirin for the treatment of aspirin-re- lated peptic ulcers. Am J Gastroenterol.2012;107:1022–9.65. Tricco AC, Alateeq A, Tashkandi M, et al. Histamine H2 receptor antagonists for decreasing gastrointestinal harms in adults using acetylsalicylic acid: systematic review and meta- analysis. Open Med.2012;6:e109–17.66. Mo C, Sun G, Lu ML, et al. Proton pump inhibitors in pre- vention of low-dose aspirin-associated upper gastrointestinal injuries. World J Gastroenterol.2015;21:5382–92.67. Mo C, Sun G, Wang Y, et al. PPI versus histamine H2 receptor antagonists for prevention of upper gastrointestinal injury associated with low-dose aspirin: Systematic review and meta- analysis. PLoS ONE.2015;10:e0131558.",1884,248,471.0,"[ 0.348471   -0.01561366 -0.9091499  ... -0.01366803  0.31680387
 -1.7291918 ]"
164,"68. Chan FK, Kyaw M, Tanigawa T, et al. Similar efﬁcacy of proton-pump inhibitors vs H2-receptor antagonists in reducing risk of upper gastrointestinal bleeding or ulcers in high-risk users of low-dose aspirin. Gastroenterology.2017;152:105–10.69. Ng FH, Wong SY, Lam KF, et al. Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Gastroenterology.2010;138:82–8.70. Ng FH, Tunggal P, Chu WM, et al. Esomeprazole compared with famotidine in the prevention of upper gastrointestinal bleeding in patients with acute coronary syndrome or myocar- dial infarction. Am J Gastroenterol.2012;107:389–96.71. Lanas A, Wu P, Medin J, et al. Low doses of acetylsaiicyiic acid increase risk of gastrointestinal bleeding in a meta-analysis. Clin Gastroenterol Hepatol.2011;9:762–8.72. Yano H, Tsukahara K, Morita S, et al. Inﬂuence of omeprazole and famotidine on the antiplatelet effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes: a prospective, randomized, multicenter study. Circ J. 2012;76:2673–80.73. Wang Z, Yang X, Cai J, et al. Inﬂuence of different proton pump inhibitors on platelet function in acute myocardial infarction patients receiving clopidogrel treatment after percutaneous coronary intervention. Biomed Res.2013;24:453–7.74. Tunggal P, Ng FH, Lam KF, et al. Effect of esomeprazole versus famotidine on platelet inhibition by clopidogrel: a double-blind, randomized trial. Am Heart J. 2011;162:870–4.320 J Gastroenterol (2021) 56:303–322 123",1541,211,385.25,[ 0.3432083 -0.237064  -1.1018828 ...  0.6219201  0.4843372 -1.955635 ]
165,"75. Chan FK, Chung SC, Suen BY, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med.2001;344:967–73.76. Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the pre- vention of recurrence of ulcer complications from long-term low-dose aspirin use. N Engl J Med.2002;346:2033–8.77. Sugano K, Matsumoto Y, Itabashi T, et al. Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term low-dose aspirin therapy: results of a prospec- tive, multicenter, double-blind, randomized, double-dummy, active-controlled trial. J Gastroenterol.2011;46:724–5.78. Sanuki T, Fujita T, Kutsumi H, Case Study Group, et al. Rabeprazole reduces the recurrence risk of peptic ulcers asso- ciated with low-dose aspirin in patients with cardiovascular or cerebrovascular disease: a prospective randomized active-con- trolled trial. J Gastroenterol.2012;47:1186–97.79. Iwakiri R, Higuchi K, Kato M, et al. Randomised clinical trial: prevention of recurrence of peptic ulcers by rabeprazole in patients taking low-dose aspirin. Aliment Pharmacol Ther.2014;40:780–95.80. Sugano K, Choi MG, Lin JT, on behalf of the LAVENDER Study Group, et al. Multinational, double-blind, randomised, placebo-controlled, prospective study of esomeprazole in the prevention of recurrent peptic ulcer in low-dose acetylsalicylic acid users: the LAVENDER study. Gut.2014;63:1061–8.81. Taha AS, McCloskey C, Prasad R, et al. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double- blind, placebo-controlled trial. Lancet.2009;374:119–25.82. Takeuchi T, Ota K, Harada S, et al. Comparison of teprenone and famotidine against gastroduodenal mucosal damage in patients taking low-dose aspirin. J Gastroenterol Hepatol.2014;29(Suppl.4):11–5.83. Scheiman JM, Devereaux PJ, Herlitz J, et al.",1968,264,492.0,[ 0.1797901 -0.3344369 -1.4751793 ...  0.5122025  0.3880015 -1.9337267]
165,"Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a ran- domised, controlled trial (OBERON). Heart.2011;97:797–802.84. Laine L, Maller ES, Yu C, et al. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhi- bition: a double-blind trial. Gastroenterology.2004;127:395–402.85. Strand V. Are COX-2 inhibitors preferable to non-selective non- steroidal anti-inﬂammatory drugs in patients with risk of car- diovascular events taking low-dose aspirin. Lancet.2007;370:2138–51.86. Goldstein J, Lowry SC, Lanza FL, et al. The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inﬂammatory drug or a cyclo-oxygenase-2-selective inhibitor. Aliment Pharmacol Ther.2006;23:1489–98.87. Goldstein JL, Cryer B, Amer F, et al. Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial. Clin Gastroenterol Hepatol.2007;5:1167–74.88. Chan FKL, Ching JYL, Tse YK, et al. Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double- dummy, randomised trial. Lancet.2017;389:2375–82.89. Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med.2016;375:2519–29.90. Mcgettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxyge- nase 2. JAMA.2006;296:1633–44.91. Lanza FL, Chan FKL, Quigley EMM. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol.2009;104:728–38.92. Goldstein JL, Huang B, Amer F, et al.",1896,241,474.0,"[ 0.33308214 -0.5959865  -1.3592055  ...  0.5883738   0.788454
 -1.760403  ]"
165,"Ulcer recurrence in high- risk patients receiving nonsteroidal anti-inﬂammatory drugs plus low-dose aspirin: results of a post Hoc subanalysis. Clin Ther.2004;26:1637–43.93. Goldstein JL, Hochberg MC, Fort JG, et al. Clinical trial: the incidence of NSAID-associated endoscopic gastric ulcers in patients treated with PN 400 (naproxen plus esomeprazole magnesium) vs. enteric-coated naproxen alone. Aliment Phar- macol Ther.2010;32:401–13.94. Mcoll KEL, LE- Nujumi AM, Chittajallu RS, et al. A study of the pathogenesis of Helicobacter pylori negative chronic duo- denal ulceration. Gut.1993;34:762–8.95. Kanno T, Iijima K, Abe Y, et al. Helicobacter pylori-negative and non-steroidal anti-inﬂammatory drugs-negative idiopathic peptic ulcers show refractoriness and high recurrence incidence: multicenter follow-up study of peptic ulcers in Japan. Dig Endosc.2016;28:556–63.96. Wong GL, Wong VW, Chan Y, et al. High incidence of mor- tality and recurrent bleeding in patients with Helicobacter pylori-negative idiopathic bleeding ulcers. Gastroenterology.2009;137:525–31.97. Wong GLH, Lau LHS, Ching JYL, et al. Prevention of recurrent idiopathic gastroduodenal ulcer bleeding: a double-blind, ran- domised trial. Gut.2020;69:652–7.98. Janke A, Stasiewicz J, Namiot Z, et al. Treatment of gastric stump ulcer: an open study with ﬁve drugs. Hepatogastroen- terology.2000;47:1195–8.99. Leivonene MK, Haglund CH, Nordling SFA. Helicobacter pylori infection after partial gastrectomy for peptic ulcer and its role in relapsing disease. Eur J Gastroenterol Hepatol.1997;9:371–4.100. Lee YT, Sung JJ, Choi CL, et al. Ulcer recurrence after gastric surgery: is Helicobacter pylori the culprit?Am J Gastroenterol.1998;93:928–31.",1720,224,430.0,"[-0.17759086 -0.03804898 -1.0851814  ...  0.5545483   0.31869304
 -1.3749559 ]"
165,"101. Huang WH, Wang HH, Wu WW, et al. Helicobacter pylori infection in patients with ulcer recurrence after partial gastrec- tomy. Hepatogastroenterology.2004;51:1551–3.102. Schilling D, Adamek HE, Wilke J, et al. Prevalence and clinical importance of Helicobacter pylori infection in patients after partial gastric resection for peptic ulcer disease. Z Gastroenterol.1999;37:127–32.103. Rodrı´guez-Sanjua´n JC, Ferna´ndez-Santiago R, Garcı´a RA, et al. Perforated peptic ulcer treated by simple closure and Heli- cobacter pylori eradication. World J Surg.2005;29:849–52.104. Ng EK, Lam YH, Sung JJ, et al. Eradication of Helicobacter pylori prevents recurrence of ulcer after simple closure of duodenal ulcer perforation: randomized controlled trial. Ann Surg.2000;231:153–8.105. Kate V, Ananthakrishnan N, Badrinath S. Effect of Helicobacter pylori eradication on the ulcer recurrence rate after simple clo- sure of perforated duodenal ulcer: retrospective and prospective randomized controlled studies. Br J Surg.2001;88:1054–8.106. Tomtitchong P, Siribumrungwong B, Vilaichone RK, et al. Systematic review and meta-analysis: Helicobacter pylori eradication therapy after simple closure of perforated duodenal ulcer. Helicobacter.2012;17:148–52.107. El-Nakeeb A, Fikry A, Abd El-Hamed TM, et al. Effect of Helicobacter pylori eradication on ulcer recurrence after simple closure of perforated duodenal ulcer. Int J Surg.2009;7:126–9.108. Force T, MacDonald D, Eade OE, et al. Ischemic gastritis and duodenitis. Dig Dis Sci.1980;25:307–10. J Gastroenterol (2021) 56:303–322 321 123",1583,206,395.75,"[-0.4344973  -0.537837   -1.3134472  ...  0.66065717  0.05538236
 -1.7912872 ]"
166,"109. Julka RN, Aduli F, Lamps LW, et al. Ischemic duodenal ulcer, an unusual presentation of sickle cell disease. J Natl Med Assoc.2008;100:339–41. Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional afﬁliations.322 J Gastroenterol (2021) 56:303–322 123",323,45,80.75,"[-0.25869238 -0.4087567  -1.1980023  ...  0.42429864 -0.41442674
 -1.5729527 ]"
167,"www.thelancet.com  Vol 390  August 5, 2017	 613 Seminar Peptic ulcer disease Angel Lanas, Francis K L Chan The rapidly declining prevalence of Helicobacter pylori infection and widespread use of potent anti-secretory drugs means peptic ulcer disease has become substantially less prevalent than it was two decades ago. Management has, however, become more challenging than ever because of the threat of increasing antimicrobial resistance worldwide and widespread use of complex anti-thrombotic therapy in the ageing population. Peptic ulcers not associated with H pylori infection or the use of non-steroidal anti-inflammatory drugs are now also imposing substantial diagnostic and therapeutic challenges. This Seminar aims to provide a balanced overview of the latest advances in the pathogenetic mechanisms of peptic ulcers, guidelines on therapies targeting H pylori infection, approaches to treatment of peptic ulcer complications associated with anti-inflammatory analgesics and anti-thrombotic agents, and the unmet needs in terms of our knowledge and management of this increasingly challenging condition. Introduction The term peptic ulcer refers to acid peptic injury of the digestive tract, resulting in mucosal break reaching the submucosa. Peptic ulcers are usually located in the stomach or proximal duodenum, but they can also be found in the oesophagus or Meckel’s diverticulum. In this Seminar, the term peptic ulcer disease refers to peptic ulcers located in the stomach or duodenum.1 Traditionally, a hypersecretory acidic environment together with dietary factors or stress were thought to cause most peptic ulcer diseases, but the discovery of Helicobacter pylori infection and the widespread use of non- steroidal anti-inflammatory drugs (NSAIDs) in the second half of the 20th century have changed this perception. Epidemiology Lifetime prevalence of peptic ulcer disease in the general population has been estimated to be about 5−10%, and incidence 0·1–0·3% per year.1–3 However, the prevalence and incidence of peptic ulcer disease is now probably lower than these estimates worldwide, especially in high- income countries, because epidemiological studies have shown a sharp decreasing trend in the incidence, rates of hospital admissions, and mortality associated with the disease in the past 20–30 years.4−9 These decreasing numbers could be due to the introduction of new therapies, or they might be due to a cohort trend that cannot be fully explained by known causes (eg, H pylori infection and NSAID treatment). Many gastrointestinal diseases are characterised by rises and falls in prevalence,4 suggesting that an underlying birth-cohort trend might be present for peptic ulcer disease. Mortality associated with peptic ulcer disease peaked in generations born at the end of the 19th century and fell in those born in the 20th century. Although the decrease noted includes all types of ulcers (H pylori-associated, NSAID-associated, and idiopathic), the overall pattern corresponds to the decreasing prevalence of H pylori infection in the population, in which a birth-cohort effect is also seen in countries with low prevalence of the infection. These observations emphasise the key role of H pylori infection in both the cause and documented temporal variations of peptic ulcer disease.4−7 In European countries with different health-care systems and socioeconomic status, between 1921 and 2004, the risk of dying from gastric ulcers preceded that of dying from duodenal ulcers by 10−30 years.5 In Central America, South America, and Asia, a decline in mortality from gastric ulcers and duodenal ulcers has also been recorded, and showed a birth-cohort effect that was similar to that in Europe, with high rates reported in people born in the late 19th century and a 10−20-year delayed peak mortality for those with duodenal ulcers.6 In Asia, a steady decline in the prevalence of peptic ulcer disease has been reported in different ethnic groups, including Malay, Chinese, and Indian populations, for the past 20 years. This decline paralleled a decrease in H pylori-associated peptic ulcer disease.7 Although increased use of NSAIDs or introduction of anti-secretory medications does not seem to explain trends in ulcer-related mortality reported by Sonnenberg,5 other studies8,9 have reported falling hospital admissions for complications of peptic ulcer disease in the 21st century, with an incidence of 79 cases per 100 000 people per year and less than 30 cases of peptic ulcer disease complications per 100 000 people per year.8,9 The reduction in peptic ulcer disease complications might be associated with the widespread use of anti- secretory drugs around the world and a more rational use of NSAIDs than before8–10 (appendix p 8). Lancet 2017; 390: 613–24 Published Online February 24, 2017 http://dx.doi.org/10.1016/ S0140-6736(16)32404-7 Service of Digestive Diseases, University Clinic Hospital Lozano Blesa, University of Zaragoza, IIS Aragón, CIBEREHD, Zaragoza, Spain (Prof A Lanas MD); and Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China (F K L Chan MD) Correspondence to: Prof Angel Lanas, Service of Digestive Diseases, University Clinic Hospital Lozano Blesa, Calle San Juan Bosco 15, Zaragoza 50009, Spain alanas@unizar.es Search strategy and selection criteria We searched MEDLINE and Embase (from Jan 1, 2010, to March 31, 2016) using the terms “peptic ulcer” in combination with “clinical trials”, “meta-analysis”, “guideline”, “epidemiology”, “risk factors”, “physiopathology”, “genetics”, or “diagnosis”. We selected publications from the past 6 years, but did not exclude commonly cited references that we regarded as seminal work. Articles or reviews published in the past 15–20 years were also identified, and we selected those publications we judged relevant. We have also cited review articles and book chapters to provide readers with additional references and a more detailed overview than this Seminar. See Online for appendix",6098,905,1524.5,"[-0.19194444 -0.38661915 -1.0371536  ...  0.15535247  0.23975585
 -1.7246455 ]"
168,"Seminar 614	 www.thelancet.com  Vol 390  August 5, 2017 Pathogenic mechanisms and risk factors H pylori and the use of NSAIDs or aspirin are the main risk factors of both gastric and duodenal ulcers.1,11−13 However, only a few people with H pylori infection or taking NSAIDs or aspirin develop peptic ulcer disease, suggesting that individual susceptibility to bacterial virulence and drug toxicity is essential to the initiation of mucosal damage. The interaction between bacterial and host factors determines the outcome of H pylori infection. The ability of H pylori strains to produce different proteins has been linked to their virulence and to the host immune response.1 The organism produces urease to create an alkaline environment, which is essential for its survival in the stomach under the mucosal barrier. It also expresses adhesins such as blood group antigen adhesin (BabA) or outer inflammatory protein adhesin (OipA), which facilitate attachment of bacteria to gastric epithelium. A genome pathogenic island encodes the virulent factors CagA and PicB, which—together with other bacterial factors—are thought to interact strongly with host tissue and be linked to gastric mucosal inflammatory cell infiltration and gastric epithelial injury (appendix p 9).14–16 Almost all H pylori strains contain the vacA gene, which encodes a vacuolating cytotoxin, although half the strains do not express the protein. The role of VacA protein in disease pathogenesis is unclear.16 Variations in the vacA gene structure (ie, a combination of signal sequence allelic types [s1a, 1b, and 2] and mid-region allelic types [m1 and m2]) might have functional implications. Most cagA-positive strains carry the vacA-s1 genotypes, whereas almost all cagA-negative strains are classified as vacA s2/m2 strains with low cytokine response and host interaction, which could have clinical consequences.14–18 Host interaction and the mucosal inflammatory response to H pylori can be determined, at least in part, genetically and define the outcome of peptic ulcer and other acid-related diseases.14 Functional polymorphisms in different cytokine genes have been related to peptic ulcer disease. Interleukin 1β, encoded by IL1B, is a cytokine associated with the inflammatory response to H pylori infection and with inhibition of gastric secretion.19 Polymorphisms of IL1B affect mucosal interleukin 1β production in diverse populations, suggesting that these polymorphisms have a role in the pathogenesis of H pylori-associated gastroduodenal diseases, including peptic ulcer disease.14,20−24 Genes encoding tumour necrosis factor and lymphotoxin-α have also proved to be associated with duodenal ulcers, gastric ulcers, and antral inflammation caused by H pylori infection.25−27 A genome-wide association study and meta-analysis28 identified an association between the locus of Toll-like receptor 1 (TLR1) and H pylori seroprevalence in a white population with European ancestry. Other cytokines have also been linked to the pathogenesis of H pylori-induced diseases, but their role is unclear.14 NSAIDs and aspirin are the other major risk factors linked to peptic ulcer disease and its complications. Compared with non-users, NSAID and aspirin use increase the risk of complications of peptic ulcer disease by four times in NSAID users, and by two times in aspirin users.13,29,30 As well as NSAID and aspirin use or H pylori infection, complications are largely driven by comorbidity31 and ageing.32−34 Concomitant use of NSAIDs or aspirin with selective serotonin-reuptake inhibitors, corticosteroids, aldosterone antagonists, or anticoagulants substantially increase the risk of upper gastrointestinal bleeding.33 The role of smoking and poor socioeconomic status is unclear.34 Studies have shown a link between aspirin use and an increased risk of peptic ulcer disease in patients carrying some specific genetic polymorphisms, but the clinical relevance of these studies also remains to be determined.35−39 Many people who habitually take NSAIDs or aspirin have concurrent H pylori infection. The interaction of these two factors in peptic ulcer disease is controversial. Randomised controlled trials have shown that eradication of H pylori is beneficial in patients who start taking NSAIDs but not in those who are on long-term NSAID treatment.40 A meta-analysis13 of observational studies found that uncomplicated peptic ulcer disease was more common in H pylori-positive patients than in H pylori- negative patients (odds ratio [OR] 2·12, 95% CI 1·68−2·67). The interpretation of this meta-analysis was that both H pylori infection and the use of NSAIDs and aspirin independently increase the risk of peptic ulcer disease, and that the disease was uncommon in patients without H pylori infection who do not take NSAIDs or aspirin.13,41,42 H pylori-negative, NSAID-negative, and aspirin-negative peptic ulcer disease can be diagnosed in at least a fifth of cases.43 Life-threatening conditions could also induce the disease. For example, soon after the Great East Japan Earthquake in 2011, an unusual increase in cases of H pylori-negative haemorrhagic multiple peptic ulcer disease was recorded.44 Accommodation in a refugee shelter was a strong risk factor for peptic ulcer bleeding after a large-scale disaster.45 A Danish study46 showed that psychological stress was associated with an increased incidence, in part by influencing health risk behaviours, and had similar effects on the disease related or unrelated to either H pylori or NSAIDs. The true prevalence of idiopathic peptic ulcer disease not related to NSAIDs or H pylori infection is unknown because a molecular investigation of patients with chronic gastritis but negative for H pylori showed that almost half were false negatives.47 Pathophysiology How H pylori induces the development of different types of lesions in the gastroduodenal mucosa is not completely understood. Inflammation associated with H pylori infection can result in either hypochlorhydria or hyperchlorhydria,48 and thus determine the type of peptic ulcer formed. These effects can be mediated by cytokines",6142,907,1535.5,"[ 0.01518853 -0.08381698 -1.1727564  ... -0.09847364 -0.3521191
 -1.7182662 ]"
169,"Seminar www.thelancet.com  Vol 390  August 5, 2017	 615 that inhibit parietal cell secretion,49 or directly by H pylori products on the H+/K+ ATPase α-subunit, activation of calcitonin-gene related peptide (CGRP) sensory neurons linked to somatostatin, or inhibition of gastrin.50 Pangastritis is associated with hyposecretion and linked to the formation of gastric ulcers. However, 10–15% of patients with H pylori infection have antral predominant gastritis associated with duodenal ulcers and increased gastric secretion derived from hyper­gastrinaemia and reduced antral somatostatin content.51 Inhibition of somatostatin and the subsequent stimulation of gastrin increases histamine secretion from enterochromaffin- like cells, leading to increased secretion of acid or pepsin from parietal and gastric chief cells. The importance of the interaction between somatostatin and gastrin in this process seems clear, because the number of D-cells and somatostatin levels are reduced, whereas G:D cell ratios and gastrin:somatostatin ratios are increased, in the antral tissue of patients with duodenal ulcers. Conversely, eradication of H pylori is followed by an increase in somatostatin mRNA expression and a concomitant decrease in gastrin mRNA expression in patients with duodenal ulcers.52 Gastric hypersecretion in antral-predominant gastritis and inadequate feedback inhibition might be associated with an acidic environment and the development of gastric metaplasia in the duodenal bulb, which might be colonised by and favour ulcer formation in the bulb15 (appendix p 10). NSAIDs damage the gastroduodenal mucosa through both systemic and local mechanisms, but the systemic inhibition of constitutively expressed cyclooxygenase 1 (COX-1)-derived prostaglandins is regarded as the main mechanism. Reduced mucosal prostaglandin values are associated with low mucus and bicarbonate secretion, inhibition of cell proliferation, and decreased mucosal blood flow, which are essential to maintenance of mucosal integrity. The COX hypothesis is supported by studies showing that coadministration of exogenous prostaglandins reduces mucosal damage.53 COX-2-selective NSAIDs, which spare COX-1, reduce the risk of ulcers.54 However, this hypothesis does not fully explain the spectrum of mucosal damage. People taking NSAIDs could have a profound decrease in mucosal prostaglandins without necessarily developing gastric lesions.55−58 NSAIDs have different physicochemical properties and a wide range of pKa values, which account for some differences in their toxicity and extent of topical damage.55 NSAIDs initiate mucosal damage in the cell through disruption of mucus phospholipids or the cell membrane and by uncoupling of mitochondrial oxidative phosphorylation. The loss of mucosal integrity is followed by tissue reaction amplified by luminal content such as acid, pepsin, food, bile, and H pylori.57−59 Therefore, COX- derived prostaglandin inhibition, vascular damage, and topical effects are the main players in the pathogenesis of ulcers caused by NSAIDs (appendix p 11). Low-dose aspirin can also induce mucosal damage in patients through both topical and systemic mechanisms, although direct evidence of the systemic effect is weak.60,61 Once the damage has been induced, prostaglandins derived from both constitutively expressed COX-1 and inducible COX-2 enzymes seem to have a central role in mucosal repair, since non-selective and COX-2-selective NSAIDs have been shown to delay healing of peptic ulcers.57,62 The pathogenic mechanisms behind the development of idiopathic peptic ulcers are largely unknown. An imbalance between mucosal defensive mechanisms and aggressive factors, including a gastric acid hypersecretory status, is believed to exist. However, most gastric secretion studies were done in the pre-H pylori era, and we now know that most of the alterations were secondary to the effect of H pylori infection. Other possible pathogenetic factors include ischaemia, drugs, metabolic disturbances, viruses, histamine, radiotherapy, basophilia, and eosinophilic infiltration.63 Clinical presentation and diagnosis Symptoms of peptic ulcer disease have limited predictive value because they are non-specific. Patients with duodenal ulcers typically feel hungry or have nocturnal abdominal pain. By contrast, patients with gastric ulcers have postprandial abdominal pain, nausea, vomiting, and weight loss. Patients with untreated peptic ulcer disease typically have relapsing symptoms because of spontaneous healing and relapse while the causal factor (eg, H pylori infection or NSAID use) persists. Elderly patients with peptic ulcer disease are frequently asymptomatic or have only mild symptoms. Bleeding, perforation, or gastric outlet obstruction are the main complications of peptic ulcer disease. Bleeding, which manifests as melena or haematemesis, can occur without any warning symptoms in almost half of patients.64 Hospital admissions for peptic ulcer bleeding have declined steadily worldwide, but the case fatality rate remains stable at 5−10%.8,9 Perforation typically presents with sudden onset of intense pain in the upper abdomen. Dependent on age and comorbidity, mortality can be as high as 20%. Endoscopy is the gold standard for diagnosis of peptic ulcer disease. Apart from exclusion of malignant disease, detection of H pylori infection with histology or rapid urease tests is essential to the subsequent treatment plan. Since H pylori is the cause of most types of peptic ulcer disease, a test-and-treat strategy with a non-invasive test (eg, urea breath and stool antigen tests) to exclude infection has been advocated in patients younger than 50−55 years (dependent on geographical areas) who present with non-investigated dyspepsia and no alarming symptoms in geographical regions where gastric cancer is uncommon and the prevalence of H pylori infection is greater than 20%.65 In older patients, upper gastrointestinal endoscopy is the recommended test to exclude or confirm the disease.",6042,855,1510.5,"[ 0.09463936 -0.5624143  -1.1065474  ...  0.60852045 -0.11748268
 -1.3722359 ]"
170,"Seminar 616	 www.thelancet.com  Vol 390  August 5, 2017 Management Prevention of ulcer recurrence is the most important long-term goal to reduce morbidity and mortality. The appendix (p 12) provides an overview of the management of peptic ulcer disease. Mounting evidence suggests that eradication of H pylori infection alone is sufficient to heal associated peptic ulcers and to prevent relapse and recurrent bleeding in the absence of maintenance acid suppressive therapy. However, successful treatment of H pylori infection is a global challenge because of the growing prevalence of antibiotic resistance. The standard first-line therapies used to be regimens, consisting of a proton-pump inhibitor (PPI) and two antibiotics, such as clarithromycin plus amoxicillin or metronidazole given for 7−14 days (termed PPI-based triple therapy).35,66−68 With increasing prevalence of antibiotic resistance, however, the effectiveness of H pylori eradication with this regimen has fallen from more than 90% two decades ago to less than 70% now in many countries.67,68 Ideally, treatment should be based on antimicrobial susceptibility tests. Since these tests are not widely available, the choice of first-line therapies should be based on local prevalence of antibiotic resistance.67−69 If susceptibility testing is not feasible, PPI-based triple therapy regimens containing clarithromycin should be abandoned in areas where the local clarithromycin resistance rate is more than 15%.67−69 In areas with low resistance to clarithromycin or when individual susceptibility to clarithromycin has been confirmed, PPI-clarithromycin-amoxicillin or PPI- clarithromycin-metronidazole regimens can be used. The rate of eradication can be increased with the use of high- dose PPI (twice the conventional dose) and by extending the duration of triple therapy from 7 days to a maximum of 14 days.40,68−73 The recommended standard first-line therapy is either a bismuth-containing quadruple therapy for 14 days (PPI, a bismuth salt, tetracycline, and metronidazole) or a non-bismuth-based quadruple concomitant therapy (PPI, clarithromycin, amoxicillin, and metronidazole) for 14 days; both regimens have an eradication rate of more than 90% (table 1).67,68,70,74,75 Sequential therapy is another form of quadruple therapy, which consists of a 5-day dual therapy with a PPI and amoxicillin followed by a 5-day triple therapy with a PPI, clarithromycin, and tinidazole or metronidazole. Overall, the eradication rate of sequential therapy is better than that of 7-day and 10-day triple therapy regimens but not better than the eradication rate of 14-day triple therapy, bismuth-based therapy, and non-bismuth-based concomitant therapy,76,77 and this treatment is not recommended (figure 1).40,67,68 Hybrid quadruple therapies combine 10−14 days of dual therapy with PPI and amoxicillin with 7 days of treatment with clarithromycin and metronidazole. Hybrid quadruple therapy has shown similar effectiveness to quadruple concomitant or sequential quadruple therapy, and is more effective in non-Italian populations than in other populations studied.78,79 In a Japanese cohort,80 vonoprazan, a potent, novel, potassium-competitive acid blocker, combined with amoxicillin and clarithromycin or metronidazole as a first-line or second-line treatment, achieved an eradication rate of more than 90% in patients with a history of peptic ulcer disease. For rescue therapy, levofloxacin-containing triple therapy (PPI, levofloxacin, and amoxicillin) achieves eradication rates of 74–81% as a second-line therapy in areas with low (<10%) quinolone resistance.40,67,68,81 However, a rapid increase in primary quinolone resistance to H pylori reduces the effectiveness of levofloxacin- containing therapy.81–83 A bismuth-containing quadruple therapy is an effective second-line therapy after failure of standard triple therapies, with eradication rates of 77–93%. This regimen is recommended after failure of other non- bismuth-containing quadruple therapies.67,68 The addition of bismuth to a levofloxacin-containing triple regimen means that a triple-therapy regimen becomes a quadruple- therapy regimen.68,84 All these strategies are now recommended to be used for 14 days.67,68 Susceptibility testing is strongly recommended after one treatment is unsuccessful (if an endoscopy is done and a non-bismuth- based therapy is considered) or after two consecutive treatment failures.68 When culture of H pylori is not available, or when at least three recommended options have been unsuccessful, rifabutin-based triple therapy Drug combinations Regimen Recommended duration Triple therapy PPI plus amoxicillin* plus clarithromycin Double dose† of PPI every 12 h 1000 mg amoxicillin every 12 h 500 mg clarithromycin every 12 h 14 days Quadruple non-bismuth-based concomitant therapy PPI plus amoxicillin plus clarithromycin plus metronidazole Standard dose of PPI every 12 h 1000 mg amoxicillin every 12 h 500 mg clarithromycin every 12 h 500 mg metronidazole every 12 h 14 days Bismuth-based quadruple therapy PPI plus bismuth subcitrate plus tetracycline plus metronidazole Standard dose of PPI every 12 h 120 mg bismuth subcitrate every 6 h 500 mg tetracycline every 6 h 500 mg metronidazole every 8 h 14 days Fluoroquinolone-based triple therapy‡ PPI plus amoxicillin plus levofloxacin with or without bismuth Standard dose of PPI every 12 h 1000 mg amoxicillin every 12 h 500 mg levofloxacin every 24 h 240 mg bismuth every 12 h 14 days Rifabutin-based triple therapy§ PPI plus amoxicillin plus rifabutin Standard dose of PPI every 12 h 1000 mg amoxicillin every 12 h 150 mg rifabutin every 12 h 10 days Other regimens used in the treatment of Helicobacter pylori combine different antibiotics with similar results (eg, triple therapy could combine a proton pump inhibitor [PPI] plus amoxicillin plus metronidazole or PPI plus metronidazole plus clarithromycin). Sequential quadruple therapy consists of a 5-day dual therapy with a PPI and amoxicillin followed by a 5-day triple therapy with a PPI plus clarithromycin plus tinidazole or metronidazole. Hybrid quadruple therapies combine 10–14 days of dual therapy with PPI and amoxicillin with 7 days of treatment with clarithromycin and metronidazole at the end (or start, for reverse therapy). *Use metronidazole if patients have penicillin allergy.†Double doses: omeprazole 40 mg, lansoprazole 60 mg, rabeprazole 40 mg, esomeprazole 40 mg. ‡Used as rescue regimen; bismuth-based therapy can be added to these drugs (for fluoroquinolone-based quadruple therapy). §To be used when at least three recommended options have failed and if H pylori susceptibility testing is not available. Table 1: Most frequent regimens recommended for treatment of Helicobacter pylori infection in peptic ulcer disease67,68",6827,985,1706.75,"[-0.19051972 -0.3528894  -1.2833041  ...  0.5147819   0.42170227
 -1.3965906 ]"
171,"Seminar www.thelancet.com  Vol 390  August 5, 2017	 617 (PPI, rifabutin, and amoxicillin) for 10 days is an effective rescue option, with eradication rates of 66–70%.85,86 In patients with penicillin allergy, a bismuth-based quadruple therapy is recommended as first-line treatment, and a fluoroquinolone-based regimen can be used as a rescue option. In areas of low (<15%) clarithromycin resistance, a PPI-clarithromycin-metronidazole combination could be prescribed as a first-line treatment (figure 1; table 1).67,68 There is growing interest in the use of probiotics as an adjuvant therapy to increase H pylori eradication rates and reduce antibiotic-related adverse events, although further studies are needed.67,68 A randomised phase 3 trial87 of an oral recombinant H pylori vaccine recruited more than 4400 children in China who had no current or past H pylori infection. The investigators reported a vaccine efficacy of 71·8% in 3 years.87 NSAIDs and aspirin are the most important cause of peptic ulcer disease in high-income countries where the prevalence of H pylori is declining.1 Since H pylori-associated ulcers cannot be differentiated from NSAID-associated ulcers, testing and treating of H pylori is recommended. More than 85% of NSAID-associated or aspirin-associated ulcers heal with 6−8 weeks of PPI therapy, provided that NSAIDs or aspirin are discontinued. Ulcer healing can be achieved, but it is delayed if patients continue to use NSAIDs. Co-therapy with an antisecretory agent is a recommended preventive strategy for patients at risk of NSAID-associated or aspirin-associated peptic ulcer disease. In a randomised placebo-controlled trial,88 a histamine H₂ receptor antagonist was effective in prevention of ulcers in average-risk aspirin users. Whether PPI is better than an H₂ receptor antagonist for aspirin users has yielded conflicting results. One randomised trial89 found that famotidine was inferior to pantoprazole for prevention of upper gastrointestinal bleeding or severe dyspepsia. By contrast, a multicentre randomised trial90 found that, among high-risk aspirin users, rates of recurrent bleeding were similar between the groups receiving PPI and standard-dose H₂ receptor antagonist. PPIs are clearly effective for the prevention of ulcer bleeding with aspirin. However, famotidine might be a reasonable alternative for patients who do not comply with or want to be on PPIs in the long term. The role of H pylori infection in aspirin users with ulcer bleeding deserves further investigation. In a 7-year prospective cohort study91 of aspirin users presenting with ulcer bleeding, one cohort of H pylori-positive patients resumed aspirin without gastroprotective therapy after eradication of H pylori was confirmed. The cumulative incidence of recurrent ulcer bleeding in these patients did not differ substantially from that of average- risk aspirin users with no history of ulcers.91 This finding suggests that eradication of H pylori is associated with a low risk of recurrent ulcer bleeding with aspirin use even in the absence of gastroprotective therapy. Among NSAID users, many strategies are available for the prevention of gastroduodenal ulcers and their Peptic ulcer associated with Helicobacter pylori infection First-line therapies Rescue therapies Penicillin allergy?Yes No Bismuth plus PPI plus tetracycline plus metronidazole (14 days) PPI plus clarithromycin plus levoﬂoxacin with or without bismuth (14 days) Bismuth plus PPI plus tetracycline plus metronidazole (14 days) Culture susceptibility testing If not available: rifabutin plus PPI plus amoxicillin for 10 days, after failure of three recommended options PPI plus amoxicillin plus levoﬂoxacin with or without bismuth (14 days) PPI plus amoxicillin plus clarithromycin plus metronidazole (14 days) Double-dose PPI plus metronidazole plus clarithromycin (14 days) Double-dose PPI plus amoxicillin plus clarithromycin (14 days) If clarithromycin resistance <15% If clarithromycin resistance <15% Bismuth plus PPI plus tetracycline plus metronidazole (14 days)* PPI plus amoxicillin plus clarithromycin plus metronidazole (14 days) Figure 1: Algorithm for management of Helicobacter pylori in peptic ulcer disease PPI=proton pump inhibitor. *Preferred option in areas with high resistance to clarithromycin and metronidazole.",4340,625,1085.0,"[-0.23224688 -0.09078896 -1.3962368  ...  0.4768207   0.27483153
 -1.7229855 ]"
172,"Seminar 618	 www.thelancet.com  Vol 390  August 5, 2017 complications. These strategies include co-therapy of NSAIDs with a PPI, H₂ receptor antagonist, or misoprostol; substitution of non-selective NSAIDs with COX-2-selective NSAIDs; or combination of a COX-2-selective NSAID with a gastroprotective agent.92−94 PPIs are the most popular prophylactic agents. A systematic review and meta-analysis95 consisting of more than 125 000 participants found that combination of COX-2-selective NSAIDs and a PPI offers the best protection against peptic ulcer complications. This combination was followed in effectiveness by COX-2- selective NSAIDs alone, non-selective NSAIDs plus a PPI, and non-selective NSAIDs plus misoprostol.95 Unlike low- dose aspirin, no evidence exists that H₂ receptor antagonists can prevent ulcer bleeding associated with NSAIDs. Another meta-analysis96 found that standard doses of H₂ receptor antagonists cannot reduce the risk of gastric ulcers. Although misoprostol effectively prevents peptic ulcer complications with NSAIDs, gastrointestinal upset and abortifacient actions limit the use of misoprostol for gastric protection. The gastroprotective effect of PPIs seems a class effect97 and is not dose-dependent. Patients taking NSAIDs often use aspirin, non-aspirin antiplatelet drugs, anticoagulants, and corticosteroids. Although concomitant aspirin use reduces the gastrointestinal-sparing effect of COX-2 inhibitors,92,96 indirect evidence suggests that patients taking COX-2 inhibitors and aspirin might have fewer peptic ulcer complications than do those taking non-selective NSAIDs and aspirin. In a meta-analysis96 of 17 276 patients, the risk of clinically significant outcomes was lower in the group receiving aspirin plus a COX-2- selective NSAID than in the group receiving aspirin plus a non-selective NSAID (relative risk 0·72, 95% CI 0·62–0·95). A similar conclusion has been reached in another meta-analysis.98 These data, however, were derived from a post-hoc analysis.96,98 Table 2 summarises the management of peptic ulcer disease prevention with NSAIDs, which requires assessment of both gastrointestinal and cardiovascular risk factors, since NSAIDs might also increase the risk of major cardiovascular events.54,92−94 Notably, NSAIDs and aspirin can cause lower gastrointestinal bleeding and acid suppression cannot prevent mucosal damage beyond the duodenum. Two large- scale randomised trials99,100 that used a combined endpoint of upper and lower gastrointestinal events showed that celecoxib was more effective than a non-selective NSAID plus a PPI. The advantage of celecoxib over non-selective NSAIDs plus a PPI is attributable to a substantial reduction in anaemia secondary to presumed small bowel bleeding. However, different non-selective NSAIDs vary in their tendency to cause lower gastrointestinal bleeding, and data suggest that PPIs could aggravate NSAID-induced small bowel injury through dysbiosis.101 Whether the superiority of celecoxib in the lower gastrointestinal tract recorded in these two large-scale trials can be extrapolated to other non- selective NSAIDs remains unclear. Most cases of peptic ulcer disease heal after 6−8 weeks of PPI therapy. If ulcers fail to heal, drug compliance should be checked. Blood tests and a carefully taken patient history can often reveal continuous or surreptitious use of NSAIDs, which is often overlooked in patients with refractory ulcers.102 Doubling of PPI dose for another 6–8 weeks is often recommended, although no reliable evidence proves that this strategy is better than standard-dose PPI in this setting. Serological tests could be useful to detect false- negative H pylori infection. After exclusion of surreptitious use of NSAIDs or aspirin, or false-negative H pylori status, unusual causes of peptic ulcer should be explored, examples of which include malignancies, infections (eg, cytomegalovirus), Crohn’s disease, vasculitis, upper abdominal radiotherapy, crack cocaine use, and Zollinger- Ellison syndrome, which is associated with high acid secretion and often causes the development of multiple ulcers extending to the distal duodenum. With the declining prevalence of H pylori infection, patients with idiopathic ulcers are increasingly being recognised, and these patients could be at increased risk of recurrence, bleeding complications, and death.103,104 Although long-term PPI therapy is often recommended, no evidence is available that this approach will improve clinical outcomes.105 Management of peptic ulcer bleeding Bleeding peptic ulcers account for 40−60% of all causes of acute upper gastrointestinal bleeding.8 Timely endoscopic treatment and acid suppressive therapy are key for successful outcomes. Although surgery is the cornerstone for management of patients with uncontrolled or massive recurrent bleeding, radiological intervention has also gained importance in recent years. Patients presenting with upper gastrointestinal bleeding should be assessed promptly and resuscitation should begin with crystalloid solutions. Transfusion policy should be restrictive and aimed to maintain haemoglobin concentrations over 70 g/L, as this approach Low gastrointestinal risk* High gastrointestinal risk† Low cardiovascular risk Non-selective NSAIDs Non-selective NSAIDs plus PPI; celecoxib plus PPI‡; eradicate Helicobacter pylori§ High cardiovascular risk¶ Naproxen; add PPI if patient is taking aspirin No NSAIDs; naproxen plus PPI; low-dose celecoxib plus aspirin plus PPI might be an alternative option Prevention of peptic ulcer disease and associated complications in patients on non-steroidal anti-inflammatory drug (NSAID) treatment requires assessment of the presence of both gastrointestinal and cardiovascular risk factors.92–94 PPI=proton pump inhibitor. *No risk factors.†Presence of risk factors (patients aged 60 years or older, with a history of ulcers, or patients on concomitant medication with antiplatelet agents, anticoagulants, corticosteroids, or selective serotonin reuptake inhibitors).‡Especially indicated in patients with a complicated ulcer history or the presence of several risk factors. §In patients with a history of ulcers, adopt a test-and-treat strategy with the use of non-invasive tests (urea breath and stool antigen tests) to exclude H pylori infection, although invasive tests with endoscopy are also possible.¶Use risk charts (eg, Framingham risk scores or the European SCORE system) to estimate cardiovascular risk on the basis of several variables. Patients with a history of cardiovascular events or diabetes are considered at high cardiovascular risk. In most cases, aspirin co-therapy might be indicated. Cyclooxygenase 2 (COX-2)-selctive NSAIDs are contraindicated by the European Medicines Agency (EMA) in patients with a history of cardiovascular events. Table 2: Management of peptic ulcer disease prevention in patients on NSAIDs",6927,956,1731.75,"[ 0.2538909  -0.33709443 -1.1202674  ...  0.31082112  0.5705398
 -1.5397613 ]"
173,"Seminar www.thelancet.com  Vol 390  August 5, 2017	 619 has been associated with reduced mortality.106 Risk stratification should identify high-risk patients for early intervention and reduce the duration of hospital stay for low-risk patients. The Rockall and Glasgow-Blatchford scores have been extensively studied. A Glasgow- Blatchford score of zero accurately identifies patients not requiring treatment in hospital.107 Maintenance of a neutral gastric pH seems essential to prevent platelet disaggregation and clot lysis over the eroded artery of a bleeding peptic ulcer. Peak acid suppression after intravenous administration of a PPI occurs within hours, compared with several days later after oral administration. The intravenous route of administration offers a faster onset of gastric suppression, achievement of intragastric pH closer to neutrality, and better bioavailability than the oral route.108 A meta-analysis109 of randomised controlled trials showed that pre-emptive intravenous high-dose PPIs led to a decreased proportion of patients with high-risk endoscopic stigmata and reduced the need for endoscopic haemostatic treatment, but intravenous administration of PPIs should not substitute or delay early endoscopy for high-risk patients. Tranexamic acid and antifibrinolytic agents do not seem to be effective in this setting.110 Prokinetic agents, such as intravenous erythromycin and metoclopramide, given before endoscopy have improved endoscopic view and reduce the need for a second look endoscopy111 (panel). Early endoscopy done within 24 h provides prognostic information based on endoscopic stigmata and effective therapy. In a meta-analysis112 of randomised controlled trials, endoscopic treatment was shown to reduce rebleeding, surgery, and mortality. Endoscopy also identifies low-risk patients suitable for early hospital discharge. Endoscopic treatment is indicated in ulcers showing active bleeding, a non-bleeding visible vessel, or an adherent clot. Two meta-analyses113,114 of randomised controlled trials have shown that addition of a second modality to epinephrine injection is better than epinephrine injection alone in reducing recurrent bleeding, surgery, and mortality. Acid suppression has a crucial role in prevention of recurrent bleeding after initial endoscopic haemostasis. In a systematic review of 24 trials,110 PPI therapy reduced recurrent bleeding and need for surgery. A substantial reduction in mortality was also noted in a subgroup of patients with active bleeding or non-bleeding visible vessels. The optimum dose of a PPI after endoscopy continues to be controversial. A meta-analysis115 of randomised controlled trials found that high-dose PPIs and low-dose PPIs were similarly effective in reducing the risk of recurrent ulcer bleeding. High-dose PPIs were defined as a dose equivalent to an 80 mg bolus of omeprazole or pantoprazole, followed by continuous intravenous infusion of the drug at 8 mg/h for 72 h. Continuous-infusion doses exceeding 192 mg per day were also considered high-dose PPIs. Other doses were considered low-dose PPIs. However, this meta-analysis included trials with suboptimum design, such as ulcers with low-risk endoscopic stigmata. Another meta- analysis,116 which was largely based on trials done in Asia, found that intermittent high-dose PPI therapy was not less effective than continuous infusion of a PPI in patients with Panel: Strategies for management of bleeding peptic ulcers Before endoscopy Risk stratiﬁcation Glasgow-Blatchford scores are superior to Rockall scores in prediction of endoscopic treatment and surgery. A Glasgow-Blatchford score of zero reliably predicts early discharge without intervention. Restrictive blood transfusion strategy Blood transfusion when haemoglobin values are below 70 g/L leads to less rebleeding and better survival than does liberal transfusion. Correction of anticoagulation with a target INR of about 1·5 The optimum INR remains undefined, and recommendations are based on expert opinion only. Use of prokinetic drugs Prokinetic drugs lead to improved endoscopic view, and reduce the need for second look endoscopy. Pre-emptive PPIs Pre-emptive PPIs reduce the presence of high-risk stigmata at endoscopy, and reduce the need for endoscopic therapy. Endoscopic treatment Addition of a second modality to epinephrine injection reduces recurrent bleeding and need for surgery. Endoscopy within 24 h There is no clear evidence that immediate endoscopy offers advantages over endoscopy done within 24 h. Combination therapy PPIs reduce rebleeding and the need for surgery. After endoscopy Mantain or initiate (if not started before endoscopy) PPI therapy. Adjuvant PPI therapy Treatment with high-dose parenteral PPI indicated if high-risk peptic ulcer stigmata present. Oral PPI given if patients had no high-risk peptic ulcer stigmata. High-dose PPI infusion for 72 h Intermittent high-dose PPI therapy seems similar to continuous high-dose PPI infusion. Recurrent bleeding Further endoscopic treatment versus early surgery One randomised controlled trial showed a higher rate of complications in the group that underwent surgery than in the group that received repeat endoscopy. High mortality was recorded in both groups. Shock and an ulcer size with a diameter greater than 2 cm was predictive of endoscopic treatment failure. Angiographic embolisation Retrospective studies suggested a higher rebleeding rate in the angiography group than in the surgery group, but no difference in mortality. INR=international normalised ratio. PPI=proton pump inhibitor.",5603,795,1400.75,"[ 0.05608879 -0.615983   -1.2735759  ...  0.75977033  0.35248256
 -1.41753   ]"
174,"Seminar 620	 www.thelancet.com  Vol 390  August 5, 2017 high-risk stigmata. Unlike Asian populations, most North American and European populations carry genetic polymorphisms associated with rapid metabolism of PPIs.117 Therefore, whether intermittent high-dose PPI is as effective as continuous high-dose PPI infusion in all high- income populations remains uncertain. Continuous high- dose PPI infusion is still the preferred post-endoscopic adjuvant treatment for high-risk patients (panel). Uncontrolled or recurrent bleeding is the most important adverse prognostic factor predicting mortality. In a randomised study118 comparing endoscopic retreatment with surgery after an initial endoscopy, large ulcers and hypotension were predictive of failure to repeat endoscopic treatment. Early surgery or angiographic embolisation are potential alternative options for these high-risk patients110,118 (panel). Management of patients on antiplatelet or anti- thrombotic therapy complicated by upper gastrointestinal bleeding is difficult because the data are scanty. Decisions often need to be tailored to individual patients on the basis of the severity of bleeding and risk of thromboembolism. In aspirin users with peptic ulcers complicated by bleeding and requiring endoscopic treatment, a randomised controlled trial showed that those who continued to take aspirin had a two-times increased risk of recurrent bleeding but a ten-times reduced risk of all-cause mortality at 8 weeks compared with those who discontinued aspirin.119 Patients receiving dual antiplatelet therapy for a drug-eluting stent should avoid stopping both antiplatelet drugs even for a brief period, because of the high risk of stent thrombosis.120,121 Patients receiving warfarin complicated by severe gastrointestinal bleeding resulting from coagulopathy can be treated with vitamin K, fresh frozen plasma, prothrombin complex concentrates, or recombinant factor VIIa. Fresh frozen plasma could precipitate fluid overload. High-dose vitamin K should be avoided because it will extend the time required for re-warfarinisation, thereby increasing the risk of thromboembolism. Prothrombin complex concentrates are preferred in patients with severe bleeding. Recombinant factor VIIa should be reserved for uncontrolled life-threatening bleeding because it increases the risk of thrombosis. The use of direct oral anticoagulants (DOACs) has gained popularity. A meta-analysis122 of randomised trials showed that DOACs are more effective than warfarin in reducing thromboembolic risk. However, some DOACs have been associated with a higher risk of major gastrointestinal bleeding than warfarin.122 Unlike bleeding induced by warfarin, that induced by DOACs cannot be reversed by vitamin K. Activated charcoal given within 4 h of ingestion can be used to treat toxicity resulting from DOAC overdose. The value of prothrombin complex concentrate or recombinant factor VIIa for massive bleeding associated with DOACs remains uncertain. Haemodialysis can be used for life- threatening bleeding with dabigatran but not for other DOACs. Idarucizumab has been approved by the For more on idarucizumab see http://www.fda.gov/Drugs/ InformationOnDrugs/ ApprovedDrugs/ucm467396.htm Peptic ulcer bleeding while on antiplatelet or anticoagulant agents High-risk stigmata on endoscopy Low-risk stigmata on endoscopy Aspirin Dual antiplatelet therapy Resume by day 3 Antiplatelet agent for primary prevention Antiplatelet agent for secondary prevention Anticoagulants* Antiplatelet agent for primary prevention Antiplatelet agent for secondary prevention Anticoagulants* Endoscopy treatment successful • Withhold antiplatelet   agent • Reassess indication • Reintroduce after  ulcer healing or earlier • Keep aspirin • Consult cardiologist for   resumption of second   antiplatelet agent • Withhold antiplatelet agent • Reassess indication • Reintroduce before   hospital discharge if   indicated for prevention • Reassess indication • Resume early or do   not interrupt if   anticoagulants within   therapeutic range Resume anticoagulants once adequate haemostasis is achieved Keep aspirin or dual antiplatelet therapy Figure 2: Management of antiplatelet or anticoagulant therapy in patients who develop peptic ulcer bleeding Modified from Gralnek and colleagues,123 by permission of Thieme Medical Publishers. In patients at high risk of developing cardiovascular disease, early resumption of antiplatelet or anticoagulant therapy is recommended, because although the risk of rebleeding increases, overall mortality decreases. *Vitamin K or prothrombin complex concentrates should be considered in patients with bleeding associated with warfarin overdose.",4714,650,1178.5,"[ 0.04734208 -0.48846036 -1.4569101  ...  0.27490664  0.61242115
 -1.518165  ]"
175,"Seminar www.thelancet.com  Vol 390  August 5, 2017	 621 US Food and Drug Administration (FDA) for reversal of uncontrolled bleeding in patients receiving dabigatran. The optimum timing for resuming anticoagulant therapy is largely based on retrospective data or expert opinion.123,124 Warfarin should be resumed once adequate haemostasis has been achieved. For patients with high thromboembolic risk, such as those with a metallic mitral valve replacement, low-molecular-weight heparin should be given on the same day of resuming warfarin until a satisfactory international normalised ratio is achieved. With the rapid onset of action of DOACs and the absence of effective or approved agents for most oral anticoagulants, re-initiation of these drugs should be delayed until adequate haemostasis has been achieved. Figure 2 summarises the standard position on the optimum timing of resuming antiplatelet or anticoagulant therapy after a peptic ulcer disease bleeding event (appendix pp 1–4). Controversies and future research questions The global decline of peptic ulcer disease during the past century has occurred most rapidly in the past two decades. This decreasing trend could be related to a cohort effect that occurred before the introduction of potent anti- secretory agents and H pylori treatment.4−9 The parallel decline in the prevalence of H pylori infection resulting from improvements in socioeconomic status has had an important role. Widespread use of PPIs has probably also contributed to the rapid decline of peptic ulcer disease. However, an overuse of PPIs, which are estimated to be used inappropriately in almost 50% of cases, might have led to unexpected new side-effects that are now being gradually unravelled.10 The reduction of H pylori-associated, NSAID-associated, and aspirin-associated peptic ulcer disease has uncovered idiopathic disease. The occurrence of idiopathic ulcers seems to be increasing and is associated with high mortality.103,104 The mechanisms and optimum management of idiopathic disease will need to be defined. How H pylori infection and NSAID or aspirin interact remains controversial, and the best strategy to manage patients with both risk factors to prevent the onset of peptic ulcer disease is a contested and unresolved issue. The ongoing HEAT trial125 in the UK to investigate whether H pylori eradication will reduce the incidence of hospital admissions for ulcer bleeding in aspirin users might provide some answers. The pathogenesis of a wide range of H pylori-related gastric lesions is still not fully understood. Development of these lesions is probably led by a combination of H pylori virulent factors and the host immune response, but the specific combination of H pylori factors and the host genetic profile has not yet been clarified. Technological advances in genome-wide association studies might provide some insight by identifying genetic polymorphisms associated with peptic ulcer disease in specific populations. Why some patients are more susceptible than others to the gastric toxicity of NSAIDs and aspirin also remains unclear. Antibiotic resistance continues to be a major challenge for successful treatment of H pylori infection. New therapies are in fact old therapies with different drug combinations and longer durations of treatment. Molecular targets against essential bacterial proteins could be key to resolving antibiotic resistance.126 Complications of peptic ulcer disease, such as bleeding, remain life-threatening. Advances in endoscopic and pharmacological therapies have not substantially reduced the mortality associated with such bleeding, because comorbidities are now the major cause of death in these patients. Increasing use of anti-thrombotic agents in patients with multiple comorbidities has led to new challenges in the management of bleeding. Prospective data and randomised controlled trials are urgently needed to define the best strategy for patient care (appendix pp 1–5). Contributors AL and FKLC contributed equally in the literature search, in designing the structure of the manuscript, and in writing the manuscript. Declaration of interests AL has served as a consultant to Bayer Pharma AG and his institution has received a researcher-initiated grant on aspirin chemoprevention from Bayer Pharma AG. FKLC has served as a consultant to Pfizer, Eisai, Takeda, and Otsuka. FLKC has received an independent research grant from Pfizer and has been paid lecture fees (including for his service on speakers’ bureaus) by Pfizer, AstraZeneca, and Takeda. Acknowledgments AL’s work was partly funded by a grant (PI11/02578) from the Carlos III Health Institute. References 1	 Del Valle J. Peptic ulcer disease and related disorders. In: Kasper DL, Fauci AS, Hauser SL, Longo DL, Jameson JL, Loscalzo J, eds. Harrison’s Principles of Internal Medicine (19th edn). New York, NY: McGraw Hill Education, 2015: 1911−32.2	 Rosenstock SJ, Jørgensen T. Prevalence and incidence of peptic ulcer disease in a Danish County—a prospective cohort study. Gut 1995; 36: 819−24.3	 Kurata JH, Nogawa AN, Abbey DE, Petersen F. A prospective study of risk for peptic ulcer disease in seventh-day adventists. Gastroenterology 1992; 102: 902−09.4	 Sonnenberg A. Review article: historic changes of Helicobacter pylori-associated diseases. Aliment Pharmacol Ther 2013; 38: 329−42.5	 Sonnenberg A. Time trends of ulcer mortality in Europe. Gastroenterology 2007; 132: 2320−27.6	 Sonnenberg A. Time trends of ulcer mortality in non-European countries. Am J Gastroenterol 2007; 102: 1101−07.7	 Leow AH, Lim YY, Liew WC, Goh KL. Time trends in upper gastrointestinal diseases and Helicobacter pylori infection in a multiracial Asian population — a 20-year experience over three time periods.",5771,853,1442.75,"[ 0.13811623 -0.7765826  -1.4441988  ...  0.3941171   0.46779674
 -1.4418784 ]"
175,"Aliment Pharmacol Ther 2016; 43: 831−37.8	 Lanas A, García-Rodríguez LA, Polo-Tomás M, et al. The changing face of hospitalisation due to gastrointestinal bleeding and perforation. Aliment Pharmacol Ther 2011; 33: 585−91.9	 Malmi H, Kautiainen H, Virta LJ, Färkkilä N, Koskenpato J, Färkkilä MA. Incidence and complications of peptic ulcer disease requiring hospitalisation have markedly decreased in Finland. Aliment Pharmacol Ther 2014; 39: 496−506.10	 Lanas A. We are using too many PPIs, and we need to stop: a European perspective. Am J Gastroenterol 2016; 111: 1085–86.11	 Zhang BB, Li Y, Liu XQ, Wang PJ,Yang B, Bian DL. Association between vacA genotypes and the risk of duodenal ulcer: a meta-analysis. Mol Biol Rep 2014; 41: 7241−54.12	 Sugimoto M, Yamaoka Y. The association of vacA genotype and Helicobacter pylori-related disease in Latin American and African populations. Clin Microbiol Infect 2009; 15: 835−42.",925,138,231.25,"[ 0.05065853 -0.43098694 -0.75850475 ...  0.38785535  0.2714284
 -1.7015064 ]"
176,"Seminar 622	 www.thelancet.com  Vol 390  August 5, 2017 13	 Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002; 359: 14−22.14	 Datta D, Roychoidhury S. To be or not to be: the host genetic factor and beyond Helicobacter pylori mediated gastro-duodenal diseases. World J Gastroenterol 2015; 21: 2883−95.15	 Shiotani A, Graham DY. Pathogenesis and therapy of gastric and duodenal ulcer disease. Med Clin North Am 2002; 86: 1447−66.16	 Yamaoka Y, Graham DY. Helicobacter pylori virulence and cancer pathogenesis. Future Oncol 2014; 10: 1487−500.17	 Wang F, Meng W, Wang B, Qiao L. Helicobacter pylori-induced gastric inflammation and gastric cancer. Cancer Lett 2014; 345: 196−20.18	 Chen MY, He CY, Meng X, Yuan Y. Association of Helicobacter pylori babA2 with peptic ulcer disease and gastric cancer. World J Gastroenterol 2013; 19: 4242−51.19	 Guo T, Qian JM, Zhao YQ, Li XB, Zhang JZ. Effects of IL-1β on the proliferation and apoptosis of gastric epithelial cells and acid secretion from isolated rabbit parietal cells. Mol Med Rep 2013; 7: 299−305.20	 Furuta T, El-Omar EM, Xiao F, Shirai N, Takashima M, Sugimura H. Interleukin 1β polymorphisms increase risk of hypochlorhydria and atrophic gastritis and reduce risk of duodenal ulcer recurrence in Japan. Gastroenterology 2002; 123: 92−105.21	 El-Omar EM, Carrington M, Chow WH, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000; 404: 398−402.22	 Chakravorty M, Ghosh A, Choudhury A, Santra A, Hembrum J, Roychoudhury S. Interaction between IL1B gene promoter polymorphisms in determining susceptibility to Helicobacter pylori associated duodenal ulcer. Hum Mutat 2006; 27: 411−19.23	 García-González MA, Lanas A, Savelkoul PH, et al. Association of interleukin 1 gene family polymorphisms with duodenal ulcer disease. Clin Exp Immunol 2003; 134: 525–31.24	 Robert A, Olafsson AS, Lancaster C, Zhang WR. Interleukin-1 is cytoprotective, antisecretory, stimulates PGE2 synthesis by the stomach, and retards gastric emptying. Life Sci 1991; 48: 123−34.25	 Zhang BB, Liu XZ, Sun J, Yin YW, Sun QQ. Association between TNF α gene polymorphisms and the risk of duodenal ulcer: a meta-analysis. PLoS One 2013; 8: e57167.26	 Trejo-de la OA, Torres J, Sánchez-Zauco N, et al. Polymorphisms in TLR9 but not in TLR5 increase the risk for duodenal ulcer and alter cytokine expression in the gastric mucosa. Innate Immun 2015; 21: 706−13.27	 Lanas A, García-González MA, Santolaria S, et al. TNF and LTA gene polymorphisms reveal different risk in gastric and duodenal ulcer patients. Genes Immun 2001; 2: 415−21.28	 Mayerle J, den Hoed CM, Schurmann C, et al. Identification of genetic loci associated with Helicobacter pylori serologic status. JAMA 2013; 309: 1912−20.",2873,433,718.25,"[ 4.9550936e-02 -3.8630590e-01 -9.5022202e-01 ...  1.3905596e-03
 -1.6453637e-01 -1.6461076e+00]"
176,"29	 Lanas A, García-Rodríguez LA, Arroyo MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006; 55: 1731−38.30	 Lanas Á, Carrera-Lasfuentes P, Arguedas Y, et al. Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants. Clin Gastroenterol Hepatol 2015; 13: 906−12.31	 Crooks CJ, West J, Card TR. Comorbidities affect risk of nonvariceal upper gastrointestinal bleeding. Gastroenterology 2013; 144: 1384−93.32	 Chan FK, Goto S, Wu MS, et al. Burden of nonsteroidal anti- inflammatory and antiplatelet drug use in Asia: a multidisciplinary working party report. Clin Gastroenterol Hepatol 2012; 10: 753−60.33	 Masclee GM, Valkhoff VE, Coloma PM, et al. Risk of upper gastrointestinal bleeding from different drug combinations. Gastroenterology 2014; 147: 784−92.34	 González-Pérez A, Sáez ME, Johansson S, Nagy P, García Rodríguez LA. Risk factors associated with uncomplicated peptic ulcer and changes in medication use after diagnosis. PLoS One 2014; 9: e101768.35	 Tanikawa C, Urabe Y, Matsuo K, et al. A genome-wide association study identifies two susceptibility loci for duodenal ulcer in the Japanese population. Nat Genet 2012; 44: 430−34.36	 García-González MA, Bujanda L, Quintero E, et al. Association of PSCA rs2294008 gene variants with poor prognosis and increased susceptibility to gastric cancer and decreased risk of duodenal ulcer disease. Int J Cancer 2015; 137: 1362−73.37	 Shiotani A, Murao T, Fujita Y, et al. Single nucleotide polymorphism markers for low-dose aspirin-associated peptic ulcer and ulcer bleeding. J Gastroenterol Hepatol 2014; 29 (suppl 4): 47−52.38	 Wang PY, Chen HP, Chen A, et al. Impact of blood type, functional polymorphism (T-1676C) of the COX-1 gene promoter and clinical factors on the development of peptic ulcer during cardiovascular prophylaxis with low-dose aspirin. Biomed Res Int 2014; 2014: 616018.39	 Shiotani A, Fujita Y, Nishio K. Low-dose aspirin-associated upper and mid gastrointestinal tract damage and gene polymorphism. Curr Pharm Des 2015; 21: 5066−72.40	 Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report. Gut 2012; 61: 646−64.41	 Sostres C, Carrera-Lasfuentes P, Benito R, et al. Peptic ulcer bleeding risk. The role of Helicobacter pylori infection in NSAID/low-dose aspirin users. Am J Gastroenterol 2015; 110: 684−89.42	 Gisbert JP, Calvet X. Review article: Helicobacter pylori-negative duodenal ulcer disease. Aliment Pharmacol Ther 2009; 30: 791−815.43	 Charpignon C, Lesgourgues B, Pariente A, et al. Peptic ulcer disease: one in five is related to neither Helicobacter pylori nor aspirin/NSAID intake.",2907,407,726.75,"[ 0.12624134 -0.57404983 -1.1524183  ...  0.04780113  0.64982164
 -1.5882046 ]"
176,"Aliment Pharmacol Ther 2013; 38: 946−54.44	 Yamanaka K, Miyatani H, Yoshida Y, et al. Hemorrhagic gastric and duodenal ulcers after the Great East Japan earthquake disaster. World J Gastroenterol 2013; 19: 7426−32.45	 Kanno T, Iijima K, Koike T, et al. Accommodation in a refugee shelter as a risk factor for peptic ulcer bleeding after the Great East Japan Earthquake: a case-control study of 329 patients. J Gastroenterol 2015; 50: 31−40.46	 Levenstein S, Rosenstock S, Jacobsen RK, Jorgensen T. Psychological stress increases risk for peptic ulcer, regardless of Helicobacter pylori infection or use of nonsteroidal anti-inflammatory drugs. Clin Gastroenterol Hepatol 2015; 13: 498−506.47	 Kiss S, Zsikla V, Frank A, Willi N, Cathomas G. Helicobacter-negative gastritis: polymerase chain reaction for Helicobacter DNA is a valuable tool to elucidate the diagnosis. Aliment Pharmacol Ther 2016; 43: 924–32.48	 Meyer-Rosberg K, Scott DR, Rex D, Melchers K, Sachs G. The effect of environmental pH on the proton motive force of Helicobacter pylori. Gastroenterology 1996; 111: 886−900.49	 Beales IL, Calam J. Inhibition of carbachol stimulated acid secretion by interleukin 1β in rabbit parietal cells requires protein kinase C. Gut 2001; 48: 782−89.50	 Zaki M, Coudron PE, McCuen RW, Harrington L, Chu S, Schubert ML. H. pylori acutely inhibits gastric secretion by activating CGRP sensory neurons coupled to stimulation of somatostatin and inhibition of histamine secretion. Am J Physiol Gastrointest Liver Physiol 2013; 304: G715−22.51	 El-Omar EM, Oien K, El-Nujumi A, et al. Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology 1997; 113: 15−24.52	 Moss SF, Legon S, Bishop AE, Polak JM, Calam J. Effect of Helicobacter pylori on gastric somatostatin in duodenal ulcer disease. Lancet 1992; 340: 930−32.53	 Silverstein FE, Graham GY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatoy drugs. Ann Int Med 1995; 123: 241−49.54	 Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013; 382: 769−79.55	 Bjarnason I, Scarpignato C, Takeuchi K, Rainsford KD. Determinants of the short-term gastric damage caused by NSAIDs in man. Aliment Pharmacol Ther 2007; 26: 95−106.56	 Ligumski M, Golanska EM, Hansen DG, Kauffman GL. Aspirin can inhibit gastric mucosal cyclo-oxigenase without causing lesions in the rat. Gastroenterology 1983; 84: 756−61.",2630,377,657.5,"[-0.42908412  0.06416345 -1.2046278  ...  0.7903257  -0.19531389
 -1.2044877 ]"
177,"Seminar www.thelancet.com  Vol 390  August 5, 2017	 623 57	 Wallace JL. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology 1997; 112: 1000−16.58	 Lanas A, Panés J, Piqué JM. Clinical implications of COX-1 and/or COX-2 inhibition for the distal gastrointestinal tract. Curr Pharm Des 2003; 9: 2253−66.59	 Sigthorsson G, Tibble J, Hayllar J, et al. Intestinal permeability and inflammation in patients on NSAIDs. Gut 1998; 43: 506−51.60	 Cryer B, Feldman M. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology 1999; 117: 17−25.61	 Sostres C, Lanas A. Gastrointestinal effects of aspirin. Nat Rev Gastroenterol Hepatol 2011; 8: 385−94.62	 Perini RF, Ma L, Wallace JL. Mucosal repair and COX-2 inhibition. Curr Pharm Des 2003; 9: 2207−11.63	 McColl KE. Helicobacter pylori-negative nonsteroidal anti-inflammatory drug-negative ulcer. Gastroenterol Clin North Am 2009; 38: 353−61.64	 Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol Suppl 1999; 56: 18−24.65	 Agréus L, Talley NJ, Jones M. Value of the “Test & Treat” strategy for uninvestigated dyspepsia at low prevalence rates of Helicobacter pylori in the population. Helicobacter 2016; 23: 186–91.66	 Fock KM, Katelaris P, Sugano K, et al. Second Asia-Pacific consensus guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 2009; 24: 1587−600.67	 Fallone CA, Chiba N, van Zanten SV, et al. The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology 2016; 151: 51−69.68	 Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report. Gut 2017; 66: 6–30.69	 Graham DY, Laine L. The Toronto Helicobacter pylori consensus in context. Gastroenterology 2016; 151: 9−12c.70	 Dore MP, Lu H, Graham DY. Role of bismuth in improving Helicobacter pylori eradication with triple therapy. Gut 2016; 65: 870−78.71	 Molina-Infante J, Romano M, Fernandez-Bermejo M, et al. Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance. Gastroenterology 2013; 145: 121−28.72	 Yuan Y, Ford AC, Khan KJ, et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev 2013; 12: CD008337.",2497,349,624.25,"[-0.00697978 -0.15769021 -1.1293423  ... -0.10998355  0.7454099
 -1.5001308 ]"
177,"73	 Villoria A, Garcia P, Calvet X, Gisbert JP, Vergara M. Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2008; 28: 868−77.74	 Sun Q, Liang X, Zheng Q, et al. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication. Helicobacter 2010; 15: 233−38.75	 Gisbert JP, Calvet X. Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. Aliment Pharmacol Ther 2011; 34: 604−17.76	 Gatta L, Vakil N, Vaira D, Scarpignato C. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ 2013; 347: f4587.77	 Nyssen OP, McNicholl AG, Megraud F, et al. Sequential versus standard triple first-line therapy for Helicobacter pylori eradication. Cochrane Database Syst Rev 2016; 6: CD009034.78	 Hsu PI, Lin PC, Graham DY. Hybrid therapy for Helicobacter pylori infection: a systemic review and meta-analysis. World J Gastroenterol 2015; 21: 12954−62.79	 Hsu PI, Kao SS, Wu DC, et al. A randomized controlled study comparing reverse hybrid therapy and standard triple therapy for Helicobacter pylori infection. Medicine 2015; 94: e2104.80	 Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut 2016; 65: 1439–46.81	 Chen PY, Wu MS, Chen CY, et al. Systematic review with meta-analysis: the efficacy of levofloxacin triple therapy as the first- or second-line treatments of Helicobacter pylori infection. Aliment Pharmacol Ther 2016; 44: 427−37.82	 Trespalacios-Rangél AA, Otero W, Arévalo-Galvis A, Poutou-Piñales RA, Rimbara E, Graham DY. Surveillance of levofloxacin resistance in Helicobacter pylori isolates in Bogotá-Colombia (2009−2014). PLoS One 2016; 11: e0160007.83	 Chuah SK, Liang CM, Lee CH, et al. A randomized control trial comparing 2 levofloxacin-containing second-line therapies for Helicobacter pylori eradication. Medicine 2016; 95: e3586.84	 Gisbert JP, Romano M, Gravina AG, et al. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments. Aliment Pharmacol Ther 2015; 41: 768−75.85	 Gisbert JP, Calvet X. Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 2012; 35: 209−21.86	 Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol 2014; 12: 177−86.87	 Zeng M, Mao XH, Li JX, et al. Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015; 386: 1457−64.88	 Taha AS, McCloskey C, Prasad R, Bezlyak V. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet 2009; 374: 119−25.89	 Ng FH, Wong SY, Lam KF, et al.",3329,461,832.25,"[-0.2167702  -0.21643558 -1.400321   ...  0.5728857   0.15971346
 -1.2654933 ]"
177,"Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Gastroenterology 2010; 138: 82−88.90	 Chan FK, Kyaw M, Tanigawa T, et al. Similar efficacy of proton-pump inhibitors vs H2-receptor antagonists in reducing risk of upper gastrointestinal bleeding or ulcers in high-risk users of low-dose aspirin. Gastroenterology 2017; 152: 105–10.e1.91	 Chan FK, Ching JY, Suen BY, Tse YK, Wu JC, Sung JJ. Effects of Helicobacter pylori infection on long-term risk of peptic ulcer bleeding in low-dose aspirin users. Gastroenterology 2013; 144: 528−35.92	 Scarpignato C, Lanas A, Blandizzi C, Lems WF, Hermann M, Hunt RH, for the International NSAID Consensus Group. Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis—an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks. BMC Med 2015; 13: 55.93	 Scheiman JM, Fendrick AM. Summing the risk of NSAID therapy. Lancet 2007; 369: 1580−81.94	 Chan FK. Primer: managing NSAID-induced ulcer complications— balancing gastrointestinal and cardiovascular risks. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 563−73.95	 Yuan JQ, Tsoi KK, Yang M, et al. Systematic review with network meta-analysis: comparative effectiveness and safety of strategies for preventing NSAID-associated gastrointestinal toxicity. Aliment Pharmacol Ther 2016; 43: 1262−75.96	 Rostom A, Muir K, Dube C, Lanas A, Jolicoeur E, Tugwell P. Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors. Drug Health Patient Saf 2009; 1: 47−71.97	 Regula J, Butruk E, Dekkers CP, et al. Prevention of NSAID-associated gastrointestinal lesions: a comparison study pantoprazole versus omeprazole. Am J Gastroenterol 2006; 101: 1747−55.98	 Yuan JQ, Yang M, Threapleton DE, et al. Systematic review with meta-analysis: the gastrointestinal benefits of COX-2 selective inhibitors with concomitant use of low-dose aspirin. Aliment Pharmacol Ther 2016; 44: 785–95.99	 Chan FK, Lanas A, Scheiman J, Berger MF, Nguyen H, Goldstein JL. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 2010; 376: 173−79.100	 Cryer B, Li C, Simon LS, Singh G, Stillman MJ, Berger MF. GI-REASONS: a novel 6-month, prospective, randomized, open-label, blinded endpoint (PROBE) trial. Am J Gastroenterol 2013; 108: 392−400.101	 Wallace JL, Syer S, Denou E, et al. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology 2011; 141: 1314−22.",2665,367,666.25,"[ 0.01499814 -0.14638937 -1.2357821  ...  0.45753062  0.51890415
 -1.925001  ]"
178,"Seminar 624	 www.thelancet.com  Vol 390  August 5, 2017 102	 Lanas AI, Remacha B, Esteva F, Sáinz R. Risk factors associated with refractory peptic ulcers. Gastroenterology 1995; 109: 1124−33.103	 Hung LC, Ching JY, Sung JJ, et al. Long-term outcome of Helicobacter pylori-negative idiopathic bleeding ulcers: a prospective cohort study. Gastroenterology 2005; 128: 1845−50.104	 Wong GL, Wong VW, Chan Y, et al. High incidence of mortality and recurrent bleeding in patients with Helicobacter pylori-negative idiopathic bleeding ulcers. Gastroenterology 2009; 137: 525−31.105	 Wong GL, Au KW, Lo AO, et al. Gastroprotective therapy does not improve outcomes of patients with Helicobacter pylori-negative idiopathic bleeding ulcers. Clin Gastroenterol Hepatol 2012; 10: 1124−29.106	 Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med 2013; 368: 11–21.107	 Stanley AJ, Dalton HR, Blatchford O, et al. Multicenter comparison of the Glasgow Blatchford and Rockall Scores in the prediction of clinical end-points after upper gastrointestinal hemorrhage. Aliment Pharmacol Ther 2011; 34: 470–75.108	 Baker DE. Peptic ulcer bleeding following therapeutic endoscopy: a new indication for intravenous esomeprazole. Rev Gastroenterol Disord 2009; 9: E111−18.109	 Sreedharan A, Martin J, Leontiadis GI, et al. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database Syst Rev 2010; 7: CD005415.110	 Lau JY, Barkun A, Fan DM, Kuipers EJ, Yang YS, Chan FK. Challenges in the management of acute peptic ulcer bleeding. Lancet 2013; 381: 2033−43.111	 Barkun A, Bardou M, Martel M, Gralnek IM, Sung JY. Prokinetics in acute upper GI bleeding: a meta-analysis. Gastrointest Endosc 2010; 72: 1138–45.112	 Cook DJ, Guyatt GH, Salena BJ, Laine LA. Endoscopic therapy for acute nonvariceal upper gastrointestinal hemorrhage: a meta-analysis. Gastroenterology 1992; 102: 139–48.113	 Sung JJ, Tsoi KK, Lai LH, Wu JC, Lau JY. Endoscopic clipping versus injection and thermo-coagulation in the treatment of non-variceal upper gastrointestinal bleeding: a meta-analysis. Gut 2007; 56: 1364–73.114	 Marmo R, Rotondano G, Bianco MA, Piscopo R, Prisco A, Cipolletta L. Outcome of endoscopic treatment for peptic ulcer bleeding: is a second look necessary?A meta-analysis. Gastrointest Endosc 2003; 57: 62–67.115	 Wang CH, Ma MH, Chou HC, et al. High-dose vs. non-high-dose proton pump inhibitors after endoscopic treatment in patients with bleeding peptic ulcer: a systematic review and meta-analysis of randomized controlled trials. Arch Intern Med 2010; 170: 751–58.116	 Sachar H, Vaidya K, Laine L. Intermittent vs continuous proton pump inhibitor therapy for high-risk bleeding ulcers: a systematic review and meta-analysis. JAMA Intern Med 2014; 174: 1755−62.",2872,409,718.0,"[ 0.1402642  -0.47946513 -1.1943505  ...  0.35107666  0.3428396
 -1.5931554 ]"
178,"117	 Hunfeld N, Touw D, Mathot R, Mulder P, Van Schaik R, Kuipers E. A comparison of the acid-inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphism. Aliment Pharmacol Ther 2010; 31: 150–59.118	 Lau JY, Sung JJ, Lam YH, et al. Endoscopic re-treatment compared with surgery in patients with recurrent bleeding after initial endoscopic control of bleeding ulcers. N Engl J Med 1999; 340: 751–56.119	 Sung JJ, Lau JY, Ching JY, et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med 2010; 152: 1–9.120	 Airoldi F, Colombo A, Morici N, et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 2007; 116: 745–54.121	 Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug eluting stent implantation. JAMA 2007; 297: 159–68.122	 Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955−62.123	 Witt DM, Delate T, Garcia DA, et al. Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding. Arch Intern Med 2012; 17: 1–8.124	 Gralnek IM, Dumonceau JM, Kuipers EJ, et al. Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2015; 47: a1−46.125	 Dumbleton JS, Avery AJ, Coupland C, et al. The Helicobacter Eradication Aspirin Trial (HEAT): a large simple randomised controlled trial using novel methodology in primary care. EBioMedicine 2015; 2: 1200−04.126	 Cremades N, Velázquez-Campoy A, Martínez-Júlvez M, et al. Discovery of specific flavodoxin inhibitors as potential therapeutic agents against Helicobacter pylori infection. ACS Chem Biol 2009; 4: 928−38.",2022,291,505.5,"[ 0.07407454 -0.796696   -1.6815726  ...  0.39089638  0.5686883
 -1.6401488 ]"
179,Acute upper gastrointestinal bleeding in over 16s: management Clinical guideline Published: 13 June 2012 www.nice.org.uk/guidance/cg141 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights). Last updated August 2016,288,32,72.0,"[ 0.9175634   0.08515978 -1.8045413  ...  0.02750075  0.14215304
 -1.7746876 ]"
180,"YYour responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals and practitioners are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or the people using their service. It is not mandatory to apply the recommendations, and the guideline does not override the responsibility to make decisions appropriate to the circumstances of the individual, in consultation with them and their families and carers or guardian. Local commissioners and providers of healthcare have a responsibility to enable the guideline to be applied when individual professionals and people using services wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Acute upper gastrointestinal bleeding in over 16s: management (CG141) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Last updated August 2016 Page 2 of 13",1674,241,418.5,"[ 7.6417470e-01 -1.2916797e-01 -1.7836045e+00 ... -8.0549903e-04
  1.5932320e-01 -2.0399809e+00]"
181,"Contents Contents Introduction ......................................................................................................................................................................... 4 Patient-centred care......................................................................................................................................................... 5 Key priorities for implementation............................................................................................................................... 6 1 Guidance ............................................................................................................................................................................ 8 1.1 Risk assessment ........................................................................................................................................................................ 8 1.2 Resuscitation and initial management............................................................................................................................. 8 1.3 Timing of endoscopy................................................................................................................................................................ 9 1.4 Management of non-variceal bleeding ............................................................................................................................ 9 1.5 Management of variceal bleeding...................................................................................................................................... 10 1.6 Control of bleeding and prevention of re-bleeding in patients on NSAIDs, aspirin or clopidogrel ......... 11 1.7 Primary prophylaxis for acutely ill patients in critical care...................................................................................... 11 1.8 Information and support for patients and carers ........................................................................................................ 11 More information............................................................................................................................................................................. 12 Update information........................................................................................................................................................... 13 Acute upper gastrointestinal bleeding in over 16s: management (CG141) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Last updated August 2016 Page 3 of 13",2646,120,661.5,"[-0.08016072 -0.68044156 -2.4677079  ... -0.10217178 -0.78181434
 -1.5798954 ]"
182,"This guideline is the basis of QS38. Introduction Introduction Acute upper gastrointestinal bleeding is a common medical emergency that has a 10% hospital mortality rate. Despite changes in management, mortality has not significantly improved over the past 50 years. Elderly patients and people with chronic medical diseases withstand acute upper gastrointestinal bleeding less well than younger, fitter patients, and have a higher risk of death. Almost all people who develop acute upper gastrointestinal bleeding are treated in hospital and the guideline therefore focuses on hospital care. The most common causes are peptic ulcer and oesophago- gastric varices. Endoscopy is the primary diagnostic investigation in patients with acute upper gastrointestinal bleeding but it has not always been clear whether urgent endoscopy is cost effective as well as clinically valuable. Endoscopy aids diagnosis, yields information that helps predict outcome and most importantly allows treatments to be delivered that can stop bleeding and reduce the risk of re-bleeding. Drugs may have a complementary role in reducing gastric acid secretion and portal vein pressure. Not every patient responds to endoscopic and drug treatments; emergency surgery and a range of radiological procedures may be needed to control bleeding. This guideline aims to identify which diagnostic and therapeutic steps are useful in managing acute upper gastrointestinal bleeding. This should enable hospitals to develop a structure in which clinical teams can deliver an optimum service for people who develop this condition. The guideline will assume that prescribers will use a drug's summary of product characteristics to inform decisions made with individual patients. Acute upper gastrointestinal bleeding in over 16s: management (CG141) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Last updated August 2016 Page 4 of 13",1976,285,494.0,"[ 0.3578819  -0.33789086 -1.6001465  ...  0.29141814  0.22449486
 -1.8925878 ]"
183,"PPatient-centred care atient-centred care This guideline offers best practice advice on the care of adults and young people aged 16 years and older with acute variceal and non-variceal upper gastrointestinal bleeding. Treatment and care should take into account patients' needs, preferences and religious beliefs. People with acute upper gastrointestinal bleeding should have the opportunity to make informed decisions about their care and treatment, in partnership with their healthcare professionals. If patients do not have the capacity to make decisions, healthcare professionals should follow the Department of Health's advice on consent and the code of practice that accompanies the Mental Capacity Act. In Wales, healthcare professionals should follow advice on consent from the Welsh Government. In taking account of patients' religious beliefs in the context of blood transfusion, healthcare professionals should follow the advice from UK Blood Transfusion and Tissue Transplantation Services. Good communication between healthcare professionals and patients is essential. It should be supported by evidence-based written information tailored to the patient's needs. Treatment and care, and the information patients are given about it, should be culturally appropriate. It should also be accessible to people with additional needs such as physical, sensory or learning disabilities, and to people who do not speak or read English. If the patient agrees, families and carers should have the opportunity to be involved in decisions about treatment and care. Families and carers should also be given the information and support they need. Acute upper gastrointestinal bleeding in over 16s: management (CG141) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Last updated August 2016 Page 5 of 13",1880,268,470.0,"[ 0.98632014 -0.43152452 -1.9444852  ... -0.18211019  0.16199996
 -1.7892643 ]"
184,"KKeey priorities for implementation y priorities for implementation The following recommendations have been identified as priorities for implementation. Risk assessment Risk assessment Use the following formal risk assessment scores for all patients with acute upper gastrointestinal bleeding: the Blatchford score at first assessment, and and the full Rockall score after endoscopy. Timing of endoscop Timing of endoscopyy Offer endoscopy to unstable patients with severe acute upper gastrointestinal bleeding immediately after resuscitation. Offer endoscopy within 24 hours of admission to all other patients with upper gastrointestinal bleeding. Units seeing more than 330 cases a year should offer daily endoscopy lists. Units seeing fewer than 330 cases a year should arrange their service according to local circumstances. Management of non-variceal bleeding Management of non-variceal bleeding Do not use adrenaline as monotherapy for the endoscopic treatment of non-variceal upper gastrointestinal bleeding. For the endoscopic treatment of non-variceal upper gastrointestinal bleeding, use one of the following: a mechanical method (for example, clips) with or without adrenaline thermal coagulation with adrenaline fibrin or thrombin with adrenaline. Offer interventional radiology to unstable patients who re-bleed after endoscopic treatment. Refer urgently for surgery if interventional radiology is not promptly available. Acute upper gastrointestinal bleeding in over 16s: management (CG141) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Last updated August 2016 Page 6 of 13",1670,223,417.5,"[ 0.26808774 -0.51593375 -1.8936769  ...  0.24375781  0.4320857
 -1.4362001 ]"
185,"Management of variceal bleeding Management of variceal bleeding Offer prophylactic antibiotic therapy at presentation to patients with suspected or confirmed variceal bleeding. Consider transjugular intrahepatic portosystemic shunts (TIPS) if bleeding from oesophageal varices is not controlled by band ligation. Control of bleeding and pre Control of bleeding and prevvention of re-bleeding in patients on NSAIDs, aspirin or clopidogrel ention of re-bleeding in patients on NSAIDs, aspirin or clopidogrel Continue low-dose aspirin for secondary prevention of vascular events in patients with upper gastrointestinal bleeding in whom haemostasis has been achieved. Acute upper gastrointestinal bleeding in over 16s: management (CG141) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Last updated August 2016 Page 7 of 13",899,119,224.75,"[ 0.6106922  -0.8555666  -1.423903   ... -0.40349156  0.56697834
 -1.2743752 ]"
186,"11 Guidance Guidance The following guidance is based on the best available evidence. The full guideline gives details of the methods and the evidence used to develop the guidance.1.1 1.1 Risk assessment Risk assessment 1.1.1 Use the following formal risk assessment scores for all patients with acute upper gastrointestinal bleeding: the Blatchford score at first assessment, and and the full Rockall score after endoscopy.1.1.2 Consider early discharge for patients with a pre-endoscopy Blatchford score of 0.1.2 1.2 Resuscitation and initial management Resuscitation and initial management 1.2.1 Transfuse patients with massive bleeding with blood, platelets and clotting factors in line with local protocols for managing massive bleeding.1.2.2 Base decisions on blood transfusion on the full clinical picture, recognising that over-transfusion may be as damaging as under-transfusion.1.2.3 Do not offer platelet transfusion to patients who are not actively bleeding and are haemodynamically stable.1.2.4 Offer platelet transfusion to patients who are actively bleeding and have a platelet count of less than 50 x 10 9/litre. Offer fresh frozen plasma to patients who are actively bleeding and have a prothrombin time (or international normalised ratio) or activated partial thromboplastin time greater than 1.5 times normal. If a patient's fibrinogen level remains less than 1.5 g/litre despite fresh frozen plasma use, offer cryoprecipitate as well.1.2.5 Offer prothrombin complex concentrate to patients who are taking warfarin Acute upper gastrointestinal bleeding in over 16s: management (CG141) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Last updated August 2016 Page 8 of 13",1768,250,442.0,"[ 0.5657133  -0.3647881  -1.3926945  ...  0.50880903  0.7396424
 -1.3681418 ]"
187,"and actively bleeding.1.2.6 Treat patients who are taking warfarin and whose upper gastrointestinal bleeding has stopped in line with local warfarin protocols.1.2.7 Do not use recombinant factor Vlla except when all other methods have failed.1.3 1.3 Timing of endoscop Timing of endoscopyy 1.3.1 Offer endoscopy to unstable patients with severe acute upper gastrointestinal bleeding immediately after resuscitation.1.3.2 Offer endoscopy within 24 hours of admission to all other patients with upper gastrointestinal bleeding.1.3.3 Units seeing more than 330 cases a year should offer daily endoscopy lists. Units seeing fewer than 330 cases a year should arrange their service according to local circumstances.1.4 1.4 Management of non-variceal bleeding Management of non-variceal bleeding Endoscopic treatment Endoscopic treatment 1.4.1 Do not use adrenaline as monotherapy for the endoscopic treatment of non- variceal upper gastrointestinal bleeding.1.4.2 For the endoscopic treatment of non-variceal upper gastrointestinal bleeding, use one of the following: a mechanical method (for example, clips) with or without adrenaline thermal coagulation with adrenaline fibrin or thrombin with adrenaline. Proton pump inhibitors Proton pump inhibitors 1.4.3 Do not offer acid-suppression drugs (proton pump inhibitors or H2-receptor antagonists) before endoscopy to patients with suspected non-variceal upper gastrointestinal bleeding. Acute upper gastrointestinal bleeding in over 16s: management (CG141) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Last updated August 2016 Page 9 of 13",1668,222,417.0,"[ 0.24859314 -0.4240505  -1.4955908  ...  0.21821839  0.31506956
 -1.5492233 ]"
188,"1.4.4 Offer proton pump inhibitors to patients with non-variceal upper gastrointestinal bleeding and stigmata of recent haemorrhage shown at endoscopy. TTreatment after first or failed endoscopic treatment reatment after first or failed endoscopic treatment 1.4.5 Consider a repeat endoscopy, with treatment as appropriate, for all patients at high risk of re-bleeding, particularly if there is doubt about adequate haemostasis at the first endoscopy.1.4.6 Offer a repeat endoscopy to patients who re-bleed with a view to further endoscopic treatment or emergency surgery.1.4.7 Offer interventional radiology to unstable patients who re-bleed after endoscopic treatment. Refer urgently for surgery if interventional radiology is not promptly available.1.5 1.5 Management of variceal bleeding Management of variceal bleeding 1.5.1 Offer terlipressin to patients with suspected variceal bleeding at presentation. Stop treatment after definitive haemostasis has been achieved, or after 5 days, unless there is another indication for its use [1].1.5.2 Offer prophylactic antibiotic therapy at presentation to patients with suspected or confirmed variceal bleeding. Oesophageal varices Oesophageal varices 1.5.3 Use band ligation in patients with upper gastrointestinal bleeding from oesophageal varices.1.5.4 Consider transjugular intrahepatic portosystemic shunts (TIPS) if bleeding from oesophageal varices is not controlled by band ligation. Gastric varices Gastric varices 1.5.5 Offer endoscopic injection of N-butyl-2-cyanoacrylate to patients with upper gastrointestinal bleeding from gastric varices. Acute upper gastrointestinal bleeding in over 16s: management (CG141) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Last updated August 2016 Page 10 of 13",1840,241,460.0,"[ 0.05087493 -0.7540454  -1.3742888  ... -0.12998141  0.4227656
 -1.4790418 ]"
189,"1.5.6 Offer TIPS if bleeding from gastric varices is not controlled by endoscopic injection of N-butyl-2-cyanoacrylate.1.6 1.6 Control of bleeding and pre Control of bleeding and prevvention of re-bleeding in ention of re-bleeding in patients on NSAIDs, aspirin or clopidogrel patients on NSAIDs, aspirin or clopidogrel 1.6.1 Continue low-dose aspirin for secondary prevention of vascular events in patients with upper gastrointestinal bleeding in whom haemostasis has been achieved.1.6.2 Stop other non-steroidal anti-inflammatory drugs (including cyclooxygenase-2 [COX-2] inhibitors) during the acute phase in patients presenting with upper gastrointestinal bleeding.1.6.3 Discuss the risks and benefits of continuing clopidogrel (or any other thienopyridine antiplatelet agents) in patients with upper gastrointestinal bleeding with the appropriate specialist (for example, a cardiologist or a stroke specialist) and with the patient.1.7 1.7 Primary proph Primary prophylaxis for acutely ill patients in critical ylaxis for acutely ill patients in critical care care 1.7.1 Offer acid-suppression therapy (H2-receptor antagonists or proton pump inhibitors) for primary prevention of upper gastrointestinal bleeding in acutely ill patients admitted to critical care. If possible, use the oral form of the drug. [2] 1.7.2 Review the ongoing need for acid-suppression drugs for primary prevention of upper gastrointestinal bleeding in acutely ill patients when they recover or are discharged from critical care.1.8 1.8 Information and support for patients and carers Information and support for patients and carers 1.8.1 Establish good communication between clinical staff and patients and their family and carers at the time of presentation, throughout their time in hospital and following discharge. This should include: giving verbal information that is recorded in medical records Acute upper gastrointestinal bleeding in over 16s: management (CG141) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Last updated August 2016 Page 11 of 13",2120,291,530.0,"[ 0.3907351  -0.35515833 -1.5102744  ... -0.19763434  0.45176703
 -1.650835  ]"
190,"different members of clinical teams providing consistent information providing written information where appropriate ensuring patients and their families and carers receive consistent information. More information More information You can also see this guideline in the NICE pathway on Acute upper gastrointestinal bleeding. To find out what NICE has said on topics related to this guideline, see our web page on Digestive tract conditions. See also the guideline committee's discussion and the evidence reviews (in the full guideline), and information about how the guideline was developed, including details of the committee. [1]At the time of publication (June 2012), terlipressin was indicated for the treatment of bleeding from oesophageal varices, with a maximum duration of treatment of 72 hours (3 days). Prescribers should consult the relevant summary of product characteristics. Informed consent for off-label use of terlipressin should be obtained and documented. [2]As of August 2016, only the H2-receptor antagonists ranitidine and cimetidine are licensed for prophylaxis of gastrointestinal bleeding in acutely ill patients. The proton pump inhibitors omeprazole, esomeprazole, lansoprazole, pantoprazole and rabeprazole are not licensed for prophylaxis of gastrointestinal bleeding in acutely ill patients. The use of proton pump inhibitors or H2-receptor antagonists other than ranitidine and cimetidine for this indication would be off label. Acute upper gastrointestinal bleeding in over 16s: management (CG141) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Last updated August 2016 Page 12 of 13",1696,235,424.0,"[ 0.50076604 -0.40954888 -1.3192635  ...  0.52964675  0.2500987
 -1.6294544 ]"
191,Update information Update information August 2016 August 2016: A footnote was added to recommendation 1.7.1 about which proton pump inhibitors and H2-receptor antagonists are licensed for use and which are classed as off-label. April 2015 April 2015: Recommendation 1.2.5 has been amended to add the use of cryoprecipitate as further treatment. ISBN: 978-1-4731-2041-9 Accreditation Accreditation Acute upper gastrointestinal bleeding in over 16s: management (CG141) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Last updated August 2016 Page 13 of 13,633,85,158.25,"[ 0.5590835   0.10916492 -1.3232567  ...  0.4597439  -0.0387786
 -2.0845942 ]"
192,"Aliment Pharmacol Ther.2020;52:789–797.	 ﻿  |  789 wileyonlinelibrary.com/journal/apt  Received: 11 March 2020  |  First decision: 28 March 2020  |  Accepted: 15 May 2020 DOI: 10.1111/apt.15865  Randomised clinical trial: tegoprazan, a novel  potassium-competitive acid blocker, or lansoprazole in the treatment of gastric ulcer Yu Kyung Cho1 |  Myung-Gyu Choi1  |  Suck Chei Choi2 |  Kee Myung Lee3 |   Tae Oh Kim4 |  Soo-Heon Park1 |  Jeong Seop Moon1 |  Yun Jeong Lim5 |   Dae Hwan Kang6 |  Gab Jin Cheon7 |  Gwang Ho Baik8 |  Kyoung Oh Kim9 |   Kwang Bum Cho10 |  Jin Seok Jang4 |  Jong-Jae Park1 |  Byoung Kwan Son1 |   Hye-Kyung Jung1  |  Byung-Wook Kim9  |  Sung Kuk Kim10 |  Soo Teik Lee11 |   Jae Myung Cha1 |  Ah Rong Kim1 |  Eun Ji Kim1 |  Hyun Wook Park1 |  Geun Seog Song1 This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.© 2020 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd The Handling Editor for this article was Dr Colin Howden, and it was accepted for publication after full peer-review. The complete list of authors' affiliation are listed in Appendix 1. 1Seoul, Korea 2Iksan, Korea 3Suwon, Korea 4Busan, Korea 5Goyang, Korea 6Yangsan, Korea 7Gangneung, Korea 8Chuncheon, Korea 9Incheon, Korea 10Daegu, Korea 11Jeonju, Korea Correspondence Prof. Myung-Gyu Choi, Division of Gastroenterology, Department of Medicine, College of Medicine, The Catholic University of Korea, Seoul St, Mary's hospital, Banpodaero 222, Seochogu, Seoul, Korea. Email: choim@catholic.ac.kr Funding information This study was funded in full by HK inno. N Corp., Seoul, Korea. Summary Background: Tegoprazan is a novel potassium-competitive acid blocker for the treat- ment of acid-related disorders. Aims: To assess whether tegoprazan is non-inferior to lansoprazole in terms of ef- ficacy and safety in patients with gastric ulcers. Methods: In this phase 3, double-blind, active control, multicentre study, 306 gastric ulcer patients were randomised to one of three treatment groups: tegoprazan 50 mg, tegoprazan 100 mg and lansoprazole 30 mg once daily for 4 or 8 weeks. The primary endpoint was the cumulative proportion of patients with healed ulcers confirmed by en- doscopy up to 8 weeks from treatment initiation. Symptoms and safety were assessed. Results: In the full analysis set, the cumulative healing rates at week 8 were 94.8% (91/96) for the tegoprazan 50 mg, 95.0% (94/99) for the tegoprazan 100 mg and 95.7% (89/93) for the lansoprazole 30 mg groups. At week 4, the respective healing rates were 90.6% (87/96), 91.9% (91/99), and 89.2% (83/93). In per protocol analysis, 4-week healing rates were 95.4% (84/88), 94.6% (88/93) and 92.9% (79/85) for tego- prazan 50 mg, tegoprazan 100 mg and lansoprazole 30 mg, respectively. Both doses of tegoprazan were non-inferior to lansoprazole in ulcer healing at 4 and 8 weeks. The incidence of drug-related treatment-emergent adverse events did not differ among groups. The increase in serum gastrin concentration was not higher in tegoprazan- treated patients than in lansoprazole-treated patients. Conclusions: Tegoprazan 50 or 100 mg were not inferior to lansoprazole 30 mg once daily in the treatment of gastric ulcers.",3451,507,862.75,"[-0.04107922  0.1658273  -1.553359   ...  0.28785858 -0.09327741
 -1.7627985 ]"
193,"790  |     CHO et al.1 | INTRODUCTION Proton pump inhibitors (PPIs) are used widely for the treatment of acid-related diseases, and their therapeutic effects are con- sidered to be satisfactory,1 although some inadequacies must be addressed. First, PPIs have a relatively short plasma half-life (60- 90 minutes), and taking PPIs twice a day may be insufficient for inhibiting gastric acid reflux at night. Second, PPIs are prodrugs that are activated under acid-secreting conditions, and the effects of PPIs can be affected by food intake. Third, a rapid response cannot be achieved because of the slow onset of the PPI effect and the time needed to achieve maximum efficacy.2-4 Potassium- competitive acid blockers (P-CABs) comprise a new class of drugs that exhibit rapid and effective anti-secretory activity by compet- itively and reversibly binding to H+/K+-ATPase in parietal cells.5 Unlike conventional PPIs, P-CABs can immediately inhibit proton pumps without gastric acid activation, even in the absence of food intake, and therefore provide a fast onset of action and full ef- fect from the first dose.6,7 Vonoprazan, which is available P-CAB in Japan, has a more potent acid-inhibitory effect.8 It is superior to PPIs for the first-line treatment for Helicobacter pylori eradication,9 and is not inferior to PPIs for the treatment of gastroesophageal re- flux disease (GERD),10 gastric ulcers (GUs) or duodenal ulcers.11-13 Tegoprazan is a novel P-CAB, originally developed by a RaQualia Pharma Inc HK inno. N Corporation which has the exclusive right, has completely developed and commercialised tegoprazan as a treat- ment for acid-related disorders. Tegoprazan was approved as a treat- ment for gastroesophageal reflux disease, gastric ulcer and H. pylori eradication in South Korea from July 2018. Tegoprazan showed rapid response from the time of initial administration, and sustained acid suppression are demonstrated in the several experimental and clinical studies.14 Tegoprazan shows dose-dependent pH >4 hold- ing time and a rapid and sustained acid suppressive effect compared with esomeprazole in healthy male volunteers.15 Its effects on intra- gastric pH >4 holding time at day 1 and day 7 are similar to vono- prazan.16 The superior ulcer healing effect of tegoprazan compared with esomeprazole was recently shown in a rat peptic ulcer model.17 Tegoprazan at doses of 50 and 100 mg is not inferior to esomepra- zole 40 mg for healing endoscopic esophagitis has been reported.18 The present study was a phase 3 clinical trial that was designed to evaluate whether tegoprazan is non-inferior in efficacy and safety to lansoprazole in treating patients with GUs. Another aim of this trial was to determine whether the proper dose of tegoprazan for healing GUs and safety is 50 mg or 100 mg.2 | MATERIALS AND METHODS 2.1 | Study design This phase 3 study was a multicentre study involving 33 investigators in 33 centres in South Korea. The study was a randomised, double- blind, active-controlled, comparative study designed to assess the non-inferiority of tegoprazan 50 and 100 mg to lansoprazole 30 mg q.d.for 4 or 8 weeks in patients with GU. The protocol for this study was approved by the institutional review boards at each institute ac- cording to the Declaration of Helsinki and the International Congress on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use-Good Clinical Practice guidelines. The study was registered with ClinicalTrials.gov under the number NCT02761512 (Study title: Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients with Gastric Ulcer).2.2 | Study population Patients who met all of the following criteria were eligible to enter the study: men or women aged 20-75 years living in South Korea and being an outpatient who had been diagnosed with one or more ac- tive GUs measuring ≥3 mm to ≤30 mm of A1 or A2 stage according to the Sakita-Miwa classification obtained with open biopsy forceps during upper gastrointestinal (GI) endoscopy within 14 days before the initiation of the study treatment. Patients with any one of the following conditions were ineligible to enter the study: Zollinger-Ellison syndrome; GI bleeding; oesoph- ageal stricture; ulcer stenosis; pyloric stenosis; oesophageal gastric varices; Barrett's oesophagus measuring >3 cm; intractable ulcer; di- gestive ulcer perforation or malignancy on upper GI endoscopy; clin- ically significant hepatic, renal, cardiovascular, respiratory, endocrine or central nervous system disorder; history of malignancy or psychi- atric disorder; pregnant or nursing mother; history of allergy to any of the study drugs or their related compounds; clinically significant liver disease or renal disease; using anti-psychotics, anti-depressants, or anxiolytics; using a PPI, H2-blocker, prokinetic agent, or antacid within 14 days before screening; or persistent daily use of non-steroidal an- ti-inflammatory drugs (NSAIDs) or aspirin during the study period.2.3 | Study protocol 2.3.1 | Randomisation, treatment and follow-up Clinical Development Division, HK inno. N Corp., Seoul, Korea, car- ried out centralised randomisation and allocation to tegoprazan 50, 100 mg or lansoprazole 30 mg group at a 1:1:1 ratio. All randomi- sation information was securely stored and could be accessed by authorised personnel only. A double-dummy method, using match- ing tegoprazan 50 mg, tegoprazan 100 mg, lansoprazole 30 mg and placebo tablets, was employed to ensure that the study was double blinded with key codes kept off site by an external data manager. All medications were provided in sealed boxes and supplied by the med- ication supervisor to ensure blinded allocation. Study patients were instructed to take two tablets and one capsule, one of tegoprazan 50, 100 mg or lansoprazole 30 mg and two placebos once daily be- fore eating breakfast. Treatment was completed after 4 weeks or 8 weeks if not healed.",5969,884,1492.25,"[-0.1945237  -0.09705228 -1.4230309  ... -0.14566228 -0.26858556
 -1.4978774 ]"
194,"|  791 CHO et al. At the start of the screening period, patient demographics and other baseline characteristics were recorded, including medical history, medication history, vital signs, physical examination, clin- ical laboratory tests, pregnancy test, electrocardiogram test and Helicobacter pylori test were performed. At week 4 or 8, vital signs, physical examination, clinical laboratory tests and pregnancy test were performed. Additionally, adverse events, concomitant medica- tion and treatment compliance were checked. Endoscopy was per- formed at screening, week 4 or 8. The follow-up period began when healing of the GU was endoscopically confirmed (ie the white ulcer coating was not visible) or at week 8. Patients whose GU had healed by week 4 had a follow-up visit for safety assessment 2 weeks later (visit 3-1). Those not achieving GU healing at week 4 received an- other batch of drugs and continued the treatment for an additional 4 weeks. For these patients, endoscopic assessment was conducted at week 8, and the final follow-up visit for safety assessment was performed 2 weeks later (visit 4-1). Symptoms were assessed using the Nepean Dyspepsia Index - Korean version (NDI-K), which was completed on the first visit before the treatment period and repeated at visits 3, 3-1 or 4, 4-1. Patient diary entries were also recorded. Serum gastrin was collected at visit 2, visit 3 and visit 3-1 for 4 weeks or at visit 2, visit 4 and visit 4-1 for 8 weeks under fasting conditions. Helicobacter pylori infection status was checked using one of silver stains, CLO test and urea breath test prior to study enrol- ment. Helicobacter infection status was notified to all of subject at time of screening. All subjects who were positive for Helicobacter were treated using standard triple therapy (lansoprazole 30  mg b.i.d + amoxicillin 1 g b.i.d + clarithromycin 500 mg b.i.d for 7 days) after last follow-up. H. pylori eradication and follow-up urea breath test were done in clinical practice.2.3.2 | Outcome parameters used to assess efficacy The primary efficacy endpoint was set as the cumulative healing rate of GUs at week 8 as assessed by upper GI endoscopy. Following the Sakita-Miwa classification, healing was defined as the disappearance of all ulcers with a white coating or healing of the mucosal defect (S1 or S2 stage). The secondary efficacy endpoints were as follows: (a) heal- ing rate of GUs, also classified according to the Sakita-Miwa classifica- tion at week 4; (b) healing rate of GUs according to H. pylori infections status; (c) change in ulcer size; and (d) improvement of GI symptoms.2.3.3 | Safety assessment Safety was evaluated through physical examination, electrocardiogra- phy, vital signs (blood pressure, heart rate and body temperature), lab- oratory test results (haematology, blood chemistry, blood coagulation and urinalysis) and incidence of treatment-emergent adverse events (TEAEs). A TEAE was defined as an adverse event (AE) occurring after the participant received a study drug. TEAEs were categorised by severity and relativity and compared between treatment groups. All TEAEs including AEs, adverse drug reactions and serious AEs were coded by system organ class and preferred term using MedDRA, and compared between treatment groups. Additional safety assessments were conducted at the discretion of the investigators.2.4 | Statistical analysis Hypothesis testing was conducted by setting the primary efficacy end- point as the cumulative GU healing rate at week 8. The union-intersec- tion test was used with the Hochberg method to adjust for multiple comparisons and to control for a family-wise type I error, which was set at 0.025 (one-sided). A power of >90% was assumed for detecting non- inferiority as shown by the difference in the percentages of patients with healed GUs between the treatment groups, with a non-inferiority margin of 8.54% at the lower limit of 95% confidence intervals (CIs). Sample size was determined according to the primary end- point. For sample size calculation, the cumulative healing rate after 8 weeks of treatment was assumed as 96.8% for both tegoprazan and lansoprazole, and a sample size of 102 patients (considering a 20% dropout rate) per treatment group was calculated, giving a total sample size of 306 patients. Efficacy assessments were performed primarily using the per-protocol set (PPS) and complementarily using the full analysis set (FAS). The safety assessments were performed on the safety set. The FAS included all patients who were randomised to the study treatment and who received ≥1 dose of a study drug and who had at least one valid efficacy assessment. The PPS included all patients in the FAS with an evaluable primary endpoint who were randomised to a study treatment, completed their study treatment and had no major protocol deviation. The safety population included all patients who received ≥1 dose of a study drug. All statistical analyses were done using SAS® (version 9.3; Windows) in accordance with the statistical analysis plan. For con- tinuous variables, the values are expressed as number of partici- pants, mean, standard deviation, median, minimum and maximum. For categorical variables, the values are presented as frequency and percentage. Demographic and other baseline characteristics, GU characteristics and serum gastrin concentrations were com- pared between treatment groups. The percentages of patients with healed GUs and GI symptoms were analysed by calculating frequencies, point estimates and two-sided 95% CIs for each treatment group.3 | RESULTS 3.1 | Patient characteristics and demographics Among the 376 patients with GUs who were screened, 51 were in- eligible based on the inclusion/exclusion criteria, 18 withdrew their consent and 1 was a foreigner. These patients were considered as screening failures, and the remaining 306 patients were randomised",5914,895,1478.5,"[ 0.07613192  0.04082274 -1.6911168  ...  0.22127472  0.3792991
 -1.076723  ]"
195,"792  |     CHO et al.in a 1:1:1 ratio to one of the three treatment arms: tegoprazan 50 mg, tegoprazan 100 mg or lansoprazole 30 mg. Among the 306 randomised patients, 28 (9.2%) were discontinued from the study because of voluntary withdrawal (n = 8, 28.6%), inclusion/exclusion criteria violation (n  =  6, 21.4%), the use of contraindicated drugs (n = 5, 17.9%), AEs (n = 5, 17.9%), follow-up loss (n = 2, 7.1%) or investigator discretion (n = 2, 7.1%). The patients' characteristics are summarised in Figure 1 and the details of the patients' demographics and baseline characteristics are summarised in Table 1. No signifi- cant differences in demographic characteristics between treatment groups were observed. Most patients were not using NSAIDs or low- dose aspirin at the time of enrolment. Most patients had a single GU and the most common size of the ulcers was <10 mm.3.2 | Efficacy analysis 3.2.1 | The primary efficacy endpoints In the PPS population, the percentages of patients with healed GUs over the 8-week treatment period were 100% in the tegoprazan 50 mg group, 97.85% in the tegoprazan 100 mg group and 100% in the lansoprazole 30 mg group. The percentage difference between tegoprazan 100  mg and lansoprazole 30  mg in PPS analysis was <8.54% (95% CI −7.66 to 2.43, P  =  0.0137), which confirmed the non-inferiority of tegoprazan 50 mg and 100 mg compared with lan- soprazole 30 mg. At week 4, the healing rates were 95.45% (84/88, P = 0.0038 vs lansoprazole 30 mg) for tegoprazan 50 mg, 94.62% (88/93, P = 0.0024 vs lansoprazole 30 mg) for tegoprazan 100 mg and 92.94% (79/85) for lansoprazole 30 mg, the percentage differences between each dose of tegoprazan and lansoprazole 30 mg showed both dose of tegoprazan were not inferior to lansoprazole (Table 2). These findings were supported by the secondary analyses in the FAS. In the FAS analysis, the cumulative healing rates at week 8 were 94.79% (91/96), 94.95% (94/99) and 95.70% (89/93) and the respec- tive healing rates at week 4 were 90.63% (87/96), 91.92% (91/99) and 89.25% (83/93) in tegoprazan 50, 100  mg and lansoprazole groups. The differences between the tegoprazan group (both doses) and the lansoprazole group were significant (P < 0.025) at both time points, for both analysis sets according to the Hochberg method, it confirmed the non-inferiority of tegoprazan to lansoprazole. Secondary endpoint analyses showed similar healing rates between pylori subgroup and both treatment of tegoprazan and lansoprazole had positive effects on gastrointestinal symptoms. Both doses of te- goprazan were non-inferior to lansoprazole 30 mg in H. pylori-positive patients at 4- and 8-week ulcer healing. In H. pylori-positive patients, the 4-week healing rates were 96.15% (50/52) for tegoprazan 50 mg, 98.33% (59/60) for tegoprazan 100 mg and 92.98% (53/57) for lanso- prazole 30 mg. The 8-week cumulative healing rates were 100% in all of three groups. In the H. pylori-negative patients, the 4-week healing rates were 94.44% (34/36) for tegoprazan 50 mg, 87.88% (29/33) for tego- prazan 100 mg and 92.86% (26/28) for lansoprazole 30 mg. The 8-week healing rates were 100% (36/36) for tegoprazan 50 mg, 93.94% (31/33), for tegoprazan 100 mg, and 100%(28/28) for lansoprazole 30 mg. FI G U R E 1 Disposition of Subjects",3302,487,825.5,"[ 0.04294372 -0.44488505 -1.6146896  ...  0.4670922   0.55877733
 -1.2649971 ]"
196,"|  793 CHO et al.3.3 | Safety analysis Safety analysis was performed in 304 patients who received ≥1 dose of a study drug and had ≥1 safety assessment in this clinical trial. Among the 304 patients, 113 cases of TEAEs were reported by 66 patients (Table 3). Drug-related TEAEs accounted for 9.80% (10/102, 17 events) in the tegoprazan 50 mg group, 13.73% (14/102, 18 events) in the te- goprazan 100 mg group, and 12.00% (12/100, 19 events) in the lanso- prazole 30 mg group. Four cases of serious TEAEs were reported in the tegoprazan 50 mg group, two in the tegoprazan 100 mg group and one in the lansoprazole 30 mg group; however, none of these were causally related to treatment with the study drug (Table 3). The most common drug-related TEAE in all treatment groups classified by system organ class was GI disorders; the incidence rates were 4.90% (5/102) for tegoprazan 50 mg, 6.86% (7/102) for tegoprazan 100 mg, and 4.00% (4/100) for lansoprazole 30 mg. Diarrhoea (2.94%) in tegoprazan 50 mg and abdominal discomfort (2%) and blood gastrin increased (2%) in lansoprazole 30 mg were the most frequently reported drug-related TEAEs (Table 4). The incidence of any TEAE did not differ between the tegoprazan 50 and 100 mg treatment groups.3.4 | Serum gastrin concentration The baseline serum gastrin concentrations were 54.84 ± 59.26 pg/mL, 55.63 ± 46.40 pg/mL, and 70.92 ± 107.08 pg/mL for the tegoprazan 50 mg, tegoprazan 100 mg and lansoprazole 30 mg groups respectively (Figure 2). The final serum gastrin concentrations at week 4 or 8 were 85.52 ± 77.97 pg/mL, 119.54 ± 94.05 pg/mL and 121.75 ± 114.84 pg/ mL. The change in serum gastrin concentration did not differ signifi- cantly between the tegoprazan and lansoprazole groups. Serum gastrin concentrations increased after treatment in all three treatment groups, but these returned to their baseline levels after completion of the treat- ment period. No significant changes in serum gastrin concentration were observed between groups during the study period (Figure 2).4 | DISCUSSION The present study was designed to evaluate whether tegoprazan is non-inferior to lansoprazole in terms of the efficacy and safety in patients with GUs. At week 8, the cumulative endoscopic healing rates of GUs were 100% in the tegoprazan 50  mg group, 97.85% in the tegoprazan 100  mg group and 100% in the lansoprazole 30 mg group. At week 4, the respective endoscopic healing rates were 95.45%, 94.62% and 92.94%. These results demonstrate the non-inferiority of both tegoprazan 50 and 100 mg compared with lansoprazole 30 mg in terms of endoscopic healing rates. Our study showed similar results to vonoprazan. A previous study reported that vonoprazan produced non- inferior healing rates for gastric and duodenal ulcers in H. pylori-positive patients at 8 weeks. In the PPS analysis, the ulcer healing rates were 93.5% in the vonoprazan group and 93.8% in the lansoprazole group.11 One aim of our study was to determine the proper dose of te- goprazan for GU healing. The PPS and FAS analyses showed similar healing rates for the two doses of tegoprazan (50 and 100 mg) at Tegoprazan 50 mg (N = 88) Tegoprazan 100 mg (N = 93) Lansoprazole 30 mg (N = 85) Age (y) 53.39 54.11 54.22 Gender Male 58 (65.91) 61(65.59) 47(55.29) Female 30 (34.09) 32 (34.41) 38 (44.71) Height (cm) 166.82 166.27 165.22 Weight (kg) 66.77 67.18 65.80 Smoking; yes 36 (40.91) 33 (35.48) 30 (35.29) Alcohol; yes 42 (47.73) 39 (41.94) 38 (44.71) NSAID/ASA 2(2.27) 4(4.30) 3(3.53) Helicobacter pylori positive 52 (59.09) 60 (64.52) 57 (67.06) Current ulcers; number Single 74 (84.09) 73 (78.49) 73 (85.88) Multiple 14 (15.91) 20 (21.51) 12 (14.12) Current ulcer; size 3-5 mm 23 (20.54) 27 (21.95) 29 (26.85) 5-10 mm 60 (53.57) 60 (48.78) 47 (43.52) 10-20 mm 25(22.32) 28 (22.76) 25(23.15) 20-30 mm 4 (3.57) 8 (6.5) 7 (6.48) TA B LE 1 Patient demographics and baseline characteristics (per protocol set)",3926,590,981.5,"[ 0.28140152 -0.38577113 -1.5815105  ... -0.05967557  0.3954926
 -1.1311061 ]"
197,"794  |     CHO et al.4 and 8 weeks. The increase in serum gastrin concentration, and safety profiles were similar in both groups. Tegoprazan 50  mg would be effective as 100 mg in GU healing. In a phase 3 dose-rang- ing study of erosive esophagitis to compare tegoprazan with es- omeprazole, the percentage of patients with erosive esophagitis and cumulative healing rates at week 8 did not differ between the tegoprazan 50  mg and tegoprazan 100  mg groups.18 It is gener- ally accepted that suppressing gastric acid secretion enhances treatment of acid-related disorders, with better efficacy achieved when intragastric pH >4 is sustained for as long of a duration as possible.19-21 There has not been the direct comparison data of in- tragastric pH >4 holding time between tegoprazan and lansopra- zole. The previous pharmacodynamic study showed pH >4 holding time over 24 hours increased in a dose-dependent manner after a single dose of 50-400 mg of tegoprazan.15 The pH 4 > holding time in multiple dosing of tegoprazan 50 mg is 54.2%-68.2%, and Tegoprazan 50 mg Tegoprazan 100 mg Lansoprazole 30 mg At 8 wks; Per protocol set N = 88 N = 93 N = 85 Number(%) of healed patients 88 (100.00) 91 (97.85) 85 (100.00) Difference from lansoprazole with 95% CId  (−7.66, 2.43)b  P valuea  — 0.0137 Full analysis set N = 96 N = 99 N = 93 Number(%) of healed patients 91 (94.79) 94 (94.95) 89 (95.70) Difference from lansoprazole with 95% CId  (−7.98, 6.09)b  (−7.69, 6.31)b  P valuea  0.0177 0.0146 At 4 wks; Per protocol set N = 88 N = 93 N = 85 Number(%) of healed patients 84 (95.45) 88 (94.62) 79 (92.94) Difference from lansoprazole with 95% CId  (−5.18, 10.77)b  (−5.44, 8.80)c  P valuea  0.0038 0.0024 Full analysis set N = 96 N = 99 N = 93 Number(%) of healed patients 87 (90.63) 91 (91.92) 83 (89.25) Difference from lansoprazole with 95% CId  (−7.20, 9.96)c  (−5.60, 10.95)c  P valuea  0.0117 0.0040 Note: Non-inferiority margin −8.54%.aNon-inferiority test. bExact unconditional confidence interval. cWald confidence interval. dAccording to Hochberg method, significant level for the test of tegoprazon and lansoprazole is 0.025 (one sided). TA B LE 2 Endoscopic healing rate (%) of gastric ulcer up to 4 and 8 weeks Tegoprazan 50 mg (N = 102) Tegoprazan 100 mg (N = 102) Lansoprazole 30 mg (N = 100) N (%) N (%) N (%) TEAE 18 (17.65) 23 (22.55) 25 (25.00) 95% CI, P valuea  [0.10-0.25], 0.2018 [0.14, 0.31], 0.6824 [0.17, 0.33] Drug-related TEAE 10 (9.80) 14 (13.73) 12 (12.00) 95% CI, P valuea  [0.04, 0.06], 0.6164 [0.07, 0.20], 0.7143 [0.06, 0.18] Serious TEAE 3 (2.94) 2 (1.96) 1 (1.00) 95% CI, P valuea  [0.00, 0.06], 0.6213 [0.00, 0.05], 1.0000 [0.00, 0.03] aχ2 or Fisher's exact test. TA B LE 3 Summary of treatment- emergent adverse events (TEAEs)",2764,428,691.0,"[ 0.16935284 -0.38985464 -1.5335606  ...  0.8641215   0.63705987
 -1.0521672 ]"
198,"|  795 CHO et al.66.55% of tegoprazan 100 mg in healthy males. Because two doses of tegoprazan showed similar ulcer healing rates, acid suppressive effect of tegoprazan seems satisfactory even in dose of 50 mg. Tegoprazan showed better efficacy in H.  pylori positive pa- tients. In patients with H. pylori infection, the both doses of te- goprazan were not inferior to lansoprazole 30  mg. The 8-week healing rates were 100% in all of three groups. Subgroup analyses of H.  pylori-negative patients showed the healing rate of tego- prazan 100 mg was not inferior, whereas tegoprazan 50 mg was not non-inferior to the lansoprazole. A previous study reported that vonoprazan also produced non- inferior healing rates to lan- soprazole for gastric and duodenal ulcers in H. pylori-positive pa- tients at 8 weeks.12 We also analysed the incidence rates of symptoms of epigastric pain, abdominal distension, nausea, heartburn and anorexia. The symptoms had resolved by the last study visit in >90% of patients in all three treatment groups. This finding shows the additional benefit to those patients who had both peptic ulcer disease and associated symptoms. Tegoprazan was generally well tolerated. The incidence of TEAEs did not differ significantly between groups, and no serious drug-related AEs were reported throughout the study. The safety and tolerability profiles were similar to those of lansoprazole. Most TEAEs were mild in severity, and few drug-related TEAEs were re- ported. Moreover, the magnitude of the increase in serum gastrin concentration did not differ significantly between groups, and the serum gastrin concentration returned to the baseline levels after the patients completed their treatment. Additionally, vonoprazan in- creased serum gastrin levels more than lansoprazole in GU study.11 But changes of serum gastrin levels were comparable among tego- prazan and lansoprazole groups in this study. This is the study to compare tegoprazan and lansoprazole, or to compare P-CABs and PPIs in the GU healing. The healing effect did not differ between the tegoprazan doses of 50 and 100  mg. The healing rate at 8 weeks was nearly 100%. The strengths of this study include the randomised, double-blind, double-dummy, mul- tisite design, the large sample size and the focus on a Korean pop- ulation. One limitation of our study is that, given the study design, we could examine only the non-inferiority and not the superiority Tegoprazan  50 mg (N = 102) Tegoprazan 100 mg (N = 102) Lansoprazole 30 mg (N = 100) N (%) N (%) N (%) Gastrointestinal disorders 5 (4.90) 7 (6.86) 4 (4.00) Diarrhoea 3 (2.94) 2 (1.96) 0 (0.00) Upper abdominal pain 0 (0.00) 1 (0.98) 0 (0.00) Constipation 0 (0.00) 1 (0.98) 0 (0.00) Dyspepsia 1 (0.98) 1 (0.98) 0 (0.00) Abdominal discomfort 0 (0.00) 0 (0.00) 2 (2.00) Investigations 2 (1.96) 2 (1.96) 3 (3.00) Serum gastrin increased 1 (0.98) 0 (0.00) 2 (2.00) Alanine aminotransferase increased 1 (0.98) 1 (0.98) 0 (0.00) Aspartate aminotransferase increased 0 (0.00) 1 (0.98) 1 (1.00) Blood bilirubin increased 0 (0.00) 1 (0.98) 0 (0.00) Gamma-glutamyltransferase increased 1 (0.98) 0 (0.00) 0 (0.00) Blood triglycerides increased 1 (0.98) 0 (0.00) 0 (0.00) Headache 1 (0.98) 0 (0.00) 1 (1.00) Chest discomfort or pain 2 (1.96) 0 (0.00) 1 (1.00) TA B LE 4 Drug-related treatment- emergent adverse events (TEAEs) reported in the treatment group FI G U R E 2 Gastrin levels from baseline (pg/mL) during treatment and follow-up periods (safety set)",3492,546,873.0,"[-0.19191803 -0.29769716 -1.507969   ...  0.37459904  0.05153184
 -1.5277388 ]"
199,"796  |     CHO et al.of tegoprazan compared with lansoprazole. In conclusion, we have shown that tegoprazan at doses of 50 and 100 mg was non-inferior to lansoprazole 30 mg and had a favourable safety profile in patients with GUs. ACKNOWLEDGEMENTS Declaration of personal interests: The authors thank all the investiga- tors who contributed to this study. Statistical analysis was supported by Kyeong min Oh, Ah Rong Kim, Chung Hyun Choi, Hyun Wook, Park, Eun Ji Kim and Geun Seog Song who are employees of HK inno. N Corp., Seoul, Korea. AUTHORSHIP Guarantor of the article: Myung-Gyu Choi. Author contributions: All authors were involved in patients' enrollment, performing the study, acquisition of data and inter- pretation of study results. Prof, Myung-Gyu Choi was involved in the study design, drafting of the manuscript and critical revision of the manuscript. DrYu Kyung Cho wrote the manuscript, all au- thors approved the final version of the manuscript, including the authorship list. ORCID Myung-Gyu Choi  https://orcid.org/0000-0002-7297-6577 Hye-Kyung Jung  https://orcid.org/0000-0002-6653-5214 Byung-Wook Kim  https://orcid.org/0000-0002-2290-4954 REFERENCES 	 1.	 Hunt RH, Cederberg C, Dent J, et al. Optimizing acid suppression for treatment of acid-related diseases. Dig Dis Sci.1995;40:24S-49S. 	 2.	 Huang JQ, Hunt RH. Pharmacological and pharmacodynamic essentials of H2-receptor antagonists and proton pump inhibi- tors for the practising physician. Best Pract Res Clin Gastroenterol. 2001;15:355-370.	 3.	 Shin JM, Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil.2013;19:25-35.	 4.	 Strand DS, Kim D, Peura DA.25 years of proton pump inhibitors: a comprehensive review. Gut Liv.2017;15:27-37.	 5.	 Oshima T, Miwa H. Potent potassium-competitive acid block- ers: a new era for the treatment of acid-related diseases. J Neurogastroenterol Motil.2018;30:334-344.	 6.	 Mori H, Suzuki H. Role of acid suppression in acid-related diseases: proton pump inhibitor and potassium-competitive acid blocker. J Neurogastroenterol Motil.2019;25:6-14.	 7.	 Matsukawa J, Hori Y, Nishida H, et al. A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands. Biochem Pharmacol.2011;81:1145-1151.	 8.	 Echizen H. The first-in-class potassium-competitive acid blocker, vonoprazan fumarate: pharmacokinetic and pharmacodynamic considerations.",2500,341,625.0,"[ 0.3178802  -0.03611046 -1.3981483  ...  0.17919835  0.39156812
 -1.5172073 ]"
199,"Clin Pharmacokinet.2016;55:409-418.	 9.	 Jung YS, Kim EH, Park CH. Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter py- lori eradication. Aliment Pharmacol Ther.2017;46:106-114.	10.	 Ashida K, Sakurai Y, Hori T, et al. Randomised clinical trial: vono- prazan, a novel potassium-competitive acid blocker, vs. lansopra- zole for the healing of erosive oesophagitis. Aliment Pharmacol Ther. 2016;43:240-251.	11.	 Komori H, Ueyama H, Nagahara A, et al. A prospective randomized trial of a potassium competitive acid blocker vs proton pump in- hibitors on the effect of ulcer healing after endoscopic submucosal dissection of gastric neoplasia. J Int Med Res.2019;47:1441-1452.	12.	 Miwa H, Uedo N, Watari J, et al. Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority ran- domised controlled trials. Aliment Pharmacol Ther.2017;45:240-252.	13.	 Liu C, Feng BC, Zhang Y, Li LX, Zuo XL, Li YQ. The efficacy of vono- prazan for management of post-endoscopic submucosal dissection ulcers compared with proton pump inhibitors: a meta-analysis. J Dig Dis.2019;20:503-511.	14.	 Takahashi N, Take Y. Tegoprazan, a novel potassium-competi- tive acid blocker to control gastric acid secretion and motility. J Pharmacol Exp Ther.2018;364:275-286.	15.	 Han S, Choi HY, Kim YH, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan (CJ-12420), a novel potas- sium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther.2019;50:751-759.	16.	 Scarpignato C, Hunt RH. Editorial: potassium-competitive acid blockers for acid-related diseases—tegoprazan, a new kid on the block. Aliment Pharmacol Ther.2019;50:960-962.	17.	 Kim DK, Lee KH, Kim SJ, et al.",1907,259,476.75,"[-0.5947463  -0.007468   -1.454363   ...  0.56683457 -0.21982728
 -1.5150263 ]"
199,"Effects of tegoprazan, a novel potas- sium-competitive acid blocker, on rat models of gastric acid-related disease. Pharmacol Exp Ther.2019;369:318-327.	18.	 Lee KJ, Son BK, Kim GH, et al. Randomised phase 3 trial: tego- prazan, a novel potassium-competitive acid blocker, vs. esomepra- zole in patients with erosive oesophagitis. Aliment Pharmacol Ther. 2019;49:864-872.	19.	 Gerson LB, Fass R. A systematic review of the definitions, preva- lence, and response to treatment of nocturnal gastroesophageal reflux disease. Clin Gastroenterol Hepatol.2009;7:372-378.	20.	 Orr WC. Review article: sleep-related gastro-oesophageal reflux as a distinct clinical entity. Aliment Pharmacol Ther.2010;31:47-56.	21.	 Schubert ML, Peura DA. Control of gastric acid secretion in health and disease. Gastroenterology.2008;134:1842-1860. How to cite this article: Cho YK, Choi M-G, Choi SC, et al. Randomised clinical trial: tegoprazan, a novel potassium- competitive acid blocker, or lansoprazole in the treatment of gastric ulcer. Aliment Pharmacol Ther.2020;52:789–797. https://doi.org/10.1111/apt.15865 APPENDIX 1 The authors' complete affiliation list Yu Kyung Cho and Myung-Gyu Choi: Catholic Photomedicine Research Institute, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. Suck Chei Choi: Wonkwang University Hospital, Iksan, Korea. Kee Myung Lee: Ajou University Hospital, Ajou University School of Medicine, Suwon, Korea. Tae Oh Kim: Haeundae Paik Hospital, Inje University School of Medicine, Busan, Korea. Soo-Heon Park: Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. Jeong Seop Moon: Seoul Paik Hospital, Inje University College of Medicine, Seoul, Korea. Yun Jeong Lim: Dongguk University IIsan Hospital, Dongguk University College of Medicine,",1844,244,461.0,"[-0.2653405  -0.13270357 -1.4088252  ...  0.21837479 -0.27328724
 -1.7444493 ]"
200,"|  797 CHO et al. Goyang, Korea. Dae Hwan Kang: Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Korea. Gab Jin Cheon: Gangneung Asan Hospital, Ulsan University College of Medicine, Gangneung, Korea. Gwang Ho Baik: Hallym University Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, Chuncheon, Korea. Kyoung Oh Kim: Gachon University Gil Medical Center, Gachon University School of Medicine, Incheon, Korea. Kwang Bum Cho: Keimyung University School of Medicine, Daegu, Korea. Jin Seok Jang: Dong-A University College of Medicine, Busan, Korea. Jong-Jae Park: Korea University College of Medicine, Seoul, Korea. Byoung Kwan Son: Eulji University Hospital, Seoul, Korea. Hye-Kyung Jung: Ewha Woman's University Mokdong Hospital, Seoul, Korea. Byung-Wook Kim: Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Incheon, Korea. Sung Kuk Kim: Kyungpook University School of Medicine, Daegu, Korea. Soo Teik Lee: Chonbuk National University Medical School, Jeonju, Korea. Jae Myung Cha: KyungHee University Hospital at Gangdong, KyungHee University School of Medicine, Seoul, Korea. Ah Rong Kim, Eun Ji Kim, Hyun Wook Park and Geun Seog Song: Clinical Development Division, HK inno. N Corp., Seoul, Korea. Jae Young Jang: Kyung Hee University College of Medicine, Seoul, Korea. Jeong Eun Shin: Dankook University College of Medicine, Cheonan, Korea. Dong Il Park: Kangbuk Samsung Hospital, Samsung Medical Center, Seoul, Korea. Su Jin Hong: Soonchunhyang University Buchen Hospital, Bucheon, Korea. Yong Chan Lee: Severance Hospital, Seoul, Korea. Eun Kwang Choi: Jeju National University School of Medicine, Jeju, Korea. Chan Guk Park: Chosun University Hospital, Chosun University College of Medicines, Gwangju, Korea. Jae Gyu Kim: Chung-Ang University College of Medicine, Seoul, Korea. Seong Woo Jeon: Gastric Cancer Center, Kyungpook National University Chilgok Hospital, Daegu, Korea. Ji Won Kim: Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Korea. Sang Woo Lee: Korea University Ansan Hospital, Ansan, Korea. Kwang Hyun Ko: Digestive Disease Center, CHA Medical Center, CHA University, Seongnam, Korea. Hyun Soo Kim: Yonsei University Wonju College of Medicine, Wonju Christian Hospital, Wonju, Korea.",2350,330,587.5,"[ 0.9735113  -0.5904592  -1.3207448  ... -0.3191511  -0.09749942
 -1.5638332 ]"
201,"The new england  journal of medicine n engl j med 382;14  nejm.org  April 2, 2020 1299 established in 1812	 April 2, 2020	 vol.382  no.14 From the Institute of Digestive Disease, the Chinese University of Hong Kong, Shatin, Hong Kong. Address reprint re‑ quests to Dr. Lau at the Department of Surgery, Rm.64026, Lui Chee Woo Clini‑ cal Science Bldg.,Prince of Wales Hospi‑ tal, 32 Ngan Shing St., Shatin, Hong Kong, or at ­laujyw@​­surgery​.­cuhk​.­edu​.­hk. N Engl J Med 2020;382:1299-308. DOI: 10.1056/NEJMoa1912484 Copyright © 2020 Massachusetts Medical Society. BACKGROUND It is recommended that patients with acute upper gastrointestinal bleeding undergo endoscopy within 24 hours after gastroenterologic consultation. The role of endos- copy performed within time frames shorter than 24 hours has not been adequately defined. METHODS To evaluate whether urgent endoscopy improves outcomes in patients predicted to be at high risk for further bleeding or death, we randomly assigned patients with overt signs of acute upper gastrointestinal bleeding and a Glasgow–Blatchford score of 12 or higher (scores range from 0 to 23, with higher scores indicating a higher risk of further bleeding or death) to undergo endoscopy within 6 hours (urgent-endoscopy group) or between 6 and 24 hours (early-endoscopy group) after gastroenterologic consultation. The primary end point was death from any cause within 30 days after randomization. RESULTS A total of 516 patients were enrolled. The 30-day mortality was 8.9% (23 of 258 patients) in the urgent-endoscopy group and 6.6% (17 of 258) in the early-endoscopy group (difference, 2.3 percentage points; 95% confidence interval [CI], −2.3 to 6.9). Further bleeding within 30 days occurred in 28 patients (10.9%) in the urgent- endoscopy group and in 20 (7.8%) in the early-endoscopy group (difference, 3.1 percentage points; 95% CI, −1.9 to 8.1). Ulcers with active bleeding or visible ves- sels were found on initial endoscopy in 105 of the 158 patients (66.4%) with peptic ulcers in the urgent-endoscopy group and in 76 of 159 (47.8%) in the early-endos- copy group. Endoscopic hemostatic treatment was administered at initial endoscopy for 155 patients (60.1%) in the urgent-endoscopy group and for 125 (48.4%) in the early-endoscopy group. CONCLUSIONS In patients with acute upper gastrointestinal bleeding who were at high risk for further bleeding or death, endoscopy performed within 6 hours after gastroen- terologic consultation was not associated with lower 30-day mortality than endos- copy performed between 6 and 24 hours after consultation. (Funded by the Health and Medical Fund of the Food and Health Bureau, Government of Hong Kong Special Administrative Region; ClinicalTrials.gov number, NCT01675856.)abstr act Timing of Endoscopy for Acute Upper Gastrointestinal Bleeding James Y. W. Lau, M. D., Yuanyuan Yu, Ph. D., Raymond S. Y. Tang, M. D., Heyson C. H. Chan, M. B., Ch. B., Hon‑Chi Yip, M. B., Ch. B., Shannon M. Chan, M. B., Ch. B., Sally W. Y. Luk, M. B., Ch. B., Sunny H. Wong, Ph. D., Louis H. S. Lau, M. B., Ch. B., Rashid N. Lui, M. B., Ch. B., Ting T. Chan, M. B., Ch. B., Joyce W. Y. Mak, M. B., Ch. B., Francis K. L. Chan, M. D., and Joseph J. Y. Sung, M. D.​ The New England Journal of Medicine Downloaded from nejm.org at Yonsei Univ Coll of Medicine on May 29, 2024. For personal use only. No other uses without permission. Copyright © 2020 Massachusetts Medical Society. All rights reserved.",3475,546,868.75,"[-0.08329073 -0.7044884  -1.8983445  ...  0.27018306  0.9188688
 -1.3521826 ]"
202,"n engl j med 382;14  nejm.org  April 2, 2020 1300 The new engl and jour nal of medicine A cute upper gastrointestinal bleed- ing is one of the most common medical emergencies. A national audit from the United Kingdom estimated a crude overall in- hospital mortality of 10% after acute upper gas- trointestinal bleeding.1 Endoscopy allows iden­ tification of the source of bleeding, as well as hemostatic treatment for actively bleeding le- sions. Endoscopic hemostatic treatment of high- risk lesions stops bleeding and reduces the risk of further bleeding and the need for surgery.2 An international consensus group recommends en- doscopy within 24 hours after presentation for patients with acute upper gastrointestinal bleed- ing.3 For patients who are at high risk for further bleeding or death, the consensus group could not make a recommendation for or against per- forming endoscopy within 12 hours as opposed to performing endoscopy later. Many observa- tional studies,4-16 three randomized, controlled trials,17-19 and two systematic reviews20,21 have shown that urgent endoscopy (the definitions of which have varied among studies, ranging from within 2 hours to within 12 hours after presen- tation) in unselected patients with acute upper gastrointestinal bleeding did not decrease mor- tality. The three randomized trials were not de- signed to focus on patients at high risk for fur- ther bleeding or death and did not report an assessment of patients’ risk. The Glasgow–Blatchford score is a validated risk-assessment score for the prediction of clini- cal outcomes, including the need for interven- tions and the risk of death (scores range from 0 to 23, with higher scores indicating a higher risk of further bleeding or death). In an interna- tional multicenter prospective study involving 3012 patients, a threshold score of 7 or higher was shown to provide the most accurate predic- tion of whether a patient will be determined to need endoscopic treatment.22 In our own valida- tion study, a higher score was associated with a greater likelihood of undergoing endoscopic treat- ment, as well as with a higher risk of death.23 Recently, two large cohort studies16,24 provided conflicting results regarding the association between urgent endoscopy (within 6 hours after admission) and mortality. In a prospective co- hort study involving 961 patients with Glasgow– Blatchford scores greater than 7, Cho et al.24 found that endoscopy performed within 6 hours, as compared with between 6 and 24 hours, was an independent predictor of lower mortality (odds ratio for death, 0.36; 95% confidence in- terval [CI], 0.14 to 0.95). However, in the study by Laursen et al.,16 involving 2944 patients, the time frame for endoscopy that was associated with the lowest mortality was between 6 and 24 hours after admission. Mortality was higher among patients with hemodynamic instability or severe coexisting illnesses, defined as an American Society of Anesthesiologists grade of 3 to 5. A risk-assessment score was not used in that study. In this trial, we hypothesized that for patients with acute gastrointestinal bleeding who were predicted to be at high risk for further bleeding or death, endoscopy performed within 6 hours after gastroenterologic consultation would fore- stall further bleeding and improve outcomes as compared with endoscopy performed between 6 and 24 hours after consultation. Methods Trial Design and Oversight The Joint Chinese University of Hong Kong–New Territories East Cluster Hospital Ethics Commit- tee approved the protocol. The authors vouch for the accuracy and completeness of the data and for the fidelity of the trial to the protocol, avail- able with the full text of this article at NEJM.org. We reported all serious adverse events, within 24 hours after their occurrence, to the Clinical Re- search and Ethics Committee at the Chinese Uni- versity of Hong Kong. Serious adverse events were defined as events that were life-threaten- ing, that led to prolongation of existing hospital- ization, or that led to persistent or substantial disability or incapacitation. The committee pro- vided ethics oversight and scientific oversight during the period of the trial. Senior physicians and biostatisticians on the committee adjudicated outcomes and monitored the progress of the trial. Patients Our gastrointestinal bleeding team screened pa- tients for eligibility and performed randomiza- tion either in the emergency department or after admission to a medical ward. Patients who had overt signs of acute upper gastrointestinal bleed- ing (hematemesis, melena, or both) and who were predicted to be at high risk for further bleeding or death on the basis of a Glasgow– Blatchford score of 12 or higher were eligible for A Quick Take is  available at  NEJM.org The New England Journal of Medicine Downloaded from nejm.org at Yonsei Univ Coll of Medicine on May 29, 2024. For personal use only. No other uses without permission. Copyright © 2020 Massachusetts Medical Society. All rights reserved.",5044,789,1261.0,"[-0.09862737 -0.30005458 -2.0276415  ...  0.2863371   0.95939267
 -1.292082  ]"
203,"n engl j med 382;14  nejm.org  April 2, 2020 1301 Endoscopy for Upper Gastrointestinal Bleeding enrollment. The Glasgow–Blatchford score is based on the systolic blood pressure, pulse rate, hemoglobin and serum urea levels at admission, whether the patient presented with melena or syncope, and the presence or absence of hepatic disease or cardiac failure. Eligible inpatients in whom gastrointestinal bleeding developed while they were hospitalized for other medical illnesses also underwent randomization at the first gastro- intestinal consultation. We calculated the Glasgow– Blatchford score on the basis of the lowest sys- tolic blood pressure and highest pulse rate recorded and the hemoglobin and urea levels on admission to the emergency department (or, for patients already hospitalized, recent values ob- tained before gastrointestinal consultation). All patients provided written informed consent. We excluded patients who were younger than 18 years of age, unable to provide written in- formed consent, pregnant, or moribund from terminal illness. We also excluded patients who were in hypotensive shock or whose condition did not stabilize after initial resuscitation, since they required urgent intervention. Randomization, Interventions, and Data Collection We randomly assigned patients in a 1:1 ratio us- ing a computer-generated sequence. After obtain- ing written informed consent from the patient, the admitting resident then logged on to a Web- based randomization program, which generated the randomization number and assigned treat- ment. We randomly assigned patients to under- go either urgent endoscopy within 6 hours after gastroenterologic consultation (urgent-endoscopy group) or early endoscopy the next morning and within 24 hours (early-endoscopy group). Patients in the early-endoscopy group whose gastroen- terologic consultation took place between mid- night and 8 a.m. underwent endoscopy in the morning endoscopy session of the same day of their admission and were scheduled for a time of endoscopy that was a minimum of 6 hours after consultation. Patients in the early-endoscopy group whose gastroenterologic consultation took place between 8 a.m. and 11:59 p.m. underwent endoscopy the next morning. We monitored these patients closely and offered emergency endoscopy if there were signs of further bleed- ing (i.e., fresh hematemesis or hematochezia, hypotensive shock, or both). The hospitals offer 24-hour endoscopy service with a fellow and a consultant on the team. All after-hours endos- copy procedures were supported by endoscopy nurses with skills in assisting with therapeutic endoscopy. Both groups of patients received an intrave- nous high-dose infusion of a proton-pump in- hibitor (80-mg bolus followed by 8 mg per hour) on admission, as well as at the first sign of bleeding during the hospital stay. Patients with suspected variceal bleeding (known liver disease, stigmata of liver cirrhosis, or a history of bleed- ing esophagogastric varices) received a vasoac- tive drug as well as intravenous antibiotic agents. At endoscopy, gastroduodenal ulcers with ac- tive bleeding or with nonbleeding visible vessels were treated with either hemoclips or contact thermocoagulation, with or without preinjection of diluted epinephrine. Bleeding esophageal and gastric varices were treated with band ligation and injection of cyanoacrylate (a tissue adhesive), respectively. After endoscopic hemostatic treat- ment of the bleeding ulcers in these patients, a high-dose intravenous infusion of a proton-pump inhibitor was continued for 72 hours. We de- fined further bleeding as a composite of persis- tent bleeding (i.e., bleeding that was not suc- cessfully controlled at the first endoscopy) or recurrent bleeding (i.e., bleeding that recurred after hemostatic treatment). We generally adopt­ed criteria from international guidelines on defini- tions of recurrent bleeding.25 Endoscopy togeth- er with further hemostatic treatment was per- formed for patients with overt signs of recurrent bleeding after initial endoscopic control. End Points The primary end point was death from any cause within 30 days after randomization. Secondary end points included receipt of endoscopic ther­ apy at first endoscopy, further bleeding (defined as persistent or recurrent bleeding),25 duration of stay in the hospital and intensive care unit, re- ceipt of further endoscopic treatment, emergency surgery or angiographic embolization to achieve hemostasis, blood transfusions, and adverse events within 30 days after randomization. Statistical Analysis We determined that a sample of 258 patients per group would provide 80% power to detect an 8-percentage-point difference (i.e., 16% vs. 8%) The New England Journal of Medicine Downloaded from nejm.org at Yonsei Univ Coll of Medicine on May 29, 2024. For personal use only. No other uses without permission. Copyright © 2020 Massachusetts Medical Society. All rights reserved.",4970,722,1242.5,"[-0.48694378 -0.47164166 -1.9257516  ...  0.05796312  0.9440189
 -1.2441331 ]"
204,"n engl j med 382;14  nejm.org  April 2, 2020 1302 The new engl and jour nal of medicine in 30-day mortality, with a two-sided α level of 5%. We considered a 50% relative difference in mortality to be clinically significant. In our vali- dation study of the Glasgow–Blatchford score,23 21% of patients had a score of 12 or higher, and the 30-day mortality in that group was 16.1%. Our analysis was performed on an intention- to-treat basis. We did not have any data missing from our data set. We used the log-rank test to compare the time from randomization to the end points of death and further bleeding and a Cox proportional-hazards model to estimate the hazard ratio and 95% confidence intervals. We used the Schoenfeld residual test to verify the assumption of proportional hazards in the Cox analysis, which was fulfilled for the end points of death from any cause and further bleeding. Secondary end points were compared between the groups with a chi-square test for difference in proportions and with Student’s t-test and a Mann–Whitney U test for parametric and nonparametric data, respectively. All tests of sig- nificance were two-tailed, and a P value of 0.025 or less was considered to indicate statistical sig- nificance for the primary end point, since we reported one unplanned interim analysis in 2015.26 There was no prespecified plan to adjust for multiple comparisons of the secondary end points; the results for secondary end points are reported with 95% confidence intervals and with- out P values. Confidence intervals have not been adjusted for multiple comparisons and should not be used to infer treatment effects. Results Patients From July 2012 through October 2018, a total of 4715 patients with acute upper gastrointesti- nal bleeding underwent screening; 598 had a Glasgow–Blatchford score of 12 or higher, and 516 were enrolled in the trial and underwent randomization (258 assigned to each group) (Fig. S1 in the Supplementary Appendix, avail- able at NEJM.org). The baseline demographic and clinical characteristics and the endoscopic findings are shown in Table  1. Peptic ulcers were the source of bleeding in 158 patients (61.2%) in the urgent-endoscopy group and 159 patients (61.6%) in the early-endoscopy group, and esophagogastric varices were the cause in 25 (9.7%) and 19 (7.3%), respectively. In the urgent-endoscopy group, 3 patients did not undergo endoscopy (1 had undergone recent endovascular repair for an abdominal aneurysm and had cardiac arrest before endoscopy could be performed, 1 had acute pulmonary edema, and 1 declined), and 6 had endoscopy performed more than 6 hours after gastroenterologic con- sultation. In the early-endoscopy group, 5 patients did not undergo endoscopy (4 died before endos- copy [2 from ongoing bleeding, 1 from acute coronary syndrome, and 1 from a ruptured tho- racic aortic aneurysm], and 1 declined). Emer- gency endoscopy was performed in 20 patients (7.8%) in the early-endoscopy group because of new-onset signs of bleeding: hypotension in 11 patients, fresh hematemesis in 6, fresh melena in 2, and a substantial decrease in hemoglobin level in 1. Three patients in the early-endoscopy group underwent endoscopy more than 24 hours after gastroenterologic consultation (Table 2). Timing of Endoscopy The mean (±SD) time from presentation to gas- troenterologic consultation was 7.4±6.2 hours in the urgent-endoscopy group and 8.0±7.1 hours in the early-endoscopy group (Table 2), and the mean time from gastroenterologic consultation to endoscopy was 2.5±1.7 hours and 16.8±6.8 hours, respectively. Therefore, the mean time from presentation to endoscopy was 9.9±6.1 hours in the urgent-endoscopy group and 24.7±9.0 hours in the early-endoscopy group. In the urgent- endoscopy group, 72 patients (27.9%) underwent endoscopy within 6 hours after presentation, and 124 patients (48.1%) underwent endoscopy within 12 hours (Fig. S3B). The time of day that patients had their gastroenterologic consultation was similar in the two groups. Endoscopy was performed between 6 p.m. and 5:59 a.m. in 96 of 255 patients (37.6%) in the urgent-endoscopy group and 17 of 253 patients (6.7%) in the early- endoscopy group. Additional details about the timing of endoscopy in each group are provided in Table 2 and Figure S3.30-Day Mortality All-cause mortality at 30 days after randomiza- tion did not differ significantly between the two groups. A total of 23 patients (8.9%) in the urgent- endoscopy group and 17 (6.6%) in the early- endoscopy group died (hazard ratio, 1.35; 95% CI, 0.72 to 2.54; P = 0.34). (Fig. 1A and Table 3). The New England Journal of Medicine Downloaded from nejm.org at Yonsei Univ Coll of Medicine on May 29, 2024. For personal use only. No other uses without permission. Copyright © 2020 Massachusetts Medical Society. All rights reserved.",4845,760,1211.25,"[ 0.19579183 -0.27722722 -1.9473116  ... -0.00345142  1.211384
 -1.3638555 ]"
205,"n engl j med 382;14  nejm.org  April 2, 2020 1303 Endoscopy for Upper Gastrointestinal Bleeding The difference in mortality between the groups was 2.3 percentage points (95% CI, −2.3 to 6.9). Deaths from gastrointestinal bleeding accounted for 5 of the 23 deaths in the urgent-endoscopy group and 2 of the 17 deaths in the early-endos- copy group. Advanced cancer was present in 11 of 23 and 8 of 17 patients who died, respectively. The causes of deaths are listed in Table S2. Table 1. Baseline Characteristics of the Patients.*Characteristics Urgent-Endoscopy Group (N = 258) Early-Endoscopy Group (N = 258) Age — yr 69.6±16.0 71.4±14.9 Male sex — no. (%)157 (60.9) 168 (65.1) Hemoglobin level on admission — g/dl 7.4±1.8 7.2±1.6 Systolic blood pressure — mm Hg 109.6±22.1 107.8±20.8 Systolic blood pressure <90 mm Hg — no. (%)46 (17.8) 37 (14.3) Heart rate >100 beats/min — no. (%)85 (32.9) 92 (35.7) Glasgow–Blatchford score† 13.7±1.5 13.7±1.6 Glasgow–Blatchford score category — no. (%)12 to 14 193 (74.8) 183 (70.9) 15 to 23 65 (25.2) 75 (29.1) Bleeding during hospitalization — no. (%)‡22 (8.5) 20 (7.8) Coexisting diseases — no. (%)Ischemic heart disease 33 (12.8) 29 (11.2) Cancer 31 (12.0) 25 (9.7) Renal disease 25 (9.7) 21 (8.1) Liver cirrhosis 11 (4.3) 10 (3.9) History of bleeding peptic ulcers — no. (%)49 (19.0) 41 (15.9) Risk factors for peptic ulcer disease — no. (%)NSAID use 42 (16.3) 45 (17.4) Aspirin use 77 (29.8) 65 (25.2) Clopidogrel use 3 (1.2) 4 (1.6) Warfarin or direct oral anticoagulant use 7 (2.7) 10 (3.9) Endoscopic findings Peptic ulcer — no. (%)158 (61.2) 159 (61.6) Gastric ulcer 69 77 Duodenal ulcer 81 74 Anastomotic ulcer or jejunal ulcer 4 4 Esophageal ulcer 4 4 Esophageal or gastric varices — no. (%)25 (9.7) 19 (7.4) Other findings on endoscopy — no. (%)§72 (27.9) 75 (29.1) No abnormality detected — no.3 12 *	Plus–minus values are means ±SD. NSAID denotes nonsteroidal antiinflammatory drug. †	The Glasgow–Blatchford score ranges from 0 to 23, with higher scores indicating a higher risk of further bleeding or death. ‡	This category includes patients who had been admitted with other medical illnesses and in whom symptoms of acute upper gastrointestinal bleeding subsequently developed during hospitalization. §	Other findings included esophagitis, gastritis, duodenitis or erosions, gastrointestinal cancers and submucosal tumors, Dieulafoy’s lesions, angiodysplasia, Mallory–Weiss tears, antral vascular ectasia, gastric polyps, duodenal diverticulum, bleeding varices at anastomosis, papilloma, hiatal hernia, submucosal hematoma, post-sphincterotomy bleeding, hemo‑ bilia, and diffuse gastric hemorrhage. The New England Journal of Medicine Downloaded from nejm.org at Yonsei Univ Coll of Medicine on May 29, 2024. For personal use only. No other uses without permission. Copyright © 2020 Massachusetts Medical Society. All rights reserved.",2895,442,723.75,"[ 0.17097168 -0.59314156 -2.1395466  ...  0.24597314  0.8507999
 -1.3391186 ]"
206,"n engl j med 382;14  nejm.org  April 2, 2020 1304 The new engl and jour nal of medicine Further Bleeding, Endoscopic Treatment,  and Other End Points Further bleeding within 30 days occurred in 28 patients (10.9%) in the urgent-endoscopy group and 20 patients (7.8%) in the early-endoscopy group (hazard ratio, 1.46; 95% CI, 0.83 to 2.58). The between-group difference in the percentage of patients with further bleeding was 3.1 per- centage points (95% CI, −1.9 to 8.1) (Fig. 1B and Table  3). Persistent bleeding at endoscopy oc- curred in 2 patients in the urgent-endoscopy group (one of whom had gastric varices and bled again on day 3 but was counted only once in the analysis of the composite end point of further bleeding) and in 1 patient in the early-endoscopy group. Recurrent bleeding occurred in 27 patients (10.5%) in the urgent-endoscopy group and in 19 patients (7.4%) in the early-endoscopy group. Endoscopic hemostatic treatment was per- formed during the first endoscopy in 155 pa- tients (60.1%) in the urgent-endoscopy group and in 125 patients (48.4%) in the early-endos- copy group (difference, 11.6 percentage points; 95% CI, 0.3 to 20.0) (Table 3). Endoscopic hemo- static treatment for bleeding peptic ulcers was performed in 109 of the 158 patients with ulcers (68.9%) in the urgent-endoscopy group and in 81 of the 159 patients with ulcers (50.9%) in the early-endoscopy group. (The endoscopic stigmata of bleeding observed in peptic ulcers are shown in Fig. S2.)Among the patients who had peptic ulcers, ulcers with active bleeding or visible vessels Table 2. Timing of Endoscopy.*Measure Urgent-Endoscopy Group (N = 258) Early-Endoscopy Group (N = 258) Time from presentation to gastroenterologic consultation — hr† 7.4±6.2 8.0±7.1 Time from gastroenterologic consultation to endoscopy — hr 2.5±1.7 16.8±6.8 Time from presentation to endoscopy — hr‡ 9.9±6.1 24.7±9.0 Distribution of time from gastroenterologic consultation to  endoscopy — no./total no. (%)‡≤6 hr 249/255 (97.6) 15/253 (5.9) >6–12 hr 5/255 (2.0) 44/253 (17.4) >12–18 hr 0/255 60/253 (23.7) >18–24 hr 0/255 131/253 (51.8) >24 hr 1/255 (0.4) 3/253 (1.2) Time of gastroenterologic consultation — no. (%)6 a.m. to 11:59 a.m. 70 (27.1) 49 (19.0) Noon to 5:59 p.m. 140 (54.3) 135 (52.3) 6 p.m. to 11:59 p.m. 35 (13.6) 48 (18.6) Midnight to 5:59 a.m. 13 (5.0) 26 (10.1) Time of endoscopy — no. (%)‡6 a.m. to 11:59 a.m. 31/255 (12.2) 152/253 (60.1) Noon to 5:59 p.m. 128/255 (50.2) 84/253 (33.2) 6 p.m. to 11:59 p.m. 83/255 (32.5) 13/253 (5.1) Midnight to 5:59 a.m. 13/255 (5.1) 4/253 (1.6) Endoscopy not performed — no. (%)3/255 (1.2) 5/253 (2.0) *	Plus–minus values are means ±SD. Percentages may not total 100 because of rounding. †	Symptoms of acute upper gastrointestinal bleeding developed during hospitalization in 8.5% of patients in the urgent- endoscopy group and in 7.8% of patients in the early-endoscopy group. ‡	In the urgent-endoscopy group, 3 patients did not undergo endoscopy; the reasons were death on the day of enrollment (1), acute pulmonary edema (1), and the patient declining to undergo endoscopy (1). In the early-endoscopy group,  5 patients did not undergo endoscopy; the reasons were death on the day of or the day after enrollment (4) and the patient declining to undergo endoscopy (1). The New England Journal of Medicine Downloaded from nejm.org at Yonsei Univ Coll of Medicine on May 29, 2024. For personal use only. No other uses without permission. Copyright © 2020 Massachusetts Medical Society. All rights reserved.",3543,564,885.75,"[-0.36870146 -0.96207243 -1.9246408  ...  0.37908006  0.6622263
 -1.4976181 ]"
207,"n engl j med 382;14  nejm.org  April 2, 2020 1305 Endoscopy for Upper Gastrointestinal Bleeding were found in 105 patients (66.4%) in the urgent- endoscopy group and in 76 (47.8) in the early- endoscopy group. The two groups did not dif- fer substantially in the number of patients who underwent surgery (2 in the urgent-endoscopy group and 1 in the early-endoscopy group) or angiographic treatment (3 and 2, respectively). The duration of hospitalization did not differ between the urgent-endoscopy group and the early-endoscopy group (median of 5 days in both groups), and the two groups were similar in the number of patients who were admitted to the in- tensive care unit (4 and 3, respectively), the per- centage of patients who received a transfusion (89.5% and 90.7%), and the mean number of units of packed red cells received by transfusion (2.4 units in both groups). Timing of Endoscopy and Clinical End Points We performed a post hoc analysis to investigate the association between the time of day during which patients underwent endoscopy and the end points of further bleeding and death (Table S1). We analyzed end points in the urgent-endos- copy group after endoscopy performed during office hours (6 a.m. to 5:59 p.m.) and after endos- copy performed after hours (6 p.m. to 5:59 a.m.). The percentage of patients with further bleeding and the percentage of patients who died did not differ significantly according to the time of day of endoscopy (further bleeding, 10.7% [17 of 159] for endoscopy performed during office hours and 10.4% [10 of 96] for endoscopy performed after hours; death, 7.5% [12 of 159] and 10.4% [10 of 96], respectively). In the early-endoscopy group, 4 of 15 patients (26.7%) who underwent endoscopy within 6 hours after randomization and 3 of 44 (6.8%) of those who underwent en- doscopy between 6 and 12 hours after random- ization died within 30 days; among the 194 pa- tients who underwent endoscopy more than 12 hours after randomization, 6 (3.1%) died. Addi- tional details regarding nonfatal and fatal serious adverse events are provided in Table S3. Discussion In this randomized trial involving patients with upper gastrointestinal bleeding who were pre- dicted to be at high risk for further bleeding or  death, we found that endoscopy performed within 6 hours after gastroenterologic consulta- tion did not lead to lower mortality or a lower incidence of further bleeding than endoscopy performed within 24 hours after consultation. In this trial, randomization was performed at the time of gastroenterologic consultation and ap- proximately 7 to 8 hours after patients presented with bleeding to the emergency department. Our trial, therefore, evaluated endoscopy performed at a mean of 9.9 hours as compared with 24.7 hours after initial presentation. In the urgent-endoscopy group, we found more Figure 1. Kaplan–Meier Estimates of the Cumulative Incidences of Death and Further Bleeding. Panel A shows the estimates of mortality during the 30 days after random‑ ization, and Panel B shows the estimates of the incidence of further bleed‑ ing during the 30 days after randomization. The inset in each panel shows the same data on an enlarged y axis. Cumulative Probability 1.00 0.80 0.90 0.70 0.60 0.40 0.30 0.10 0.50 0.20 0.00 0 5 10 15 20 25 30 Days since Randomization B Cumulative Probability of Further Bleeding A Cumulative Probability of Death No.at Risk Urgent endoscopy Early endoscopy 258 258 252 249 246 245 242 245 238 243 238 242 235 241 Urgent endoscopy Early endoscopy 0.25 0.20 0.10 0.05 0.15 0.00 0 5 10 15 20 25 30 Cumulative Probability 1.00 0.80 0.90 0.70 0.60 0.40 0.30 0.10 0.50 0.20 0.00 0 5 10 15 20 25 30 Days since Randomization No.at Risk Urgent endoscopy Early endoscopy 258 258 243 237 228 231 220 230 214 228 213 226 210 223 Urgent endoscopy Early endoscopy 0.25 0.20 0.10 0.05 0.15 0.00 0 5 10 15 20 25 30 The New England Journal of Medicine Downloaded from nejm.org at Yonsei Univ Coll of Medicine on May 29, 2024. For personal use only. No other uses without permission. Copyright © 2020 Massachusetts Medical Society. All rights reserved.",4127,687,1031.75,"[ 0.0287395  -0.92725    -1.932414   ...  0.40208948  0.7817489
 -1.2714162 ]"
208,"n engl j med 382;14  nejm.org  April 2, 2020 1306 The new engl and jour nal of medicine ulcers that were actively bleeding and that had major stigmata of bleeding, resulting in more frequent endoscopic treatment. The more fre- quent endoscopic treatment, however, did not translate into a lower incidence of further bleed- ing or fewer deaths. Patients in the early-endos- copy group, on the other hand, received over- night acid suppression. The longer period until endoscopy and longer duration of acid suppres- sion reduced the number of ulcers with active bleeding and major stigmata of bleeding. This observation corroborates the findings from an earlier randomized, controlled trial27 that evalu- ated the use of a high-dose proton-pump inhibi- tor before endoscopy. Acid suppression before endoscopy can reduce the need for endoscopic treatment. In our trial, the observed mortality was lower than what was assumed in the sample-size calcu- lation. There may be several explanations. First, Table 3. Primary and Secondary End Points.*Outcome Urgent-Endoscopy  Group (N = 258) Early-Endoscopy  Group (N = 258) Relative Risk or Hazard Ratio  (95% CI)† P Value Primary end point Death from any cause within 30 days — no. (%)23 (8.9) 17 (6.6) 1.35 (0.72–2.54) 0.34 Secondary end points Further bleeding — no. (%)‡Within 7 days 15 (5.8) 14 (5.4) 1.07 (0.53–2.17) Within 30 days 28 (10.9) 20 (7.8) 1.46 (0.83–2.58) Source of further bleeding — no. Bleeding peptic ulcers 19 12 Bleeding esophagogastric varices 4 3 Other 5 5 Treatment for bleeding Endoscopic treatment administered during initial endoscopy — no. (%)155 (60.1) 125 (48.4) 1.24 (1.06–1.46) Endoscopic treatment for bleeding ulcers — no.of patients/total no.with ulcers 109/158 81/159 1.35 (1.13–1.63) Endoscopic treatment for varices — no.of patients/ total no.with varices 20/25 17/19 0.89 (0.70–1.15) Endoscopic treatment for other conditions — no.of  patients/total no.of patients 26/72 27/75 1.02 (0.66–1.56) Surgical treatment — no. (%)2 (0.8) 1 (0.4) 2.00 (0.18–21.92) Angiographic embolization — no. (%)3 (1.2) 2 (0.8) 1.50 (0.25–8.90) Median duration of hospitalization after randomization (range) — days§ 5 (4–9) 5 (3–8) ICU admission — no. (%)4 (1.6) 3 (1.2) 1.33 (0.30–5.90) Red-cell transfusion — no. (%)231 (89.5) 234 (90.7) 0.99 (0.93–1.05) Units of red cells received by transfusion 2.4±2.3 2.4±2.1 *	Plus–minus values are means ±SD. †	The relative risk is shown for all end points with the exception of death from any cause within 30 days and further bleeding within 30 days, for which the hazard ratio is shown. ‡	Further bleeding was defined as a composite of persistent bleeding or recurrent bleeding. Persistent bleeding occurred in 2 patients in the urgent-endoscopy group (1 had gastric varices and bled again on day 3 but was counted only once in the analysis of the composite end point of further bleeding) and in 1 patient in the early-endoscopy group, and recurrent bleeding occurred in 27 patients and 19 patients, ­respectively. §	For patients in whom bleeding developed during hospitalization, the duration of the hospital stay was calculated from the day of randomi­ zation. The New England Journal of Medicine Downloaded from nejm.org at Yonsei Univ Coll of Medicine on May 29, 2024. For personal use only. No other uses without permission. Copyright © 2020 Massachusetts Medical Society. All rights reserved.",3409,530,852.25,"[-0.15311588 -0.51152766 -1.6614168  ...  0.690299    0.6949083
 -1.7738314 ]"
209,"n engl j med 382;14  nejm.org  April 2, 2020 1307 Endoscopy for Upper Gastrointestinal Bleeding our earlier validation study was conducted over a 12-month period in 2006. Our management of these conditions may have improved over the past decade, resulting in better outcomes. Second, in this trial, we enrolled only patients whose condi- tion could be stabilized after initial resuscitation. These patients probably belonged to a lower-risk group than we had assumed in our predictions of mortality. Third, patients are better moni- tored in the context of a clinical trial, and their outcomes are better in general than those in real-life contexts. The observed higher incidences of further bleeding and death with urgent endoscopy than with early endoscopy contrast sharply with our hypothesis that urgent endoscopy would be asso- ciated with improved outcomes. With a between- group difference in mortality of 2.3 percentage points and a 95% confidence interval of −2 to 7 percentage points in favor of early endoscopy, our trial ruled out a mortality benefit of greater than 2 percentage points in association with urgent endoscopy. A substantially larger sample would have been required to rule out smaller benefits. We observed numerically more deaths in the urgent-endoscopy group. This raises the possibility that patients may benefit from treat- ment for coexisting medical illnesses and a peri- od of acid suppression. In a post hoc analysis, outcomes after endoscopy performed during of- fice hours and endoscopy performed after hours were similar, which suggests that the quality of after-hours endoscopy was not inferior. To detect possible benefits of urgent endos- copy, we selected high-risk patients who present- ed with acute upper gastrointestinal bleeding. We used the Glasgow–Blatchford score as a measure of risk; the score has been shown to correlate with mortality.22 In an observational study from Asia,14 a delay of endoscopy in patients with a Glasgow–Blatchford score of 12 or higher was as- sociated with a significant increase in mortality. There were limitations of our trial. Although we enrolled patients who were predicted to be at high risk for further bleeding and death, we ex- cluded patients who had persistent hypotensive shock despite undergoing resuscitation. Thus, our results are not generalizable to patients with on- going bleeding and hypotensive shock, who re- quire urgent intervention. In addition, our hospi- tals offered around-the-clock endoscopy service with a fellow and a senior endoscopist. Our re- sults are not generalizable to hospitals that do not have such support. Finally, the proportion of patients with variceal bleeding in our cohort was small. Our trial findings may not be applicable in localities with a high prevalence of esophago- gastric varices. In this trial, endoscopy that was performed within 6 hours, rather than between 6 and 24 hours, after gastroenterologic consultation did not reduce mortality among patients in stable condition who were hospitalized with acute upper gastrointestinal bleeding and who were assessed as having a high risk of further bleeding and death. Supported by the Health and Medical Fund of the Food and Health Bureau, Government of Hong Kong Special Administra- tive Region. Dr. J. Lau reports receiving fees for serving as an investi- gator for Boston Scientific; and Dr. F. Chan, receiving grant support from Triangle Pharmaceuticals and Given Imaging, grant support, advisory fees, and lecture fees from Pfizer and AstraZeneca, advisory fees from the Rome Foundation and Antibe Therapeutics, lecture fees from Eisai, EA Pharma, Pfizer Upjohn Korea, and Fuji Film, and grant support and lecture fees from Takeda Pharmaceuticals, Takeda (China) Holdings, and Olympus Hong Kong and China. No other potential conflict of interest relevant to this article was reported. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org. A data sharing statement provided by the authors is available with the full text of this article at NEJM.org. References 1.	 Hearnshaw SA, Logan RF, Lowe D, Travis SP, Murphy MF, Palmer KR. Acute upper gastrointestinal bleeding in the UK: patient characteristics, diagnoses and outcomes in the 2007 UK audit. Gut 2011;​ 60:​1327-35.2.	 Laine L, Jensen DM. Management of patients with ulcer bleeding. Am J Gastro- enterol 2012;​107:​345-60.3.	 Barkun AN, Almadi M, Kuipers EJ,  et al. Management of nonvariceal upper gastrointestinal bleeding: guideline rec- ommendations from the International Consensus Group. Ann Intern Med 2019;​ 171:​805-22.4.	 Choudari CP, Palmer KR. Outcome of endoscopic injection therapy for bleeding peptic ulcer in relation to the timing of the procedure. Eur J Gastroenterol Hepa- tol 1993;​5:​951-3.5.",4808,737,1202.0,"[-0.03236737 -0.41661307 -1.9089751  ...  0.44577178  1.1142308
 -1.6177    ]"
209,"Cooper GS, Chak A, Connors AF Jr, Harper DL, Rosenthal GE. The effective- ness of early endoscopy for upper gastro- intestinal hemorrhage: a community- based analysis. Med Care 1998;​36:​462-74.6.	 Cooper GS, Chak A, Way LE, Hammar PJ, Harper DL, Rosenthal GE. Early en- doscopy in upper gastrointestinal hemor- rhage: associations with recurrent bleed- ing, surgery, and length of hospital stay. Gastrointest Endosc 1999;​49:​145-52.7.	 Chak A, Cooper GS, Lloyd LE, Kolz CS, Barnhart BA, Wong RC. Effectiveness of endoscopy in patients admitted to the intensive care unit with upper GI hemor- rhage. Gastrointest Endosc 2001;​53:​6-13.8.	 Adamopoulos AB, Baibas NM, Efsta- thiou SP, et al. Differentiation between patients with acute upper gastrointestinal The New England Journal of Medicine Downloaded from nejm.org at Yonsei Univ Coll of Medicine on May 29, 2024. For personal use only. No other uses without permission. Copyright © 2020 Massachusetts Medical Society. All rights reserved.",993,147,248.25,"[-0.17079614 -0.41465598 -1.4241445  ...  0.21773556  0.612289
 -1.4383187 ]"
210,"n engl j med 382;14  nejm.org  April 2, 2020 1308 Endoscopy for Upper Gastrointestinal Bleeding bleeding who need early urgent upper gas- trointestinal endoscopy and those who do not: a prospective study. Eur J Gastroen- terol Hepatol 2003;​15:​381-7.9.	 Schacher GM, Lesbros-Pantoflickova D, Ortner MA, Wasserfallen JB, Blum AL, Dorta G. Is early endoscopy in the emer- gency room beneficial in patients with bleeding peptic ulcer?A “fortuitously controlled” study. Endoscopy 2005;​37:​ 324-8.10.	 Robins GG, Sarwar MS, Armstrong MJ, et al. Evaluation of the need for en- doscopy to identify low-risk patients pre- senting with an acute upper gastrointesti- nal bleed suitable for early discharge. Postgrad Med J 2007;​83:​768-72.11.	 Romagnuolo J, Barkun AN, Enns R, Armstrong D, Gregor J. Simple clinical predictors may obviate urgent endoscopy in selected patients with nonvariceal up- per gastrointestinal tract bleeding. Arch Intern Med 2007;​167:​265-70.12.	Tai CM, Huang SP, Wang HP, et al. High-risk ED patients with nonvariceal upper gastrointestinal hemorrhage under- going emergency or urgent endoscopy:  a retrospective analysis. Am J Emerg Med 2007;​25:​273-8.13.	 Targownik LE, Murthy S, Keyvani L, Leeson S. The role of rapid endoscopy for high-risk patients with acute nonvariceal upper gastrointestinal bleeding. Can J Gas- troenterol 2007;​21:​425-9.14.	 Lim LG, Ho KY, Chan YH, et al. Ur- gent endoscopy is associated with lower mortality in high-risk but not low-risk nonvariceal upper gastrointestinal bleed- ing. Endoscopy 2011;​43:​300-6.15.	 Kumar NL, Travis AC, Saltzman JR. Initial management and timing of endos- copy in nonvariceal upper  GI bleeding. Gastrointest Endosc 2016;​84:​10-7.16.	 Laursen SB, Leontiadis GI, Stanley AJ, Møller MH, Hansen JM, Schaffalitzky de Muckadell OB. Relationship between tim- ing of endoscopy and mortality in patients with peptic ulcer bleeding: a nationwide cohort  study. Gastrointest Endosc 2017;​ 85(5):​936-944.e3.17.	 Lin HJ, Wang K, Perng CL, et al. Early or delayed endoscopy for patients with peptic ulcer bleeding: a prospective ran- domized study. J Clin Gastroenterol 1996;​ 22:​267-71.18.	Lee JG, Turnipseed S, Romano PS,  et al. Endoscopy-based triage significant- ly reduces hospitalization rates and costs of treating upper GI bleeding: a random- ized controlled trial. Gastrointest Endosc 1999;​50:​755-61.19.	 Bjorkman DJ, Zaman A, Fennerty MB, Lieberman D, Disario JA, Guest-Warnick G. Urgent vs. elective endoscopy for acute non-variceal upper-GI bleeding: an effec- tiveness study. Gastrointest Endosc 2004;​ 60:​1-8.",2602,366,650.5,"[-0.35500824 -0.78744245 -1.7829056  ...  0.34456488  0.77847356
 -1.1087679 ]"
210,"20.	Spiegel BMR, Vakil NB, Ofman JJ. En- doscopy for acute nonvariceal upper gas- trointestinal tract hemorrhage: is sooner better?A systematic review. Arch Intern Med 2001;​161:​1393-404.21.	Tsoi KK, Ma TK, Sung JJ. Endoscopy for upper gastrointestinal bleeding: how urgent is it?Nat Rev Gastroenterol Hepa- tol 2009;​6:​463-9.22.	Stanley AJ, Laine L, Dalton HR, et al. Comparison of risk scoring systems for patients presenting with upper gastroin- testinal bleeding: international multi- centre prospective study. BMJ 2017;​356:​ i6432.23.	Pang SH, Ching JY, Lau JY, Sung JJ, Graham DY, Chan FK. Comparing the Blatchford and pre-endoscopic Rockall score in predicting the need for endo- scopic therapy in patients with upper GI hemorrhage. Gastrointest Endosc 2010;​ 71:​1134-40.24.	Cho SH, Lee YS, Kim YJ, et al. Out- comes and role of urgent endoscopy in high-risk patients with acute nonvariceal gastrointestinal bleeding. Clin Gastroen- terol Hepatol 2018;​16:​370-7.25.	Laine L, Spiegel B, Rostom A, et al. Methodology for randomized trials of pa- tients with nonvariceal upper gastrointes- tinal bleeding: recommendations from an international consensus conference. Am J Gastroenterol 2010;​105:​540-50.26.	Wong JC, Lau JY, Tang RS, Au KWL, Chan FKL, Sung JJY. Urgent versus early endoscopy for upper gastrointestinal bleed- ing with Glasgow–Blatchford score ≥12. Gastroenterology 2015;​148:​Suppl:​S-154.ab- stract.27.	 Lau JY, Leung WK, Wu JCY, et al. Omeprazole before endoscopy in patients with gastrointestinal bleeding. N Engl J Med 2007;​356:​1631-40. Copyright © 2020 Massachusetts Medical Society. ARTICLE METRICS NOW AVAILABLE Visit the article page at NEJM.org and click on Metrics to view comprehensive and cumulative article metrics compiled from multiple sources, including Altmetrics. NEJM.org/about-nejm/article-metrics. The New England Journal of Medicine Downloaded from nejm.org at Yonsei Univ Coll of Medicine on May 29, 2024. For personal use only. No other uses without permission. Copyright © 2020 Massachusetts Medical Society. All rights reserved.",2081,284,520.25,"[-0.26949185 -0.4869845  -1.8815701  ...  0.08864291  0.71297604
 -1.2552786 ]"
211,"Indications for the Use of Proton Pump Inhibitors for Stress Ulcer Prophylaxis and Peptic Ulcer Bleeding in Hospitalized Patients Karen Clarke, MD, MSc, MPH,a Nicole Adler, MD,b Deepak Agrawal, MD, MPH,c Dimpal Bhakta, MD,d Suchita Shah Sata, MD,e Sarguni Singh, MD,f Arjun Gupta, MD,g Amit Pahwa, MD,h Emily Pherson, PharmD,i Alexander Sun, MD,e Frank Volpicelli, MD,b,j Hyung J. Cho, MDj,k aDivision of Hospital Medicine, Emory University School of Medicine, Atlanta, Ga; bDepartment of Medicine, New York University Gross- man School of Medicine, New York, NY; cDivision of Gastroenterology and Hepatology, Dell Seton Medical Center, Austin, Tex; dDivision of Gastroenterology, New York University School of Medicine, New York, NY; eDepartment of Medicine, Duke University School of Medi- cine, Durham, NC; fDivision of Hospital Medicine, University of Colorado, Aurora; gSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Md; hDivision of General Internal Medicine, Division of General Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Md; iDepartment of Pharmacy, Johns Hopkins Hospital, Baltimore, Md; jDivision of Hospital Medicine, Icahn School of Medicine at Mount Sinai, New York, NY; kNew York City Health and Hospitals, New York, NY. ABSTRACT Proton pump inhibitors are widely used throughout the world for the treatment of gastrointestinal disorders that are related to acid secretion, such as peptic ulcer disease and dyspepsia. Another common indication for proton pump inhibitors is stress ulcer prophylaxis. Proton pump inhibitors have proven efﬁcacy for the treatment of acid-related gastrointestinal disorders, but there is concern that their use may be associated with the development of signiﬁcant complications, such as fractures, Clostridium difﬁcile infection, acute kidney injury, chronic kidney disease, and hypomagnesemia. Proton pump inhibitors are overused in the hospital setting, both for stress ulcer prophylaxis and gastrointestinal bleeding, and then they are often inappropriately continued after discharge from the hospital. This narrative review article outlines the evi- dence surrounding appropriate proton pump inhibitor use for stress ulcer prophylaxis and peptic ulcer bleeding. 2021 Elsevier Inc. All rights reserved. The American Journal of Medicine (2022) 135:313−317 KEYWORDS: Gastrointestinal bleed; Indications; Peptic ulcer; Proton pump inhibitor; Stress ulcer prophylaxis INTRODUCTION Proton pump inhibitors are one of the most commonly pre- scribed medications in the world because they are effective for the treatment of acid-related gastrointestinal orders, including gastroesophageal disease and peptic ulcer dis- ease.1 Use of acid-suppressive therapy is common among hospitalized patients; that is, approximately 40%-70% of them receive either proton pump inhibitors or histamine 2 receptor antagonists during their hospitalization.2,3 Unfortu- nately, about half of the patients who are newly started on acid suppressive therapy during their hospitalization are discharged to home on this medication, even though its ongoing use is usually not warranted.2,3 Although proton pump inhibitors were previously thought to be relatively safe medications with few side effects, over time their association with signiﬁcant com- plications has been demonstrated, including acute kidney injury,4 chronic kidney disease,4 Clostridium difﬁcile infection,5 hypomagnesemia,⁶ and fractures.7 Because there is concern about the ubiquitous use of proton pump inhibitors and the complications associated with these medications, their appropriate use in the hospital setting should be a priority. With the intention of pro- moting value-based quality improvement, in this narra- tive review article we discuss the evidence behind the Requests for reprints should be addressed to Karen Clarke, Division of Hospital Medicine, Emory University School of Medicine, 1364 Clifton Road NE, Atlanta, GA, 30322. E-mail address: summarizephilosophy@yahoo.com 0002-9343/© 2021 Elsevier Inc. All rights reserved.https://doi.org/10.1016/j.amjmed.2021.09.010 REVIEW",4157,571,1039.25,"[-0.0357988  -0.2743339  -1.0864022  ...  0.46494874  0.03527363
 -1.5227834 ]"
212,"use of proton pump inhibitors for stress ulcer prophy- laxis and peptic ulcer bleeding. EVIDENCE AND GUIDELINES FOR PROTON PUMP INHIBITOR USE FOR SPECIFIC INDICATIONS In this narrative review we address 2 indications for proton pump inhibitor use, that is, stress ulcer prophylaxis and peptic ulcer bleeding, and provide our evidence- based recommendations on appro- priate use. Stress Ulcer Prophylaxis Stress ulcers usually start to develop within hours following the onset of serious illness or major trauma. They are most commonly noted in the body and fundus of the stomach and are typically shallow. Stress ulcers are thought to develop most often because of deﬁcient mucosal protection (which is com- monly noted in patients with critical illness). Hypersecretion of acid is a less common factor in the develop- ment of stress ulcers. Stress ulcers in the upper gastrointestinal tract can lead to gastrointesti- nal bleeding, the severity of which can range from being minimal (ie, no overt bleeding) to clinically important stress-related gastrointestinal bleeding (ie, overt gastroin- testinal bleeding: hematemesis or melena). Medications such as proton pump inhibitors and histamine 2 receptor antagonists are often administered prophylactically to decrease the risk of stress ulcer development. However, recent studies have questioned the efﬁcacy of stress ulcer prophylaxis. A pilot randomized controlled trial and meta-analysis in 2017 evaluating the safety of withholding pantoprazole for stress ulcer prophylaxis in critically ill patients found no signiﬁcant increase in risk for upper gastrointestinal tract bleeding, mortality, or infections when pantoprazole was held for stress ulcer prophylaxis.8 A 2018 European study enrolled 3298 patients in 33 intensive care units in Denmark, Finland, Netherlands, Nor- way, Switzerland, and the United Kingdom.9 This multicen- ter, parallel-group, blinded, randomized controlled trial evaluated patients who were admitted to an intensive care unit and were at risk for clinically important stress-related gastrointestinal bleeding. The trial compared pantoprazole with placebo, and it did not show a difference in 90-day mortality or composite outcome of clinically important event, which was a composite of clinically important stress- related gastrointestinal bleeding, pneumonia, C. difﬁcile infection, or myocardial ischemia.9 For patients receiving pantoprazole, 2.5% had clinically important stress-related gastrointestinal bleeding, in comparison with 4.2% of those who received a placebo. Although the relative risk was 0.58, no P value was presented because the study did not make adjustments for multiple comparisons. Multiple national and international clinical guidelines outline the role of stress ulcer prophylaxis in intensive care unit settings, including the American Society of Health Sys- tem Pharmacists in 1999, Surviving Sepsis Campaign in 2016 and the Danish Society of Intensive Care Medicine and the Danish Society of Anesthesiology and Intensive Care Medicine in 2014.10-12 No national or society guidelines recommend routine stress ulcer prophylaxis in noncriti- cal care settings. All guidelines rec- ommend stress ulcer prophylaxis to be administered to patients with critical illness with additional risk factors for clinically important stress-related gastrointestinal bleed- ing. The most important additional risk factors are coagulopathy and the need for mechanical ventilation for more than 48 hours. Other risk factors for clinically important stress-related gastrointestinal bleed- ing include the requirement for renal replacement therapy, established liver disease, and elevated scores of organ failure. Prior studies on the utility of stress ulcer prophy- laxis had been inconclusive and suggested the need for a large randomized controlled trial. With the recent data discussed previously it appears that stress ulcer prophylaxis is not beneﬁcial overall in hospitalized patients, although it may decrease the rate of clinically important stress-related gastrointestinal bleeding in the critically ill at high risk.12 However, patients with a valid indication for proton pump inhibitors for other medical reasons, who take these medications in the out- patient setting, should continue to take them during their hospitalization. Peptic Ulcer Bleeding In vitro studies have shown that a pH > 4 (some studies suggest pH > 6) helps in platelet aggregation and clot stabi- lization and, thus, reduces risk of rebleeding.13,14 This pro- vides the rationale for prescribing proton pump inhibitors to patients who have high-risk stigmata of bleeding on endos- copy (ie, active bleeding, overlying clot on an ulcer, or a visible vessel). Before endoscopy, it is not known which patients have high-risk stigmata. Hence, the conservative and practical approach has been to assume all patients are at high risk when they present with upper gastrointestinal tract bleed- ing. However, it is important to note that there is no strong evidence to support the widespread (and now considered CLINICAL SIGNIFICANCE  Proton pump inhibitors are widely used for treatment of gastrointestinal bleeding related to acid secretion and also for stress ulcer prophylaxis. Overuse of proton pump inhibitors may be associated with complications. Proton pump inhibitors are often inap- propriately initiated in the hospital setting and then are often inappropri- ately continued after hospital dis- charge. Clinicians require guidance in regard to appropriate proton pump inhibitor use to improve patient outcomes.314 The American Journal of Medicine, Vol 135, No 3, March 2022",5654,821,1413.5,"[-0.30800933  0.06705403 -0.96450734 ...  0.4805115   0.10827832
 -1.2214307 ]"
213,"standard of care) practice of administering proton pump inhibitors to patients before endoscopy. There have been 2 randomized trials of intravenous omeprazole versus placebo administered to patients with hematemesis or melena before endoscopy. In both studies, omeprazole failed to reduce transfusion requirements, rebleeding, or mortality, but patients were less likely to have high-risk stigmata of bleed- ing on endoscopy and, thus, had a reduced need for endo- scopic therapy.15,16 This, in turn, may also help to reduce length of hospital stay because patients with high-risk stig- mata on endoscopy are often monitored in the hospital for 72 hours.1⁶ There are 4 factors to consider when prescribing proton pump inhibitors: dose, frequency, route, and type. High- dose proton pump inhibitor (Table) is often thought to be necessary to consistently achieve pH > 4 (or pH > 6) across different populations. Given the pharmacokinetics of proton pump inhibitors and diurnal variation in acid secretion, at least twice-a-day dosing may be necessary. Proton pump inhibitors have a half-life of about 60-90 minutes, and they covalently bind to active H+-K+ pumps. Hence, their inhibitory effects last much longer (up to 48 hours). However, newly activated H+-K+ pumps may con- tinue to produce some acid.17 A theoretical explanation notwithstanding, a meta-analysis of 9 randomized con- trolled trials comparing rebleeding rates with high-dose proton pump inhibitor versus low-dose proton pump inhibitor following endoscopic treatment showed that the 2 dosages had similar efﬁcacy.18 Moreover, the initial studies on proton pump inhibitors and upper gastrointesti- nal tract bleeding used the intravenous route and given the favorable clinical results, this was adopted in clinical practice. However, oral proton pump inhibitors have excellent bioavailability ranging from 70%-90% and should be as efﬁcacious as those administered intrave- nously.18 Studies comparing oral proton pump inhibitors versus placebo achieved clinical outcomes similar to those that used intravenous proton pump inhibitors.19-21 Three studies directly comparing intravenous and oral proton pump inhibitors in preventing rebleeding after endoscopic treatment found the 2 routes to have similar outcomes.22-24 However, giving a loading dose intrave- nously may achieve higher pH up to an hour earlier.24 After review of the evidence, there was no consistent clin- ical difference between different formulations of proton pump inhibitors, but it is worth noting that the dosages vary among the studies. Practice patterns do not consistently follow this evidence, in turn leading to lower value care.25 The American College of Gastroenterology Guidelines for Management of Patients with Ulcer Bleeding makes a conditional recommendation for pre-endoscopic medical therapy, such as proton pump inhibitor 80 mg bolus fol- lowed by 8 mg/h infusion, which may reduce the frequency of higher risk stigmata of hemorrhage at the time of endoscopy.26,27 Following endoscopy, the American Col- lege of Gastroenterology has a strong recommendation for the administration of intravenous proton pump inhibitor 80 mg bolus followed by 8 mg/h infusion for 72 hours for patients who have any of the following: ulcer with active bleeding, adherent clot, or a nonbleeding visible vessel.27 For generalizability, ease in formulating recommenda- tions, and a value-based approach, while remaining cogni- zant that it may be difﬁcult to change practices (pending more data), we recommend a bolus dose of intravenous pro- ton pump inhibitor when patients present with active upper gastrointestinal bleeding (hematemesis or melena) followed by oral or intravenous proton pump inhibitor twice a day (high-dose proton pump inhibitor). After endoscopy, patients with high-risk stigmata (especially those with sig- niﬁcant comorbidities) remain at rebleeding risk for up to 72 hours. Hence, high-dose proton pump inhibitor (twice-a- day dosing) should be continued for 72 hours. This can be given orally if the patient is having per oral intake. It should be noted that the data on high-dose proton pump inhibitor (twice-a-day dosing) is geared to lower rebleeding risk and not for ulcer healing, so patients need not be discharged home on high-dose proton pump inhibitors. Further, if patients are given oral proton pump inhibitor, they need not stay in the hospital for 72 hours provided they are otherwise stable to be discharged and understand there may be a risk of rebleeding (due to lack of studies). Duration of treatment with proton pump inhibitors for gastric ulcer is generally 2 months except when the risk of bleeding is not mitigated (ongoing use of nonsteroidal anti-inﬂammatory drugs, anti- coagulation, or antiplatelets, unresectable malignant ulcer). At the time of discharge, the frequency and duration of pro- ton pump inhibitors should be speciﬁed. REDUCING INAPPROPRIATE USE OF PROTON PUMP INHIBITORS AFTER HOSPITAL DISCHARGE Proton pump inhibitors are often initiated in the hospital setting, and up to half of these new prescriptions are contin- ued at discharge.28-30 The inappropriate continuation of proton pump inhibi- tors at the time of discharge exposes patients to an excess risk of long-term adverse events.31 Therefore, it is desirable to implement interventions that lead to the discontinuation of inappropriate proton pump inhibitor use both during hos- pitalization and at the time of discharge from the hospital. Such interventions focus on appropriate indications for pro- ton pump inhibitor use and include education for providers, Table PPI Dose, Frequency, Route, and Type PPI Standard dose High dose Esomeprazole 20 mg once a day 40 mg once a day Lansoprazole 30 mg once a day 30 mg twice a day Omeprazole 20 mg once a day 40 mg once a day Pantoprazole 40 mg once a day 40 mg twice a day Rabeprazole 20 mg once a day 20 mg twice a day Clarke et al Indications for the Use of Proton Pump Inhibitors in Hospitalized Patients 315",6015,922,1503.75,"[ 0.15278351 -0.28036624 -1.2526685  ...  1.0684618   0.37404132
 -1.1715621 ]"
214,"development of clinical guidelines, and pharmacist-led interventions.32-37 COMPLICATIONS OF LONG-TERM PROTON PUMP INHIBITOR USE Complications of proton pump inhibitor use include bone fractures, hypomagnesemia, C. difﬁcile infection, acute kid- ney injury, and chronic kidney disease. An increased risk of bone fractures may be noted within the ﬁrst year of proton pump inhibitor use.38 In a meta-analysis that included 18 observational studies (with 244,109 fracture cases), Zhou et al38 concluded that the use of proton pump inhibitors modestly increased the risk of fractures. The relative risk of fractures occurring in the hip was 1.26 in proton pump inhibitor users compared with nonusers. For fractures in the spine, the relative risk in proton pump inhibitor users versus nonusers was 1.58, and for fractures at any site, the relative risk was 1.33 in proton pump inhibitor users versus nonusers.38 Proton pump inhibitor use can lead to hypomagnesemia, which when severe can precipitate cardiac arrhythmias, seizures, muscle weakness, tetany, and hypotension. Also, the risk of developing acute kidney injury is increased in patients with hypomagnesemia, and this electrolyte abnor- mality decreases the likelihood of resolution of acute kid- ney injury. For proton pump inhibitor users who develop hypomagnesemia, the initiation of magnesium supplemen- tation may not be sufﬁcient to replete low magnesium lev- els, unless the proton pump inhibitor is discontinued. The pooled risk ratio of hypomagnesemia was 1.43 in proton pump inhibitor users compared with nonusers, according to a meta-analysis of 9 observational studies (which included 109,798 patients).6 An increased risk of C. difﬁcile infection has been noted in proton pump inhibitor users. In their meta-analysis of 39 observational studies, Kwok et al5 found that the risk of developing a C. difﬁcile infection was increased in proton pump inhibitor users, who had an odds ratio of 1.74 com- pared with nonusers. Similarly, the risk of recurrent C. difﬁ- cile infection was higher in proton pump inhibitor users, who had an odds ratio of 2.51 compared with nonusers. Adverse effects of proton pump inhibitor use on kidney function have been documented; that is, this may lead to the development of both acute kidney injury and chronic kidney disease. Acute interstitial nephritis may be the mechanism by which proton pump inhibitors cause acute kidney injury. In a population-based study that included 290,592 patients, Antoniou et al39 found that in comparison with nonusers, proton pump inhibitor users had a hazard ratio of 2.52 for the development of acute kidney injury. The study also showed a hazard ratio of 3.00 in proton pump inhibitor users versus nonusers for the development of acute interstitial nephritis. The nested case control study involving 184,480 patients that was done by Klepser et al40 showed that proton pump inhibitor use was associated with an increased risk of acute kidney injury in proton pump inhibitor users, who had an odds ratio of 1.72 compared with nonusers. In a population-based cohort study by Lazarus et al41 that involved 10,482 patients who were followed for 13.9 years, the hazard ratio for incident chronic kidney dis- ease was 1.45 for proton pump inhibitor users compared with nonusers. A dose response was noted in this study because the risk of developing chronic kidney disease was higher in patients who used a proton pump inhibitor twice daily, in comparison with those who used a proton pump inhibitor once daily. These ﬁndings were reproduced in another large cohort study.41 The mechanism by which pro- ton pump inhibitor use leads to chronic kidney disease may be either hypomagnesemia or recurrent episodes of acute kidney injury. CONCLUSION The use of proton pump inhibitors for stress ulcer prophy- laxis should be limited to high-risk patients in the intensive care unit. Patients who receive proton pump inhibitor for treatment for gastrointestinal bleeding during their hospital- ization do not need to be discharged home on high-dose (twice daily) proton pump inhibitors. Overuse of proton pump inhibitors during hospitalization is prevalent and often leads to the inappropriate continuation of these medi- cations at the time of hospital discharge. Because the long- term use of proton pump inhibitors is often inappropriate and may be associated with signiﬁcant adverse effects, it is important to limit their use to only appropriate indications. References 1. Safer D. Overprescribed medications for US adults: 4 major examples. J Clin Med Res 2019;11(9):617–22.2. Sattayalertyanyong O, Thitilertdecha P, Auesomwang C. The inappro- priate use of proton pump inhibitors during admission and after dis- charge: a prospective cross-sectional study. Int J Clin Pharm 2020;42:174–83.3. Shin S. Evaluation of costs accrued through inadvertent continuation of hospital-initiated proton pump inhibitor therapy for stress ulcer pro- phylaxis beyond hospital discharge: a retrospective chart review. Ther Clin Risk Manag 2015;11:649–57.4. Moledina DG, Perazella MA. PPIs and kidney disease: from AIN to CKD. J Nephrol 2016;29(5):611–6.5. Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK. Risk of Clostridium difﬁcile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol 2012;107(7):1011–9.6. Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W, et al. Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies. Ren Fail 2015;37 (7):1237–41.7.",5579,841,1394.75,"[ 0.28134662 -0.14734063 -1.3757198  ...  0.5225666   0.47780502
 -1.6810455 ]"
214,"Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006;296(24):2947– 53.8. Alhazzani W, Guyatt G, Alshahrani M, et al. Withholding pantopra- zole for stress ulcer prophylaxis in critically ill patients: a pilot ran- domized clinical trial and meta-analysis. Crit Care Med 2017;45:1121–9.9. Krag M, Marker S, Perner A, et al. Pantoprazole in patients at risk for gastrointestinal bleeding in the ICU. N Engl J Med 2018;379:2199– 208.316 The American Journal of Medicine, Vol 135, No 3, March 2022",555,88,138.75,"[ 0.2064005  -0.045587   -1.1615305  ...  0.5047613   0.52324516
 -1.5595785 ]"
215,"10. ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998. Am J Health Syst Pharm, 56; 1999.p. 1999347–79.11. Rhodes A, Evans LE, Alhazzani W, et al.surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med 2017;43(3):304–77.12. Madsen KR, Lorentzen K, Clausen N, et al. Guideline for stress ulcer prophylaxis in the intensive care unit. Dan Med J 2014;61(3):C4811.13. Green FW Jr, Kaplan MM, Curtis LE, Levine PH. Effect of acid and pepsin on blood coagulation and platelet aggregation. A possible con- tributor prolonged gastroduodenal mucosal hemorrhage. Gastroenter- ology 1978;74(1):38–43.14. Patchett SE, Enright H, Afdhal N, O'Connell W, O'Donoghue DP. Clot lysis by gastric juice: an in vitro study. Gut 1989;30(12):1704–7.15. Daneshmend TK, Hawkey CJ, Langman MJ, Logan RF, Long RG, Walt RP. Omeprazole versus placebo for acute upper gastrointestinal bleeding: randomised double blind controlled trial. BMJ 1992;304 (6820):143–7.16. Lau JY, Leung WK, Wu JC, et al. Omeprazole before endoscopy in patients with gastrointestinal bleeding. N Engl J Med 2007;356 (16):1631–40.17. Shin JM, Sachs G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep 2008;10(6):528–34.18. Wu LC, Cao YF, Huang JH, Liao C, Gao F. High-dose vs low-dose proton pump inhibitors for upper gastrointestinal bleeding: a meta- analysis. World J Gastroenterol 2010;16(20):2558–65.19. Khuroo MS, Yattoo GN, Javid G, et al. A comparison of omeprazole and placebo for bleeding peptic ulcer. N Engl J Med 1997;336 (15):1054–8.20. Javid G, Masoodi I, Zargar SA, et al. Omeprazole as adjuvant therapy to endoscopic combination injection sclerotherapy for treating bleed- ing peptic ulcer.",1834,267,458.5,"[ 0.02959132 -0.37691274 -1.1227124  ...  0.7925534   0.01135917
 -1.7798434 ]"
215,"Am J Med 2001;111(4):280–4.21. Kaviani MJ, Hashemi MR, Kazemifar AR, et al. Effect of oral omep- razole in reducing re-bleeding in bleeding peptic ulcers: a prospective, double-blind, randomized, clinical trial. Aliment Pharmacol Ther 2003;17(2):211–6.22. Bajaj JS, Dua KS, Hanson K, Presberg K. Prospective, randomized trial comparing effect of oral versus intravenous pantoprazole on rebleeding after nonvariceal upper gastrointestinal bleeding: a pilot study. Dig Dis Sci 2007;52(9):2190–4.23. Yen HH, Yang CW, Su WW, Soon MS, Wu SS, Lin HJ. Oral versus intravenous proton pump inhibitors in preventing re-bleeding for patients with peptic ulcer bleeding after successful endoscopic ther- apy. BMC Gastroenterol 2012;12:66.24. Laine L, Shah A, Bemanian S. Intragastric pH with oral vs intravenous bolus plus infusion proton-pump inhibitor therapy in patients with bleeding ulcers. Gastroenterol 2008;134(7):1836–41.25. Rodriguez E, Donath E, Waljee A, Sussman D. Value of oral proton pump inhibitors in acute nonvariceal upper gastrointestinal bleeding: a network meta-analysis. J Clin Gastroenterol 2017;51(8):707–19.26. Leontiadis GI, Sreedharan A, Dorward S, et al. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. Health Technol Assess 2007;11(51) [iii-iv, 1-164.27. Laine L, Jensen D. Guidelines for the management of patients with ulcer bleeding. Am J Gastroenterol 2012;107(3):345–60.28. Nardino RJ, Vender RJ, Herbert PN. Overuse of acid-suppressive ther- apy in hospitalized patients. Am J Gastroenterol 2000;95(11):3118– 22.https://doi.org/10.1111/j.1572-0241.2000.03259.x.29. Zink DA, Pohlman M, Barnes M, Cannon ME. Long-term use of acid suppression started inappropriately during hospitalization. Aliment Pharmacol Ther 2005;21(10):1203–9.https://doi.org/10.1111/j.1365- 2036.2005.02454.x.30. Pham CQ, Regal RE, Bostwick TR, Knauf KS. Acid suppressive ther- apy use on an inpatient internal medicine service. Ann Pharmacother 2006;40(7-8):1261–6.https://doi.org/10.1345/aph.1g703.31. Schoenfeld AJ, Grady D. Adverse effects associated with proton pump inhibitors [editorial]. JAMA Intern Med 2016;176(2):172–4.",2217,280,554.25,"[-0.15038393 -0.14031953 -1.1434419  ...  0.6901781   0.19725518
 -1.3686208 ]"
215,"https:// doi.org/10.1001/jamainternmed.2015.7927.32. Belﬁeld KD, Kuyumjian AG, Teran R, Amadi M, Blatt M, Bicking K. Impact of a collaborative strategy to reduce the inappropriate use of acid suppressive therapy in non-intensive care unit patients. Ann Pharmac- other 2017;51(7):577–83.https://doi.org/10.1177/1060028017698797.33. Del Giorno R, Ceschi A, Pironi M, Zasa A, Greco A, Gabutti L. Multi- faceted intervention to curb in-hospital over-prescription of proton pump inhibitors: a longitudinal multicenter quasi-experimental before-and-after study. Eur J Intern Med 2018;50:52–9.https://doi.org/10.1016/j.ejim.2017.11.002.34. Gupta R, Marshall J, Munoz JC, Kottoor R, Jamal MM, Vega KJ. Decreased acid suppression therapy overuse after education and medi- cation reconciliation. Int J Clin Pract 2013;67(1):60–5.https://doi.org/10.1111/ijcp.12046.35. Hatch JB, Schulz L, Fish JT. Stress ulcer prophylaxis: reducing non- indicated prescribing after hospital discharge. Ann Pharmacother 2010;44(10):1565–71.https://doi.org/10.1345/aph.1p167.36. McDonald EG, Jones J, Green L, Jayaraman D, Lee TC. Reduction of inappropriate exit prescriptions for proton pump inhibitors: a before- after study using education paired with a web-based quality-improve- ment tool. J Hosp Med 2015;10(5):281–6.https://doi.org/10.1002/ jhm.2330.37. Tasaka CL, Burg C, VanOsdol SJ, et al. An interprofessional approach to reducing the overutilization of stress ulcer prophylaxis in adult medical and surgical intensive care units. Ann Pharmacother 2014;48 (4):462–9.https://doi.org/10.1177/1060028013517088.38. Zhou B, Huang Y, Li H, Sun W, Liu J. Proton-pump inhibitors and risk of fractures: an updated meta-analysis. Osteoporosis Int 2016;27:339–47.39. Antoniou T, Macdonald EM, Hollands S, et al. Proton pump inhibitors and the risk of acute kidney injury in older patients: a population- based cohort study. CMAJ Open 2015;3(2):E166–71.40. Klepser DG, Collier DS, Cochran GL. Proton pump inhibitors and acute kidney injury: a nested case-control study. BMC Nephrol 2013;14:150.41.",2067,258,516.75,"[ 0.28041673 -0.4160292  -0.9463992  ...  0.89055264 -0.13834535
 -2.0051274 ]"
215,"Lazarus B, Yuan , Wilson FP, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med 2016;176(2): 238–46. Clarke et al Indications for the Use of Proton Pump Inhibitors in Hospitalized Patients 317",230,39,57.5,"[-0.248194   -0.05721145 -1.3508697  ...  0.09570661  0.46965122
 -1.423032  ]"
216,"CLINICAL PRACTICE UPDATE AGA Clinical Practice Update on Endoscopic Therapies for Non- Variceal Upper Gastrointestinal Bleeding: Expert Review Daniel K. Mullady,1 Andrew Y. Wang,2 and Kevin A. Waschke3 1Division of Gastroenterology, Washington University in St Louis School of Medicine, St Louis, Missouri; 2Division of Gastroenterology and Hepatology, University of Virginia, Charlottesville, Virginia; and 3Division of Gastroenterology, McGill University, Montreal, Quebec, Canada DESCRIPTION: The purpose of this American Gastroenterolog- ical Association (AGA) Institute Clinical Practice Update is to re- view the available evidence and best practice advice statements regarding the use of endoscopic therapies in treating patients with non-variceal upper gastrointestinal bleeding. METHODS: This expert review was commissioned and approved by the AGA Institute Clinical Practice Updates Committee and the AGA Gov- erning Board to provide timely guidance on a topic of high clinical importance to the AGA membership, and underwent internal peer review by the Clinical Practice Updates Committee and external peer review through standard procedures of Gastroen- terology. This review is framed around the 10 best practice advice points agreed upon by the authors, which reﬂect landmark and recent published articles in this ﬁeld. This expert review also reﬂects the experiences of the authors who are gastroenterolo- gists with extensive experience in managing and teaching others to treat patients with non-variceal upper gastrointestinal bleeding (NVUGIB). BEST PRACTICE ADVICE 1: Endoscopic therapy should achieve hemostasis in the majority of patients with NVUGIB. BEST PRACTICE ADVICE 2: Initial management of the patient with NVUGIB should focus on resuscitation, triage, and preparation for upper endoscopy. After stabilization, patients with NVUGIB should undergo endoscopy with endoscopic treat- ment of sites with active bleeding or high-risk stigmata for rebleeding. BEST PRACTICE ADVICE 3: Endoscopists should be familiar with the indications, efﬁcacy, and limitations of currently available tools and techniques for endoscopic hemostasis, and be comfortable applying conventional thermal therapy and placing hemoclips. BEST PRACTICE ADVICE 4: Monopolar hemostatic forceps with low-voltage coagulation can be an effective alter- native to other mechanical and thermal treatments for NVUGIB, particularly for ulcers in difﬁcult locations or those with a rigid and ﬁbrotic base. BEST PRACTICE ADVICE 5: Hemostasis using an over-the-scope clip should be considered in select patients with NVUGIB, in whom conventional electrosurgical coagulation and hemostatic clips are unsuccessful or predicted to be inef- fective. BEST PRACTICE ADVICE 6: Hemostatic powders are a noncontact endoscopic option that may be considered in cases of massive bleeding with poor visualization, for salvage therapy, and for diffuse bleeding from malignancy. BEST PRACTICE ADVICE 7: Hemostatic powder should be preferentially used as a rescue therapy and not for primary hemostasis, except in cases of ma- lignant bleeding or massive bleeding with inability to perform thermal therapy or hemoclip placement. BEST PRACTICE ADVICE 8: Endoscopists should understand the risk of bleeding from therapeutic endoscopic interventions (eg, endoluminal resection and endoscopic sphincterotomy) and be familiar with the endoscopic tools and techniques to treat intraprocedural bleeding and minimize the risk of delayed bleeding. BEST PRACTICE ADVICE 9: In patients with endoscopically refractory NVUGIB, the etiology of bleeding (peptic ulcer disease, unknown source, post surgical); patient factors (hemodynamic instability, coagulopathy, multi-organ failure, surgical history); risk of rebleeding; and potential adverse events should be taken into consideration when deciding on a case-by-case basis between transcatheter arterial embolization and surgery. BEST PRACTICE ADVICE 10: Prophylactic transcatheter arterial embolization of high-risk ulcers after successful endoscopic therapy is not encouraged. Keywords: Upper Gastrointestinal Tract Bleeding; Endoscopy; Hemostatic Powder; Hemospray; Hemostatic Forceps; Clips; Rebleeding. N on-variceal upper gastrointestinal bleeding (NVUGIB) is a serious clinical problem with an incidence of approximately 61–78 cases per 100,000 per- sons in the United States in 2009–2012.1 Mortality from NVUGIB is estimated to be between 2% and 10%.1,2 Endoscopic evaluation and treatment for NVUGIB remains the clinical mainstay of care in patients who can be hemo- dynamically stabilized to undergo upper gastrointestinal endoscopy, typically by esophagogastroduodenoscopy. Numerous endoscopic devices have been developed over the past 30 years with demonstrated effectiveness in treating NVUGIB, including the use of hemoclips,3 over-the-scope clips,4 hemostatic forceps,5 and sprayed hemostatic pow- der.6 The purpose of this Clinical Practice Update is to review the key concepts, new devices, and therapeutic strategies in endoscopically combating this age-old clinical dilemma. Initial Management Although endoscopy is a cornerstone in the management of NVUGIB, it should come after triage, medical management, and stabilization. The treating provider should consider patient- Abbreviations used in this paper: AT, antithrombotic; EMR, endoscopic mucosal resection; ESD, endoscopic submucosal dissection; MHF, monopolar hemostatic forceps; NVUGIB, non-variceal upper gastroin- testinal bleeding; RCT, randomized controlled trial; TAE, transcatheter arterial embolization. Most current article © 2020 by the AGA Institute 0016-5085/$36.00 https://doi.org/10.1053/j.gastro.2020.05.095 Gastroenterology 2020;159:1120–1128 CLINICAL PRACTICE UPDATE",5767,774,1441.75,"[ 0.23114227 -0.23269448 -1.8271928  ...  0.24261326  0.37199467
 -1.4972371 ]"
217,"related issues, including age, comorbid conditions, prior sur- gery, history of gastrointestinal bleeding, and medications (eg, antihypertensives, antithrombotics, nonsteroidal anti- inﬂammatory medications), which can contribute to the pa- tient’s clinical presentation and hemodynamic status and might predict bleedingthatisdifﬁcult to control. Patientswith NVUGIB may have variable presentations ranging from harmless, minor, self-limited bleeding that can be managed with an outpatient workup, to hypovolemic shock requiring transfer to the inten- sive care unit. The treating provider should be familiar with various scoring systems that have been developed to help triage patients with NVUGIB.7–10 These scoring systems are based on clinical parameters and endoscopic ﬁndings that predict mor- tality and rebleeding risk in patients with NVUGIB (Table 1). After proper triage of the patient with suspected NVU- GIB, the focus should be on medical management, including volume resuscitation with intravenous ﬂuids and blood products via large bore catheters. Target hemoglobin is generally 9 g/dL in patients with signiﬁcant cardiovascular disease and 7 g/dL for all others.11–13 The consensus recommendation by an international group of experts was for blood transfusion for hemoglobin levels <8 g/dL with a higher threshold for those with cardiovascular disease.14 The need for reversal of antithrombotic (AT) medications (which for this article includes anticoagulant and antiplatelet agents) requires careful consideration of the risks of throm- boembolic events, particularly in patients who present with active upper gastrointestinal tract bleeding.15,16 These de- cisions should be made by the gastroenterologist in consul- tation with intensivists, cardiologists, neurologists, and hematologists when appropriate to provide advice, including use of reversal agents, safe length of time to hold AT medi- cations, and whether alternative shorter-acting agents (eg, heparin drip) should be used as bridge therapy.17 When there is doubt, it is usually better to err on the side of not reversing AT medication because a cardiopulmonary or neurologic thromboembolic event is usually far more devastating than ongoing NVUGIB, which can often be managed with sup- portive care in relatively stable patients. Intravenous proton pump inhibitors should be administered to all patients with suspected NVUGIB because these have the effect of downgrading the stigmata of recent hemorrhage on subsequent endoscopy, but should not delay endoscopic inter- vention.14,18 High-dose intravenous proton pump inhibitors should be continued post endoscopy because their use is asso- ciated with decreased risk of rebleeding.14,19 A single dose of Table 1. Three Established and Commonly Used Risk Assessment Scores That Stratify Patients Into Lower- and Higher-Risk Groups for Poor Outcomes Related to Gastrointestinal Bleeding Scoring system Components No.of points Key concepts Glasgow-Blatchford score Systolic BP 1, 2, 3 Score ranges from 0–23 BUN 2, 3, 4, 6 Calculated on admission Hemoglobin 1, 3, 6 (men); 1, 6 (women) Patients with a score of 0 or 1 can be managed as an outpatient Tachycardia 1 Superior in predicting a combined end point of intervention and death Potentially leads to overadmission (ie, has low sensitivity) Melena 1 Syncope 2 Hepatic disease 2 Cardiac failure 2 Rockall score Age 0, 1, 2 Requires endoscopic evaluation to determine the full score Predicts risk of additional bleeding and death in hospitalized patients Signs of hemodynamic shock 0,1 , 2 Major comorbidities 0, 2, 3 Endoscopic diagnosis 0, 2 Stigmata of recent hemorrhage and/or presence of blood on endoscopy 0, 2 AIMS-65 Albumin (<3 mg/dL) 0, 1 Easy to calculate INR (>1.5) 0, 1 Can be calculated pre-endoscopy Altered mental status 0, 1 Less sensitive for than Glasgow-Blatchford score and Rockall Systolic BP (<100 mm Hg) 0, 1 AIMS-65 score (% inpatient mortality): Age (>65 years) 0, 1 0 (0.3%), 1 (3.2%), 2 (5.3%), 3 (10.3%), 4 (16.5%), 5 (24.5%) NOTE. These risk assessment scores cannot precisely identify individual high-risk patients who will die from gastrointestinal bleeding if they do not receive an intervention, but may have a clinical role in identifying patients who are at very low risk for mortality and may be amenable to outpatient medical care/endoscopy.1 BP, blood pressure; BUN, blood urea nitrogen; GI, gastrointestinal; INR, international normalized ratio. September 2020 Endoscopic Therapies for NVUGIB 1121 CLINICAL PRACTICE UPDATE",4544,672,1136.0,"[ 0.07758848 -0.4073602  -1.5114095  ...  0.03941666  0.559847
 -1.0831562 ]"
218,"erythromycin or metoclopramide may be given intravenously to selected patients before upper endoscopy to aid gastric emptying of clot to improve visualization, particularly of the gastric fundus, where clots tend to obscure complete visualiza- tion. Use of these prokinetics have been associated with reduced need for repeat endoscopy, with the published data favoring the use of erythromycin.20 Both erythromycin and metoclopramide should be used cautiously in patients with prolonged QT in- tervals.20,21 Use of octreotide is not recommended in NVUGIB, but there should be a low threshold for its use if there is concern for underlying portal hypertension. Prophylactic antibiotics are not indicated in the setting of NVUGIB. The use of nasogastric tubes in the evaluation and management of suspected NVUGIB is controversial, as their use does not impact clinical outcomes. Nasogastric lavage can assist in the removal of blood from the stomach and suggests the need for emergent endoscopy if there is return of continuous and copious bright red blood; however, a negative lavage should not delay endoscopy, particularly if other parameters are suggestive of active NVUGIB.14 Endoscopy Best Practices After assessment, triage, resuscitation, and medical opti- mization, endoscopy should be performed to determine the source of bleeding, to assess rebleeding risk, and to treatlesions at high risk for rebleeding (Figure 1). Exactly when the endoscopy should be performed is a clinical judgment made by the gastroenterologist in consultation with the primary service. Understanding that the deﬁnitions of emergent, urgent, and elective endoscopy are somewhat variable, endoscopy should generally be performed within 12 hours for emergent cases, within 24 hours for urgent cases, and can wait more than 24 hours for elective cases.22,23 A common decision is deciding whether or not to wait until the next morning to perform endoscopy on a patient presenting after hours with suspected NVUGIB. Patients with suspected NVUGIB with persistent he- modynamic compromise after initial resuscitation and those with moderate- to large-volume hematemesis likely have persistent NVUGIB and should undergo emergent endoscopy. It should be noted, however, that patients undergoing emergent endoscopy may have worse outcomes, possibly due to inade- quate resuscitation.22,23 Patients who are hemodynamically stable, do not have ongoing hematemesis, and have melena only can generally be deferred to the following morning. A recently published trial included patients who presented with acute upper gastrointestinal tract bleeding and were at high risk for further bleeding or death (Glasgow-Blatchford score 12). Patients were randomized to urgent (within 6 hours) or early (the next morning and within 24 hours) endoscopy after gastroenterology consultation, which occurred on average 7–8 hours after presentation. This study included patients with variceal hemorrhage and excluded, among others, patients in hypotensive shock or whose con- dition did not stabilize after initial resuscitation. This pivotal trial demonstrated that urgent endoscopy was not associated with lower 30-day mortality than endoscopy performed the next morning or between 6 and 24 hours after consultation.24 In general, patients with suspected NVUGIB and a Glasgow- Blatchford score of 0–1 may be discharged from the emer- gency department for timely outpatient management.25,26 The method of sedation (endoscopist-directed or requiring anesthesia support) and whether airway protec- tion is necessary are important considerations before endoscopy. Patients with suspected ongoing or massive NVUGIB, active hematemesis, or suspected retained gastric contents should undergo endotracheal intubation to decrease the risk of aspiration.27 The choice of endoscope is largely at the discretion of the endoscopist. Therapeutic upper endoscopes have a larger working channel that accommodate 10F accessories and also enable improved suction of retained gastric contents and blood clots and may be preferred in situations of severe bleeding.27 Upper endoscopy in the patient with suspected NVUGIB should be performed methodically. The esophagus should be examined carefully for pathology such as varices and Mallory- Weiss tears. Careful examination of the esophagus should be done on the initial scope insertion because retching during the procedure can cause a Mallory-Weiss tear and create a diag- nostic and treatment dilemma. If there is a large clot in the stomach, it is not advised to spend time clearing the clot unless a source is not found distally. There are various ways to manipulate clots and improve visualization of the fundus, including repositioning the patient (eg, reverse Trendelenburg or supine/right lateral decubitus), preprocedural prokinetics, using “clot busting” tubing/6-mm channel endoscopes (that provide increased suction power), and extraction/foreign-body retrieval nets. If no bleeding source is found and retained clot prevents full examination of the stomach, endoscopy should be Figure 1. Approach to the initial management, clinical triage, and endoscopic decision making in treating patients with acute NVU- GIB. ETT, endotracheal tube; GBS, Glasgow- Blatchford bleeding score; IV, intravenous; PPI, pro- ton pump inhibitor.1122 Mullady et al Gastroenterology Vol.159, No.3 CLINICAL PRACTICE UPDATE",5398,781,1349.5,"[-0.10492459 -0.47705364 -1.7752578  ...  0.4745065   0.3768764
 -0.9162442 ]"
219,"repeated after allowing time for gastric emptying to complete the examination of the stomach, with the timing dependent on patient stability and the degree of bleeding. The etiology of bleeding frequently dictates endoscopic therapy. Broadly speaking, deﬁnitive endoscopic therapy can be categorized as mechanical (eg, clips) or thermal (eg, heater probes, bipolar/multipolar catheters, hemostatic forceps). Within each group, there are multiple available endoscopic tools and techniques for the management of NVUGIB.28,29 Diluted epinephrine (1:10,000 dilution, which is equivalent to 100 mg/mL) can be injected at or near the bleeding site to attain initial hemostasis by inducing vasospasm, but this is only a temporizing measure that allows for improved visualization to target deﬁnitive therapy. Epinephrine monotherapy should be avoided, given the high risk for rebleeding.30–32 If epinephrine injection is used, a second endoscopic-hemostasis modality should be employed;27,32 however, dual therapy with epinephrine and another endoscopic therapy has no advantage over properly applied thermal or mechanical monotherapy.30 In subgroup analyses from meta-analyses, there was no dif- ference between hemoclips and thermal treatment in terms of peptic ulcer rebleeding rates30–32; data showing superiority of one modality over the other are largely lacking. As there is no deﬁnitively superior modality for endo- scopic hemostasis, use of through-the-scope hemoclips vs thermal therapy for active NVUGIB or for treatment of stigmata of recent hemorrhage is largely at the discretion of the endoscopist. In terms of active peptic ulcer bleeding and stigmata of recent hemorrhage (using the Forrest classiﬁ- cation), the endoscopist should consider the location of the bleeding, as certain locations (eg, posterior wall of duo- denum, lesser curvature of the stomach) and certain ulcer characteristics (eg ﬁbrosis, large ulceration, size of visible vessel) can make clip placement more challenging and less effective than thermal therapy. In many situations, a low- proﬁle distal attachment cap on a forward-viewing endo- scope can facilitate visualization and therapy.33 Similarly, a duodenoscope might be required for lesions in the posterior duodenal bulb and second portion of the duodenum. Endoscopically identiﬁed lesions at increased risk for persistent bleeding or rebleeding, such as Forrest Ia (spurting), Ib (oozing), and IIa (nonbleeding visible vessel) ulcers should receive endoscopic-hemostasis therapy. Peptic ulcers with an adherent clot should be treated by endo- scopic clot removal to evaluate for high-risk stigmata that might require endotherapy.27 When applying contact thermal therapy, the endoscopist should use, when possible a 10F probe. Generator settings of 25–30 J per pulse, for 4–5 pulses, for a total of 100–150 J, should be used with a heater probe, and 15–20 W are rec- ommended for bipolar/multipolar probes. Forceful contact using the probe should be applied for an extended period (at least 8 seconds), with the tip of the scope as close as possible to the treatment site to ensure complete obliteration of the culprit vessel.28,34–36 Failure to obliterate the culprit vessel may cause bleeding during treatment or increase the risk for rebleeding. Excellent visualization is paramount to successful hemostasis, and endoscopes that possess a dedicated water jet should be used to treat NVUGIB. After achievement of hemostasis, use of a through-the-scope Doppler probe can be considered, as data suggest presence of Doppler signal after hemostasis is a risk factor for rebleeding. A single-blind randomized controlled trial (RCT) demonstrated a signiﬁcantly decreased rate of rebleeding within 30 days of endoscopic hemostasis in patients randomized to post-treatment Doppler assessment compared with controls.37 Hemostatic Forceps and Concepts in Electrosurgical Energy Monopolar hemostatic forceps (MHF) were initially used for the treatment of bleeding during endoscopic submucosal dissection (ESD) using low-voltage current.38 The MHF have relatively small, ﬂat, rotatable jaws (Coagrasper, Olympus America, Center Valley, PA) that can be used to grasp and coagulate exposed submucosal vessels in order to treat active bleeding and prevent delayed bleeding from ESD. Using the low-voltage, soft coagulation mode (80W, effect 4) produced by the ERBE VIO series of the electrosurgical generators limits peak voltage thereby minimizing depth of penetration and tissue effect. A variety of studies have examined the use of MHF soft coagulation in peptic ulcer bleeding, including a recent randomized trial of 112 patients that demonstrated their effectiveness compared with the use of hemostatic clips for Forest Ia, Ib, and IIa gastric or duodenal ulcers.5 The initial hemostasis success rate was 98% in the MHF soft coagulation group and 80% in the hemoclip group (P ¼ .004).5 Of note, in peptic ulcer bleeding studies, the technique differs from ESD, as the MHF are applied to a bleeding point closed (without ﬁrst opening the atraumatic jaws to grasp the bleeding vessel), followed by applying soft coagulation (80W, effect 4, 1–2 seconds), and then retracting the forceps and retreating as needed. A particular advantage of the MHF stems from the ease and ﬂexibility of targeting with the forceps. The smaller- sized forceps can be used in difﬁcult locations, particularly when clip application is deemed difﬁcult due to location or a rigid ﬁbrotic base. Unlike certain thermal probes units, which apply a ﬁxed current for a deﬁned time, the application of current is also controlled by the endoscopist and the elec- trosurgical generator, making retreatment more controlled, with less tissue injury. A potential downside to the use of MHF soft coagulation occurs when there is limited coagulation ef- fect at the bleeding point. Treating in the presence of a large blood clot would potentially dissipate the coagulation effect, preventing hemostasis from occurring. Another situation where the limited tissue effect is potentially suboptimal is when a large area of tissue needs to be treated and repeated applications could be required. As the hemostatic forceps (typically available in ESD centers) are relatively costly, some endoscopists use a snare tip to apply soft coagulation for hemostasis, and others have tried to apply noncontact thermal methods (such as argon plasma coagulation) to conduct and/or provide heat through already applied hemostatic clips. Another less costly alternative is to use closed, hot biopsy forceps that usually cost a fraction of the cost of MHF. However, these uses of thermal energy delivery to treat peptic ulcer bleeding have not been formally studied. Switching September 2020 Endoscopic Therapies for NVUGIB 1123 CLINICAL PRACTICE UPDATE",6825,1015,1706.25,"[-0.4639097  -0.09659034 -1.258869   ...  0.7877672   0.20319553
 -1.4777998 ]"
220,"generator settings to a forced coagulation mode (available on several commercially available electrosurgical genera- tors), for example, could be used to overcome pools of liquid or blood between the forceps and bleeding point; however, the endoscopist could potentially treat a larger area than desired and have less ability to limit the depth of tissue injury. Endoscopists should monitor the coagulum being created and be aware of the potential for deep tissue injury, perforation, or delayed bleeding whenever electrosurgical energy is applied. Until their effectiveness is formally studied, these latter techniques should be employed only by endoscopists very familiar with their use in advanced endoscopic procedures and who possess a good under- standing of electrosurgical current settings. Over-the-Scope Clips In selected patients with peptic ulcer bleeding or other causes of NVUGIB, over-the-scope clips can be an effective treatment option. There are currently 2 clips (OTSC; Ovesco Endoscopy, Cary, NC) and (Padlock clip; Steris Endoscopy, Mentor, OH) with different designs and deployment mecha- nisms. There have been no head-to-head comparisons of these clips or head-to-head trials of over-the-scope clips to through- the-scope clips or thermal therapy. Most of the reported experience with over-the-scope clips in NVUGIB has been with peptic ulcer bleeding. There are several scenarios in which over-the-scope clips may be utilized in NVUGIB, including rescue treatment, rebleeding, and initial treatment. In the setting of persistent bleeding despite conventional methods of hemostasis, data from small case series suggest that over-the-scope clips are an effective rescue modality.39–42 A recent RCT demonstrated that over-the-scope clips were more effective than standard therapy in patients with recur- rent peptic ulcer bleeding.4 There are also nonrandomized data suggesting that over-the-scope clips may be superior to standard treatment in initial treatment of peptic ulcer bleeding compared with historical rebleeding rates.43–46 Before suggesting a paradigm shift to over-the-scope clips, large RCTs are needed that demonstrate considerable beneﬁt. However, there may be situations in which over-the-scope clips should be considered as ﬁrst-line treatment—namely, large, ﬁbrotic ulcer beds with a large visible vessel that may not be amenable to through-the-scope hemoclip ﬁxation or when thermal therapy is predicted to be ineffective. Hemostatic Powder Topical hemostatic agents are a noncontact modality that can be used to treat NVUGIB. The main advantage of these agents is related to their mode of action and technique of deployment. Unlike other endoscopic hemostatic modal- ities, topical hemostatic powders can be diffusely deployed from a catheter without having to be positioned en face and do not require advanced endoscopic training or skills. Much of the initial clinical experience with these agents occurred in countries outside of the United States. Initially, hemo- static powder was used only in cases of NVUGIB due to concern of embolization risk, but a recent study in patients with variceal bleeding demonstrated clinical effectiveness without adverse events.47 Although patients in hemostatic powder studies have experienced adverse events, they were unlikely to be due to the sprayed powder.48 Although there are a few hemostatic agents available worldwide, the commercially available product in North America is TC-325 (Hemospray, Cook Medical, Bloomington, IN). This agent is propelled through a delivery catheter on to a bleeding lesion using a carbon dioxide canister. Upon contact with moisture, the endoscopic powder aggregates, creating a mechanical barrier upon the mucosa.49 This makes it particularly useful in situations where bleeding is diffuse, cannot be localized, or if visualization is poor due to bleeding (Figure 2). In most instances, hemostatic powder should be preferentially used as a rescue therapy and not for primary hemostasis, except in cases of malignant bleeding or massive bleeding with inability to perform thermal therapy or hemoclip placement. When using this type of hemostatic powder and delivery system, the endoscopist should make an effort to prevent the delivery catheter from becoming blocked. Both 7F and 10F catheters are available for different-sized accessory channels (such as those found in diagnostic vs therapeutic endoscopes). Care must be taken when using duodenoscope elevators or when in retroﬂexed positions to avoid kinking the delivery catheter. Additional steps must also be taken to avoid moisture coming into contact with the catheter, such as keeping the catheter tip out of contact with pools of ﬂuid or blood, as this will prematurely activate the powder within the catheter and prevent deployment. Keeping the accessory channel free of moisture by preﬂushing with air (using a 60-mL syringe) and detaching suction tubing temporarily before inserting the de- livery catheter to avoid inadvertent suctioning are steps that may minimize unintended activation of the powder within the delivery catheter. Once in position near the bleeding site, the spray is typically deployed from a distance of 1–2 cm away in short controlled bursts. Once delivery begins, the endoscopist should take care to avoid accidental powder spray on the lens. Overapplication can lead to a diffuse spray effect, potentially limiting subsequent mucosal assessment. Subsequent washing at the lesion site is not recommended, as this can wash away the powder. If multiple treatment modalities are planned, it is ideal to plan the timing and sequence of modalities due to the effect of powder deployment on endoscopic visibility. Retrospective studies demonstrated the powder remains present less than 24 hours,50 hence monotherapy with TC- 325 is not recommended in ulcers with high-risk stigmata for rebleeding. In these situations, hemostatic powder should be used as a temporary measure to stop bleeding, followed by another treatment modality either at the index procedure or during a second-look endoscopy.14 However, 2 pilot RCTs6,51 and a noncontrolled registry study52 have suggested a potential role for TC-325/Hemospray as mon- otherapy in patients with upper gastrointestinal tract bleeding, raising the need for an appropriately powered clinical trial. Hemostatic powder may be particularly useful in centers where advanced endoscopic expertise is not al- ways available and temporizing methods are needed before more deﬁnitive therapy or transfer to a specialized center.1124 Mullady et al Gastroenterology Vol.159, No.3 CLINICAL PRACTICE UPDATE",6643,978,1660.75,"[ 0.03324954 -0.33198234 -1.522304   ...  0.75410885  0.21342894
 -1.388025  ]"
221,"Diffuse tumor bleeding is a challenging clinical problem that is often not responsive to conventional endoscopic therapy. A pilot RCT51 did show that hemostatic powder may be useful in such situations, optimally as a bridge to radiotherapy or surgery. According to the US Food and Drug Administration, on February 4, 2020 Cook Medical recalled their Hemospray Endoscopic Hemostat (hemostatic powder) device due to “Complaints that the handle and/or activation knob on He- mostat devices have cracked or broken when the device is activated. In some cases, this has caused the carbon dioxide cartridge to exit the handle.”53 This was in conjunction with a voluntary global recall initiated by the company in January 2020 for the same reason. Cook Medical has addressed this issue. On June 10, 2020 the US Food and Drug Administration issued 510(k) premarket approval (K200972) for Hemospray. At the time this Clinical Practice Update went to print, Hemospray is available again in the US and Canadian markets and in many other countries worldwide. Hemostatic Considerations in Advanced Endoscopy Settings There are certain endoscopic interventions that are asso- ciated with an increased risk for inducing bleeding.15 These include endoscopic mucosal resection (EMR), ESD, and endoscopic sphincterotomy. Bleeding can be immediate/ intraprocedural or delayed/postprocedural. Endoscopists who perform these procedures should be comfortable man- aging bleeding and have tools readily available in the event of intraprocedural bleeding. Procedure-related bleeding is treated in the same manner as other types of NVUGIB, but with special considerations. For example, thermal therapy, particularly with hemostatic forceps, for bleeding during EMR or ESD may be preferable to treatment with hemoclips because the latter may interfere with completing the resec- tion. For post-sphincterotomy bleeding, biliary stents may be used to tamponade a bleeding site. Clips and thermal therapy can also be used to treat post-sphincterotomy bleeding; however, the endoscopist needs to be aware of the potential difﬁculty in clip placement through a duodenoscope and the possibility of pancreatitis with thermal therapy or errant clip placement. Therefore, when clips or thermal coagulation are used in post-sphincterotomy bleeding, a low threshold for placing a prophylactic pancreatic duct stent should exist. Endoscopists should be prepared to perform an endoscopic retrograde cholangiopancreatography, if needed, for all delayed post-sphincterotomy bleeds, as biliary and/or pancreatic duct stenting may be required. Postprocedural bleeding prophylaxis is an important issue that the endoscopist should address. This is particularity important in patients who require reinstitution of AT therapy. Although there is recent evidence that clip closure of right- sided colonic EMR sites might decrease the risk of post- polypectomy bleeding,54 there is no similar high-level evi- dence for upper gastrointestinal interventions. For bleeding prophylaxis of upper gastrointestinal EMR or ESD sites, op- tions include use of MHF to treat visible vessels or closure of the defect with clips or endosuturing. There are no compar- ative trials to guide practice, but consideration should be Figure 2. Flow diagram incorporating hemostatic powder therapy as an op- tion for the management of acute NVUGIB. September 2020 Endoscopic Therapies for NVUGIB 1125 CLINICAL PRACTICE UPDATE",3454,505,863.5,"[-0.58132946  0.03129269 -1.700063   ...  0.7635356   0.3893593
 -1.3080775 ]"
222,"given to closing sites, when amenable, in patients who require immediate resumption of AT medications. There are no data with regard to prophylaxis of post-sphincterotomy bleeding; however, in patients who require immediate resumption of AT medication, a fully covered metallic biliary stent may be used. Interventions for Recurrent or Refractory Bleeding In patients who rebleed after endoscopic therapy, a sec- ond attempt at endoscopic hemostasis is typically advised. In patients treated initially with thermal therapy who rebleed, additional thermal therapy might be possible, or mechanical therapy with a clip could be applied. Hemospray should also be considered as rescue therapy. In difﬁcult situations, a second opinion from a colleague or assistance from a more experienced endoscopist are important considerations. However, despite the increasing availability of different effective endoscopic modalities, a subset of patients with NVUGIB will still develop rebleeding despite high-quality endoscopic interventions. The exact point at which an endo- scopist will determine that repeat endoscopic invention has a low chance of technical and clinical success is a complex de- cision that will depend on local expertise and resources; fa- miliarity with advanced endoscopic techniques; and clinical predictors, such as type of disease, severity, and location. Second-look endoscopy should not be performed routinely, but it does have a role in cases where rebleeding risk is high, despite initial endoscopic success or if the index procedure does not adequately control bleeding. Prior endoscopic therapy can be suboptimal due to ulcer characteristics, such as size, location, or presence of ﬁbrosis; the use of epinephrine- injection monotherapy or single use of a hemostatic powder for a high-risk lesion; or if thermal or mechanical therapy alone or in combination was performed but did not adequately control bleeding for technical reasons (eg, inadequate coagu- lation or insufﬁcient tissue grasped by a hemostatic clip). The main options in cases of endoscopic failure with rebleeding or refractory bleeding are transcatheter arterial embolization (TAE) and surgery. In earlier studies, a variety of surgical options were used, with TAE reserved for poor sur- gical candidates. With high technical and clinical success rates, TAE has been shown to be equally effective, with trends to- ward lower 30-day mortality rates compared with surgical intervention.55–57 TAE has become increasingly available, with the advantage of being able to be used in patients who are unﬁt for surgery, even in the setting of coagulopathy. Studies of TAE have shown fewer complications than surgery, albeit with higher rebleeding rates.57 Embolization is most effective when active extravasation can be demonstrated, or if a site can be endoscopically prelocalized (either anatomically or by using a hemoclip) before empiric embolization. Studies of embolization show that multiple or large duodenal ulcers, gastritis, coagulopathy, or multi-organ failure are believed to contribute to clinical failures.58 The choice of embolic agent should also be taken into account by the performing inter- ventional radiologist, as the multiple agents that exist have different properties that inﬂuence rebleeding rate, risk of recanalization, and subsequent ischemic complications. An important point is that prophylactic TAE of high-risk ulcers after successful endoscopic therapy is not recommended.1,59 As patients with rebleeding and refractory bleeding are typically complex, with multiple comorbidities, often receiving anticoagulants, or with severe coagulopathies (such as seen in hematologic malignancies), the choice among repeat endoscopy, surgery, and TAE must be decided on a case-by-case basis. Weighing the risks and beneﬁts of each intervention will depend on the expected rates of clinical success, risk of rebleeding, potential adverse events, and after taking into account local expertise and resource availability. For optimal clinical outcomes in refractory bleeding, a multidisciplinary approach is required involving gastrointestinal endoscopists, intensivists, surgeons, inter- ventional radiologists, and in some cases hematologists and/or oncologists. Summary Recent advances in endoscopic devices and techniques now enable endoscopists to treat NVUGIB lesions more effectively and with a variety of often complementary methods. With this expanded endoscopic armamentarium, endoscopic therapy should achieve hemostasis in the majority of patients with NVUGIB. Hemostatic forceps, over-the-scope clips, and sprayed hemostatic powders are newer and rela- tively expensive endoscopic devices that have established roles in treating NVUGIB, and may be particularly useful in difﬁcult-to-treat or recurrent bleeding lesions. Despite the increased costs of newer devices or multimodal therapy, effective hemostasis to prevent rebleeding and the need for hospital readmission is likely to be a dominant cost-saving strategy. Practicing endoscopists should be comfortable applying conventional thermal therapy and placing hemoclips, and they should familiarize themselves with newer tech- niques to manage NVUGIB, which can occur from a variety of etiologies ranging from peptic ulcer disease to adverse events after therapeutic endoscopy. In situations where thermal or mechanical therapies are not successful at achieving hemo- stasis, sprayed hemostatic powder is a valuable rescue ther- apy; and it might also enable endoscopists with limited training or backup to temporize severely bleeding lesions to allow time for transfer to a specialized referral center. Finally, multidisciplinary consultation and an assessment of endo- scopic, radiographic, and surgical expertise should inform the selection of therapy in refractory NVUGIB. References 1. Stanley AJ, Laine L. Management of acute upper gastrointestinal bleeding. BMJ 2019;364:l536.2. Wang AY, Peura DA. The prevalence and incidence of Helicobacter pylori-associated peptic ulcer disease and upper gastrointestinal bleeding throughout the world. Gastrointest Endosc Clin N Am 2011;21:613–635.3. Binmoeller KF, Thonke F, Soehendra N. Endoscopic hemoclip treatment for gastrointestinal bleeding. Endoscopy 1993;25:167–170.1126 Mullady et al Gastroenterology Vol.159, No.3 CLINICAL PRACTICE UPDATE",6359,892,1589.75,"[-0.13675106 -0.22634661 -1.7434043  ...  0.31107146  0.7686125
 -1.3522558 ]"
223,"4. Schmidt A, Golder S, Goetz M, et al. Over-the-scope clips are more effective than standard endoscopic ther- apy for patients with recurrent bleeding of peptic ulcers. Gastroenterology 2018;155:674–686.e6.5. Toka B, Eminler AT, Karacaer C, et al. Comparison of monopolar hemostatic forceps with soft coagulation versus hemoclip for peptic ulcer bleeding: a random- ized trial (with video). Gastrointest Endosc 2019; 89:792–802.6. Baracat FI, de Moura DTH, Brunaldi VO, et al. Ran- domized controlled trial of hemostatic powder versus endoscopic clipping for non-variceal upper gastrointes- tinal bleeding. Surg Endosc 2020;34:317–324.7. Blatchford O, Murray WR, Blatchford M. A risk score to predict need for treatment for upper-gastrointestinal haemorrhage. Lancet 2000;356:1318–1321.8. Rockall TA, Logan RF, Devlin HB, et al. Variation in outcome after acute upper gastrointestinal haemorrhage. The National Audit of Acute Upper Gastrointestinal Haemorrhage. Lancet 1995;346:346–350.9. Rockall TA, Logan RF, Devlin HB, et al. Incidence of and mortality from acute upper gastrointestinal haemorrhage in the United Kingdom. Steering Committee and mem- bers of the National Audit of Acute Upper Gastrointes- tinal Haemorrhage. BMJ 1995;311:222–226.10. Saltzman JR, Tabak YP, Hyett BH, et al. A simple risk score accurately predicts in-hospital mortality, length of stay, and cost in acute upper GI bleeding. Gastrointest Endosc 2011;74:1215–1224.11. Odutayo A, Desborough MJ, Trivella M, et al. Restrictive versus liberal blood transfusion for gastrointestinal bleeding: a systematic review and meta-analysis of randomised controlled trials. Lancet Gastroenterol Hep- atol 2017;2:354–360.12. Qaseem A, Humphrey LL, Fitterman N, et al. Treatment of anemia in patients with heart disease: a clinical practice guideline from the American College of Physi- cians. Ann Intern Med 2013;159:770–779.13. Villanueva C, Colomo A, Bosch A. Transfusion for acute upper gastrointestinal bleeding. N Engl J Med 2013; 368:1362–1363.14. Barkun AN, Almadi M, Kuipers EJ, et al. Management of nonvariceal upper gastrointestinal bleeding: guideline recommendations from the International Consensus Group.",2186,301,546.5,"[ 0.03772722 -0.49657726 -1.5284646  ...  0.54984814  0.35961777
 -1.6622523 ]"
223,"Ann Intern Med 2019;171:805–822.15. ASGE Standards of Practice Committee, Acosta RD, Abraham NS, et al. The management of antithrombotic agents for patients undergoing GI endoscopy. Gastro- intest Endosc 2016;83:3–16.16. Chan FKL, Goh KL, Reddy N, et al. Management of pa- tients on antithrombotic agents undergoing emergency and elective endoscopy: Joint Asian Paciﬁc Association of Gastroenterology (APAGE) and Asian Paciﬁc Society for Digestive Endoscopy (APSDE) practice guidelines. Gut 2018;67:405–417.17. Nagata N, Yasunaga H, Matsui H, et al. Therapeutic endoscopy-related GI bleeding and thromboembolic events in patients using warfarin or direct oral antico- agulants: results from a large nationwide database analysis. Gut 2018;67:1805–1812.18. Dorward S, Sreedharan A, Leontiadis GI, et al. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database Syst Rev 2006:CD005415.19. Chan WH, Khin LW, Chung YF, et al. Randomized controlled trial of standard versus high-dose intravenous omeprazole after endoscopic therapy in high-risk patients with acute peptic ulcer bleeding. Br J Surg 2011;98:640–644.20. Barkun AN, Bardou M, Martel M, et al. Prokinetics in acute upper GI bleeding: a meta-analysis. Gastrointest Endosc 2010;72:1138–1145.21. Ellidokuz E, Kaya D. The effect of metoclopramide on QT dynamicity: double-blind, placebo-controlled, cross-over study in healthy male volunteers. Aliment Pharmacol Ther 2003;18:151–155.22. Kumar NL, Cohen AJ, Nayor J, et al. Timing of upper endos- copy inﬂuences outcomes in patients with acute nonvariceal upper GI bleeding. Gastrointest Endosc 2017;85:945–952.e1.23. Laursen SB, Leontiadis GI, Stanley AJ, et al. Relationship between timing of endoscopy and mortality in patients with peptic ulcer bleeding: a nationwide cohort study. Gastrointest Endosc 2017;85:936–944.e3.24. Lau JYW, Yu Y, Tang RSY, et al. Timing of endoscopy for acute upper gastrointestinal bleeding. N Engl J Med 2020;382:1299–1308.25. Stanley AJ, Ashley D, Dalton HR, et al. Outpatient man- agement of patients with low-risk upper-gastrointestinal haemorrhage: multicentre validation and prospective evaluation.",2206,298,551.5,"[ 0.08284141 -0.58634263 -1.5902125  ...  0.8543113   0.6531565
 -1.5881456 ]"
223,"Lancet 2009;373:42–47.26. Laursen SB, Dalton HR, Murray IA, et al. Performance of new thresholds of the Glasgow Blatchford score in managing patients with upper gastrointestinal bleeding. Clin Gastroenterol Hepatol 2015;13:115–121 e2.27. Gralnek IM, Dumonceau JM, Kuipers EJ, et al. Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2015;47:a1–46.28. ASGE Technology Committee, Parsi MA, Schulman AR, et al. Devices for endoscopic hemostasis of nonvariceal GI bleeding (with videos). VideoGIE 2019;4:285–299.29. Martinez-Alcala A, Monkemuller K. Emerging endoscopic treatments for nonvariceal upper gastrointestinal hemor- rhage. Gastrointest Endosc Clin N Am 2018;28:307–320.30. Marmo R, Rotondano G, Piscopo R, et al. Dual therapy versus monotherapy in the endoscopic treatment of high-risk bleeding ulcers: a meta-analysis of controlled trials. Am J Gastroenterol 2007;102:279–289; quiz 469.31. Vergara M, Bennett C, Calvet X, et al. Epinephrine in- jection versus epinephrine injection and a second endoscopic method in high-risk bleeding ulcers. Cochrane Database Syst Rev 2014:CD005584.32. Sung JJ, Tsoi KK, Lai LH, et al. Endoscopic clipping versus injection and thermo-coagulation in the treatment of non-variceal upper gastrointestinal bleeding: a meta- analysis. Gut 2007;56:1364–1373.33. Sanchez-Yague A, Kaltenbach T, Yamamoto H, et al. The endoscopic cap that can (with videos). Gastrointest Endosc 2012;76:169–178; e1–e2.34. Laine L. Determination of the optimal technique for bi- polar electrocoagulation treatment. An experimental September 2020 Endoscopic Therapies for NVUGIB 1127 CLINICAL PRACTICE UPDATE",1723,225,430.75,"[-0.09742378 -0.42970186 -1.5030097  ...  0.53496504  0.20139532
 -1.4309622 ]"
224,"evaluation of the BICAP and Gold probes. Gastroenter- ology 1991;100:107–112.35. Laine L, Long GL, Bakos GJ, et al. Optimizing bipolar electrocoagulation for endoscopic hemostasis: assess- ment of factors inﬂuencing energy delivery and coagu- lation. Gastrointest Endosc 2008;67:502–508.36. Laine L, Jensen DM. Management of patients with ulcer bleeding. Am J Gastroenterol 2012;107:345–360; quiz 361.37. Jensen DM, Kovacs TOG, Ohning GV, et al. Doppler Endoscopic probe monitoring of blood ﬂow improves risk stratiﬁcation and outcomes of patients with severe nonvariceal upper gastrointestinal hemorrhage. Gastro- enterology 2017;152:1310–1318.e1.38. Sugawa C, Masuyama H. An endoscopic monopolar hemostatic electrocoagulation forceps (grasping coagu- lator). Gastrointest Endosc 1986;32:114–116.39. Chan SM, Chiu PW, Teoh AY, et al. Use of the over-the- scope clip for treatment of refractory upper gastroin- testinal bleeding: a case series. Endoscopy 2014; 46:428–431.40. El Douaihy Y, Kesavan M, Deeb L, et al. Over-the-scope clip to the rescue of a bleeding gastroduodenal artery pseudoaneurysm. Gastrointest Endosc 2016;84:854–855.41. Manta R, Galloro G, Mangiavillano B, et al. Over-the- scope clip (OTSC) represents an effective endoscopic treatment for acute GI bleeding after failure of conven- tional techniques. Surg Endosc 2013;27:3162–3164.42. Skinner M, Gutierrez JP, Neumann H, et al. Over-the- scope clip placement is effective rescue therapy for se- vere acute upper gastrointestinal bleeding. Endosc Int Open 2014;2:E37–E40.43. Golder S, Neuhas L, Freuer D, et al. Over-the-scope clip in peptic ulcer bleeding: clinical success in primary and secondary treatment and factors associated with treat- ment failure. Endosc Int Open 2019;7:E846–E854.44. Manno M, Mangiaﬁco S, Caruso A, et al. First-line endoscopic treatment with OTSC in patients with high- risk non-variceal upper gastrointestinal bleeding: pre- liminary experience in 40 cases. Surg Endosc 2016; 30:2026–2029.45. Richter-Schrag HJ, Glatz T, Walker C, et al.",2041,280,510.25,"[ 0.41596657 -0.1951323  -1.233112   ...  0.6576765   0.29710495
 -1.4177033 ]"
224,"First-line endoscopic treatment with over-the-scope clips signiﬁcantly improves the primary failure and rebleeding rates in high-risk gastrointestinal bleeding: a single-center experience with 100 cases. World J Gastroenterol 2016;22:9162–9171.46. Wedi E, Fischer A, Hochberger J, et al. Multicenter evaluation of ﬁrst-line endoscopic treatment with the OTSC in acute non-variceal upper gastrointestinal bleeding and comparison with the Rockall cohort: the FLETRock study. Surg Endosc 2018;32:307–314.47. Ibrahim M, El-Mikkawy A, Abdel Hamid M, et al. Early application of haemostatic powder added to standard management for oesophagogastric variceal bleeding: a randomised trial. Gut 2019;68:844–853.48. Rodriguez de Santiago E, Burgos-Santamaria D, Perez- Carazo L, et al. Hemostatic spray powder TC-325 for GI bleeding in a nationwide study: survival and predictors of failure via competing risks analysis. Gastrointest Endosc 2019;90:581–590.e6.49. Barkun AN, Moosavi S, Martel M. Topical hemostatic agents: a systematic review with particular emphasis on endoscopic application in GI bleeding. Gastrointest Endosc 2013;77:692–700.50. Chen YI, Barkun AN. Hemostatic powders in gastroin- testinal bleeding: a systematic review. Gastrointest Endosc Clin N Am 2015;25:535–552.51. Chen YI, Wyse J, Lu Y, et al. TC-325 hemostatic powder versus current standard of care in managing malignant GI bleeding: a pilot randomized clinical trial. Gastrointest Endosc 2020;91:321–328.e1.52. Alzoubaidi D, Hussein M, Rusu R, et al. Outcomes from an international multicenter registry of patients with acute gastrointestinal bleeding undergoing endoscopic treatment with Hemospray. Dig Endosc 2020;32:96–105.53. US Food and Drug Administration. Class 2 Device Recall Cook Hemospray Endoscopic Hemostat (Recall Number: Z-1746-2020). Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRes/res.cfm?ID¼179474. Accessed April 25, 2020.54. Pohl H, Grimm IS, Moyer MT, et al. Clip closure prevents bleeding after endoscopic resection of large colon polyps in a randomized trial. Gastroenterology 2019; 157:977–984.e3.55. Jairath V, Kahan BC, Logan RF, et al. National audit of the use of surgery and radiological embolization after failed endoscopic haemostasis for non-variceal upper gastrointestinal bleeding. Br J Surg 2012;99:1672–1680.",2337,304,584.25,"[-0.36586982 -0.44202372 -0.9331815  ...  0.3966599   0.29992968
 -1.6838881 ]"
224,"56. Ripoll C, Banares R, Beceiro I, et al. Comparison of transcatheter arterial embolization and surgery for treat- ment of bleeding peptic ulcer after endoscopic treatment failure. J Vasc Interv Radiol 2004;15:447–450.57. Tarasconi A, Baiocchi GL, Pattonieri V, et al. Trans- catheter arterial embolization versus surgery for re- fractory non-variceal upper gastrointestinal bleeding: a meta-analysis. World J Emerg Surg 2019;14:3.58. Loffroy R, Rao P, Ota S, et al. Embolization of acute nonvariceal upper gastrointestinal hemorrhage resistant to endoscopic treatment: results and predictors of recurrent bleeding. Cardiovasc Intervent Radiol 2010; 33:1088–1100.59. Lau JYW, Pittayanon R, Wong KT, et al. Prophylactic angiographic embolisation after endoscopic control of bleeding to high-risk peptic ulcers: a randomised controlled trial. Gut 2019;68:796–803. Received March 25, 2020. Accepted May 18, 2020. Correspondence Address correspondence to: Andrew Y. Wang, MD, AGAF, FACG, FASGE, Division of Gastroenterology and Hepatology, University of Virginia, Box 800708, Charlottesville, Virginia 22908.e-mail: ayw7d@virginia.edu; fax: 434- 244-7590. Acknowledgments Author contributions: Each of the authors contributed to drafting of the manuscript and critical revision of the manuscript for important intellectual content. Conﬂicts of interest Daniel Mullady discloses the following: consultant, Boston Scientiﬁc; consultant, ConMed; Hemospray Advisory Board, Cook Medical. The remaining authors disclose no conﬂicts.1128 Mullady et al Gastroenterology Vol.159, No.3 CLINICAL PRACTICE UPDATE",1597,208,399.25,"[-0.30672932 -0.8678677  -1.7254537  ...  0.2996038   0.58775276
 -1.5559603 ]"
225,"For personal use only 	 1 of 13 summarizing evidence for risk assessment, resuscitation, blood transfusion, medical and endoscopic therapy, and early post-endoscopic management. We will not review interventions for long term secondary prevention of bleeding, such as testing for and treating Helicobacter pylori infection, use of non-steroidal anti-inflammatory drugs (NSAIDs), or maintenance antisecretory therapy. Upper gastrointestinal bleeding is managed by many cli­ nicians across many specialties, including emergency room physicians, hospitalists, internists, gastroenterologists, surgeons, interventional radiologists, and hematologists. A variety of topics—including risk assessment, the threshold for blood transfusion, the timing of endoscopy, and medical and endoscopic therapies—have continued to evolve in recent years. In addition, it has become increas­ ingly important and complex to determine the appropriate management of patients who need antithrombotic agents, with gastroenterological, cardiovascular, and hematologi­ cal aspects needing to be considered. This article provides a comprehensive and evidence based summary of the assessment and management of patients with acute upper gastrointestinal bleeding, which is relevant to clinician specialists, academics, and clinical researchers. A summary of management is provided in the box. STATE OF THE ART REVIEW	 Introduction Upper gastrointestinal bleeding is a common medical emergency worldwide and refers to bleeding from the esophagus, stomach, or duodenum. Patients present with hematemesis (bloody or coffee ground emesis) or melena, although hematochezia can occur in the context of a major bleed and is typically associated with hemodynamic insta­ bility. Patients with melena present with lower hemo­ globin values than patients with hematemesis, probably because presentation is more likely to be delayed.1 There­ fore, patients with melena more often require transfusion, although mortality is lower in patients with melena than in those with hematemesis in some series.1 Numerous improvements in the management of upper gastrointesti­ nal bleeding have been incorporated into clinical practice in recent years. However, many patients now have risk factors for a poorer outcome, including increasing age and major medical comorbidities.2 Although the cause of a bleeding episode is uncertain until endoscopy is undertaken, guidelines often separate upper gastrointestinal bleeding into variceal and non- variceal bleeding because management and outcomes differ.3‑9 This article covers the acute management of patients with overt upper gastrointestinal bleeding, ABSTRACT Upper gastrointestinal bleeding (UGIB) is a common medical emergency, with a reported mortality of 2-10%. Patients identified as being at very low risk of either needing an intervention or death can be managed as outpatients. For all other patients, intravenous fluids as needed for resuscitation and red cell transfusion at a hemoglobin threshold of 70-80 g/L are recommended. After resuscitation is initiated, proton pump inhibitors (PPIs) and the prokinetic agent erythromycin may be administered, with antibiotics and vasoactive drugs recommended in patients who have cirrhosis. Endoscopy should be undertaken within 24 hours, with earlier endoscopy considered after resuscitation in patients at high risk, such as those with hemodynamic instability. Endoscopic treatment is used for variceal bleeding (for example, ligation for esophageal varices and tissue glue for gastric varices) and for high risk non-variceal bleeding (for example, injection, thermal probes, or clips for lesions with active bleeding or non-bleeding visible vessel). Patients who require endoscopic therapy for ulcer bleeding should receive high dose proton pump inhibitors after endoscopy, whereas those who have variceal bleeding should continue taking antibiotics and vasoactive drugs. Recurrent ulcer bleeding is treated with repeat endoscopic therapy, with subsequent bleeding managed by interventional radiology or surgery. Recurrent variceal bleeding is generally treated with transjugular intrahepatic portosystemic shunt. In patients who require antithrombotic agents, outcomes appear to be better when these drugs are reintroduced early Management of acute upper gastrointestinal bleeding Adrian J Stanley,1 Loren Laine2 1Department of Gastroenterology, Glasgow Royal Infirmary, Glasgow G4 OSF, UK 2Section of Digestive Diseases, Yale School of Medicine, New Haven, and VA Connecticut Healthcare System, West Haven, Connecticut, CT 06520, USA Correspondence to: A J Stanley adrian.stanley@ggc.scot.nhs.uk and adrianstanley99@gmail.com Cite this as: BMJ 2019;364:l536 doi: 10.1136/bmj.l536 Series explanation: State of the Art Reviews are commissioned on the basis of their relevance to academics and specialists in the US and internationally. For this reason they are written predominantly by US authors on 29 May 2024 at Yonsei University (Medical Library and Hospital). Protected by copyright.http://www.bmj.com/ BMJ: first published as 10.1136/bmj.l536 on 25 March 2019. Downloaded from",5134,702,1283.5,"[ 0.7230368  -0.37094563 -1.3988308  ...  0.3668641   0.6619191
 -1.4976761 ]"
226,"STATE OF THE ART REVIEW For personal use only 	 2 of 13 Overall quality of evidence Numerous randomized controlled trials (RCTs) and meta-analyses have assessed the use of medical and endoscopic therapy, and the optimal blood transfusion strategy in patients with acute upper gastrointestinal bleeding, thereby providing high quality data to guide management. Although the evidence regarding resuscita­ tion, risk assessment, timing of endoscopy, and reintro­ duction of antithrombotic drugs is of lower quality, large recent studies in these areas have helped inform patient management. Incidence The incidence of upper gastrointestinal bleeding in the United Kingdom in the 1990s was 103-172/100 000 adults per year.10 11 Recent reports from the United States using nationwide administrative databases indicate that the incidence of hospital admission for the condition was 61-78 per 100 000 persons in 2009-2012.12‑14 Peptic ulcers are the most common cause of hospital admission for upper gastrointestinal bleeding, accounting for just over half of all cases.12 14 The incidence of hospital admis­ sion for the condition has decreased 21-23% during the past 10 years.12 14 This decrease is largely accounted for by decreases in peptic ulcer bleeding (and bleeding ascribed to “gastritis”) probably because of the decreas­ ing prevalence of H pylori and increasing use of antisecre­ tory drugs. Case fatality rates from these database studies were low, in the range of 1.9-2.5%.12‑14 By contrast, large observational cohort studies from Europe suggest higher fatality rates of around 10%.15 16 The reason for these differences is unknown but might be partly related to reliance on coding in database studies and differences in practice, such as low risk patients being more often managed in outpatient settings in Europe. Sources and selection criteria We searched PubMed, Medline, and Cochrane databases from 2010 to August 2018 using the search terms gastro­ intestinal hemorrhage, peptic ulcer bleeding, and variceal bleeding. References were also identified from the inter­ national, UK, European, American, and Asia-Pacific guidelines on upper gastrointestinal bleeding published during this period in addition to relevant review articles. We selected systematic reviews, meta-analyses, RCTs, and observational studies (excluding case reports and small (<15 cases) case series). We also excluded articles that were not peer reviewed and those not published in Eng­ lish. Studies were prioritized by design, as noted above, and by patient numbers, quality, and publication date. Initial resuscitation As with any new patient with a medical emergency, the initial clinical evaluation of patients presenting with upper gastrointestinal bleeding involves assessment of the patient’s airway, breathing, and circulation. Many patients are hemodynamically stable at presentation, but for those with major bleeding, early resuscitation is essential. In general, two large bore intravenous cannu­ lae are inserted, although central venous access may be preferred in certain cases. Regular monitoring of pulse, blood pressure, and oxygen saturations is crucial. Hypo­ tension is associated with increased mortality; a multi­ center observational study of 1882 patients reported an odds ratio of 9.8 (95% confidence interval 5.1 to 19) with systolic blood pressure <90 mm Hg versus ≥90 mm Hg.11 Tracheal intubation may be used to protect the airway in patients with severe ongoing hematemesis, especially in those at increased risk of aspiration (such as those with an altered mental status or lack of gag reflex). No RCTs have assessed fluid resuscitation in upper gas­ trointestinal bleeding. By contrast, a comparative study and an RCT in patients with hemorrhagic shock as a result of trauma suggest that a more restrictive fluid resuscita­ tion may be better (or not worse) than more intensive fluid resuscitation.17 18 The choice of intravenous fluid for ini­ tial resuscitation is unclear, with crystalloids or colloids often being used while the need for the transfusion of blood products is assessed. A meta-analysis of 70 trials with 22 392 patients found no difference in mortality between colloid and crystalloid solutions for fluid resus­ citation in critically ill patients: relative risk 1.01 (0.93 to 1.10) for albumin or plasma proteins versus crystalloid solutions, and similar negative results when other col­ loids were compared with crystalloids.19 An RCT of 15 802 critically ill hospital inpatients found reduced acute SUMMARY OF THE MANAGEMENT OF UPPER GASTROINTESTINAL BLEEDING Pre-endoscopic management •	Hemodynamic assessment and resuscitation as needed •	Blood transfusion at a hemoglobin threshold of 70-80 g/L; higher threshold if severe bleeding with hypotension •	Risk assessment: -If Glasgow-Blatchford score ≤1 consider outpatient endoscopy and management •	Erythromycin (as a prokinetic agent) and proton pump inhibitor may be considered •	Patients with cirrhosis should receive vasoactive drugs and antibiotics Endoscopic •	Endoscopy is generally recommended within 24 hours in patients admitted to hospital –– If the patient has severe bleeding with hemodynamic instability, urgent endoscopy should be performed after resuscitation •	Ulcers with active bleeding and non-bleeding visible vessels should receive endoscopic therapy; endoscopic therapy may also be used for ulcers with adherent clots •	Injection therapy (eg, epinephrine), thermal probes (eg, bipolar electrocoagulation, heater probe), or clips should be used •	Epinephrine injection should always be followed by a second modality •	Recurrent bleeding should be treated with repeat endoscopic therapy but subsequent bleeding by transarterial embolization or surgery •	Esophageal variceal bleeding should be treated with ligation and gastric varices with the injection of tissue adhesive •	Refractory variceal bleeding should be treated with transjugular portosystemic shunt •	For massive refractory esophageal variceal bleeding a removable covered metal stent is preferred to balloon tamponade as a temporizing measure Post-endoscopic management •	Patients who have ulcers with high risk lesions (active bleeding, visible vessel, adherent clot) should receive high dose proton pump inhibitors for 72 h •	Patients with cirrhosis should continue antibiotics for up to seven days regardless of the bleeding source •	Variceal bleeding should be treated with vasoactive drugs for up to five days •	When used for secondary prevention, aspirin should be continued or reintroduced soon after hemostasis is achieved •	Early reintroduction of other antithrombotic drugs is also recommended after hemostasis is achieved to reduce thrombotic events and death on 29 May 2024 at Yonsei University (Medical Library and Hospital). Protected by copyright.http://www.bmj.com/ BMJ: first published as 10.1136/bmj.l536 on 25 March 2019. Downloaded from",6930,994,1732.5,"[ 0.69854766 -0.5890019  -1.2809844  ...  0.18428205  0.7221148
 -1.4618572 ]"
227,"STATE OF THE ART REVIEW For personal use only 	 3 of 13 kidney injury (odds ratio 0.91, 0.84 to 0.99) and a trend towards reduced mortality in hospital (10.3% v 11.1%; P=0.08) with balanced crystalloids versus saline.20 Whether these data can be fully extrapolated to upper gastrointestinal bleeding is uncertain. Red blood cell transfusion A meta-analysis of 31 RCTs comprising 12 587 patients in a variety of populations found that a more restrictive approach to red cell transfusion (variably defined at hemoglobin threshold 70-90 g/L) does not adversely affect outcomes; hospital mortality was lower with a restrictive strategy but 30 day mortality was not significantly differ­ ent (risk ratio 0.97, 0.81 to 1.16).21 This systematic review concluded that a restrictive policy seemed to be safe in patients with underlying cardiovascular disease but no evidence was available for patients presenting with acute coronary syndrome. On that basis, current US guidelines recommend transfusion at a threshold of hemoglobin of 70 g/L for hemodynamically stable adult inpatients and 80 g/L for those undergoing orthopedic or cardiac surgery or with pre-existing cardiovascular disease.22 Others have suggested a threshold in patients with cardiovascular dis­ ease of ≥80 g/L.23 Importantly, results for the general populations described above may not be applicable to those with upper gastrointestinal bleeding. In such patients a restrictive transfusion approach appears not only to be safe but also to provide clinical benefit for rebleeding and mortality. A small study in 1986 first showed reduced rebleeding with restrictive transfusion.24 A large high quality Spanish RCT in 921 patients found significantly lower mortality at six weeks (hazard ratio 0.55, 0.33 to 0.92) and rebleeding (0.68, 0.47 to 0.98) with a transfusion hemoglobin thresh­ old of 70 g/L versus 90 g/L.25 A subsequent six center cluster randomized feasibility trial in the UK reported no benefit from a liberal transfusion policy when hemoglobin thresholds of 80 g/L versus 100 g/L were compared (mor­ tality difference −1%, −8% to 6% in 640 patients).26 A meta-analysis of five RCTs comprising 1965 patients with upper gastrointestinal bleeding reported that restrictive transfusion was associated with lower mortality (relative risk 0.65, 0.44 to 0.97) and reduced rebleeding (0.58, 0.40 to 0.84) (fig 1).27 Thus, in most patients with upper gastrointestinal bleeding, red cell transfusion should be withheld until a hemoglobin threshold of 70-80 g/L is reached.5 6 28 Patients with severe bleeding and hemodynamic com­ promise, who were generally excluded from the trials described above, require transfusion at higher thresholds because their hemoglobin will equilibrate to much lower levels as their intravascular volume is repleted with fluid. Transfusion thresholds in patients with cardiovascular disease, especially those with acute coronary syndrome, are less certain, but thresholds of 80 g/L or higher are vari­ ably recommended.22 23 Risk assessment Many risk assessment scores have been developed for patients with upper gastrointestinal bleeding, includ­ ing those that can be calculated early after presentation (pre-endoscopy) and those that include endoscopic find­ ings.29‑34 They were designed to predict a variety of end­ points. We believe pre-endoscopy scores are of greater practical use because it is probably most important to predict risk soon after presentation to help direct man­ agement. The use of risk scores has been recommended to stratify patients into those at higher or lower risk of poor )DYRUVUHVWULFWLYH )DYRUVOLEHUDO 0RUWDOLW\ )DYRUVUHVWULFWLYH )DYRUVOLEHUDO %ODLU -DLUDWK 9LOODQXHYD 7RWDOO 3  $ %ODLU /HH -DLUDWK 9LOODQXHYD 7RWDOO 3  %    5HVWULFWLYH Q1     5HVWULFWLYH Q1    /LEHUDO Q1     /LEHUDO Q1 5HEOHHGLQJ WR WR WR WR 55&O WR WR WR WR WR 55&O      :HLJKWLQJ       :HLJKWLQJ Fig 1 |  Blood transfusion meta-analysis: liberal versus restrictive transfusion for (A) mortality and (B) rebleeding.27 Reproduced with permission from Elsevier. Abbreviations: CI=confidence interval; RR=relative risk. on 29 May 2024 at Yonsei University (Medical Library and Hospital). Protected by copyright.http://www.bmj.com/ BMJ: first published as 10.1136/bmj.l536 on 25 March 2019. Downloaded from",4634,658,1158.5,"[ 1.0723214  -0.48987097 -1.2964647  ...  0.37089014  0.72712684
 -1.1737641 ]"
228,"STATE OF THE ART REVIEW For personal use only 	 4 of 13 outcome.3 6 This enables patients predicted to be high risk to be managed in high dependency or intensive care units and receive urgent endoscopy, whereas those at very low risk can be managed as outpatients. The most well established and commonly used pre- endoscopic scores are the Glasgow Blatchford score (GBS), the pre-endoscopic or “admission” Rockall score, and the AIMS65score (Albumin <3 mg/dL, International normalized ratio >1.5, altered Mental status, Systolic blood pressure <90 mm Hg, age >65 years).29 32 34 The GBS was developed to predict a composite of clinical intervention or death, whereas the other two were designed to predict death. Many studies have compared these and other scores, and GBS seems to be superior at predicting a combined endpoint of intervention or death (fig 2).35‑37 These risk assessment scores cannot precisely identify individual high risk patients who will definitely die if they do not receive the intervention. Therefore, they have limited clinical utility for predicting which patients are at higher risk. However, risk scores do seem to have a clini­ cal role in identifying patients who are at very low risk.38 When aiming to identify a cohort of patients who are at very low risk and could be managed as outpatients, it is important to achieve a very high sensitivity so that almost no patients who may come to harm are sent home. A systematic review of 16 studies on the use of pre- endoscopy scores in emergency departments to predict intervention, rebleeding, or death concluded that a GBS of zero provided the highest sensitivity (0.99), although specificity was very low (0.08).39 In 2012, both US and UK guidelines recommended that a GBS of zero could be used to identify very low risk patients who could avoid admis­ sion and be offered outpatient endoscopy.4 28 Subsequently two large international comparative studies of risk assessment scores, with 3012 and 2305 patients, were published.35 40 These studies reported that GBS ≤1 was the optimum low risk threshold, with a sen­ sitivity of 99% and specificity of 35-40%. The authors suggested that this threshold could be used to identify patients who could be safely discharged from the emer­ gency department for outpatient management, thereby avoiding admission in 19-24% of patients presenting with upper gastrointestinal bleeding. This approach has been accepted by recent European and Asia-Pacific guide­ lines.5 6 No high quality interventional trial has assessed outcomes after the introduction of a risk score, although a pre-post design study showed the safety of outpatient management in 84 patients with a GBS score of zero.38 Management of patients taking antithrombotic drugs The increasing use of antiplatelet and anticoagulant (antithrombotic) medication in the management of car­ diovascular disease means that many patients now pre­ senting with upper gastrointestinal bleeding are taking these drugs. A recent multicenter observational study of 619 patients requiring endoscopic therapy for upper gastrointestinal bleeding reported that 44% were taking an antithrombotic drug at presentation, with 25% taking more than one.41 Although these drugs are a recognized risk factor for upper gastrointestinal bleeding,42 43 no clear evidence indicates that their use worsens outcomes after the bleed.41 44 The 2016 US guideline on management of antithrom­ botic agents for patients undergoing endoscopy suggests that platelet transfusion is an option for life threaten­ ing or serious bleeding in patients taking antiplatelet agents.45 However, observational studies have failed to identify clinical benefit, and a cohort study with 408 patients showed significantly higher mortality with plate­ let transfusion (odds ratio 5.6, 1.5 to 27.1).46 This find­ ing led the recent Asia-Pacific guideline panel to suggest that platelet transfusions should not be used in patients taking antiplatelet agents who present with upper gas­ trointestinal bleeding.6 Platelet dysfunction may also be present in patients on hemodialysis or those who have had cardiac bypass surgery.47 Less information is available regarding the manage­ ment of anticoagulants, including warfarin and the newer direct oral anticoagulants (DOACs), in patients with upper gastrointestinal bleeding. For patients taking warfarin, recent guidelines suggested the use of prothrombin com­ plex concentrate (PCC) along with vitamin K to prevent rebound coagulopathy in patients with a life threatening bleed or hemodynamic instability.5 6 PCC is preferable *%6$852& $56$852& )56$852& $,06$852& 31('$852& 5HIHUHQFH      6HQVLWLYLW\ VSHFLƟFLW\      Fig 2 |  Comparison of five upper gastrointestinal bleeding risk scores in prediction of the need for any intervention (transfusion, endoscopic therapy, interventional radiology, or surgery) or 30 day mortality (n=1704).35 Abbreviations: AIMS65=see text; ARS=admission Rockall score; AUROC=area under the receiver operating characteristic curve; FRS=full Rockall score; GBS=Glasgow Blatchford score; PNED=Progetto Nazionale Emorragia digestive score. on 29 May 2024 at Yonsei University (Medical Library and Hospital). Protected by copyright.http://www.bmj.com/ BMJ: first published as 10.1136/bmj.l536 on 25 March 2019. Downloaded from",5414,792,1353.5,"[ 0.28398448 -0.359769   -2.0593944  ...  0.3872911   1.1643631
 -0.8974272 ]"
229,"STATE OF THE ART REVIEW For personal use only 	 5 of 13 to fresh frozen plasma because of the smaller volume needed, its more rapid onset, lack of the need to check the patient’s blood group, and the minimal infectious risk.5 US guidelines suggest either four factor PCC plus vitamin K or fresh frozen plasma.45 Guidelines also suggest that the international normal­ ized ratio (INR) should be corrected to <2.5 if possible before undertaking endoscopy, with the potential need for endoscopic therapy if the clinical situation allows.5 45 This suggestion is based on observational studies which indicate that the outcome after endoscopic therapy is similar in patients with an INR of 1.3-2.7 to that in those not taking warfarin.48 49 Other studies report that the INR value does not predict rebleeding.50 Data on DOACs are limited, but because of their short half lives (5-17 h), anticoagulant activity wanes rapidly over one to two days (in the absence of renal disease). Thus, European guidelines state that “time is the most important antidote against DOACs.”5 Although PCC may be of some use in severe bleeding, particularly for Xa inhibitors, neither vitamin K nor fresh frozen plasma has been shown to be beneficial.5 51 Reversal agents for dabigatran (idarucizumab)52 and the factor Xa inhibitors (andexanet alfa)53 are now approved in the US. Their role in patients with upper gastrointestinal bleeding is unclear given the uncertain risk of thrombotic events and the short half lives of DOACS. They would mainly be used in patients with a severe ongoing bleed, especially if DOAC ingestion was recent or if renal disease was present. Coagulopathy and thrombocytopenia in patients with cirrhosis Interpretation of the complex clotting abnormalities seen in cirrhosis can be difficult. Patients with cirrhosis have parallel decreases in procoagulant and anticoagulant factors.54 The prothrombin time measures procoagulant activity only; therefore, prothrombin time or INR is not a reliable indicator of coagulation status in patients with cirrhosis.54 Fresh frozen plasma is often given to patients with upper gastrointestinal bleeding, cirrhosis, and raised prothrombin time, but it has not been shown to provide benefit and could have adverse effects. For these reasons, the most recent US guidelines on portal hyper­ tensive bleeding recommend against correcting INR with fresh frozen plasma or recombinant factor VIIa in patients with cirrhosis and acute variceal bleeding.9 Platelets from patients with cirrhosis generate throm­ bin in a similar way to those from healthy controls, and patients with cirrhosis have pro-hemostatic fac­ tors (increased von-Willebrand factor and decreased ADAMTS-13, a protease that cleaves von-Willebrand factor).54 55 However, patients with cirrhosis often have thrombocytopenia as a result of splenic sequestra­ tion. The experimental finding that a platelet count of 56×109/L leads to thrombin generation at the 10th centile of healthy control values54 provides the basis for giving platelet transfusions at around 50×109/L.4 7 However, no studies have assessed platelet thresholds or results with platelet transfusions, and some current guidelines state that no recommendation can be made regarding platelet transfusions.8 9 Pre-endoscopic medical therapy The use of pre-endoscopic intravenous proton pump inhibitors (PPIs) has been assessed in several studies. A meta-analysis of six RCTs comprising 2223 patients found that the use of these drugs before endoscopy is associated with both reduced high risk stigmata of bleeding and the need for endoscopic therapy (odds ratio 0.68, 0.50 to 0.93) but has no effect on patient outcomes, including rebleeding, need for surgery, or mortality (1.12, 0.72 to 1.73).56 As a result, UK National Institute for Health and Care Excellence (NICE) guidelines do not support the routine use of these drugs before endoscopy.4 However, several other international guidelines suggest PPIs may have a role before endoscopy, particularly for patients in whom endoscopy may be delayed.3 5 6 28 57 Prokinetic agents have been assessed for their ability to improve gastric emptying, thereby improving visu­ alization at endoscopy. Erythromycin, usually given as a 250 mg infusion 30-120 minutes before endoscopy, has been most widely studied. The most recent meta-analysis of 598 patients in eight RCTs showed improved visuali­ zation, reduced need for second look endoscopy, and reduced length of hospital stay (mean difference −1.75 days, 2.43 to −1.06) after erythromycin infusion before endoscopy.58 Tranexamic acid (TXA) inhibits the fibrinolytic activity of plasmin. A meta-analysis reported reduced mortality with TXA in patients with upper gastrointestinal bleed­ ing, but many studies were of poor quality and had been undertaken before the widespread use of PPIs and endo­ scopic therapy.59 Furthermore, other outcomes such as bleeding episodes and transfusions were not reduced. Therefore, it is difficult to draw firm conclusions from these data. A meta-analysis of two RCTs comprising 40 138 patients with acute severe traumatic or postpar­ tum bleeding suggested even a short delay in the admin­ istration of TXA reduces benefit: immediate treatment improved survival (odds ratio 1.72, 1.42 to 2.10), but survival fell 10% with every 15 minutes delay, with no benefit beyond three hours.60 A large international study (HALT-IT) will finish recruitment shortly and the results should help clarify the role of TXA in upper gastrointes­ tinal bleeding.61 Pre-endoscopic medical therapy in patients with cirrhosis Vasoactive drugs (terlipressin, somatostatin, or its ana­ logs octreotide and vapreotide), which cause splanch­ nic artery vasoconstriction, are used in patients with cirrhosis and variceal bleeding. When combined with endoscopic therapy, the different vasoactive drugs seem to have similar efficacy.62 Three double blind RCTs exam­ ined the use of vasoactive drugs (terlipressin, somatosta­ tin, and vapreotide) given before endoscopy in patients with cirrhosis and upper gastrointestinal bleeding.63‑65 Two studies reported less active bleeding at endoscopy in the active treatment group,64 65 and the third noted significantly more control of bleeding (clear gastric lav­ age and stable hemoglobin) at 12 hours with vasoactive drug therapy.63 Current guidelines recommend starting vasoactive drugs as soon as variceal hemorrhage is suspected.7‑9  on 29 May 2024 at Yonsei University (Medical Library and Hospital). Protected by copyright.http://www.bmj.com/ BMJ: first published as 10.1136/bmj.l536 on 25 March 2019. Downloaded from",6637,983,1659.25,[ 0.2091213 -0.6460344 -1.3221729 ...  0.4664058  0.3834992 -1.4194472]
230,"STATE OF THE ART REVIEW For personal use only 	 6 of 13 PPIs should not be given concurrently to patients who are receiving somatostatin (or analogs) because somato­ statin provides inhibition of gastric acid secretion compa­ rable to that provided by PPIs.66 67 Recommended doses are terlipressin 2 mg every four hours, somatostatin 250 μg bolus followed by 250-500 μg/h, and octreotide and vapreotide 50 μg bolus followed by 50 μg/h.9 These drugs are generally given for up to five days.7‑9 A meta-analysis of 12 RCTs compromising 1241 patients showed that antibiotics reduce infections, rebleeding, and mortality (relative risk 0.79, 0.63 to 0.98) in patients with cirrhosis and upper gastrointestinal bleeding.68 An RCT comparing intravenous ceftriaxone versus oral norfloxacin for seven days in 111 patients with advanced cirrhosis and gastrointestinal bleeding showed reduced proven infections with ceftriaxone (11% v 26%; P=0.03).69 However, the results may not be gener­ alizable to all patients with cirrhosis because only 9% of screened patients were enrolled. Current guidelines sug­ gest that antibiotics should be given from admission for up to seven days.7‑9 Intravenous ceftriaxone is preferred in patients with advanced cirrhosis or those taking qui­ nolone prophylaxis and those in areas of high quinolone resistance, although the choice of antibiotic is dependent on local antimicrobial sensitivity patterns.7‑9 Role of non-endoscopic diagnostic modalities before endoscopy Because upper gastrointestinal bleeding can be diag­ nosed and treated with endoscopy, which is available in most hospitals, the role of other diagnostic modalities in patients presenting with an acute bleed is limited. In almost all cases, the initial diagnostic test will be upper endoscopy. Rarely, angiography or computed tomogra­ phy is used in patients who are not candidates for endos­ copy. However, these investigations are most commonly used if no source of bleeding is identified at endoscopy in patients with melena. A technetium-99m labelled red cell scan may also be used in this situation, but computed tomography angiography seems to be more accurate.70 71 Early use of capsule endoscopy has been reported, with goals including stratifying risk and determining the timing of endoscopy,72 but more studies are needed to establish any potential role. Timing of endoscopy On the basis of improved outcomes in observational studies,3 5 28 guidelines recommend that, after appropri­ ate resuscitation, most patients who are admitted with upper gastrointestinal bleeding should undergo endos­ copy within 24 hours. Some guidelines suggest that patients with hemodynamic compromise and those with cirrhosis, who may have varices, undergo endoscopy within 12 hours after presentation,5 6 8 9 28 because some observational studies and subgroup analysis of an RCT provided limited evidence of improved outcome in high risk patients when endoscopy is performed within six to 13 hours.73‑75 Features that have been considered high risk include GBS ≥8-12, bloody gastric lavage or persis­ tent bloody emesis in hospital, hypotension, tachycardia, and comorbidities such as cirrhosis. However, evidence that can precisely identify high risk patients who should undergo early endoscopy is not available. In general, patients with persistent hemodynamic instability despite aggressive resuscitation will require urgent endoscopy. Endoscopy should not be undertaken before the patient’s hemodynamic status is dealt with by initiating appropriate resuscitation and aiming to optimize comor­ bidities. This is illustrated by a recent observational study of 12 601 Danish patients with upper gastrointestinal bleeding secondary to peptic ulcers. This study suggested a survival benefit from delaying endoscopy for 12 hours in hemodynamically stable patients with American Society of Anesthesiologists score 3-5 (odds ratio 0.48, 0.34 to 0.67), and for six hours in patients with hemodynamic instability (0.73, 0.54 to 0.98) (fig 3).76 Most deaths after upper gastrointestinal bleeding are caused by underlying comorbidities rather than exsanguination, so attention to other medical problems is key to patient management.77 Two small RCTs compared urgent (<2-6 h) with elective (>48 h) endoscopy for patients presenting with upper gas­ trointestinal bleeding who were hemodynamically stable and had no serious comorbidities.78 79 As expected in these low risk patients, no difference in clinical outcomes was identified. However, ~40-45% of patients had low risk endoscopic findings that would allow for early discharge. Thus, non-emergent endoscopy, undertaken as soon as possible within routine business hours, is recommended in low risk patients to allow safe early discharge in many of these patients.80 Endoscopic therapy Non-variceal bleeding Recommended modalities for ulcer bleeding include injection of epinephrine (eg, 1:10 000 dilution), injection $6$ $6$ )LWWHGYDOXHV     7LPLQJK 0RUWDOLW\      3  Fig 3 |  Association between timing of endoscopy and mortality in hospital patients with hemodynamic instability after correction for confounding variables.76 Abbreviation: ASA=American Society of Anesthesiologists score. on 29 May 2024 at Yonsei University (Medical Library and Hospital). Protected by copyright.http://www.bmj.com/ BMJ: first published as 10.1136/bmj.l536 on 25 March 2019. Downloaded from",5443,785,1360.75,"[ 0.27335817 -0.87496114 -1.2812591  ...  0.44569486  0.5621544
 -1.0954336 ]"
231,"STATE OF THE ART REVIEW For personal use only 	 7 of 13 of sclerosants such as absolute ethanol, thermal contact devices such as bipolar electrocoagulation probes or heater probes, and through-the-scope clips.5 28 RCT data supporting efficacy in ulcer bleeding are more limited for non-contact thermal devices such as argon plasma coagulation.28 Vascular ectasias may also be treated with thermal methods, commonly argon plasma coagu­ lation; radiofrequency ablation is another thermal con­ tact modality sometimes used for gastric antral vascular ectasia.81 Endoscopic injection of epinephrine should not be used as a single modality treatment. Meta-analyses have reported lower rates of further bleeding with an alterna­ tive modality compared with epinephrine alone (relative risk 0.58, 0.36 to 0.93) and with epinephrine combined with a second modality versus epinephrine alone (relative risk 0.34, 0.23 to 0.50).82 83 Epinephrine can be used for temporary control of bleeding to aid visualization of the lesion before definitive treatment with another modal­ ity (such as a thermal or mechanical) or to decrease the risk of inducing bleeding with the application of a second modality. Most data on non-variceal upper gastrointestinal bleed­ ing are from patients with peptic ulcer bleeding. The For­ rest classification of endoscopic stigmata is commonly used by endoscopists to identify higher risk lesions that require the application of endoscopic therapy.84 Endo­ scopic therapy significantly decreases further bleeding and the need for urgent intervention in patients with ulcers with spurting or oozing blood (Forrest 1a or 1b) or with non-bleeding visible vessels (Forrest 2a; fig 4A).28 Patients with adherent clots (Forrest 2b) were not shown to benefit from endoscopic therapy in a meta-analysis of RCTs, but results of individual trials were very heteroge­ neous.80 This has led to guideline recommendations that either endoscopic plus medical therapy or medical man­ agement alone may be used for patients with adherent clots.5 28 Around 25-50% of patients admitted to hospital with bleeding ulcers have Forrest 1a, 1b, 2a, or 2b stig­ mata.76 85 Endoscopic treatment is not needed for ulcers with flat pigmented spots or a clean base (Forrest 2c or 3).5 28 Variceal bleeding Variceal bleeding accounted for 11% of patients admit­ ted to hospital with acute upper gastrointestinal bleed­ ing in a nationwide UK audit.15 However, the proportion of patients with variceal bleeding varies widely and is related to the proportion of people with liver disease in the population served. Patients with variceal bleeding have a higher mortality than those with non-variceal bleeding, and this is largely related to the severity of underlying liver disease.14 86 The optimal endoscopic therapy for esophageal variceal bleeding is variceal band ligation, which is associated with less rebleeding and fewer side effects than sclero­ therapy.4 7 9 87 If gastric varices are found, ligation can be used for gastroesophageal varices type-1, where esopha­ geal varices extend several centimeters distally along the gastric lesser curve. Injection of tissue adhesive (eg, N-butyl-cyanoacrylate) is the recommended endoscopic approach for all other types of gastric varices, although thrombin injection can be considered.7 9 88-90 Thrombin injection has been described for gastric variceal bleeding in cohort studies, but to date no RCTs have compared it with other treatments.91‑93 Post-endoscopic management PPI therapy A meta-analysis of RCTs comparing PPIs to placebo or no therapy in high risk patients undergoing successful endo­ scopic therapy showed that high dose PPIs, usually given as an intravenous bolus of 80 mg followed by continu­ ous infusion at 8 mg/h for 72 hours, reduced rebleeding (relative risk 0.40, 0.28 to 0.59) and mortality (0.41, 0.20 to 0.84). Intermittent intravenous or oral PPIs reduced rebleeding (0.53, 0.35 to 0.78) but not mortality.82 A Fig 4 |  (A) Endoscopic view of a large posterior duodenal ulcer with intermittent bleeding from a visible vessel. The patient, a middle aged man taking anticoagulant drugs, was admitted with hematemesis, hemodynamic instability, and a hemoglobin concentration of 55 g/L. After resuscitation, transfusion to hemoglobin 70-80 g/L, and correction of coagulopathy, endoscopy was undertaken. (B) Through-the-scope clips were applied after dilute epinephrine was injected into the four quadrants of the ulcer base. The fibrotic base made application of the clips problematic. (C) There was ongoing intermittent oozing of blood. Given the high risk ulcer, hemostatic powder spray was then applied to good effect. High dose intravenous proton pump inhibitors (PPIs) were given and the patient was managed in the hospital high dependency unit. Because of the clinical situation and the difficulty in providing endoscopic therapy to this large fibrotic ulcer, the plan for urgent referral for radiological embolization—should early rebleeding occur—was clearly documented by the endoscopist as a “rebleeding plan.” (D) Fifteen hours later the patient rebled and became hemodynamically unstable. He was again resuscitated appropriately, after which an interventional radiologist performed coil embolization of the gastroduodenal artery. The patient had no further bleeding and was restarted on anticoagulants on day 3. When he was discharged from hospital a week later he was still taking oral PPIs twice daily, but when the 14 day course was finished, the dose was reduced to once daily. on 29 May 2024 at Yonsei University (Medical Library and Hospital). Protected by copyright.http://www.bmj.com/ BMJ: first published as 10.1136/bmj.l536 on 25 March 2019. Downloaded from",5739,855,1434.75,"[-0.19834886 -0.50889266 -1.1976237  ...  0.51483995  0.14715455
 -1.2879516 ]"
232,"STATE OF THE ART REVIEW For personal use only 	 8 of 13 meta-analysis of 13 studies found that a bolus followed by intermittent doses of intravenous or oral PPIs was non- inferior to continuous infusion (further bleeding risk ratio 0.72; one sided 95% confidence interval upper boundary 0.97), although most individual studies were relatively small and not designed to answer this question.94 No conclusions could be made regarding oral versus intra­ venous dosing,94 although oral administration provides an antisecretory effect comparable to equivalent doses of intravenous PPIs.95 Guidelines have recommended an intravenous bolus followed by continuous infusion PPI therapy,3 5 6 28 although recent guidelines also suggest con­ sidering intermittent high doses of oral or intravenous PPI (eg, 80-160 mg daily in divided doses after an initial 80 mg bolus), rather than continuous infusion.5 6 Patients with peptic ulcer bleeding generally receive four to eight weeks of once daily oral PPIs. Those with low risk endoscopic lesions (clean base, flat spot) should receive PPIs once a day from the time of diagnosis. Those with high risk endoscopic lesions and clinical features should receive high dose PPIs on days one to three as above, followed by twice daily oral PPI on days four to 14. This regimen is based on an RCT of 187 patients that showed significantly less rebleeding with twice daily ver­ sus once daily PPIs (relative risk 0.41, 0.18 to 0.93) during this period.96 The benefits of PPIs outweigh potential risks when used after bleeding from a peptic ulcer. Multiple phar­ macodynamics studies report that omeprazole reduces the antiplatelet effect of clopidogrel, but a double blind placebo controlled trial in 3761 clopidogrel users found no evidence that omeprazole increased cardiovascular events (hazard ratio 0.99, 0.68 to 1.44).97 The US Food and Drug Administration recommends avoiding the use of omeprazole or esomeprazole in patients who are taking clopidogrel.98 Patients with cirrhosis and variceal bleeding As noted above, in patients with cirrhosis and upper gas­ trointestinal bleeding, antibiotics should be continued for up to seven days,7‑9 regardless of whether varices are identified as the source of the bleeding. Patients who have documented variceal bleeding at endoscopy should also have their vasoactive drugs continued for up to five days.7‑9 Combined treatment with endoscopic ligation and vasoac­ tive drugs is superior to ligation alone or vasoactive drugs alone in reducing further bleeding in hospital or during the first seven days after treatment.99 100 Transjugular intrahepatic portosystemic shunt (TIPS) may also be used after initial endoscopic therapy in the first three days after presentation for the treatment of acute esophageal variceal bleeding in patients with Child-Pugh class C cirrhosis (score 10-13)8 9 A multicenter RCT com­ pared early (within 72 h) TIPS placement versus standard treatment with variceal ligation plus drug therapy in 63 patients with Child-Pugh C cirrhosis or Child-Pugh B cir­ rhosis with active bleeding. It reported that more patients were free from further bleeding at one year with early TIPS (97% v 50%; P<0.001).101 One year survival was also higher with early TIPS (86% v 61%; P<0.001) and encephalopathy was not increased. Subsequent reports suggest that the benefit is primarily in those with Child- Pugh C disease.102 However the evidence for early TIPS remains relatively limited and the practicalities may be challenging for many units. Reintroduction of antithrombotic drugs Several studies suggest a survival benefit from continuing or reintroducing antithrombotic drugs after upper gastroin­ testinal bleeding.103 104 This is perhaps unsurprising given that mortality after presentation with a bleed is more often caused by underlying comorbidities, particularly cardio­ vascular disease, rather than the bleed itself.77 However, balancing the risks and benefits of reintroducing these drugs after a patient presents with upper gastrointestinal bleeding can be challenging. If an antithrombotic drug is reintroduced, a PPI is usually also administered. Aspirin is the most widely studied antithrombotic drug in patients with upper gastrointestinal bleeding. Strati­ fication of patients must be based on whether aspirin is given for secondary or primary cardiovascular preven­ tion. This is because the benefit in secondary prevention is far greater than that for primary prevention, with a number needed to treat to prevent myocardial infarction, stroke, or vascular death of 67 versus 1745.80 A randomized study of 156 patients with peptic ulcer bleeding who had been taking aspirin for secondary prevention reported reduced mortality at eight weeks in those who continued aspirin compared with those who discontinued the drug (1.3% v 12.9%; difference 11.6%, 3.7% to 19.5%).103 Therefore, current guidelines suggest continuing aspirin (or reintroducing the drug within three days for higher risk endoscopic lesions) once hemosta­ sis is achieved.4-6 105 106 It has been suggested that when aspirin has been prescribed for primary prophylaxis, it should be stopped in most patients because the bleed­ ing risk probably outweighs the cardiovascular benefit.28 If primary prevention is still clinically required after the bleed, it can be reintroduced after the ulcer has healed, or earlier depending on the clinical situation.5 No randomized studies are available to guide clinicians on the reintroduction of thienopyridines (eg, clopidogrel) or anticoagulants. Recent guidelines suggest that for patients receiving dual antiplatelet therapy, at least one drug, usually aspirin, should be reintroduced early as above, with the second drug withheld for up to five days after hemostasis, or the timing discussed with a cardio­ vascular specialist.5 6 105 Similar to the situation with antiplatelet agents, obser­ vational studies in patients who develop upper gastro­ intestinal bleeding while taking warfarin indicate that those who restart warfarin have markedly lower rates of death and thromboembolic events, without a higher rate of recurrent bleeding, when compared with those whose warfarin is not restarted.104 107 Recent guidelines suggest restarting warfarin from “as soon as hemostasis is estab­ lished”6 to seven to 15 days after the bleeding event.5 The indication for anticoagulation should be assessed at the time of the bleed, with early reintroduction (zero to seven days) recommended in patients with a higher thrombo­ embolic risk.5 6 However, robust data on the optimal tim­ ing of reintroduction are not available. on 29 May 2024 at Yonsei University (Medical Library and Hospital). Protected by copyright.http://www.bmj.com/ BMJ: first published as 10.1136/bmj.l536 on 25 March 2019. Downloaded from",6821,1020,1705.25,"[ 0.17060773 -0.2814612  -1.3139939  ...  0.47858864  0.6193064
 -0.9656343 ]"
233,"STATE OF THE ART REVIEW For personal use only 	 9 of 13 Data on the timing of the reintroduction of DOACs after bleeding has been controlled are limited, and this clearly depends on the balance of risk between rebleeding and thromboembolic events. Use of the CHA2DS2-VASC (Congestive heart failure, Hypertension, Age-2, Diabetes, Stroke/TIA-2, Vascular disease) and HAS-BLED (Hyper­ tension, Abnormal renal and liver function, Stroke, prior Bleeding, Labile INRs, Elderly (>65 years), Drugs and alcohol) scores may help in this situation.108‑110 The recent Asia-Pacific guidelines suggest reintroducing DOACs in patients with a high thromboembolic risk as soon as hemostasis is achieved, although others have suggested that patients should have their anticoagulant restarted at day 7, with possible bridging therapy with low molecu­ lar weight heparin from days 2 to 7 in those with a low bleeding risk.6 In general, patients with an increased thromboembolic risk should have early reintroduction of antithrombotic drugs, because the risks and severity of thromboembolic events generally outweigh those of bleeding events. Management of persistent or recurrent bleeding, including role of interventional radiology and surgery Non-variceal bleeding The results of an RCT comparing repeat endoscopic ther­ apy with surgery in 92 patients with recurrent peptic ulcer bleeding indicate that endoscopic therapy should be repeated when bleeding recurs after initial endoscopic control.111 This study reported similar mortality, although more patients had complications with surgery (36.4% v 14.6%; P=0.03). For patients with persistent or refrac­ tory bleeding from non-variceal sources despite optimal standard endoscopic and medical therapy, the addition of hemostatic powder spray for temporary control (12-24 h) or over-the-scope clips (OTSC) as a rescue modality is suggested, in parallel with ongoing resuscitation.5 6 112 113 For peptic ulcer bleeding not controlled by endoscopic therapy, two recent meta-analyses of observational stud­ ies that compared surgery with radiological interven­ tion reported lower rebleeding with surgery, but similar mortality and need for further interventions, although patients receiving radiological intervention were older and in worse general health.114 115 Because many patients with recurrent bleeding are elderly with comorbidities, interventional radiology is generally preferred if locally available. Therefore, if bleeding continues despite opti­ mal endoscopic therapy, transarterial embolization is recommended, although surgery should be considered if radiological therapy is likely to be delayed.4 5 Prophylactic transarterial embolization of high risk ulcers after endoscopic therapy is not recommended: it did not significantly reduce rebleeding when compared with standard treatment (10.2% v 11.4%) in an RCT of 241 patients.116 Variceal bleeding Patients with rebleeding after initial endoscopic and medical therapy for varices may have repeat endoscopic therapy performed.8 TIPS is recommended for those with persistent or severe recurrent bleeding.7‑9 For patients with severe bleeding refractory to endoscopic therapy, balloon tamponade has been recommended as a tempo­ rary bridge to definitive therapy.7 8 However, balloon tam­ ponade is associated with serious complications (such as esophageal rupture and aspiration pneumonia) in about 12% of patients and its use was lethal in 6% of patients in a case series.117 Recently, removable self expanding covered metal esophageal stents designed for the treat­ ment of severe esophageal variceal bleeding have become available (although they are not approved in the US). An RCT of 28 patients compared these stents with balloon tamponade in patients with esophageal variceal bleed­ ing refractory to medical and endoscopic therapy and showed that the stents led to improved bleeding control (85% v 47%; Fisher’s exact test P=0.055), with similar mortality.118 Emerging treatments Hemostatic powder spray Hemostatic powder spray provides high rates of initial hemostasis for active non-variceal upper gastrointestinal bleeding, but with relatively high rebleeding rates, sug­ gesting a temporary effect.119‑123 A systematic review of 195 cases reported initial hemostasis in 92% and a seven day rebleeding rate of 21%.112 Currently, hemostatic powder is often used as a temporary rescue treatment for bleeding that cannot be controlled using established methods, and it may have a role for the initial control of diffuse bleeding from tumors.6 112 More limited data are available on hemostatic powder spray for variceal bleeding, often as a temporizing method until definitive therapy is applied.124 Over-the-scope clips Treatment with OTSC is another relatively new technique. These clips are much larger than standard through-the- scope clips so may be successful when applied to larger fibrotic lesions or larger feeding vessels. A multicenter RCT of 66 patients with recurrent ulcer bleeding after ini­ tial hemostasis showed that significantly fewer patients treated with OTSC had further bleeding compared with those on standard therapy (15% v 58%; difference 42%, 22% to 63%).125 Further data are awaited, but at present OTSC may be considered as a rescue therapy when stand­ ard therapies do not achieve permanent hemostasis. Doppler probes Endoscopic Doppler probes have also been studied as a guide to endoscopic therapy. A recent dual center RCT of 148 patients with severe non-variceal upper gastro­ intestinal bleeding that compared endoscopic therapy guided by Doppler probe positive signals with standard endoscopic therapy guided by endoscopic stigmata found reduced 30 day rebleeding with Doppler guided therapy (11.1% v 26.3%; P=0.02).126 Further data on the clinical utility and practicalities of this approach are needed, and currently the use of these probes is not recommended by guidelines.5 6 Guidelines As already noted, international, UK (NICE), American, European, and Asia-Pacific guidelines on upper gastro­ on 29 May 2024 at Yonsei University (Medical Library and Hospital). Protected by copyright.http://www.bmj.com/ BMJ: first published as 10.1136/bmj.l536 on 25 March 2019. Downloaded from",6226,894,1556.5,"[ 0.23581892 -0.9553228  -1.7014208  ...  0.18261853  0.7207941
 -1.3656539 ]"
234,"STATE OF THE ART REVIEW For personal use only 	 10 of 13 intestinal bleeding (non-variceal and variceal) have been published over the past eight years. We have therefore referenced them as appropriate throughout. The most recent ones—the European (2015) and Asia-Pacific (2018) guidelines on non-variceal bleeding, and the UK, international, and US guidelines on variceal bleed­ ing—differ slightly from earlier ones, largely because they assessed more recently published studies (table). These guidelines have generally been written by experts in this field, although methodology has varied. Conclusions Upper gastrointestinal bleeding remains a common cause of presentation to hospitals worldwide, and many recent studies have assessed the management of patients with this condition. The evidence of improved outcomes from a relatively restrictive approach to blood transfusion and the ability to identify patients who are at very low risk and suitable for outpatient management have recently altered clinical practice, and these alterations to management are now recommended by international guidelines. RCTs and meta-analyses confirm a benefit from pre-endoscopy anti­ biotics and vasoactive drugs in patients with cirrhosis, and post-endoscopy high dose PPIs for high risk peptic ulcer bleeding. Endoscopic therapy has advanced dramatically over the past decades, with recent additions to the endoscopist’s “toolkit,” including hemostatic powder spray, over-the- scope clips, and Doppler probes. These join the estab­ lished and widely studied injection therapies, thermal probes, and clips used for non-variceal bleeding, and endoscopic band ligation and tissue adhesive injection for variceal bleeding. However, the newer modalities require further study to clarify their exact role in endo­ scopic management. Technical improvements and more widely available services for interventional radiology have led to it being the most commonly used rescue therapy for persistent or recurrent upper gastrointestinal bleeding that is refractory to endoscopic treatment. Surgery is now typically reserved for situations in which interventional radiology is unavailable, delayed, or unsuccessful. The more widespread use of antiplatelet and anti­ coagulants drugs has led to uncertainty in managing patients taking these medications who develop upper gastrointestinal bleeding. However, recent data suggest that relatively early reintroduction of these drugs once hemostasis has been achieved is the best approach in those with appropriate cardiovascular indications. New approaches under investigation for managing upper gastrointestinal bleeding include the early use of TXA and novel endoscopic techniques to reduce rebleeding. These and other developments will hopefully continue to improve management and outcomes for patients with upper gastrointestinal bleeding. Recommendations from major published guidelines on non-variceal UGIB Guideline Risk scoring Prokinetics Pre-endoscopy PPIs Timing of endoscopy Post-endoscopy PPIs International, 20103 Prognostic scales recommended to identify high and low risk groups Promotility agents should not be used routinely May be considered but should not delay endoscopy Within 24 h for most patients IV PPI bolus then infusion if high risk stigmata and have had successful endoscopic therapy US, ACG (ulcer bleeding only) 201228 Carry out risk assessment to stratify into higher and lower risk groups. Consider discharge from ED if GBS=0 Consider IV erythromycin IV PPIs may be considered Within 24 h after resuscitation. Consider within 12 h if high risk features (eg, hemodynamic instability, bloody emesis in hospital) After successful endoscopic hemostasis, give IV PPI bolus then infusion to those with active bleeding, NBVV, or adherent clot US, ASGE 201257 No specific recommendation but notes that GBS=0 identifies a very low risk group Suggest IV prokinetic if high probability of fresh blood or clot in stomach IV PPIs recommended Depends on clinical factors but recommends within 24 h in the presence of cancer, cirrhosis, hematemesis, hypovolemia, or Hb <80 g/L IV PPI bolus then infusion after endoscopic therapy for ulcers with high risk stigmata UK, NICE 20124 Use GBS before endoscopy and full Rockall score after endoscopy. Consider early discharge if GBS=0 Not assessed Do not give PPIs before endoscopy Within 24 h, but immediately after resuscitation if unstable and severe UGIB Offer PPIs if stigmata of recent bleeding seen at endoscopy Europe, ESGE 20155 Patients with GBS 0-1 do not require early endoscopy or admission Recommend IV erythromycin if clinically severe or ongoing active UGIB IV bolus then infusion but should not delay endoscopy Within 24 h of resuscitation, but consider within 12 h if high risk features (eg, hemodynamic instability despite resuscitation, inpatient bloody emesis, contraindication to stopping anticoagulants) IV PPI bolus then 72 h infusion for patients who receive endoscopic hemostasis and those with adherent clots. Consider giving PPIs as intermittent IV bolus or high dose oral Asia-Pacific, 20186 Use GBS; adopting a cut off at GBS ≤1 allows most hospitals to reduce unnecessary admissions Not assessed IV PPIs recommended if suspected UGIB awaiting endoscopy (especially if endoscopy is not available within 24 h) Within 24 h, but urgent (within 12 h) if hemodynamic instability, after resuscitation and stabilization After endoscopic hemostasis is achieved high dose oral PPIs can be used for 72 h as an alternative to high dose IV PPIs Abbreviations: ACG=American College of Gastroenterology; ASGE=American Society for Gastrointestinal Endoscopy; ED=emergency department; ESGE= European Society of Gastrointestinal Endoscopy; GBS=Glasgow Blatchford score; Hb=hemoglobin; NBVV=non-bleeding visible vessel; NICE=National Institute for Health and Care Excellence; PPIs=proton pump inhibitors; IV=intravenous; UGIB=upper gastrointestinal bleeding. QUESTIONS FOR FUTURE RESEARCH •	What is the optimal approach to fluid resuscitation in patients with acute upper gastrointestinal bleeding? •	Can risk assessment tools be developed to allow accurate early identification of high risk patients with upper gastrointestinal bleeding, such as those who require endoscopic therapy or those with high mortality? •	What is the optimal timing of endoscopy after upper gastrointestinal bleeding? •	What is the exact role of hemostatic powder spray, over-the-scope clips, and Doppler ultrasound probes in the endoscopic management of upper gastrointestinal bleeding? •	When is the best time to reintroduce antithrombotic drugs after upper gastrointestinal bleeding? on 29 May 2024 at Yonsei University (Medical Library and Hospital). Protected by copyright.http://www.bmj.com/ BMJ: first published as 10.1136/bmj.l536 on 25 March 2019. Downloaded from",6845,975,1711.25,"[ 0.52909863 -0.40756673 -1.3634635  ...  0.06860925  0.5377381
 -1.1910449 ]"
235,"STATE OF THE ART REVIEW For personal use only 	 11 of 13 Thanks to Deepak Vishwanath for help with the radiological image in fig 4. Contributors: Both authors contributed equally to the planning and writing of the article and both are responsible for the overall content as guarantors. Competing interests: We have read and understood BMJ policy on declaration of interests and declare the following interests: AJS, none; LL has had single consultancies to Takeda and to Bayer and his full competing interests are available from her on request.1	 Laine L, Laursen SB, Zakko L, et al. Severity and outcomes of upper gastrointestinal bleeding with bloody vs coffee-grounds hematemesis. Am J Gastroenterol 2018;113:358-66.10.1038/ ajg.2018.5.  pmid:29380820.2	 Lanas A. Editorial: Upper GI bleeding-associated mortality: challenges to improving a resistant outcome. Am J Gastroenterol 2010;105:90-2. 10.1038/ajg.2009.517  pmid:20054306.3	 Barkun AN, Bardou M, Kuipers EJ, et al. International Consensus Upper Gastrointestinal Bleeding Conference Group. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 2010;152:101-13. 10.7326/0003-4819-152-2-201001190-00009  pmid:20083829.4	 National Institute for Health and Care Excellence. Acute upper gastrointestinal bleeding in over 16s: management. CG141.2012.https:// www.nice.org.uk/guidance/cg141.5	 Gralnek IM, Dumonceau JM, Kuipers EJ, et al. Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2015;47:a1-46. 10.1055/s-0034-1393172  pmid:26417980.6	 Sung JJ, Chiu PW, Chan FKL, et al. Asia-Pacific working group consensus on non-variceal upper gastrointestinal bleeding: an update 2018. Gut 2018;67:1757-68.10.1136/gutjnl-2018-316276.  pmid:29691276.7	 Tripathi D, Stanley AJ, Hayes PC, et al. Clinical Services and Standards Committee of the British Society of Gastroenterology. U. K. guidelines on the management of variceal haemorrhage in cirrhotic patients. Gut 2015;64:1680-704.10.1136/gutjnl-2015-309262  pmid:25887380.8	 de Franchis R. Baveno VI Faculty. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol 2015;63:743- 52.10.1016/j.jhep.2015.05.022  pmid:26047908.9	 Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology 2017;65:310-35.10.1002/hep.28906  pmid:27786365.10	 Rockall TA, Logan RFA, Devlin HB, Northfield TC.",2754,286,688.5,"[ 0.78467387 -0.0909842  -1.3299794  ...  0.14266804  0.36268514
 -1.251594  ]"
235,"Incidence of and mortality from acute upper gastrointestinal haemorrhage in the UK. BMJ 1995;311:222-6.10.1136/bmj.311.6999.222  pmid:7627034.11	 Blatchford O, Davidson LA, Murray WR, Blatchford M, Pell J. Acute upper gastrointestinal haemorrhage in west of Scotland: case ascertainment study. BMJ 1997;315:510-4.10.1136/ bmj.315.7107.510  pmid:9329304.12	 Laine L, Yang H, Chang SC, Datto C. Trends for incidence of hospitalization and death due to GI complications in the United States from 2001 to 2009. Am J Gastroenterol 2012;107:1190-5, quiz 1196.10.1038/ ajg.2012.168  pmid:22688850.13	 Abougergi MS, Travis AC, Saltzman JR. The in-hospital mortality rate for upper GI hemorrhage has decreased over 2 decades in the United States: a nationwide analysis. Gastrointest Endosc 2015;81:882-8.e1.10.1016/j. gie.2014.09.027  pmid:25484324.14	 Wuerth BA, Rockey DC. Changing epidemiology of upper gastrointestinal hemorrhage in the last decade: a nationwide analysis. Dig Dis Sci 2018;63:1286-93.10.1007/s10620-017-4882-6  pmid:29282637.15	 Hearnshaw SA, Logan RFA, Lowe D, Travis SP, Murphy MF, Palmer KR. Acute upper gastrointestinal bleeding in the UK: patient characteristics, diagnoses and outcomes in the 2007 UK audit. Gut 2011;60:1327-35.10.1136/ gut.2010.228437  pmid:21490373.16	 Nahon S, Hagège H, Latrive JP, et al. Groupe des Hémorragies Digestives Hautes de l’ANGH. Epidemiological and prognostic factors involved in upper gastrointestinal bleeding: results of a French prospective multicenter study. Endoscopy 2012;44:998-1008.10.1055/s-0032- 1310006  pmid:23108771.17	 Bickell WH, Wall MJ Jr, , Pepe PE, et al. Immediate versus delayed fluid resuscitation for hypotensive patients with penetrating torso injuries. N Engl J Med 1994;331:1105-9.10.1056/ NEJM199410273311701  pmid:7935634.18	 Carrick MM, Morrison CA, Tapia NM, et al. Intraoperative hypotensive resuscitation for patients undergoing laparotomy or thoracotomy for trauma: Early termination of a randomized prospective clinical trial. J Trauma Acute Care Surg 2016;80:886-96.10.1097/ TA.0000000000001044  pmid:27015578.19	 Perel P, Roberts I, Ker K. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev 2013;28:CD000567 .pmid:23450531.20	 Semler MW, Self WH, Wanderer JP, et al. SMART Investigators and the Pragmatic Critical Care Research Group. Balanced crystalloids versus saline in critically ill adults. N Engl J Med 2018;378:829-39.10.1056/ NEJMoa1711584  pmid:29485925.21	 Carson JL, Stanworth SJ, Roubinian N, et al. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion.",2652,250,663.0,"[ 0.6845779  -0.37119824 -1.5490229  ... -0.11936995  0.7041617
 -1.3977164 ]"
235,"Cochrane Database Syst Rev 2016;10:CD002042.pmid:27731885.22	 Carson JL, Guyatt G, Heddle NM, et al. Clinical practice guidelines from the AABB: red blood cell transfusion thresholds and storage. JAMA 2016;316:2025-35.10.1001/jama.2016.9185  pmid:27732721.23	 Docherty AB, O’Donnell R, Brunskill S, et al. Effect of restrictive versus liberal transfusion strategies on outcomes in patients with cardiovascular disease in a non-cardiac surgery setting: systematic review and meta- analysis. BMJ 2016;352:i1351.10.1136/bmj.i1351  pmid:27026510.24	 Blair SD, Janvrin SB, McCollum CN, Greenhalgh RM. Effect of early blood transfusion on gastrointestinal haemorrhage. Br J Surg 1986;73:783-5. 10.1002/bjs.1800731007  pmid:3533203.25	 Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med 2013;368:11-21. 10.1056/NEJMoa1211801  pmid:23281973.26	 Jairath V, Kahan BC, Gray A, et al. Restrictive versus liberal blood transfusion for acute upper gastrointestinal bleeding (TRIGGER): a pragmatic, open-label, cluster randomised feasibility trial. Lancet 2015;386:137-44.10.1016/S0140-6736(14)61999- 1  pmid:25956718.27	 Odutayo A, Desborough MJ, Trivella M, et al. Restrictive versus liberal blood transfusion for gastrointestinal bleeding: a systematic review and meta-analysis of randomised controlled trials. Lancet Gastroenterol Hepatol 2017;2:354-60.10.1016/S2468-1253(17)30054- 7.  pmid:28397699.28	 Laine L, Jensen DM. Management of patients with ulcer bleeding. Am J Gastroenterol 2012;107:345-60, quiz 361.10.1038/ ajg.2011.480  pmid:22310222.29	 Rockall TA, Logan RF, Devlin HB, Northfield TC. Risk assessment after acute upper gastrointestinal haemorrhage. Gut 1996;38:316-21.10.1136/ gut.38.3.316  pmid:8675081.30	 Saeed ZA, Winchester CB, Michaletz PA, Woods KL, Graham DY. A scoring system to predict rebleeding after endoscopic therapy of nonvariceal upper gastrointestinal hemorrhage, with a comparison of heat probe and ethanol injection. Am J Gastroenterol 1993;88:1842-9.pmid:8237930.31	 Hay JA, Maldonado L, Weingarten SR, Ellrodt AG. Prospective evaluation of a clinical guideline recommending hospital length of stay in upper gastrointestinal tract hemorrhage. JAMA 1997;278:2151-6.10.1001/ jama.1997.03550240041031  pmid:9417008.32	 Blatchford O, Murray WR, Blatchford M. A risk score to predict need for treatment for upper-gastrointestinal haemorrhage. Lancet 2000;356:1318- 21.",2458,214,614.5,"[ 1.1337031  -0.87367654 -1.0389439  ...  0.7117804   0.53154504
 -0.9895915 ]"
235,"10.1016/S0140-6736(00)02816-6  pmid:11073021.33	 Marmo R, Koch M, Cipolletta L, et al. Italian registry on upper gastrointestinal bleeding (Progetto Nazionale Emorragie Digestive--PNED 2). Predicting mortality in non-variceal upper gastrointestinal bleeders: validation of the Italian PNED Score and Prospective Comparison with the Rockall Score. Am J Gastroenterol 2010;105:1284-91.10.1038/ ajg.2009.687  pmid:20051943.34	 Saltzman JR, Tabak YP, Hyett BH, Sun X, Travis AC, Johannes RS. A simple risk score accurately predicts in-hospital mortality, length of stay, and cost in acute upper GI bleeding. Gastrointest Endosc 2011;74:1215-24. 10.1016/j.gie.2011.06.024  pmid:21907980.35	 Stanley AJ, Laine L, Dalton HR, et al. International Gastrointestinal Bleeding Consortium. Comparison of risk scoring systems for patients presenting with upper gastrointestinal bleeding: international multicentre prospective study. BMJ 2017;356:i6432.10.1136/bmj.i6432  pmid:28053181.36	 Laursen SB, Hansen JM, Schaffalitzky de Muckadell OB. The Glasgow Blatchford score is the most accurate assessment of patients with upper gastrointestinal hemorrhage. Clin Gastroenterol Hepatol 2012;10:1130- 1135.e1.10.1016/j.cgh.2012.06.022  pmid:22801061.37	 Yang HM, Jeon SW, Jung JT, et al. Daegu-Gyeongbuk Gastrointestinal Study Group (DGSG). Comparison of scoring systems for nonvariceal upper gastrointestinal bleeding: a multicenter prospective cohort study. J Gastroenterol Hepatol 2016;31:119-25.10.1111/ jgh.13057  pmid:26211939.38	 Stanley AJ, Ashley D, Dalton HR, et al. Outpatient management of patients with low-risk upper-gastrointestinal haemorrhage: multicentre validation and prospective evaluation. Lancet 2009;373:42-7.10.1016/S0140- 6736(08)61769-9  pmid:19091393.39	 Ramaekers R, Mukarram M, Smith CA, Thiruganasambandamoorthy V. The predictive value of preendoscopic risk scores to predict adverse outcomes in emergency department patients with upper gastrointestinal bleeding: a systematic review. Acad Emerg Med 2016;23:1218-27.10.1111/ acem.13101  pmid:27640399.40	 Laursen SB, Dalton HR, Murray IA, et al. Upper Gastrointestinal Hemorrhage International Consortium Upper Gastrointestinal Hemorrhage International Consortium. Performance of new thresholds of the Glasgow Blatchford score in managing patients with upper gastrointestinal bleeding. Clin Gastroenterol Hepatol 2015;13:115-21.e2.10.1016/j.cgh.2014.07.023  pmid:25058843. HOW PATIENTS WERE INVOLVED IN THE CREATION OF THIS ARTICLE After email communication from the UK Gastroenterology Charity “Guts-UK” (previously CORE) to their members and related charities, three patients kindly volunteered to review the manuscript. In response to their comments, the sections on blood transfusion and timing of endoscopy were revised. on 29 May 2024 at Yonsei University (Medical Library and Hospital). Protected by copyright.http://www.bmj.com/ BMJ: first published as 10.1136/bmj.l536 on 25 March 2019.",2958,282,739.5,"[ 0.15471919 -0.2810588  -1.2526488  ... -0.04395463  1.1444877
 -1.1792941 ]"
236,"STATE OF THE ART REVIEW For personal use only 	 12 of 13 41	 Dunne PDJ, Laursen SB, Laine L, et al. Previous use of antithrombotic agents reduces mortality and length of hospital stay in patients with high-risk upper gastrointestinal bleeding. Clin Gastroenterol Hepatol 2019;17:440-447.e2.10.1016/j.cgh.2018.04.046.   pmid:29705263.42	 Chang HY, Zhou M, Tang W, Alexander GC, Singh S. Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study. BMJ 2015;350:h1585.10.1136/bmj.h1585  pmid:25911526.43	 Huang ES, Strate LL, Ho WW, Lee SS, Chan AT. Long-term use of aspirin and the risk of gastrointestinal bleeding. Am J Med 2011;124:426-33. 10.1016/j.amjmed.2010.12.022  pmid:21531232.44	 Ahsberg K, Höglund P, Kim WH, von Holstein CS. Impact of aspirin, NSAIDs, warfarin, corticosteroids and SSRIs on the site and outcome of non-variceal upper and lower gastrointestinal bleeding. Scand J Gastroenterol 2010;45:1404-15. 10.3109/00365521.2010.510567  pmid:20695720.45	 Acosta RD, Abraham NS, Chandrasekhara V, et al. ASGE Standards of Practice Committee. The management of antithrombotic agents for patients undergoing GI endoscopy. Gastrointest Endosc 2016;83:3-16. 10.1016/j.gie.2015.09.035  pmid:26621548.46	 Zakko L, Rustagi T, Douglas M, Laine L. No benefit from platelet transfusion for gastrointestinal bleeding in patients taking antiplatelet agents. Clin Gastroenterol Hepatol 2017;15:46-52.10.1016/j. cgh.2016.07.017  pmid:27464591.47	 Razzaghi A, Barkun AN. Platelet transfusion threshold in patients with upper gastrointestinal bleeding: a systematic review. J Clin Gastroenterol 2012;46:482-6.10.1097/ MCG.0b013e31823d33e3  pmid:22688143.48	 Choudari CP, Rajgopal C, Palmer KR. Acute gastrointestinal haemorrhage in anticoagulated patients: diagnoses and response to endoscopic treatment. Gut 1994;35:464-6.10.1136/gut.35.4.464  pmid:8174982.49	 Wolf AT, Wasan SK, Saltzman JR. Impact of anticoagulation on rebleeding following endoscopic therapy for nonvariceal upper gastrointestinal hemorrhage. Am J Gastroenterol 2007;102:290-6.10.1111/j.1572- 0241.2006.00969.x  pmid:17100959.50	 Shingina A, Barkun AN, Razzaghi A, Martel M, Bardou M, Gralnek I. RUGBE Investigators. Systematic review: the presenting international normalised ratio (INR) as a predictor of outcome in patients with upper nonvariceal gastrointestinal bleeding. Aliment Pharmacol Ther 2011;33:1010-8. 10.1111/j.1365-2036.2011.04618.x  pmid:21385193.51	 Veitch AM, Vanbiervliet G, Gershlick AH, et al. Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines.",2752,244,688.0,"[ 0.71161044 -0.52320373 -1.7452134  ...  0.34051755  0.8761294
 -1.3970429 ]"
236,"Gut 2016;65:374-89. 10.1136/gutjnl-2015-311110  pmid:26873868.52	 Pollack CV Jr, , Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal—full cohort analysis. N Engl J Med 2017;377:431-41.10.1056/ NEJMoa1707278  pmid:28693366.53	 Connolly SJ, Milling TJ Jr, , Eikelboom JW, et al. ANNEXA-4 Investigators. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med 2016;375:1131-41.10.1056/ NEJMoa1607887  pmid:27573206.54	 Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med 2011;365:147-56.10.1056/NEJMra1011170  pmid:21751907.55	 Tripodi A, Primignani M, Chantarangkul V, et al. Thrombin generation in patients with cirrhosis: the role of platelets. Hepatology 2006;44:440-5. 10.1002/hep.21266  pmid:16871542.56	 Sreedharan A, Martin J, Leontiadis GI, et al. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database Syst Rev 2010;7:CD005415.pm id:20614440.57	 Hwang JH, Fisher DA, Ben-Menachem T, et al. Standards of Practice Committee of the American Society for Gastrointestinal Endoscopy. The role of endoscopy in the management of acute non-variceal upper GI bleeding. Gastrointest Endosc 2012;75:1132-8.10.1016/j. gie.2012.02.033  pmid:22624808.58	 Rahman R, Nguyen DL, Sohail U, et al. Pre-endoscopic erythromycin administration in upper gastrointestinal bleeding: an updated meta- analysis and systematic review. Ann Gastroenterol 2016;29:312- 7.pmid:27366031.59	 Gluud LL, Klingenberg SL, Langholz E. Tranexamic acid for upper gastrointestinal bleeding. Cochrane Database Syst Rev 2012;1:CD00664 0.pmid:22258969.60	 Gayet-Ageron A, Prieto- Merino D, Ker K, Shakur H, Ageron FX, Roberts I. Antifibrinolytic Trials Collaboration. Effect of treatment delay on the effectiveness and safety of antifibrinolytics in acute severe haemorrhage: a meta-analysis of individual patient-level data from 40 138 bleeding patients. Lancet 2018;391:125-32.10.1016/S0140-6736(17)32455- 8.  pmid:29126600.61	 Roberts I, Coats T, Edwards P, et al. HALT-IT--tranexamic acid for the treatment of gastrointestinal bleeding: study protocol for a randomised controlled trial. Trials 2014;15:450.10.1186/1745-6215-15- 450.  pmid:25409738.62	 Seo YS, Park SY, Kim MY, et al.",2298,202,574.5,"[ 0.3903916  -1.2510291  -1.1781027  ... -0.06491727  0.542052
 -1.617379  ]"
236,"Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal hemorrhage. Hepatology 2014;60:954-63.10.1002/ hep.27006  pmid:24415445.63	 Levacher S, Letoumelin P, Pateron D, Blaise M, Lapandry C, Pourriat JL. Early administration of terlipressin plus glyceryl trinitrate to control active upper gastrointestinal bleeding in cirrhotic patients. Lancet 1995;346:865-8.10.1016/S0140-6736(95)92708- 5  pmid:7564670.64	 Avgerinos A, Nevens F, Raptis S, Fevery J. Early administration of somatostatin and efficacy of sclerotherapy in acute oesophageal variceal bleeds: the European Acute Bleeding Oesophageal Variceal Episodes (ABOVE) randomised trial. Lancet 1997;350:1495-9.10.1016/S0140- 6736(97)05099-X  pmid:9388396.65	 Calès P, Masliah C, Bernard B, et al. French Club for the Study of Portal Hypertension. Early administration of vapreotide for variceal bleeding in patients with cirrhosis. N Engl J Med 2001;344:23-8.10.1056/ NEJM200101043440104  pmid:11136956.66	 Avgerinos A, Sgouros S, Viazis N, et al. Somatostatin inhibits gastric acid secretion more effectively than pantoprazole in patients with peptic ulcer bleeding: a prospective, randomized, placebo-controlled trial. Scand J Gastroenterol 2005;40:515-22. 10.1080/00365520510015458  pmid:16036503.67	 Whitehouse I, Beglinger C, Fried M, Gyr K. The effect of an octapeptide somatostatin analogue (SMS 201-995) and somatostatin-14 (SST-14) on pentagastrin-stimulated gastric acid secretion: a comparative study in man. Hepatogastroenterology 1984;31:227-9.pmid:6150888.68	 Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila F, et al. Meta-analysis: antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding—an updated Cochrane review. Aliment Pharmacol Ther 2011;34:509-18.10.1111/j.1365- 2036.2011.04746.x  pmid:21707680.69	 Fernández J, Ruiz del Arbol L, Gómez C, et al. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenterology 2006;131:1049-56, quiz 1285. 10.1053/j.gastro.2006.07.010  pmid:17030175.70	 Strate LL, Gralnek IM. ACG clinical guideline: management of patients with acute lower gastrointestinal bleeding. Am J Gastroenterol 2016;111:459- 74.10.1038/ajg.2016.41.  pmid:26925883.71	 Pasha SF, Shergill A, Acosta RD, et al. ASGE Standards of Practice Committee. The role of endoscopy in the patient with lower GI bleeding. Gastrointest Endosc 2014;79:875-85.10.1016/j. gie.2013.10.039  pmid:24703084.72	 Nadler M, Eliakim R. The role of capsule endoscopy in acute gastrointestinal bleeding. Therap Adv Gastroenterol 2014;7:87-92. 10.1177/1756283X13504727  pmid:24587821.73	 Lim LG, Ho KY, Chan YH, et al.",2735,243,683.75,"[-0.24497615 -0.5462979  -1.0781347  ...  0.26062518  0.10618474
 -1.1016814 ]"
236,"Urgent endoscopy is associated with lower mortality in high-risk but not low-risk nonvariceal upper gastrointestinal bleeding. Endoscopy 2011;43:300-6.10.1055/s-0030- 1256110  pmid:21360421.74	 Cho SH, Lee YS, Kim YJ, et al. Outcomes and role of urgent endoscopy in high-risk patients with acute nonvariceal gastrointestinal bleeding. Clin Gastroenterol Hepatol 2018;16:370-7.10.1016/j. cgh.2017.06.029  pmid:28634135.75	 Lin HJ, Wang K, Perng CL, et al. Early or delayed endoscopy for patients with peptic ulcer bleeding. A prospective randomized study. J Clin Gastroenterol 1996;22:267-71.10.1097/00004836-199606000- 00005  pmid:8771420.76	 Laursen SB, Leontiadis GI, Stanley AJ, Møller MH, Hansen JM, Schaffalitzky de Muckadell OB. Relationship between timing of endoscopy and mortality in patients with peptic ulcer bleeding: a nationwide cohort study. Gastrointest Endosc 2017;85:936-944.e3.10.1016/j. gie.2016.08.049  pmid:27623102.77	 Sung JJ, Tsoi KK, Ma TK, Yung MY, Lau JY, Chiu PW. Causes of mortality in patients with peptic ulcer bleeding: a prospective cohort study of 10,428 cases. Am J Gastroenterol 2010;105:84-9.10.1038/ ajg.2009.507  pmid:19755976.78	 Lee JG, Turnipseed S, Romano PS, et al. Endoscopy-based triage significantly reduces hospitalization rates and costs of treating upper GI bleeding: a randomized controlled trial. Gastrointest Endosc 1999;50:755-61.10.1016/S0016-5107(99)70154- 9  pmid:10570332.79	 Bjorkman DJ, Zaman A, Fennerty MB, Lieberman D, Disario JA, Guest- Warnick G. Urgent vs. elective endoscopy for acute non-variceal upper-GI bleeding: an effectiveness study. Gastrointest Endosc 2004;60:1-8. 10.1016/S0016-5107(04)01287-8  pmid:15229417.80	 Laine L. Upper gastrointestinal bleeding due to a peptic ulcer. N Engl J Med 2016;374:2367-76.10.1056/NEJMcp1514257  pmid:27305194.81	 Maida M, Camilleri S, Manganaro M, Garufi S, Scarpulla G. Radiofrequency ablation for treatment of refractory gastric antral vascular ectasia: a systematic review of the literature. Gastroenterol Res Pract 2017;2017:5609647.10.1155/2017/5609647  pmid:28835751.82	 Laine L, McQuaid KR. Endoscopic therapy for bleeding ulcers: an evidence-based approach based on meta-analyses of randomized controlled trials. Clin Gastroenterol Hepatol 2009;7:33-47, quiz 1-2. 10.1016/j.cgh.2008.08.016  pmid:18986845.83	 Vergara M, Bennett C, Calvet X, Gisbert JP. Epinephrine injection versus epinephrine injection and a second endoscopic method in high-risk bleeding ulcers. Cochrane Database Syst Rev 2014;10:CD005584.pm id:25308912.84	 Forrest JA, Finlayson ND, Shearman DJ. Endoscopy in gastrointestinal bleeding. Lancet 1974;2:394-7.",2648,232,662.0,"[-0.1746761  -0.8979534  -1.7755811  ...  0.24435896  0.80232775
 -1.3101896 ]"
236,10.1016/S0140- 6736(74)91770-X  pmid:4136718. on 29 May 2024 at Yonsei University (Medical Library and Hospital). Protected by copyright.http://www.bmj.com/ BMJ: first published as 10.1136/bmj.l536 on 25 March 2019. Downloaded from,231,27,57.75,"[ 0.21721825  0.12449855 -1.6386006  ... -0.40914953 -0.35440123
 -1.5066086 ]"
237,"STATE OF THE ART REVIEW For personal use only 	 13 of 13 85	 Enestvedt BK, Gralnek IM, Mattek N, Lieberman DA, Eisen G. An evaluation of endoscopic indications and findings related to nonvariceal upper-GI hemorrhage in a large multicenter consortium. Gastrointest Endosc 2008;67:422-9.10.1016/j.gie.2007.09.024  pmid:18206878.86	 Jairath V, Rehal S, Logan R, et al. Acute variceal haemorrhage in the United Kingdom: patient characteristics, management and outcomes in a nationwide audit. Dig Liver Dis 2014;46:419-26.10.1016/j. dld.2013.12.010  pmid:24433997.87	 Laine L, Cook D. Endoscopic ligation compared with sclerotherapy for treatment of esophageal variceal bleeding. A meta-analysis. Ann Intern Med 1995;123:280-7.10.7326/0003-4819-123-4-199508150- 00007  pmid:7611595.88	 Lo GH, Lai KH, Cheng JS, Chen MH, Chiang HT. A prospective, randomized trial of butyl cyanoacrylate injection versus band ligation in the management of bleeding gastric varices. Hepatology 2001;33:1060-4.10.1053/ jhep.2001.24116  pmid:11343232.89	 Tan PC, Hou MC, Lin HC, et al. A randomized trial of endoscopic treatment of acute gastric variceal hemorrhage: N-butyl-2-cyanoacrylate injection versus band ligation. Hepatology 2006;43:690-7.10.1002/ hep.21145  pmid:16557539.90	 Cheng LF, Wang ZQ, Li CZ, Lin W, Yeo AE, Jin B. Low incidence of complications from endoscopic gastric variceal obturation with butyl cyanoacrylate. Clin Gastroenterol Hepatol 2010;8:760-6.10.1016/j. cgh.2010.05.019  pmid:20621678.91	 Ramesh J, Limdi JK, Sharma V, Makin AJ. The use of thrombin injections in the management of bleeding gastric varices: a single-center experience. Gastrointest Endosc 2008;68:877-82.10.1016/j. gie.2008.02.065  pmid:18534583.92	 McAvoy NC, Plevris JN, Hayes PC. Human thrombin for the treatment of gastric and ectopic varices. World J Gastroenterol 2012;18:5912-7.10.3748/wjg.v18.i41.5912  pmid:23139607.93	 Smith MR, Tidswell R, Tripathi D. Outcomes of endoscopic human thrombin injection in the management of gastric varices. Eur J Gastroenterol Hepatol 2014;26:846-52.10.1097/MEG.0000000000000119  pmid:24892515.94	 Sachar H, Vaidya K, Laine L. Intermittent vs continuous proton pump inhibitor therapy for high-risk bleeding ulcers: a systematic review and meta-analysis. JAMA Intern Med 2014;174:1755-62.10.1001/ jamainternmed.2014.4056  pmid:25201154.95	 Freston JW, Pilmer BL, Chiu YL, et al. Evaluation of the pharmacokinetics and pharmacodynamics of intravenous lansoprazole. Aliment Pharmacol Ther 2004;19:1111-22.10.1111/j.1365- 2036.2004.01942.x  pmid:15142201.96	 Cheng HC, Wu CT, Chang WL, Cheng WC, Chen WY, Sheu BS. Double oral esomeprazole after a 3-day intravenous esomeprazole infusion reduces recurrent peptic ulcer bleeding in high-risk patients: a randomised controlled study.",2790,251,697.5,"[ 0.6458784  -0.67880154 -1.7225095  ... -0.10078595  0.5183788
 -1.2562308 ]"
237,"Gut 2014;63:1864-72.10.1136/ gutjnl-2013-306531  pmid:24658598.97	 Bhatt DL, Cryer BL, Contant CF, et al. COGENT Investigators. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010;363:1909-17.10.1056/NEJMoa1007964  pmid:20925534.98	 Sanofi; Bristol-Myers Squibb. Plavix. Highlights of prescribing information.2018.https://www.accessdata.fda.gov/drugsatfda_docs/ label/2018/020839s069lbl.pdf.99	 Lo GH, Chen WC, Wang HM, et al. Low-dose terlipressin plus banding ligation versus low-dose terlipressin alone in the prevention of very early rebleeding of oesophageal varices. Gut 2009;58:1275-80.10.1136/ gut.2008.165910  pmid:19386609.100	 Sung JJ, Chung SC, Yung MY, et al. Prospective randomised study of effect of octreotide on rebleeding from oesophageal varices after endoscopic ligation. Lancet 1995;346:1666-9.10.1016/S0140-6736(95)92840- 5  pmid:8551824.101	 García-Pagán JC, Caca K, Bureau C, et al. Early TIPS (Transjugular Intrahepatic Portosystemic Shunt) Cooperative Study Group. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med 2010;362:2370-9. 10.1056/NEJMoa0910102  pmid:20573925.102	 Conejo I, Guardascione MA, Tandon P, et al. Multicenter external validation of risk stratification criteria for patients with variceal bleeding. Clin Gastroenterol Hepatol 2018;16:132-139.e8.10.1016/j. cgh.2017.04.042  pmid:28501536.103	 Sung JJ, Lau JY, Ching JY, et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med 2010;152:1-9. 10.7326/0003-4819-152-1-201001050-00179  pmid:19949136.104	 Qureshi W, Mittal C, Patsias I, et al. Restarting anticoagulation and outcomes after major gastrointestinal bleeding in atrial fibrillation. Am J Cardiol 2014;113:662-8.10.1016/j.amjcard.2013.10.044  pmid:24355310.105	 Chan FKL, Goh KL, Reddy N, et al. Management of patients on antithrombotic agents undergoing emergency and elective endoscopy: joint Asian Pacific Association of Gastroenterology (APAGE) and Asian Pacific Society for Digestive Endoscopy (APSDE) practice guidelines. Gut 2018;67:405-17. 10.1136/gutjnl-2017-315131  pmid:29331946.106	 Scott MJ, Veitch A, Thachil J. Reintroduction of anti-thrombotic therapy after a gastrointestinal haemorrhage: if and when?Br J Haematol 2017;177:185-97. 10.1111/bjh.14599.",2336,204,584.0,"[ 0.21761982 -0.70282704 -1.2303473  ...  0.09218201  0.7931202
 -1.6467147 ]"
237,"pmid:28272736.107	 Witt DM, Delate T, Garcia DA, et al. Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding. Arch Intern Med 2012;172:1484-91. 10.1001/archinternmed.2012.4261  pmid:22987143.108	 Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864-70. 10.1001/jama.285.22.2864  pmid:11401607.109	 Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol 2011;57:173-80. 10.1016/j.jacc.2010.09.024  pmid:21111555.110	 Zulkifly H, Lip GYH, Lane DA. Bleeding risk scores in atrial fibrillation and venous thromboembolism. Am J Cardiol 2017;120:1139-45.10.1016/j. amjcard.2017.06.058  pmid:28800833.111	 Lau JYW, Sung JJY, Lam YH, et al. Endoscopic retreatment compared with surgery in patients with recurrent bleeding after initial endoscopic control of bleeding ulcers. N Engl J Med 1999;340:751-6.10.1056/ NEJM199903113401002  pmid:10072409.112	 Chen Y-I, Barkun AN. Hemostatic powders in gastrointestinal bleeding: a systematic review. Gastrointest Endosc Clin N Am 2015;25:535-52. 10.1016/j.giec.2015.02.008  pmid:26142037.113	 Troland D, Stanley A. Endotherapy for peptic ulcer bleeding. Gastrointest Endosc Clin N Am 2018;28:277-89.10.1016/j. giec.2018.02.002  pmid:29933775.114	 Kyaw M, Tse Y, Ang D, Ang TL, Lau J. Embolization versus surgery for peptic ulcer bleeding after failed endoscopic hemostasis: a meta-analysis. Endosc Int Open 2014;2:E6-14.10.1055/s-0034- 1365235  pmid:26134614.115	 Beggs AD, Dilworth MP, Powell SL, Atherton H, Griffiths EA. A systematic review of transarterial embolization versus emergency surgery in treatment of major nonvariceal upper gastrointestinal bleeding. Clin Exp Gastroenterol 2014;7:93-104.10.2147/CEG. S56725  pmid:24790465.116	 Lau JYW, Pittayanon R, Wong KT, et al. Prophylactic angiographic embolisation after endoscopic control of bleeding to high-risk peptic ulcers: a randomised controlled trial. Gut 2018;gutjnl-2018-316074. 10.1136/gutjnl-2018-316074.  pmid:29802172.117	 Cook D, Laine L. Indications, technique, and complications of balloon tamponade for variceal gastrointestinal bleeding. J Intensive Care Med 1992;7:212-8.",2609,233,652.25,"[-0.052774   -0.6605984  -1.6165447  ... -0.19792321  1.1375057
 -1.555749  ]"
237,"10.1177/088506669200700408  pmid:10147943.118	 Escorsell À, Pavel O, Cárdenas A, et al. Variceal Bleeding Study Group. Esophageal balloon tamponade versus esophageal stent in controlling acute refractory variceal bleeding: A multicenter randomized, controlled trial. Hepatology 2016;63:1957-67.10.1002/ hep.28360  pmid:26600191.119	 Sung JJ, Luo D, Wu JC, et al. Early clinical experience of the safety and effectiveness of Hemospray in achieving hemostasis in patients with acute peptic ulcer bleeding. Endoscopy 2011;43:291-5.10.1055/s- 0030-1256311  pmid:21455870.120	 Smith LA, Stanley AJ, Bergman JJ, et al. Hemospray application in nonvariceal upper gastrointestinal bleeding: results of the Survey to Evaluate the Application of Hemospray in the Luminal Tract. J Clin Gastroenterol 2014;48:e89-92.10.1097/MCG.054.   pmid:24326829.121	 Sulz MC, Frei R, Meyenberger C, Bauerfeind P, Semadeni GM, Gubler C. Routine use of Hemospray for gastrointestinal bleeding: prospective two-center experience in Switzerland. Endoscopy 2014;46:619-24. 10.1055/s-0034-1365505  pmid:24770964.122	 Changela K, Papafragkakis H, Ofori E, et al. Hemostatic powder spray: a new method for managing gastrointestinal bleeding. Therap Adv Gastroenterol 2015;8:125-35. 10.1177/1756283X15572587  pmid:26082803.123	 Kwek BEA, Ang TL, Ong PLJ, et al. TC-325 versus the conventional combined technique for endoscopic treatment of peptic ulcers with high- risk bleeding stigmata: A randomized pilot study. J Dig Dis 2017;18:323- 9.10.1111/1751-2980.12481.  pmid:28485544.124	 Ibrahim M, El-Mikkawy A, Abdel Hamid M, et al. Early application of haemostatic powder added to standard management for oesophagogastric variceal bleeding: a randomised trial. Gut 2018;gutjnl-2017-314653.10.1136/ gutjnl-2017-314653.  pmid:29730601.125	 Schmidt A, Gölder S, Goetz M, et al. Over the scope clips are more effective than standard endoscopic therapy for patients with recurrent bleeding of peptic ulcers. Gastroenterology 2018;155:674-686.e6. 10.1053/j.gastro.2018.05.037.  pmid:29803838.126	 Jensen DM, Kovacs TOG, Ohning GV, et al. Doppler endoscopic probe monitoring of blood flow improves risk stratification and outcomes of patients with severe nonvariceal upper gastrointestinal hemorrhage. Gastroenterology 2017;152:1310-1318.e1.10.1053/j. gastro.2017.01.042  pmid:28167214. on 29 May 2024 at Yonsei University (Medical Library and Hospital). Protected by copyright.",2437,225,609.25,"[-0.28070325 -0.55360246 -1.2587721  ...  0.4127342   0.33416504
 -1.4671239 ]"
238,STATE OF THE ART REVIEW For personal use only 	 14 of 13 on 29 May 2024 at Yonsei University (Medical Library and Hospital). Protected by copyright.http://www.bmj.com/ BMJ: first published as 10.1136/bmj.l536 on 25 March 2019. Downloaded from,242,38,60.5,"[ 0.54322743  0.33129853 -1.7091072  ... -0.35180062 -0.8018276
 -1.2507416 ]"
239,STATE OF THE ART REVIEW For personal use only 	 15 of 13 on 29 May 2024 at Yonsei University (Medical Library and Hospital). Protected by copyright.http://www.bmj.com/ BMJ: first published as 10.1136/bmj.l536 on 25 March 2019. Downloaded from,242,38,60.5,"[ 0.4997689   0.36987793 -1.7065513  ... -0.3185393  -0.81848496
 -1.2643743 ]"
240,"The new engl and jour nal of medicine n engl j med 374;24  nejm.org  June 16, 2016 2367 Clinical Practice A 55-year-old woman presents to the emergency department at 11:30 p.m. with hematemesis. She is otherwise healthy and has no risk factors for liver disease. Her only medication is aspirin (at a dose of 81 mg daily), which she started to take 6 months ago after reading that it reduces the risk of heart disease. The blood pres- sure is 94/60 mm Hg, and the heart rate is 108 beats per minute; the physical exami- nation is otherwise normal. The hemoglobin level is 11.0 g per deciliter, platelet count 220,000 per cubic millimeter, international normalized ratio 1.0, and blood urea nitrogen level 20 mg per deciliter (7.1 mmol per liter). How should this case be further evaluated and managed?The Clinical Problem G astrointestinal bleeding, the most common cause of hospital- ization due to gastrointestinal disease in the United States, accounts for more than 507,000 hospitalizations and $4.85 billion in costs annually.1 Upper gastrointestinal bleeding, defined as bleeding from the esophagus, stomach, or duodenum, is responsible for 50% or more of these hospitalizations.2 The case fatality rate among hospitalized patients with upper gastrointestinal bleeding has decreased over the past 20 years and ranges from 2.1 to 2.5% in U. S. nationwide database studies3,4 to 10% in large, prospective European observational studies.5,6 The rate of death among patients who are already hospitalized for another condi- tion when upper gastrointestinal bleeding develops is approximately 3 to 4 times as high as the rate among patients who are admitted to the hospital for upper gastrointestinal bleeding.5 Peptic ulcers, which are primarily due to Helicobacter pylori infection or the use of nonsteroidal antiinflammatory drugs (NSAIDs), occur in the stomach or duo- denum and are the most frequent cause of upper gastrointestinal bleeding.4 Ero- sions in the esophagus (which are caused by gastroesophageal reflux disease) or in the stomach or duodenum (which are frequently due to NSAIDs) are also common sources of upper gastrointestinal bleeding. Erosions are breaks confined to the mucosa (the most superficial layer of the gastrointestinal tract) and should not cause severe bleeding because veins and arteries are not normally present in the mucosa. Mallory–Weiss tears, linear tears that usually occur on the gastric side of the gastroesophageal junction, may cause severe bleeding and usually occur after retching or vomiting. Less common causes of nonvariceal upper gastrointestinal An audio version of this article is available at NEJM.org From the Yale School of Medicine, New Haven, and VA Connecticut Healthcare System, West Haven — both in Connecti- cut. Address reprint requests to Dr. Laine at the Section of Digestive Diseases, Yale School of Medicine, P. O. Box 208019, New Haven, CT 06520-8019, or at ­loren​.­laine@​ ­yale​.­edu. N Engl J Med 2016;374:2367-76. DOI: 10.1056/NEJMcp1514257 Copyright © 2016 Massachusetts Medical Society. Caren G. Solomon, M. D., M. P. H., Editor Upper Gastrointestinal Bleeding Due  to a Peptic Ulcer Loren Laine, M. D.​ This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence ­supporting various strategies is then presented, followed by a review of formal guidelines, when they exist. The article ends with the author’s clinical recommendations. The New England Journal of Medicine Downloaded from nejm.org at Yonsei Univ Coll of Medicine on May 29, 2024. For personal use only. No other uses without permission. Copyright © 2016 Massachusetts Medical Society. All rights reserved.",3683,570,920.75,"[ 0.05733269 -0.65305614 -1.3474456  ... -0.23186666  0.64881366
 -1.2097163 ]"
241,"n engl j med 374;24  nejm.org  June 16, 2016 2368 The new engl and jour nal of medicine 2368 bleeding include neoplasms, vascular ectasias (in- cluding gastric antral vascular ectasias), Dieulafoy’s lesions (aberrant vessels in the mucosa), bleed- ing from the bile duct or pancreatic duct, and aortoenteric fistulas. The proportion of upper gastrointestinal bleeding that is attributable to varices varies widely, from 1.9% to more than 30%,4,6 depending on the characteristics of the patient population (e.g., the prevalence of injec- tion-drug or alcohol use and the country of origin). This article, which considers only nonvariceal upper gastrointestinal bleeding, focuses on ulcer bleeding. Str ategies and Evidence Initial Assessment At the initial encounter with a patient, risk as- sessment is performed to determine the severity of upper gastrointestinal bleeding according to vital signs and patient factors. Tachycardia (heart rate ≥100 beats per minute), hypotension (systolic blood pressure ≤100 mm Hg), age older than 60 years, and major coexisting conditions are associated with an increased risk of further bleeding and death.7 Risk-assessment tools are available and are use- ful in identifying patients at very low risk. For example, discharge from the emergency depart- ment followed by outpatient care has been sug- gested for patients with a Glasgow–Blatchford score of 0, 0 to 1, or, in patients who are younger than 70 years of age, 0 to 2 (on a scale of 0 to 23, with higher scores indicating higher risk) (Table  1).8-11 A prospective study showed that when hospitalized, less than 1% of such patients require intervention and less than 0.5% die.10 Hemoglobin levels should be monitored; how- ever, unlike blood pressure and heart rate, they are a poor initial indicator of the severity of up- per gastrointestinal bleeding. Because patients bleed whole blood, the hemoglobin level does not drop immediately but takes hours to equili- brate as the intravascular volume is replenished with intravenous and interstitial fluid. Initial Therapy before Endoscopy Transfusion of red cells is generally recommend- ed when the hemoglobin level decreases below 7 g per deciliter. A randomized trial showed lower rates of death (the primary outcome), rebleeding, and adverse events with a transfusion threshold of 7 g per deciliter than with a transfusion threshold of 9 g per deciliter.12 For patients in hemodynamically stable condition who have pre- existing cardiovascular disease, guidelines recom- mend transfusion at a hemoglobin level of less than 8 g per deciliter or in patients with symp- toms. These guidelines are based on random- ized trials that primarily involved patients with- out gastrointestinal bleeding who had undergone surgery.13 In patients with hypotension due to severe upper gastrointestinal bleeding, transfu- sion before the hemoglobin level decreases be- low 7 g per deciliter is reasonable to prevent the decreases to levels well below 7 g per deciliter that will occur with fluid resuscitation alone. A meta-analysis of six randomized trials showed that a proton-pump inhibitor adminis- tered to patients with upper gastrointestinal Key Clinical Points Upper Gastrointestinal Bleeding •	 Gastrointestinal bleeding is the most common cause of hospitalization due to gastrointestinal disease in the United States. •	 Peptic ulcers, primarily due to Helicobacter pylori infection and the use of nonsteroidal antiinflammatory drugs (NSAIDs), are the most common cause of upper gastrointestinal bleeding. •	 In patients with upper gastrointestinal bleeding, tachycardia (heart rate, ≥100 beats per minute), hypotension (systolic blood pressure, ≤100 mm Hg), age older than 60 years, and major coexisting conditions are associated with increased risks of further bleeding and death. •	 Patients with bleeding ulcers due to H. pylori infection should receive treatment for this infection and, after eradication is confirmed, discontinue antisecretory medications. •	 Patients with bleeding ulcers due to NSAIDs other than low-dose aspirin should discontinue NSAIDs; if NSAIDs must be resumed, a cyclooxygenase-2 (COX-2)–selective NSAID plus a proton-pump inhibitor should be used. •	 Patients with bleeding ulcers due to low-dose aspirin taken for secondary cardiovascular prevention should resume the use of aspirin within 1 to 7 days after bleeding stops. The New England Journal of Medicine Downloaded from nejm.org at Yonsei Univ Coll of Medicine on May 29, 2024. For personal use only. No other uses without permission. Copyright © 2016 Massachusetts Medical Society. All rights reserved.",4635,698,1158.75,"[ 0.05452739 -0.90077984 -1.2020609  ... -0.35662156  0.5577332
 -1.0648168 ]"
242,"n engl j med 374;24  nejm.org  June 16, 2016 2369 Clinical Practice bleeding soon after presentation did not signifi- cantly reduce the risks of further bleeding, sur- gery, or death. The use of this therapy was associ- ated with a decrease in the frequency of high-risk endoscopic findings (active bleeding, a nonbleed- ing visible vessel, or an adherent clot) and the need for endoscopic therapy.14 Although they are based on the same data, guidelines vary sub- stantively regarding the use of proton-pump in- hibitors before endoscopy. Some recommend high-dose intravenous proton-pump inhibitors,11,15 others indicate that proton-pump inhibitors “may be considered,”8,16 and still others recommend that clinicians not administer proton-pump in- hibitors.17 Erythromycin (at a dose of 250 mg intrave- nously 30 minutes before endoscopy) increases gastric motility and improves visualization of the gastric mucosa at endoscopy. A meta-analysis of four randomized trials showed that the use of erythromycin decreased the need for blood trans- fusion and repeat endoscopy.18 Use of a Nasogastric Tube A nasogastric tube is not required in patients with upper gastrointestinal bleeding.8 Observa- tional evidence does not suggest a clinical bene- fit. Standard-bore nasogastric tubes probably do not allow sufficient clearance of clots to sub- stantially improve visualization of the gastric mucosa at endoscopy. Endoscopy Most patients who are hospitalized with upper gastrointestinal bleeding should undergo endos- copy within 24 hours, after appropriate resusci- tation and transfusion, as needed, to a hemoglo- bin level greater than 7 g per deciliter. In some observational studies, prompt endoscopy, as compared with endoscopy after 24 hours, has been associated with reductions in the need for surgery, length of hospitalization, and mortal- ity.8,11,16,17,19,20 Most patients with a low clinical risk (normal blood pressure and heart rate and no major co- existing conditions) should undergo endoscopy as soon as possible during routine clinical hours. Approximately 40 to 45% of patients who undergo endoscopy within 2 to 6 hours have low-risk endoscopic findings that allow dis- charge, thereby reducing costs.21,22 An observa- tional study and a subgroup analysis of a ran- domized trial suggest that endoscopy within 12 to 13 hours in patients with high clinical risk (Glasgow–Blatchford score ≥12, bloody nasogas- tric aspirate, hypotension, and tachycardia) may be associated with improved outcomes.8,23,24 Endoscopic features of ulcers are key in pre- dicting risk and determining management strat- egies (Fig. 1). Rates of further bleeding are high- est among patients with active bleeding and nonbleeding visible vessels. If endoscopic treat- ment is not provided, serious further bleeding Values at Admission Points Blood urea nitrogen — mg/dl <18.2 0 18.2 to <22.4 2 22.4 to <28.0 3 28.0 to <70.0 4 ≥70.0 6 Hemoglobin — g/dl ≥13.0 (men); ≥12.0 (women) 0 12.0 to <13.0 (men); 10.0 to <12.0 (women) 1 10.0 to <12.0 (men) 3 <10.0 (men and women) 6 Systolic blood pressure — mm Hg ≥110 0 100–109 1 90–99 2 <90 3 Heart rate — beats/min <100 0 ≥100 1 Other variables Melena 1 Syncope 2 Hepatic disease according to history or clinical and laboratory evidence 2 Cardiac failure according to history or clinical and echocardio- graphic evidence 2 *	Glasgow–Blatchford scores range from 0 to 23, with higher scores indicating higher risk. Positive predictive values were calculated in a study by Laursen et al.10 Among 2305 patients presenting to a hospital with upper gastrointestinal bleeding, 313 (14%) had a score of 0 (positive predictive value, 99.0%), 562 (24%) had a score of 0 or 1 (positive predictive value, 98.8%), and 588 (26%) had a score of 0 to 2 and were younger than 70 years of age (positive predic- tive value, 99.0%). To convert the values for blood urea nitrogen to millimoles per liter, multiply by 0.357. Table 1. Glasgow–Blatchford Score.*The New England Journal of Medicine Downloaded from nejm.org at Yonsei Univ Coll of Medicine on May 29, 2024. For personal use only. No other uses without permission. Copyright © 2016 Massachusetts Medical Society. All rights reserved.",4208,653,1052.0,"[ 0.01512747 -0.23758242 -1.4448864  ...  0.5249401   0.5793228
 -1.0013937 ]"
243,"n engl j med 374;24  nejm.org  June 16, 2016 2370 The new engl and jour nal of medicine occurs in approximately 25% of patients with actively oozing hemorrhage, approximately 35% with nonbleeding visible vessels, and more than 60% with actively spurting hemorrhage.8,25 An adherent clot is also a high-risk endoscopic find- ing, although randomized trials show that rates of rebleeding without endoscopic therapy vary widely, from 0 to 35%.26 Flat, pigmented spots and clean-base ulcers, which are detected at en- doscopy in approximately 70% of patients with ulcer bleeding,27 are associated with low rates of serious rebleeding (5.6% and 0.5%, respectively, in a pooled analysis).25 Endoscopic therapy with injection (e.g., of epinephrine or alcohol), thermal devices (such as bipolar electrocoagulation probes or heater probes), or clips (Fig. 2) is performed in patients who have ulcers with active bleeding or a non- bleeding visible vessel. A meta-analysis of ran- domized trials revealed absolute risk reductions in further bleeding of 58 percentage points among patients with active bleeding and 20 per- centage points among patients with nonbleeding visible vessels.26 Endoscopic therapy may be con- sidered for ulcers with adherent clots, for which randomized trials show heterogeneous results.26 If bleeding recurs, endoscopic therapy should be repeated. A randomized trial involving pa- tients with rebleeding after endoscopic therapy showed that surgery was avoided in 73% of cases and adverse events were significantly less common with endoscopic therapy than with surgical therapy.28 Transcatheter arterial emboli- zation or surgery is performed if repeat endo- scopic therapy fails. Complications of bleeding or perforation occur in approximately 0.5% of patients who undergo endoscopic therapy.26 En- doscopic therapy also may be used for vascular ectasias, Dieulafoy’s lesions, neoplasms, and actively bleeding Mallory–Weiss tears.11 In patients with ulcers or erosions, biopsy specimens should be obtained from lesion-free areas of the gastric body and antral mucosa for assessment of H. pylori infection.8,11 A pooled analysis indicated that such testing has 83% sensitivity and 100% specificity for H. pylori.29 If this testing is negative for H. pylori, subsequent retesting (e.g., with a stool test or breath test) Figure 1. Initial Treatment of Patients with Ulcer Bleeding, According to the Endoscopic Features of the Ulcer. Intensive proton-pump inhibitor (PPI) therapy is an intravenous bolus (80 mg) followed by an infusion (8 mg per hour) for 72 hours or an oral or intravenous bolus (e.g., 80 mg) followed by intermittent high-dose PPI therapy (e.g., 40 to 80 mg twice daily) for 3 days.11 The diets shown are diets after endoscopy in patients who do not have nausea or vomiting. The duration of hospital stay after endoscopy is shown in patients who are in stable condition and do not have further bleeding or concurrent medical conditions requiring hospitalization. Endoscopic therapy Active bleeding or visible vessel May consider endoscopic therapy Adherent clot No endoscopic therapy Flat pigmented spot No endoscopic therapy Clean base Intensive PPI therapy Intensive PPI therapy Once-daily PPI therapy Once-daily PPI therapy Clear liquids for approximately 2 days Clear liquids for approximately 2 days Clear liquids for approximately 1 day Regular diet Hospitalize for 3 days Hospitalize for 3 days Hospitalize for 1 or 2 days Discharge after endoscopy Endoscopic Features Endoscopic Therapy Medical Therapy Diet Hospital Stay The New England Journal of Medicine Downloaded from nejm.org at Yonsei Univ Coll of Medicine on May 29, 2024. For personal use only. No other uses without permission. Copyright © 2016 Massachusetts Medical Society. All rights reserved.",3800,571,950.0,"[-0.3733781  -0.47927397 -1.708477   ...  0.7454209   0.6408135
 -1.4348458 ]"
244,"n engl j med 374;24 nejm.org June 16, 2016 2371 Clinical Practice has been recommended because some observa- tional studies suggest decreased sensitivity of testing during acute upper gastrointestinal bleeding.11,16,29 Care after Endoscopy Guidelines recommend that patients with ulcers and high-risk endoscopic findings receive an intravenous proton-pump inhibitor bolus (at a dose of 80 mg) followed by a continuous infu- sion (8 mg per hour) for 72 hours.8,11,16 A meta- analysis of randomized trials showed that this strategy, as compared with endoscopic therapy alone, significantly reduced risks of further bleeding, the need for surgery, and mortality.26 However, a recent meta-analysis showed that intermittent oral or intravenous proton-pump inhibitor therapy resulted in outcomes that were noninferior to those after continuous infusion30; this suggests that intermittent proton-pump in- hibitor may be used in place of continuous infu- sion.11 The most appropriate intermittent dosing is not known, but an initial oral or intravenous bolus of 80 mg followed by 40 to 80 mg twice daily for 72 hours has been suggested.11 Early studies suggested that rebleeding was uncommon more than 3 days after endoscopy, so patients who present with ulcers and high-risk endoscopic findings typically are hospitalized for 3 days after endoscopy if they have no fur- ther bleeding and no other reasons for hospital- ization. However, in a systematic review of five randomized trials in which patients received endoscopic therapy and infusion of high-dose proton-pump inhibitors, among patients who had rebleeding (overall rate, 11% over 30 days), rebleeding occurred after 3 days in 44% of pa- tients and after 7 days in 24%.31 Nevertheless, anticipation that a small number of patients may have rebleeding in the coming weeks does not justify hospitalization for more than 3 days in patients who are in stable condition and do not have other medical problems. Patients should be informed about symptoms of recurrent upper gastrointestinal bleeding and the need to return to the emergency department if any occur. After discharge, patients who presented with high-risk endoscopic findings and clinical fac- tors (hemodynamic instability, older age, or a major coexisting condition) should receive twice- daily proton-pump inhibitor therapy for 2 weeks, followed by a proton-pump inhibitor once daily. Figure 2. Endoscopic Hemostatic Therapies. Panel A shows an injection catheter with the retractable needle extruded and the needle placed into the base of the ulcer next to the visible vessel. The visible vessel marks the site from which the ulcer bled and is asso- ciated with a high risk of recurrent bleeding. Panel B shows a thermal probe being applied to the visible vessel in the ulcer base. Panel C shows closed clips on either side of the visible vessel in the ulcer base and an open clip over the visible vessel. The open clip is about to be closed on the visible vessel. Injection catheter Ulcer base Visible vessel B Thermal Therapy C Clipping base Thermal probe Open clip Closed clip Closed clip clip Closed Closed A Injection catheter The New England Journal of Medicine Downloaded from nejm.org at Yonsei Univ Coll of Medicine on May 29, 2024. For personal use only. No other uses without permission. Copyright © 2016 Massachusetts Medical Society. All rights reserved.",3380,529,845.0,"[-0.03726195 -0.43674022 -1.5878183  ...  0.42876658  0.7469973
 -0.8106401 ]"
245,"n engl j med 374;24  nejm.org  June 16, 2016 2372 The new engl and jour nal of medicine A trial compared once-daily with twice-daily proton-pump inhibitor dosing for 11 days (fol- lowed in both groups by 2 weeks of treatment with a proton-pump inhibitor once daily) in high- risk patients who had undergone infusion of a proton-pump inhibitor for 3 days.32 This trial showed a significantly lower rate of ulcer rebleed- ing with twice-daily therapy than with once- daily therapy (11% vs. 29%). Patients with low-risk clinical features (a nor- mal heart rate and blood pressure and no major coexisting conditions), low-risk endoscopic find- ings (clean-base ulcers, erosions, or nonbleeding Mallory–Weiss tears), and outpatient support can be discharged home after endoscopy, and a regu- lar diet can be resumed33 (Fig.  1). Once-daily proton-pump inhibitor therapy is recommended in patients with erosions or ulcers without high- risk endoscopic features.16 Prevention of Recurrent Ulcer Bleeding Rebleeding is common after ulcer healing if strategies to prevent recurrence are not used. For example, a systematic review of studies with a 12-month follow-up showed a 26% rebleeding rate among patients with H. pylori–associated bleeding ulcers who did not receive treatment for H. pylori infection.34 Strategies to prevent recurrent ulcer bleeding depend on the cause of the ulcer. The three major causes are H. pylori infection, the use of NSAIDs (including aspirin), and an idiopathic cause (Fig. 3). H. pylori Infection Patients with H. pylori infection should receive therapy to eradicate the bacteria. A meta-analy- sis of randomized trials of such therapy showed significantly less rebleeding in patients who re- ceived this therapy than in patients who did not receive treatment for H. pylori infection and in those who received maintenance antisecretory therapy.34 Eradication of H. pylori should be confirmed after therapy with a breath test, a stool test, or, if repeat endoscopy is performed for another reason, gastric biopsy. Patients must not receive bismuth or antibiotics for at least 4 weeks and should not receive proton-pump inhibitors for at least 2 weeks before testing to avoid false nega- tive results; histamine H2-receptor antagonists are permissible. In a systematic review of studies with a mean follow-up of 11 to 53 months,34 the incidence of rebleeding was only 1.3% among patients with confirmed eradication of H. pylori. NSAIDs Other Than Low-Dose Aspirin Patients who have bleeding ulcers while taking NSAIDs should discontinue NSAIDs permanently if possible. If NSAIDs must be resumed, a com- bination of a cyclooxygenase-2 (COX-2)–selective NSAID and a proton-pump inhibitor is recom- mended. Studies have shown rates of rebleeding of 4 to 6% within 6 months among patients who had a bleeding ulcer and were subsequently treated with COX-2–selective NSAIDs alone or traditional NSAIDs plus a proton-pump inhibi- tor.36-38 A 12-month double-blind trial showed significantly less ulcer rebleeding with a COX-2– selective NSAID plus a proton-pump inhibitor than with a COX-2–selective NSAID alone (0 vs. 9%).39 Low-Dose Aspirin Decisions regarding continuation of low-dose aspirin (50 to 325 mg daily) for prevention of cardiovascular events should be based on wheth- er the therapy is for primary or secondary preven- tion. When used for primary prevention, aspirin has been shown to result in significant but small reductions in the absolute risk of cardiovascular events; the estimated number needed to treat to prevent one myocardial infarction, stroke, or vascular death is 1745.40 The risk of recurrent upper gastrointestinal bleeding probably out- weighs the potential benefit of resuming pri- mary prevention in most patients. In contrast, the absolute reduction in cardio- vascular events is much greater when aspirin is used for secondary prevention (estimated num- ber needed to treat, 67).41 A randomized trial involving patients with bleeding ulcers and high- risk endoscopic features who were taking low- dose aspirin for secondary prevention compared resumption of aspirin use within 24 hours ver- sus withholding aspirin for 8 weeks.42 Patients assigned to prompt resumption of aspirin, as compared with those in whom aspirin was with- held, had no significant increase in the risk of rebleeding and had significantly lower mortality at 30 days (1% vs. 9%) and 8 weeks (1% vs. 13%). The risk of cardiovascular events may increase within 1 to 2 weeks after discontinuing aspirin The New England Journal of Medicine Downloaded from nejm.org at Yonsei Univ Coll of Medicine on May 29, 2024. For personal use only. No other uses without permission. Copyright © 2016 Massachusetts Medical Society. All rights reserved.",4761,733,1190.25,"[-0.5041505  -0.41461962 -1.5092304  ...  0.45145553  0.36526656
 -1.1909298 ]"
246,"n engl j med 374;24  nejm.org  June 16, 2016 2373 Clinical Practice used for secondary prevention43,44; thus, aspirin should be resumed 1 to 7 days after bleeding stops.8,11,45 Cotherapy with a proton-pump in- hibitor also should be administered to reduce rebleeding.8,45,46 Combined H. pylori Infection and NSAID Use In patients who have received NSAIDs and who are found to have H. pylori infection, both eradi- cation of H. pylori infection and discontinuation of NSAIDs are recommended. Randomized trials have compared outcomes of treatment for H. py- lori infection with the use of a proton-pump in- hibitor (omeprazole at a dose of 20 mg daily) in H. pylori–positive patients who had upper gastro- intestinal bleeding while taking low-dose aspi- rin or an NSAID other than aspirin. Among pa- tients who had bleeding while taking an NSAID and received naproxen after ulcer healing, re- bleeding occurred by 6 months in 19% after treatment for H. pylori infection and in 4% of patients who received maintenance therapy with a proton-pump inhibitor.36 In contrast, among patients who had bleeding while taking low- dose aspirin and resumed low-dose aspirin after ulcer healing, rebleeding occurred by 6 months in 2% and 1%, respectively; this suggests that eradication of H. pylori infection may reduce risk among patients who receive low-dose aspirin (although no placebo group was included).36 Figure 3. Long-Term Treatment of Patients with Bleeding Ulcers, According to the Cause of the Ulcer. Patients with Helicobacter pylori infection who receive low-dose aspirin or other nonsteroidal antiinflammatory drugs (NSAIDs) require interventions for both causes. Two first-line therapies (both administered for 14 days) are recom- mended for H. pylori infection if local patterns of clarithromycin resistance or eradication rates with triple therapy are not known: bismuth-containing quadruple therapy and concomitant (non–bismuth-containing quadruple) ther­ apy.35 Bismuth-containing quadruple therapy is a PPI at a dose of 20 to 40 mg twice daily, bismuth (bismuth sub- salicylate at a dose of 262 mg, 2 tablets four times a day; colloidal bismuth subcitrate at a dose of 120 mg, 2 tablets twice daily or 1 tablet four times a day; bismuth biskalcitrate at a dose of 140 mg, 3 tablets four times a day; or bis- muth subcitrate potassium at a dose of 140 mg as part of combination tablets, 3 tablets four times a day), metroni- dazole at a dose of 500 mg three times a day or 400 mg four times a day, and tetracycline 500 mg four times a day. Concomitant (non–bismuth-containing quadruple) therapy is a PPI at a dose of 20 to 40 mg twice daily, amoxicillin at a dose of 1 g twice daily, clarithromycin at a dose of 500 mg twice daily, and metronidazole at a dose of 500 mg twice daily. Triple therapy (e.g., a PPI at a dose of 20 to 40 mg twice daily, amoxicillin 1 g twice daily, and clarithro- mycin at a dose of 500 mg twice daily, all administered for 14 days) should only be used in geographic areas where the prevalence of clarithromycin-resistant H. pylori is known to be less than 15% or the eradication rate is known to be greater than 85%. Continue PPI therapy in the long term Idiopathic cause Therapy for H. pylori infection H. pylori infection Discontinue NSAIDs Document cure of H. pylori infection and discontinue antisecretory therapy If NSAIDs are resumed, use COX-2–selective NSAID+PPI NSAIDs (other than low-dose aspirin) Low-dose aspirin for prevention of cardio- vascular events Secondary prevention Primary prevention Resume aspirin 1–7 days after bleeding stops in most patients and continue PPI therapy in the long term Discontinue aspirin permanently in most patients The New England Journal of Medicine Downloaded from nejm.org at Yonsei Univ Coll of Medicine on May 29, 2024. For personal use only. No other uses without permission. Copyright © 2016 Massachusetts Medical Society. All rights reserved.",3932,637,983.0,[-0.1333221 -0.1917189 -1.6323488 ...  0.3177213  0.8305652 -1.4809278]
247,"n engl j med 374;24  nejm.org  June 16, 2016 2374 The new engl and jour nal of medicine However, treatment with a proton-pump inhibi- tor is still recommended if aspirin is continued. A 12-month randomized trial involving H. pylori– positive patients with ulcer complications who were receiving low-dose aspirin showed that even after eradication of H. pylori infection, ulcer rebleeding was significantly less frequent with a proton-pump inhibitor than with a placebo (2% vs. 15%).46 Idiopathic Ulcer An observational study47 showed a 42% incidence of rebleeding at 7 years among patients who did not have H. pylori infection, use NSAIDs, or have another uncommon identified cause of an ulcer (e.g., the Zollinger–Ellison syndrome or neo- plasm) and who did not receive gastroprotective therapy. Thus, these patients should continue to receive once-daily maintenance therapy with a proton-pump inhibitor.8,16 Areas of Uncertainty Data from studies of new endoscopic tools such as Doppler ultrasonography (to assess bleeding risk and the adequacy of endoscopic therapy) and application of powders or cryotherapy (for hemostasis) are insufficient to establish the role of these tools in clinical practice. The appropri- ate dosing of proton-pump inhibitors to treat ul- cers in patients with high-risk findings requires further study. In addition, more data are needed to guide the choice between interventional radio- logic and surgical treatment in patients in whom endoscopic therapy has failed. Observational studies show associations between proton-pump inhibitors and adverse outcomes (e.g., dementia, chronic kidney disease, cardiovascular events, fractures, pneumonia, and enteric infections).48-50 The strengths of these associations are generally modest (odds ratios or hazard ratios <2 except for enteric infections), and it is not known whether they are causal.48-50 In patients with a prior bleeding ulcer, the documented benefit of proton-pump inhibitors outweighs the small and uncertain risks. Guidelines Guidelines for the management of upper gastro- intestinal bleeding have been published by U. S. and international professional societies.8,11,15,17 The recommendations in this article are gener- ally concordant with these guidelines. Only the European Society of Gastrointestinal Endoscopy guideline,11 which was published after the meta- analysis comparing intermittent with continuous proton-pump inhibitors30 became available, sug- gests consideration of intermittent rather than continuous proton-pump inhibitors for bleeding ulcers in patients with high-risk endoscopic findings. Conclusions and Recommendations Ulcer bleeding is the most likely cause of upper gastrointestinal bleeding in the patient described in the vignette. Her aspirin use may have caused a new ulcer or may have induced bleeding from a preexisting lesion (e.g., an H. pylori–related ulcer). I would initiate an intravenous normal saline infusion and recheck the patient’s hemoglobin level after volume resuscitation. I would perform endoscopy the next morning, within 12 hours after presentation because of the patient’s initial hypotension. If an ulcer is detected, I would perform endoscopic therapy for active bleeding or a nonbleeding visible vessel, perform biopsies of the gastric mucosa to detect H. pylori, initiate treatment with a proton-pump inhibitor, and discontinue aspirin given the patient’s low car- diovascular risk. If H. pylori was not present, I would prescribe a proton-pump inhibitor for 6 to 8 weeks. If H. pylori was detected, I would pre- scribe therapy for H. pylori infection for 2 weeks, followed by 2 to 4 weeks of a proton-pump in- hibitor. I would confirm eradication of the infec- tion by retesting for H. pylori after switching the patient’s treatment to a histamine H2-receptor antagonist for 2 weeks. If H. pylori infection was eradicated (or was never present) and the patient agreed not to use aspirin and other NSAIDs, I would discontinue antisecretory medications. Dr. Laine reports receiving fees for serving on data and safety monitoring boards from Bayer and Pharmaceutical Product De- velopment (a contract research organization that oversaw trials sponsored by Eisai), and providing a review for a law firm repre- senting Mylan in a patent-litigation case regarding formulation of a pill combining an NSAID and a proton-pump inhibitor. No other potential conflict of interest relevant to this article was reported. Disclosure forms provided by the author are available with the full text of this article at NEJM.org. The New England Journal of Medicine Downloaded from nejm.org at Yonsei Univ Coll of Medicine on May 29, 2024. For personal use only. No other uses without permission. Copyright © 2016 Massachusetts Medical Society. All rights reserved.",4795,710,1198.75,"[-0.01506522 -0.28122717 -1.3393195  ...  0.5332624   0.5497876
 -1.4713587 ]"
248,"n engl j med 374;24  nejm.org  June 16, 2016 2375 Clinical Practice References 1.	 Peery AF, Crockett SD, Barritt AS, et al. Burden of gastrointestinal, liver, and pan- creatic diseases in the United States. Gas- troenterology 2015;​149(7):​1731-1741.e3.2.	 Lanas A, García-Rodríguez LA, Polo- Tomás M, et al. Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. Am J Gastroenterol 2009;​104:​1633-41.3.	 Abougergi MS, Travis AC, Saltzman JR. The in-hospital mortality rate for up- per GI hemorrhage has decreased over  2 decades in the United States: a nation- wide analysis. Gastrointest Endosc 2015;​ 81(4):​882-888.e1.4.	 Laine L, Yang H, Chang SC, Datto C. Trends for incidence of hospitalization and death due to GI complications in the United States from 2001 to 2009. Am J Gastroenterol 2012;​107:​1190-5.5.	 Hearnshaw SA, Logan RFA, Lowe D, Travis SPL, Murphy MF, Palmer KR. Acute upper gastrointestinal bleeding in the UK: patient characteristics, diagnoses and out- comes in the 2007 UK audit. Gut 2011;​60:​ 1327-35.6.	 Nahon S, Hagège H, Latrive JP, et al. Epidemiological and prognostic factors involved in upper gastrointestinal bleed- ing: results of a French prospective multi- center study. Endoscopy 2012;​44:​998-1008.7.	 Rockall TA, Logan RF, Devlin HB, Northfield TC. Risk assessment after acute upper gastrointestinal haemorrhage. Gut 1996;​38:​316-21.8.	 Laine L, Jensen DM. Management of patients with ulcer bleeding. Am J Gastro- enterol 2012;​107:​345-60.9.	 Stanley AJ, Ashley D, Dalton HR, et al. Outpatient management of patients with low-risk upper-gastrointestinal haemor- rhage: multicentre validation and pro- spective evaluation. Lancet 2009;​373:​ 42-7.10.	 Laursen SB, Dalton HR, Murray IA, et al. Performance of new thresholds of the Glasgow Blatchford score in managing patients with upper gastrointestinal bleed- ing. Clin Gastroenterol Hepatol 2015;​ 13(1):​115-121.e2.11.	 Gralnek IM, Dumonceau JM, Kuipers EJ, et al. Diagnosis and management of nonvariceal upper gastrointestinal hemor- rhage: European Society of Gastrointesti- nal Endoscopy (ESGE) Guideline. Endos- copy 2015;​47(10):​a1-46.",2189,306,547.25,"[ 0.5102301  -0.74431336 -1.1771646  ... -0.35580236  0.9097549
 -1.487908  ]"
248,"12.	Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med 2013;​368:​11-21.13.	 Carson JL, Grossman BJ, Kleinman S, et al. Red blood cell transfusion: a clinical practice guideline from the AABB. Ann Intern Med 2012;​157:​49-58.14.	 Sreedharan A, Martin J, Leontiadis GI, et al. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database Syst Rev 2010;​7:​CD005415.15.	 Hwang JH, Fisher DA, Ben-Menachem T, et al. The role of endoscopy in the man- agement of acute non-variceal upper GI bleeding. Gastrointest Endosc 2012;​75:​ 1132-8.16.	 Barkun AN, Bardou M, Kuipers EJ, et al. International consensus recommenda- tions on the management of patients with nonvariceal upper gastrointestinal bleed- ing. Ann Intern Med 2010;​152:​101-13.17.	 National Institute for Health and Clin- ical Excellence. Acute upper gastrointesti- nal bleeding: management. London:​ Na- tional Clinical Guideline Centre at the Royal College of Physicians, 2012.18.	Bai Y, Guo JF, Li ZS. Meta-analysis: erythromycin before endoscopy for acute upper gastrointestinal bleeding. Aliment Pharmacol Ther 2011;​34:​166-71.19.	 Cooper GS, Chak A, Connors AF Jr, Harper DL, Rosenthal GE. The effective- ness of early endoscopy for upper gastro- intestinal hemorrhage: a community-based analysis. Med Care 1998;​36:​462-74.20.	Wysocki JD, Srivastav S, Winstead NS. A nationwide analysis of risk factors for mortality and time to endoscopy in upper gastrointestinal haemorrhage. Aliment Pharmacol Ther 2012;​36:​30-6.21.	Lee JG, Turnipseed S, Romano PS, et al. Endoscopy-based triage significantly reduces hospitalization rates and costs of treating upper GI bleeding: a randomized controlled trial. Gastrointest Endosc 1999;​ 50:​755-61.22.	Bjorkman DJ, Zaman A, Fennerty MB, Lieberman D, Disario JA, Guest-Warnick G. Urgent vs. elective endoscopy for acute non-variceal upper-GI bleeding: an effec- tiveness study. Gastrointest Endosc 2004;​ 60:​1-8.",2051,276,512.75,"[ 0.48813337 -0.35573265 -1.2088935  ...  0.35804644  0.59291625
 -1.3918369 ]"
248,"23.	Lim LG, Ho KY, Chan YH, et al. Ur- gent endoscopy is associated with lower mortality in high-risk but not low-risk nonvariceal upper gastrointestinal bleed- ing. Endoscopy 2011;​43:​300-6.24.	Lin HJ, Wang K, Perng CL, et al. Early or delayed endoscopy for patients with peptic ulcer bleeding: a prospective ran- domized study. J Clin Gastroenterol 1996;​ 22:​267-71.25.	Laine L, Peterson WL. Bleeding peptic ulcer. N Engl J Med 1994;​331:​717-27.26.	Laine L, McQuaid KR. Endoscopic therapy for bleeding ulcers: an evidence- based approach based on meta-analyses of randomized controlled trials. Clin Gas- troenterol Hepatol 2009;​7:​33-47.27.	 Enestvedt BK, Gralnek IM, Mattek N, Lieberman DA, Eisen G. An evaluation of endoscopic indications and findings re- lated to nonvariceal upper-GI hemorrhage in a large multicenter consortium. Gas- trointest Endosc 2008;​67:​422-9.28.	Lau JYW, Sung JJY, Lam Y, et al. Endo- scopic retreatment compared with sur- gery in patients with recurrent bleeding after initial endoscopic control of bleed- ing ulcers. N Engl J Med 1999;​340:​751-6.29.	 Gisbert JP, Abraira V. Accuracy of Helicobacter pylori diagnostic tests in patients with bleeding peptic ulcer: a sys- tematic review and meta-analysis. Am J Gastroenterol 2006;​101:​848-63.30.	Sachar H, Vaidya K, Laine L. Intermit- tent vs continuous proton pump inhibitor therapy for high-risk bleeding ulcers:  a systematic review and meta-analysis. JAMA Intern Med 2014;​174:​1755-62.31.	 El Ouali S, Barkun A, Martel M, Mag- gio D. Timing of rebleeding in high-risk peptic ulcer bleeding after successful hemo- stasis: a systematic review. Can J Gastro- enterol Hepatol 2014;​28:​543-8.32.	Cheng HC, Wu CT, Chang WL, Cheng WC, Chen WY, Sheu BS. Double oral esomeprazole after a 3-day intravenous esomeprazole infusion reduces recurrent peptic ulcer bleeding in high-risk pa- tients: a randomised controlled study. Gut 2014;​63:​1864-72.33.	 Laine L, Cohen H, Brodhead J, Cantor D, Garcia F, Mosquera M. Prospective eval- uation of immediate versus delayed refeed- ing and prognostic value of endoscopy in patients with upper gastrointestinal hem- orrhage. Gastroenterology 1992;​102:​314-6.34.	Gisbert JP, Khorrami S, Carballo F, Calvet X, Gene E, Dominguez-Muñoz E. Meta-analysis: Helicobacter pylori eradi- cation therapy vs. antisecretory non-eradi- cation therapy for the prevention of recur- rent bleeding from peptic ulcer. Aliment Pharmacol Ther 2004;​19:​617-29.35.",2468,344,617.0,"[-0.17907518 -0.62044084 -1.5408754  ...  0.61166376  0.58821464
 -1.5540988 ]"
248,"Fallone CA, Chiba N, van Zanten SV, et al. The Toronto consensus for the treat- ment of Helicobacter pylori infection in adults. Gastroenterology 2016 April 18 (Epub ahead of print).36.	Chan FKL, Chung SCS, Suen BY, et al. Preventing recurrent upper gastrointesti- nal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001;​ 344:​967-73.37.	 Chan FKL, Hung LCT, Suen BY, et al. Celecoxib versus diclofenac and omepra- zole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002;​347:​2104-10.38.	Lai KC, Chu KM, Hui WM, et al. Cele- coxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med 2005;​118:​1271-8.39.	 Chan FK, Wong VW, Suen BY, et al. Combination of a cyclo-oxygenase-2 in- hibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 2007;​369:​1621-6.40.	Berger JS, Lala A, Krantz MJ, Baker GS, Hiatt WR. Aspirin for the prevention The New England Journal of Medicine Downloaded from nejm.org at Yonsei Univ Coll of Medicine on May 29, 2024. For personal use only. No other uses without permission. Copyright © 2016 Massachusetts Medical Society. All rights reserved.",1323,202,330.75,"[-0.14744832 -0.0087935  -1.1757675  ...  0.2841197   0.61746126
 -2.0319333 ]"
249,"n engl j med 374;24  nejm.org  June 16, 2016 2376 Clinical Practice nejm clinical practice center Explore a new page designed specifically for practicing clinicians,  the NEJM Clinical Practice Center, at NEJM.org/clinical-practice-center. Find practice-changing research, reviews from our Clinical Practice series,  a curated collection of clinical cases, and interactive features  designed to hone your diagnostic skills.of cardiovascular events in patients with- out clinical cardiovascular disease: a meta- analysis of randomized trials. Am Heart J 2011;​162(1):​115-124.e2.41.	 Antithrombotic Trialists’ (ATT) Col- laboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;​373:​1849-60.42.	Sung JJ, Lau JY, Ching JY, et al. Con- tinuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med 2010;​152:​1-9.43.	 Biondi-Zoccai GG, Lotrionte M, Agos- toni P, et al. A systematic review and meta-analysis on the hazards of discon- tinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J 2006;​27:​2667-74.44.	Burger W, Chemnitius JM, Kneissl GD, Rücker G. Low-dose aspirin for sec- ondary cardiovascular prevention — car- diovascular risks after its perioperative withdrawal versus bleeding risks with its continuation — review and meta-analy- sis. J Intern Med 2005;​257:​399-414.45.	 Bhatt DL, Scheiman J, Abraham NS,  et al. ACCF/ACG/AHA 2008 expert con- sensus document on reducing the gastro- intestinal risks of antiplatelet therapy and NSAID use: a report of the American Col- lege of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2008;​118:​1894-909.46.	Lai KC, Lam SK, Chu KM, et al. Lanso- prazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002;​ 346:​2033-8.47.	 Wong GL, Wong VW, Chan Y, et al. High incidence of mortality and recurrent bleeding in patients with Helicobacter pylori-negative idiopathic bleeding ulcers. Gastroenterology 2009;​137:​525-31.48.	Abraham NS. Proton pump inhibitors: potential adverse effects. Curr Opin Gas- troenterol 2012;​28:​615-20.49.	 Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med 2016;​176:​238-46.50.	Gomm W, von Holt K, Thomé F, et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepide- miological claims data analysis. JAMA Neurol 2016;​73:​410-6.",2609,363,652.25,"[ 0.07241143 -0.7076428  -1.3830519  ...  0.04564463  0.8808574
 -1.6627119 ]"
249,"Copyright © 2016 Massachusetts Medical Society. The New England Journal of Medicine Downloaded from nejm.org at Yonsei Univ Coll of Medicine on May 29, 2024. For personal use only. No other uses without permission. Copyright © 2016 Massachusetts Medical Society. All rights reserved.",283,43,70.75,"[-0.43156743 -0.04241422 -1.3885763  ... -0.0661636  -0.4322753
 -1.35982   ]"
250,"Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group Alan N. Barkun, MD; Majid Almadi, MD; Ernst J. Kuipers, MD; Loren Laine, MD; Joseph Sung, MD; Frances Tse, MD; Grigorios I. Leontiadis, MD; Neena S. Abraham, MD; Xavier Calvet, MD; Francis K. L. Chan, MD; James Douketis, MD; Robert Enns, MD; Ian M. Gralnek, MD; Vipul Jairath, MD; Dennis Jensen, MD; James Lau, MD; Gregory Y. H. Lip, MD; Romaric Loffroy, MD; Fauze Maluf-Filho, MD; Andrew C. Meltzer, MD; Nageshwar Reddy, MD; John R. Saltzman, MD; John K. Marshall, MD; and Marc Bardou, MD Description: This update of the 2010 International Consensus Recommendations on the Management of Patients With Non- variceal Upper Gastrointestinal Bleeding (UGIB) reﬁnes previous important statements and presents new clinically relevant recommendations. Methods: An international multidisciplinary group of experts developed the recommendations. Data sources included evi- dence summarized in previous recommendations, as well as sys- tematic reviews and trials identiﬁed from a series of literature searches of several electronic bibliographic databases from in- ception to April 2018. Using an iterative process, group mem- bers formulated key questions. Two methodologists prepared evidence proﬁles and assessed quality (certainty) of evidence rel- evant to the key questions according to the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach. Group members reviewed the evidence proﬁles and, using a consensus process, voted on recommendations and determined the strength of recommendations as strong or conditional. Recommendations: Preendoscopic management: The group suggests using a Glasgow Blatchford score of 1 or less to identify patients at very low risk for rebleeding, who may not require hospitalization. In patients without cardiovascular disease, the suggested hemoglobin threshold for blood transfusion is less than 80 g/L, with a higher threshold for those with cardiovascular disease. Endoscopic management: The group suggests that pa- tients with acute UGIB undergo endoscopy within 24 hours of presentation. Thermocoagulation and sclerosant injection are recommended, and clips are suggested, for endoscopic therapy in patients with high-risk stigmata. Use of TC-325 (hemostatic powder) was suggested as temporizing therapy, but not as sole treatment, in patients with actively bleeding ulcers. Pharmaco- logic management: The group recommends that patients with bleeding ulcers with high-risk stigmata who have had successful endoscopic therapy receive high-dose proton-pump inhibitor (PPI) therapy (intravenous loading dose followed by continuous infusion) for 3 days. For these high-risk patients, continued oral PPI therapy is suggested twice daily through 14 days, then once daily for a total duration that depends on the nature of the bleeding lesion. Secondary prophylaxis: The group suggests PPI therapy for patients with previous ulcer bleeding who re- quire antiplatelet or anticoagulant therapy for cardiovascu- lar prophylaxis. Ann Intern Med.2019;171:805-822.doi:10.7326/M19-1795 Annals.org For author afﬁliations, see end of text. This article was published at Annals.org on 22 October 2019. A cute upper gastrointestinal bleeding (UGIB) is common, but the annual incidence has been de- creasing: from 78 to 61 cases in 100 000 persons from 2001 to 2009 in one survey (1). Nonetheless, 30-day mortality remains high, at up to 11% (2). The most recent guidelines for managing UGIB were published primarily between 2010 and 2015, including those from our group (in 2003, with an up- date in 2010) (3, 4), the American College of Gastro- enterology (in 2012) (5), the American Society for Gastrointestinal Endoscopy (in 2012) (6), the National Institute for Health and Care Excellence (NICE) (in 2012) (7), and the European Society of Gastrointesti- nal Endoscopy (in 2015) (8). More recently, guide- lines from the Asia-Paciﬁc Working Group were up- dated in 2018 (9). The management of UGIB has advanced with new endoscopic techniques, and the pharmacologic landscape has changed. Anticoagulant or antiplatelet therapy, including combination therapy, is becoming more common, substantially increasing the risk for UGIB (10). Thus, the International Consensus Group agreed that an update to the 2010 recommendations for the management of UGIB (4) was warranted. METHODS Scope and Purpose Similar to the 2003 (3) and 2010 (4) guidelines, this update focuses on resuscitation and risk assessment; preendoscopic, endoscopic, and pharmacologic man- agement; and secondary prophylaxis for recurrent UGIB. Speciﬁc PICO (patient population, intervention, comparator, and outcome) questions were developed by the cochairs (A. N. B. and M. B.), steering committee (L. L., M. A., J. S., and E. J. K.), and GRADE (Grading of Recommendations Assessment, Development and Evaluation) methodologists (F. T. and G. I. L.) and ﬁnal- ized through a consensus process of iterative discus- sions with all other voting participants. See also: Editorial comment . . . . . . . . . . . . . . . . . . . . . . . . .853 Web-Only Supplement CME/MOC activity Annals of Internal Medicine CLINICAL GUIDELINE © 2019 American College of Physicians 805 Downloaded from https://annals.org by Yonsei University Medical Library on 05/29/2024.",5388,797,1347.0,"[ 0.46256375 -0.20852414 -1.5477272  ... -0.09330449  0.43124187
 -1.093152  ]"
251,"Sources, Literature Searches, and Systematic Reviews Sources included the evidentiary base of previous guidelines (3, 4) and English-language literature searches of MEDLINE, EMBASE (Elsevier), the Co- chrane Database of Systematic Reviews (Wiley), and the Cochrane Central Register of Controlled Trials (Wi- ley) done by the editorial ofﬁce of the Cochrane Upper Gastrointestinal and Pancreatic Diseases Group at Mc- Master University. Initial searches were conducted from database inception to 2 April 2018, with supplemental, focused searches to mid-May 2018. Key search terms and details of search strategies are shown in Supple- ment Appendix 1 (available at Annals.org). Conference abstracts, case reports, and studies in animals were excluded. Teams of reviewers (A. B., M. B., X. C., L. L., G. I. L., and F. T.) screened titles and abstracts in duplicate and in- dependently, and obtained full texts of potentially rel- evant studies. Reviewers also scanned bibliographies of retrieved systematic reviews. The cochairs, steering committee, and methodologists then selected the stud- ies relevant for each PICO question. Discrepancies re- garding inclusion were resolved by consensus. A modiﬁed version of AMSTAR-2 (A Measurement Tool to Assess Systematic Reviews) (11) was used as a decision tool to assess the methodological quality of existing systematic reviews. We selected the most re- cent of the well-conducted, relevant systematic reviews as our baseline source. Selected reviews were used wholly or partially (with only some of the following com- ponents: included studies, study characteristics, numer- ical data extractions, forest plots, or risk-of-bias tables) and were updated or improved as needed by adding new studies, removing inappropriate studies, or further assessing the quality of the included studies (Supple- ment Appendix 2, available at Annals.org). Assessment of the Quality of Evidence The methodologists (F. T. and G. I. L.) assessed risk of bias, indirectness, inconsistency, imprecision, and other limitations (including publication bias) of the evi- dence by using the GRADE approach (12). Overall quality of evidence (QoE) was graded as very low, low, moderate, or high for each recommendation. Evidence proﬁles (GRADE tables) were prepared for each PICO question and contained clear descrip- tions of beneﬁts and harms as well as a QoE rating for individual outcomes. The proﬁles, systematic reviews, and meta-analyses were made available to voting par- ticipants 1 week before the consensus meeting (Sup- plement Appendix 2). One statement (A1) met the criteria for “good prac- tice” (13). The consensus group agreed that this recom- mendation was clinically obvious and that collection and analysis of evidence were unnecessary. Consensus Process Participants in the multidisciplinary consensus group were from 11 countries and included gastroen- terologists, a cardiologist, a hematologist, a radiologist, a surgeon, and an emergency medicine specialist. The meeting included up to 20 voting participants for each statement (numbers varied, mainly because of travel difﬁculties), 2 nonvoting GRADE methodologists, and a nonvoting moderator (J. K. M). The cochairs, other steering committee members, and methodologists generated a list of new and old statements that were presented to the group through an anonymous, Web-based consensus platform (ECD Solutions). Via teleconference, the steering committee members reached consensus on which statements war- ranted inclusion in the guideline by focusing on priority areas. Using a modiﬁed Delphi process (14), all voting participants modiﬁed and ﬁnalized the new statements. After reviewing the evidence proﬁles, the participants anonymously voted on their degree of agreement or disagreement with each statement and submitted com- ments. Votes were nonbinding and designed to gauge the extent of agreement and the pattern of evidence uncertainty to guide the allotment of time for discus- sion during the meeting. The Canadian Association of Gastroenterology (CAG) ofﬁce tabulated the votes and comments and presented the results to the group. Al- though initially discussed in the form of declarative statements, these were edited into speciﬁc PICO ques- tions by the methodologists before the consensus meeting. At a 2-day consensus meeting in May 2018, the group applied the GRADE Evidence to Decision frame- work to move from evidence to recommendations by assessing 7 key criteria: the balance between desirable and undesirable effects, quality (certainty) of the evi- dence, variability in patients' values and preferences, resource requirements, cost-effectiveness, acceptabil- ity, and feasibility (Supplement Appendix 2) (15–17). Participants voted on the direction of the PICO ques- tion (for or against) as yes, uncertain, or no. Consensus for or against a speciﬁc strategy was reached if at least 75% of the participants voted yes or no, respectively. For PICO questions on which agreement was reached, the group then discussed the strength of the recom- mendation (strong vs. conditional) by considering the factors in the Evidence to Decision framework (18). In cases of low or very low QoE, unless at least 1 of the other 3 factors was overwhelmingly strong, the strength of the recommendation would default (without a vote) to “conditional” by using the phrase “we suggest.”If the statement warranted a vote and at least 75% of the par- ticipants voted “strong,” then the recommendation would be designated as strong with the phrase “we recommend.”Consensus was not reached on 4 PICO questions (no recommendation A to D), because fewer than 75% of the participants voted either yes or no. No corre- sponding statements were developed for these ques- tions, but the pertinent evidence and discussions are summarized brieﬂy in the text. Oversight and Review The guideline process was overseen by the CAG clinical affairs committee to ensure methodological quality and a transparent, nonbiased, evidence-based CLINICAL GUIDELINE Management of Upper Gastrointestinal Bleeding 806 Annals of Internal Medicine • Vol.171 No.11 • 3 December 2019 Annals.org Downloaded from https://annals.org by Yonsei University Medical Library on 05/29/2024.",6245,927,1561.25,"[ 0.461433   -0.04263531 -1.0602982  ...  0.05644806  0.49465597
 -1.2407434 ]"
252,"decision-making process. Recommendations are based on evidence from the literature and consensus discus- sion and may not fully reﬂect the product labeling for a given country. The manuscript was initially drafted by the cochairs (A. N. B. and M. B.) and the GRADE experts (F. T. and G. I. L.). It was reviewed and revised by the steering com- mittee members (E. J. K., J. S., L. L., and M. A.) before dis- semination to the full consensus group for feedback. Finally, the manuscript was posted on the CAG Web site, and members were invited via e-mail to submit comments over a 2-week period. In accordance with CAG policy, written conﬂict-of- interest disclosures for the 24 months preceding the consensus meeting were provided by all participants and made available to the group. Role of the Funding Source Funding for the consensus meeting was provided by unrestricted, arms-length grants to the CAG from the Institute of Nutrition, Metabolism and Diabetes of the Canadian Institutes of Health Research and the Saudi Gastroenterology Association. The CAG adminis- tered all aspects of the meeting; the funding sources had no involvement in, nor were they made aware of, any part of the process, from the development of search strings and statements to drafting and approv- ing these guidelines. RECOMMENDATION STATEMENTS FOR UGIB Each statement is followed by the strength of evi- dence based on GRADE analyses and a discussion of the evidence. The voting results are shown in Table 1, along with summaries of the new recommendations es- tablished from this consensus, recommendations that were revised from the 2003 and 2010 guidelines (3, 4), and recommendations that were unchanged because most of the group believed that they currently did not require revision (3, 4). Section A: Resuscitation, Risk Assessment, and Preendoscopy Management Statement A1 For patients with acute UGIB and hemodynamic in- stability, resuscitation should be initiated. (Designated a good practice statement.)Discussion. Fluid resuscitation should be initiated in patients with UGIB and hemodynamic instability, be- cause hemorrhagic shock may lead to multiorgan fail- ure and death. The goals of ﬂuid resuscitation are to restore end-organ perfusion and tissue oxygenation while steps are taken to control bleeding. Uncertainty remains regarding the type of ﬂuid (colloid vs. crystalloid) and the rate and timing of resus- citation (aggressive vs. restrictive). A Cochrane system- atic review including 70 randomized controlled trials found no difference in mortality between critically ill patients who received colloids (albumin or plasma pro- tein fraction, hydroxyethyl starch, modiﬁed gelatin, dextran, colloids in hypertonic crystalloid, or colloids in isotonic crystalloid) and those who received crystalloids (normal saline, Ringer lactate, or hypertonic saline) for ﬂuid resuscitation (19). One small randomized trial con- ducted in patients with UGIB who had hemorrhagic shock found no statistically signiﬁcant difference in mortality between hypertonic saline dextran and Ringer lactate (relative risk [RR], 0.18 [95% CI, 0.02 to 1.41]) (20). A large trial, published after the systematic review, that included 2857 critically ill patients showed no dif- ference in 28-day mortality between those given col- loids and those who received crystalloids (21). The trial found an unexpected borderline reduction in 90-day mortality among patients receiving colloids (RR, 0.92 [CI, 0.86 to 0.99])—a ﬁnding that was considered hy- pothesis generating (21). Because current evidence does not show that colloids increase survival rates com- pared with crystalloids and because colloids are more expensive, the consensus group agreed that routine use in clinical practice is not justiﬁed (19). Uncertainty also exists regarding the type of crys- talloid for use in ﬂuid resuscitation. A recent random- ized trial in 15 802 critically ill patients found a small reduction in acute kidney injury (odds ratio [OR], 0.91 [CI, 0.84 to 0.99]) and a possible small reduction in in- hospital mortality (10.3% vs. 11.1%; P = 0.08) with bal- anced crystalloids (such as Ringer lactate) vs. saline (22). Animal models have shown that early aggressive ﬂuid resuscitation to increase blood pressure to normal values may exacerbate blood loss, disrupt coagulation, and increase mortality (23, 24). The alternative is restric- tive or hypotensive resuscitation, in which ﬂuid is given but the target end point is less than normotension. A Cochrane systematic review included 6 randomized tri- als that examined timing and volume of ﬂuid adminis- tration in 2128 patients with bleeding. Trials were het- erogeneous regarding patient types, clinical settings, types of ﬂuids, and resuscitation protocols (25). None found restrictive ﬂuid resuscitation (with a delayed or smaller volume of ﬂuid) to be inferior to more aggres- sive ﬂuid resuscitation (with an early or a larger volume of ﬂuid) with regard to mortality (25). Two randomized trials published since the review also found no differ- ences in mortality between restrictive and aggressive resuscitation in patients with trauma and hemorrhagic shock (26, 27). The consensus group agreed that the evidence was insufﬁcient to make a recommendation regarding restrictive ﬂuid resuscitation. The important issue in patients with hemorrhagic shock due to trauma or UGIB is to stop the bleeding while minimizing hemo- dynamic compromise. Statement A2a For patients with acute UGIB, we suggest using a Glasgow Blatchford score of 1 or less to identify pa- tients who are at very low risk for rebleeding or mor- tality and thus may not require hospitalization or in- patient endoscopy. (GRADE: conditional recommendation, low-quality evidence) Management of Upper Gastrointestinal Bleeding CLINICAL GUIDELINE Annals.org Annals of Internal Medicine • Vol.171 No.11 • 3 December 2019 807 Downloaded from https://annals.org by Yonsei University Medical Library on 05/29/2024.",5993,910,1498.25,"[ 0.10783394 -0.16990194 -1.5456042  ...  0.15296237  0.71335876
 -1.2800391 ]"
253,"Table 1. Summary of Consensus Recommendations for the Management of UGIB* A. Resuscitation, risk assessment, and preendoscopy management A1. For patients with acute UGIB and hemodynamic instability, resuscitation should be initiated. Designated a good practice statement (see PICO question 1 in Supplement Appendix 2, available at Annals.org) A2a. For patients with acute UGIB, we suggest using a Glasgow Blatchford score of ≤1 to identify patients who are at very low risk for rebleeding or mortality and thus may not require hospitalization or inpatient endoscopy. GRADE: conditional recommendation, low-quality evidence. Vote on PICO question: yes, 76%; uncertain/neutral, 18%; no, 6% (see PICO question 2 in Supplement Appendix 2) A2b. For patients with acute UGIB, we suggest against using the AIMS65 prognostic score to identify patients who are at very low risk for rebleeding or mortality and thus may not require hospitalization or inpatient endoscopy. GRADE: conditional recommendation, low-quality evidence. Vote on PICO question: no, 100% (see PICO question 2 in Supplement Appendix 2) A3. Consider placement of a nasogastric tube in selected patients because the ﬁndings may have prognostic value.† A4. In patients with acute UGIB without underlying cardiovascular disease, we suggest giving blood transfusions for those with a hemoglobin level <80 g/L. GRADE: conditional recommendation, low-quality evidence. Vote on PICO question: yes, 75%; uncertain/neutral, 15%; no, 10% (see PICO question 3a in Supplement Appendix 2) A5. In patients with acute UGIB with underlying cardiovascular disease, we suggest giving blood transfusions at a higher hemoglobin threshold than for those without cardiovascular disease. GRADE: conditional recommendation, very low-quality evidence. Vote on PICO question: yes, 80%; uncertain/neutral, 5%; no, 15% (see PICO question 3b in Supplement Appendix 2) A6. In patients with acute UGIB receiving anticoagulants (vitamin K antagonists, DOACs), we suggest not delaying endoscopy (with or without endoscopic hemostatic therapy). GRADE: conditional recommendation, very low-quality evidence. Vote on PICO question: yes, 100% (see PICO question 4 in Supplement Appendix 2) A7. Promotility agents should not be used routinely before endoscopy to increase the diagnostic yield.‡ A8. Selected patients with acute ulcer bleeding who are at low risk for rebleeding on the basis of clinical and endoscopic criteria may be discharged promptly after endoscopy.‡ A9. Pre-endoscopic PPI therapy may be considered to downstage the endoscopic lesion and decrease the need for endoscopic intervention but should not delay endoscopy.‡ B. Endoscopic management B1. Develop institution-speciﬁc protocols for multidisciplinary management. Include access to an endoscopist trained in endoscopic hemostasis.† B2. Have support staff trained to assist in endoscopy available on an urgent basis.† B3: For patients admitted with acute UGIB, we suggest performing early endoscopy (within 24 hours of presentation). GRADE: conditional recommendation, very low-quality evidence. Vote on PICO question: yes, 100% (see PICO question 5a in Appendix 2) B4. Endoscopic hemostatic therapy is not indicated for patients with low-risk stigmata (a clean-based ulcer or a nonprotuberant pigmented dot in an ulcer bed).† B5. A ﬁnding of a clot in an ulcer bed warrants targeted irrigation in an attempt at dislodgement, with appropriate treatment of the underlying lesion.‡ B6. The role of endoscopic therapy for ulcers with adherent clots is controversial. Endoscopic therapy may be considered, although intensive PPI therapy alone may be sufﬁcient.‡ B7. Endoscopic hemostatic therapy is indicated for patients with high-risk stigmata (active bleeding or a visible vessel in an ulcer bed).† B8. Epinephrine injection alone provides suboptimal efﬁcacy and should be used in combination with another method.‡ B9. No single method of endoscopic thermal coaptive therapy is superior to another.† B10a. For patients with acutely bleeding ulcers with high-risk stigmata, we recommend endoscopic therapy with thermocoagulation or sclerosant injection. GRADE: strong recommendation, low-quality evidence. Vote on PICO question: yes, 94%; uncertain/neutral, 6% (see PICO question 6a1 in Supplement Appendix 2) B10b. For patients with acutely bleeding ulcers with high-risk stigmata, we suggest endoscopic therapy with (through-the-scope) clips. GRADE: conditional recommendation, very low-quality evidence. Vote on PICO question: yes, 94%; uncertain/neutral, 6% (see PICO question 6a2 in Supplement Appendix 2) B11a. In patients with actively bleeding ulcers, we suggest using TC-325 as a temporizing therapy to stop bleeding when conventional endoscopic therapies are not available or fail. GRADE: conditional recommendation, very low-quality evidence. Vote on PICO question: yes, 82%; uncertain/neutral, 18% (see PICO question 6b2 in Supplement Appendix 2) B11b.",4960,708,1240.0,"[ 0.46810675 -0.21150902 -1.4740599  ...  0.10086305  1.0690016
 -1.1258835 ]"
253,"In patients with actively bleeding ulcers, we suggest against using TC-325 as a single therapeutic strategy vs. conventional endoscopic therapy (clips alone, thermocoagulation alone, or combination therapy). GRADE: conditional recommendation, very low-quality evidence. Vote on PICO question: yes, 12%; uncertain/neutral, 12%; no, 76% (see PICO question 6b1 in Supplement Appendix 2) B12. Routine second-look endoscopy is not recommended.‡ B13. A second attempt at endoscopic therapy is generally recommended in cases of rebleeding.† C. Pharmacologic management C1. H2RAs are not recommended for patients with acute ulcer bleeding.† C2. Somatostatin and octreotide are not routinely recommended for patients with acute ulcer bleeding.† C3. For patients with bleeding ulcers with high-risk stigmata who have undergone successful endoscopic therapy, we recommend using PPI therapy via intravenous loading dose followed by continuous intravenous infusion (as opposed to no treatment or H2RAs). GRADE: strong recommendation, moderate-quality evidence. Vote on PICO question: yes, 100% (see PICO question 8a in Supplement Appendix 2) C4. For patients who present with ulcer bleeding at high risk for rebleeding (that is, an ulcer requiring endoscopic therapy followed by 3 days of high-dose PPI therapy), we suggest using twice-daily oral PPIs (vs. once-daily) through 14 days, followed by once daily. GRADE: conditional recommendation, very low-quality evidence. Vote on PICO question: yes, 95%; uncertain/neutral, 5% (see PICO question 10 in Supplement Appendix 2) C5. Patients should be discharged with a prescription for a single daily-dose oral PPI for a duration as dictated by the underlying cause.‡ Continued on following page CLINICAL GUIDELINE Management of Upper Gastrointestinal Bleeding 808 Annals of Internal Medicine • Vol.171 No.11 • 3 December 2019 Annals.org Downloaded from https://annals.org by Yonsei University Medical Library on 05/29/2024.",1958,277,489.5,"[ 0.06267455 -0.2081149  -1.2257478  ...  0.57103336  0.28438503
 -1.2756064 ]"
254,"No Recommendation A For patients with acute UGIB, the consensus group could not make a recommendation for or against using the preendoscopic Rockall prognostic scale to identify patients who are at very low risk for rebleeding or mor- tality and thus may not require hospitalization or inpa- tient endoscopy. (GRADE for PICO: very low-quality evidence) Statement A2b For patients with acute UGIB, we suggest against using the AIMS65 prognostic score to identify patients who are at very low risk for rebleeding or mortality and thus may not require hospitalization or inpatient endoscopy. (GRADE: conditional recommendation, low-quality evidence) Key Evidence. Evidence proﬁles for the 3 best- studied prognostic scores (Glasgow Blatchford [GBS], preendoscopic Rockall, and AIMS65) were considered separately. The QoE review focused on studies that as- sessed the use of preendoscopic scoring systems to identify patients at very low risk for undesirable out- comes. No randomized trials that directly assessed the clinical impact of using versus not using prognostic scales were identiﬁed. Therefore, the evidence was de- rived from “before–after” studies (28) and studies of di- agnostic test accuracy that assessed the surrogate out- come of diagnostic (prognostic) accuracy of the scales. A beforeafter study by Stanley and colleagues (28) assessed a strategy of not admitting emergency Table 1—Continued D. Nonendoscopic and nonpharmacologic in-hospital management D1. Patients at low risk after endoscopy can be fed within 24 hours.† D2. Most patients who have undergone endoscopic hemostasis for high-risk stigmata should be hospitalized for at least 72 hours thereafter.‡ D3. Seek surgical consultation for patients for whom endoscopic therapy has failed.† D4. Where available, percutaneous embolization can be considered as an alternative to surgery for patients for whom endoscopic therapy has failed.‡ D5. Patients with bleeding peptic ulcers should be tested for Helicobacter pylori and receive eradication therapy if it is present, with conﬁrmation of eradication.‡ D6. Negative H pylori diagnostic tests obtained in the acute setting should be repeated.‡ E. Secondary prophylaxis§ E1. In patients with previous ulcer bleeding who require an NSAID, it should be recognized that treatment with a traditional NSAID plus a PPI or COX-2 inhibitor alone is still associated with a clinically important risk for recurrent ulcer bleeding.‡ E2. In patients with previous ulcer bleeding who require an NSAID, the combination of a PPI and a COX-2 inhibitor is recommended to reduce the risk for recurrent bleeding from that of COX-2 inhibitors alone.‡ E3. In patients who receive low-dose ASA and develop acute ulcer bleeding, ASA therapy should be restarted as soon as the risk for cardiovascular complication is thought to outweigh the risk for bleeding.‡ E4. In patients with previous ulcer bleeding receiving cardiovascular prophylaxis with single- or dual-antiplatelet therapy, we suggest using PPI therapy vs. no PPI therapy. GRADE: conditional recommendation, low-quality evidence. Vote on PICO question (single): yes, 95%; uncertain/neutral: 5%. Vote on PICO question (double): yes, 100% (see PICO questions 9a and 9c in Supplement Appendix 2) E5. In patients with previous ulcer bleeding requiring continued cardiovascular prophylaxis with anticoagulant therapy (vitamin K antagonists, DOACs), we suggest using PPI therapy vs. no PPI therapy. GRADE: conditional recommendation, very low-quality evidence. Vote on PICO question: yes, 85%; uncertain/neutral, 15% (see PICO question 9b in Supplement Appendix 2) No recommendation statements No recommendation A: For patients with acute UGIB, the consensus group could not make a recommendation for or against using the preendoscopic Rockall prognostic scale to identify patients who are at very low risk for rebleeding or mortality and thus may not require hospitalization or inpatient endoscopy. GRADE: no recommendation, very low-quality evidence. Vote on PICO question: yes, 12%; uncertain/neutral, 18%; no, 71% (see PICO question 2 in Supplement Appendix 2) No recommendation B: For patients with acute UGIB at high risk for rebleeding or mortality, the consensus group could not make a recommendation for or against performing endoscopy within 12 hours vs. performing endoscopy later. GRADE: no recommendation, very low-quality evidence. Vote on PICO question: yes, 41%; uncertain/neutral, 47%; no, 12% (see PICO question 5b in Supplement Appendix 2) No recommendation C: In patients with acutely bleeding ulcers who have undergone endoscopic therapy, the consensus group could not make a recommendation for or against using DEP vs. no DEP to assess the need for further endoscopic therapy. GRADE: no recommendation, very low-quality evidence. Vote on PICO question: yes, 47%; uncertain/neutral, 41%; no, 12% (see PICO question 7 in Supplement Appendix 2) No recommendation D: For patients with bleeding ulcers with high-risk stigmata who have undergone successful endoscopic therapy, the consensus group could not make a recommendation for or against using non–high-dose PPI therapy (as opposed to no treatment or H2RAs). GRADE: no recommendation, very low-quality evidence. Vote on PICO question: yes, 24%; uncertain/neutral, 47%; no, 29% (see PICO question 8b in Supplement Appendix 2) ASA = acetylsalicylic acid; COX-2 = cyclooxygenase-2; DEP = Doppler endoscopic probe; DOAC = direct oral anticoagulant; GRADE = Grading of Recommendations Assessment, Development and Evaluation; H2RA = H2-receptor antagonist; NSAID = nonsteroidal anti-inﬂammatory drug; PICO = patient population, intervention, comparator, and outcome; PPI = proton-pump inhibitor; UGIB = upper gastrointestinal bleeding. *The strength of each recommendation was assigned by the consensus group, according to the GRADE system, as strong (“we recommend...”) or conditional (“we suggest...”) on the basis of 4 components: QoE, beneﬁt–harm balance, patients' values and preferences, and resource require- ments (18). However, when quality of evidence was low or very low, the strength of the recommendation would typically default (without a vote) to conditional, unless at least 1 of the other 3 factors was overwhelmingly strong. †Recommendation unchanged from the 2003 guidelines. See reference 3 for supporting evidence and discussions. ‡Recommendation unchanged from the 2010 guidelines. See reference 4 for supporting evidence and discussions. §Section was titled “Postdischarge, ASA, and NSAIDs” in the 2010 consensus recommendations (4). Voting threshold of ≥75 for either yes or no was not reached. Management of Upper Gastrointestinal Bleeding CLINICAL GUIDELINE Annals.org Annals of Internal Medicine • Vol.171 No.11 • 3 December 2019 809 Downloaded from https://annals.org by Yonsei University Medical Library on 05/29/2024.",6874,1004,1718.5,"[ 0.2851776  -0.34634325 -1.9770341  ...  0.32130852  1.1956502
 -0.95594037]"
255,"department patients with UGIB who were predicted to be at very low risk for undesirable outcomes (GBS of 0). This reduced the number of hospitalization, and no dif- ference was demonstrated in safety outcomes, al- though the study was not powered for safety outcomes. The relevant evidence included 2 high-quality sys- tematic reviews and meta-analyses of studies of diag- nostic test accuracy (7, 29) as well as 2 additional stud- ies notable for their quality and sample sizes (30, 31). The sensitivity of low cutoff values for detecting pa- tients at high risk for undesirable clinical outcomes was very good for the GBS (0.99) and preendoscopic Rock- all score (range, 0.93 to 0.96, but with more heteroge- neity), and lower for AIMS65 (range, 0.78 to 0.82) (Ap- pendix Table 1, available at Annals.org) (7, 29–31). For the GBS and AIMS65, the QoE was low, with the evidence being downgraded for indirectness, im- precision, and inconsistency. For the preendoscopic Rockall score, QoE was very low, with the evidence be- ing downgraded for the same reasons plus risk of bias. Discussion. Use of prognostic scales and early dis- charge of patients at low risk have the potential to re- duce the need for endoscopy, hospital stays, and asso- ciated costs without increasing harms. Sensitivity for detecting high-risk patients is a critical outcome, be- cause it is important to avoid incorrectly classifying high risk as low risk when making decisions about early dis- charge. Speciﬁcity is less crucial, because low speciﬁc- ity results in more low-risk patients being hospitalized but not in high-risk patients being discharged. Patient preferences also should be considered; some patients may prefer diagnostic certainty, whereas others may prefer not to be hospitalized. Other factors when con- sidering early discharge include urban versus rural en- vironment, access to hospital or ambulance services, access to out-of-hours endoscopy, and reimbursement issues. Whether using a prognostic scale results in better patient outcomes than using clinical judgment alone is not known. Because clinical judgment cannot be stan- dardized, the consensus group agreed that use of a prognostic scoring system would help ensure consis- tent risk assessment and communication. Education is now needed to embed a scoring tool into clinical prac- tice (such as in electronic medical records). The consensus group suggests the GBS as the pre- ferred prognostic tool because of its high sensitivity (misclassifying ≤1% of high-risk patients as low risk). The preendoscopic Rockall scale has good sensitivity, but it may misclassify 4% to 7% of high-risk patients. Given differing views regarding the threshold sensitiv- ity for discharge, the consensus group could not make a recommendation for or against use of the pre- endoscopic Rockall score. The AIMS65 was designed to be used with high cutoff values to identify patients at high risk for death (32) rather than those at low risk for safe discharge. The consensus group suggested not using AIMS65 in this setting, because even at low cutoff values approxi- mately 20% of high-risk patients may be misclassiﬁed as low risk. Statement A4 In patients with acute UGIB without underlying car- diovascular disease, we suggest giving blood transfu- sions for those with a hemoglobin level less than 80 g/L. (GRADE: conditional recommendation, low-quality evidence) Key Evidence. Evidence for a hemoglobin thresh- old for the effectiveness and safety of red blood cell transfusions was available from a summary of studies comparing restrictive (70 to 80 g/L) versus liberal (90 to 100 g/L) transfusion thresholds for patients with acute UGIB (33). In the systematic review of 5 randomized con- trolled trials in patients with UGIB (n = 1965), restrictive transfusion was associated with a lower risk for all- cause mortality (RR, 0.65 [CI, 0.45 to 0.97]) and further bleeding (RR, 0.58 [CI, 0.40 to 0.84]) (33) (Appendix Table 2, available at Annals.org). No subgroup differ- ences were found with regard to risks for myocardial infarction, stroke or transient ischemic attack, or acute kidney injury (33), or to the rate of surgical or radiologic intervention between the 2 strategies (34, 35). These data were downgraded for serious risk of bias and se- rious indirectness. However, the QoE for the superiority of the restrictive transfusion strategy is higher (less in- directness) than the QoE for speciﬁc thresholds of transfusion. Two other systematic reviews and meta-analyses that provided supportive data on patients in various clinical settings (cardiac surgery, orthopedic surgery, vascular surgery, acute blood loss or trauma, critical care, acute myocardial infarction, and hematologic can- cer) including UGIB, found no difference in 30-day mor- tality, rebleeding, cardiac events, myocardial infarction, or stroke between the 2 strategies in the combined pa- tient groups (36, 37). Discussion. The data suggest that a restrictive transfusion strategy is beneﬁcial in patients with UGIB (33) and is not associated with adverse events (36, 37). The restrictive threshold led to a decrease in the pro- portion of patients exposed to transfusions (36, 37) and in the mean number of units transfused (33). A study assessing direct and indirect costs reported that the to- tal cost per red blood cell unit in 2008 was approxi- mately $760 (38). Although cost per unit may vary greatly across institutions, a restrictive strategy is prob- ably the least expensive. Only 3 randomized trials provided mortality data in the UGIB-speciﬁc review, with 2 high-quality trials pro- viding 98.2% of the weight in the meta-analysis (33). A single-center study found reductions in mortality and rebleeding with a hemoglobin threshold of 70 g/L ver- sus 90 g/L (35), whereas a cluster randomized trial found no reduction in mortality or rebleeding with a threshold of 80 g/L versus 100 g/L (34). Although it did not look at hemoglobin thresholds, 1 trial in UGIB pa- tients with hemodynamic instability found no difference in mortality between early versus delayed blood trans- fusion; however, the study was underpowered (RR, 5.4 [CI, 0.3 to 107.1]) (39). Factors that may affect the timing of transfusions include the availability of venipuncture staff, capacity for frequent assessments, timing of blood typing, avail- CLINICAL GUIDELINE Management of Upper Gastrointestinal Bleeding 810 Annals of Internal Medicine • Vol.171 No.11 • 3 December 2019 Annals.org Downloaded from https://annals.org by Yonsei University Medical Library on 05/29/2024.",6585,1025,1646.25,"[ 0.35851645 -0.5674465  -1.8219017  ...  0.08439353  1.1637557
 -1.0347136 ]"
256,"ability of units, hemodilution factors, and degree of he- modynamic stability. In addition, some patients may have underlying, undiagnosed cardiovascular disease, potentially placing them at higher risk for negative out- comes. Therefore, the consensus group suggested that a more conservative hemoglobin threshold of 80 g/L is prudent, with a target of greater than 80 g/L. The threshold recommendation does not apply to patients with exsanguinating bleeding. In the setting of acute blood loss, hemoglobin values may initially remain un- changed from baseline because of plasma equilibrium times. In such situations, transfusion should not be dic- tated by current hemoglobin level alone but should take into account the predicted drop in hemoglobin and the patient's clinical status. Statement A5 In patients with acute UGIB and underlying cardio- vascular disease, we suggest giving blood transfusions at a higher hemoglobin threshold than for those without cardiovascular disease. (GRADE: conditional recommendation, very low- quality evidence) Key Evidence. Two meta-analyses, 1 in patients with UGIB (33) and 1 in patients with cardiovascular disease in various clinical settings (40), included an analysis of 1 randomized trial (34) that provided sub- group data on patients with and without cardiovascular disease. This small, underpowered trial (34) found no signiﬁcant difference between liberal (hemoglobin threshold, 100 g/L) and restrictive (hemoglobin thresh- old, 80 g/L) transfusion with regard to mortality (RR, 4.10 [CI, 0.86 to 19.47]) (40) or further bleeding in adults with or without ischemic heart disease (RR, 0.50 [CI, 0.23 to 1.12], and RR, 0.69 [CI, 0.13 to 3.77]) (33). This study was downgraded for serious risk of bias (lack of blinding, possible selection bias) and very serious imprecision (very small sample size). Reanalysis of the overall data from the meta- analysis of 11 trials in patients with cardiovascular dis- ease (40) found no signiﬁcant differences between the liberal (90 to 113 g/L) and restrictive (70 to 97 g/L) strategies with regard to 30-day mortality (RR, 0.87 [CI, 0.67 to 1.13]) or acute pulmonary edema (RR, 1.58 [CI, 0.55 to 4.53]) but did ﬁnd a reduced risk for cardiovas- cular events with the liberal transfusion strategy (RR, 0.56 [CI, 0.37 to 0.85]). This analysis was downgraded for serious risk of bias, very serious indirectness, and serious imprecision. Because of the variation in out- comes included in the trials as well as in the meta- analyses, several sensitivity analyses were conducted. Although the results became more imprecise, the di- rection of effect did not change. Discussion. The data suggest that a more liberal hemoglobin threshold for transfusion may be associ- ated with a lower risk for cardiovascular events in pa- tients with cardiovascular disease. This is based on data from studies in various clinical settings with heteroge- neous patient subgroups (such as those with coronary syndromes, ischemic heart disease, congestive heart failure, peripheral vascular disease, or stroke or those with only cardiovascular risk factors, such as hyperten- sion and diabetes). The effects of liberal versus restric- tive transfusion strategies may differ among various subgroups. In addition, various deﬁnitions were used for the restrictive and liberal groups, including hemo- globin levels and the presence of anemia, and hemo- globin cutoff values varied. On the basis of these limited data, the consensus group suggested that a higher hemoglobin threshold be considered in patients with cardiovascular disease than in those without it (<80 g/L; statement A4). The group did not recommend a speciﬁc cutoff, stating that a cutoff would depend on other factors, including the patient's clinical status, the type and severity of cardio- vascular disease, and the severity of bleeding. Guide- lines from NICE recommend a higher transfusion level for patients with cardiovascular disease than for those without it, whereas the AABB (formerly known as the American Association of Blood Banks) (41) recom- mends a hemoglobin threshold of 80 g/L for patients with cardiovascular disease, compared with 70 g/L for those without it. Again, this statement does not apply to patients with exsanguinating bleeding, who may re- quire more liberal transfusion. Statement A6 In patients with acute UGIB receiving anticoagu- lants (vitamin K antagonists, direct oral anticoagulants), we suggest not delaying endoscopy (with or without en- doscopic hemostatic therapy). (GRADE: conditional recommendation, very low- quality evidence) Key Evidence. No systematic reviews, randomized trials, or observational studies that speciﬁcally ad- dressed the timing of endoscopy as a primary outcome in patients receiving anticoagulants were found. A ret- rospective cohort study in patients with acute UGIB (47%) or lower gastrointestinal bleeding compared 157 patients using anticoagulants with 157 matched control participants (42). An international normalized ratio (INR) greater than 2.5 was seen in 22.9% of the patients re- ceiving anticoagulants versus 6.4% of the control par- ticipants. No statistically signiﬁcant differences were observed in rates of rebleeding (13.4% vs. 15.9%; P = 0.52) or thromboembolism (5.7% vs. 3.2%; P = 0.68) between the anticoagulant and control groups. Among the patients receiving anticoagulants, early endoscopy (<24 hours after onset) was not associated with re- bleeding (OR, 0.7 [CI, 0.3 to 1.8]), thromboembolic events (OR, 0.5 [CI, 0.1 to 2.1]), or endoscopy-related adverse events (0%). Rebleeding also was not associ- ated with an INR of 2.5 or greater (OR, 0.7 [CI, 0.2 to 2.3]). In contrast, probably because of rapid correction of INR periendoscopically (43, 44), thromboembolism was associated with an INR of 2.5 or greater (OR, 7.3 [CI, 1.5 to 35.3]) and the use of a reversal agent (OR, 4.1 [CI, 1.0 to 16.5]) (42). No differences were found in rebleeding or throm- boembolism risks between patients receiving direct oral anticoagulants (DOACs) and those receiving war- farin. However, patients using warfarin had a greater need for transfusion (4.3 ± 5.9 units vs. 2.2 ± 3.1 units; P = 0.046). Periendoscopic use of a reversal agent (vi- tamin K) was associated with a higher risk for thrombo- Management of Upper Gastrointestinal Bleeding CLINICAL GUIDELINE Annals.org Annals of Internal Medicine • Vol.171 No.11 • 3 December 2019 811 Downloaded from https://annals.org by Yonsei University Medical Library on 05/29/2024.",6535,992,1633.75,"[ 0.63119876 -0.34947038 -1.2748165  ...  0.17602116  1.0677418
 -1.0053048 ]"
257,"embolism but not rebleeding, whereas anticoagulant interruption did not affect the risk for either outcome. The results of anticoagulant use in patients with UGIB were not reported separately, but UGIB was associated with a higher rate of endoscopic therapy and transfu- sions compared with lower gastrointestinal bleeding, suggesting that the combined results may not be en- tirely generalizable to patients with UGIB (42). This study was downgraded for serious indirectness and imprecision. Discussion. For patients receiving anticoagulants, the 2010 UGIB guidelines suggested that coagulopathy be corrected but that endoscopy not be delayed (4). This recommendation was made on the basis of cohort studies suggesting that early endoscopy (≤24 hours) may be performed safely in patients using anticoagu- lants after partial correction of the INR, without an in- crease in rebleeding rates versus persons not using anticoagulants (45, 46). In the study by Nagata and col- leagues (42), anticoagulant interruption did not affect risks and no increased risk was found in patients with an INR of 2.5 or greater. The consensus group cannot specify an INR cutoff level that should prompt correc- tion of the INR. Although available new data were limited, the in- troduction of DOACs prompted the update to this rec- ommendation. Nagata and colleagues (42) found that patients receiving DOACs had less need for transfusion than those receiving warfarin. The DOACs have a short half-life—8 to 12 hours—and their anticoagulant effect resolves more rapidly than that of warfarin. Reversal agents are now available, although criteria for their use in patients with UGIB are not yet deﬁned and availabil- ity may be limited in some areas. Whether the type or extent of anticoagulation would affect the type of en- doscopic hemostatic therapy was not addressed. Other guidelines recommend administration of vi- tamin K supplemented with intravenous prothrombin complex concentrate (PCC), with use of fresh frozen plasma only if PCC is unavailable (8, 9, 47). Four-factor PCC has demonstrated efﬁcacy in correcting INR (43, 44), as have speciﬁcally targeted anticoagulant reversal agents (48, 49). Some data suggest a higher risk for thrombosis with rapid reversal of anticoagulation (42, 48), but this is beyond the scope of these guidelines. The consensus group agreed that the degree of coagulopathy should be assessed objectively before therapeutic decisions are made. The anticoagulant agent, patient physiology, and patient compliance with therapy may affect anticoagulation. Because of the rec- ognized beneﬁts of early endoscopy (statement B3), coagulopathy should be treated as necessary but en- doscopy should not be delayed. Section B: Endoscopic Management Statement B3 For patients admitted with acute UGIB, we sug- gest performing early endoscopy (within 24 hours of presentation). (GRADE: conditional recommendation, very low- quality evidence) Key Evidence. Evidence for early endoscopy was assessed separately for patients at low and high risk for unfavorable outcomes (death, rebleeding) (Supple- ment Appendix 2). Low-risk patients: Two systematic reviews (4, 50) in- cluding 3 randomized trials (51–53) assessed the timing of endoscopy in patients with UGIB. Two of the trials included low-risk patients randomly assigned to early versus later endoscopy (within 1 to 2 hours vs. 1 to 2 days [52], or within 6 hours vs. 48 hours [53]). No dif- ferences in mortality or rebleeding were found be- tween groups in either trial (52, 53), but 1 study found that early endoscopy reduced length of stay and cost of care (52). The QoE was downgraded for serious risk of bias, indirectness, and very serious imprecision. Observational studies were seriously confounded by severity of bleeding and comorbidity, which may bias the results in favor or against early endoscopy. Three retrospective cohort studies included exclusively or separately reported data on low-risk patients and adjusted for confounders (54–56). In 1 study, urgent endoscopy was a predictor of negative outcomes (com- posite of death; rebleeding; and surgical, radiologic, or endoscopic intervention) among low-risk patients with UGIB (adjusted OR, 0.71 per 6 hours [CI, 0.55 to 0.91]) (54). The deﬁnition of low risk in this study was a GBS less than 12, instead of the more common GBS of 2 or less. In another study using the same criterion, time to endoscopy was not associated with in-hospital mortal- ity (55). In the largest study, among low-risk patients endoscopy within 24 hours was associated with lower in-hospital mortality (OR, 0.48 [CI, 0.24 to 0.97]), but not rebleeding, compared with later endoscopy (56). The QoE was downgraded for serious risk of bias and indirectness. High-risk patients: See text under “No Recommen- dation B.” Discussion. Safety concerns regarding early en- doscopy, including the potential for inadequate resus- citation before the procedure and the need to perform endoscopy during off-hours when fewer endoscopy re- sources are available, must be weighed against the po- tential for worse outcomes due to ongoing bleeding. Because such concerns are less of an issue in low-risk patients than in high-risk ones, the decision to perform early endoscopy in those at low risk is driven mainly by cost and length of stay. The 2010 UGIB guidelines recommended early en- doscopy (within 24 hours of presentation) for most pa- tients with acute UGIB (4). This recommendation was based on data suggesting that early endoscopy al- lowed for safe discharge of low-risk patients, improved outcomes for high-risk patients, and reduced resource use (4). Although the data were very low quality, they sup- port the conclusion that for low-risk patients, early en- doscopy may be performed safely and can reduce re- source use. To reduce hospitalization and costs, the endoscopist's recommendations for early discharge of low-risk patients must be embraced by the attending physician. In the trial in which early endoscopy did not reduce resource use, only 21% of eligible patients were discharged early (53). Early endoscopy may also yield CLINICAL GUIDELINE Management of Upper Gastrointestinal Bleeding 812 Annals of Internal Medicine • Vol.171 No.",6246,962,1561.5,"[ 0.21057624 -0.8106166  -1.7316172  ...  0.35003945  0.90555906
 -1.1657099 ]"
258,"more high-risk endoscopic stigmata that would have resolved spontaneously (52, 53), which may offset ben- eﬁts in terms of hospitalization. Availability of endoscopy resources is an important consideration. A meta-analysis of 20 cohort studies found that patients with UGIB hospitalized during off- hours were less likely to undergo endoscopy within 24 hours and had higher mortality rates (57). This was not the case in hospitals with formal out-of-hours endos- copy services. On the basis of the available data, the consensus group suggested that endoscopy be performed within 24 hours of presentation, both for low- and high-risk patients. For high-risk patients, see the discussion under “No Recommendation B.” No Recommendation B For patients with acute UGIB at high risk for re- bleeding or mortality, the consensus group could not make a recommendation for or against performing en- doscopy within 12 hours versus performing endoscopy later. (GRADE for PICO: very low-quality evidence) Key Evidence. No randomized trial assessed the timing of endoscopy speciﬁcally in high-risk patients with UGIB. One trial in patients with peptic ulcer bleed- ing, including a high proportion of high-risk patients (44% with shock), found no difference in mortality with endoscopy before or after 12 hours (Appendix Table 3, available at Annals.org) (51). The QoE was down- graded for serious risk of bias and indirectness, and very serious imprecision. Seven observational studies in high-risk patients with UGIB were assessed (54–56, 58–61); however, only 2 provided adjusted results for mortality (Appen- dix Table 3) (56, 58). One study found a reduction in mortality with very early endoscopy (<6 hours) com- pared with later endoscopy (>6 to ≤48 hours) (58). A large cohort study suggested that among hemodynam- ically unstable patients, very early endoscopy (≤6 hours) may increase mortality risk, whereas early en- doscopy between 6 and 24 hours may reduce mortality risk compared with endoscopy outside that time frame (56). These data were downgraded for serious risk of bias, inconsistency, and imprecision. Unadjusted results from observational studies were not considered for this guideline. Such results conﬂict and are difﬁcult to interpret, because the effects of the confounders are bidirectional. More severe bleeding or comorbid conditions are associated with worse out- comes and present a clear bias toward more rapid en- doscopy; however, if the severity is too great, then en- doscopy might be delayed. Discussion. Statement B3 recommends endoscopy within 24 hours for patients with UGIB. Whether high- risk patients would beneﬁt from very early endoscopy (within 12 hours) remains unanswered. Although active bleeding is associated with a poor prognosis, patients who are hemodynamically unstable may have more ad- verse outcomes during endoscopy. Therefore, very early endoscopy may be associated with a paradoxical negative effect in high-risk patients (56). Because of conﬂicting data, widely variable patient populations (such as those differing in age, bleeding severity, comorbid conditions, or hemodynamic insta- bility), and the potential for harm, the consensus group concluded that insufﬁcient data exist to recommend for or against endoscopy more urgently than the 24-hour window in high-risk patients. Practitioners are re- minded that for patients with suspected variceal bleed- ing, existing recommendations suggest endoscopy within 12 hours of presentation (62, 63). Statement B10a For patients with acutely bleeding ulcers with high- risk stigmata, we recommend endoscopic therapy with thermocoagulation or sclerosant injection. (GRADE: strong recommendation, low-quality evidence) Statement B10b For patients with acutely bleeding ulcers with high- risk stigmata, we suggest endoscopic therapy with (through-the-scope) clips. (GRADE: conditional recommendation, very low- quality evidence) Key Evidence. Systematic reviews and meta-analyses have assessed the role of endoscopic therapy in pa- tients with UGIB (64–67). One review looked only at epinephrine injection alone and in combination (66), whereas another was suboptimally reported (67). For this guideline, the evidence was derived mainly from the 2009 reviews by Laine and McQuaid (64) and Barkun and colleagues (65), which were updated via new literature searches from 2006 to 2018. For the comparison of endoscopic treatment with no endo- scopic treatment, no new randomized trials were found; therefore, these analyses remain unchanged (64, 65). Compared with pharmacotherapy or no treatment, thermocoagulation (heater probe or bipolar electroco- agulation) or sclerosant injection reduced mortality and rebleeding (64, 65). No randomized trials were found comparing hemoclips with no treatment. The QoE was downgraded for risk of bias (mainly lack of blinding). The QoE for efﬁcacy was moderate for all therapies combined and for sclerosant injection; QoE was low for thermocoagulation and was down- graded further for imprecision. For comparisons of various active treatments, the meta-analysis by Barkun and colleagues (65) was up- dated with 3 new trials (68–70) (Supplement Appendix 2). No differences were found for mortality or rebleed- ing in comparisons of thermocoagulation, sclerosant in- jection, hemoclips, and combination therapies (64, 65). Meta-analysis of data from 2 trials showed that hemo- clips were superior to epinephrine injection alone with regard to rebleeding (RR, 0.17 [CI, 0.05 to 0.55]) but not mortality (RR, 2.15 [CI, 0.59 to 7.78]) (68, 71). Discussion. Endoscopic hemostatic therapy has been well documented to improve outcomes. The con- Management of Upper Gastrointestinal Bleeding CLINICAL GUIDELINE Annals.org Annals of Internal Medicine • Vol.171 No.11 • 3 December 2019 813 Downloaded from https://annals.org by Yonsei University Medical Library on 05/29/2024.",5896,864,1474.0,"[ 0.11008881 -0.60729563 -1.6374822  ...  0.5406138   0.82616276
 -0.9218466 ]"
259,"sensus group agreed with the prior statements that en- doscopic therapy is indicated in patients with high-risk stigmata (active bleeding, visible vessel) and may be considered in patients with an adherent clot (state- ments B6 and B7). Debate continues with regard to the optimal method. Sclerosant therapy is used less com- monly in clinical practice but remains a viable option. Lack of routine PPI therapy and the constantly changing prevalence of Helicobacter pylori may affect the results of older studies. The group chose not to address other endoscopic mechanical techniques, such as over-the- scope clips. On the basis of the available data, a strong recom- mendation was made for thermocoagulation or sclero- sant injections, whereas hemoclips were suggested (conditional recommendation). However, the data gen- erally have failed to show superiority of any one method, and each may be useful depending on loca- tion of the bleeding source and patient characteristics. Statement B11a In patients with actively bleeding ulcers, we suggest using TC-325 as a temporizing therapy to stop bleeding when conventional endoscopic therapies are not avail- able or fail. (GRADE: conditional recommendation, very low- quality evidence) Statement B11b In patients with actively bleeding ulcers, we suggest against using TC-325 as a single therapeutic strategy versus conventional endoscopic therapy (clips alone, thermocoagulation alone, or combination therapy). (GRADE: conditional recommendation, very low- quality evidence) Key Evidence. Evidence for the efﬁcacy of TC-325 (hemostatic powder spray) was available from 1 small underpowered trial (72) and from observational studies (73, 74). The trial randomly assigned 20 patients and found no statistically signiﬁcant differences in initial he- mostasis (90% vs. 100%) or rebleeding (33% vs. 10%) with TC-325 monotherapy versus a conventional com- bination endoscopic technique (epinephrine injection with either hemoclip or heater probe application) (72). Among 8 patients with actively bleeding (spurting or oozing) ulcers, 4 of 5 in the TC-325 group had success- ful initial hemostasis, but 3 had rebleeding. In contrast, all 3 in the conventional treatment group achieved ini- tial hemostasis and none had rebleeding. A systematic review of observational data found an immediate hemostasis rate of 90% but very high re- bleeding rates (72-hour, 19%; 7-day, 22%) among 86 patients with ulcer bleeds treated with TC-325 (73). Re- bleeding rates (72-hour and 7-day) were highest among patients with active bleeding (spurting, 40% and 60%; oozing, 13% and 16%). Another large pro- spective cohort study included 202 patients with bleed- ing treated with TC-325; the rate of initial hemostasis was 97%, with day 8 and day 30 rebleeding rates of 27% and 34%, respectively (74). Evidence was downgraded for serious risk of bias (lack of blinding) and very serious imprecision (small sample sizes and low total number of events). Discussion. The success of TC-325 hemostatic powder spray seems to depend on the cause of bleed- ing and whether the powder is used alone or in com- bination with other hemostatic therapy. The powder adheres only to actively bleeding lesions (73), its resi- dency time is 24 hours or less (75), and it does not induce tissue healing (73). TC-325 use in UGIB is associated with a low com- plication rate, although rare cases of perforation and transient biliary obstruction have been reported (73, 76). Additional experience is needed to deﬁne the safety proﬁle more clearly. Decision modeling suggests that a strategy of con- ventional therapy followed by TC-325 improved the ef- fectiveness and was less costly compared with conven- tional therapy alone or TC-325 alone in most patient populations with nonvariceal UGIB (77). TC-325 fol- lowed by conventional therapy was the most effective strategy for nonulcer high-risk bleeding lesions at low risk for delayed rebleeding. On the basis of TC-325's mechanism of action and the clinical evidence, the consensus group concluded that TC-325 monotherapy may not adequately treat ul- cers with high-risk stigmata, but may be useful as a tem- porary measure to stop bleeding, and that second-look endoscopy or a second hemostatic technique should be used. No Recommendation C In patients with acutely bleeding ulcers who have undergone endoscopic therapy, the consensus group could not make a recommendation for or against Doppler endoscopic probe (DEP) versus no DEP to as- sess the need for further endoscopic therapy. (GRADE for PICO: very low-quality evidence) Key Evidence. Two randomized trials compared DEP-guided versus conventional endoscopic treatment in patients with acute UGIB (78, 79). In a 1997 study by Kohler and colleagues (78), all patients had peptic ulcer bleeding, but actively bleeding lesions were excluded. Endoscopic treatment was directed by Doppler ﬁnd- ings, injection therapy alone was used, and second- look endoscopy was performed for all patients. In a 2017 study by Jensen and colleagues (79), most of the 148 patients with severe nonvariceal UGIB (85%) had peptic ulcer bleeding (active bleeding, visible vessel, adherent clot, or ﬂat spot). A meta-analysis of these 2 studies (78, 79) was performed for this guideline (Sup- plement Appendix 2). However, at the face-to-face meeting, it was decided to focus the evidence proﬁles on the trial by Jensen and colleagues, which reported data for patients with high-risk lesions (active bleeding, visible vessel) or adherent clot. Data for patients with low-risk lesions (ﬂat spot) were considered indirect, be- cause these lesions are not routinely subjected to en- doscopic therapy. In Jensen and colleagues' study (79), DEP reduced rebleeding for all lesions (RR, 0.42 [CI, 0.20 to 0.90]) but not for high-risk lesions (RR, 0.50 [CI, 0.24 to 1.08]). Overall, the QoE was downgraded for risk of bias, indirectness (population and intervention), and impre- cision (moderate sample size). CLINICAL GUIDELINE Management of Upper Gastrointestinal Bleeding 814 Annals of Internal Medicine • Vol.171 No.11 • 3 December 2019 Annals.org Downloaded from https://annals.org by Yonsei University Medical Library on 05/29/2024.",6222,949,1555.5,"[-0.3085444  -0.15439737 -1.4316032  ...  0.47903115  0.49339485
 -1.515672  ]"
260,"Discussion. More studies are needed to determine whether DEP would be useful to guide endoscopic treatment decisions before or after initial therapy or in both settings. One study found only 58% agreement between DEP and ﬁndings at index endoscopy (78). Used to determine the need for additional therapy, DEP would be an add-on test with conventional endo- scopic treatment for high-risk lesions, which would add cost related to the DEP technology. A cost-minimization analysis found that DEP-directed combination endo- scopic therapy was cost-effective compared with com- bination therapy only for the management of high-risk patients (80). The consensus group concluded that data suggest- ing efﬁcacy for DEP is very limited and that lack of avail- ability and expertise in many centers affects feasibility. The group generally agreed that although making a recommendation for or against DEP to manage UGIB is premature, it has the potential to alter the usual ap- proach to visually assessing bleeding lesion risk when evaluating the need for, and adequacy of, endoscopic hemostasis. Section C: Pharmacologic Management Statement C3 For patients with bleeding ulcers with high-risk stigmata who have undergone successful endoscopic therapy, we recommend using PPI therapy via intra- venous loading dose followed by continuous intrave- nous infusion (as opposed to no treatment or H2- receptor antagonists). (GRADE: strong recommendation, moderate-quality ev- idence) No Recommendation D For patients with bleeding ulcers with high-risk stigmata who have undergone successful endoscopic therapy, the consensus group could not make a rec- ommendation for or against non–high-dose PPI ther- apy (as opposed to no treatment or H2-receptor antagonists). (GRADE for PICO: very low-quality evidence) Key Evidence. Two Cochrane reviews on PPIs in UGIB were updated for this guideline (81, 82). The ﬁrst (81), which included 24 trials comparing PPIs with pla- cebo or H2-receptor antagonists (H2RAs), was updated with an additional 14 randomized trials. Of these, 12 included data on patients with high-risk stigmata (active bleeding, visible vessel) or adherent clot who had un- dergone appropriate endoscopic therapy. There was moderate QoE that PPI therapy versus no PPIs or H2RAs reduced mortality risk (OR, 0.56 [CI, 0.34 to 0.94]) and high QoE that it reduced rebleeding risk (OR, 0.43 [CI, 0.29 to 0.63]) (Table 2). The evidence for mortality was downgraded because of serious risk of bias (mainly lack of blinding in some trials). The second meta-analysis (82), which included 22 trials comparing various PPI regimens, was updated with an additional 18 trials. Of these, 25 compared high-dose PPIs (deﬁned as an 80-mg intravenous bolus followed by 72 hours of an 8-mg/h continuous intrave- nous infusion) with non–high-dose PPIs, and 17 in- cluded data on patients with high-risk stigmata or adherent clots who had undergone endoscopic treatment. No differences were found in the risk for mortality or rebleeding between high-dose and non– high-dose PPIs (low and moderate QoE) or between high-dose and oral PPIs (very low and low QoE) (Table 2). Indirect comparisons between high-dose PPIs and no treatment or H2RAs and between non–high-dose PPIs and no treatment or H2RAs yielded very low QoE for the superiority of high-dose PPI therapy (update of [81]). Moderate QoE supported the superiority of non–high-dose PPIs versus no PPIs for the outcome of rebleeding, but the QoE for mortality was low. The evidence was downgraded, mainly because of impreci- sion and risk of bias for some comparisons. Adverse effects were poorly reported in most of the studies. Overall, no consistent signal of a difference was found between PPI therapy and placebo or H2RAs, between high-dose and non–high-dose PPIs, or be- tween intravenous and oral PPI therapy. The exception was an increased risk for thrombophlebitis with PPIs administered intravenously versus orally. Discussion. High-dose PPI therapy (that is, an 80-mg intravenous bolus followed by 72 hours of 8-mg/h continuous intravenous infusion) reduces re- bleeding and mortality. Because non–high-dose ther- apy has been associated with a reduction in rebleeding Table 2. Pooled ORs and Absolute Risks of Unfavorable Outcomes, According to PPI Regimen, in Patients with High-Risk Stigmata Who Had Endoscopic Therapy Studies Active Treatment, n/N (%) Control, n/N (%) OR (95% CI)* Absolute Effect, per 1000 Persons (95% CI) PPIs vs. placebo or H2RAs Deaths: 1 SR and MA (update of reference 81); 10 RCTs 24/1202 (2.0) 43/1220 (3.5) 0.56 (0.34 to 0.94) −15 (−23 to −2) Rebleeds: 1 SR and MA (update of reference 81); 12 RCTs 88/1269 (6.9) 169/1277 (13.2) 0.43 (0.29 to 0.63) −71 (−90 to −45) High-dose vs. non–high-dose PPIs Deaths: 1 SR and MA (update of reference 82); 15 RCTs 28/1042 (2.7) 27/1027 (2.6) 1.02 (0.59 to 1.76) 1 (−11 to +20) Rebleeds: 1 SR and MA (update of reference 82); 17 RCTs 126/1175 (10.7) 107/1191 (9.0) 1.25 (0.93 to 1.66) 20 (−6 to +51) High-dose vs. oral PPIs Deaths: 1 SR and MA (update of reference 81); 3 RCTs 0/117 (0) 2/116 (1.7) 0.31 (0.04 to 2.93) −12 (−17 to +33) Rebleeds: 1 SR and MA (update of reference 81); 4 RCTs 16/235 (6.8) 15/242 (6.2) 1.09 (0.54 to 2.17) 6 (−29 to +72) OR = odds ratio; H2RA = H2-receptor antagonist; MA = meta-analysis; PPI = proton-pump inhibitor; RCT = randomized controlled trial; SR = systematic review. *Boldface signiﬁes statistically signiﬁcant results. Management of Upper Gastrointestinal Bleeding CLINICAL GUIDELINE Annals.org Annals of Internal Medicine • Vol.171 No.11 • 3 December 2019 815 Downloaded from https://annals.org by Yonsei University Medical Library on 05/29/2024.",5701,894,1425.25,"[ 0.4160902  -0.35603425 -1.3697128  ...  0.48573035  0.5997513
 -1.4024762 ]"
261,"but not mortality compared with no PPI therapy, a ma- jority of the consensus group did not vote to recom- mend non–high-dose PPI therapy. The consensus group is not conﬁdent that the precision of the esti- mates of absolute differences between high- and non– high-dose PPI therapy regarding mortality and rebleed- ing is sufﬁcient to consider the 2 therapies equivalent. Studies of non–high-dose PPI therapy are complicated by different dosing regimens and methods of adminis- tration, including continuous intravenous infusion, in- travenous bolus, and oral regimens. Cost-effectiveness studies have suggested that high-dose intravenous PPIs after successful endoscopic hemostasis improve outcomes at a modest cost in- crease relative to non–high-dose intravenous or oral PPI strategies (83–86). In addition, the incremental costs of different PPI regimens (continuous or intermit- tent, before or after endoscopic therapy) are modest compared with total per-patient costs. The consensus group concluded that the evidence supports a strong recommendation for high-dose PPIs for patients with bleeding ulcers with high-risk stigmata (active bleeding or visible vessel) who have had suc- cessful endoscopic therapy. The recommendation for patients with adherent clots remains unchanged (state- ment B6) and includes endoscopic therapy or consid- eration of PPI therapy alone (Table 1). Given the dem- onstrated beneﬁts on rebleeding outcomes and that the costs and availability of intravenous formulations may be issues in some areas, the consensus group also did not make a recommendation against using lower PPI doses. Statement C4 For patients who present with ulcer bleeding at high risk for rebleeding (that is, an ulcer requiring en- doscopic therapy followed by 3 days of high-dose PPI therapy), we suggest using twice-daily oral PPIs (vs. once daily) through 14 days, followed by once daily. (GRADE: conditional recommendation, very low- quality evidence) Key Evidence. One trial enrolled patients at high- risk for rebleeding (Rockall scores ≥6) who had under- gone successful endoscopic therapy and received 3 days of high-dose PPI therapy (intravenous esomepra- zole, 80-mg loading dose followed by 8-mg/h continu- ous infusion) (87). Patients were randomly assigned to receive oral esomeprazole, 40 mg, either once or twice daily for 11 days (days 3 to 14). All patients received an additional 2 weeks of once-daily PPI therapy. A reduc- tion was found in rebleeding (RR, 0.37 [CI, 0.19 to 0.73]) but not mortality rates (RR, 0.38 [CI, 0.10 to 1.38]) with twice- versus once-daily PPIs. The QoE was down- graded for risk of bias and imprecision. Discussion. Based on the data suggesting superi- ority over the standard dosage for rebleeding, the con- sensus group suggested the use of twice-daily PPIs to complete 2 weeks of PPI therapy, after 3 days of high- dose therapy. Section D: Nonendoscopic and Nonpharmacologic In-Hospital Management No updates to the 2010 international UGIB guide- lines (4). Section E: Secondary Prophylaxis Statement E4 In patients with previous ulcer bleeding receiving cardiovascular prophylaxis with single- or dual- antiplatelet therapy, we suggest using PPI therapy ver- sus no PPI therapy. (GRADE: conditional recommendation, low-quality evidence) Key Evidence. Single-antiplatelet therapy: Evidence for the role of PPI therapy in patients receiving single- agent antiplatelet therapy was available from 5 ran- domized trials (88–92) comparing PPIs versus no PPIs in patients requiring continued antiplatelet therapy. Be- cause of heterogeneity in study designs and compari- son groups, a meta-analysis of all 5 studies was not done. All 5 trials were conducted in Hong Kong. A his- tory of H pylori infection and eradication treatment was common. One trial found PPIs to be more effective than pla- cebo in reducing recurrent complications (bleeding, perforation, and obstruction) (RR, 0.11 [CI, 0.01 to 0.84]) in patients with previous ulcer complications who had successful H pylori eradication and required con- tinued antiplatelet therapy (acetylsalicylic acid [ASA]) (88). A meta-analysis of 2 trials showed that PPIs plus ASA reduced rebleeding rates versus clopidogrel alone (RR, 0.07 [CI, 0.01 to 0.34]) in patients with pre- vious ASA-associated ulcer bleeding who did not have H pylori infection or who had it successfully eradicated (90, 91). In patients with previous ASA-associated ulcer bleeding, trials found no difference between PPIs and eradication treatment in those with H pylori infection (89), or between PPIs and H2RAs in patients without H pylori infection or those in whom H pylori infection was eradicated (92). Two trials found no differences in mor- tality rates between PPI and placebo groups (88) or be- tween PPIs plus ASA versus clopidogrel (89). The evidence was downgraded, primarily for very serious imprecision (small studies, very low number of events). Dual-antiplatelet therapy (DAPT): No randomized trials were found assessing the use of PPIs in patients receiving DAPT who had a history of ulcer bleeding. Two systematic reviews were found in patients receiv- ing DAPT after percutaneous coronary intervention or in the presence of coronary artery disease (93, 94). The reporting and methodological quality of both reviews were suboptimal, with inclusion of studies that were not eligible (for example, because of patients not receiving DAPT, incorrect comparisons, or double counting). A meta-analysis conducted for this guideline included 4 randomized trials (n = 4805) comparing PPI versus no PPI therapy in patients receiving prophylactic DAPT (ASA and clopidogrel). The largest study was interna- tional (95), whereas the other 3 were conducted in China (96–98). The meta-analysis showed a reduction in gastrointestinal bleeding risk with PPI therapy versus placebo (n = 4 studies; RR, 0.25 [CI, 0.14 to 0.45]) and CLINICAL GUIDELINE Management of Upper Gastrointestinal Bleeding 816 Annals of Internal Medicine • Vol.171 No.11 • 3 December 2019 Annals.org Downloaded from https://annals.org by Yonsei University Medical Library on 05/29/2024.",6137,924,1534.25,"[ 0.03006919 -0.03910893 -1.3996753  ...  0.57322514  0.5066303
 -1.1964338 ]"
262,"no effects on mortality (n = 3 studies; RR, 1.02 [CI, 0.68 to 1.54]) or myocardial infarction risk (n = 2 studies; RR, 0.96 [CI, 0.51 to 1.81]). No studies were found that assessed ASA in com- bination with other antiplatelet drugs, such as prasug- rel or ticagrelor. The evidence was downgraded for high or unclear risk of bias in the Chinese studies and for serious indirectness in all 4 trials (most patients did not have a history of ulcer bleeding). Discussion. The evidence consistently supports a beneﬁt with PPI therapy in patients with previous ulcer bleeding who continue single- or dual-antiplatelet ther- apy and suggest that PPI therapy is superior to clopi- dogrel alone in patients receiving ASA. Most patients in these studies had H pylori infection before PPI therapy, and in 1 study eradication treat- ment alone was as effective as PPI therapy (89). Obser- vational data suggest that ulcer rebleeding risk in pa- tients receiving low-dose ASA may be reduced among those who had H pylori infection eradicated compared with those who were never infected (99). It is antici- pated that PPI therapy should be beneﬁcial in popula- tions with lower rates of H pylori infection, although the magnitude of effect may be decreased. The consensus group suggested that eradication therapy alone may be sufﬁcient to reduce bleeding risk for some patients with H pylori infection, with only incremental beneﬁts associated with additional PPI therapy. Although various adverse events have been re- ported with PPI therapy (statement E5), the systematic review and meta-analysis conducted for this guideline found no increased risk for myocardial infarction in pa- tients receiving DAPT. On the basis of the evidence, the consensus group suggests PPI therapy to prevent rebleeding in most pa- tients who require single- or dual-antiplatelet therapy for a duration consistent with the ongoing need for an- tiplatelet therapy. Statement E5 In patients with previous ulcer bleeding requiring continued cardiovascular prophylaxis with anticoagu- lant therapy (vitamin K antagonists, DOACs), we sug- gest using PPI therapy versus no PPI therapy. (GRADE: conditional recommendation, very low- quality evidence) Key Evidence. Compared with no PPI therapy, the use of PPIs in patients receiving anticoagulant therapy was associated with a reduced risk for rebleeding in 2 large cohort studies (100, 101) but not in 3 case– control studies (102–104). Most patients included in these studies did not have a history of ulcer bleeding. In 1 small case–control study in patients with a history of UGIB, rebleeding risk was not signiﬁcantly reduced in patients receiving warfarin plus PPIs (RR, 1.93 [CI, 0.23 to 16.28]) compared with those not receiving war- farin (103). In contrast, in 1 of the cohort studies the greatest risk reduction with PPI therapy versus no PPI therapy was seen in patients with a history of peptic ulcers or gastrointestinal bleeding (adjusted incidence rate ratio, 0.14 [CI, 0.06 to 0.30]) (101). None of the included studies assessed mortality. The evidence was downgraded for indirectness (most patients did not have previous ulcer bleeding). Discussion. A history of ulcer bleeding is associ- ated with an increased risk for bleeding, and although anticoagulants do not cause ulcer bleeding, they in- crease the risk for bleeding from sites that have muco- sal breaks. Meta-analyses of primarily observational studies have suggested potential associations between PPI therapy and adverse effects, including community- acquired pneumonia, hip fracture, colorectal cancer, chronic kidney disease, community-acquired enteric in- fection, and Clostridium difﬁcile infection (105–109). An analysis of factors, such as consistency, speciﬁcity, tem- porality, and biological plausibility, as well as con- founding factors, showed that the evidence for causal- ity is very weak (110). The consensus group concluded that for high-risk patients with an ongoing need for an- ticoagulants, the evidence suggests that the beneﬁts of secondary prophylaxis outweigh the risks. The un- proven potential and rare safety concerns should not prevent treatment for patients at risk for life-threatening consequences. ONGOING AND RESEARCH RECOMMENDATIONS Although UGIB management has improved sub- stantially during the past 2 decades, areas remain in which more data are needed (Appendix Table 4, avail- able at Annals.org). In particular, more studies are needed to deﬁne the beneﬁts of speciﬁc prognostic scales, the role of a restrictive versus liberal transfusion practice in patients with UGIB and cardiovascular dis- ease, optimal PPI regimens, optimal endoscopic hemo- static therapies, and the role of PPIs in patients receiv- ing antithrombotic therapy. Planned analyses from the COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) trial may clarify the efﬁcacy and safety of PPIs versus no PPIs in patients receiving anticoagulant therapy (111). Several pertinent articles that were not available at the time of this consensus have been published since the literature searches were completed (as of May 2018). These include a large randomized trial in pa- tients with cardiovascular disease that compared the efﬁcacy and safety of DOACs or ASA with or without PPI therapy (112, 113). Randomized trials have assessed PPIs versus H2RAs for recurrent UGIB (114), as well as endoscopic therapy with hemostatic powder and he- moclips (115, 116). In addition, the use of DEP to guide hemostasis has been studied further (117). Although a discussion of over-the-scope clips for recurrent peptic ulcer bleeding is beyond the scope of the statements addressed in this guideline, data are emerging (118). These are just some examples of new or ongoing stud- ies that have the potential to affect clinical practice, but they may not do so. The consensus group cannot com- ment on the results of these trials, because a systematic Management of Upper Gastrointestinal Bleeding CLINICAL GUIDELINE Annals.org Annals of Internal Medicine • Vol.171 No.11 • 3 December 2019 817 Downloaded from https://annals.org by Yonsei University Medical Library on 05/29/2024.",6185,948,1546.25,"[ 0.36313653 -0.06116703 -1.5449148  ...  0.6283978   0.6959236
 -1.500062  ]"
263,"literature search was not performed and the GRADE approach was not applied. APPLICABILITY AND IMPLEMENTATION ISSUES Plans are under way to develop a user-friendly clin- ical algorithm for UGIB management, slide presenta- tions, short videos, and CAG podcasts. The guidelines and supporting materials will be disseminated to all participating societies and regions through such ven- ues as symposia sessions or workshops at society meet- ings. Major recommendations will be posted on society and government health Web sites. Finally, we antici- pate that these guidelines will continue to be updated as new data become available. From McGill University, Montreal, Quebec, Canada (A. N. B.); McGill University, Montreal, Quebec, Canada, and King Saud University, Riyadh, Saudi Arabia (M. A.); Erasmus University Medical Center, Rotterdam, the Netherlands (E. J. K.); Yale School of Medicine, New Haven, Connecticut, and VA Con- necticut Healthcare System, West Haven, Connecticut (L. L.); Chinese University of Hong Kong, Hong Kong SAR (J. S., F. K. C., J. L.); McMaster University, Hamilton, Ontario, Canada (F. T., G. I. L., J. D., J. K. M.); Mayo Clinic, Scottsdale, Arizona (N. S. A.); Hospital Parc Taulı´ de Sabadell, University of Barce- lona, Sabadell, Spain, and CiberEHD (Instituto de Salud Car- los III), Madrid, Spain (X. C.); St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada (R. E.); Technion-Israel Institute of Technology, Emek Medical Center, Afula, Israel (I. M. G.); Western University, London, Ontario, Canada (V. J.); University of California, Los Angeles, Los Angeles, California (D. J.); University of Liverpool and Liverpool Heart and Chest Hospital, Liverpool, United Kingdom, and Aalborg Univer- sity, Aalborg, Denmark (G. Y. L.); Dijon-Bourgogne University Hospital, Dijon, France (R. L., M. B.); University of Sa˜o Paulo, Sa˜o Paulo, Brazil (F. M.); George Washington University, Washington, DC (A. C. M.); Asian Institute of Gastroenterology, Hyderabad, In- dia (N. R.); and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts (J. R. S.). Note: This clinical practice guideline (CPG) on UGIB was de- veloped under the direction of Drs. Alan N. Barkun and Marc Bardou, in accordance with the policies and procedures of the CAG and under the direction of CAG Clinical Affairs. It has been reviewed by the CAG Clinical Affairs Committee and the CAG Board of Directors. The CPG was developed after a thor- ough consideration of the medical literature and the best available evidence and clinical experience. It represents the consensus of a Canadian and international panel comprising experts on this topic. The CPG aims to provide a reasonable and practical approach to care for specialists and allied health professionals who are charged with providing optimal care to patients and their families, and it may be subject to change as scientiﬁc knowledge and technology advance and as practice patterns evolve. Disclaimer: The CPG is not intended as a substitute for physi- cians using their individual judgment in managing clinical care in consultation with the patient, with appropriate regard to all the individual circumstances of the patient, the diagnos- tic and treatment options available, and the available re- sources. Adherence to these recommendations will not nec- essarily produce successful outcomes in every case. Acknowledgment: The CAG thanks the Canadian Institutes of Health Research (CIHR) Institute of Nutrition, Metabolism and Diabetes and the Saudi Gastroenterology Association for their generous support of the guideline process. The consensus group thanks Dr. Waleed Alhazzani (McMaster University) for participation in the development of PICO questions and in preliminary discussions and voting; Paul Sinclair, Cindy Roll, and Lesley Marshall (CAG representatives) for administrative and technical support and logistical assistance; and Pauline Lavigne and Steven Portelance for editorial assistance and medical writing services (supported by funds from the CAG). Financial Support: By an unrestricted grant to the CAG by the CIHR Institute of Nutrition, Metabolism and Diabetes and the Saudi Gastroenterology Association. Disclosures: Dr. Barkun reports grants and consulting fees from and advisory board membership at Pendopharm and At- Gen, and advisory membership at Olympus and Cook, outside the submitted work. Dr. Chan reports grants from the Research Grant Council of Hong Kong during the conduct of the study and advisory board membership at Pﬁzer, AstraZeneca, the Rome Foundation, Antibe Therapeutics, and the AGA Council; personal fees and honoraria from Pﬁzer, AstraZeneca, Eisai, Takeda Pharmaceuticals, EA Pharma, Japan Gastroenterological Endoscopy Society, Takeda (China) Holdings, Ministry of Health of Singapore, Olympus Hong Kong and China, Medical Associ- ation of Guangdong Province, and Associacao Dos Medicos Hospitalares Da Funcao Publica De Macau; personal fees and royalties from Wiley; grants from Pﬁzer, AstraZeneca, Triangle Pharmaceuticals, Given Imaging, Osaka City University, and Olympus Hong Kong and China; and commentary for American College of Physicians Journal Club, Nature Review: Gastroenter- ology and Hepatology, Evidence-based Medicine and Ministry of Health P. R. China, and Ministry of Health of Singapore, outside the submitted work. Dr. Douketis reports personal fees from Boehringer Ingelheim, Janssen, Pﬁzer, Bayer, Bristol-Myers Squibb, Sanoﬁ, and Daiichi Sankyo outside the submitted work. Dr. Gralnek reports personal fees from Boston Scientiﬁc and Taro Pharmaceuticals outside the submitted work. Dr. Jairath re- ports personal fees from AbbVie, Takeda, Pﬁzer, Sandoz, Jans- sen, Arena Pharma, GSK, Eli Lilly, Ferring, Shire, Robarts Clinical Trials, Genentech, Merck, Topivert, Celltrion, Sublimity Thera- peutics, F. Hoffman-La Roche, and Sigmatic Limited outside the submitted work. Dr. Jensen reports grants from the National In- stitute of Diabetes and Digestive and Kidney Diseases; U. S. Vet- erans Affairs Clinical Merit Review, and American Society for Gastrointestinal Endoscopy Research Foundation; grants and personal fees from Vascular Technology; and personal fees from Boston Scientiﬁc outside the submitted work. Dr. Lip reports consulting and speakers fees from Bayer, Bayer/Janssen, BMS/ Pﬁzer, Biotronik, Medtronic, Boehringer Ingelheim, Microlife, Roche, and Daiichi Sankyo outside the submitted work. Dr. Melt- zer reports an active research grant from Medtronic to study gas- trointestinal bleeding and serves on an advisory board for AnX Robotics. Dr. Saltzman reports personal fees from Cook Endos- copy outside the submitted work. Authors not named here have disclosed no conﬂicts of interest. Disclosures can also be viewed at www.acponline.org/authors/icmje/ConﬂictOfInterestForms.do ?msNum=M19-1795. CLINICAL GUIDELINE Management of Upper Gastrointestinal Bleeding 818 Annals of Internal Medicine • Vol.171 No.11 • 3 December 2019 Annals.org Downloaded from https://annals.org by Yonsei University Medical Library on 05/29/2024.",7124,1030,1781.0,"[ 0.36044735  0.0236378  -1.5101013  ... -0.14923687  0.3279612
 -1.599554  ]"
264,"Corresponding Author: Alan N. Barkun, MD, Division of Gas- troenterology, McGill University and the McGill University Health Centre, 1650 Cedar Avenue, Room D7.346, Montreal, Quebec H3G 1A4, Canada; e-mail, alan.barkun@muhc.mcgill.ca. Current author addresses and author contributions are avail- able at Annals.org. References 1. Laine L, Yang H, Chang SC, et al. Trends for incidence of hospi- talization and death due to GI complications in the United States from 2001 to 2009. Am J Gastroenterol.2012;107:1190-5; quiz 1196. [PMID: 22688850] doi:10.1038/ajg.2012.168 2. Rosenstock SJ, Møller MH, Larsson H, et al. Improving quality of care in peptic ulcer bleeding: nationwide cohort study of 13,498 consecutive patients in the Danish Clinical Register of Emergency Surgery. Am J Gastroenterol.2013;108:1449-57. [PMID: 23732464] doi:10.1038/ajg.2013.162 3. Barkun A, Bardou M, Marshall JK; Nonvariceal Upper GI Bleeding Consensus Conference Group. Consensus recommendations for managing patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med.2003;139:843-57. [PMID: 14623622] 4. Barkun AN, Bardou M, Kuipers EJ, et al; International Consensus Upper Gastrointestinal Bleeding Conference Group. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med.2010; 152:101-13. [PMID: 20083829] doi:10.7326/0003-4819-152-2 -201001190-00009 5. Laine L, Jensen DM. Management of patients with ulcer bleeding. Am J Gastroenterol.2012;107:345-60; quiz 361. [PMID: 22310222] doi:10.1038/ajg.2011.480 6. Hwang JH, Fisher DA, Ben-Menachem T, et al; Standards of Prac- tice Committee of the American Society for Gastrointestinal Endos- copy. The role of endoscopy in the management of acute non- variceal upper GI bleeding. Gastrointest Endosc.2012;75:1132-8. [PMID: 22624808] doi:10.1016/j.gie.2012.02.033 7. National Institute for Health and Care Excellence. Acute upper gastrointestinal bleeding: management (NICE clinical guideline 141), 2012. Last update: November 2018. Accessed at www.nice.org .uk/guidance/cg141 on 12 August 2019.8. Gralnek IM, Dumonceau JM, Kuipers EJ, et al. Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: eu- ropean society of gastrointestinal endoscopy (ESGE) guideline. En- doscopy.2015;47:a1-46. [PMID: 26417980] doi:10.1055/s-0034 -1393172 9.",2383,304,595.75,"[-0.03696106 -0.50006974 -1.3093398  ...  0.21819256  0.51828843
 -1.3574282 ]"
264,"Sung JJ, Chiu PW, Chan FKL, et al. Asia-Paciﬁc working group consensus on non-variceal upper gastrointestinal bleeding: an update 2018. Gut.2018;67:1757-1768. [PMID: 29691276] doi:10 .1136/gutjnl-2018-316276 10. Abraham NS, Hartman C, Richardson P, et al. Risk of lower and upper gastrointestinal bleeding, transfusions, and hospi- talizations with complex antithrombotic therapy in elderly pa- tients. Circulation.2013;128:1869-77. [PMID: 24025594] doi:10 .1161/CIRCULATIONAHA.113.004747 11. Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non- randomised studies of healthcare interventions, or both. BMJ.2017; 358:j4008. [PMID: 28935701] doi:10.1136/bmj.j4008 12. Guyatt GH, Oxman AD, Vist GE, et al; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ.2008;336:924-6. [PMID: 18436948] doi:10.1136/bmj.39489.470347. AD 13. Guyatt GH, Schu¨nemann HJ, Djulbegovic B, et al. Guideline pan- els should not GRADE good practice statements. J Clin Epidemiol.2015;68:597-600. [PMID: 25660962] doi:10.1016/j.jclinepi.2014 .12.011 14. Dalkey N. An experimental study of group opinion: the Delphi method. Futures.1969;1:408-26.15. Schu¨nemann HJ, Mustafa R, Brozek J, et al; GRADE Working Group. GRADE Guidelines: 16. GRADE evidence to decision frame- works for tests in clinical practice and public health. J Clin Epidemiol.2016;76:89-98. [PMID: 26931285] doi:10.1016/j.jclinepi.2016.01 .032 16. Alonso-Coello P, Oxman AD, Moberg J, et al; GRADE Working Group. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices.2: Clinical practice guidelines. BMJ.2016;353:i2089. [PMID: 27365494] doi:10.1136/bmj.i2089 17. Alonso-Coello P, Schu¨nemann HJ, Moberg J, et al; GRADE Working Group. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices.",2012,261,503.0,"[ 0.8039393  -0.3397362  -1.3501778  ... -0.09730451  0.7996156
 -1.4393469 ]"
264,"1: Introduction. BMJ.2016;353:i2016. [PMID: 27353417] doi:10.1136/bmj.i2016 18. Guyatt GH, Oxman AD, Kunz R, et al; GRADE Working Group. Going from evidence to recommendations. BMJ.2008;336:1049-51. [PMID: 18467413] doi:10.1136/bmj.39493.646875. AE 19. Perel P, Roberts I, Ker K. Colloids versus crystalloids for ﬂuid resuscitation in critically ill patients. Cochrane Database Syst Rev. 2013:CD000567. [PMID: 23450531] doi:10.1002/14651858 . CD000567.pub6 20. Cha´vez-Negrete A, Majluf Cruz S, Frati Munari A, et al. Treatment of hemorrhagic shock with intraosseous or intravenous infusion of hypertonic saline dextran solution. Eur Surg Res.1991;23:123-9. [PMID: 1718756] 21. Annane D, Siami S, Jaber S, et al; CRISTAL Investigators. Effects of ﬂuid resuscitation with colloids vs crystalloids on mortality in criti- cally ill patients presenting with hypovolemic shock: the CRISTAL randomized trial. JAMA.2013;310:1809-17. [PMID: 24108515] doi:10.1001/jama.2013.280502 22. Semler MW, Self WH, Wanderer JP, et al; SMART Investigators and the Pragmatic Critical Care Research Group. Balanced crystal- loids versus saline in critically ill adults. N Engl J Med.2018;378:829- 839. [PMID: 29485925] doi:10.1056/NEJMoa1711584 23. Kowalenko T, Stern S, Dronen S, et al. Improved outcome with hypotensive resuscitation of uncontrolled hemorrhagic shock in a swine model. J Trauma.1992;33:349-53; discussion 361-2. [PMID: 1404501] 24. Stern SA, Dronen SC, Birrer P, et al. Effect of blood pressure on hemorrhage volume and survival in a near-fatal hemorrhage model incorporating a vascular injury. Ann Emerg Med.1993;22:155-63. [PMID: 8427424] 25. Kwan I, Bunn F, Chinnock P, et al. Timing and volume of ﬂuid administration for patients with bleeding. Cochrane Database Syst Rev. 2014:CD002245. [PMID: 24599652] doi:10.1002/14651858 . CD002245.pub2 26. Schreiber MA, Meier EN, Tisherman SA, et al; ROC Investigators. A controlled resuscitation strategy is feasible and safe in hypotensive trauma patients: results of a prospective randomized pilot trial.",2048,277,512.0,"[ 0.58195704 -0.29985052 -0.80035245 ...  0.60110146  0.6182709
 -0.8433426 ]"
264,"J Trauma Acute Care Surg.2015;78:687-95; discussion 695-7. [PMID: 25807399] doi:10.1097/TA.0000000000000600 27. Carrick MM, Morrison CA, Tapia NM, et al. Intraoperative hypo- tensive resuscitation for patients undergoing laparotomy or thora- cotomy for trauma: early termination of a randomized prospective clinical trial. J Trauma Acute Care Surg.2016;80:886-96. [PMID: 27015578] doi:10.1097/TA.0000000000001044 28. Stanley AJ, Ashley D, Dalton HR, et al. Outpatient management of patients with low-risk upper-gastrointestinal haemorrhage: multi- centre validation and prospective evaluation. Lancet.2009;373:42-7. [PMID: 19091393] doi:10.1016/S0140-6736(08)61769-9 29. Ramaekers R, Mukarram M, Smith CA, et al. The predictive value of preendoscopic risk scores to predict adverse outcomes in emer- gency department patients with upper gastrointestinal bleeding: a systematic review. Acad Emerg Med.2016;23:1218-1227. [PMID: 27640399] doi:10.1111/acem.13101 30. Laursen SB, Dalton HR, Murray IA, et al; Upper Gastrointestinal Hemorrhage International Consortium. Performance of new thresh- olds of the Glasgow Blatchford score in managing patients with up- Management of Upper Gastrointestinal Bleeding CLINICAL GUIDELINE Annals.org Annals of Internal Medicine • Vol.171 No.11 • 3 December 2019 819 Downloaded from https://annals.org by Yonsei University Medical Library on 05/29/2024.",1386,172,346.5,"[ 0.07940052 -0.81479305 -1.2415419  ...  0.5673632   1.0158795
 -1.1478342 ]"
265,"per gastrointestinal bleeding. Clin Gastroenterol Hepatol.2015;13: 115-21.e2. [PMID: 25058843] doi:10.1016/j.cgh.2014.07.023 31. Stanley AJ, Laine L, Dalton HR, et al; International Gastrointesti- nal Bleeding Consortium. Comparison of risk scoring systems for patients presenting with upper gastrointestinal bleeding: interna- tional multicentre prospective study. BMJ.2017;356:i6432. [PMID: 28053181] doi:10.1136/bmj.i6432 32. Saltzman JR, Tabak YP, Hyett BH, et al. A simple risk score accu- rately predicts in-hospital mortality, length of stay, and cost in acute upper GI bleeding. Gastrointest Endosc.2011;74:1215-24. [PMID: 21907980] doi:10.1016/j.gie.2011.06.024 33. Odutayo A, Desborough MJ, Trivella M, et al. Restrictive versus liberal blood transfusion for gastrointestinal bleeding: a systematic review and meta-analysis of randomised controlled trials. Lancet Gastroenterol Hepatol.2017;2:354-360. [PMID: 28397699] doi:10 .1016/S2468-1253(17)30054-7 34. Jairath V, Kahan BC, Gray A, et al. Restrictive versus liberal blood transfusion for acute upper gastrointestinal bleeding (TRIGGER): a pragmatic, open-label, cluster randomised feasibility trial. Lancet.2015;386:137-44. [PMID: 25956718] doi:10.1016/S0140-6736(14) 61999-1 35. Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med.2013;368:11- 21. [PMID: 23281973] doi:10.1056/NEJMoa1211801 36. Carson JL, Stanworth SJ, Roubinian N, et al. Transfusion thresh- olds and other strategies for guiding allogeneic red blood cell trans- fusion. Cochrane Database Syst Rev. 2016;10:CD002042. [PMID: 27731885] 37. Holst LB, Petersen MW, Haase N, et al. Restrictive versus liberal transfusion strategy for red blood cell transfusion: systematic review of randomised trials with meta-analysis and trial sequential analysis. BMJ.2015;350:h1354. [PMID: 25805204] doi:10.1136/bmj.h1354 38. Shander A, Hofmann A, Ozawa S, et al. Activity-based costs of blood transfusions in surgical patients at four hospitals. Transfusion.2010;50:753-65. [PMID: 20003061] doi:10.1111/j.1537-2995.2009 .02518.x 39.",2117,257,529.25,"[ 0.9767057  -0.7760781  -0.9430245  ...  0.22512026  0.5231769
 -1.1551344 ]"
265,"Blair SD, Janvrin SB, McCollum CN, et al. Effect of early blood transfusion on gastrointestinal haemorrhage. Br J Surg.1986;73: 783-5. [PMID: 3533203] 40. Docherty AB, O’Donnell R, Brunskill S, et al. Effect of restrictive versus liberal transfusion strategies on outcomes in patients with car- diovascular disease in a non-cardiac surgery setting: systematic re- view and meta-analysis. BMJ.2016;352:i1351. [PMID: 27026510] doi:10.1136/bmj.i1351 41. Carson JL, Guyatt G, Heddle NM, et al. Clinical practice guide- lines from the AABB: red blood cell transfusion thresholds and stor- age. JAMA.2016;316:2025-2035. [PMID: 27732721] doi:10.1001 /jama.2016.9185 42. Nagata N, Sakurai T, Moriyasu S, et al. Impact of INR monitoring, reversal agent use, heparin bridging, and anticoagulant interruption on rebleeding and thromboembolism in acute gastrointestinal bleeding. PLoS One.2017;12:e0183423. [PMID: 28863196] doi:10 .1371/journal.pone.0183423 43. Goldstein JN, Refaai MA, Milling TJ Jr, et al. Four-factor pro- thrombin complex concentrate versus plasma for rapid vitamin K an- tagonist reversal in patients needing urgent surgical or invasive in- terventions: a phase 3b, open-label, non-inferiority, randomised trial. Lancet.2015;385:2077-87. [PMID: 25728933] doi:10.1016/S0140 -6736(14)61685-8 44. Sarode R, Milling TJ Jr, Refaai MA, et al. Efﬁcacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma- controlled, phase IIIb study. Circulation.2013;128:1234-43. [PMID: 23935011] doi:10.1161/CIRCULATIONAHA.113.002283 45. Choudari CP, Rajgopal C, Palmer KR. Acute gastrointestinal haemorrhage in anticoagulated patients: diagnoses and response to endoscopic treatment. Gut.1994;35:464-6. [PMID: 8174982] 46. Thomopoulos KC, Mimidis KP, Theocharis GJ, et al. Acute upper gastrointestinal bleeding in patients on long-term oral anticoagula- tion therapy: endoscopic ﬁndings, clinical management and out- come. World J Gastroenterol.2005;11:1365-8. [PMID: 15761977] 47. National Institute for Health and Care Excellence. Blood transfu- sion (NICE clinical guideline 24), 2015. Last update: November 2015.",2201,284,550.25,[ 0.6964209 -0.9124074 -1.0800692 ...  0.3198639  0.5008909 -1.1774685]
265,"Accessed at www.nice.org.uk/guidance/ng24 on 12 August 2019.48. Connolly SJ, Milling TJ Jr, Eikelboom JW, et al; ANNEXA-4 In- vestigators. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med.2016;375:1131-41. [PMID: 27573206] doi:10.1056/NEJMoa1607887 49. Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for dab- igatran reversal - full cohort analysis. N Engl J Med.2017;377:431- 441. [PMID: 28693366] doi:10.1056/NEJMoa1707278 50. Spiegel BM, Vakil NB, Ofman JJ. Endoscopy for acute non- variceal upper gastrointestinal tract hemorrhage: is sooner better?A systematic review. Arch Intern Med.2001;161:1393-404. [PMID: 11386888] 51. Lin HJ, Wang K, Perng CL, et al. Early or delayed endoscopy for patients with peptic ulcer bleeding. A prospective randomized study. J Clin Gastroenterol.1996;22:267-71. [PMID: 8771420] 52. Lee JG, Turnipseed S, Romano PS, et al. Endoscopy-based triage signiﬁcantly reduces hospitalization rates and costs of treating upper GI bleeding: a randomized controlled trial. Gastrointest Endosc.1999;50:755-61. [PMID: 10570332] 53. Bjorkman DJ, Zaman A, Fennerty MB, et al. Urgent vs. elective endoscopy for acute non-variceal upper-GI bleeding: an effective- ness study. Gastrointest Endosc.2004;60:1-8. [PMID: 15229417] 54. Kumar NL, Cohen AJ, Nayor J, et al. Timing of upper endo- scopy inﬂuences outcomes in patients with acute nonvariceal upper GI bleeding. Gastrointest Endosc.2017;85:945-952.e1. [PMID: 27693643] doi:10.1016/j.gie.2016.09.029 55. Lim LG, Ho KY, Chan YH, et al. Urgent endoscopy is asso- ciated with lower mortality in high-risk but not low-risk non- variceal upper gastrointestinal bleeding. Endoscopy.2011;43: 300-6. [",1718,234,429.5,"[ 0.18778935 -0.7891072  -1.6285102  ...  0.29426843  0.2573759
 -1.4737195 ]"
265,"PMID: 21360421] doi:10.1055/s-0030-1256110 56. Laursen SB, Leontiadis GI, Stanley AJ, et al. Relationship be- tween timing of endoscopy and mortality in patients with peptic ul- cer bleeding: a nationwide cohort study. Gastrointest Endosc.2017; 85:936-944.e3. [PMID: 27623102] doi:10.1016/j.gie.2016.08.049 57. Xia XF, Chiu PWY, Tsoi KKF, et al. The effect of off-hours hospital admission on mortality and clinical outcomes for patients with upper gastrointestinal hemorrhage: a systematic review and meta-analysis of 20 cohorts. United European Gastroenterol J. 2018;6:367-381. [PMID: 29774150] doi:10.1177/2050640617732651 58. Cho SH, Lee YS, Kim YJ, et al. Outcomes and role of urgent endoscopy in high-risk patients with acute nonvariceal gastrointesti- nal bleeding. Clin Gastroenterol Hepatol.2018;16:370-377. [PMID: 28634135] doi:10.1016/j.cgh.2017.06.029 59. Ahn DW, Park YS, Lee SH, et al. Clinical outcome of acute non- variceal upper gastrointestinal bleeding after hours: the role of ur- gent endoscopy. Korean J Intern Med.2016;31:470-8. [PMID: 27048253] doi:10.3904/kjim.2014.099 60. Targownik LE, Murthy S, Keyvani L, et al. The role of rapid en- doscopy for high-risk patients with acute nonvariceal upper gastro- intestinal bleeding. Can J Gastroenterol.2007;21:425-9. [PMID: 17637943] 61. Tai CM, Huang SP, Wang HP, et al. High-risk ED patients with nonvariceal upper gastrointestinal hemorrhage undergoing emer- gency or urgent endoscopy: a retrospective analysis. Am J Emerg Med.2007;25:273-8. [PMID: 17349900] 62. Garcia-Tsao G, Sanyal AJ, Grace ND, et al; Practice Guidelines Committee of American Association for Study of Liver Diseases. Pre- vention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Am J Gastroenterol.2007;102:2086-102. [PMID: 17727436] 63.de Franchis R; Baveno V Faculty. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on meth- odology of diagnosis and therapy in portal hypertension. J Hepatol.2010;53:762-8. [PMID: 20638742] doi:10.1016/j.jhep.2010.06.004 64. Laine L, McQuaid KR. Endoscopic therapy for bleeding ulcers: an evidence-based approach based on meta-analyses of randomized CLINICAL GUIDELINE Management of Upper Gastrointestinal Bleeding 820 Annals of Internal Medicine • Vol.171 No.",2309,307,577.25,"[ 0.13821878 -0.90690947 -1.7805128  ...  0.28809538  0.7168385
 -1.0241721 ]"
266,"controlled trials. Clin Gastroenterol Hepatol.2009;7:33-47; quiz 1-2. [PMID: 18986845] doi:10.1016/j.cgh.2008.08.016 65. Barkun AN, Martel M, Toubouti Y, et al. Endoscopic hemostasis in peptic ulcer bleeding for patients with high-risk lesions: a series of meta-analyses. Gastrointest Endosc.2009;69:786-99. [PMID: 19152905] doi:10.1016/j.gie.2008.05.031 66. Vergara M, Bennett C, Calvet X, et al. Epinephrine injection ver- sus epinephrine injection and a second endoscopic method in high- risk bleeding ulcers. Cochrane Database Syst Rev. 2014:CD005584. [PMID: 25308912] doi:10.1002/14651858. CD005584.pub3 67. Baracat F, Moura E, Bernardo W, et al. Endoscopic hemostasis for peptic ulcer bleeding: systematic review and meta-analyses of randomized controlled trials. Surg Endosc.2016;30:2155-68. [PMID: 26487199] doi:10.1007/s00464-015-4542-x 68. Ljubicic N, Budimir I, Biscanin A, et al. Endoclips vs large or small-volume epinephrine in peptic ulcer recurrent bleeding. World J Gastroenterol.2012;18:2219-24. [PMID: 22611315] doi:10.3748 /wjg.v18.i18.2219 69. Cui J, Huang LY, Liu YX, et al. Efﬁcacy of endoscopic therapy for gastrointestinal bleeding from Dieulafoy's lesion. World J Gastroen- terol.2011;17:1368-72. [PMID: 21455339] doi:10.3748/wjg.v17.i10 .1368 70. Grgov S, Radovanovic-Dinic B, Tasic T. Could application of epi- nephrine improve hemostatic efﬁcacy of hemoclips for bleeding peptic ulcers?A prospective randomized study. Vojnosanit Pregl.2013;70:824-9. [PMID: 24266309] 71. Chung IK, Ham JS, Kim HS, et al. Comparison of the hemostatic efﬁcacy of the endoscopic hemoclip method with hypertonic saline- epinephrine injection and a combination of the two for the manage- ment of bleeding peptic ulcers. Gastrointest Endosc.1999;49:13-8. [PMID: 9869717] 72. Kwek BEA, Ang TL, Ong PLJ, et al. TC-325 versus the conven- tional combined technique for endoscopic treatment of peptic ul- cers with high-risk bleeding stigmata: A randomized pilot study. J Dig Dis.2017;18:323-329. [PMID: 28485544] doi:10.1111/1751 -2980.12481 73.",2047,264,511.75,"[-0.53224695 -0.7772798  -1.158284   ...  0.9331777   0.2746812
 -1.4890174 ]"
266,"Chen YI, Barkun AN. Hemostatic powders in gastrointestinal bleeding: a systematic review. Gastrointest Endosc Clin N Am.2015; 25:535-52. [PMID: 26142037] doi:10.1016/j.giec.2015.02.008 74. Haddara S, Jacques J, Lecleire S, et al. A novel hemostatic powder for upper gastrointestinal bleeding: a multicenter study (the “GRAPHE” registry). Endoscopy.2016;48:1084-1095. [PMID: 27760437] 75. Chen YI, Barkun A, Nolan S. Hemostatic powder TC-325 in the management of upper and lower gastrointestinal bleeding: a two- year experience at a single institution. Endoscopy.2015;47:167-71. [PMID: 25264762] doi:10.1055/s-0034-1378098 76. Hagel AF, Albrecht H, Na¨gel A, et al. The application of hemos- pray in gastrointestinal bleeding during emergency endoscopy. Gastroenterol Res Pract.2017;2017:3083481. [PMID: 28232848] doi:10.1155/2017/3083481 77. Barkun AN, Adam V, Lu Y, et al. Using hemospray improves the cost-effectiveness ratio in the management of upper gastrointestinal nonvariceal bleeding. J Clin Gastroenterol.2018;52:36-44. [PMID: 27749635] doi:10.1097/MCG.0000000000000709 78. Kohler B, Maier M, Benz C, et al. Acute ulcer bleeding. A pro- spective randomized trial to compare Doppler and Forrest classiﬁca- tions in endoscopic diagnosis and therapy. Dig Dis Sci.1997;42: 1370-4. [PMID: 9246030] 79. Jensen DM, Kovacs TOG, Ohning GV, et al. Doppler endo- scopic probe monitoring of blood ﬂow improves risk stratiﬁcation and outcomes of patients with severe nonvariceal upper gastro- intestinal hemorrhage. Gastroenterology.2017;152:1310-1318.e1. [PMID: 28167214] doi:10.1053/j.gastro.2017.01.042 80. Chen VK, Wong RC. Endoscopic Doppler ultrasound versus en- doscopic stigmata-directed management of acute peptic ulcer hem- orrhage: a multimodel cost analysis. Dig Dis Sci.2007;52:149-60. [PMID: 17109216] 81. Leontiadis GI, Sharma VK, Howden CW. Proton pump inhibitor treatment for acute peptic ulcer bleeding. Cochrane Database Syst Rev. 2006:CD002094. [",1964,253,491.0,"[-0.28236175 -0.14598565 -0.9906517  ...  0.7703761   0.32671136
 -1.2909676 ]"
266,"PMID: 16437441] 82. Neumann I, Letelier LM, Rada G, et al. Comparison of different regimens of proton pump inhibitors for acute peptic ulcer bleeding. Cochrane Database Syst Rev. 2013:CD007999. [PMID: 23760821] doi:10.1002/14651858. CD007999.pub2 83. Leontiadis GI, Sreedharan A, Dorward S, et al. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. Health Technol Assess.2007;11:iii-iv, 1-164. [PMID: 18021578] 84. Barkun AN, Adam V, Sung JJ, et al. Cost effectiveness of high- dose intravenous esomeprazole for peptic ulcer bleeding. Phar- macoeconomics.2010;28:217-30. [PMID: 20151726] doi:10.2165 /11531480-000000000-00000 85. Al-Sabah S, Barkun AN, Herba K, et al. Cost-effectiveness of proton-pump inhibition before endoscopy in upper gastro- intestinal bleeding. Clin Gastroenterol Hepatol.2008;6:418-25. [PMID: 18304891] doi:10.1016/j.cgh.2007.12.037 86. Lu Y, Adam V, Teich V, et al. Timing or dosing of intravenous proton pump inhibitors in acute upper gastrointestinal bleeding has low impact on costs. Am J Gastroenterol.2016;111:1389-1398. [PMID: 27140030] doi:10.1038/ajg.2016.157 87. Cheng HC, Wu CT, Chang WL, et al. Double oral esomeprazole after a 3-day intravenous esomeprazole infusion reduces recurrent peptic ulcer bleeding in high-risk patients: a randomised controlled study. Gut.2014;63:1864-72. [PMID: 24658598] doi:10.1136/gutjnl -2013-306531 88. Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med.2002;346:2033-8. [PMID: 12087138] 89. Chan FK, Chung SC, Suen BY, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infec- tion who are taking low-dose aspirin or naproxen. N Engl J Med.2001;344:967-73. [PMID: 11274623] 90. Chan FK, Ching JY, Hung LC, et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med.",2013,271,503.25,"[ 0.42278928 -0.31425852 -0.9658363  ...  0.59269184  0.30179822
 -1.2157556 ]"
266,"2005;352:238-44. [PMID: 15659723] 91. Lai KC, Chu KM, Hui WM, et al. Esomeprazole with aspirin versus clopidogrel for prevention of recurrent gastrointestinal ulcer complications. Clin Gastroenterol Hepatol.2006;4:860-5. [PMID: 16797240] 92. Chan FK, Kyaw M, Tanigawa T, et al. Similar efﬁcacy of proton- pump inhibitors vs H2-receptor antagonists in reducing risk of upper gastrointestinal bleeding or ulcers in high-risk users of low-dose as- pirin. Gastroenterology.2017;152:105-110.e1. [PMID: 27641510] doi:10.1053/j.gastro.2016.09.006 93. Khan MY, Siddiqui WJ, Alvarez C, et al. Reduction in postpercu- taneous coronary intervention angina in addition to gastrointestinal events in patients on combined proton pump inhibitors and dual antiplatelet therapy: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol.2018;30:847-853. [PMID: 29596078] doi:10 .1097/MEG.0000000000001125 94. Hu W, Tong J, Kuang X, et al. Inﬂuence of proton pump inhibi- tors on clinical outcomes in coronary heart disease patients receiving aspirin and clopidogrel: a meta-analysis. Medicine (Baltimore).2018; 97:e9638. [PMID: 29504996] doi:10.1097/MD.0000000000009638 95. Bhatt DL, Cryer BL, Contant CF, et al; COGENT Investigators. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med.2010;363:1909-17. [PMID: 20925534] doi:10.1056 /NEJMoa1007964 96. Wei P, Zhang YG, Ling L, et al. Effects of the short-term applica- tion of pantoprazole combined with aspirin and clopidogrel in the treatment of acute STEMI. Exp Ther Med.2016;12:2861-2864. [PMID: 27882086] 97. Ren YH, Zhao M, Chen YD, et al. Omeprazole affects clopidogrel efﬁcacy but not ischemic events in patients with acute coronary syn- drome undergoing elective percutaneous coronary intervention. Chin Med J (Engl).2011;124:856-61. [PMID: 21518592] Management of Upper Gastrointestinal Bleeding CLINICAL GUIDELINE Annals.org Annals of Internal Medicine • Vol.171 No.11 • 3 December 2019 821 Downloaded from https://annals.org by Yonsei University Medical Library on 05/29/2024.",2059,273,514.75,"[ 0.11046261 -0.37499997 -1.2242055  ...  0.6008134   0.33082002
 -1.6497221 ]"
267,"98. Wu H, Jing Q, Wang J, et al. Pantoprazole for the prevention of gastrointestinal bleeding in high-risk patients with acute coronary syndromes. J Crit Care.2011;26:434.e1-6. [PMID: 21273036] doi:10 .1016/j.jcrc.2010.12.007 99. Chan FK, Ching JY, Suen BY, et al. Effects of Helicobacter pylori infection on long-term risk of peptic ulcer bleeding in low-dose as- pirin users. Gastroenterology.2013;144:528-35. [PMID: 23333655] doi:10.1053/j.gastro.2012.12.038 100. Ray WA, Chung CP, Murray KT, et al. Association of proton pump inhibitors with reduced risk of warfarin-related serious upper gastrointestinal bleeding. Gastroenterology.2016;151:1105-1112.e10. [PMID: 27639805] doi:10.1053/j.gastro.2016.08.054 101. Chan EW, Lau WC, Leung WK, et al. Prevention of dabigatran- related gastrointestinal bleeding with gastroprotective agents: a population-based study. Gastroenterology.2015;149:586-95.e3. [PMID: 25960019] doi:10.1053/j.gastro.2015.05.002 102. Lin KJ, Herna´ndez-Dı´az S, Garcı´a Rodrı´guez LA. Acid suppres- sants reduce risk of gastrointestinal bleeding in patients on anti- thrombotic or anti-inﬂammatory therapy. Gastroenterology.2011; 141:71-9. [PMID: 21458456] doi:10.1053/j.gastro.2011.03.049 103. Masso´ Gonza´lez EL, Garcı´a Rodrı´guez LA. Proton pump inhibi- tors reduce the long-term risk of recurrent upper gastrointestinal bleeding: an observational study. Aliment Pharmacol Ther.2008;28: 629-37. [PMID: 18616644] doi:10.1111/j.1365-2036.2008.03780.x 104. Lanas A, Garcı´a-Rodrı´guez LA, Arroyo MT, et al; Investigators of the Asociacio´ n Espan˜ola de Gastroenterologı´a (AEG). Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associ- ated with nonsteroidal anti-inﬂammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol.2007;102:507-15. [PMID: 17338735] 105. Islam MM, Poly TN, Walther BA, et al. Adverse outcomes of long-term use of proton pump inhibitors: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol.2018;30:1395-1405. [PMID: 30028775] doi:10.1097/MEG.0000000000001198 106. Hussain S, Siddiqui AN, Habib A, et al. Proton pump inhibitors' use and risk of hip fracture: a systematic review and meta-analysis.",2205,269,551.25,"[ 0.02754923 -0.42712027 -1.5533144  ...  0.46451172  0.5278651
 -1.507866  ]"
267,"Rheumatol Int.2018;38:1999-2014. [PMID: 30159775] doi:10.1007 /s00296-018-4142-x 107. Nochaiwong S, Ruengorn C, Awiphan R, et al. The association between proton pump inhibitor use and the risk of adverse kidney outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant.2018;33:331-342. [PMID: 28339835] doi:10.1093/ndt /gfw470 108. Haﬁz RA, Wong C, Paynter S, et al. The risk of community- acquired enteric infection in proton pump inhibitor therapy: system- atic review and meta-analysis. Ann Pharmacother.2018;52:613-622. [PMID: 29457492] doi:10.1177/1060028018760569 109. Cao F, Chen CX, Wang M, et al. Updated meta-analysis of con- trolled observational studies: proton-pump inhibitors and risk of Clostridium difﬁcile infection. J Hosp Infect.2018;98:4-13. [PMID: 28842261] doi:10.1016/j.jhin.2017.08.017 110. Vaezi MF, Yang YX, Howden CW. Complications of proton pump inhibitor therapy. Gastroenterology.2017;153:35-48. [PMID: 28528705] doi:10.1053/j.gastro.2017.04.047 111. Bosch J, Eikelboom JW, Connolly SJ, et al. Rationale, design and baseline characteristics of participants in the cardiovascular out- comes for people using anticoagulation strategies (COMPASS) trial. Can J Cardiol.2017;33:1027-1035. [PMID: 28754388] doi:10.1016 /j.cjca.2017.06.001 112. Moayyedi P, Eikelboom JW, Bosch J, et al; COMPASS Investi- gators. Pantoprazole to prevent gastroduodenal events in patients receiving rivaroxaban and/or aspirin in a randomized, double-blind, placebo-controlled trial. Gastroenterology.2019;157:403-412.e5. [PMID: 31054846] doi:10.1053/j.gastro.2019.04.041 113. Moayyedi P, Eikelboom JW, Bosch J, et al; COMPASS Investi- gators. Safety of proton pump inhibitors based on a large, multi- year, randomized trial of patients receiving rivaroxaban or aspirin. Gastroenterology.2019;157:682-691.e2. [PMID: 31152740] doi:10 .1053/j.gastro.2019.05.056 114. Wong GLH, Lau LHS, Ching JYL, et al. Prevention of recurrent idiopathic gastroduodenal ulcer bleeding: a double-blind, ran- domised trial. Gut.2019. [PMID: 31229990] doi:10.1136/gutjnl-2019 -318715 115.",2085,250,521.25,"[ 0.3523571  -0.10916254 -1.5140991  ...  0.12060338  0.6874652
 -1.6204023 ]"
267,"Baracat FI, de Moura DTH, Brunaldi VO, et al. Randomized con- trolled trial of hemostatic powder versus endoscopic clipping for non-variceal upper gastrointestinal bleeding. Surg Endosc.2019. [PMID: 30927124] doi:10.1007/s00464-019-06769-z 116. Toka B, Eminler AT, Karacaer C, et al. Comparison of monopo- lar hemostatic forceps with soft coagulation versus hemoclip for pep- tic ulcer bleeding: a randomized trial (with video). Gastrointest En- dosc.2019;89:792-802. [PMID: 30342026] doi:10.1016/j.gie.2018 .10.011 117. Kantowski M, Schoepfer AM, Settmacher U, et al. Assessment of endoscopic Doppler to guide hemostasis in high risk peptic ulcer bleeding. Scand J Gastroenterol.2018;53:1311-1318. [PMID: 30394134] doi:10.1080/00365521.2018.1509121 118. Schmidt A, Go¨ lder S, Goetz M, et al. Over-the-scope clips are more effective than standard endoscopic therapy for patients with recurrent bleeding of peptic ulcers. Gastroenterology.2018;155: 674-686.e6. [PMID: 29803838] doi:10.1053/j.gastro.2018.05.037 CLINICAL GUIDELINE Management of Upper Gastrointestinal Bleeding 822 Annals of Internal Medicine • Vol.171 No.11 • 3 December 2019 Annals.org Downloaded from https://annals.org by Yonsei University Medical Library on 05/29/2024.",1239,156,309.75,"[-0.06282642 -0.51232016 -1.2586582  ...  0.7962378   0.19437905
 -1.3403476 ]"
268,"Current Author Addresses: Dr. Barkun: Division of Gastroen- terology, McGill University and the McGill University Health Centre, 1650 Cedar Avenue, Room D7.346, Montreal, Que- bec H3G 1A4, Canada. Dr. Almadi: Division of Gastroenterology, Department of Medicine, College of Medicine, King Khalid University Hospi- tal, King Saud University 12372, Riyadh, Saudi Arabia. Dr. Kuipers: Erasmus MC University Medical Center, P. O. Box 2040, 3000CA Rotterdam, the Netherlands. Dr. Laine: Section of Digestive Diseases, Yale School of Med- icine, P. O. Box 208019, New Haven, CT 06520. Dr. Sung: Department of Medicine and Therapeutics, Institute of Digestive Disease, The Chinese University of Hong Kong, Shatin, Hong Kong. Dr. Tse: Division of Gastroenterology, Department of Medi- cine, McMaster University, Room 2F53, 1200 Main Street West, Hamilton, Ontario L8N 3Z5, Canada. Dr. Leontiadis: Division of Gastroenterology, Department of Medicine, McMaster University, 1280 Main Street West, Health Sci- ences Centre, Suite 3V3, Hamilton, Ontario L8S 4K1, Canada. Dr. Abraham: Mayo Clinic, 13400 East Shea Boulevard, Scotts- dale, AZ 85259. Dr. Calvet: Servei d’Aparell Digestiu, Coproracio´ Sanita´ria Universita´ria Parc Taulı´, Parc Taulı´ 1, 08208 Sabadell, Barce- lona, Catalunya, Spain. Dr. Chan: Institute of Digestive Disease, Chinese University of Hong Kong, Hong Kong SAR. Dr. Douketis: Department of Medicine, McMaster University and St. Joseph's Healthcare, 50 Charlton Avenue East, Hamil- ton, Ontario L8N 4A6, Canada. Dr. Enns: Division of Gastroenterology, University of British Columbia, Vancouver, British Columbia V6Z 2K5, Canada. Dr. Gralnek: Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel. Dr. Jairath: London Health Sciences Centre, Room A10-228, University Hospital, London, Ontario N6A 4V2, Canada. Dr. Jensen: Ronald Reagan UCLA Medical Center, Digestive Diseases–Westwood, 200 MP, 200 UCLA Medical Plaza, Suite 365C, Los Angeles, CA 90024. Dr. Lau: Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong SAR. Dr. Lip: Liverpool Centre for Cardiovascular Science, Univer- sity of Liverpool, William Henry Duncan Building, 6 West Derby Street, Liverpool L7 8TX, United Kingdom. Dr. Loffroy: Department of Interventional Radiology, Image- Guided Therapy Centre, Dijon-Bourgogne University Hospi- tal, 14 rue Gaffarel, 21000 Dijon, France. Dr. Maluf-Filho: Cancer Institute of Sa˜o Paulo–ICESP–USP, Av. Dr. Arnaldo, 251, CEP 01246-000, Sa˜o Paulo–SP, Brazil. Dr. Meltzer: Department of Emergency Medicine, GW Medi- cal Faculty Associates, 2120 L Street Northwest, Washington, DC 20037. Dr. Reddy: Asian Institute of Gastroenterology, 6-3-661, Somajiguda, Hyderabad–500 082, India. Dr. Saltzman: Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115. Dr. Marshall: Division of Gastroenterology, McMaster Univer- sity, 1280 Main Street West, Room 2F59, Hamilton, Ontario L8S 4K1, Canada. Dr. Bardou: Clinical Investigation Centre INSERM 1432, Hos- pitalisation Unit and Gastroenterology and Liver Department, CHU Dijon-Bourgogne, Hopital Francois Mitterrand, 14 rue Gaffarel, BP77908, 21079 Dijon Cedex, France. Author Contributions: Conception and design: A. N. Barkun, M. Almadi, E. J. Kuipers, L. Laine, F. Tse, G. I. Leontiadis, I. M. Gralnek, A. C. Meltzer, J. K. Marshall, M. Bardou. Analysis and interpretation of the data: A. N. Barkun, M. Almadi, E. J. Kuipers, L. Laine, J. Sung, F. Tse, G. I. Leontiadis, N. S. Abraham, X. Calvet, J. Douketis, R. Enns, I. M. Gralnek, V. Jairath, J. Lau, G. Y. H. Lip, R. Loffroy, F. Maluf-Filho, A. C. Meltzer, J. R. Saltzman, M. Bardou. Drafting of the article: A. N. Barkun, M. Almadi, J. Sung, F. Tse, G. I. Leontiadis, N. S. Abraham, F. K. L. Chan, R. Enns, I. M. Gralnek, M. Bardou. Critical revision for important intellectual content: A. N. Barkun, M. Almadi, E. J. Kuipers, L. Laine, J. Sung, F. Tse, G. I. Leontiadis, N. S. Abraham, X. Calvet, F. K. L. Chan, J. Douketis, I. M. Gralnek, V. Jairath, D. Jensen, G. Y. H. Lip, R. Loffroy, F. Maluf-Filho, A. C. Meltzer, N. Reddy, J. R. Saltzman, J. K. Marshall. Final approval of the article: A. N. Barkun, M. Almadi, E. J. Kuipers, L. Laine, J. Sung, F. Tse, G. I. Leontiadis, N. S. Abraham, X. Calvet, F. K. L. Chan, J. Douketis, R. Enns, I. M. Gralnek, V. Jairath, D. Jensen, J. Lau, G. Y. H. Lip, R. Loffroy, F. Maluf-Filho, A. C. Meltzer, N. Reddy, J. R. Saltzman, J. K. Marshall, M. Bardou. Statistical expertise: A. N. Barkun, M. Almadi, L. Laine, G. I. Leontiadis. Obtaining of funding: A. N. Barkun, M. Almadi. Administrative, technical, or logistic support: A. N. Barkun, G. I. Leontiadis, M. Bardou. Collection and assembly of data: A. N. Barkun, F. Tse, G. I. Leontiadis, X. Calvet, R. Enns, I. M. Gralnek, F. Maluf-Filho, A. C. Meltzer, J. K. Marshall, M. Bardou. Annals.org Annals of Internal Medicine • Vol.171 No.11 • 3 December 2019 Downloaded from https://annals.org by Yonsei University Medical Library on 05/29/2024.",5107,780,1276.75,"[ 0.15792903  0.1604483  -1.3798342  ...  0.04717754  0.46234697
 -1.2624983 ]"
269,"Appendix Table 1. Pooled Sensitivity and Speciﬁcity of Pre-endoscopic Scoring Systems to Identify Patients at High Risk for Undesirable Clinical Outcomes Study, Year (Reference) Study Type Cutoff Value Pooled Sensitivity (95% CI)* Pooled Speciﬁcity (95% CI)* Glasgow Blatchford score NICE CPG, 2012 (7) 1 SR and MA of 7 DTA studies 0 0.99 (0.98–1.00) 0.20 (0.06–0.34) Ramaekers et al, 2016 (29) 1 SR and MA of 6 DTA studies 0 0.99 (0.98–1.00) 0.08 (0.07–0.09) Laursen et al, 2015 (30) 1 DTA study 0 1 0.997 (NR) 0.992 (NR) 0.222 (NR) 0.398 (NR) Stanley et al, 2017 (31) 1 DTA study 1 0.986 (NR) 0.346 (NR) Pre-endoscopic Rockall score NICE CPG, 2012 (7) 1 SR and MA of 7 DTA studies Not speciﬁed 0.96 (0.84–1.00) 0.29 (0.17–0.41) Ramaekers et al, 2016 (29) 1 SR and MA of 8 DTA studies 0 (6 studies) 2 (2 studies) 0.93 (0.91–0.94) 0.95 (0.91–0.97) 0.19 (0.18–0.20) 0.38 (0.35–0.40) Stanley et al, 2017 (31) 1 DTA study 0 0.956 (NR) 0.234 (NR) AIMS65 score Ramaekers et al, 2016 (29) 1 SR and MA of 3 DTA studies 0 (2 studies) 2 (1 study) 0.78 (0.73–0.83) 0.79 (0.76–0.82) 0.49 (0.45–0.53) 0.61 (0.61–0.61) Stanley et al, 2017 (31) 1 DTA study 0 0.815 (NR) 0.499 (NR) CPG = clinical practice guideline; DTA = diagnostic test accuracy; MA = meta-analysis; NICE = National Institute for Health and Care Excellence; NR = not reported; SR = systematic review. *Boldface signiﬁes statistically signiﬁcant results. Appendix Table 2. Pooled Relative and Absolute Risks for Adverse Outcomes, According to Restrictive or Liberal RBC Transfusion Thresholds in Patients With UGIB Outcome Studies (Reference) Transfusion Strategy, n/N (%) RR (95% CI)* Absolute Risk, per 1000 (95% CI) Restrictive† Liberal‡ Death 1 SR and MA, 3 RCTs (33)§ 37/727 (5.1) 68/851 (8.0) 0.65 (0.44 to 0.97) −28 (−45 to −2) Further bleeding (persistent or recurrent) 1 SR and MA, 5 RCTs (33) 64/765 (8.5) 117/877 (13.5) 0.58 (0.40 to 0.84) −56 (−80 to −21) Surgical or radiologic intervention 2 RCTs (34, 35) 14/485 (2.9) 23/592 (3.9) 0.73 (0.38 to 1.42) −10 (−24 to +16) Myocardial infarction 1 SR and MA, 2 RCTs (33) 10/684 (1.5) 15/787 (1.9) 0.79 (0.33 to 1.89) −4 (−13 to +17) Stroke or transient ischemic attack 1 SR and MA, 1 RCT (33) 3/444 (0.7) 6/445 (1.3) 0.49 (0.12 to 2.01) −7 (−12 to +14) Acute kidney injury 1 SR and MA, 2 RCTs (33) 83/685 (12.1) 110/792 (13.9) 0.77 (0.56 to 1.05) −32 (−61 to +6) MA = meta-analysis; RBC = red blood cell; RCT = randomized controlled trial; RR = relative risk; SR = systematic review; UGIB = upper gastroin- testinal bleeding. *Boldface signiﬁes statistically signiﬁcant results. †Hemoglobin threshold, 70–80 g/L. ‡ Hemoglobin threshold, 90–100 g/L. § 2 RCTs provided 97% of all patients. 2 RCTs provided 91% of all patients. Annals of Internal Medicine • Vol.171 No.11 • 3 December 2019 Annals.org Downloaded from https://annals.org by Yonsei University Medical Library on 05/29/2024.",2900,493,725.0,"[ 0.04045494 -0.28773826 -2.4514637  ...  0.655188    1.0580289
 -0.87786937]"
270,"Appendix Table 3. Summary of Adjusted Results From Studies Assessing Timing of Endoscopy in Patients With UGIB at High Risk for Rebleeding or Death Study, Year (Reference) Type of Study Deﬁnition of High Risk Very Early Endoscopy, n/N (%) Later Endoscopy, n/N (%) Adjusted Risk* Absolute Effect Mortality Lin et al, 1996 (51)† RCT In-hospital mortality ≤12 h: 1/162 (0.6) >12 h: 1/163 (0.6) RR, 1.01 (95% CI, 0.06 to 16.0) Comparator risk (later endoscopy): 6 deaths per 1000 Very early endoscopy: 0 fewer deaths per 1000 (CI, −1 to +96) Cho et al, 2018 (58) Cohort GBS >7 at initial ED presentation, 28-d mortality ≤6 h, unadjusted: 9/571 (1.6) >6 to ≤48 h, unadjusted: 15/390 (3.8) OR, 0.36 (CI, 0.14 to 0.95) Comparator risk (later endoscopy): 38 deaths per 1000 Very early endoscopy: 24 fewer deaths per 1000 (CI, −33 to −2) Laursen et al, 2017 (56) Cohort Hemodynamically unstable patients, in-hospital mortality ≤6 h: 261/1808 (14) >6 to ≤24 h: 85/908 (9.4) >24 h: 23/217 (11) Early endoscopy (>6 to ≤24 h) vs. <6 or >24 h: OR, 0.73 (CI, 0.54 to 0.98) Very early endoscopy (≤6 h) vs. >6 to 24 h: higher mortality with very early endoscopy (≤6 h), but OR not reported and statistical signiﬁcance not assessed‡ Comparator risk (endoscopy <6 or >24 h): 94 deaths per 1000 Early endoscopy (>6 to ≤24 h): 34 fewer deaths per 1000 (CI, −59 to −2) Very early endoscopy (≤6 h) vs. >6 to 24 h: not calculable Rebleeding Lin et al, 1996 (51)† RCT — ≤12 h: 6/162 (4) >12 h: 8/163 (5) RR, 0.76 (CI, 0.27 to 2.15) Comparator risk (later endoscopy): 50 rebleeds per 1000 Very early endoscopy: 12 fewer rebleeds per 1000 (CI, −37 to +57) ED = emergency department; GBS = Glasgow Blatchford score; OR = odds ratio; RCT = randomized controlled trial; RR = relative risk; UGIB = upper gastrointestinal bleeding. *Boldface signiﬁes statistically signiﬁcant results. †Not all patients were high risk; 44% had shock at presentation. ‡Similar results for hemodynamically stable patients with severe comorbid conditions. Endoscopy in <12 h was associated (adjusted results) with higher mortality than endoscopy at 12–36 h, but statistical signiﬁcance was not assessed. Annals.org Annals of Internal Medicine • Vol.171 No.11 • 3 December 2019 Downloaded from https://annals.org by Yonsei University Medical Library on 05/29/2024.",2311,389,577.75,"[ 0.04807769 -0.63405764 -2.068636   ...  0.545503    1.2293558
 -1.0640455 ]"
271,"Appendix Table 4. Areas of Future Research A. Resuscitation, risk assessment, and preendoscopy management Optimal ﬂuid resuscitation strategy (including timing and volume) for patients with UGIB and hemodynamic instability Beneﬁts of using vs. not using a prognostic scale, with outcomes of mortality, rebleeding, and cost-effectiveness Low risk-of-bias DTA studies comparing existing prognostic scales Patient preferences for early discharge based on prognostic scales vs. diagnostic certainty with early endoscopy Optimal transfusion threshold and targets, and comparison of restrictive vs. liberal transfusion strategies in patients with UGIB and cardiovascular disease, with outcomes of mortality, rebleeding, and cost-effectiveness Effectiveness of targeted reversal vs. nonreversal of anticoagulant therapy in patients with UGIB with access to early endoscopy Optimal endoscopic hemostatic therapies in patients receiving anticoagulant therapy, with outcomes of mortality, rebleeding, and cost-effectiveness B. Endoscopic management Cost-effectiveness analysis of performing endoscopy at various time frames, earlier vs. later Analysis of potential for poorer outcomes with very early endoscopy Comparison of clips and thermal contact therapies, with blinded caregiver and outcome assessments A greater characterization of the role of over-the-scope clips in UGIB Effectiveness of TC-325 as a monotherapy for actively bleeding ulcers with high-risk stigmata (spurting or oozing), or as a temporizing measure in peptic ulcer or other causes of bleeding followed by endoscopy therapy, with outcomes of mortality and rebleeding Effectiveness of DEP after endoscopic therapy to guide further treatment, or as a triage test to determine the need for endoscopic therapy C. Pharmacologic management Efﬁcacy and safety of various PPI regimens (including timing, dose, and duration), with outcomes of mortality, rebleeding, and cost-effectiveness E. Secondary prophylaxis Efﬁcacy, safety, and cost-effectiveness of PPI vs. no PPI therapy in patients receiving single-, dual-, or triple-antithrombotic therapy, particularly in populations who are Helicobacter pylori naive DEP = Doppler endoscopic probe; DTA = diagnostic test accuracy; PPI = proton-pump inhibitor; UGIB = upper gastrointestinal bleeding. Annals of Internal Medicine • Vol.171 No.11 • 3 December 2019 Annals.org Downloaded from https://annals.org by Yonsei University Medical Library on 05/29/2024.",2461,331,615.25,"[ 0.28394324 -0.69723403 -1.4128933  ...  0.7670556   0.24482532
 -1.5266498 ]"
